0.21784335.16027115.html.plaintext.txt	0	high secretase activity elicits neurodegeneration transgenic mouse despite reduction amyloid level implication treatment alzheimer disease edward rockenstein michael mante michael alford anthony adame leslie crew makoto hashimoto luke esposito lennart mucke eliezer masliahnum
0.21784335.16027115.html.plaintext.txt	1	neuroscience pathology university california san diego school medicine la jolla california num num gladstone institute neurological disease department neurology university california san francisco california num
0.21784335.16027115.html.plaintext.txt	2	received publication june num num revised form july num num
0.21784335.16027115.html.plaintext.txt	3	cleavage app secretase result secretion large n terminal ectodomain
0.21784335.16027115.html.plaintext.txt	4	alternative pathway secretase generates shorter secreted n terminal fragment app c terminal fragment ctfs cnum cnum remain membrane bound
0.21784335.16027115.html.plaintext.txt	5	latter fragment cleaved secretase resulting production peptide
0.21784335.16027115.html.plaintext.txt	6	site app cleaving enzyme bacenum account secretase activity brain num num num num
0.21784335.16027115.html.plaintext.txt	7	bacenum typical aspartic protease cleavage prodomain generate mature enzyme occurs c terminal site resulting generation mature protein starting glu num num
0.21784335.16027115.html.plaintext.txt	8	recent evidence suggests pathogenesis ad involves alteration activity bacenum
0.21784335.16027115.html.plaintext.txt	9	polymorphism bacenum gene reported influence ad risk num
0.21784335.16027115.html.plaintext.txt	10	compared nondemented control bacenum immunoreactivity increased around amyloid plaque ad brain level bacenum elevated ad brain homogenate num num correlated level app ctfs anum x anum num num
0.21784335.16027115.html.plaintext.txt	11	potential pathogenic role increased bace activity investigated vivo analyzing metabolism app human h bace transgenic tg mouse num num
0.21784335.16027115.html.plaintext.txt	12	study shown expression hbacenum moderate level happ tg model result increased generation happ ctfs case associated enhanced amyloid deposition
0.21784335.16027115.html.plaintext.txt	13	study confirmed importance hbacenum app processing vivo
0.21784335.16027115.html.plaintext.txt	14	however relationship high level hbacenum activity app processing neurodegeneration remains established
0.21784335.16027115.html.plaintext.txt	15	address issue used strong thynum promoter express hbacenum neuron tg mouse either alone combination happ
0.21784335.16027115.html.plaintext.txt	16	high level bacenum activity significantly increased cerebral accumulation happ ctfs caused prominent age related neurodegeneration neurological decline
0.21784335.16027115.html.plaintext.txt	17	different age mouse anesthetized chloral hydrate flush perfused transcardially num
0.21784335.16027115.html.plaintext.txt	18	brain peripheral tissue removed brain divided sagittally
0.21784335.16027115.html.plaintext.txt	19	one hemibrain postfixed phosphate buffered num paraformaldehyde ph num
0.21784335.16027115.html.plaintext.txt	20	num num degree c num h neuropathological analysis
0.21784335.16027115.html.plaintext.txt	21	snap frozen stored num degree c rna protein analysis
0.21784335.16027115.html.plaintext.txt	22	rna analysis total rna extracted tri reagent molecular research center cincinnati oh snap frozen hemibrains dissected brain region neocortex hippocampus stored formazol buffer molecular research num degree c
0.21784335.16027115.html.plaintext.txt	23	rna analyzed solution hybridization ribonuclease protection assay rpa essentially described previously num
0.21784335.16027115.html.plaintext.txt	24	sample separated num acrylamide num m urea tris borate edta gel dried gel exposed kodak xar film eastman kodak
0.21784335.16027115.html.plaintext.txt	25	mrna level quantitated phosphorimager reading probe specific signal corrected rna contentloading error normalization actin signal num
0.21784335.16027115.html.plaintext.txt	26	following nump labeled antisense riboprobes used identify specific mrna protected nucleotide genbank accession number hbacenum nucleotide num num accession number afnum genbank mouse m bacenum num num accession number afnum genbank mappnum num num accession number xmnum mapp exon num num m actin num num accession number xnum genbank
0.21784335.16027115.html.plaintext.txt	27	western blot analysis hbacenum happ app ctfs determination protein content lowry method frontal cortex homogenate loaded num microg proteinlane separated num sd polyacrylamide gel blotted onto nitrocellulose
0.21784335.16027115.html.plaintext.txt	28	blot labeled rabbit polyclonal antibody hbacenum prosci inc
0.21784335.16027115.html.plaintext.txt	29	poway ca numnumnum mouse monoclonal antibody n terminus app numcnum chemicon international temecula ca numnumnum mouse monoclonal antibody happ numenum elan numnumnum rabbit polyclonal antibody cnum cnum app ctnum courtesy dr
0.21784335.16027115.html.plaintext.txt	30	edward koo numnumnum mouse monoclonal antibody numgnum senetek plc napa ca numnumnum followed anti mouse anti rabbit secondary antibody
0.21784335.16027115.html.plaintext.txt	31	blot incubated numi protein icn pharmaceutical costa mesa ca exposed phosphorimager molecular dynamic piscataway nj screen incubated super signal west pico chemiluminescent substrate pierce exposed film
0.21784335.16027115.html.plaintext.txt	32	detail regarding antibody utilized described table one
0.21784335.16027115.html.plaintext.txt	33	control variation loading blot stripped incubated mouse monoclonal antibody actin chemicon numnum
0.21784335.16027115.html.plaintext.txt	34	signal intensity quantitated imagequant software molecular dynamic
0.21784335.16027115.html.plaintext.txt	35	view table table one antibody bace app app metabolite used study
0.21784335.16027115.html.plaintext.txt	36	additional western blot analysis performed highly denaturing condition described previously num modification
0.21784335.16027115.html.plaintext.txt	37	neocortical tissue homogenized num formic acid num final concentration icn dounce homogenizer centrifuged num min numnum x g num degree c
0.21784335.16027115.html.plaintext.txt	38	supernatant collected used highly denaturing acetic acidurea page western blot analysis
0.21784335.16027115.html.plaintext.txt	39	num mg mouse without plaque num microg mouse plaque total protein determined micro lowry assay loaded per lane numnumnum step gradient polyacrylamide gel containing num m urea num acetic acid electrophoresed anode cathode num
0.21784335.16027115.html.plaintext.txt	40	num acetic acid running buffer overnight num degree c
0.21784335.16027115.html.plaintext.txt	41	gel neutralized five num min incubation trisglycine transfer buffer num methanol ph num
0.21784335.16027115.html.plaintext.txt	42	num transferred nitrocellulose membrane num
0.21784335.16027115.html.plaintext.txt	43	membrane boiled phosphate buffered saline num min blocked num milk tris buffered saline num
0.21784335.16027115.html.plaintext.txt	44	num tween num tbst num h incubated overnight num degree c anti antibody num num
0.21784335.16027115.html.plaintext.txt	45	membrane washed three time num min num bovine serum albumin tbst incubated anti mouse igghorseradish peroxidase secondary antibody num h room temperature
0.21784335.16027115.html.plaintext.txt	46	membrane washed three time num min tbst detection carried super signal west pico chemiluminescent substrate pierce
0.21784335.16027115.html.plaintext.txt	47	synthetic anum num anum num peptide num pg biopeptide san diego ca run standard
0.21784335.16027115.html.plaintext.txt	48	view larger version numk figure num
0.21784335.16027115.html.plaintext.txt	49	bacenum expression brain bacenum tg mouse non tg control
0.21784335.16027115.html.plaintext.txt	50	brain tissue obtained num month old tg mouse line num num num age matched non tg control num year old nondemented human
0.21784335.16027115.html.plaintext.txt	51	c human h mouse m bacenum mrna frontal cortex quantitated rpa
0.21784335.16027115.html.plaintext.txt	52	representative autoradiograph
0.21784335.16027115.html.plaintext.txt	53	lane contains sample different mouse human
0.21784335.16027115.html.plaintext.txt	54	b c relative mrna level expressed hbacenumactin b mbacenumactin c ratio correct loading error
0.21784335.16027115.html.plaintext.txt	55	rpa signal quantitated described previously num
0.21784335.16027115.html.plaintext.txt	56	d relative level hbacenum protein frontal cortex determined western blot analysis
0.21784335.16027115.html.plaintext.txt	57	representative western blot demonstrates association bacenum particulate fraction
0.21784335.16027115.html.plaintext.txt	58	lane contains sample different mouse
0.21784335.16027115.html.plaintext.txt	59	e western blot band quantitated imagequant software
0.21784335.16027115.html.plaintext.txt	60	f bacenum activity determined red fret peptide substrate based swapp mutant
0.21784335.16027115.html.plaintext.txt	61	assay differentiate activity human murine bacenum
0.21784335.16027115.html.plaintext.txt	62	level non tg control defined num
0.21784335.16027115.html.plaintext.txt	63	g j photomicrograph depicting immunoperoxidase staining hbacenum frontal cortex non tg mouse g hbacenum tg mouse line num hnumi num j
0.21784335.16027115.html.plaintext.txt	64	num versus line num num tukey kramer test p num
0.21784335.16027115.html.plaintext.txt	65	num versus non tg control dunnetts test
0.21784335.16027115.html.plaintext.txt	66	analysis app metabolism related pathway human peptide quantitated enzyme linked immunosorbent assay elisa described previously num
0.21784335.16027115.html.plaintext.txt	67	anum num elisa detects anum num whereas anum x elisa detects anum num anum num well form containing amino acid num num
0.21784335.16027115.html.plaintext.txt	68	analysis app ctfs cortex homogenate analyzed lowry method determine protein concentration loaded num microg proteinlane num num microglane jnum inum mouse respectively onto num tricinesds polyacrylamide gel blotted onto nitrocellulose probed antibody app ctfs ctnum numnumnum phospho p app cell signaling beverly ma numnumnum tubulin loading control numnumnum
0.21784335.16027115.html.plaintext.txt	69	evaluate effect hbacenum expression related pathway western blot probed antibody neprilysin cdnum mouse monoclonal abcam cambridge ma numnum insulin degrading enzyme ide rabbit polyclonal calbiochem san diego ca numnumnum notchnum rabbit polyclonal santa cruz biotechnology santa cruz ca numnumnum
0.21784335.16027115.html.plaintext.txt	70	analysis bacenum enzymatic activity bacenum activity determined adapting bacenum fluorescence resonance energy transfer fret assay kit panvera madison wi us red fret peptide derived swedish sw mutant app substrate sequence described previously num
0.21784335.16027115.html.plaintext.txt	71	briefly brain homogenate tg mouse incubated bacenum substrate final concentration num x reagent
0.21784335.16027115.html.plaintext.txt	72	stop buffer containing num
0.21784335.16027115.html.plaintext.txt	73	num m sodium acetate added signal determined num nm spectrofluorometer
0.21784335.16027115.html.plaintext.txt	74	control experiment performed standard curve generated using baculovirus expressed bacenum bacenum product standard rh evnl bacenum inhibitor provided kit
0.21784335.16027115.html.plaintext.txt	75	confirm bacenum activity level independent method extracted supernatant homogenized sample neutralized tris assayed bacenum activity utilizing substrate bacterial maltose binding protein mbp fused c terminal num amino acid app mbp appcnum described previously num
0.21784335.16027115.html.plaintext.txt	76	briefly assay carried num mm sodium acetate ph num
0.21784335.16027115.html.plaintext.txt	77	num triton x num num microgml mbp appcnum
0.21784335.16027115.html.plaintext.txt	78	reaction mixture diluted numnum incubated num degree c num h quenched reaction mixture loaded onto num well plate coated polyclonal antibody raised mbp
0.21784335.16027115.html.plaintext.txt	79	cleaved product detected using biotinylated swnum specific reporter antibody purified hbacenum used standard activity assay
0.21784335.16027115.html.plaintext.txt	80	view larger version numk figure num
0.21784335.16027115.html.plaintext.txt	81	decrease fl app increase app ctfs hbacenum tg mouse
0.21784335.16027115.html.plaintext.txt	82	homogenate frontal cortex num month old hbacenum tg mouse non tg littermates separated cytosolic particulate fraction analyzed western blotting antibody fl app numcnum mouse monoclonal app ctfs ctnum rabbit polyclonal actin mouse monoclonal expression level quantitated
0.21784335.16027115.html.plaintext.txt	83	representative western blot sample different hbacenum tg line
0.21784335.16027115.html.plaintext.txt	84	lane contains sample different mouse
0.21784335.16027115.html.plaintext.txt	85	b c quantitation western blot band n num micegenotype
0.21784335.16027115.html.plaintext.txt	86	d double immunolabeling confocal microscopic analysis hbacenum red app ctfs green frontal cortex num month old non tg d f hbacenum tg g mouse
0.21784335.16027115.html.plaintext.txt	87	num versus non tg control dunnetts test
0.21784335.16027115.html.plaintext.txt	88	behavioral analysis mouse free access food water experiment carried light cycle
0.21784335.16027115.html.plaintext.txt	89	experimental control group contained similar proportion male female
0.21784335.16027115.html.plaintext.txt	90	water maze test carried described previously num
0.21784335.16027115.html.plaintext.txt	91	briefly pool diameter num cm filled opaque water num degree c mouse first trained locate visible platform day num num submerged hidden platform day num num three daily trial num num min apart
0.21784335.16027115.html.plaintext.txt	92	mouse failed find hidden platform within num placed num
0.21784335.16027115.html.plaintext.txt	93	platform location used session mouse
0.21784335.16027115.html.plaintext.txt	94	starting point mouse placed water changed randomly two alternative entry point located similar distance platform
0.21784335.16027115.html.plaintext.txt	95	day num another visible platform trial performed exclude difference motivation fatigue
0.21784335.16027115.html.plaintext.txt	96	time reach platform latency path length swim speed recorded noldus instrument ethovision video tracking system san diego instrument san diego set analyze two sample
0.21784335.16027115.html.plaintext.txt	97	immunohistochemistry vibratome section num microm brain tissue incubated overnight num degree c primary antibody hbacenum prosci inc
0.21784335.16027115.html.plaintext.txt	98	numnum happ numenum elan numnumnum table one
0.21784335.16027115.html.plaintext.txt	99	binding primary antibody detected vector abc elite kit vector laboratory burlingame ca diaminobenzidine tetrahydrochloride num
0.21784335.16027115.html.plaintext.txt	100	double labeling study performed essentially described previously num
0.21784335.16027115.html.plaintext.txt	101	briefly vibratome section incubated overnight num degree c anti hbacenum numnum developed tyramide signal amplification direct red system perkinelmer life science numnum
0.21784335.16027115.html.plaintext.txt	102	section incubated overnight antibody app ctfs ctnum numnum followed incubation fitc tagged secondary goat anti rabbit vector numnum imaging laser scanning confocal microscopy lscm mrc num bio rad
0.21784335.16027115.html.plaintext.txt	103	neuropathological analysis vibratome section incubated overnight num degree c mouse monoclonal antibody neuronal dendritic marker microtubule associated protein num mapnum chemicon numnum axonal neurofilament marker sminum sternberger immuocytochemicals baltimore md numnum astroglial marker glial fibrillary acidic protein gfap chemicon numnum described previously num
0.21784335.16027115.html.plaintext.txt	104	binding primary antibody detected vector elite kit diaminobenzidine tetrahydrochloridehnumonum fitc conjugated igg secondary antibody vector numnum
0.21784335.16027115.html.plaintext.txt	105	immunoperoxidase labeled section examined olympus vanox light microscope
0.21784335.16027115.html.plaintext.txt	106	fitc labeled section analyzed confocal microscopy num num
0.21784335.16027115.html.plaintext.txt	107	ultrastructural analysis block neocortex hippocampus postfixed num glutaraldehyde num
0.21784335.16027115.html.plaintext.txt	108	num m sodium cacodylate buffer embedded epoxy
0.21784335.16027115.html.plaintext.txt	109	block sectioned ultracut e ultramicrotome leica nussloch germany analyzed zeiss emnum electron microscope carl zeiss oberkochen germany num
0.21784335.16027115.html.plaintext.txt	110	statistical analysis analysis carried statview num
0.21784335.16027115.html.plaintext.txt	111	difference among mean assessed student test one way anova followed dunnetts tukey kramer post hoc test indicated
0.21784335.16027115.html.plaintext.txt	112	learning curve analyzed repeated measure anova
0.21784335.16027115.html.plaintext.txt	113	null hypothesis rejected num
0.21784335.16027115.html.plaintext.txt	114	view larger version numk figure num
0.21784335.16027115.html.plaintext.txt	115	decrease fl app increase app ctfs hbacenumhapp tg mouse
0.21784335.16027115.html.plaintext.txt	116	homogenate frontal cortex num month old hbacenum tg happ tg hbacenumhapp doubly tg mouse non tg littermates separated cytosolic particulate fraction analyzed western blotting antibody fl app numcnum mouse monoclonal app ctfs ctnum rabbit polyclonal actin mouse monoclonal expression level quantitated
0.21784335.16027115.html.plaintext.txt	117	representative western blot sample hbacenumhapp doubly tg mouse singly tg hbacenum happ control
0.21784335.16027115.html.plaintext.txt	118	b c quantitation western blot band n num micegroup
0.21784335.16027115.html.plaintext.txt	119	d double immunolabeling confocal microscopic analysis hbacenum red happ green frontal cortex num month old happ tg d f hbacenumhapp tg g mouse
0.21784335.16027115.html.plaintext.txt	120	num versus non tg control dunnetts test p num
0.21784335.16027115.html.plaintext.txt	121	num versus hbacenumhapp doubly tg mouse tukey kramer test
0.21784335.16027115.html.plaintext.txt	122	high level hbacenum expression increase app ctfs decrease level full length app full length fl app detected western blot brain homogenate triple band fig
0.21784335.16027115.html.plaintext.txt	123	compared non tg control high expresser hbacenum tg mouse decreased level fl app fig
0.21784335.16027115.html.plaintext.txt	124	numa b decrease marked two upper band
0.21784335.16027115.html.plaintext.txt	125	contrast level app ctfs num num fold higher hbacenum mouse non tg control determined western blot analysis ctnum antibody recognizes hbacenum generated cnum cnum fragment app fig
0.21784335.16027115.html.plaintext.txt	126	num c well secretase generated cnum fragment num
0.21784335.16027115.html.plaintext.txt	127	double labeling analysis confirmed intraneuronal accumulation app ctfs higher hbacenum mouse non tg control fig
0.21784335.16027115.html.plaintext.txt	128	moreover neuron displaying highest level hbacenum expression also showed highest level app ctf immunoreactivity fig
0.21784335.16027115.html.plaintext.txt	129	characterize effect high level hbacenum expression happ processing homogenate happ singly tg mouse expressing familial ad mutant happ line num num hbacenumline numhappline num doubly tg mouse analyzed western blot
0.21784335.16027115.html.plaintext.txt	130	singly tg happ mouse showed increase overall level cerebral app expression compared non tg control fig
0.21784335.16027115.html.plaintext.txt	131	compared mouse hbacenumhapp mouse lower level fl app higher level app ctfs fig
0.21784335.16027115.html.plaintext.txt	132	immunoreactivities hbacenum app ctfs hbacenumhapp mouse colocalized neuron fig
0.21784335.16027115.html.plaintext.txt	133	num g consistent notion increase app ctfs resulted increased cleavage happ hbacenum
0.21784335.16027115.html.plaintext.txt	134	investigate app metabolism greater detail mouse app ctfs detected immunoblot analysis separation tricinesds polyacrylamide gel
0.21784335.16027115.html.plaintext.txt	135	analysis revealed increase app ctfs hbacenumhapp mouse represents primarily accumulation cnum result app cleavage site fig
0.21784335.16027115.html.plaintext.txt	136	whereas secretase cleavage cnum would result production anum x secretase cleavage cnum would result production anum x
0.21784335.16027115.html.plaintext.txt	137	surprisingly hbacenumhapp mouse decreased level anum x truncated specie
0.21784335.16027115.html.plaintext.txt	138	hippocampal level anum x fig
0.21784335.16027115.html.plaintext.txt	139	numc much lower hbacenumhapp mouse happ singly tg mouse
0.21784335.16027115.html.plaintext.txt	140	elisa used obtain measurement specifically detect peptide containing first five amino acid also analyzed level antibody num raised middle portion peptide amino acid num num table one num
0.21784335.16027115.html.plaintext.txt	141	extraction hippocampal protein formic acid followed high resolution acid urea page western blot analysis num antibody confirmed reduction detectable specie hbacenumhapp mouse compared happ singly tg mouse fig
0.21784335.16027115.html.plaintext.txt	142	consistent biochemical data amyloid plaque detected num num month age frontal cortex hippocampus happ mouse hbacenumhapp mouse fig
0.21784335.16027115.html.plaintext.txt	143	num e f data shown
0.21784335.16027115.html.plaintext.txt	144	view larger version numk figure num
0.21784335.16027115.html.plaintext.txt	145	accumulation app ctfs decrease level deposition hbacenumhapp doubly tg mouse
0.21784335.16027115.html.plaintext.txt	146	homogenate frontal cortex num num month old singly tg mouse happ line num hbacenum line num doubly tg hbacenumhapp mouse non tg control separated differential centrifugation particulate fraction separated num tricine gel analyzed western blotting antibody app ctfs ctnum rabbit polyclonal
0.21784335.16027115.html.plaintext.txt	147	representative western blot sample happ hbacenumhapp doubly tg mouse
0.21784335.16027115.html.plaintext.txt	148	confirm approach detect difference relative abundance different app ctfs included sample hippocampus two previously characterized pdgf happ tg line expressing comparable level familial ad mutant jnum wild type inum happ num
0.21784335.16027115.html.plaintext.txt	149	consistent known effect swedish mutation app cleavage bacenum jnum mouse cnum cnum fragment whereas inum mouse mostly cnum
0.21784335.16027115.html.plaintext.txt	150	b c hippocampal level anum x b anum num c num month old mouse n num num miceline determined elisa
0.21784335.16027115.html.plaintext.txt	151	d anum num anum num anum num specie detected high resolution acid urea page western blot analysis num antibody described previously num
0.21784335.16027115.html.plaintext.txt	152	lane contained protein extracted neocortex num mglane different mouse
0.21784335.16027115.html.plaintext.txt	153	e f deposit detected hippocampal vibratome section immunostaining numgnum antibody
0.21784335.16027115.html.plaintext.txt	154	num month age happ tg mouse line num amyloid deposit e whereas hbacenumhapp tg mouse f
0.21784335.16027115.html.plaintext.txt	155	g comparison level neprilysin ide notch non tg control happ hbacenum hbacenumhapp tg mouse western blot analysis
0.21784335.16027115.html.plaintext.txt	156	level actin immunoreactivity used loading control
0.21784335.16027115.html.plaintext.txt	157	homogenate frontal cortex num month old mouse
0.21784335.16027115.html.plaintext.txt	158	h quantitative analysis level neprilysin ide notch expression
0.21784335.16027115.html.plaintext.txt	159	analysis phosphorylated fl app app p phosphorylated app ctfs cnum p cnum p cnum p happ hbacenumhapp tg mouse
0.21784335.16027115.html.plaintext.txt	160	homogenate frontal cortex num month old mouse separated polyacrylamide tricine gel transferred nitrocellulose probed app p thr num antibody
0.21784335.16027115.html.plaintext.txt	161	j quantitative analysis showing level app p cnum p cnum p reduced bigenic mouse
0.21784335.16027115.html.plaintext.txt	162	num versus happ tg mouse unpaired two tailed student test
0.21784335.16027115.html.plaintext.txt	163	view larger version numk figure num
0.21784335.16027115.html.plaintext.txt	164	learning deficit hbacenum hbacenumhapp tg mouse
0.21784335.16027115.html.plaintext.txt	165	num month age hbacenum line num happ mouse line num hbacenumhapp mouse non tg littermates n num micegroup mouse trained morris water maze locate visible platform day num num submerged platform day num num visible platform day num
0.21784335.16027115.html.plaintext.txt	166	day num cued component test platform visible four group achieved comparable escape latency
0.21784335.16027115.html.plaintext.txt	167	platform hidden three group tg mouse showed significant learning deficit compared non tg control p num
0.21784335.16027115.html.plaintext.txt	168	num day num num tg group repeated measure anova
0.21784335.16027115.html.plaintext.txt	169	trend toward severe deficit observed hbacenumhapp mouse repeated measure anova curve hidden platform different among three group tg mouse
0.21784335.16027115.html.plaintext.txt	170	however last day hidden platform testing day num hbacenumhapp mouse performed poorly hbacenum mouse happ tg mouse p num
0.21784335.16027115.html.plaintext.txt	171	finding raise possibility decreased level anum x anum num result alteration activity secretase availability substrate rate turnover enzyme neprilysin insulin degrading enzyme ide
0.21784335.16027115.html.plaintext.txt	172	immunoblot analysis antibody neprilysin ide showed roughly comparable level enzyme hbacenum mouse happ mouse hbacenumhapp mouse non tg control fig
0.21784335.16027115.html.plaintext.txt	173	addition level notch another secretase substrate comparable among four group mouse fig
0.21784335.16027115.html.plaintext.txt	174	result suggest decrease level mouse high level hbacenum activity result increased degradation decreased secretase activity
0.21784335.16027115.html.plaintext.txt	175	similar decrease independent line hbacenum tg mouse recently related decreased availability mature phosphorylated app app p num
0.21784335.16027115.html.plaintext.txt	176	consistent possibility western blot analysis antibody app p threonine num revealed cerebral level fl app p cnum p lower hbacenumhapp mouse happ mouse fig
0.21784335.16027115.html.plaintext.txt	177	result support notion high level hbacenum activity increase happ cleavage early secretory pathway depleting mature happ p transported axon terminal large proportion generation secretase complex take place num
0.21784335.16027115.html.plaintext.txt	178	increased activity hbacenum elicits learning deficit neurodegenerative alteration num month age hbacenum tg mouse highest expresser line num showed mild weakness spasticity hind limb
0.21784335.16027115.html.plaintext.txt	179	phenotype apparent num month progressed prominent spastic paraparesis num month age
0.21784335.16027115.html.plaintext.txt	180	hbacenum mouse intermediate expresser line num num showed obvious neurological deficit inspected num num month age although num month mild tremor
0.21784335.16027115.html.plaintext.txt	181	hbacenum tg mouse line num developed age dependent neurological deficit precluded assessment water maze test hbacenum tg mouse line num selected cross happ tg mouse behavioral analysis
0.21784335.16027115.html.plaintext.txt	182	num month age hbacenum mouse line num happ mouse hbacenumhapp mouse non tg littermates tested morris water maze examine spatial learning memory
0.21784335.16027115.html.plaintext.txt	183	day num cued component test platform visible four group achieved similar escape latency fig
0.21784335.16027115.html.plaintext.txt	184	platform hidden three group tg mouse showed significant learning deficit compared non tg control fig
0.21784335.16027115.html.plaintext.txt	185	trend toward severe deficit observed hbacenumhapp mouse repeated measure anova curve hidden platform different among three group tg mouse
0.21784335.16027115.html.plaintext.txt	186	however last day test day num performance deficit hbacenumhapp group significantly different one way anova p num
0.21784335.16027115.html.plaintext.txt	187	num compared hbacenum happ tg mouse
0.21784335.16027115.html.plaintext.txt	188	ass extent neurodegenerative alteration hbacenum mouse immunolabeling performed antibody marker neuronal dendritic integrity
0.21784335.16027115.html.plaintext.txt	189	compared non tg control fig
0.21784335.16027115.html.plaintext.txt	190	numa mouse expressing high level hbacenum displayed shrinkage pyramidal neuron canum region hippocampus fig
0.21784335.16027115.html.plaintext.txt	191	numb worst alteration seen mouse highest expresser line num fig
0.21784335.16027115.html.plaintext.txt	192	compared non tg control fig
0.21784335.16027115.html.plaintext.txt	193	numd pyramidal neuron layer num num neocortex also shrunken condensed three hbacenum tg line fig
0.21784335.16027115.html.plaintext.txt	194	contrast normal labeling neurites antibody neurofilament fig
0.21784335.16027115.html.plaintext.txt	195	numj non tg control axonal dendritic process pyramidal neuron hbacenum mouse diminished disrupted vacuolized fig
0.21784335.16027115.html.plaintext.txt	196	alteration prominent num month fig
0.21784335.16027115.html.plaintext.txt	197	num l detectable albeit lesser extent num num month age shown
0.21784335.16027115.html.plaintext.txt	198	num month age neurodegenerative alteration hbacenum tg mouse associated reactive astrocytosis fig
0.21784335.16027115.html.plaintext.txt	199	numn observed non tg control fig
0.21784335.16027115.html.plaintext.txt	200	contrast non tg littermate control fig
0.21784335.16027115.html.plaintext.txt	201	nump hbacenum mouse line num showed collapsed neuronal cytoplasm accumulation electrodense material extensive vacuolization dendritic arbor fig
0.21784335.16027115.html.plaintext.txt	202	numq wide spread degeneration axonal process splinting disorganization myelin lamination fig
0.21784335.16027115.html.plaintext.txt	203	significant loss alteration neuritic structure also detected happ singly tg mouse hbacenum mouse hbacenumhapp mouse considerable damage also canum region hippocampus fig
0.21784335.16027115.html.plaintext.txt	204	compared non tg control fig
0.21784335.16027115.html.plaintext.txt	205	numc mouse reduced level mapnum immunoreactivity frontal cortex alteration even prominent hbacenumhapp mouse fig
0.21784335.16027115.html.plaintext.txt	206	canum region hippocampus three tg group showed loss dendritic complexity severe hbacenum hbacenumhapp mouse fig
0.21784335.16027115.html.plaintext.txt	207	hbacenum cleaves app two site generating classical c terminal stub cnum alternative cnum fragment num num
0.21784335.16027115.html.plaintext.txt	208	although current research ad focused potential neurotoxic effect app ctfs also shown deleterious effect
0.21784335.16027115.html.plaintext.txt	209	example primary neuronal culture accumulation cnum fragment promotes apoptosis num tg mouse overexpressing ctfs neuron develop hippocampal degeneration well deficit memory long term potentiation num num
0.21784335.16027115.html.plaintext.txt	210	view larger version numk figure num
0.21784335.16027115.html.plaintext.txt	211	neuropathological ultrastructural alteration brain hbacenum tg mouse
0.21784335.16027115.html.plaintext.txt	212	vibratome section num month old mouse either stained cresyl violet f immunostained antibody neurofilaments g mapnum j l gfap m o processed electron microscopy p r
0.21784335.16027115.html.plaintext.txt	213	b representative image hippocampus d o image neocortex non tg hbacenum tg line num mouse
0.21784335.16027115.html.plaintext.txt	214	b neuronal shrinkage degeneration arrow canum region hbacenum tg mouse
0.21784335.16027115.html.plaintext.txt	215	c quantitative assessment cell density canum revealing significant loss neuron mouse line num num n num micegroup
0.21784335.16027115.html.plaintext.txt	216	d e neuronal shrinkage degeneration arrow layer ii iii fronto parietal region hbacenum tg mouse
0.21784335.16027115.html.plaintext.txt	217	f quantitative assessment cell density neocortex revealing significant loss neuron mouse line num n num micegroup
0.21784335.16027115.html.plaintext.txt	218	g h loss phosphorylated high intermediate molecular mass neurofilaments hbacenum tg mouse revealed immunostaining sminum mouse monoclonal bright field microscopy
0.21784335.16027115.html.plaintext.txt	219	quantitation sminum immunoreactivity showing significant decrease three line hbacenum tg mouse n num micegroup
0.21784335.16027115.html.plaintext.txt	220	j k alteration mapnum positive neuronal dendritic structure hbacenum tg mouse demonstrated lscm
0.21784335.16027115.html.plaintext.txt	221	l quantitative assessment percent area neocortex occupied mapnum immunoreactive dendrite neocortex revealing significant loss line hbacenum tg mouse n num micegroup
0.21784335.16027115.html.plaintext.txt	222	m n reactive astrocytosis hbacenum tg mouse revealed gfap immunostaining bright field microscopy
0.21784335.16027115.html.plaintext.txt	223	o quantitation gfap immunoreactivity neocortex showing significant increase hbacenum tg mouse line num n num micegroup
0.21784335.16027115.html.plaintext.txt	224	p ultrastructural analysis demonstrating well preserved neuronal n dendritic axonal structure non tg mouse
0.21784335.16027115.html.plaintext.txt	225	q contrast hbacenum tg mouse line num showed considerable neuronal shrinkage condensation vacuolization dendrite d
0.21784335.16027115.html.plaintext.txt	226	r axon hbacenum mouse showing thinning degeneration myelin sheath
0.21784335.16027115.html.plaintext.txt	227	bar num microma b d e g h m n num micromj k num micromp q num micromr
0.21784335.16027115.html.plaintext.txt	228	num versus non tg control dunnetts test
0.21784335.16027115.html.plaintext.txt	229	view larger version numk figure num
0.21784335.16027115.html.plaintext.txt	230	neurodegenerative alteration hbacenumhapp tg mouse
0.21784335.16027115.html.plaintext.txt	231	section brain num month old mouse immunolabeled antibody mapnum mouse monoclonal imaged lscm
0.21784335.16027115.html.plaintext.txt	232	d frontal cortex f hippocampus hipp
0.21784335.16027115.html.plaintext.txt	233	although neuron dendrite well preserved non tg control f evidence neurodegeneration happ tg b g hbacenum tg c h mouse
0.21784335.16027115.html.plaintext.txt	234	neurodegenerative alteration even severe hbacenumhapp tg mouse d
0.21784335.16027115.html.plaintext.txt	235	e j quantitation percent area neuropil covered mapnum immunoreactive dendrite revealed significant depletion mapnum positive neuronal structure hbacenum tg line
0.21784335.16027115.html.plaintext.txt	236	num versus non tg control dunnetts test
0.21784335.16027115.html.plaintext.txt	237	increased activity hbacenum led increase level app ctfs hbacenum mouse hbacenumhapp mouse consistent previous observation num num num num
0.21784335.16027115.html.plaintext.txt	238	moreover level app ctfs different line hbacenum mouse related extent neurological neuropathological alteration highest level app ctfs found severely impaired line num
0.21784335.16027115.html.plaintext.txt	239	although previous study num num num num shown increase cnum cnum decrease cnum present study found significant increase level cnum whereas cnum level decreased
0.21784335.16027115.html.plaintext.txt	240	suggests model app processing may occur preferentially cleavage site num num
0.21784335.16027115.html.plaintext.txt	241	interestingly despite overall increase cnum cnum previous study level cnum p decreased significantly hbacenumhapp mouse decrease c num phosphorylation apparent mouse expressing higher level hbacenum num
0.21784335.16027115.html.plaintext.txt	242	compared happ tg mouse hbacenumhapp mouse showed lower level cnum cnum p decreased hbacenum overexpression
0.21784335.16027115.html.plaintext.txt	243	phosphorylation app post translational modification necessary maturation axonal transport cnum num num decrease cnum p indicates app cleavage hbacenumhapp mouse might occur early compartment num
0.21784335.16027115.html.plaintext.txt	244	high level hbacenum app ctfs hbacenumhapp mouse associated decreased level human anum x anum num determined highly quantitative elisa measurement
0.21784335.16027115.html.plaintext.txt	245	result consistent recent study num differ result obtained hbacenumhapp model num num num num
0.21784335.16027115.html.plaintext.txt	246	several factor might account difference including genetic background mouse analyzed
0.21784335.16027115.html.plaintext.txt	247	however critical factor determining effect hbacenum activity might level hbacenum transgene expression num
0.21784335.16027115.html.plaintext.txt	248	although low intermediate level hbacenum expression enhanced amyloid production deposition doubly tg mouse higher level hbacenum expression reduced production presumably high level hbacenum activity shifted subcellular location app cleavage neuronal cell body early secretory pathway resulting depletion mature app p trans golgi compartment num
0.21784335.16027115.html.plaintext.txt	249	thus lesser amount app might targeted distal axon would preclude secretase mediated generation synaptic site
0.21784335.16027115.html.plaintext.txt	250	factor may result degeneration neuron high level bacenum activity recent evidence suggests toxicity ctfs may mediated caspase generated c terminal cnum fragment num num
0.21784335.16027115.html.plaintext.txt	251	therefore interesting test whether preventing generation cnum prevents neurodegeneration hbacenumhapp mouse
0.21784335.16027115.html.plaintext.txt	252	similar vein expression hbacenum mapp deficient mouse might reveal app independent mechanism hbacenum induced neurotoxicity
0.21784335.16027115.html.plaintext.txt	253	conceivably increased bacenum activity might trigger neurodegeneration cleavage substrate app
0.21784335.16027115.html.plaintext.txt	254	example vitro num vivo num bacenum cleaves stnumgal sialyltransferase whose cleavage product secreted
0.21784335.16027115.html.plaintext.txt	255	recently shown bacenum also cleaves subunit voltage gated sodium channel num
0.21784335.16027115.html.plaintext.txt	256	increased level hbacenum activity could broaden substrate specificity enzyme tg mouse human ad
0.21784335.16027115.html.plaintext.txt	257	indeed recent study identified increased level hbacenum immunoreactivity app ctfs ad brain num num suggesting increased bacenum activity may causally involved also pathogenesis ad
0.21784335.16027115.html.plaintext.txt	258	current study support extends notion demonstrating increased neuronal hbacenum activity cause progressive neurodegenerative alteration vivo
0.21784335.16027115.html.plaintext.txt	259	whereas inhibiting secretase alter secretase processing decrease production increase accumulation app ctfs num num inhibiting bacenum may block dependent independent pathogenic mechanism ad
0.21784335.16027115.html.plaintext.txt	260	footnote work supported national institute health grant agnum agnum agnum agnum
0.21784335.16027115.html.plaintext.txt	261	cost publication article defrayed part payment page charge
0.21784335.16027115.html.plaintext.txt	262	article must therefore hereby marked advertisement accordance num u
0.21784335.16027115.html.plaintext.txt	263	section num solely indicate fact
0.21784335.16027115.html.plaintext.txt	264	num correspondence addressed dept
0.21784335.16027115.html.plaintext.txt	265	neuroscience university california san diego num gilman dr
0.21784335.16027115.html.plaintext.txt	266	num num num fax num num num e mail emasliahatucsd
0.21784335.16027115.html.plaintext.txt	267	num abbreviation used ad alzheimer disease peptide amyloid peptide anova analysis variance app amyloid precursor protein bacenum site app cleaving enzyme ctf c terminal fragment elisa enzyme linked immunosorbent assay fitc fluorescein isothiocyanate fl full length fret fluorescence resonance energy transfer gfap glial fibrillary acidic protein h human ide insulin degrading enzyme lscm laser scanning confocal microscopy m mouse mapnum microtubule associated protein num mbp maltose binding protein p phosphorylated rpa ribonuclease protection assay sw swedish tg transgenic tricine n num hydroxy numnum bishydroxymethylethylglycine
0.21784335.16027115.html.plaintext.txt	268	acknowledgment thank dr
0.21784335.16027115.html.plaintext.txt	269	van der putten providing mthynum cassette dr
0.21784335.16027115.html.plaintext.txt	270	lisa mcconlogue hbace antibody activity assay dr
0.21941808.16055825.html.plaintext.txt	0	brief psychotherapy alzheimers disease randomised controlled trial alistair burn md frcp frcpsych
0.21941808.16055825.html.plaintext.txt	1	department psychiatry wythenshawe hospital manchester
0.21941808.16055825.html.plaintext.txt	2	department psychiatry manchester royal infirmary manchester
0.21941808.16055825.html.plaintext.txt	3	federica marino francis charlotte busby mrcpsych
0.21941808.16055825.html.plaintext.txt	4	department psychiatry wythenshawe hospital manchester
0.21941808.16055825.html.plaintext.txt	5	department medical statistic wythenshawe hospital manchester
0.21941808.16055825.html.plaintext.txt	6	eve russell md mrcpsych frank margison frcpsych sean lennon frcpsych jane byrne frcpsych
0.21941808.16055825.html.plaintext.txt	7	department psychiatry wythenshawe hospital manchester uk
0.21941808.16055825.html.plaintext.txt	8	correspondence professor alistair burn department psychiatry numnd floor education research centre wythenshawe hospital southmoor road manchester mnum numlt uk
0.21941808.16055825.html.plaintext.txt	9	tel num numnum num num fax num numnum num num e mail alistair
0.21941808.16055825.html.plaintext.txt	10	aim aim ass randomised controlled trial whether psychotherapeutic intervention could benefit cognitive function affective symptom global well
0.21941808.16055825.html.plaintext.txt	11	method individual randomised receive six session psychodynamic interpersonal therapy treatment usual cognitive function activity daily living global measure change carer stress coping assessed prior intervention
0.21941808.16055825.html.plaintext.txt	12	result improvement found majority outcome measure
0.21941808.16055825.html.plaintext.txt	13	suggestion therapy improved carers reaction symptom
0.21941808.16055825.html.plaintext.txt	14	conclusion evidence support widespread introduction brief psychotherapeutic approach alzheimers disease
0.21941808.16055825.html.plaintext.txt	15	however technique acceptable helpful individually
0.21941808.16055825.html.plaintext.txt	16	aim study ass randomised controlled trial whether psychotherapeutic approach directed towards individual alzheimers disease could benefit cognitive function affective symptom global well
0.21941808.16055825.html.plaintext.txt	17	view larger version numk fig
0.21941808.16055825.html.plaintext.txt	18	num design trial brief psychotherapy alzheimers disease
0.21941808.16055825.html.plaintext.txt	19	procedure individual carers recruited referral memory clinic south manchester uk
0.21941808.16055825.html.plaintext.txt	20	inclusion criterion diagnosis alzheimers disease according nincds adrda criterion mckhann et al num clinical dementia rating num morris num indicating mild dementia score num mini mental state examination folstein et al num living home carer regular contact ability communicate verbally
0.21941808.16055825.html.plaintext.txt	21	following consent individual allocated one two group treatment control using computer generated random number organised independently department medical statistic south manchester
0.21941808.16055825.html.plaintext.txt	22	allocated control group could elect therapeutic session study
0.21941808.16055825.html.plaintext.txt	23	assessment therapeutic intervention conducted individual home
0.21941808.16055825.html.plaintext.txt	24	taking anticholinesterase drug treatment alzheimers disease psychotropic medication antidepressant clinically stable medication least num month prior study entry
0.21941808.16055825.html.plaintext.txt	25	therapeutic intervention treatment group received six session psychodynamic interpersonal therapy experienced psychotherapist
0.21941808.16055825.html.plaintext.txt	26	control group received standard care consisted general advice regarding diagnosis treatment dementia patient review
0.21941808.16055825.html.plaintext.txt	27	psychodynamic interpersonal therapy psychodynamic interpersonal therapy formerly known conversational model psychotherapy hobson num used treat wide variety disorder including depression shapiro firth num shapiro et al num somatisation guthrie et al num hamilton et al num self harm guthrie et al num
0.21941808.16055825.html.plaintext.txt	28	principal aim therapy brief format identification interpersonal conflict difficulty causing helping maintain emotional distress
0.21941808.16055825.html.plaintext.txt	29	client therapist work together find test solution problem intrapsychic practical change encouraged
0.21941808.16055825.html.plaintext.txt	30	adaptation technique therapy adapted people alzheimers disease
0.21941808.16055825.html.plaintext.txt	31	full detail available elsewhere brierley et al num
0.21941808.16055825.html.plaintext.txt	32	main adaptation included delivery individual home involving carer treatment
0.21941808.16055825.html.plaintext.txt	33	four specific psychological area targeted
0.21941808.16055825.html.plaintext.txt	34	autobiographical narrative used strengthen self worth
0.21941808.16055825.html.plaintext.txt	35	important past conflict resonated current difficulty explored resolved
0.21941808.16055825.html.plaintext.txt	36	illness discussed emphasis placed improving social interpersonal relationship including emphasising role partner
0.21941808.16055825.html.plaintext.txt	37	addition individual therapy therapist spent num min session carer listening carers need informing carer therapeutic progress
0.21941808.16055825.html.plaintext.txt	38	implementation technique psychotherapy session lasted num min
0.21941808.16055825.html.plaintext.txt	39	psychotherapy summarised manual shapiro firth num treatment fidelity ensured regular supervision using audiotape
0.21941808.16055825.html.plaintext.txt	40	one session individual therapy rated adherence model using sheffield psychotherapy rating scale shapiro startup num
0.21941808.16055825.html.plaintext.txt	41	scale allows session rated according three main subscales one psychodynamic interpersonal therapy one cognitive behavioural therapy one generic aspect psychotherapy
0.21941808.16055825.html.plaintext.txt	42	intervention showed high score psychodynamic interpersonal therapy generic sub scale low score cognitive behavioural therapy scale confirming adherence model
0.21941808.16055825.html.plaintext.txt	43	assessment patient following assessment carried start therapy end therapy num week recruitment num month follow
0.21941808.16055825.html.plaintext.txt	44	cornell scale depression dementia num item scale assessing depressive symptom people dementia alexopoulos et al num
0.21941808.16055825.html.plaintext.txt	45	rated three point scale absent mild intermittent severe
0.21941808.16055825.html.plaintext.txt	46	score num indicative significant depressive symptom
0.21941808.16055825.html.plaintext.txt	47	mini mental state examination num item measure cognitive function maximum score num point folstein et al num
0.21941808.16055825.html.plaintext.txt	48	normally take num num min complete
0.21941808.16055825.html.plaintext.txt	49	revised memory behavior problem checklist num item questionnaire rating frequency behavioural problem dementia intensity reaction carers teri et al num
0.21941808.16055825.html.plaintext.txt	50	frequency reaction rated six point scale
0.21941808.16055825.html.plaintext.txt	51	bristol activity daily living scale num item questionnaire rated carer num num min buck et al num
0.21941808.16055825.html.plaintext.txt	52	twenty area daily activity rated five point scale problem severe problem
0.21941808.16055825.html.plaintext.txt	53	assessment carers general health questionnaire num item self report questionnaire ass psychological distress psychiatric morbidity goldberg williams num
0.21941808.16055825.html.plaintext.txt	54	completed num min le item rated four point scale
0.21941808.16055825.html.plaintext.txt	55	beck depression inventory num item self report questionnaire ass depression respondent beck et al num
0.21941808.16055825.html.plaintext.txt	56	normally take num num min complete
0.21941808.16055825.html.plaintext.txt	57	item scored num num total score derived
0.21941808.16055825.html.plaintext.txt	58	total score num suggests presence depression
0.21941808.16055825.html.plaintext.txt	59	way coping checklist num item self report questionnaire ass carers coping strategy vitaliano et al num
0.21941808.16055825.html.plaintext.txt	60	normally take num num min complete rated four point scale applicable much used
0.21941808.16055825.html.plaintext.txt	61	global assessment clinician interview based global impression change seven point scale used researcher external supervisor detect change patient num week num month follow guy num
0.21941808.16055825.html.plaintext.txt	62	scale go much improved much worse
0.21941808.16055825.html.plaintext.txt	63	rating completed following discussion research assistant f
0.21941808.16055825.html.plaintext.txt	64	masked group membership treatment control
0.21941808.16055825.html.plaintext.txt	65	num individual took part treatment arm study completed satisfaction survey
0.21941808.16055825.html.plaintext.txt	66	four statement presented patient asked reply
0.21941808.16055825.html.plaintext.txt	67	statistical analysis randomisation calculation sample size analysis used intention treat principle
0.21941808.16055825.html.plaintext.txt	68	effect intervention assessed comparing change mean score time continuous variable using analysis covariance baseline score age covariants
0.21941808.16055825.html.plaintext.txt	69	score required natural logarithmic transformation prior analysis produce satisfactory approximation normal distribution
0.21941808.16055825.html.plaintext.txt	70	score geometric mean detransformed log mean presented rather simple arithmetic mean
0.21941808.16055825.html.plaintext.txt	71	chi squared test appropriate performed categorical measure
0.21941808.16055825.html.plaintext.txt	72	current data upon base power calculation
0.21941808.16055825.html.plaintext.txt	73	previous study marriott et al num group size num sufficient detect statistically significant difference
0.21941808.16055825.html.plaintext.txt	74	based data allowed withdrawal rate num chose recruit num individual group
0.21941808.16055825.html.plaintext.txt	75	part rationale pilot study obtain normative data calculate sample size definitive study
0.21941808.16055825.html.plaintext.txt	76	table num describes study group main result assessment
0.21941808.16055825.html.plaintext.txt	77	num people recruited group
0.21941808.16055825.html.plaintext.txt	78	commonly spouse cared patient num treatment group num control group antidepressant approximately two third group one anticholinesterase drug alzheimers disease
0.21941808.16055825.html.plaintext.txt	79	participant completed study follow
0.21941808.16055825.html.plaintext.txt	80	view table table num participant characteristic participant carer assessment baseline num week num month follow
0.21941808.16055825.html.plaintext.txt	81	significant difference course study outcome measure patient including rating cornell scale mini mental state examination activity daily living scale global rating outcome measure carers
0.21941808.16055825.html.plaintext.txt	82	change course study general health questionnaire beck depression inventory
0.21941808.16055825.html.plaintext.txt	83	trend towards slight improvement carers reaction behavioural problem
0.21941808.16055825.html.plaintext.txt	84	section num way coping checklist showed significant decline p num
0.21941808.16055825.html.plaintext.txt	85	num section rate carers interaction people aid coping
0.21941808.16055825.html.plaintext.txt	86	difference rating patient divided two group mini mental state examination score num
0.21941808.16055825.html.plaintext.txt	87	however evidence carers le cognitive impairment score num benefited treatment blamed le problem section num way coping checklist num month mean value num
0.21941808.16055825.html.plaintext.txt	88	qualitative assessment every participant agreed statement able discus difficulty counsellor became clear
0.21941808.16055825.html.plaintext.txt	89	eighty three per cent agreed following three statement find thing thinking much help feel le frustrated although sometimes felt painful talking past felt good get thing chest felt calm able talk thing difficult talk anyone else
0.21941808.16055825.html.plaintext.txt	90	positive comment patient included
0.21941808.16055825.html.plaintext.txt	91	able confide talk easy friendly way
0.21941808.16055825.html.plaintext.txt	92	drew point never realised
0.21941808.16055825.html.plaintext.txt	93	beneficial dont know
0.21941808.16055825.html.plaintext.txt	94	counsellor allowed bring thing would discussed relative friend
0.21941808.16055825.html.plaintext.txt	95	comment carers included
0.21941808.16055825.html.plaintext.txt	96	provided opportunity discus problem attached full time carer husband
0.21941808.16055825.html.plaintext.txt	97	b also made feel le guilty making time home
0.21941808.16055825.html.plaintext.txt	98	c husband said enjoyed talking gone forgot afterwards would coming
0.21941808.16055825.html.plaintext.txt	99	c chance discus openly wife problem
0.21941808.16055825.html.plaintext.txt	100	num participant received therapy visited num num month recruitment
0.21941808.16055825.html.plaintext.txt	101	semi structured open ended interview carried
0.21941808.16055825.html.plaintext.txt	102	five patient recollection session five confirmed found helpful
0.21941808.16055825.html.plaintext.txt	103	therapist clearly major source support carers patient
0.21941808.16055825.html.plaintext.txt	104	rationale trial chose target area received relatively little attention alzheimers disease
0.21941808.16055825.html.plaintext.txt	105	traditional therapy tended pharmacological nature targeting either cognitive non cognitive symptom tariot num
0.21941808.16055825.html.plaintext.txt	106	non pharmacological intervention aside behavioural technique allen burge et al num concentrated carers psychological approach proven benefit reducing carer strain marriott et al num
0.21941808.16055825.html.plaintext.txt	107	far aware first randomised controlled trial psychotherapeutic intervention people alzheimers disease using standardised outcome measure
0.21941808.16055825.html.plaintext.txt	108	psychotherapeutic approach determined following pilot study adapted individual need participant model dictate
0.21941808.16055825.html.plaintext.txt	109	joint session participant carers merely helped therapist focus symptom considered important distressing
0.21941808.16055825.html.plaintext.txt	110	reason non response finding intervention effect measure reflect core feature illness cognitive function activity daily living surprising
0.21941808.16055825.html.plaintext.txt	111	six session provided psychotherapeutic term low dose treatment may partly explain lack effect
0.21941808.16055825.html.plaintext.txt	112	addition longer study would needed ass likely benefit term stabilisation disease
0.21941808.16055825.html.plaintext.txt	113	beneficial effect carers indicated score way coping checklist showed therapy helped carers providing someone talk caring people mild dementia diminished carers sense self blame
0.21941808.16055825.html.plaintext.txt	114	minimal involvement carers therapy
0.21941808.16055825.html.plaintext.txt	115	beneficial effect patient inferred improvement global rating well
0.21941808.16055825.html.plaintext.txt	116	surprising involvement therapist appeared positive impact accordance experience field
0.21941808.16055825.html.plaintext.txt	117	important therapy adapted use people cognitive impairment
0.21941808.16055825.html.plaintext.txt	118	trend towards improvement carer patient outcome attests potential benefit non pharmacological intervention group
0.21941808.16055825.html.plaintext.txt	119	future study area concentrate specifically approach combine outcome carers care
0.21941808.16055825.html.plaintext.txt	120	interdependency aspiration outcome people alzheimers disease carers emphasised project influence future study area
0.21941808.16055825.html.plaintext.txt	121	limitation sample size small
0.21941808.16055825.html.plaintext.txt	122	outcome measure chosen probably sensitive enough measure marginal improvement
0.21941808.16055825.html.plaintext.txt	123	psychotherapeutic method previously validated older people
0.21941808.16055825.html.plaintext.txt	124	num effective behavioral intervention decreasing dementia related challenging behavior nursing home
0.21941808.16055825.html.plaintext.txt	125	international journal geriatric psychiatry num num num
0.21941808.16055825.html.plaintext.txt	126	conum slinktypedoi crossrefmedline
0.21941808.16055825.html.plaintext.txt	127	num psychodynamic treatment alzheimers disease
0.21941808.16055825.html.plaintext.txt	128	revue medicale de la suisse romande num num num
0.21941808.16055825.html.plaintext.txt	129	et al num inventory measuring depression
0.21941808.16055825.html.plaintext.txt	130	archive general psychiatry num num num
0.21941808.16055825.html.plaintext.txt	131	et al num psychodynamic interpersonal therapy early alzheimers disease
0.21941808.16055825.html.plaintext.txt	132	british journal psychotherapy num num num
0.21941808.16055825.html.plaintext.txt	133	et al num assessment activity daily living dementia development bristol activity daily living scale
0.21941808.16055825.html.plaintext.txt	134	et al num effect donepezil alzheimers disease result multinational trial
0.21941808.16055825.html.plaintext.txt	135	dementia geriatric cognitive disorder num num num
0.21941808.16055825.html.plaintext.txt	136	num psychotherapeutic work people dementia review literature
0.21941808.16055825.html.plaintext.txt	137	british journal medical psychology num num num
0.21941808.16055825.html.plaintext.txt	138	num impact symptom dementia caregiver
0.21941808.16055825.html.plaintext.txt	139	british journal psychiatry num num num
0.21941808.16055825.html.plaintext.txt	140	num mini mental state practical method grading cognitive state patient clinician
0.21941808.16055825.html.plaintext.txt	141	journal psychiatric research num num num
0.21941808.16055825.html.plaintext.txt	142	num user guide general health questionnaire
0.21941808.16055825.html.plaintext.txt	143	et al num controlled trial psychological treatment irritable bowel syndrome
0.21941808.16055825.html.plaintext.txt	144	gastroenteroloy num num num
0.21941808.16055825.html.plaintext.txt	145	et al num randomised controlled trial brief psychological intervention deliberate self poisoning
0.21941808.16055825.html.plaintext.txt	146	num clinical global impression
0.21941808.16055825.html.plaintext.txt	147	ecdeu assessment manual psychopharmacology
0.21941808.16055825.html.plaintext.txt	148	rockville md national institute mental health
0.21941808.16055825.html.plaintext.txt	149	et al num randomised controlled trial psychotherapy patient chronic functional dyspepsia
0.21941808.16055825.html.plaintext.txt	150	gastroenterology num num num
0.21941808.16055825.html.plaintext.txt	151	num form feeling heart psychotherapy
0.21941808.16055825.html.plaintext.txt	152	london tavistock publication
0.21941808.16055825.html.plaintext.txt	153	num music therapy effective intervention dementia meta analytic review literature
0.21941808.16055825.html.plaintext.txt	154	journal music therapy num num num
0.21941808.16055825.html.plaintext.txt	155	et al num effectiveness cognitive behavioural family intervention reducing burden care carers patient alzheimers disease
0.21941808.16055825.html.plaintext.txt	156	british journal psychiatry num num num
0.21941808.16055825.html.plaintext.txt	157	et al num clinical diagnosis alzheimers disease report nincds adrda work group auspex department health human service task force alzheimers disease
0.21941808.16055825.html.plaintext.txt	158	et al num family intervention delay nursing home placement patient alzheimers disease
0.21941808.16055825.html.plaintext.txt	159	num clinical dementia rating cdr current version scoring rule
0.21941808.16055825.html.plaintext.txt	160	num validation therapy dementia
0.21941808.16055825.html.plaintext.txt	161	cochrane database systematic review issue num cdnum
0.21941808.16055825.html.plaintext.txt	162	outcome sheffield psychotherapy project
0.21941808.16055825.html.plaintext.txt	163	british journal psychiatry num num num
0.21941808.16055825.html.plaintext.txt	164	num measuring therapist adherence exploratory therapy
0.21941808.16055825.html.plaintext.txt	165	journal psychotherapy practice research num num num
0.21941808.16055825.html.plaintext.txt	166	et al num reminiscence therapy dementia cochrane review
0.21941808.16055825.html.plaintext.txt	167	chichester john wiley son
0.21941808.16055825.html.plaintext.txt	168	num treatment agitation dementia
0.21941808.16055825.html.plaintext.txt	169	journal clinical psychiatry num num num
0.21941808.16055825.html.plaintext.txt	170	et al num assessment behavioural problem dementia revised memory behavior problem checklist
0.21941808.16055825.html.plaintext.txt	171	psychology aging num num num
0.21941808.16055825.html.plaintext.txt	172	et al num way coping checklist revision psychometric property
0.21941808.16055825.html.plaintext.txt	173	multivariate behavioral research num num num
0.21941808.16055825.html.plaintext.txt	174	num non pharmacological technique
0.21941808.16055825.html.plaintext.txt	175	evidence based dementia practice ed n
0.21941808.16055825.html.plaintext.txt	176	received publication june num num
0.21941808.16055825.html.plaintext.txt	177	revision received october num num
0.21941808.16055825.html.plaintext.txt	178	accepted publication november num num
0.21941808.16055825.html.plaintext.txt	179	highlight issue kimberlie dean bjp num num num
0.22005783.15615772.html.plaintext.txt	0	elevated amyloid s protein assnum late onset alzheimers disease associated single nucleotide polymorphism urokinase type plasminogen activator gene nilufer ertekin tanernum james ronaldnum lars feuknum jonathan princenum michael tuckernumnum linda younkinnum maria hellanum shushant jainnum alyssa hackettnum leah scanlinnum jason kellynum muthoni kihiko ehmannumnum matthew neltnernumnum louis hershnum mark kindynum william markesberynum michael huttonnum mariza de andradenum ronald c
0.22005783.15615772.html.plaintext.txt	1	petersennum neill graff radfordnum steve estusnumnum anthony j
0.22005783.15615772.html.plaintext.txt	2	numdepartment neuroscience numdepartment neurology mayo clinic jacksonville num san pablo road jacksonville fl num usa numcenter genomics bioinformatics karolinska institute stockholm sweden numdepartment physiology numsanders brown center aging university kentucky lexington ky usa numdepartment health science research numdepartment neurology mayo clinic rochester num first street sw rochester mn num usa
0.22005783.15615772.html.plaintext.txt	3	correspondence addressed
0.22005783.15615772.html.plaintext.txt	4	received june num num revised october num num accepted december num num
0.22005783.15615772.html.plaintext.txt	5	given genomic location potential functional relevance ad tested plau candidate gene load
0.22005783.15615772.html.plaintext.txt	6	plau relatively small num bp gene found ntnum chromosome num contig also defined afnum sequence www
0.22005783.15615772.html.plaintext.txt	7	genotyped total seven single nucleotide polymorphism snp spanning whole length gene numnd numth bp
0.22005783.15615772.html.plaintext.txt	8	found evidence significant linkage disequilibrium ld among variant allowing complex genotype analysis
0.22005783.15615772.html.plaintext.txt	9	article initially depict result association analysis plasma assnum plau haplotype num load family ad plau compound genotype forming haplotype pair three case control series
0.22005783.15615772.html.plaintext.txt	10	establishing significant association plau variant two ad phenotype plasma assnum level ad affected status focus single missense mutation larger data set num load family six case control series
0.22005783.15615772.html.plaintext.txt	11	missense mutation variant exon num rsnumplaunum cause proline leucine change pnuml within kringle domain plau junction two s pleated sheet numnum
0.22005783.15615772.html.plaintext.txt	12	minor variant plaunum appear affect plau activity yoshimoto et al
0.22005783.15615772.html.plaintext.txt	13	num reported pnum plau zymogen bind fibrin aggregate le efficiently lnum plau zymogen suggesting possibility altered extracellular plau localization stability
0.22005783.15615772.html.plaintext.txt	14	num shown significant association major cc genotype rsnum load series germany switzerland italy
0.22005783.15615772.html.plaintext.txt	15	article show evidence significant association load minor allele variant discus potential reason discrepancy
0.22005783.15615772.html.plaintext.txt	16	find evidence significant association plau variant extended load family independent case control series using plasma assnum load affected status phenotype
0.22005783.15615772.html.plaintext.txt	17	addition provide functional data plau knock ko mouse supporting role gene as metabolism
0.22005783.15615772.html.plaintext.txt	18	result depicted subsequently
0.22005783.15615772.html.plaintext.txt	19	plau snp frequency plau snp genotype family member plau snp haplotype identified using haplotyping algorithm within computer program simwalknum numnum
0.22005783.15615772.html.plaintext.txt	20	three major plau snp haplotype identified three minor haplotype
0.22005783.15615772.html.plaintext.txt	21	collectively six plau snp haplotype accounted num haplotype family
0.22005783.15615772.html.plaintext.txt	22	frequency plau snp haplotype num ad family summarized table num
0.22005783.15615772.html.plaintext.txt	23	profound ld d num
0.22005783.15615772.html.plaintext.txt	24	num snp except exon num snp five seven snp required construct six haplotype
0.22005783.15615772.html.plaintext.txt	25	table num summarizes ld parameter lewontins standardized disequilibrium coefficient num d dnum estimated founder num extended load family
0.22005783.15615772.html.plaintext.txt	26	profound ld snp easily appreciated table
0.22005783.15615772.html.plaintext.txt	27	exon num deletion mutant complete ld exon num snp
0.22005783.15615772.html.plaintext.txt	28	exon num snp rare yield meaningful result
0.22005783.15615772.html.plaintext.txt	29	thus two snp omitted ld analysis
0.22005783.15615772.html.plaintext.txt	30	ld also estimated mcr mcj uky series within case control yielded similar result
0.22005783.15615772.html.plaintext.txt	31	individual carry two haplotype termed genotype formed two haplotype compound genotype
0.22005783.15615772.html.plaintext.txt	32	described subsequently compound genotype essentially unambiguously defines haplotype pair due profound ld plau snp limited haplotype diversity
0.22005783.15615772.html.plaintext.txt	33	next tested association plasma assnum level plau haplotype
0.22005783.15615772.html.plaintext.txt	34	plau snp ld association plau variant plasma assnum level num load family test association plasma assnum plau variant family member used variance component methodology implemented computer program solar num
0.22005783.15615772.html.plaintext.txt	35	using within pedigree identity state model hopper mathews num plau snp haplotype initially analyzed family member age num num year age group plasma assnum linked chromosome num locus num
0.22005783.15615772.html.plaintext.txt	36	age group significant association plau variant plasma assnum level table num
0.22005783.15615772.html.plaintext.txt	37	inspection data suggested might association plau snp haplotype plasma assnum older family member performed second analysis using family member age
0.22005783.15615772.html.plaintext.txt	38	remarkably group showed significant association plau snp haplotype plasma assnum pnum
0.22005783.15615772.html.plaintext.txt	39	num plau association accounting estimated num total variance assnum
0.22005783.15615772.html.plaintext.txt	40	association plau snp haplotype plasma assnum num load family association plau variant ad three case control series working hypothesis gene variant influencing assnum likely variant influencing risk ad
0.22005783.15615772.html.plaintext.txt	41	determine whether plau variant associated ad case control series analyzed plau snp three independent series obtained mcr mcj uky
0.22005783.15615772.html.plaintext.txt	42	three series entirely composed caucasian subject every ad patient age onset num year
0.22005783.15615772.html.plaintext.txt	43	using computer program gold num analyze plau snp determined profound ld among five plau snp case control series similar load family founder data shown
0.22005783.15615772.html.plaintext.txt	44	important consequence profound ld among five plau snp analyzed relatively common genotype num num subject accounted num compound genotype table num
0.22005783.15615772.html.plaintext.txt	45	table num two haplotype producing six num compound genotype d f j k unambiguous one snp heterozygous
0.22005783.15615772.html.plaintext.txt	46	remaining six genotype produced one one pair six haplotype identified load family table num
0.22005783.15615772.html.plaintext.txt	47	pair could produce category would include least one haplotype rare never identified unambiguously case control series simwalknum haplotype analysis load family
0.22005783.15615772.html.plaintext.txt	48	combination rare plau snp haplotype num num subject load case control series easily identified essentially unambiguous table num
0.22005783.15615772.html.plaintext.txt	49	association plau compound genotype ad three case control series evaluate association ad compound genotype summarized table num performed num test series using monte carlo approach tnum implemented clump determine significance
0.22005783.15615772.html.plaintext.txt	50	three series examined genotype showed significant association ad mcr pnum
0.22005783.15615772.html.plaintext.txt	51	compound genotype tended trend two series analyzed e
0.22005783.15615772.html.plaintext.txt	52	numnum numnum numnum suggesting presence functional variant backbone genotype
0.22005783.15615772.html.plaintext.txt	53	found association plau compound genotype three case control series mcr mcj uky tested association missense plaunum snp larger data set six case control series result depicted subsequently
0.22005783.15615772.html.plaintext.txt	54	finally went back test association plau compound genotype three additional case control series gothenburg gothenburg postmortem scottish find significant association series data shown
0.22005783.15615772.html.plaintext.txt	55	association plaunum snp rsnum plasma assnum level num load family plau variant analyzed rsnum internally termed plaunum relatively common missense snp lead proline leucine change kringle domain plau junction two s pleated sheet numnum shown functional effect fibrin binding plau zymogen num
0.22005783.15615772.html.plaintext.txt	56	determine whether plaunum genotype associated plasma assnum analyzed larger set num extended load family includes original group num family
0.22005783.15615772.html.plaintext.txt	57	take family relationship account analysis performed using variance component methodology implemented program solar num
0.22005783.15615772.html.plaintext.txt	58	member num family change occurs plasma assnum aging complex
0.22005783.15615772.html.plaintext.txt	59	plasma assnum elevated young subject first decrease increase age num
0.22005783.15615772.html.plaintext.txt	60	shown figure num plasma assnum stratified plaunum genotype plotted function age
0.22005783.15615772.html.plaintext.txt	61	non linear analysis analyzed age agenum plaunum genotype cc ct tt cttt interaction among age agenum plaunum genotype variance component framework showed significant age dependent association plasma assnum plaunum ct tt genotype ctxage ttxagenum ctttxagenum agenum significant p num
0.22005783.15615772.html.plaintext.txt	62	main concern determine whether significant age dependent elevation plasma assnum elderly subject associated ct tt pooled cttt genotype performed second analysis family member num year fig
0.22005783.15615772.html.plaintext.txt	63	num analyzed using linear regression variance component framework
0.22005783.15615772.html.plaintext.txt	64	analysis showed ctxage ttxage covariates significant effect pnum
0.22005783.15615772.html.plaintext.txt	65	num respectively num load family table num
0.22005783.15615772.html.plaintext.txt	66	ct tt variable tested single cttt variable ctttxage covariate even significant pnum
0.22005783.15615772.html.plaintext.txt	67	noteworthy even correct fact three age group tested prior analysis num age group summarized table num using conservative approach bonferroni correction still highly significant age related plau genotype effect family overall corrected p value num
0.22005783.15615772.html.plaintext.txt	68	view larger version numk figure num
0.22005783.15615772.html.plaintext.txt	69	plasma assnum member age num load family
0.22005783.15615772.html.plaintext.txt	70	curve shown plaunum rsnum genotype polynomial function age agenum cc genotype nnum b ct genotype nnum c tt genotype nnum d combined cttt genotype nnum
0.22005783.15615772.html.plaintext.txt	71	plasma assnum member num year age num load family
0.22005783.15615772.html.plaintext.txt	72	curve shown plaunum rsnum genotype linear function age cc genotype nnum b ct genotype nnum c tt genotype nnum d combined cttt genotype nnum
0.22005783.15615772.html.plaintext.txt	73	multivariate regression analysis member num year age num load family basis finding re analyzed haplotypic association num load family subject num year age association even significant pnum
0.22005783.15615772.html.plaintext.txt	74	subsequently went back analyze haplotype num family age group accounted num total variance plasma assnum phenotype also significant pnum
0.22005783.15615772.html.plaintext.txt	75	association plaunum snp rsnum ad six case control series initially analyzed three series two group mcr mcj series mayo clinic uky series university kentucky
0.22005783.15615772.html.plaintext.txt	76	analyze missense plaunum snp obtained three series collaborator karolinska institute gothenburg load control series autopsy confirmed load series gothenburg scottish early onset ad load series
0.22005783.15615772.html.plaintext.txt	77	mcr series significant association observed ct pnum
0.22005783.15615772.html.plaintext.txt	78	num genotype odds ratio num
0.22005783.15615772.html.plaintext.txt	79	tt genotype enriched load patient mcr series enrichment achieve significance
0.22005783.15615772.html.plaintext.txt	80	uky series first series plaunum analyzed tt genotype showed significant pnum
0.22005783.15615772.html.plaintext.txt	81	num association load num
0.22005783.15615772.html.plaintext.txt	82	three four remaining series mcj gothenburg scottish showed non significant enrichment ct andor tt genotype table num occur autopsy confirmed gothenburg series
0.22005783.15615772.html.plaintext.txt	83	testing homogeneity breslow day showed evidence heterogeneity among six series pnum
0.22005783.15615772.html.plaintext.txt	84	num meta analysis gave pooled estimate cttt genotype num
0.22005783.15615772.html.plaintext.txt	85	or plaunum rsnum cttt versus cc genotype case control series
0.22005783.15615772.html.plaintext.txt	86	or shown num confidence interval
0.22005783.15615772.html.plaintext.txt	87	ad case scottish series early age onset
0.22005783.15615772.html.plaintext.txt	88	others load versus control series
0.22005783.15615772.html.plaintext.txt	89	analysis as plau knockout mouse finding plau variant associated elevated plasma assnum predicts plasma assnum elevated ko mouse lacking functional plau gene
0.22005783.15615772.html.plaintext.txt	90	test analyzed plasma assnum num plau ko mouse num num control mouse genetic background
0.22005783.15615772.html.plaintext.txt	91	comparison ko mouse lacking functional neprilysin gene known involved as degradation num analyzed parallel
0.22005783.15615772.html.plaintext.txt	92	compared control num num month old plau ko mouse showed highly significant increase plasma assnum pnum
0.22005783.15615772.html.plaintext.txt	93	num mann whitney test fig
0.22005783.15615772.html.plaintext.txt	94	plasma assnum also increased pnum
0.22005783.15615772.html.plaintext.txt	95	num month plasma assnum assnum increased difference ko control mouse appeared increase small number mouse analyzed two plau ko versus six control
0.22005783.15615772.html.plaintext.txt	96	thus plau gene influence plasma assnum data suggest effect may become pronounced aging consistent genetic analysis load family
0.22005783.15615772.html.plaintext.txt	97	numb showed detectable increase plau ko mouse compared control mouse
0.22005783.15615772.html.plaintext.txt	98	implication result presented discussion
0.22005783.15615772.html.plaintext.txt	99	view larger version numk figure num
0.22005783.15615772.html.plaintext.txt	100	plasma assnum b plasma assnum analyzed sandwich elisa previously described num
0.22005783.15615772.html.plaintext.txt	101	ko mouse homozygous null allele
0.22005783.15615772.html.plaintext.txt	102	result normalized as present num num month old control wild type mouse
0.22005783.15615772.html.plaintext.txt	103	value shown mean plus minus se
0.22005783.15615772.html.plaintext.txt	104	number analyzed num num month old plau ko num nnum control mouse nnum num month old plau ko mouse nnum control mouse nnum mouse num num month old neprilysin ko num nnum control mouse nnum
0.22005783.15615772.html.plaintext.txt	105	neprilysin ko mouse used additional positive control num
0.22005783.15615772.html.plaintext.txt	106	mouse plasma assnum assnum b increased
0.22005783.15615772.html.plaintext.txt	107	view larger version numk figure num
0.22005783.15615772.html.plaintext.txt	108	brain assnum b brain assnum extracted directly num formic acid
0.22005783.15615772.html.plaintext.txt	109	brain assnum assnum analyzed elisa following direct extraction formic acid neutralization previously described num
0.22005783.15615772.html.plaintext.txt	110	value shown mean plus minus se
0.22005783.15615772.html.plaintext.txt	111	number analyzed num num month old plau ko mouse nnum control mouse nnum num month old plau ko mouse nnum control mouse nnum num num month old neprilysin ko mouse nnum control mouse nnum
0.22005783.15615772.html.plaintext.txt	112	additional positive control investigated neprilysin ko mouse num
0.22005783.15615772.html.plaintext.txt	113	mouse brain assnum assnum increased previously reported num
0.22005783.15615772.html.plaintext.txt	114	numb also increased neprilysin ko mouse
0.22005783.15615772.html.plaintext.txt	115	analyzed common missense snp plaunum rsnum larger set num family six case control series include initial series analyzed
0.22005783.15615772.html.plaintext.txt	116	extended family snp associated age related elevation plasma as level individual num year age
0.22005783.15615772.html.plaintext.txt	117	plasma as display complex characteristic appears decline age related fashion num year age increase thereafter
0.22005783.15615772.html.plaintext.txt	118	characteristic much pronounced subject ct tt genotype plaunum
0.22005783.15615772.html.plaintext.txt	119	also noteworthy significance association plau haplotype enhanced num age group analyzed separately num family expected table num
0.22005783.15615772.html.plaintext.txt	120	finding age related increase as also evident plasma as plau ko mouse consistent finding human
0.22005783.15615772.html.plaintext.txt	121	mouse significantly higher plasma as level compared wild type littermates however brain as level show significant difference
0.22005783.15615772.html.plaintext.txt	122	finding could several explanation
0.22005783.15615772.html.plaintext.txt	123	may suggest plau variant influence ad effect plasma brain assnum
0.22005783.15615772.html.plaintext.txt	124	conceivable likely plau influence plasma brain as way evident ko mouse
0.22005783.15615772.html.plaintext.txt	125	thus plau may greater influence secreted cell associated as
0.22005783.15615772.html.plaintext.txt	126	brain as cell associated num effect secreted as easily detected plasma could hard detect brain
0.22005783.15615772.html.plaintext.txt	127	alternatively compensatory change triggered plau ko may maintain brain as effectively plasma as
0.22005783.15615772.html.plaintext.txt	128	analyzed plaunum six case control series using meta analysis
0.22005783.15615772.html.plaintext.txt	129	num reported meta analysis published genetic association various disease phenotype
0.22005783.15615772.html.plaintext.txt	130	num reported association investigated meta analysis eight showed significant association replicated original study or num
0.22005783.15615772.html.plaintext.txt	131	basis finding author recommended large collaborative genetic association study encouraged sound study positive negative published report association include meta analysis available data
0.22005783.15615772.html.plaintext.txt	132	meta analysis plaunum snp six case control series indicate plaunum cttt associated modest ornum
0.22005783.15615772.html.plaintext.txt	133	num marginally significant pnum
0.22005783.15615772.html.plaintext.txt	134	result similar lohmueller et al
0.22005783.15615772.html.plaintext.txt	135	num whose meta analysis identified many common genetic variant modest significant effect disease phenotype
0.22005783.15615772.html.plaintext.txt	136	two group previously published finding snp numnum
0.22005783.15615772.html.plaintext.txt	137	num found significant association three case control series germany switzerland italy whereas myers et al
0.22005783.15615772.html.plaintext.txt	138	num find evidence association plau snp analyzed including plaunum
0.22005783.15615772.html.plaintext.txt	139	interestingly former found series cc genotype associated increased risk load whereas series ct tt genotype
0.22005783.15615772.html.plaintext.txt	140	furthermore another group germany also found significant association ct tt genotype m
0.22005783.15615772.html.plaintext.txt	141	riemenschneider personal communication
0.22005783.15615772.html.plaintext.txt	142	thus clearly heterogeneity among finding one group significant result direction series m
0.22005783.15615772.html.plaintext.txt	143	riemenschneider another finding significance common genotype num third group finding significance
0.22005783.15615772.html.plaintext.txt	144	clearly result need analyzed one meta analysis subsequent publication
0.22005783.15615772.html.plaintext.txt	145	nonetheless demonstrated lohmueller et al
0.22005783.15615772.html.plaintext.txt	146	num discrepancy frequent among study common genetic variant complex disease particularly effect size modest
0.22005783.15615772.html.plaintext.txt	147	many reason discrepancy including small sample size gene gene gene environment interaction modelled study intra sample heterogeneitypopulation substructure analysis marker variant instead disease variant varying degree ld
0.22005783.15615772.html.plaintext.txt	148	tried minimize factor gathering large series age matching mayo clinic series choosing variant likely functional still plausible problem may contributing inter series variation observed plaunum
0.22005783.15615772.html.plaintext.txt	149	indeed association plaunum marginally significant confidence interval num
0.22005783.15615772.html.plaintext.txt	150	nonetheless statistical result considered presence evidence family animal data effect plau as understanding likely exist variant plau affect risk ad suggested compound genotype data case control series
0.22005783.15615772.html.plaintext.txt	151	furthermore given likely presence important variant gene vrnum ide finding highly significant p value variant modest effect complex disease may need await identification functional mutation multiple gene analysis multiple large series
0.22005783.15615772.html.plaintext.txt	152	recently published finding significant association two gene chromosome num numnum ide vrnum
0.22005783.15615772.html.plaintext.txt	153	tested key variant three gene find evidence ld
0.22005783.15615772.html.plaintext.txt	154	joint analysis key variant demonstrates separate independent effect
0.22005783.15615772.html.plaintext.txt	155	variant vrnum account linkage chromosome num
0.22005783.15615772.html.plaintext.txt	156	plau variant different two age related effect manifest strongly age num
0.22005783.15615772.html.plaintext.txt	157	thus gene appears act independently one another via apparent separate mechanism
0.22005783.15615772.html.plaintext.txt	158	unequivocal effect gene pathogenesis ad await identification functional variant testing large series finding provide evidence existence load risk variant affect as within andor vicinity gene
0.22005783.15615772.html.plaintext.txt	159	addition extended load family six different case control series analyzed study
0.22005783.15615772.html.plaintext.txt	160	series named follows mayo clinic rochester mcr mayo clinic jacksonville mcj university kentucky uky gothenburg gothenburg postmortem scottish
0.22005783.15615772.html.plaintext.txt	161	mcr sample collected part mayo clinic alzheimers disease patient registry community based prospective registry mayo clinic rochester memory disorder clinic case control series
0.22005783.15615772.html.plaintext.txt	162	mcj sample collected mayo clinic jacksonville memory disorder clinic
0.22005783.15615772.html.plaintext.txt	163	uky series collected part university kentucky memory disorder clinic brain program
0.22005783.15615772.html.plaintext.txt	164	mcr mcj uky series consisted caucasian subject united state
0.22005783.15615772.html.plaintext.txt	165	gothenburg gothenburg postmortem series consisted swedish ad case recruited prospective longitudinal study patient dementia molndal prospective dementia study
0.22005783.15615772.html.plaintext.txt	166	swedish control consisted healthy volunteer gothenburg autopsy case gothenburg postmortem
0.22005783.15615772.html.plaintext.txt	167	finally scottish sample composed eoad patient lothian psychiatric case register scottish control consisting local church congregation volunteer lothian region
0.22005783.15615772.html.plaintext.txt	168	eoad material selected non familial case common presenilin mutation screened
0.22005783.15615772.html.plaintext.txt	169	positive found discarded test set
0.22005783.15615772.html.plaintext.txt	170	clinical ad diagnosis series made according nincds adrda criterion num
0.22005783.15615772.html.plaintext.txt	171	neuropathologically diagnosed ad patient gothenburg postmortem also fulfilled clinical nincds criterion probable ad met neuropathological cerad criterion definitive ad
0.22005783.15615772.html.plaintext.txt	172	ad series except scottish series age onset num year
0.22005783.15615772.html.plaintext.txt	173	study approved appropriate institutional review board appropriate informed consent obtained participant
0.22005783.15615772.html.plaintext.txt	174	identification genotyping plau snp eleven member selected num extended load family gave linkage signal chromosome num num
0.22005783.15615772.html.plaintext.txt	175	genomic dna five family member two probands high plasma as level two member two married spouse low level sequenced
0.22005783.15615772.html.plaintext.txt	176	sample came four different family three probands extreme high as level
0.22005783.15615772.html.plaintext.txt	177	intronic primer flanking plau exon used pcr amplification
0.22005783.15615772.html.plaintext.txt	178	coding region num bp num untranslated region num utr num bp num utr plau sequenced
0.22005783.15615772.html.plaintext.txt	179	sequencing done via semi automated fluorescent method using abinum sequencer associated factura software package
0.22005783.15615772.html.plaintext.txt	180	snp database national center biotechnology information ncbi url httpwww
0.22005783.15615772.html.plaintext.txt	181	govsnp university washington fred hutchinson cancer research center uw fhcrc url httppga
0.22005783.15615772.html.plaintext.txt	182	edu also screened snp identification
0.22005783.15615772.html.plaintext.txt	183	snp identified via sequencing effort used analysis well rare missense snp exon num identified bioinformatics screen
0.22005783.15615772.html.plaintext.txt	184	seven snp thus identified analyzed haplotype analysis determined two missense exon num snp exon num deletion snp yielded redundant information
0.22005783.15615772.html.plaintext.txt	185	therefore remainder analysis carried five snp
0.22005783.15615772.html.plaintext.txt	186	plau snp frequency estimated mcj mcr uky series num load family summarized table num
0.22005783.15615772.html.plaintext.txt	187	snp tested group rare exon num snp hardy weinberg disequilibrium control group mcj mcr
0.22005783.15615772.html.plaintext.txt	188	snp used compound genotype analysis
0.22005783.15615772.html.plaintext.txt	189	addition exon num snp hardy weinberg disequilibrium mcj control series
0.22005783.15615772.html.plaintext.txt	190	dna extracted peripheral blood leukocyte using routine method
0.22005783.15615772.html.plaintext.txt	191	gothenburg gothenburg postmortem scottish series genotyped using dynamic allele specific hybridization numnum
0.22005783.15615772.html.plaintext.txt	192	series genotyped abinum instrument using taqman technology
0.22005783.15615772.html.plaintext.txt	193	taqman assay software designing primer probe implemented within abi prism num ht sequence detection system utilized
0.22005783.15615772.html.plaintext.txt	194	ncbi genbank plau gene sequence afnum used
0.22005783.15615772.html.plaintext.txt	195	pedigree structure phenotypic genotypic information maintained pedsys num httpwww
0.22005783.15615772.html.plaintext.txt	196	orgsfbrpublicsoftwarepedsyspedsys
0.22005783.15615772.html.plaintext.txt	197	html also produced output file analysis performed solar explained subsequently
0.22005783.15615772.html.plaintext.txt	198	analysis ld among snp measured ld snp within num extended load family using gold program num
0.22005783.15615772.html.plaintext.txt	199	program determines various pairwise statistical parameter ld lewontins standardized disequilibrium coefficient num d dnum
0.22005783.15615772.html.plaintext.txt	200	ld detected founder married in using expectation maximization algorithm slatkin excoffier num
0.22005783.15615772.html.plaintext.txt	201	also detected ld within ad control mcr mcj uky series using program
0.22005783.15615772.html.plaintext.txt	202	test association plau snp haplotype plasma as level load family estimated haplotype five plau snp genotyped member ten load family using gold num simwalknum num
0.22005783.15615772.html.plaintext.txt	203	highly significant ld among five plau snp crossover event observed
0.22005783.15615772.html.plaintext.txt	204	num extended load family tested association plau haplotype plasma assnum phenotype using variance component method implemented computer program solar num
0.22005783.15615772.html.plaintext.txt	205	method described detail elsewhere num estimate amount variance quantitative trait owing residual genetic factor gnum shared family environment numh individual specific random environmental factor nume based phenotype covariance arbitrary relative pair
0.22005783.15615772.html.plaintext.txt	206	covariance matrix take form
0.22005783.15615772.html.plaintext.txt	207	num matrix kinship coefficient describing polygenic factor identity matrix describing sporadic environmental factor h household matrix
0.22005783.15615772.html.plaintext.txt	208	matrix whose ijth element equal num individual j share specified environment num otherwise
0.22005783.15615772.html.plaintext.txt	209	family collection largely composed extended pedigree measured plasma as member family single batch elisa
0.22005783.15615772.html.plaintext.txt	210	rigorously account possible assay batch batch variation may affect variance plasma as included household matrix model
0.22005783.15615772.html.plaintext.txt	211	almost individual family measured one batch household matrix included element equal num individual extended family num otherwise
0.22005783.15615772.html.plaintext.txt	212	realize may overly conservative
0.22005783.15615772.html.plaintext.txt	213	collection largely weighted towards family high as segregating within family
0.22005783.15615772.html.plaintext.txt	214	given shared family effect household overlap kinship may corrected underestimated shared genetic effect including household term model
0.22005783.15615772.html.plaintext.txt	215	scalar gnum hnum enum estimated using maximum likelihood
0.22005783.15615772.html.plaintext.txt	216	formulate association model plau snp haplotype used within pedigree association model hopper mathews num
0.22005783.15615772.html.plaintext.txt	217	model matrix allelic sharing within pedigree ij defined ijnum individual j pedigree share allele haplotype identical state ijnumnum individual j pedigree share one allele identical state ijnum otherwise
0.22005783.15615772.html.plaintext.txt	218	association model solar estimate variance quantitative trait owing association anum residual genetic factor gnum household effect hnum environmental effect enum
0.22005783.15615772.html.plaintext.txt	219	null model association anum fixed zero
0.22005783.15615772.html.plaintext.txt	220	difference lognum likelihood two model produce test statistic distribution lod score genetic linkage analysis
0.22005783.15615772.html.plaintext.txt	221	one degree freedom two model association fixed association tested one sided test performed
0.22005783.15615772.html.plaintext.txt	222	test association load case control series clump case control series tested association plau compound genotype load using clump
0.22005783.15615772.html.plaintext.txt	223	clump program num measure statistical significance variety numxm contingency table simulation
0.22005783.15615772.html.plaintext.txt	224	employed tnum test within clump analyzes raw numxm table m total number category
0.22005783.15615772.html.plaintext.txt	225	application clump numxm table consisted two diagnostic category m genotypic category corresponding unique combination genotype five plau snp
0.22005783.15615772.html.plaintext.txt	226	as analysis plasma assnum assnum measured previously described num
0.22005783.15615772.html.plaintext.txt	227	relationship plasma assnum age plaunum genotype load family member initially analyzed fitting polynomial regression curve separately family member rsnum cc ct tt cttt genotype using num logassnum dependent variable age agenum independent variable
0.22005783.15615772.html.plaintext.txt	228	analysis showed genotype specific age related effect plasma assnum level indicated plasma assnum increase aging beginning age num individual ct tt genotype
0.22005783.15615772.html.plaintext.txt	229	used num num year age group previous study found linkage plasma as level locus chromosome num num
0.22005783.15615772.html.plaintext.txt	230	described previously num num year age group initially chosen observation plasma as elevated individual num num year old
0.22005783.15615772.html.plaintext.txt	231	addition plasma as appears complex likely deposition related change individual ad num age group
0.22005783.15615772.html.plaintext.txt	232	study determined significant age related effect plaunum genotype plasma as level individual num year depicted subsequent
0.22005783.15615772.html.plaintext.txt	233	thus analysis performed age num num year old num year group
0.22005783.15615772.html.plaintext.txt	234	test association plaunum rsnum snp plasma as level load family applied variance component methodology implemented software package solar num estimate effect covariates plasma as level controlling pairwise genetic relationship shared family effect among family member extended load pedigree
0.22005783.15615772.html.plaintext.txt	235	tested association plaunum genotype plasma as performing multivariate regression analysis including kinship identity household matrix described earlier model
0.22005783.15615772.html.plaintext.txt	236	tested two different model
0.22005783.15615772.html.plaintext.txt	237	significance coefficient covariates tested using polygenic screen option solar provides p value coefficient comparing model includes covariate model excludes
0.22005783.15615772.html.plaintext.txt	238	option cause covariates stay model regardless significance
0.22005783.15615772.html.plaintext.txt	239	model num covariates tested ct tt genotype age ct genotypexage tt genotypexage
0.22005783.15615772.html.plaintext.txt	240	model num ct tt genotype pooled single cttt variable encoded one subject ct tt genotype zero cc genotype
0.22005783.15615772.html.plaintext.txt	241	analysis performed family member num year age
0.22005783.15615772.html.plaintext.txt	242	selected subset determined age related increase plasma assnum level age num individual plaunum genotype ct tt
0.22005783.15615772.html.plaintext.txt	243	analysis performed as value second time excluding two extreme outlier plasma as level plus minus num sd beyond mean
0.22005783.15615772.html.plaintext.txt	244	plaunum ctxage plaunum ctttxage still significant variable model num num respectively excluding outlier
0.22005783.15615772.html.plaintext.txt	245	determine age related effect plaunum genotype plaunum genotype plasma assnum level load family member age fitted two non linear regression model taking account variance component described earlier
0.22005783.15615772.html.plaintext.txt	246	model num family member age agenum plaunum ctxagenum plaunum ttxagenum tested covariates addition age plaunum ct plaunum tt plaunum ctxage plaunum ttxage
0.22005783.15615772.html.plaintext.txt	247	model num agenum plaunum ctttxagenum included covariates besides age plaunum cttt plaunum ctttxage
0.22005783.15615772.html.plaintext.txt	248	rationale testing non linear model described detail main text
0.22005783.15615772.html.plaintext.txt	249	logistic regression analysis test association plaunum rsnum snp case control logistic regression analysis implemented sa version num utilized test association ad plaunum genotype
0.22005783.15615772.html.plaintext.txt	250	initially model estimated tested effect plaunum ct tt genotype separately utilized
0.22005783.15615772.html.plaintext.txt	251	result analysis suggested similar risky estimate genotype
0.22005783.15615772.html.plaintext.txt	252	given result plaunum tt genotype relatively rare second model fitted ct tt genotype combined one variable cttt coded num ct tt genotype num cc genotype
0.22005783.15615772.html.plaintext.txt	253	meta analysis plaunum rsnum snp num case control series using genotype count plaunum cttt versus cc genotype ad case control six series described article performed meta analysis implemented statsdirect statistical package
0.22005783.15615772.html.plaintext.txt	254	breslow day test performed test heterogeneity among sample
0.22005783.15615772.html.plaintext.txt	255	pooled estimate calculated using fixed effect random effect model implemented mantel haenszel dersimonian laird test respectively
0.22005783.15615772.html.plaintext.txt	256	analysis plasma brain as plau ko mouse plasma assnum assnum analyzed sandwich elisa previously described num
0.22005783.15615772.html.plaintext.txt	257	brain assnum assnum analyzed elisa following direct extraction formic acid neutralization previously described num
0.22005783.15615772.html.plaintext.txt	258	ko mouse homozygous null allele
0.22005783.15615772.html.plaintext.txt	259	result normalized as present num num month old control wild type mouse
0.22005783.15615772.html.plaintext.txt	260	number analyzed follows num num month old plau ko mouse num nnum control mouse nnum num month old plau ko mouse nnum control nnum mouse num num month old neprilysin ko mouse num nnum control mouse nnum
0.22005783.15615772.html.plaintext.txt	261	neprilysin ko mouse used additional positive control num
0.22005783.15615772.html.plaintext.txt	262	evaluate brain assnum assnum used method previously employed demonstrate endogenous brain assnum increase transgenic mouse expressing presenilin num mutation linked early onset familial ad num
0.22005783.15615772.html.plaintext.txt	263	num susceptibility locus alzheimers disease chromosome num
0.22005783.15615772.html.plaintext.txt	264	num plasmin system induced degrades amyloid beta aggregate
0.22005783.15615772.html.plaintext.txt	265	num alzheimers disease down syndrome sharing unique cerebrovascular amyloid fibril protein
0.22005783.15615772.html.plaintext.txt	266	num amyloid beta protein beta alzheimers disease brain
0.22005783.15615772.html.plaintext.txt	267	biochemical immunocytochemical analysis antibody specific form ending beta num beta numnum
0.22005783.15615772.html.plaintext.txt	268	num mutation beta amyloid precursor protein familial alzheimers disease increase beta protein production
0.22005783.15615772.html.plaintext.txt	269	num increased percentage long amyloid beta protein secreted familial amyloid beta protein precursor beta appnum mutant
0.22005783.15615772.html.plaintext.txt	270	num familial alzheimers disease linked presenilin num variant elevate abetanum numnum num ratio vitro vivo
0.22005783.15615772.html.plaintext.txt	271	num increased amyloid betanumnum brain mouse expressing mutant presenilinnum
0.22005783.15615772.html.plaintext.txt	272	num correlative memory deficit abeta elevation amyloid plaque transgenic mouse
0.22005783.15615772.html.plaintext.txt	273	num secreted amyloid beta protein similar senile plaque alzheimers disease increased vivo presenilin num num app mutation linked familial alzheimers disease
0.22005783.15615772.html.plaintext.txt	274	num mutant presenilins alzheimers disease increase production num residue amyloid beta protein transfected cell transgenic mouse
0.22005783.15615772.html.plaintext.txt	275	num solution structure kringle domain urokinase type plasminogen activator
0.22005783.15615772.html.plaintext.txt	276	num characterization single chain urokinase type plasminogen activator novel amino acid substitution kringle structure
0.22005783.15615772.html.plaintext.txt	277	num association late onset alzheimer disease genotype plau gene encoding urokinase type plasminogen activator chromosome numqnum
0.22005783.15615772.html.plaintext.txt	278	num physiological consequence loss plasminogen activator gene function mouse
0.22005783.15615772.html.plaintext.txt	279	num computer program multilocus haplotyping general pedigree
0.22005783.15615772.html.plaintext.txt	280	num descent graph pedigree analysis application haplotyping location score marker sharing statistic
0.22005783.15615772.html.plaintext.txt	281	num evolutionary dynamic complex polymorphism
0.22005783.15615772.html.plaintext.txt	282	num multipoint quantitative trait linkage analysis general pedigree
0.22005783.15615772.html.plaintext.txt	283	num extension multivariate normal model pedigree analysis
0.22005783.15615772.html.plaintext.txt	284	num gold graphical overview linkage disequilibrium
0.22005783.15615772.html.plaintext.txt	285	bioinformatics num num num
0.22005783.15615772.html.plaintext.txt	286	num monte carlo test association disease allele highly polymorphic locus
0.22005783.15615772.html.plaintext.txt	287	num metabolic regulation brain abeta neprilysin
0.22005783.15615772.html.plaintext.txt	288	num block limited haplotype diversity revealed high resolution scanning human chromosome num
0.22005783.15615772.html.plaintext.txt	289	num high resolution haplotype structure human genome
0.22005783.15615772.html.plaintext.txt	290	num structure haplotype block human genome
0.22005783.15615772.html.plaintext.txt	291	num age dependent change brain csf plasma amyloid s protein tgnum transgenic mouse model alzheimers disease
0.22005783.15615772.html.plaintext.txt	292	num meta analysis genetic association study support contribution common variant susceptibility common disease
0.22005783.15615772.html.plaintext.txt	293	num variation urokinase plasminogen activator gene explain chromosome num linkage signal late onset ad
0.22005783.15615772.html.plaintext.txt	294	num fine mapping alpha catenin gene quantitative trait locus chromosome num late onset alzheimers disease pedigree
0.22005783.15615772.html.plaintext.txt	295	num genetic variant haplotype block spanning ide significantly associated plasma assnum level risk alzheimers disease
0.22005783.15615772.html.plaintext.txt	296	num clinical diagnosis alzheimers disease report nincds adrda work group auspex department health human service task force alzheimers disease
0.22005783.15615772.html.plaintext.txt	297	num dynamic allele specific hybridization
0.22005783.15615772.html.plaintext.txt	298	new method scoring single nucleotide polymorphism
0.22005783.15615772.html.plaintext.txt	299	num robust accurate single nucleotide polymorphism genotyping dynamic allele specific hybridization dash design criterion assay validation
0.22005783.15615772.html.plaintext.txt	300	num pedsys pedigree data management system version num
0.22005783.15615772.html.plaintext.txt	301	population genetics laboratory department genetics southwest foundation biomedical research san antonio tx
0.22005783.15615772.html.plaintext.txt	302	num maximum likelihood estimation molecular haplotype frequency diploid population
0.22522588.11983636.html.plaintext.txt	0	genetic host factor dementia down syndrome nicole schupf phd
0.22522588.11983636.html.plaintext.txt	1	laboratory epidemiology new york state institute basic research developmental disability staten island
0.22522588.11983636.html.plaintext.txt	2	center columbia university college physician surgeon new york usa
0.22522588.11983636.html.plaintext.txt	3	correspondence nicole schupf phd new york state institute basic research num forest hill road staten island ny num
0.22522588.11983636.html.plaintext.txt	4	tel num num num num fax num num num num e mail nsnumatcolumbia
0.22522588.11983636.html.plaintext.txt	5	declaration interest grant iirg num num rgnum num num alzheimers association federal grant agnum hdnum pnumagnum fund new york state office mental retardation developmental disability
0.22522588.11983636.html.plaintext.txt	6	presented part blake marsh lecture annual meeting royal college psychiatrist num july num edinburgh
0.22522588.11983636.html.plaintext.txt	7	aim identify factor influence age onset dementia down syndrome
0.22522588.11983636.html.plaintext.txt	8	method study factor influence formation beta amyloid as reviewed including atypical karyotype susceptibility genotype gender oestrogen deficiency individual difference as peptide level
0.22522588.11983636.html.plaintext.txt	9	result apolipoprotein e num allele oestrogen deficiency high level assnum num peptide associated earlier onset dementia atypical karyotype apolipoprotein e num allele associated reduced mortality reduced risk dementia
0.22522588.11983636.html.plaintext.txt	10	conclusion factor influence as level rather overexpression app may account difference age onset dementia down syndrome
0.22522588.11983636.html.plaintext.txt	11	several line evidence suggest deposition as num important initial step pathogenesis alzheimers disease
0.22522588.11983636.html.plaintext.txt	12	assnum num aggregate rapidly deposited earlier alzheimers disease plaque assnum num iwatsubo et al num
0.22522588.11983636.html.plaintext.txt	13	mutation gene app presenilin psnumnum gene associated early onset familial alzheimers disease selective increase assnum num borchelt et al num mann et al num scheuner et al num kosaka et al num younkin num
0.22522588.11983636.html.plaintext.txt	14	brain level assnum num increase early development alzheimers disease strongly correlated cognitive decline cummings cotman num naslund et al num plasma level assnum num higher elderly people subsequently develop alzheimers disease remain free dementia mayeux et al num
0.22522588.11983636.html.plaintext.txt	15	virtually individual down syndrome neuropathological change consistent diagnosis alzheimers disease time reach num year age including deposition as diffuse neuritic plaque wisniewski h
0.22522588.11983636.html.plaintext.txt	16	et al num mann num develop dementia end seventh decade life lai williams num
0.22522588.11983636.html.plaintext.txt	17	despite nearly universal occurrence alzheimers disease pathology middle age wide variation age onset dementia
0.22522588.11983636.html.plaintext.txt	18	prevalence alzheimers disease age num ranged num num zigman et al num
0.22522588.11983636.html.plaintext.txt	19	study shown average age onset dementia num num year range num num year lai williams num prasher krishnan num
0.22522588.11983636.html.plaintext.txt	20	methodological problem may account variation estimated prevalence alzheimers disease down syndrome
0.22522588.11983636.html.plaintext.txt	21	diagnosis alzheimers disease population requires documentation clinically significant decline cognitive adaptive competence previously attained level performance documentation absence condition might cause decline performance aylward et al num
0.22522588.11983636.html.plaintext.txt	22	requirement particularly difficult address adult down syndrome given lifelong intellectual disability
0.22522588.11983636.html.plaintext.txt	23	wide range premorbid level performance associated difference level intellectual disability requires specific criterion clinically significant decline indicative dementia level function beginning developed
0.22522588.11983636.html.plaintext.txt	24	yet consensus set cognitive assessment task diagnostic criterion existing cognitive assessment battery differentiate adult down syndrome dementia early stage
0.22522588.11983636.html.plaintext.txt	25	presently diagnosis alzheimers disease adult down syndrome made clinically relatively late stage disease without systematic cognitive functional testing time
0.22522588.11983636.html.plaintext.txt	26	neuropathological manifestation alzheimers disease down syndrome attributed triplication overexpression gene app located chromosome num rumble et al num increased risk dementia down syndrome may mediated increased substrate cellular production as peptide
0.22522588.11983636.html.plaintext.txt	27	recent neuropathological study shown diffuse plaque prevalent alzheimer type lesion seen individual down syndrome age num associated dementia
0.22522588.11983636.html.plaintext.txt	28	diffuse plaque contain non fibrillar amyloid appear younger age neuritic plaque associated neuronal degeneration appear affect structure function neuron
0.22522588.11983636.html.plaintext.txt	29	contrast increase number neuritic plaque containing substantial amount fibrillised as peptide observed adult down syndrome predominantly num year age associated neuronal degeneration loss function wisniewski
0.22522588.11983636.html.plaintext.txt	30	examination age specific prevalence dementia down syndrome support hypothesis clinical manifestation alzheimers disease down syndrome closely associated development fibrillised plaque lai williams num visser et al num holland et al num lai et al num see fig
0.22522588.11983636.html.plaintext.txt	31	although prevalence study employed varying sampling diagnostic method remarkable agreement across study risk alzheimers disease increase primarily num year age
0.22522588.11983636.html.plaintext.txt	32	addition adult down syndrome develop dementia even reach age presence high density neuritic plaque presumed
0.22522588.11983636.html.plaintext.txt	33	thus triplication gene app may serve increase diffuse plaque adult down syndrome factor distinct app triplication must account individual difference susceptibility formation fibrillised plaque wide range age onset dementia
0.22522588.11983636.html.plaintext.txt	34	central task epidemiology dementia down syndrome identify factor may influence risk alzheimers disease accelerating formation as
0.22522588.11983636.html.plaintext.txt	35	several avenue investigation suggested existing finding review role atypical karyotype b genetic susceptibility factor c gender oestrogen deficiency d individual difference as peptide level
0.22522588.11983636.html.plaintext.txt	36	view larger version numk fig
0.22522588.11983636.html.plaintext.txt	37	num age specific prevalence dementia adult down syndrome
0.22522588.11983636.html.plaintext.txt	38	data lai williams num data visser et al num data lai et al num
0.22522588.11983636.html.plaintext.txt	39	data holland et al num
0.22522588.11983636.html.plaintext.txt	40	polymorphism gene apolipoprotein e apoe associated risk common late onset alzheimers disease onset num year age
0.22522588.11983636.html.plaintext.txt	41	three common variant gene apoe encoded three allele num num num
0.22522588.11983636.html.plaintext.txt	42	numerous cross sectional case control study patient alzheimers disease found significantly likely peer one copy apoe num allele corder et al num mayeux et al num saunders et al num
0.22522588.11983636.html.plaintext.txt	43	apoe num protein may act increasing rate process lead alzheimers disease predisposing greater accumulation as without alzheimers disease rose et al num hyman et al num polvikoski et al num
0.22522588.11983636.html.plaintext.txt	44	presence least common allele apoe num associated delay disease onset even protection investigator corder et al num rose et al num
0.22522588.11983636.html.plaintext.txt	45	apolipoprotein e down syndrome relation apoe genotype risk alzheimers disease down syndrome difficult establish
0.22522588.11983636.html.plaintext.txt	46	study consistently found presence apoe num allele increase longevity reduces risk dementia role num allele controversial hardy et al num royston et al num martin et al num van gool et al num cosgrave et al num lambert et al num schupf et al num prasher et al num schupf et al num sekijima et al num tyrrell et al num lai et al num rubinszstein et al num deb et al num
0.22522588.11983636.html.plaintext.txt	47	small sample size importantly failure consider difference age onset dementia among without num allele may account negative finding
0.22522588.11983636.html.plaintext.txt	48	since effect num allele expressed midlife inclusion sufficient number adult num year age analysis using survival method adjust age year follow important methodological consideration
0.22522588.11983636.html.plaintext.txt	49	group used survival method analysis found presence num allele associated earlier onset dementia greater decline adaptive behaviour schupf et al num
0.22522588.11983636.html.plaintext.txt	50	compared apoe numnum genotype adult down syndrome num allele five time likely develop dementia age num one num allele developed dementia see fig
0.22522588.11983636.html.plaintext.txt	51	among affected individual mean age onset dementia num
0.22522588.11983636.html.plaintext.txt	52	num year num allele num
0.22522588.11983636.html.plaintext.txt	53	num year numnum genotype
0.22522588.11983636.html.plaintext.txt	54	four study found increased frequency num allele adult down syndrome dementia compared down syndrome without dementia martin et al num sekijima et al num rubinsztein et al num deb et al num
0.22522588.11983636.html.plaintext.txt	55	view larger version numk fig
0.22522588.11983636.html.plaintext.txt	56	num cumulative incidence dementia adult down syndrome apolipoprotein e apoe genotype unk unk apoe numnum numnum genotype apoe numnum genotype apoe numnum numnum numnum genotype
0.22522588.11983636.html.plaintext.txt	57	based schupf et al num kind permission lippincott williams wilkins
0.22522588.11983636.html.plaintext.txt	58	result study apoe genotype adult down syndrome mixed
0.22522588.11983636.html.plaintext.txt	59	several study found apoe num allele decreased risk dementia sample size small demonstrate significant effect num allele hardy et al num royston et al num wisniewski
0.22522588.11983636.html.plaintext.txt	60	two case control study adult down syndrome compared allele frequency individual without dementia found significant association apoe genotype alzheimers disease adjust age van gool et al num prasher et al num
0.22522588.11983636.html.plaintext.txt	61	one large study examined num adult down syndrome num num year age used survival analysis examine age onset dementia apoe genotype lai et al num
0.22522588.11983636.html.plaintext.txt	62	cumulative incidence dementia age num num apoe numnum genotype num apoe numnum genotype num num allele
0.22522588.11983636.html.plaintext.txt	63	effect num allele stronger younger age consistent finding study general population effect num allele accelerate onset alzheimers disease corder et al num saunders et al num meyer et al num
0.22522588.11983636.html.plaintext.txt	64	cumulative incidence age num num
0.22522588.11983636.html.plaintext.txt	65	num among num allele num
0.22522588.11983636.html.plaintext.txt	66	num among apoe numnum genotype
0.22522588.11983636.html.plaintext.txt	67	author suggested num effect study may attenuated high rate dementia advanced age
0.22522588.11983636.html.plaintext.txt	68	concluded effect num allele may dependent age study sample
0.22522588.11983636.html.plaintext.txt	69	finding consistent reduced as deposition polvikoski et al num le plaque formation benjamin et al num lippa et al num num allele acceleration as pathology num allele hymen et al num polvikoski et al num
0.22522588.11983636.html.plaintext.txt	70	size num effect relation presence num allele early mortality interaction apoe genotype risk factor dementia down syndrome gender level learning disability remain resolved
0.22522588.11983636.html.plaintext.txt	71	require larger older sample analytic procedure provide better adjustment age potential confounders
0.22522588.11983636.html.plaintext.txt	72	human study data show higher age specific rate alzheimers disease woman compared men bachman et al num approximately half risk alzheimers disease woman received oestrogen replacement therapy barrett conner kritz silverstein num brenner et al num henderson et al num paganini hill henderson num mortel meyer num tang et al num
0.22522588.11983636.html.plaintext.txt	73	finding support hypothesis oestrogen deficiency contributes aetiology alzheimers disease
0.22522588.11983636.html.plaintext.txt	74	contrast randomised controlled clinical trial oestrogen replacement therapy woman moderate severe alzheimers disease failed show cognitive improvement suggesting major effect oestrogen delay onset rather reverse cognitive functional decline henderson et al num mulnard et al num
0.22522588.11983636.html.plaintext.txt	75	gender difference effect oestrogen down syndrome systematically investigated work needed clarify hormonal risk factor may influence onset dementia
0.22522588.11983636.html.plaintext.txt	76	study presented result separately men woman
0.22522588.11983636.html.plaintext.txt	77	study compared woman men found conflicting result different study showing earlier onset raghaven et al num lai et al num later onset farrer et al num schupf et al num difference age onset visser et al num lai williams num gender
0.22522588.11983636.html.plaintext.txt	78	two study employed survival method examine age onset distribution gender adjusting age level learning disability found conflicting result
0.22522588.11983636.html.plaintext.txt	79	colleague found men down syndrome three time likely woman develop alzheimers disease age num see fig
0.22522588.11983636.html.plaintext.txt	80	numa effect gender observed age group num year schupf et al num
0.22522588.11983636.html.plaintext.txt	81	men woman down syndrome show elevation follicle stimulating hormone fsh luteinising hormone puberty indicative primary gonadal dysfunction appear progress age frequent men woman hasen et al num campbell et al num hsiang et al num hestnes et al num
0.22522588.11983636.html.plaintext.txt	82	thus older men may benefit relative preservation oestrogen proposed account lower risk alzheimers disease men general population
0.22522588.11983636.html.plaintext.txt	83	contrast another study found woman down syndrome approximately twice likely develop dementia men lai et al num see fig
0.22522588.11983636.html.plaintext.txt	84	study effect gender seen primarily younger age
0.22522588.11983636.html.plaintext.txt	85	study gender difference largest apoe numnum genotype suggesting high risk associated presence apoe num allele mask gender effect
0.22522588.11983636.html.plaintext.txt	86	basis different result study gender difference clear
0.22522588.11983636.html.plaintext.txt	87	view larger version numk fig
0.22522588.11983636.html.plaintext.txt	88	num cumulative incidence dementia adult down syndrome gender based schupf et al num b based lai et al num kind permission lippincott williams wilkins
0.22522588.11983636.html.plaintext.txt	89	one published study examined influence oestrogen deficiency age onset dementia woman down syndrome cosgrave et al num
0.22522588.11983636.html.plaintext.txt	90	menstrual profile risk dementia num woman down syndrome studied
0.22522588.11983636.html.plaintext.txt	91	twelve woman postmenopausal diagnosed dementia
0.22522588.11983636.html.plaintext.txt	92	significant relationship age menopause age onset dementia subsample rnum
0.22522588.11983636.html.plaintext.txt	93	although sample size small result consistent hypothesis higher endogenous oestrogen level lower risk dementia decreasing as peptide level maintaining cholinergic function critical neuronal population
0.22522588.11983636.html.plaintext.txt	94	association age menopause onset dementia confirmed supporting hormonal data provided oestrogen replacement therapy might prove important intervention delay onset dementia
0.22522588.11983636.html.plaintext.txt	95	view larger version numk fig
0.22522588.11983636.html.plaintext.txt	96	num plasma level assnum num assnum num adult down syndrome without dementia apoe genotype
0.22522588.11983636.html.plaintext.txt	97	schupf et al num permission elsevier science
0.22522588.11983636.html.plaintext.txt	98	limitation reliable valid cognitive assessment battery diagnostic criterion required detect dementia early stage improve study risk factor
0.22522588.11983636.html.plaintext.txt	99	study small sample size controlled potential confounders modifier age gender level intellectual disability
0.22522588.11983636.html.plaintext.txt	100	study used prevalent rather incident case may mask effect risk factor disease onset confounding differential survival
0.22522588.11983636.html.plaintext.txt	101	et al num incidence dementia probable alzheimers disease general population framingham study
0.22522588.11983636.html.plaintext.txt	102	num estrogen replacement therapy cognitive function older woman
0.22522588.11983636.html.plaintext.txt	103	journal american medical association num num num
0.22522588.11983636.html.plaintext.txt	104	et al num protective effect apoe num alzheimers disease
0.22522588.11983636.html.plaintext.txt	105	et al num familial alzheimers disease linked presenilin variant elevate abetal numnum num ratio vitro vivo
0.22522588.11983636.html.plaintext.txt	106	et al num postmenopausal estrogen replacement therapy risk alzheimers disease population based case control study
0.22522588.11983636.html.plaintext.txt	107	american journal epidemiology num num num
0.22522588.11983636.html.plaintext.txt	108	et al num serum gonadotrophin syndrome
0.22522588.11983636.html.plaintext.txt	109	journal medical genetics num num num
0.22522588.11983636.html.plaintext.txt	110	num longevity woman syndrome case study
0.22522588.11983636.html.plaintext.txt	111	mental retardation num num num
0.22522588.11983636.html.plaintext.txt	112	et al num gene dose apolipoprotein e type num allele risk alzheimers disease late onset family
0.22522588.11983636.html.plaintext.txt	113	et al num protective effect apolipoprotein e type num allele late onset alzheimers disease
0.22522588.11983636.html.plaintext.txt	114	et al num lower frequency apolipoprotein enum allele elderly down syndrome population
0.22522588.11983636.html.plaintext.txt	115	biological psychiatry num num num
0.22522588.11983636.html.plaintext.txt	116	et al num age onset dementia age menopause woman down syndrome
0.22522588.11983636.html.plaintext.txt	117	journal intellectual disability research num num num
0.22522588.11983636.html.plaintext.txt	118	num image analysis beta amyloid load alzheimers disease relation dementia severity
0.22522588.11983636.html.plaintext.txt	119	num apoe num influence manifestation alzheimers disease adult down syndrome
0.22522588.11983636.html.plaintext.txt	120	british journal psychiatry num num num
0.22522588.11983636.html.plaintext.txt	121	et al num allelic variability dnumsnum app apoe associated cognitive decline syndrome
0.22522588.11983636.html.plaintext.txt	122	et al num segregation missense mutation amyloid precursor protein gene familial alzheimers disease
0.22522588.11983636.html.plaintext.txt	123	et al num estrogen attenuate corticosterone exacerbates excitotoxicity oxidative injury amyloid beta peptide toxicity hippocampal neuron
0.22522588.11983636.html.plaintext.txt	124	journal neurochemistry num num num
0.22522588.11983636.html.plaintext.txt	125	et al num apoe genotype down syndrome
0.22522588.11983636.html.plaintext.txt	126	num gonadal function trisomy num
0.22522588.11983636.html.plaintext.txt	127	et al num estrogen replacement therapy older woman
0.22522588.11983636.html.plaintext.txt	128	archive neurology num num num
0.22522588.11983636.html.plaintext.txt	129	et al num estrogen alzheimers disease woman randomized double blind placebo controlled trial
0.22522588.11983636.html.plaintext.txt	130	et al num hormonal biochemical disturbance down syndrome
0.22522588.11983636.html.plaintext.txt	131	journal mental deficiency research num num num
0.22522588.11983636.html.plaintext.txt	132	et al num presenilin num polymorphism alzheimers disease
0.22522588.11983636.html.plaintext.txt	133	et al num population based study prevalence presentation dementia adult down syndrome
0.22522588.11983636.html.plaintext.txt	134	british journal psychiatry num num num
0.22522588.11983636.html.plaintext.txt	135	et al num gonadal function patient syndrome
0.22522588.11983636.html.plaintext.txt	136	american journal medical genetics num num num
0.22522588.11983636.html.plaintext.txt	137	et al num quantitative analysis senile plaque alzheimer disease observation log normal size distribution molecular epidemiology difference associated apolipoprotein e genotype trisomy num syndrome
0.22522588.11983636.html.plaintext.txt	138	proceeding national academy science usa num num num
0.22522588.11983636.html.plaintext.txt	139	et al num visualization abnumnum abnum senile plaque end specific ab monoclonal evidence initially deposited specie abnumnum
0.22522588.11983636.html.plaintext.txt	140	et al num amyloid beta protein beta deposition beta numnum precedes beta num syndrome
0.22522588.11983636.html.plaintext.txt	141	annals neurology num num num
0.22522588.11983636.html.plaintext.txt	142	et al num estrogen regulates metabolism alzheimer amyloid beta precursor protein
0.22522588.11983636.html.plaintext.txt	143	journal biological chemistry num num num
0.22522588.11983636.html.plaintext.txt	144	et al num presenilin num polymorphism alzheimers disease
0.22522588.11983636.html.plaintext.txt	145	uk alzheimers disease collaborative group
0.22522588.11983636.html.plaintext.txt	146	et al num beta appnum alzheimer mutation increase percentage plasma amyloid beta protein ending beta numnum
0.22522588.11983636.html.plaintext.txt	147	num prospective study alzheimer disease syndrome
0.22522588.11983636.html.plaintext.txt	148	archive neurology num num num
0.22522588.11983636.html.plaintext.txt	149	et al num apoe genotype gender effect alzheimer disease num adult syndrome
0.22522588.11983636.html.plaintext.txt	150	et al num analysis apoe allele impact down syndrome
0.22522588.11983636.html.plaintext.txt	151	neuroscience letter num num num
0.22522588.11983636.html.plaintext.txt	152	et al num candidate gene chromosome num familial alzheimers disease locus
0.22522588.11983636.html.plaintext.txt	153	et al num apolipoprotein e num alzheimers disease genotype influence pathologic phenotype
0.22522588.11983636.html.plaintext.txt	154	jr et al num amyloid associated protein alpha num antichymotrypsin apolipoprotein e promote assembly alzheimer beta protein filament
0.22522588.11983636.html.plaintext.txt	155	num association alzheimer disease syndrome
0.22522588.11983636.html.plaintext.txt	156	alzheimer disease syndrome relationship ed j
0.22522588.11983636.html.plaintext.txt	157	oxford oxford university press
0.22522588.11983636.html.plaintext.txt	158	et al num predominant deposition amyloid beta numnum plaque case alzheimers disease hereditary cerebral hemorrhage associated mutation amyloid precursor protein gene
0.22522588.11983636.html.plaintext.txt	159	american journal pathology num num num
0.22522588.11983636.html.plaintext.txt	160	et al num apoe genotype australia role early late onset alzheimers disease down syndrome
0.22522588.11983636.html.plaintext.txt	161	et al num apolipoprotein epsilon num allele patient alzheimers disease
0.22522588.11983636.html.plaintext.txt	162	annals neurology num num num
0.22522588.11983636.html.plaintext.txt	163	et al num plasma amyloid beta peptide num num incipient alzheimers disease
0.22522588.11983636.html.plaintext.txt	164	annals neurology num num num
0.22522588.11983636.html.plaintext.txt	165	conum alinktypedoi crossrefmedline
0.22522588.11983636.html.plaintext.txt	166	num apolipoprotein e genotype deposit abetanum abetanum alzheimer disease
0.22522588.11983636.html.plaintext.txt	167	archive neurology num num num
0.22522588.11983636.html.plaintext.txt	168	et al num increased plasma amyloid beta protein num num level syndrome
0.22522588.11983636.html.plaintext.txt	169	neuroscience letter num num num
0.22522588.11983636.html.plaintext.txt	170	et al num apoe genotype predicts whetherone predisposed alzheimers disease
0.22522588.11983636.html.plaintext.txt	171	num lack postmenopausal estrogen therapy risk dementia
0.22522588.11983636.html.plaintext.txt	172	journal neuropsychiatry clinical neuroscience num num num
0.22522588.11983636.html.plaintext.txt	173	num estrogen replacement therapy treatment mild moderate alzheimer disease randomized controlled trial
0.22522588.11983636.html.plaintext.txt	174	alzheimers disease cooperative study
0.22522588.11983636.html.plaintext.txt	175	journal american medical association num num num
0.22522588.11983636.html.plaintext.txt	176	et al num correlation elevated level amyloid b peptide brain cognitive decline
0.22522588.11983636.html.plaintext.txt	177	journal american medical association num num num
0.22522588.11983636.html.plaintext.txt	178	num estrogen deficiency risk alzheimers disease woman
0.22522588.11983636.html.plaintext.txt	179	american journal epidemiology num num num
0.22522588.11983636.html.plaintext.txt	180	et al num ovariectomy num beta estradiol modulate level alzheimers amyloid beta peptide brain
0.22522588.11983636.html.plaintext.txt	181	et al num apolipoprotein e dementia cortical deposition beta amyloid protein
0.22522588.11983636.html.plaintext.txt	182	new england journal medicine num num num
0.22522588.11983636.html.plaintext.txt	183	num age onset duration dementia people syndrome integration num reported case literature
0.22522588.11983636.html.plaintext.txt	184	international journal geriatric psychiatry num num num
0.22522588.11983636.html.plaintext.txt	185	et al num apoe genotype alzheimers disease adult syndrome meta analysis
0.22522588.11983636.html.plaintext.txt	186	american journal mental retardation num num num
0.22522588.11983636.html.plaintext.txt	187	et al num molecular mapping alzheimer type dementia down syndrome
0.22522588.11983636.html.plaintext.txt	188	annals neurology num num num
0.22522588.11983636.html.plaintext.txt	189	et al num gender difference phenotypic expression alzheimers disease down syndrome trisomy num
0.22522588.11983636.html.plaintext.txt	190	et al num clinical application apolipoprotein e genotyping alzheimers disease
0.22522588.11983636.html.plaintext.txt	191	et al num apolipoprotein e epsilon num allele promotes longevity protects patient down syndrome dementia
0.22522588.11983636.html.plaintext.txt	192	et al num apoe genotype risk dementia syndrome
0.22522588.11983636.html.plaintext.txt	193	american journal medical genetics num num num
0.22522588.11983636.html.plaintext.txt	194	conum tlinktypedoi crossrefmedline
0.22522588.11983636.html.plaintext.txt	195	et al num amyloid anum protein precursor down syndrome alzheimers disease
0.22522588.11983636.html.plaintext.txt	196	new england journal medicine num num num
0.22522588.11983636.html.plaintext.txt	197	et al num apolipoprotein e epsilon num allele distribution late onset alzheimers disease amyloid forming disease
0.22522588.11983636.html.plaintext.txt	198	et al num secreted amyloid beta protein similar senile plaque alzheimers disease increased vivo presenilin num num app mutation linked familial alzheimers disease
0.22522588.11983636.html.plaintext.txt	199	et al num onset dementia associated apolipoprotein e num syndrome
0.22522588.11983636.html.plaintext.txt	200	annals neurology num num num
0.22522588.11983636.html.plaintext.txt	201	et al num earlier onset alzheimers disease men syndrome
0.22522588.11983636.html.plaintext.txt	202	et al num elevated plasma amyloid s peptide num onset dementia syndrome
0.22522588.11983636.html.plaintext.txt	203	neuroscience letter num num num
0.22522588.11983636.html.plaintext.txt	204	et al num presenilin num polymorphism alzheimers disease
0.22522588.11983636.html.plaintext.txt	205	et al num prevalence dementia alzheimer type apolipoprotein e phenotype aged patient syndrome
0.22522588.11983636.html.plaintext.txt	206	european neurology num num num
0.22522588.11983636.html.plaintext.txt	207	et al num cloning novel gene bearing missense mutation early familial alzheimers disease
0.22522588.11983636.html.plaintext.txt	208	et al num effect oestrogen menopause risk age onset alzheimers disease
0.22522588.11983636.html.plaintext.txt	209	et al num plasma level amyloid s protein abnum num abnum numnum elevated down syndrome
0.22522588.11983636.html.plaintext.txt	210	annals neurology num num num
0.22522588.11983636.html.plaintext.txt	211	et al num estrogen receptor colocalize low affinity nerve growth factor receptor cholinergic neuron basal forebrain
0.22522588.11983636.html.plaintext.txt	212	proceeding national academy science usa num num num
0.22522588.11983636.html.plaintext.txt	213	et al num protective effect apolipoprotein e enum allele dementia down syndrome
0.22522588.11983636.html.plaintext.txt	214	biological psychiatry num num num
0.22522588.11983636.html.plaintext.txt	215	et al num presenilin num alpha num antichymotrypsin polymorphism syndrome effect presence dementia
0.22522588.11983636.html.plaintext.txt	216	american journal medical genetics num num num
0.22522588.11983636.html.plaintext.txt	217	conum ilinktypedoi crossrefmedline
0.22522588.11983636.html.plaintext.txt	218	num case control study apolipoprotein e genotype alzheimers disease associated down syndrome
0.22522588.11983636.html.plaintext.txt	219	dutch study group down syndrome ageing
0.22522588.11983636.html.plaintext.txt	220	annals neurology num num num
0.22522588.11983636.html.plaintext.txt	221	et al num prospective study prevalence alzheimer type dementia institutionalized individual syndrome
0.22522588.11983636.html.plaintext.txt	222	american journal mental retardation num num num
0.22522588.11983636.html.plaintext.txt	223	num age associated development diffuse thioflavin positive plaque syndrome
0.22522588.11983636.html.plaintext.txt	224	developmental brain dysfunction num num num
0.22522588.11983636.html.plaintext.txt	225	et al num influence apolipoprotein e isotypes alzheimers disease pathology num case down syndrome
0.22522588.11983636.html.plaintext.txt	226	annals neurology num num num
0.22522588.11983636.html.plaintext.txt	227	num genetic association intronic polymorphism presenilin num gene late onset alzheimers disease
0.22522588.11983636.html.plaintext.txt	228	num role beta num alzheimers disease
0.22522588.11983636.html.plaintext.txt	229	journal physiology paris num num num
0.22522588.11983636.html.plaintext.txt	230	et al num epidemiology alzheimer disease intellectual disability result recommendation international conference
0.22522588.11983636.html.plaintext.txt	231	journal intellectual disability research num num num
0.22522588.11983636.html.plaintext.txt	232	received publication january num num
0.22522588.11983636.html.plaintext.txt	233	revision received june num num
0.22522588.11983636.html.plaintext.txt	234	accepted publication june num num
0.22725685.14559775.html.plaintext.txt	0	fine mapping catenin gene quantitative trait locus chromosome num late onset alzheimers disease pedigree nilufer ertekin tanernum james ronaldnum hideaki asaharanum linda younkinnum maria hellanum shushant jainnum eugene gnidanum samuel younkinnum daniel fadalenum yasumasa ohyaginum adam singletonnum leah scanlinnum mariza de andradenum ronald petersennum neill graff radfordnum michael huttonnum steven younkinnum
0.22725685.14559775.html.plaintext.txt	1	numdepartment neuroscience mayo clinic jacksonville jacksonville fl usa numdepartment neurology neurological institute graduate school medical science kyushu university fukuoka japan numdepartment health science research division biostatistics mayo clinic rochester rochester mn usa numdepartment neurology mayo clinic rochester rochester mn usa numdepartment neurology mayo clinic jacksonville jacksonville fl usa
0.22725685.14559775.html.plaintext.txt	2	received july num num revised september num num accepted october num num
0.22725685.14559775.html.plaintext.txt	3	several group num num suggested quantitative intermediate phenotype may useful unraveling complex genetics disorder load
0.22725685.14559775.html.plaintext.txt	4	clinical disease state load likely result uncertain complex sequence pathophysiologic event whereas intermediate phenotype may directly related action set gene easily identified
0.22725685.14559775.html.plaintext.txt	5	thus identification gene variant contribute specific intermediate phenotype may tractable way identify least gene contribute disease governed complex genetics
0.22725685.14559775.html.plaintext.txt	6	optimize utility approach important select intermediate phenotype highly heritable close biological link disease question
0.22725685.14559775.html.plaintext.txt	7	study focused level amyloid s protein as specifically assnum quantitative intermediate phenotype load
0.22725685.14559775.html.plaintext.txt	8	as secreted protein num num derived set large precursor protein collectively referred amyloid s protein precursor
0.22725685.14559775.html.plaintext.txt	9	secreted as produced virtually cell readily detected human plasma cerebrospinal fluid
0.22725685.14559775.html.plaintext.txt	10	secreted as forty amino acid assnum small fraction num num two additional amino acid carboxyl terminus assnum num num
0.22725685.14559775.html.plaintext.txt	11	brain patient ad large amount as aggregate deposited senile plaque much form highly insoluble amyloid fibril
0.22725685.14559775.html.plaintext.txt	12	make definite diagnosis ad large number senile plaque neurofibrillary tangle must demonstrated brain autopsy num
0.22725685.14559775.html.plaintext.txt	13	load patient large amount as deposited senile plaque end assnum
0.22725685.14559775.html.plaintext.txt	14	one third case as ending assnum essentially form as deposited one third predominant form one third large amount assnum also deposited num
0.22725685.14559775.html.plaintext.txt	15	worth noting synthetic assnum assnum spontaneously assemble amyloid fibril vitro assnum form amyloid fibril far rapidly assnum numnum
0.22725685.14559775.html.plaintext.txt	16	brain high level app mrna concentration as cerebrospinal fluid num time higher plasma mixed fetal brain culture produce far as type cultured cell numnumnum
0.22725685.14559775.html.plaintext.txt	17	thus likely senile plaque form specifically brain as level higher brain organ
0.22725685.14559775.html.plaintext.txt	18	app presenilin num presenilin num gene many fully penetrant mutation cause early onset familial ad eofad num num
0.22725685.14559775.html.plaintext.txt	19	apart early onset causation specific mutation eofad clinically pathologically indistinguishable load
0.22725685.14559775.html.plaintext.txt	20	others shown eofad mutation increase assnum sometimes increase assnum well numnum num
0.22725685.14559775.html.plaintext.txt	21	importantly observed plasma assnum elevation eofad patient young cognitively normal carrier eofad mutation num
0.22725685.14559775.html.plaintext.txt	22	also observed assnum elevation plasma non demented relative load patient age num num num
0.22725685.14559775.html.plaintext.txt	23	importantly elevation associated apoenum allele variant eofad gene num
0.22725685.14559775.html.plaintext.txt	24	num found longitudinal study unrelated elderly individual subsequently developed ad higher plasma level assnum remained free dementia
0.22725685.14559775.html.plaintext.txt	25	collectively finding show assnum closely linked ad
0.22725685.14559775.html.plaintext.txt	26	investigate heritability plasma as analyzed extended load family found plasma assnum assnum level substantial heritability num
0.22725685.14559775.html.plaintext.txt	27	given finding level plasma assnum likely useful intermediate quantitative phenotype load performed variance component linkage analysis trait group extended load pedigree
0.22725685.14559775.html.plaintext.txt	28	analysis showed significant linkage locus num cm chromosome num num
0.22725685.14559775.html.plaintext.txt	29	linkage region obtained independently study affected load sib pair num
0.22725685.14559775.html.plaintext.txt	30	together two study provide strong evidence novel load locus chromosome num act increase assnum
0.22725685.14559775.html.plaintext.txt	31	sib pair group estimated effect locus equivalent apoe suggesting likely major risk factor load
0.22725685.14559775.html.plaintext.txt	32	third group found linkage downstream region chromosome num focused insulin degrading enzyme ide possible candidate gene region num
0.22725685.14559775.html.plaintext.txt	33	recently fourth group using age onset quantitative phenotype ad parkinson disease pd family found suggestive linkage chromosome num num num cm num
0.22725685.14559775.html.plaintext.txt	34	important advantage variance component approach employed candidate gene identified likely effect assnum evaluated systematically determine much various within gene variant contribute linkage
0.22725685.14559775.html.plaintext.txt	35	study analyzed vrnum variant contribute linkage signal chromosome num
0.22725685.14559775.html.plaintext.txt	36	location function make vrnum strong candidate gene
0.22725685.14559775.html.plaintext.txt	37	located num cm peak previously reported linkage signal vrnum encodes novel catenin catenin recently cloned jannsens et al
0.22725685.14559775.html.plaintext.txt	38	catenins interact closely s catenin play important role intercellular adhesion strong intercellular adhesion depends linkage cadherins actin cytoskeleton via s catenin complex
0.22725685.14559775.html.plaintext.txt	39	catenin closely homologous n catenin neuron specific e catenin expressed tissue
0.22725685.14559775.html.plaintext.txt	40	catenin expressed high level testis heart also expressed human mouse brain num
0.22725685.14559775.html.plaintext.txt	41	catenin overall sequence identity num num e n catenin respectively
0.22725685.14559775.html.plaintext.txt	42	num shown catenin interacts s catenin functionally effective fashion
0.22725685.14559775.html.plaintext.txt	43	make vrnum strong functional candidate s catenin interacts presenilin num num many mutation increase assnum numnumnum cause early onset familial ad num
0.22725685.14559775.html.plaintext.txt	44	num shown loss signalling s catenin pathway lead enhanced neuronal vulnerability as
0.22725685.14559775.html.plaintext.txt	45	addition s catenin presenilin form complex lead stabilization former destabilization complex lead s catenin degradation enhanced neuronal apoptosis
0.22725685.14559775.html.plaintext.txt	46	presenilin mutation shown lead destabilization s catenin presenilin complex degradation s catenin enhanced as production
0.22725685.14559775.html.plaintext.txt	47	given catenins provide link s catenin binding counterpart presenilins actin cytoskeleton possible postulate mutation catenins could lead disruption stability s catenin presenilin complex resulting enhanced neuronal vulnerability cell as increased as production
0.22725685.14559775.html.plaintext.txt	48	dose dependent effect vrnum num snp plasma assnum level extended load family
0.22725685.14559775.html.plaintext.txt	49	box plot depicting median middle part box numth percentile lower limit box numth percentile upper limit box numth percentile lower end line numth percentile upper end line numlogassnum level num num year old family member num load family
0.22725685.14559775.html.plaintext.txt	50	plot depicted separately vrnum num genotype tt red ct green cc blue
0.22725685.14559775.html.plaintext.txt	51	determine snp region vrnum gene show stronger association analyzed num additional snp total num snp analyzed region spanning num
0.22725685.14559775.html.plaintext.txt	52	num kb table num hcvnum hcvnum
0.22725685.14559775.html.plaintext.txt	53	num kb region linkage disequilibrium
0.22725685.14559775.html.plaintext.txt	54	many snp region showed nominally significant association none showed association stronger observed num num table num
0.22725685.14559775.html.plaintext.txt	55	p value association plasma assnum num num year old subject extended load family bounding association vrnum snp plasma assnum bound region vrnum numnum association evaluated total num additional snp spaced either side num num snp
0.22725685.14559775.html.plaintext.txt	56	snp selected several group designed span entire vrnum gene num kb interval well region num vrnum
0.22725685.14559775.html.plaintext.txt	57	known exon vrnum num
0.22725685.14559775.html.plaintext.txt	58	num kb median away closest snp closest snp group meannum
0.22725685.14559775.html.plaintext.txt	59	given extent ld human genome estimated different study anywhere num num kb num num extent one genomic region predictable priori possible miss association signal due variant snp group
0.22725685.14559775.html.plaintext.txt	60	however given size vrnum extent coverage throughout outside gene association signal identify num num vrnum snp well bounded within vrnum snp genotyping design
0.22725685.14559775.html.plaintext.txt	61	three six snp analyzed group linkage disequilibrium significantly associating num snp snp analyzed num combined family fig
0.22725685.14559775.html.plaintext.txt	62	using covariate style regression approach snp analyzed association plasma assnum num num num combined load family table num fig
0.22725685.14559775.html.plaintext.txt	63	view larger version numk figure num
0.22725685.14559775.html.plaintext.txt	64	boundary vrnum numnum association
0.22725685.14559775.html.plaintext.txt	65	marker marker linkage disequilibrium snp analyzed respect num snp
0.22725685.14559775.html.plaintext.txt	66	horizontal line show position num
0.22725685.14559775.html.plaintext.txt	67	b marker phenotype plasma assnum association
0.22725685.14559775.html.plaintext.txt	68	horizontal line show position num
0.22725685.14559775.html.plaintext.txt	69	num num side strongly associating num snp ld flanking snp fell essentially baseline level within large vrnum gene
0.22725685.14559775.html.plaintext.txt	70	num side snp association assnum also decreased baseline level within vrnum gene fig
0.22725685.14559775.html.plaintext.txt	71	num side significance snp association decreased num order magnitude num
0.22725685.14559775.html.plaintext.txt	72	num significantly associated snp nearest snp group hcvnum fig
0.22725685.14559775.html.plaintext.txt	73	association baseline level num side num num kb num margin vrnum
0.22725685.14559775.html.plaintext.txt	74	bounding approach effectively limit region potential association num num side num within vrnum
0.22725685.14559775.html.plaintext.txt	75	thus data provide strong evidence association num num snp plasma assnum due variant vrnum gene
0.22725685.14559775.html.plaintext.txt	76	given total num snp genotyped issue multiple testing raised
0.22725685.14559775.html.plaintext.txt	77	many snp linkage disequilibrium therefore independent one another fig
0.22725685.14559775.html.plaintext.txt	78	therefore simple bonferroni correction assumption num independent test overly conservative study
0.22725685.14559775.html.plaintext.txt	79	nonetheless even bonferroni correction applied num num snp still significant num family pnum
0.22725685.14559775.html.plaintext.txt	80	num num combined family pnum
0.22725685.14559775.html.plaintext.txt	81	association smaller set num family longer significant overly conservative correction pnum num num num respectively nonetheless inclusion analysis lead improved evidence association
0.22725685.14559775.html.plaintext.txt	82	contribution vrnum association linkage num cm next investigated contribution vrnum numnum association linkage previously reported
0.22725685.14559775.html.plaintext.txt	83	initial linkage finding obtained using seven marker covering num cm chromosome num
0.22725685.14559775.html.plaintext.txt	84	analyze entirety chromosome num genotyped num additional marker spanning num cm num load family
0.22725685.14559775.html.plaintext.txt	85	num family combined best two point lod score obtained num num
0.22725685.14559775.html.plaintext.txt	86	peak described multipoint lod score broadened flattened considerably incorporation additional marker maximum multipoint lod score continued num cm fig
0.22725685.14559775.html.plaintext.txt	87	view larger version numk figure num
0.22725685.14559775.html.plaintext.txt	88	effect vrnum snp num multipoint lod score ml load family
0.22725685.14559775.html.plaintext.txt	89	effect vrnum num linkage plasma assnum num load family
0.22725685.14559775.html.plaintext.txt	90	black line linkage gray line linkage conditional upon association vrnum num snp
0.22725685.14559775.html.plaintext.txt	91	multipoint ibds used analysis generated using num marker described text
0.22725685.14559775.html.plaintext.txt	92	reason broader flatter peak fine mapping analysis may several fold
0.22725685.14559775.html.plaintext.txt	93	first utilized mcmc mibd estimation implemented simwalknum package numnum multipoint linkage result presented paper opposed regression based mibd estimation algorithm implemented solar used original paper num see also subject method
0.22725685.14559775.html.plaintext.txt	94	second genotyping additional marker lead information regarding recombination could potentially lead decrease original linkage signal obtained fewer marker
0.22725685.14559775.html.plaintext.txt	95	third utilizing larger number marker increase likelihood map genotyping error despite implementation strict genotype quality control measure
0.22725685.14559775.html.plaintext.txt	96	indeed others also found fine mapping marker lead lowering original lod score obtained lesser number marker numnum
0.22725685.14559775.html.plaintext.txt	97	evaluate extent num num snp functional snp associated tightly linked pair account linkage observed repeated linkage analysis regressing effect vrnum num association including covariate linkage model
0.22725685.14559775.html.plaintext.txt	98	regressing effect snp multipoint linkage signal diminished substantially num combined family fig
0.22725685.14559775.html.plaintext.txt	99	marked diminution lod score indicates substantial proportion linkage signal plasma assnum accounted vrnum num association
0.22725685.14559775.html.plaintext.txt	100	residual linkage signal persisted regressing vrnum num association indicates likely additional variant contribute linkage though residual signal may also due random variation
0.22725685.14559775.html.plaintext.txt	101	diminution maximum multipoint lod score upon inclusion num snp covariate also evident comparison variance component model excludes covariate table numb one includes table numc
0.22725685.14559775.html.plaintext.txt	102	p value major gene effect maximum multipoint locus go num
0.22725685.14559775.html.plaintext.txt	103	trend observed twopoint linkage num snp assessed without including num covariate table numd e
0.22725685.14559775.html.plaintext.txt	104	p value major gene num locus loses significance pnum
0.22725685.14559775.html.plaintext.txt	105	since intronic snp located num
0.22725685.14559775.html.plaintext.txt	106	num kb nearest exon num num unlikely functional effect association assnum presumably occurs ld one several functional vrnum snp
0.22725685.14559775.html.plaintext.txt	107	sequencing vrnum exon reported vrnum transcript num failed identify potentially functional snp could account numnum association
0.22725685.14559775.html.plaintext.txt	108	possible functional snp affect splicing known alternatively spliced exon strong ld numnum
0.22725685.14559775.html.plaintext.txt	109	basic premise studying plasma assnum intermediate phenotype gene variant influence plasma assnum gene variant influence risk load
0.22725685.14559775.html.plaintext.txt	110	result reported useful identify vrnum gene variant influence plasma assnum thereby increasing likelihood vrnum gene one gene num cm region chromosome num variant influence risk load
0.22725685.14559775.html.plaintext.txt	111	important unanswered question well effect snp plasma assnum correlate effect ad phenotype
0.22725685.14559775.html.plaintext.txt	112	unlikely change plasma assnum caused specific genetic variant directly increase risk ad increased risk ad probably produced related effect variant within brain
0.22725685.14559775.html.plaintext.txt	113	thus conceivable perhaps even likely specific variant strong influence plasma assnum may sometimes little influence ad phenotype vice versa
0.22725685.14559775.html.plaintext.txt	114	thoroughly studying several gene elucidating effect entire set functional variant plasma assnum ad phenotype question answered
0.22725685.14559775.html.plaintext.txt	115	may effect two phenotype correlate well variant gene poorly others
0.22725685.14559775.html.plaintext.txt	116	result reported indicate vrnum variant significantly associate plasma assnum account substantial portion linkage signal chromosome num
0.22725685.14559775.html.plaintext.txt	117	additional analysis needed identify entire set functional variant account assnum linkage num cm
0.22725685.14559775.html.plaintext.txt	118	identified important test effect as production vrnum gene function biological experiment well determine whether functional variant modify risk ad
0.22725685.14559775.html.plaintext.txt	119	microsatellite genotyping dna extracted peripheral blood leukocyte using routine method
0.22725685.14559775.html.plaintext.txt	120	genotype microsatellites obtained using abi num num sequencer associated genescangenotyper software package
0.22725685.14559775.html.plaintext.txt	121	single nucleotide polymorphism snp genotyped using taqman chemistry software designing primer probe implemented within abi prism num ht sequence detection system
0.22725685.14559775.html.plaintext.txt	122	pedigree structure phenotypic genotypic information maintained pedsys httpwww
0.22725685.14559775.html.plaintext.txt	123	orgsfbrpublicsoftwarepedsyspedsys
0.22725685.14559775.html.plaintext.txt	124	html num also produced output file analysis performed solar explained
0.22725685.14559775.html.plaintext.txt	125	order location num chromosome num microsatellite marker determined marshfield linkage map
0.22725685.14559775.html.plaintext.txt	126	two marker dnumsnum dnumsnum location marshfield linkage map num placed linkage map according location estimate obtained map o mat program httpcompgen
0.22725685.14559775.html.plaintext.txt	127	two snp found vrnum gene also used marker linkage analysis
0.22725685.14559775.html.plaintext.txt	128	snp numtc numag located num num bp respectively chromosome num genomic map celera database httpwww
0.22725685.14559775.html.plaintext.txt	129	two snp placed linkage map based approximate centimorgan location estimated physical map
0.22725685.14559775.html.plaintext.txt	130	identification genotyping snp vrnum genomic mrna sequence initially obtained national center biotechnology information ncbi web site using genomic contig ntnum afnum
0.22725685.14559775.html.plaintext.txt	131	order identify snp primer designed cover known exon num kb intronic region exon num num
0.22725685.14559775.html.plaintext.txt	132	load case elderly control subject family member extended load pedigree sequenced identify polymorphism
0.22725685.14559775.html.plaintext.txt	133	initial sequencing vrnum exon num kb intronic region identified three snp intronic num kb region num num num
0.22725685.14559775.html.plaintext.txt	134	subsequently many additional snp vrnum flanking gene identified using celera database
0.22725685.14559775.html.plaintext.txt	135	aim cover region using snp group located every num kb group composed num num snp separated num num kb
0.22725685.14559775.html.plaintext.txt	136	total num snp including vrnum num num genotyped throughout vrnum num anxanumpnum num sirtnum flanking gene
0.22725685.14559775.html.plaintext.txt	137	snp within group found strong ld
0.22725685.14559775.html.plaintext.txt	138	snp location obtained celera sequence map
0.22725685.14559775.html.plaintext.txt	139	variance component analysis employed variance component methodology implemented software package solar numnum estimate heritability plasma assnum level perform linkage association analysis detect quantitative trait locus qtls affect variance assnum extended load family
0.22725685.14559775.html.plaintext.txt	140	method described detail elsewhere numnum estimate amount variance quantitative trait due particular genetic locus qnum residual genetic factor gnum individual specific random environmental factor enum based phenotype covariance arbitrary relative pair
0.22725685.14559775.html.plaintext.txt	141	covariance matrix take form
0.22725685.14559775.html.plaintext.txt	142	matrix probability pair individual share genetic material identical descent given chromosomal location estimated genetic marker data num matrix kinship coefficient describing polygenic factor identity matrix describing sporadic environmental factor
0.22725685.14559775.html.plaintext.txt	143	addition effect shared environment hnum variance trait also estimated including household matrix model
0.22725685.14559775.html.plaintext.txt	144	matrix whose ijth element equal num individual j share specified environment num otherwise
0.22725685.14559775.html.plaintext.txt	145	family collection largely composed extended pedigree measured plasma as member family single batch elisa
0.22725685.14559775.html.plaintext.txt	146	rigorously account possible assay batch batch variation may affect variance plasma assnum included household matrix model
0.22725685.14559775.html.plaintext.txt	147	since almost individual family measured one batch household matrix included elementnum individual extended family num otherwise
0.22725685.14559775.html.plaintext.txt	148	realize probably overly conservative
0.22725685.14559775.html.plaintext.txt	149	since shared family household effect employed account potential batch batch variance assay overlap kinship effect num inclusion household matrix almost certainly overcorrects batch batch variance underestimate shared genetic effect
0.22725685.14559775.html.plaintext.txt	150	reason performed heritability linkage analysis without household matrix model
0.22725685.14559775.html.plaintext.txt	151	multipoint result shown figure num num include household matrix
0.22725685.14559775.html.plaintext.txt	152	analysis without household matrix yielded slightly better lod score higher heritabilities general
0.22725685.14559775.html.plaintext.txt	153	scalar qnum gnum hnum enum estimated using maximum likelihood
0.22725685.14559775.html.plaintext.txt	154	heritability estimation compared environmental model qnum gnum fixed zero hnum enum estimated polygenic model gnum hnum enum estimated
0.22725685.14559775.html.plaintext.txt	155	linkage analysis performed comparing polygenic model linkage model qnum also estimated
0.22725685.14559775.html.plaintext.txt	156	difference two lognum likelihood model produce lod score equivalent classical lod score linkage analysis
0.22725685.14559775.html.plaintext.txt	157	incorporated sex age agenum sexage sexagenum covariates heritability estimation
0.22725685.14559775.html.plaintext.txt	158	none covariates significant p num
0.22725685.14559775.html.plaintext.txt	159	num therefore excluded multipoint linkage analysis
0.22725685.14559775.html.plaintext.txt	160	order minimize age dementia related environmental effect plasma assnum level performed analysis num num year age group previous study numnum
0.22725685.14559775.html.plaintext.txt	161	since variance component method based underlying assumption quantitative trait analyzed normal distribution numlogassnum level used phenotype
0.22725685.14559775.html.plaintext.txt	162	extreme outlier plasma as level plus minus num standard deviation beyond mean excluded analysis
0.22725685.14559775.html.plaintext.txt	163	thus numlogassnum phenotype analyzed normal distribution
0.22725685.14559775.html.plaintext.txt	164	plasma as measurement done using well established sandwich elisa system described previously num
0.22725685.14559775.html.plaintext.txt	165	sample measured duplicate
0.22725685.14559775.html.plaintext.txt	166	elisa plate included sample five volunteer
0.22725685.14559775.html.plaintext.txt	167	result five standard sample used normalize value obtained reduce plate plate day day variance
0.22725685.14559775.html.plaintext.txt	168	identity descent probability estimation identity descent ibd probability genotyped marker estimated using pairwise likelihood based estimation method implemented solar num
0.22725685.14559775.html.plaintext.txt	169	ibd estimate used obtain twopoint lod score
0.22725685.14559775.html.plaintext.txt	170	multipoint ibd probability also estimated centimorgan pair adjacent marker using markov chain monte carlo mcmc multipoint ibd estimation approach implemented simwalknum package numnum
0.22725685.14559775.html.plaintext.txt	171	mcmc process run twice default length num replicates second time doubling process length
0.22725685.14559775.html.plaintext.txt	172	multipoint linkage analysis using mibd matrix done using variance component methodology implemented solar
0.22725685.14559775.html.plaintext.txt	173	result using shorter longer run similar
0.22725685.14559775.html.plaintext.txt	174	result latter presented
0.22725685.14559775.html.plaintext.txt	175	given computation time increase marker number two upstream marker yielded evidence linkage datasets two marker dnumsnum dnumsnum omitted mibd estimation
0.22725685.14559775.html.plaintext.txt	176	two major difference mibd estimation utilized previous report linkage chromosome num current study num
0.22725685.14559775.html.plaintext.txt	177	result previous linkage obtained result genotyping seven marker num cm region current study utilizes num marker spread num
0.22725685.14559775.html.plaintext.txt	178	second mibd estimation approach used previous current study different
0.22725685.14559775.html.plaintext.txt	179	mcmc approach implemented simwalknum numnum utilized study different mibd probability estimation algorithm implemented solar approach utilized initial analysis seven chromosome num marker
0.22725685.14559775.html.plaintext.txt	180	num demonstrated significant difference result obtained two method using dataset concluded multipoint mcmc approach yielded accurate mibd probability estimate inter marker locus
0.22725685.14559775.html.plaintext.txt	181	reason utilized mcmc approach study
0.22725685.14559775.html.plaintext.txt	182	test association initially tested association snp plasma assnum num extended load family using regression based covariate approach variance component paradigm implemented computer program solar num
0.22725685.14559775.html.plaintext.txt	183	order control effect linkage included linkage component qnum null alternative model tested
0.22725685.14559775.html.plaintext.txt	184	used multipoint ibd matrix yielded maximum multipoint lod score num cm num extended load family
0.22725685.14559775.html.plaintext.txt	185	multipoint ibd probability matrix estimated simwalk using genetic marker information described
0.22725685.14559775.html.plaintext.txt	186	test effect specific snp genotype used measured genotype approach included copy number snp allele covariate analysis regressed plasma assnum phenotype covariate individual
0.22725685.14559775.html.plaintext.txt	187	measured genotype approach classical test difference trait mean genotype described theoretically previously numnum
0.22725685.14559775.html.plaintext.txt	188	approach also utilized previous association study snp various quantitative trait extended family numnum
0.22725685.14559775.html.plaintext.txt	189	individual xx xy yy snp genotype used covariate take value num num num respectively
0.22725685.14559775.html.plaintext.txt	190	formulation assumes snp additive qtl
0.22725685.14559775.html.plaintext.txt	191	model includes covariate tested model include determine effect quantitative trait interest
0.22725685.14559775.html.plaintext.txt	192	twice difference natural log likelihood two model distributed num distribution num degree freedom
0.22725685.14559775.html.plaintext.txt	193	order test association beyond linkage residual genetic household effect three component included null alternative model
0.22725685.14559775.html.plaintext.txt	194	first tested association snp assnum num load family previously used describe linkage chromosome num num
0.22725685.14559775.html.plaintext.txt	195	order control effect linkage residual genetic effect household effect group estimated effect snp background model included num cm multipoint identity descent matrix well kinship household matrix
0.22725685.14559775.html.plaintext.txt	196	tested snp association assnum second independent set num load family also analyzed combined group num family
0.22725685.14559775.html.plaintext.txt	197	linkage analysis conditional upon association conditional linkage analysis account association functional polymorphism one strong ld linkage locus decrease eliminate linkage signal numnum
0.22725685.14559775.html.plaintext.txt	198	reason performed linkage analysis conditional association strongly associating snp numtc
0.22725685.14559775.html.plaintext.txt	199	performed test estimating proportion variance due linkage background model included snp covariate comparing linkage model excluded covariate
0.22725685.14559775.html.plaintext.txt	200	analysis linkage disequilibrium measured linkage disequilibrium ld snp haplotype group within num extended load family using gold program num
0.22725685.14559775.html.plaintext.txt	201	used expectation maximization algorithm slatkin excoffier num determine various pairwise statistical parameter ld lewontins standardized disequilibrium coefficient d num
0.22725685.14559775.html.plaintext.txt	202	algorithm determines ld founder married in
0.22725685.14559775.html.plaintext.txt	203	ld estimated vrnum num snp snp
0.22725685.14559775.html.plaintext.txt	204	footnote correspondence addressed mayo clinic jacksonville num san pablo road birdsall num jacksonville fl num usa
0.22725685.14559775.html.plaintext.txt	205	tel num num fax num num email younkin
0.22725685.14559775.html.plaintext.txt	206	author wish known opinion first two author regarded joint first author
0.22725685.14559775.html.plaintext.txt	207	num role heredity late onset alzheimer disease vascular dementia
0.22725685.14559775.html.plaintext.txt	208	num heritability alzheimers disease study dementia swedish twin
0.22725685.14559775.html.plaintext.txt	209	num gene dose apolipoprotein e type num allele risk alzheimers disease late onset family
0.22725685.14559775.html.plaintext.txt	210	num effect age sex ethnicity association apolipoprotein e genotype alzheimer disease
0.22725685.14559775.html.plaintext.txt	211	apoe alzheimer disease meta analysis consortium
0.22725685.14559775.html.plaintext.txt	212	num number trait locus late onset alzheimer disease
0.22725685.14559775.html.plaintext.txt	213	num variance component method detecting complex trait locus
0.22725685.14559775.html.plaintext.txt	214	num geneticist approach complex disease
0.22725685.14559775.html.plaintext.txt	215	num sometimes hot sometimes
0.22725685.14559775.html.plaintext.txt	216	num production alzheimer amyloid s protein normal proteolytic processing
0.22725685.14559775.html.plaintext.txt	217	num isolation quantification soluble alzheimers beta peptide biological fluid
0.22725685.14559775.html.plaintext.txt	218	num amyloid beta peptide produced cultured cell normal metabolism
0.22725685.14559775.html.plaintext.txt	219	num cell familial alzheimers disease mutation produce authentic beta peptide
0.22725685.14559775.html.plaintext.txt	220	num characterization beta amyloid peptide human cerebrospinal fluid
0.22725685.14559775.html.plaintext.txt	221	num increased percentage long amyloid beta protein secreted familial amyloid beta protein precursor beta appnum mutant
0.22725685.14559775.html.plaintext.txt	222	num clinical diagnosis alzheimers disease report nincds adrda work group auspex department health human service task force alzheimers disease
0.22725685.14559775.html.plaintext.txt	223	num amyloid beta protein beta alzheimers disease brain
0.22725685.14559775.html.plaintext.txt	224	biochemical immunocytochemical analysis antibody specific form ending betanum beta numnum
0.22725685.14559775.html.plaintext.txt	225	jr num carboxy terminus beta amyloid protein critical seeding amyloid formation implication pathogenesis alzheimers disease
0.22725685.14559775.html.plaintext.txt	226	biochemistry num num num
0.22725685.14559775.html.plaintext.txt	227	num amyloid beta aggregation selective inhibition aggregation mixture amyloid different chain length
0.22725685.14559775.html.plaintext.txt	228	num localization amyloid beta protein messenger rna brain patient alzheimers disease
0.22725685.14559775.html.plaintext.txt	229	num amyloid beta protein gene cdna mrna distribution genetic linkage near alzheimer locus
0.22725685.14559775.html.plaintext.txt	230	num segregation missense mutation amyloid precursor protein gene familial alzheimers disease
0.22725685.14559775.html.plaintext.txt	231	num candidate gene chromosome num familial alzheimers disease locus
0.22725685.14559775.html.plaintext.txt	232	num familial alzheimers disease kindred missense mutation gene chromosome num related alzheimers disease type num gene
0.22725685.14559775.html.plaintext.txt	233	num cloning gene bearing missense mutation early onset familial alzheimers disease
0.22725685.14559775.html.plaintext.txt	234	num familial alzheimers disease linked presenilin num variant elevate abetanum numnum num ratio vitro vivo
0.22725685.14559775.html.plaintext.txt	235	num release excess amyloid beta protein mutant amyloid beta protein precursor
0.22725685.14559775.html.plaintext.txt	236	num mutation beta amyloid precursor protein familial alzheimersdisease increase beta protein production
0.22725685.14559775.html.plaintext.txt	237	num increased amyloid betanumnum brain mouse expressing mutant presenilinnum
0.22725685.14559775.html.plaintext.txt	238	num correlative memory deficit abeta elevation amyloid plaque transgenic mouse
0.22725685.14559775.html.plaintext.txt	239	num secreted amyloid beta protein similar senile plaque alzheimers disease increased vivo presenilin num num app mutation linked familial alzheimers disease
0.22725685.14559775.html.plaintext.txt	240	num role elevated amyloid s protein patient typical late onset alzheimers disease
0.22725685.14559775.html.plaintext.txt	241	num plasma amyloid beta peptide num num incipient alzheimers disease
0.22725685.14559775.html.plaintext.txt	242	conum alinktypedoi crossrefisimedline
0.22725685.14559775.html.plaintext.txt	243	num heritability plasma as level typical late onset alzheimers disease pedigree
0.22725685.14559775.html.plaintext.txt	244	num linkage plasma assnum quantitative locus chromosome num late onset alzheimers disease pedigree
0.22725685.14559775.html.plaintext.txt	245	num susceptibility locus alzheimers disease chromosome num
0.22725685.14559775.html.plaintext.txt	246	num evidence genetic linkage alzheimers disease chromosome numq
0.22725685.14559775.html.plaintext.txt	247	num age onset two common neurodegenerative disease genetically controlled
0.22725685.14559775.html.plaintext.txt	248	num alphat catenin novel tissue specific beta catenin binding protein mediating strong cell cell adhesion
0.22725685.14559775.html.plaintext.txt	249	num destabilization beta catenin mutation presenilin num potentiates neuronal apoptosis
0.22725685.14559775.html.plaintext.txt	250	num pattern linkage disequilibrium human genome
0.22725685.14559775.html.plaintext.txt	251	num high resolution haplotype structure human genome
0.22725685.14559775.html.plaintext.txt	252	num structure haplotype block human genome
0.22725685.14559775.html.plaintext.txt	253	num block limited haplotype diversity revealed high resolution scanning human chromosome num
0.22725685.14559775.html.plaintext.txt	254	num genetic variation numqnum cytokine gene cluster confers susceptibility crohn disease
0.22725685.14559775.html.plaintext.txt	255	num descent graph pedigree analysis application haplotyping location score marker sharing statistic
0.22725685.14559775.html.plaintext.txt	256	num multipoint estimation identity descent probability arbitrary position among marker locus general pedigree
0.22725685.14559775.html.plaintext.txt	257	num inheritance multiple locus familial alzheimer disease
0.22725685.14559775.html.plaintext.txt	258	ed alzheimers disease advance clinical basic research
0.22725685.14559775.html.plaintext.txt	259	john wiley son new york pp
0.22725685.14559775.html.plaintext.txt	260	num fine mapping chromosome numlate onset alzheimer disease locus potential genetic phenotypic heterogeneity
0.22725685.14559775.html.plaintext.txt	261	num pedsys pedigree data management system num
0.22725685.14559775.html.plaintext.txt	262	population genetics laboratory department genetics southwest foundation biomedical research san antonio tx
0.22725685.14559775.html.plaintext.txt	263	num comprehensive human genetic map individual sex specific variation recombination
0.22725685.14559775.html.plaintext.txt	264	num construction multilocus geneticlinkage map human proc
0.22725685.14559775.html.plaintext.txt	265	num multipoint quantitative trait linkage analysis general pedigree
0.22725685.14559775.html.plaintext.txt	266	num solar sequential oligogenic linkage analysis routine
0.22725685.14559775.html.plaintext.txt	267	population genetics laboratory southwest foundation biomedical research san antonio tx num
0.22725685.14559775.html.plaintext.txt	268	num exposure schistosoma mansoni infection rural area brazil
0.22725685.14559775.html.plaintext.txt	269	num extension multivariate normal model pedigree analysis
0.22725685.14559775.html.plaintext.txt	270	num use measured genotype information analysis quantitative phenotype man
0.22725685.14559775.html.plaintext.txt	271	num linkage analysis demonstrates prothrombin gnuma mutation jointly influence plasma prothrombin level risk thrombosis
0.22725685.14559775.html.plaintext.txt	272	num quantitative trait locus human factor xii gene influence plasma factor xii level susceptibility thrombotic disease
0.22725685.14559775.html.plaintext.txt	273	num gold graphical overview linkage disequilibrium
0.22725685.14559775.html.plaintext.txt	274	bioinformatics num num num
0.22725685.14559775.html.plaintext.txt	275	num maximum likelihood estimation molecular haplotype frequency diploid population
0.22725685.14559775.html.plaintext.txt	276	num evolutionary dynamic complex polymorphism
0.227683.9700196.html.plaintext.txt	0	organization expression polymorphism human persyn gene
0.227683.9700196.html.plaintext.txt	1	patersonnum liz delaneynum brian b
0.227683.9700196.html.plaintext.txt	2	cohennum stefan imrehnum nikolai v
0.227683.9700196.html.plaintext.txt	3	numschool biomedical science university st andrew bute medical building st andrew fife kynum numts uk numinstitute gene biology russian academy science numnum vavilov street moscow b num russia nummicrobiology tumor biology center mtc karolinska institute box num num stockholm sweden numneuropa ltd robertson building dumbarton road glasgow gnum numnu uk
0.227683.9700196.html.plaintext.txt	4	received april num num revised accepted june num num
0.227683.9700196.html.plaintext.txt	5	ddbjemblgenbank accession no afnum afnum
0.227683.9700196.html.plaintext.txt	6	persyn recently identified member synuclein family distinct pattern expression pre postnatal development mouse peripheral central nervous system
0.227683.9700196.html.plaintext.txt	7	synucleins persyn believed involved pathogenesis human neurodegenerative disease
0.227683.9700196.html.plaintext.txt	8	however contrast synucleins high level persyn mrna expression also found advanced breast carcinoma suggesting involvement encoded protein breast tumour progression
0.227683.9700196.html.plaintext.txt	9	used antibody specific human persyn demonstrate level protein increased ageing cerebral cortex breast tumour
0.227683.9700196.html.plaintext.txt	10	cloned characterized sequenced human persyn genomic locus localized long arm chromosome num qnum
0.227683.9700196.html.plaintext.txt	11	sequence information used search specific mutation protein coding region persyn mrna persyn gene breast tumour tumour cell line
0.227683.9700196.html.plaintext.txt	12	tumour specific mutation found two linked polymorphism coding region detected mrna exon iii iv gene
0.227683.9700196.html.plaintext.txt	13	result suggest development breast tumour correlate overexpression wild type persyn protein
0.227683.9700196.html.plaintext.txt	14	detailed characterization human persyn locus important study involvement persyn neurodegeneration malignancy
0.227683.9700196.html.plaintext.txt	15	three gene synuclein family recently identified human genome
0.227683.9700196.html.plaintext.txt	16	first two code alpha beta synucleins closely related presynaptic protein similar pattern expression abundant evolutionarily recent region central nervous system num num
0.227683.9700196.html.plaintext.txt	17	protein believed natively unfolded random coiled numnum tend aggregate solution forming amyloid like fibril num
0.227683.9700196.html.plaintext.txt	18	another important feature synucleins ability bind trigger aggregation amyloid abeta peptide num num
0.227683.9700196.html.plaintext.txt	19	result together detection peptide nac derived alpha synuclein senile plaque alzheimers brain numnum raise possibility synucleins involved pathogenesis alzheimers disease num
0.227683.9700196.html.plaintext.txt	20	although mutation polymorphism synuclein gene yet correlated alzheimers disease numnum two point mutation human alpha synuclein gene found several family early onset autosomal dominant parkinson disease numnum
0.227683.9700196.html.plaintext.txt	21	finding together immunohistochemical detection high level alpha synuclein lewy body parkinson disease patient brain numnum implicates alpha synuclein pathogenesis certain form neurodegenerative disorder
0.227683.9700196.html.plaintext.txt	22	recently identified member synuclein family persyn share main structural feature alpha beta synucleins distinctive pattern expression num
0.227683.9700196.html.plaintext.txt	23	mouse embryonic development persyn expressed primary sensory neuron motoneuron
0.227683.9700196.html.plaintext.txt	24	postnatally persyn expression remains high neuron becomes detectable sympathetic neuron subset neuron cerebral cortex
0.227683.9700196.html.plaintext.txt	25	contrast decrease alpha synuclein expression ageing cerebral cortex num persyn mrna expression increase persyn protein accumulates mouse cerebral cortex age num
0.227683.9700196.html.plaintext.txt	26	although persyn present senile plaque lewy body neurofibrillary tangle clinical case studied far high level persyn immunoreactivity detectable dot like structure characteristic axonal lesion brain patient neurodegenerative disease v
0.227683.9700196.html.plaintext.txt	27	davy submitted publication
0.227683.9700196.html.plaintext.txt	28	clinical finding consistent developmental regional pattern persyn expression experimental evidence suggests persyn play role regulating neurofilament network integrity num
0.227683.9700196.html.plaintext.txt	29	persyn nearly identical protein coded expressed sequence tag est bcsgnum isolated breast cancer cdna library num
0.227683.9700196.html.plaintext.txt	30	although bcsgnum mrna detected normal breast tissue benign breast tumour level dramatically increase highly infiltrating malignant carcinoma num
0.227683.9700196.html.plaintext.txt	31	level encoded protein reflects level persynbcsgnum mrna could useful breast cancer progression marker
0.227683.9700196.html.plaintext.txt	32	dual role persyn neurodegeneration malignancy could involve common mechanism
0.227683.9700196.html.plaintext.txt	33	change organization cell cytoskeleton among prominent characteristic process
0.227683.9700196.html.plaintext.txt	34	involvement persyn regulating neurofilament network integrity raise possibility may also affect intermediate filament network malignant breast epithelial cell
0.227683.9700196.html.plaintext.txt	35	important question whether breast tumour progression correlate high level expression wild type persyn presence mutation persyn coding region obligatory characteristic process
0.227683.9700196.html.plaintext.txt	36	multiple difference including three resulted amino acid substitution bcsgnum isolated tumour tissue persyn isolated normal brain tissue consistent latter possibility
0.227683.9700196.html.plaintext.txt	37	mutation could somatic germline might reflect advanced tumour progression predisposition individual malignant progression tumour
0.227683.9700196.html.plaintext.txt	38	clarification question requires study human persyn gene persyn protein
0.227683.9700196.html.plaintext.txt	39	report organization human persyn locus chromosomal localization study human persyn protein expression
0.227683.9700196.html.plaintext.txt	40	also show mutation persyn gene specific breast tumour confirmed difference result natural sequence polymorphism
0.227683.9700196.html.plaintext.txt	41	result cloning analysis human persyn genomic locus
0.227683.9700196.html.plaintext.txt	42	two human persyn cdna clone previously isolated juvenile human cdna library
0.227683.9700196.html.plaintext.txt	43	one cdna clone clone hnum used screen human genomic library lambdaemblnum num
0.227683.9700196.html.plaintext.txt	44	two identical independent clone isolated genomic library position exon determined restriction analysis hybridization cdna oligonucleotide probe direct sequencing locus genomic southern hybridization
0.227683.9700196.html.plaintext.txt	45	figure num show human persyn gene consists five exon span num kbp
0.227683.9700196.html.plaintext.txt	46	difference sequence cdna clone hnum used probe genomic library exonic sequence genomic clone isolated
0.227683.9700196.html.plaintext.txt	47	however another shorter cdna clone numc isolated juvenile human cdna library two substitution coding region found g c position num position num cdna sequence afnum boxed fig
0.227683.9700196.html.plaintext.txt	48	num latter resulting amino acid substitution valnumglu
0.227683.9700196.html.plaintext.txt	49	cdna library constructed individual juvenile brainstem likely substitution result natural polymorphism persyn gene allele gene transcriptionally active tissue
0.227683.9700196.html.plaintext.txt	50	organization human persyn gene
0.227683.9700196.html.plaintext.txt	51	physical map locus displayed upper part figure
0.227683.9700196.html.plaintext.txt	52	restriction endonuclease site ecori e saci kpni k xbai x shown
0.227683.9700196.html.plaintext.txt	53	exon vertical black box numbered roman numeral
0.227683.9700196.html.plaintext.txt	54	sequence exon adjacent part intron shown lower part figure
0.227683.9700196.html.plaintext.txt	55	encoded amino acid one letter code shown nucleotide sequence
0.227683.9700196.html.plaintext.txt	56	nucleotide substitution est bcsgnum shown nucleotide sequence deduced amino acid substitution shown amino acid sequence
0.227683.9700196.html.plaintext.txt	57	two substitution also found human persyn clone numc result gene polymorphism boxed
0.227683.9700196.html.plaintext.txt	58	polyadenylation site marked arrowhead
0.227683.9700196.html.plaintext.txt	59	full sequence human persyn locus deposited genbank accession
0.227683.9700196.html.plaintext.txt	60	persyn mrna expression tumour cell line
0.227683.9700196.html.plaintext.txt	61	persyn gene expression various normal tumour tissue cell line studied northern blot analysis using human persyn cdna clone hnum hybridization probe
0.227683.9700196.html.plaintext.txt	62	num kb transcript observed tumour cell line highest level transcript detected sub line mcfnumprime breast tumour cell line mcfnum normally express persyn mrna fig
0.227683.9700196.html.plaintext.txt	63	similar result obtained semi quantitative rt pcr shown
0.227683.9700196.html.plaintext.txt	64	however increasing number amplification cycle detected low level persyn mrna tumour cell line persyn negative northern western blot example line ginum shown fig num numa num
0.227683.9700196.html.plaintext.txt	65	persyn transcript breast tumour cell line
0.227683.9700196.html.plaintext.txt	66	northern hybridization total rna isolated tumour cell line human persyn cdna probe
0.227683.9700196.html.plaintext.txt	67	stripping probe filter hybridized nick translated cdna fragment encoding mouse gapdh provide indication amount total rna cell line present filter
0.227683.9700196.html.plaintext.txt	68	cell line derived breast cancer except skovnum derived ovarian carcinoma
0.227683.9700196.html.plaintext.txt	69	persyn protein human tissue cell line
0.227683.9700196.html.plaintext.txt	70	western blot showing expression persyn protein human tissue cell line
0.227683.9700196.html.plaintext.txt	71	aliquot num microg total cellular protein separated num polyacrylamide gel transferred hybond pvdf membrane probed sknum anti persyn antibody followed ecl detection
0.227683.9700196.html.plaintext.txt	72	protein extracted following source tumour cell line designation fig
0.227683.9700196.html.plaintext.txt	73	num b normal breast tissue n breast tumour four patient c cerebral cortex two patient suffered alzheimers disease numnum numnum two normal individual age group numnum numnum fetal cerebral cortex mouse spinal cord unstimulated pbl pha stimulated pbl pha peripheral blood lymphocyte
0.227683.9700196.html.plaintext.txt	74	detection persyn protein breast cancer cell
0.227683.9700196.html.plaintext.txt	75	confocal microscope section human breast cancer cell stained antibody persyn green channel keratin num red channel
0.227683.9700196.html.plaintext.txt	76	persyn protein expression human tissue
0.227683.9700196.html.plaintext.txt	77	study persyn protein expression human tissue used western blotting polyclonal antibody raised synthetic peptide human persyn protein see material method
0.227683.9700196.html.plaintext.txt	78	antibody cross react either alpha beta synuclein western blot detects single band disappears antibody preincubated excess immunizing peptide shown
0.227683.9700196.html.plaintext.txt	79	persyn detected human fetal cerebral cortex abundant cortex elderly individual fig
0.227683.9700196.html.plaintext.txt	80	substantial difference level persyn noticed cerebral cortex alzheimers disease patient normal individual age group fig
0.227683.9700196.html.plaintext.txt	81	persyn mrna persyn protein also detected unstimulated phytohaemagglutinin pha stimulated cultured lymphocyte peripheral blood normal donor fig numc num data shown
0.227683.9700196.html.plaintext.txt	82	breast cancer cell line pattern persyn protein expression corresponded mrna detected western blotting cell line persyn mrna detected northern hybridization fig num numa
0.227683.9700196.html.plaintext.txt	83	shown previously situ hybridization persynbcsgnum mrna expressed normal adult breast tissue high level mrna present advanced infiltrating breast tumour num
0.227683.9700196.html.plaintext.txt	84	detected persyn protein breast tumour normal breast tissue fig
0.227683.9700196.html.plaintext.txt	85	used immunocytochemistry anti persyn antibody localize persyn cultured breast cancer cell
0.227683.9700196.html.plaintext.txt	86	paraformaldehyde pfa fixed cell persyn displayed punctuate cytoplasmic staining fig
0.227683.9700196.html.plaintext.txt	87	num pattern usually associated marker endoplasmic reticulum vesicular structure
0.227683.9700196.html.plaintext.txt	88	persyn co localized cytokeratin actin tubulin array cell fig
0.227683.9700196.html.plaintext.txt	89	sequence polymorphism human persyn coding region
0.227683.9700196.html.plaintext.txt	90	nucleotide substitution reported sequence bcsgnum transcript num shown figure numa
0.227683.9700196.html.plaintext.txt	91	two position num num cdna sequence boxed fig
0.227683.9700196.html.plaintext.txt	92	numa identical substitution found cdna clone numc
0.227683.9700196.html.plaintext.txt	93	substitution present clone may correlated transformed phenotype cell bcsgnum est isolated
0.227683.9700196.html.plaintext.txt	94	study presence frequency mutation persyn gene breast cancer cell carried rt pcr mrna isolated breast tumour tumour cell line
0.227683.9700196.html.plaintext.txt	95	control used mrna isolated post mortem cerebral cortex pha stimulated peripheral blood lymphocyte normal donor
0.227683.9700196.html.plaintext.txt	96	pcr amplification product digested restriction endonuclease hphi styi mnli
0.227683.9700196.html.plaintext.txt	97	using digestion four mutation coding region reported bcsgnum including two polymorphism present cdna clone numc could detected
0.227683.9700196.html.plaintext.txt	98	studied sample digestion mnli generated pattern fragment fig
0.227683.9700196.html.plaintext.txt	99	numa corresponds pattern predicted sequence persyn clone
0.227683.9700196.html.plaintext.txt	100	identical predicted pattern also obtained styi shown
0.227683.9700196.html.plaintext.txt	101	result reflect absence two g consequently glu lys substitution reported bcsgnum est studied tumour cell line tumour control tissue
0.227683.9700196.html.plaintext.txt	102	contrast rt pcr product digested hphi three type fragment pattern revealed fig
0.227683.9700196.html.plaintext.txt	103	pattern represented figure numa ginum cell line corresponds persyn transcript sequence similar hnum gnum presence hphi site num bp num bp hphi fragment tnum absence hphi site num bp num num bp fragment
0.227683.9700196.html.plaintext.txt	104	pattern mcfnumprime figure numa corresponds persyn transcript sequence similar numc cnum absence hphi site num bp num bp hphi fragment anum presence hphi site num num bp num bp fragment
0.227683.9700196.html.plaintext.txt	105	pbl n figure numa example cell transcript expressed
0.227683.9700196.html.plaintext.txt	106	direct sequencing rt pcr fragment amplified four persyn expressing breast tumour reveal alteration apart gnumc tnuma
0.227683.9700196.html.plaintext.txt	107	detection polymorphism human persyn gene transcript
0.227683.9700196.html.plaintext.txt	108	representative example different cell type designation fig
0.227683.9700196.html.plaintext.txt	109	num different combination persyn allele shown
0.227683.9700196.html.plaintext.txt	110	size fragment given base pair
0.227683.9700196.html.plaintext.txt	111	ethidium bromide stained num metaphor agarose gel fragment amplified rt pcr human rna digested restriction endonuclease mnli upper hphi lower
0.227683.9700196.html.plaintext.txt	112	rna isolated breast cancer cell line mcfnumprime ginum peripheral blood lymphocyte donor n pbl n
0.227683.9700196.html.plaintext.txt	113	b ethidium bromide stained num agarose gel fragment amplified pcr human dna digested restriction endonuclease hphi
0.227683.9700196.html.plaintext.txt	114	product digestion num bp fragment includes human persyn exon iii shown upper panel num bp fragment includes human persyn exon iv shown lower panel
0.227683.9700196.html.plaintext.txt	115	data confirmed pcr amplification individual exon persyn gene followed digestion product restriction endonuclease hphi styi mnli
0.227683.9700196.html.plaintext.txt	116	polymorphic styi mnli site found illustrated figure numb expected polymorphic hphi site present exon three gnumc four tnuma human persyn gene
0.227683.9700196.html.plaintext.txt	117	allele gene expressed heterozygotic cell instance peripheral blood lymphocyte donor n demonstrated fig
0.227683.9700196.html.plaintext.txt	118	expected two nearby polymorphic site genome found linked studied dna
0.227683.9700196.html.plaintext.txt	119	frequency two allele genome breast cancer normal cell num gnumtnum num cnumanum
0.227683.9700196.html.plaintext.txt	120	assignment human persyn gene chromosome numqnum
0.227683.9700196.html.plaintext.txt	121	dna lambdawnumh genomic clone labelled biotin used fluorescence situ hybridization fish metaphase chromosome prepared donor peripheral blood lymphocyte
0.227683.9700196.html.plaintext.txt	122	unique hybridization site assigned long arm chromosome num qnum
0.227683.9700196.html.plaintext.txt	123	localization persyn gene human metaphase chromosome using fish
0.227683.9700196.html.plaintext.txt	124	arrow show specific hybridization signal lambdawnumh probe chromosome num
0.227683.9700196.html.plaintext.txt	125	b magnified image chromosome num different metaphase plate
0.227683.9700196.html.plaintext.txt	126	two image shown chromosome fish signal white arrow inverted dapi banding black arrow show dapi band numq num
0.227683.9700196.html.plaintext.txt	127	num hybridized lambdawnumh probe
0.227683.9700196.html.plaintext.txt	128	member synuclein family implicated pathogenesis alzheimers parkinson neurodegenerative disease numnumnum num
0.227683.9700196.html.plaintext.txt	129	family hereditary form parkinson disease point mutation gene coding alpha synuclein believed responsible development pathology numnumnum
0.227683.9700196.html.plaintext.txt	130	finding suggests mutation gene encoding member synuclein family could linked neurodegenerative condition underlies need study gene
0.227683.9700196.html.plaintext.txt	131	cloned defined structure human gene encoding persyn recently identified member synuclein family num
0.227683.9700196.html.plaintext.txt	132	general organization gene term position exon intron junction size intron similar mouse persyn gene unpublished data
0.227683.9700196.html.plaintext.txt	133	although complete structure gene synuclein family published available sequence data num deduction position exon intron junction known splice variant alpha beta synucleins numnumnum suggest close similarity organization synuclein gene
0.227683.9700196.html.plaintext.txt	134	addition potential involvement neurodegeneration persyn possibly involved breast tumour progression
0.227683.9700196.html.plaintext.txt	135	shown expression est bcsgnum nearly identical nucleotide sequence persyn mrna increased dramatically infiltrating breast cancer compared normal breast tissue benign tumour num
0.227683.9700196.html.plaintext.txt	136	shown expression persyn protein also follows pattern persyn could detected western blotting normal breast tissue whereas persyn protein detectable breast tumour tissue
0.227683.9700196.html.plaintext.txt	137	established breast cancer cell line level persyn protein expression found substantially different correlated level persyn mrna
0.227683.9700196.html.plaintext.txt	138	find amplification persyn gene studied cell line data shown
0.227683.9700196.html.plaintext.txt	139	observation suggest persyn expression regulated predominantly level persyn gene transcription andor persyn mrna stability
0.227683.9700196.html.plaintext.txt	140	thus breast cancer cell line could used study mechanism regulate persyn expression investigate physiological consequence persyn overexpression
0.227683.9700196.html.plaintext.txt	141	shown previously experimental overexpression persyn cultured sensory neuron lead dramatic change neurofilament network num
0.227683.9700196.html.plaintext.txt	142	interesting see acute overexpression persyn similar effect intermediate filament network epithelial cell
0.227683.9700196.html.plaintext.txt	143	immunocytochemical data suggest persyn could associated membranous structure cytoplasm breast cancer cell
0.227683.9700196.html.plaintext.txt	144	however subcellular fractionation neural tissue breast cancer cell demonstrated presence persyn cytosolic particulate fraction data shown
0.227683.9700196.html.plaintext.txt	145	result similar result obtained study alpha synuclein believed loosely associated synaptic vesicle membrane presynaptic terminal numnum num
0.227683.9700196.html.plaintext.txt	146	interesting light recent demonstration alpha synuclein able bind synthetic membrane vitro
0.227683.9700196.html.plaintext.txt	147	association dramatically change protein secondary structure natively unfolded predominantly alpha helical perhaps alters functional feature protein num
0.227683.9700196.html.plaintext.txt	148	one feature ability alpha beta synuclein inhibit phospholipase dnum num
0.227683.9700196.html.plaintext.txt	149	inhibition dependent bulk lipid concentration reaction suggesting interaction enzyme occurs membrane surface num thus involves alpha helical natively unfolded synucleins
0.227683.9700196.html.plaintext.txt	150	phospholipase dnum implicated various intracellular pathway including regulation cell growth differentiation interesting study effect persyn activity enzyme neuron tumour cell
0.227683.9700196.html.plaintext.txt	151	substantial change persyn expression accompany breast tumour progression also take place nervous system development
0.227683.9700196.html.plaintext.txt	152	current study shown persyn expressed human fetal cerebral cortex abundant cerebral cortex elderly individual
0.227683.9700196.html.plaintext.txt	153	consistent previous observation persyn expression increased ageing mouse cerebral cortex num
0.227683.9700196.html.plaintext.txt	154	observe substantial difference level persyn protein cerebral cortex patient suffered alzheimers disease normal age matched individual
0.227683.9700196.html.plaintext.txt	155	result agreement immunohistochemical data implicate persyn axonal pathology neurodegenerative condition dot like structure white matter without significant change persyn immunoreactivity cortical neuron v
0.227683.9700196.html.plaintext.txt	156	davy submitted publication
0.227683.9700196.html.plaintext.txt	157	important question whether wild type mutated persyn protein expressed breast tumour
0.227683.9700196.html.plaintext.txt	158	sequence analysis suggests protein tumour cell bcsgnum different protein expressed nervous system cdna clone hnum numc coded genomic clone wnumh
0.227683.9700196.html.plaintext.txt	159	substitution two lysine glutamate bcsgnum change overall charge persyn molecule disturbs ektkegv repeat highly conserved synuclein family
0.227683.9700196.html.plaintext.txt	160	change serious consequence protein structure function
0.227683.9700196.html.plaintext.txt	161	however fact bcsgnum est generated rt pcr amplification raise question accurately sequence clone reflects sequence mrna tumour cell
0.227683.9700196.html.plaintext.txt	162	studied number breast tumour tumour cell line presence mutation underlie lys glu amino acid substitution human persyn sequence
0.227683.9700196.html.plaintext.txt	163	although persyn mrna exon persyn gene analysed mlui styi digestion pcr product mutation found studied tissue cell line
0.227683.9700196.html.plaintext.txt	164	contrast using hphi digestion able detect two nucleotide polymorphism initially recognized sequence difference persyn cdna clone hnum numc
0.227683.9700196.html.plaintext.txt	165	two linked polymorphic site discriminate two allele human persyn gene
0.227683.9700196.html.plaintext.txt	166	allele transcriptionally active expressed similar efficiency heterozygote
0.227683.9700196.html.plaintext.txt	167	find obvious correlation presence particular persyn allele pathological phenotype
0.227683.9700196.html.plaintext.txt	168	although limited number sample analysed two allele breast tumour tumour cell line occur frequency normal cell
0.227683.9700196.html.plaintext.txt	169	data suggest least spontaneous breast tumour high level wild type persyn protein correlate malignant phenotype reported mutation bcsgnum est artefactual may result taq polymerase error
0.227683.9700196.html.plaintext.txt	170	mapped human persyn gene long arm chromosome num qnum
0.227683.9700196.html.plaintext.txt	171	hereditary disorder affected gene yet known located locus
0.227683.9700196.html.plaintext.txt	172	taking account pattern persyn expression sensory neuron peripheral nervous system motoneuron central nervous system interesting check possible involvement persyn gene infantile onset spinocerebellar ataxia sensory neuropathy iosca scanum num
0.227683.9700196.html.plaintext.txt	173	also intriguing loss heterozygosity loh numqnum occurs high frequency different human tumour
0.227683.9700196.html.plaintext.txt	174	mutation ptenmmacnum gene located region implicated many breast carcinoma germline mutation gene believed associated cowden disease rare autosomal dominant familial cancer syndrome high risk breast cancer num
0.227683.9700196.html.plaintext.txt	175	however family individual cowden disease mutation ptenmmacnum gene somatic mutation gene occur small fraction primary breast cancer loh breast cancer necessarily involve ptenmmacnum locus num num
0.227683.9700196.html.plaintext.txt	176	correlation persyn expression breast tumour progression interesting search mutation coding regulatory region gene hereditary spontaneous form breast cancer
0.227683.9700196.html.plaintext.txt	177	defining organization human persyn gene reported important step towards genetic study involvement gene neurodegenerative neoplastic disorder
0.227683.9700196.html.plaintext.txt	178	material method molecular cloning
0.227683.9700196.html.plaintext.txt	179	human persyn cdna clone hnum numc isolated juvenile brainstem cdna library stratagene hybridization mouse persyn cdna probe low stringency described previously num
0.227683.9700196.html.plaintext.txt	180	hnum clone labelled nick translation used probe screening genomic library southern northern hybridization described previously num
0.227683.9700196.html.plaintext.txt	181	construction human genomic library lambdaemblnum described previously num
0.227683.9700196.html.plaintext.txt	182	ecori fragment lambdawnumh dna subcloned pgemnum vector strand sequenced using specific oligonucleotide primer
0.227683.9700196.html.plaintext.txt	183	cycle sequencing carried abi drhodamine big dye terminator amplitaq f abi
0.227683.9700196.html.plaintext.txt	184	reaction product analysed abi prism num dna sequencer
0.227683.9700196.html.plaintext.txt	185	localization persyn gene human metaphase chromosome
0.227683.9700196.html.plaintext.txt	186	fish biotin labelled lambda dna metaphase chromosome obtained standard technique pha stimulated human lymphocyte accomplished described elsewhere numnum
0.227683.9700196.html.plaintext.txt	187	signal analysed using zeiss axiophot fluorescence microscope equipped cooled ccd camera hamamatsu adobe photoshop software package
0.227683.9700196.html.plaintext.txt	188	rt pcr analysis human persyn mrna
0.227683.9700196.html.plaintext.txt	189	total cellular rna reverse transcribed amplified described earlier num
0.227683.9700196.html.plaintext.txt	190	amount total rna sample normalized amplification num bp fragment glyceraldehyde num phosphate dehydrogenase gapdh mrna
0.227683.9700196.html.plaintext.txt	191	primer amplification human persyn coding region follows numprime agcagcacaaccctgcacac numprime numprime tcttcaggtcatccacgctg numprime
0.227683.9700196.html.plaintext.txt	192	amplification num bp fragment carried num cycle num degree c num num degree c num num degree c num
0.227683.9700196.html.plaintext.txt	193	cell low level persyn expression amplified fragment purified agarose gel electrophoresis re amplified another num cycle
0.227683.9700196.html.plaintext.txt	194	amplified fragment digested appropriate restriction endonuclease analysed num metaphor agarose gel fmc
0.227683.9700196.html.plaintext.txt	195	pcr analysis human persyn gene exon
0.227683.9700196.html.plaintext.txt	196	analysis human persyn gene exon human genomic dna amplified using primer located inside intron proximity exon intron junction
0.227683.9700196.html.plaintext.txt	197	condition amplification restriction endonuclease analysis similar condition used rt pcr product except annealing temperature num degree c exon iii num degree c exon iv
0.227683.9700196.html.plaintext.txt	198	primer numprime tgcgagcctgactccagcag numprime numprime ggtgtggagtggagtgatgc numprime used amplification exon iii numprime ttgaggccagggtagacaag numprime numprime ccactcaggttcagggttag numprime exon iv
0.227683.9700196.html.plaintext.txt	199	dna fragment analysed num agarose tbe gel
0.227683.9700196.html.plaintext.txt	200	western blotting used detect persyn protein cell lysates described earlier num
0.227683.9700196.html.plaintext.txt	201	rabbit polyclonal antibody sknum synthetic peptide human persyn v
0.227683.9700196.html.plaintext.txt	202	davy submitted publication affinity purified recombinant human persyn protein bound nh activated column supelco used dilution numnum
0.227683.9700196.html.plaintext.txt	203	secondary antibody horseradish peroxidase linked donkey anti rabbit igg diluted numnum amersham
0.227683.9700196.html.plaintext.txt	204	ecl detection carried according manufacturer protocol amersham
0.227683.9700196.html.plaintext.txt	205	cell culture dish washed phosphate buffered saline pb fixed num pfa pb num degree c num min washed tbt num mm tris hcl ph num
0.227683.9700196.html.plaintext.txt	206	num triton x num blocked num goat serum tbt followed incubation rabbit polyclonal sknum anti persyn antibody numnum mouse monoclonal anti keratin num antibody mabnum numnum chemicon num degree c num h num goat serum tbt
0.227683.9700196.html.plaintext.txt	207	detection tritc conjugated anti rabbit fitc conjugated anti mouse secondary antibody used dilution recommended supplier jackson laboratory
0.227683.9700196.html.plaintext.txt	208	thanks due jim lowe department histopathology university nottingham tissue sample alex houston dna sequencing unit university st andrew automatic dna sequencing
0.227683.9700196.html.plaintext.txt	209	work supported grant wellcome trust royal society
0.227683.9700196.html.plaintext.txt	210	est expression sequence tag fish fluorescence situ hybridization gapdh glyceraldehyde num phosphate dehydrogenase loh loss heterozygosity pb phosphate buffered saline pfa paraformaldehyde pha phytohaemagglutinin
0.227683.9700196.html.plaintext.txt	211	num molecular cloning cdna encoding unrecognized component amyloid alzheimer disease
0.227683.9700196.html.plaintext.txt	212	num tissue dependent alternative splicing mrna nacp precursor non abeta component alzheimers disease amyloid
0.227683.9700196.html.plaintext.txt	213	num identification two distinct synucleins human brain
0.227683.9700196.html.plaintext.txt	214	num precursor protein non abeta component alzheimers disease amyloid presynaptic protein central nervous system
0.227683.9700196.html.plaintext.txt	215	num evidence precursor protein non abeta component alzheimers disease amyloid nacp extended structure primarily composed random coil
0.227683.9700196.html.plaintext.txt	216	jr num nacp protein implicated alzheimers disease learning natively unfolded
0.227683.9700196.html.plaintext.txt	217	num non abeta component alzheimers disease amyloid nac amyloidogenic
0.227683.9700196.html.plaintext.txt	218	num nacp precursor protein non amyloid betaanum protein abeta component alzheimer disease amyloid bind abeta stimulates abeta aggregation
0.227683.9700196.html.plaintext.txt	219	num residue synuclein consensus motif alpha synuclein fragment nac participate transglutaminase catalysed cross linking alzheimer disease amiloid betaanum peptide
0.227683.9700196.html.plaintext.txt	220	num binding abeta alpha beta synucleins identification segment alpha synucleinnac precursor bind abeta nac
0.227683.9700196.html.plaintext.txt	221	num synuclein protein alzheimers disease
0.227683.9700196.html.plaintext.txt	222	num nacpsynuclein gene chromosomal assignment screening alteration alzheimer disease
0.227683.9700196.html.plaintext.txt	223	num human nacpalpha synuclein gene chromosome assignment numqnum
0.227683.9700196.html.plaintext.txt	224	num mutation alpha synuclein gene identified family parkinson disease
0.227683.9700196.html.plaintext.txt	225	num alanumpro mutation gene encoding alpha synuclein parkinson disease
0.227683.9700196.html.plaintext.txt	226	num alpha synuclein lewy body
0.227683.9700196.html.plaintext.txt	227	num abnormal accumulation nacpalpha synuclein neurodegenerative disorder
0.227683.9700196.html.plaintext.txt	228	num persyn member synuclein family influence neurofilament network integrity
0.227683.9700196.html.plaintext.txt	229	num synucleinnacp mrna expression rat hippocampus cerebral cortex development
0.227683.9700196.html.plaintext.txt	230	abstract numth annual meeting society neuroscience new orleans la vol
0.227683.9700196.html.plaintext.txt	231	num identification breast cancer specific gene bcsgnum direct differential cdna sequencing
0.227683.9700196.html.plaintext.txt	232	num variation structure protein coding region human pnum gene
0.227683.9700196.html.plaintext.txt	233	num genetics parkinson disease
0.227683.9700196.html.plaintext.txt	234	num alpha synuclein link parkinson alzheimer disease nature genet
0.227683.9700196.html.plaintext.txt	235	num awakening alpha synuclein
0.227683.9700196.html.plaintext.txt	236	num large kindred autosomal dominant parkinson disease
0.227683.9700196.html.plaintext.txt	237	num mapping gene parkinson disease chromosome numqnum qnum
0.227683.9700196.html.plaintext.txt	238	num characterization novel protein regulated critical period song learning zebra finch
0.227683.9700196.html.plaintext.txt	239	num characterization precursor protein non abeta component senile plaque nacp human central nervous system
0.227683.9700196.html.plaintext.txt	240	num altered presynaptic protein nacp associated plaque formation neurodegeneration alzheimers disease
0.227683.9700196.html.plaintext.txt	241	num stabilization alpha synuclein secondary structure upon binding synthetic membrane
0.227683.9700196.html.plaintext.txt	242	num regulation phospholipase dnum selective inhibition mammalian phospholipase d isoenzymes alpha beta synucleins
0.227683.9700196.html.plaintext.txt	243	num random search shared chromosomal region four affected individual assignment new hereditary ataxia locus
0.227683.9700196.html.plaintext.txt	244	num pten putative protein tyrosine phosphatase gene mutated human brain breast prostate cancer
0.227683.9700196.html.plaintext.txt	245	num role mmacnum mutation early onset breast cancer causative association cowden syndrome excluded brcanum negative case
0.227683.9700196.html.plaintext.txt	246	num mutation analysis putative tumor suppressor gene ptenmmacnum primary breast carcinoma
0.227683.9700196.html.plaintext.txt	247	num loss heterozygosity human breast carcinoma ataxia telangiectasia cowden disease brcanum gene region
0.227683.9700196.html.plaintext.txt	248	num dnum gene family human genome
0.227683.9700196.html.plaintext.txt	249	num differential splicing creates diversity transcript neurospecific developmentally regulated gene encoding protein new zinc finger motif
0.227683.9700196.html.plaintext.txt	250	num assignment ordering twenty three unique noti linking clone containing expressed gene including guanosine numprime monophosphate synthetase gene human chromosome num
0.227683.9700196.html.plaintext.txt	251	num rat chicken rexnsp mrna nucleotide sequence main transcript expression splice variant rat tissue
0.227683.9700196.html.plaintext.txt	252	num trkb variant deletion leucine rich motif extracellular domain
0.227683.9700196.html.plaintext.txt	253	num num num medline abstract
0.227683.9700196.html.plaintext.txt	254	correspondence addressed
0.227683.9700196.html.plaintext.txt	255	tel num num num fax num num num email vlbst andrew
0.227683.9700196.html.plaintext.txt	256	uk page run oxford university press great clarendon street oxford oxnum numdp part oup journal comment feedback www adminatoup
0.227683.9700196.html.plaintext.txt	257	uk u d last modification num aug num copyright oxford university press num
0.23021185.11823314.html.plaintext.txt	0	old age psychiatry alistair burn frcpsych
0.23021185.11823314.html.plaintext.txt	1	university manchester withington hospital manchester
0.23021185.11823314.html.plaintext.txt	2	newcastle general hospital newcastle upon tyne uk
0.23021185.11823314.html.plaintext.txt	3	correspondence professor alistair burn department psychiatry education research centre wythenshawe hospital southmoor road manchester mnum numlt uk
0.23021185.11823314.html.plaintext.txt	4	tel num num num num num fax num num num num num e mail aburnsatfsl
0.23021185.11823314.html.plaintext.txt	5	fashionable necessary day start presentation declaring one conflict interest
0.23021185.11823314.html.plaintext.txt	6	editor special supplement therefore declare interest old age psychiatry
0.23021185.11823314.html.plaintext.txt	7	long ago cynically described cinderella speciality old age psychiatry past year become increasingly popular clinical career choice
0.23021185.11823314.html.plaintext.txt	8	community oriented multi disciplinary service remain relatively unfettered excessive bureaucracy would attractive option largely demoralised health care system reason speciality thriving
0.23021185.11823314.html.plaintext.txt	9	least enormous advance made past decade understanding neurobiological basis late life psychiatric disorder
0.23021185.11823314.html.plaintext.txt	10	dementia particular attracted attention top level neuroscientist applied combination classical neuropathology molecular genetics protein chemistry reveal key event underlying neurodegeneration
0.23021185.11823314.html.plaintext.txt	11	result conceivable effective treatment delay prevent onset alzheimers disease could available within decade something virtually unthinkable num year ago
0.23021185.11823314.html.plaintext.txt	12	old age psychiatry clinician near enough buzz feel excited
0.23021185.11823314.html.plaintext.txt	13	differential diagnosis dementia subtype important part assessment convergence clinical description lewy body dementia frontotemporal dementia give two example covered issue allowing increased sophistication term diagnostic reporting clinician
0.23021185.11823314.html.plaintext.txt	14	distinction lead directly important management decision avoidance neuroleptic agent lewy body disease use cholinesterase inhibitor alzheimers disease
0.23021185.11823314.html.plaintext.txt	15	recognition disorder hitherto regarded functional nature organic basis stimulated research uncovering aetiological factor influenced clinical practice
0.23021185.11823314.html.plaintext.txt	16	furthermore improved method measuring symptom valid reliable way enabled effect therapeutic intervention especially drug trial assessed way sufficiently robust allow regulatory authority convinced worth
0.23021185.11823314.html.plaintext.txt	17	reason presenting series invited paper subject old age psychiatry inform general reader major issue challenge success speciality today
0.23021185.11823314.html.plaintext.txt	18	following contribution intended comprehensive survey increasingly widening field chosen give flavour richness clinical practice research
0.23021185.11823314.html.plaintext.txt	19	chosen concentrate description organically based syndrome differential diagnosis effect
0.23021185.11823314.html.plaintext.txt	20	holmes num issue summarised much current information concerning molecular biology alzheimers disease emphasising importance gene risk factor disease stepping outside often narrow way thinking tends tunnel vision equating genetics disease early onset rare mutation
0.23021185.11823314.html.plaintext.txt	21	clearly field much promise term treatment
0.23021185.11823314.html.plaintext.txt	22	theme continued bullock num issue summary new drug alzheimers disease
0.23021185.11823314.html.plaintext.txt	23	three anticholinesterase drug available treatment mild moderate alzheimers disease approved national institute clinical excellence uk
0.23021185.11823314.html.plaintext.txt	24	role drug treatment alzheimers disease become apparent continued clinical practice influenced appropriate audit use benefit patient
0.23021185.11823314.html.plaintext.txt	25	snowden et al num issue provide date summary frontotemporal dementia drawing together clinical neuropsychological pathological expertise group instrumental clinical description relatively common underrecognised cause dementia particularly younger people
0.23021185.11823314.html.plaintext.txt	26	vascular dementia sample pip frontotemporal dementia post one common cause syndrome summarised stewart num issue lack clear blue water alzheimers disease vascular dementia plainly acknowledged problem increasingly influencing clinical practice well taxing epidemiologist
0.23021185.11823314.html.plaintext.txt	27	theme vascular disease continued review vascular basis depression baldwin obrien num issue
0.23021185.11823314.html.plaintext.txt	28	condition may explain element treatment resistance practice also implication management patient
0.23021185.11823314.html.plaintext.txt	29	subcortical dementia summarised turner et al num issue emphasise phenomenological aspect dementia aetiological importance
0.23021185.11823314.html.plaintext.txt	30	jacoby num issue brings fore many legal aspect old age psychiatry increasingly becoming part everyday clinical practice particularly relation consent euthanasia mental capacity
0.23021185.11823314.html.plaintext.txt	31	interface health social care highlighted challis hughes num issue current political climate distinction clinically blurred many situation becoming important administrative financial term
0.23021185.11823314.html.plaintext.txt	32	cost care essential underpinning consideration clinical care kavanagh knapp num issue describe model underlying many assumption made predicting cost caring people cognitive impairment
0.23021185.11823314.html.plaintext.txt	33	contribution concern dementia lewy body mckeith num issue use rating scale old age psychiatry burn et al num issue
0.23021185.11823314.html.plaintext.txt	34	hope useful new information practising old age psychiatry
0.23021185.11823314.html.plaintext.txt	35	two cost rapidly changing expanding field keeping abreast new information meeting rising public expectation might done
0.23021185.11823314.html.plaintext.txt	36	uncommon patient present one burgeoning number memory clinic uk asking early diagnosis treatment well aware recent guidance national institute clinical excellence new antidementia drug made available within national health service recently published national service framework older people set specific standard care aspiration good practice across wide range mental health care issue
0.23021185.11823314.html.plaintext.txt	37	challenge plenty
0.23021185.11823314.html.plaintext.txt	38	collection paper give indication responding
0.23021185.11823314.html.plaintext.txt	39	num vascular basis late onset depressive disorder
0.23021185.11823314.html.plaintext.txt	40	british journal psychiatry num num num
0.23021185.11823314.html.plaintext.txt	41	num new drug alzheimers disease dementia
0.23021185.11823314.html.plaintext.txt	42	british journal psychiatry num num num
0.23021185.11823314.html.plaintext.txt	43	num rating scale old age psychiatry
0.23021185.11823314.html.plaintext.txt	44	british journal psychiatry num num num
0.23021185.11823314.html.plaintext.txt	45	num frail old people margin care recent research finding
0.23021185.11823314.html.plaintext.txt	46	british journal psychiatry num num num
0.23021185.11823314.html.plaintext.txt	47	department health num national service framework older people
0.23021185.11823314.html.plaintext.txt	48	num genotype phenotype alzheimers disease
0.23021185.11823314.html.plaintext.txt	49	british journal psychiatry num num num
0.23021185.11823314.html.plaintext.txt	50	num old age psychiatry law
0.23021185.11823314.html.plaintext.txt	51	british journal psychiatry num num num
0.23021185.11823314.html.plaintext.txt	52	num cost cognitive disability modelling underlying association
0.23021185.11823314.html.plaintext.txt	53	british journal psychiatry num num num
0.23021185.11823314.html.plaintext.txt	54	num dementia lewy body
0.23021185.11823314.html.plaintext.txt	55	british journal psychiatry num num num
0.23021185.11823314.html.plaintext.txt	56	num frontotemporal dementia
0.23021185.11823314.html.plaintext.txt	57	british journal psychiatry num num num
0.23021185.11823314.html.plaintext.txt	58	num vascular dementia diagnosis running time
0.23021185.11823314.html.plaintext.txt	59	british journal psychiatry num num num
0.23021185.11823314.html.plaintext.txt	60	british journal psychiatry num num num
0.23021185.11823314.html.plaintext.txt	61	received publication august num num
0.23021185.11823314.html.plaintext.txt	62	revision received august num num
0.23021185.11823314.html.plaintext.txt	63	accepted publication august num num
0.23021185.11823314.html.plaintext.txt	64	highlight issue elizabeth walsh bjp num num num
0.23021185.11823314.html.plaintext.txt	65	old age psychiatry law robin jacoby bjp num num num num
0.23021185.11823314.html.plaintext.txt	66	cost cognitive disability modelling underlying association shane kavanagh martin knapp bjp num num num num
0.23021185.11823314.html.plaintext.txt	67	frail old people margin care recent research finding david challis jane hughes bjp num num num num
0.23021185.11823314.html.plaintext.txt	68	genotype phenotype alzheimers disease clive holmes bjp num num num num
0.23021185.11823314.html.plaintext.txt	69	new drug alzheimers disease dementia roger bullock bjp num num num num
0.23021185.11823314.html.plaintext.txt	70	frontotemporal dementia julie
0.23021185.11823314.html.plaintext.txt	71	snowden david neary david m
0.23021185.11823314.html.plaintext.txt	72	dementia lewy body ian g
0.23021185.11823314.html.plaintext.txt	73	kopelman bjp num num num num
0.23021185.11823314.html.plaintext.txt	74	vascular dementia diagnosis running time robert stewart bjp num num num num
0.23021185.11823314.html.plaintext.txt	75	vascular basis late onset depressive disorder robert c
0.23021185.11823314.html.plaintext.txt	76	baldwin john obrien bjp num num num num
0.23021185.11823314.html.plaintext.txt	77	rating scale old age psychiatry alistair burn brian lawlor sarah craig bjp num num num num
0.23021185.11823314.html.plaintext.txt	78	article full text pdf submit response alert article cited alert eletters posted alert correction posted citation map service email article friend related article bjp similar article journal similar article pubmed alert new issue journal download citation manager google scholar article burn
0.23021185.11823314.html.plaintext.txt	79	article citing article pubmed pubmed citation article burn
0.23021185.11823314.html.plaintext.txt	80	home help feedback subscription archive search table content psychiatric bulletin advance psychiatric treatment rcpsych journal
0.23427205.14718220.html.plaintext.txt	0	relation education occupation based socioeconomic status incident alzheimer disease anita karpnumnum ingemar kareholtnum chengxuan qiunumnum tom bellandernum bengt winbladnumnum laura fratiglioninumnum
0.23427205.14718220.html.plaintext.txt	1	num aging research center division geriatric epidemiology medicine neurotec karolinska institutet stockholm sweden
0.23427205.14718220.html.plaintext.txt	2	num stockholm gerontology research center stockholm sweden
0.23427205.14718220.html.plaintext.txt	3	num department occupational environmental health stockholm county council institute environmental medicine karolinska institutet stockholm sweden
0.23427205.14718220.html.plaintext.txt	4	received publication june num num accepted publication july num num
0.23427205.14718220.html.plaintext.txt	5	aged alzheimer disease dementia education social class
0.23427205.14718220.html.plaintext.txt	6	abbreviation abbreviation ci confidence interval s socioeconomic status
0.23427205.14718220.html.plaintext.txt	7	known education indicator socioeconomic status s
0.23427205.14718220.html.plaintext.txt	8	different study shown high num moderate num correlation education occupation based s
0.23427205.14718220.html.plaintext.txt	9	nevertheless two variable represent different aspect period life course may generate difference health various mechanism num num
0.23427205.14718220.html.plaintext.txt	10	lynch kaplan describe education transition socio economic position largely received parent achieved socio economic position adult num p
0.23427205.14718220.html.plaintext.txt	11	socioeconomic factor acting life course found affect health premature death well risk cardiovascular disease num num
0.23427205.14718220.html.plaintext.txt	12	cumulative economic hardship found lead poorer cognitive functioning num
0.23427205.14718220.html.plaintext.txt	13	num examined relation socioeconomic mobility cognitive function among finish men late middle age suggested stage life course play role influencing adult cognitive function
0.23427205.14718220.html.plaintext.txt	14	study reported association adult s based occupation incidence alzheimer disease dementia
0.23427205.14718220.html.plaintext.txt	15	num found investigated marker s education occupational prestige income predicted development alzheimer disease
0.23427205.14718220.html.plaintext.txt	16	reported manual work involves production good could increase risk clinical alzheimer disease dementia num
0.23427205.14718220.html.plaintext.txt	17	however study focused principal occupation occupational period
0.23427205.14718220.html.plaintext.txt	18	addition relation social mobility different socioeconomic level life course risk dementia old age studied
0.23427205.14718220.html.plaintext.txt	19	general aim study determine whether reported association low education increased risk alzheimer disease dementia could explained occupation based s
0.23427205.14718220.html.plaintext.txt	20	specifically examined risk alzheimer disease dementia varied different combination num education main occupation based s num education lifetime number year spent low occupation based s
0.23427205.14718220.html.plaintext.txt	21	since education occupation based s interrelated special attention given category deviated expected pattern combination high educationlow occupation based s low educationhigh occupation based s
0.23427205.14718220.html.plaintext.txt	22	furthermore investigated social mobility pattern explore whether later advancement setback occupation based s may affect relation education alzheimer disease incidence
0.23427205.14718220.html.plaintext.txt	23	identification incident case alzheimer disease dementia follow subject clinically examined physician neuropsychologically assessed psychologist interviewed nurse
0.23427205.14718220.html.plaintext.txt	24	incident case dementia defined developed follow period
0.23427205.14718220.html.plaintext.txt	25	diagnosis clinical dementia made according criterion diagnostic statistical manual mental disorder third edition revised num using three step procedure
0.23427205.14718220.html.plaintext.txt	26	first preliminary diagnosis made examining physician
0.23427205.14718220.html.plaintext.txt	27	second case independently reviewed specialized clinician second diagnosis made
0.23427205.14718220.html.plaintext.txt	28	diagnosis agreement accepted final
0.23427205.14718220.html.plaintext.txt	29	case disagreement third opinion obtained concordant diagnosis accepted
0.23427205.14718220.html.plaintext.txt	30	diagnosis dementia made subject completely fulfilled criterion diagnostic statistical manual mental disorder third edition revised
0.23427205.14718220.html.plaintext.txt	31	diagnosis alzheimer disease particular required gradual onset progressive deterioration cognitive functioning exclusion specific cause dementia
0.23427205.14718220.html.plaintext.txt	32	neuroimaging autopsy data available
0.23427205.14718220.html.plaintext.txt	33	clinical diagnosis alzheimer disease corresponds diagnosis probable alzheimer disease according nincds adrda national institute neurological communicative disorder stroke alzheimer disease related disorder association criterion num
0.23427205.14718220.html.plaintext.txt	34	num deceased subject preliminary diagnosis made physician consulted medical record death certificate diagnosis reviewed senior clinician
0.23427205.14718220.html.plaintext.txt	35	discharge diagnosis hospital n num death certificate n num available reported diagnosis accepted
0.23427205.14718220.html.plaintext.txt	36	repeated analysis survivor cohort result similar
0.23427205.14718220.html.plaintext.txt	37	measurement educational attainment information total year formal education collected baseline
0.23427205.14718220.html.plaintext.txt	38	study educational level divided two main category num num year num year primary school case num extra year practical vocational training bordernumnum year intermediate university level
0.23427205.14718220.html.plaintext.txt	39	dichotomization based previous analysis num different level education examined relation alzheimer disease
0.23427205.14718220.html.plaintext.txt	40	person intermediate amount education num num year schooling differ university educated subject bordernumnum year schooling term alzheimer disease risk
0.23427205.14718220.html.plaintext.txt	41	data educational background missing three person
0.23427205.14718220.html.plaintext.txt	42	subject omitted analysis concerning education
0.23427205.14718220.html.plaintext.txt	43	assessment occupation based s main occupation based s specially trained nurse interviewed relative another person significant subject subject full lifetime work history
0.23427205.14718220.html.plaintext.txt	44	questionnaire developed occupational hygienist
0.23427205.14718220.html.plaintext.txt	45	eight occupational period specific information regarding time place listed
0.23427205.14718220.html.plaintext.txt	46	subject longest held job considered main occupation
0.23427205.14718220.html.plaintext.txt	47	occupation grouped according socioeconomic classification system developed statistic sweden num
0.23427205.14718220.html.plaintext.txt	48	swedish socioeconomic classification system primarily contains dimension ownership mean production division blue collar white collar occupation assessed normal trade union affiliation
0.23427205.14718220.html.plaintext.txt	49	also contains aspect skill subdivision inside blue collar white collar occupational category
0.23427205.14718220.html.plaintext.txt	50	however customary educational requirement respective occupation used information education individual level
0.23427205.14718220.html.plaintext.txt	51	quite woman num percent homemaker longest occupational period
0.23427205.14718220.html.plaintext.txt	52	information husband occupation frequently used estimate s wife available
0.23427205.14718220.html.plaintext.txt	53	instead including homemaker category used second longest held job estimate s
0.23427205.14718220.html.plaintext.txt	54	eighteen subject housewife throughout working life excluded analysis involving main occupation
0.23427205.14718220.html.plaintext.txt	55	first analyzed relation s incidence alzheimer disease dementia using three category blue collar worker white collar employee self employed person plus academic profession
0.23427205.14718220.html.plaintext.txt	56	since two last category similar risk two group merged
0.23427205.14718220.html.plaintext.txt	57	lifetime occupational s data gathered length occupational period subject lifetime occupation classified described exception substitution occupational period could made homemaker work period
0.23427205.14718220.html.plaintext.txt	58	instead classified nonmanual period num woman often held nonmanual job occupational period num generally highly educated nonhousewives
0.23427205.14718220.html.plaintext.txt	59	finally added number year period manual labor obtain sum year spent low occupation based s
0.23427205.14718220.html.plaintext.txt	60	current study report result analysis number year low s le equal num versus num median amount time spent low s low s fraction population
0.23427205.14718220.html.plaintext.txt	61	socioeconomic mobility computed occupation based s age num num num year order estimate individual socioeconomic mobility pattern
0.23427205.14718220.html.plaintext.txt	62	information particular time period missing substituted equal number year two closest work period
0.23427205.14718220.html.plaintext.txt	63	sixty three person lacked information occupational position num year age instead information concerning occupational period prior chosen represent
0.23427205.14718220.html.plaintext.txt	64	covariates used covariates available information database may acted confounding factor
0.23427205.14718220.html.plaintext.txt	65	major possible confounders considered age gender vascular disease alcohol data
0.23427205.14718220.html.plaintext.txt	66	information age gender derived swedish national population register
0.23427205.14718220.html.plaintext.txt	67	information cerebrovascular heart disease diabetes mellitus derived computerized stockholm inpatient registry system admission discharge diagnosis every hospital stockholm recorded
0.23427205.14718220.html.plaintext.txt	68	current study diagnosis made time num baseline examination used
0.23427205.14718220.html.plaintext.txt	69	disease diagnosed according international classification disease eighth revision code num num cerebrovascular disease code num num coronary disease code num heart failure code num arrhythmia code num diabetes mellitus
0.23427205.14718220.html.plaintext.txt	70	information diabetes patient register integrated self report doctor diagnosis diabetes use oral hypoglycemic medication insulin blood glucose level greater num mmolliter
0.23427205.14718220.html.plaintext.txt	71	arterial blood pressure measured baseline mercury sphygmomanometer trained nurse
0.23427205.14718220.html.plaintext.txt	72	first reading abnormal systolic pressure bordernumnum mmhg diastolic pressure bordernumnum mmhg two additional reading made
0.23427205.14718220.html.plaintext.txt	73	mean second third reading used analysis num
0.23427205.14718220.html.plaintext.txt	74	furthermore created simple additive index ranging num num vascular disease risk factor described
0.23427205.14718220.html.plaintext.txt	75	information alcohol use collected relative specified many glass wine bottle beer andor glass liquor proband consumed weekly
0.23427205.14718220.html.plaintext.txt	76	since consumption alcohol predominantly female elderly population found particularly low num
0.23427205.14718220.html.plaintext.txt	77	num percent person available data alcohol reported used alcohol num
0.23427205.14718220.html.plaintext.txt	78	num percent consumed amount corresponding five glass wine per week decided divide alcohol data three category use use information
0.23427205.14718220.html.plaintext.txt	79	latter category included analysis reporting alcohol use sometimes sensitive matter found relevant investigate whether absence information associated risk dementia
0.23427205.14718220.html.plaintext.txt	80	covariates controlled analysis num cognitive status baseline measured mini mental state examination num num social network baseline measured four grade index poor limited moderate rich social network defined previous study num num engagement mental physical activity baseline graded three frequency category num
0.23427205.14718220.html.plaintext.txt	81	statistical analysis logistic regression used evaluate difference baseline characteristic participant dropout
0.23427205.14718220.html.plaintext.txt	82	cox proportional hazard regression analysis used estimate relative risk incident alzheimer disease dementia associated different combination education occupation based s well socioeconomic mobility
0.23427205.14718220.html.plaintext.txt	83	follow time nondemented person estimated date baseline interview date follow examination death
0.23427205.14718220.html.plaintext.txt	84	demented person half time calculated since dementia onset assumed midpoint baseline follow examination
0.23427205.14718220.html.plaintext.txt	85	age gender vascular disease index alcohol use entered model
0.23427205.14718220.html.plaintext.txt	86	additional model used verify possible confounding effect baseline mini mental state examination score social network leisure activity
0.23427205.14718220.html.plaintext.txt	87	also repeated analysis excluding stroke case purpose examining whether stroke might obscure increase diagnostic difficulty dementia due cognitive dysfunction subject previous stroke
0.23427205.14718220.html.plaintext.txt	88	interrelation education s explored using two stratification
0.23427205.14718220.html.plaintext.txt	89	first study population divided four stratum characterized num high education high s num high education low s num low education high s num low education low s
0.23427205.14718220.html.plaintext.txt	90	second used four stratum combining low high education defined permanence low s le equal num year versus num year
0.23427205.14718220.html.plaintext.txt	91	total num subject developed clinically definite dementia follow period
0.23427205.14718220.html.plaintext.txt	92	among dementia case type num person diagnosed clinically definite dementia alzheimer type
0.23427205.14718220.html.plaintext.txt	93	table num provides characteristic participant dementia status follow
0.23427205.14718220.html.plaintext.txt	94	baseline characteristic study population n num dementia status follow kungsholmen project stockholm sweden num num relative risk clinical dementia alzheimer type type relation education occupation based s reported table num
0.23427205.14718220.html.plaintext.txt	95	compared person high level education bordernumnum year adjusted relative risk dementia alzheimer type dementia type similar subject intermediate amount num num year education elevated subject low level num num year education see model numa
0.23427205.14718220.html.plaintext.txt	96	model numb merged high intermediate level education one reference category
0.23427205.14718220.html.plaintext.txt	97	model numb model num subject either low level education low occupation based s found higher risk alzheimer disease dementia even adjustment covariates examined
0.23427205.14718220.html.plaintext.txt	98	however education s introduced model simultaneously table num model num low education remained significant risk factor alzheimer disease dementia
0.23427205.14718220.html.plaintext.txt	99	result similar men woman although relative risk men statistically significant probably le statistical power
0.23427205.14718220.html.plaintext.txt	100	relative risk clinically diagnosed alzheimer disease dementia associated education occupation based socioeconomic status lifetime longest held job derived separate model model num num model model num kungsholmen project stockholm sweden num num subject low educationlow occupation based s category often female num percent subject high educationhigh occupation based s category num percent
0.23427205.14718220.html.plaintext.txt	101	number person high educationlow occupation based s group smaller n num comparison group contained largest proportion woman num percent housewife num percent
0.23427205.14718220.html.plaintext.txt	102	low educationhigh occupation based s group differed noticeably num percent member self employed whereas num percent person high educationhigh occupation based s group self employed
0.23427205.14718220.html.plaintext.txt	103	low education combination either low high occupation based s associated increased risk alzheimer disease dementia even adjustment major covariates
0.23427205.14718220.html.plaintext.txt	104	combination high education low occupation based s associated increased risk alzheimer disease dementia table num
0.23427205.14718220.html.plaintext.txt	105	relative risk clinically diagnosed alzheimer disease dementia associated combination education occupation based socioeconomic status lifetime longest held job kungsholmen project stockholm sweden num num stratified analysis relation combination education total year low occupation based s alzheimer disease showed result similar stratified analysis depicted table num
0.23427205.14718220.html.plaintext.txt	106	compared person high education le num year low s subgroup low education num year low s adjusted relative risk num
0.23427205.14718220.html.plaintext.txt	107	num subgroup low education fewer num year low s adjusted relative risk num
0.23427205.14718220.html.plaintext.txt	108	high education conjunction num year low s associated increased risk alzheimer disease
0.23427205.14718220.html.plaintext.txt	109	table num model num show relative risk alzheimer disease relation eight social mobility pattern controlling age gender
0.23427205.14718220.html.plaintext.txt	110	low occupation based s age num num num year resulted borderline significant elevated risk alzheimer disease compared reference category high s three age
0.23427205.14718220.html.plaintext.txt	111	low occupation based s age num num year age num year also associated significantly elevated risk alzheimer disease
0.23427205.14718220.html.plaintext.txt	112	furthermore low occupation based s num year age regardless whether s high age num andor age num associated elevated alzheimer disease risk though statistically significantly
0.23427205.14718220.html.plaintext.txt	113	however additional adjustment education none significant association remained
0.23427205.14718220.html.plaintext.txt	114	twenty eight percent subject high occupational s age num num num year num percent subject low s age num num num year low educational level
0.23427205.14718220.html.plaintext.txt	115	analysis type dementia showed similar result
0.23427205.14718220.html.plaintext.txt	116	relative risk clinically diagnosed alzheimer disease associated social mobility occupation based socioeconomic status age num num num year kungsholmen project stockholm sweden num num finally baseline cognitive status variable mini mental state examination score social network engagement physical mental activity included model covariates relation s education alzheimer disease dementia substantially change
0.23427205.14718220.html.plaintext.txt	117	repeated analysis excluding case stroke association education alzheimer disease education dementia similar result showed pattern main analysis
0.23427205.14718220.html.plaintext.txt	118	result agreement previous finding positive association low level education increased risk alzheimer disease dementia num num
0.23427205.14718220.html.plaintext.txt	119	num reported socioeconomic measure education income occupational prestige predicted alzheimer disease risk
0.23427205.14718220.html.plaintext.txt	120	however included three measure model education income occupational prestige retained significant association alzheimer disease
0.23427205.14718220.html.plaintext.txt	121	recently investigator nurse health study num reported strong association low education cognitive decline little association marker s
0.23427205.14718220.html.plaintext.txt	122	fact association low education increased risk alzheimer disease dementia general present independently main occupation based s fact association s alzhei mer disease dementia mainly due s early work life seems indicate unknown education related factor acting first two decade life may involved development alzheimer disease dementia
0.23427205.14718220.html.plaintext.txt	123	interpretation agreement number previous report
0.23427205.14718220.html.plaintext.txt	124	recent article kaplan et al
0.23427205.14718220.html.plaintext.txt	125	num concluded higher childhood socioeconomic position well greater educational attainment associated better cognitive function adulthood
0.23427205.14718220.html.plaintext.txt	126	study education dementia italian population middle high socioeconomic level first decade life suggested critical period development dementia later life num
0.23427205.14718220.html.plaintext.txt	127	num discussed possibility low education major risk factor alzhei mer disease rather marker accompanying deleterious socioeconomic environmental influence childhood
0.23427205.14718220.html.plaintext.txt	128	poor quality childhood adolescent environment suggested prevent brain reaching complete level maturation turn may put people higher risk alzheimer disease num num
0.23427205.14718220.html.plaintext.txt	129	result paquid study num showed occupation change risk alzheimer disease instead related cognitive ability childhood adolescence
0.23427205.14718220.html.plaintext.txt	130	early life factor question may early socioeconomic factor mental stimulation cognitive ability
0.23427205.14718220.html.plaintext.txt	131	cognitive ability may affected environmental num genetic influence num
0.23427205.14718220.html.plaintext.txt	132	since many study like lack independent measure intelligence importance early life cognitive ability difficult evaluate
0.23427205.14718220.html.plaintext.txt	133	number study given special attention effect early life circumstance health mortality general
0.23427205.14718220.html.plaintext.txt	134	early life s reported connected cardiovascular disease general health status later life num num
0.23427205.14718220.html.plaintext.txt	135	disadvantaged childhood living condition hypothesized trigger unhealthy life trajectory increased illness risk sum several health damaging factor num
0.23427205.14718220.html.plaintext.txt	136	new result random swedish national sample indicate occupational class difference adult mortality depend fairly large extent childhood condition num
0.23427205.14718220.html.plaintext.txt	137	examined relation s alzheimer disease dementia lifetime perspective ranging school retirement unfortunately lacked specific data s family origin
0.23427205.14718220.html.plaintext.txt	138	thus suggest involvement early life factor development alzheimer disease dementia hypothesis
0.23427205.14718220.html.plaintext.txt	139	alternative explanation finding education may better indicator adult lifestyle habit occupational s lifestyle habit alcohol use smoking may explain detected association
0.23427205.14718220.html.plaintext.txt	140	however data adjusted alcohol use additionally current social network index engagement physical mental activity entered model covariates obtained similar result
0.23427205.14718220.html.plaintext.txt	141	smoking related alzheimer disease dementia population num
0.23427205.14718220.html.plaintext.txt	142	regard cognitive function late middle age turrell et al
0.23427205.14718220.html.plaintext.txt	143	num reported disadvantaged socioeconomic circumstance childhood may extent overcome later upward mobility
0.23427205.14718220.html.plaintext.txt	144	however study low education remained associated increased risk alzheimer disease even adjustment adult social mobility
0.23427205.14718220.html.plaintext.txt	145	potential limitation study must considered
0.23427205.14718220.html.plaintext.txt	146	person dropped study le educated participant
0.23427205.14718220.html.plaintext.txt	147	since low education related alzheimer disease dementia may affected result likely skewed finding towards underestimation association towards overestimation
0.23427205.14718220.html.plaintext.txt	148	occupational data obtained informant
0.23427205.14718220.html.plaintext.txt	149	however single open ended question occupation without specification time place number year already posed participant baseline interview possible compare response informant data regarding subject main job
0.23427205.14718220.html.plaintext.txt	150	information two different source used estimate s agreement num percent
0.23427205.14718220.html.plaintext.txt	151	swedish system classification s occupation well established evaluated num
0.23427205.14718220.html.plaintext.txt	152	however remains occupation based s difficult evaluate education
0.23427205.14718220.html.plaintext.txt	153	estimation s occupation difficult housewife cohort num percent
0.23427205.14718220.html.plaintext.txt	154	approximation likely create nondifferential misclassification s leading dilution association
0.23427205.14718220.html.plaintext.txt	155	performed additional analysis data shown treating housewife third occupational category affect result
0.23427205.14718220.html.plaintext.txt	156	finally must cautious interpreting finding reflecting direct effect education alzheimer disease risk one mediated occupation based s
0.23427205.14718220.html.plaintext.txt	157	fact possibility unmeasured confounders responsible pattern association found study
0.23427205.14718220.html.plaintext.txt	158	example work related stress may associated occupation based s education may increase risk alzheimer disease dementia though currently clear evidence literature concerning association
0.23427205.14718220.html.plaintext.txt	159	main conclusion drawn study low level education directly associated increased alzheimer disease incidence mediated low adult occupation based s regardless whether low s occupational period extended substantial number year bordernumnum year regardless adult socioeconomic mobility pattern
0.23427205.14718220.html.plaintext.txt	160	result inconsistent already suggested hypothesis cognitive brain reserve num num
0.23427205.14718220.html.plaintext.txt	161	alternatively finding may partly reflect detection bias subject low level education tend clinically diagnosed alzheimer disease dementia earlier point time num
0.23427205.14718220.html.plaintext.txt	162	however possibility factor related early life s may play role development alzheimer disease dementia disregarded
0.23427205.14718220.html.plaintext.txt	163	finding support hypothesis stress importance collecting data early life condition studying dementia old age
0.23427205.14718220.html.plaintext.txt	164	acknowledgment research grant received swedish council work life research
0.23427205.14718220.html.plaintext.txt	165	fnumnum swedish council social research
0.23427205.14718220.html.plaintext.txt	166	num num gamla tjanarinnor foundation solstickan foundation
0.23427205.14718220.html.plaintext.txt	167	author thank member kungsholmen project study group cooperation data collection management
0.23427205.14718220.html.plaintext.txt	168	note reprint request anita karp aging research center karolinska institutet box num olivecronas vag num num num stockholm sweden e mail anita
0.23731914.12456513.html.plaintext.txt	0	managing behavioural psychological symptom dementia brian lawlor frcpsych
0.23731914.12456513.html.plaintext.txt	1	jonathan swift clinic department psychiatry st james hospital st james street dublin num ireland
0.23731914.12456513.html.plaintext.txt	2	received honorarium hospitality pharmaceutical company working field alzheimers disease behavioural psychological symptom dementia
0.23731914.12456513.html.plaintext.txt	3	behavioural psychological symptom dementia bpsd common problematic clinical practice represent significant part day day workload old age psychiatry team hospital institution community setting
0.23731914.12456513.html.plaintext.txt	4	improving recognition management bpsd positive impact quality life patient carers potentially delay transition home institutional care
0.23731914.12456513.html.plaintext.txt	5	behavioural psychological symptom dementia umbrella term embrace heterogeneous group non cognitive symptom behaviour occur people dementia
0.23731914.12456513.html.plaintext.txt	6	concept bpsd descriptive one reflect diagnostic entity rather high light important clinical dimension dementia recently ignored research therapeutic point view
0.23731914.12456513.html.plaintext.txt	7	one approach description bpsd use list observed behaviour wandering agitation sexually inappropriate behaviour elicited psychological symptom depression anxiety delusion finkel et al num
0.23731914.12456513.html.plaintext.txt	8	approach fails take account fact many called elicited symptom depression delusion also represent observed behaviour look depressed act though hallucinating deluded fact symptom behaviour occur isolation tend occur together cluster syndrome
0.23731914.12456513.html.plaintext.txt	9	number syndrome described basis factor analytical study using rating instrument designed measure bpsd frisoni et al num
0.23731914.12456513.html.plaintext.txt	10	syndrome include depression psychosis psychomotor agitation aggression apathy
0.23731914.12456513.html.plaintext.txt	11	depression psychosis included descriptor dsm iv criterion alzheimers disease american psychiatric association num recently diagnostic criterion distinct syndrome psychosis alzheimers disease related dementia depression alzheimers disease proposed jeste finkel num olin et al num
0.23731914.12456513.html.plaintext.txt	12	likely diagnostic criterion behavioural syndrome dementia also developed near future facilitate recognition future therapeutic targeting specific aspect bpsd
0.23731914.12456513.html.plaintext.txt	13	although behaviour psychological symptom included core feature definition dementia syndrome two third people dementia experience bpsd one time point one third community dwelling people dementia level bpsd clinically significant range lyketsos et al num
0.23731914.12456513.html.plaintext.txt	14	figure clinically significant bpsd rise almost num people dementia residing care environment margallo lana et al num
0.23731914.12456513.html.plaintext.txt	15	prevalence estimate bpsd vary widely heterogeneity patient population studied term setting type dementia different definition used bpsd
0.23731914.12456513.html.plaintext.txt	16	recent application standardised validated assessment instrument resulting consistent data community clinic based population
0.23731914.12456513.html.plaintext.txt	17	two population based study one usa lyketsos et al num one uk burn et al num show similar prevalence figure num bpsd people alzheimers disease
0.23731914.12456513.html.plaintext.txt	18	unlike cognitive dysfunction dementia progressively worsens time many bpsd tend fluctuate psycho motor agitation persistent devanand et al num
0.23731914.12456513.html.plaintext.txt	19	research needed natural history longitudinal course bpsd inform clinician appropriate duration pharmacological intervention advice information given family distressed symptom behaviour
0.23731914.12456513.html.plaintext.txt	20	occurrence bpsd often triggering event recognition referral people dementia specialist service patient family present crisis disarray relatively late course illness
0.23731914.12456513.html.plaintext.txt	21	development bpsd major risk factor caregiver burden coen et al num institutionalisation odonnell et al num important regard enduring cognitive deficit disease process steele et al num
0.23731914.12456513.html.plaintext.txt	22	aspect bpsd associated caregiver burden paranoia aggression sleep wake cycle disturbance appear particularly important driver caregiver burden institutionalisation odonnell et al num
0.23731914.12456513.html.plaintext.txt	23	development bpsd also associated worse prognosis rapid rate illness progression paulsen et al num add significantly direct indirect cost care
0.23731914.12456513.html.plaintext.txt	24	expert assessment targeted treatment bpsd alleviate patient suffering promote caregiver well le effective intervention occur support system ruptured
0.23731914.12456513.html.plaintext.txt	25	assessment individual dementia stage illness careful enquiry must made regarding presence bpsd
0.23731914.12456513.html.plaintext.txt	26	emphasis must detect bpsd caregiver burn irretrievable damage support environment occur
0.23731914.12456513.html.plaintext.txt	27	collateral history use objective performance based test must part comprehensive cognitive assessment history assessment focus behavioural psychological symptom given high frequency impact patient caregiver quality life
0.23731914.12456513.html.plaintext.txt	28	recognition bpsd first important step devising management plan facilitated use standardised assessment scale behavioural pathology alzheimers disease rating scale behave ad reisberg et al num neuro psychiatric inventory npi cummings et al num
0.23731914.12456513.html.plaintext.txt	29	characteristic behaviour symptom together frequency severity impact patient caregiver must identified formulating tailored targeted plan action likely involve pharmacological non pharmacological intervention
0.23731914.12456513.html.plaintext.txt	30	useful identify target syndrome patient primarily psychotic syndrome hallucination delusion main problem psycho motor agitation sleep disturbance context behaviour symptom impact also key element assessment
0.23731914.12456513.html.plaintext.txt	31	aggressive resistance personal activity carried patient may warrant immediate pharmacological intervention
0.23731914.12456513.html.plaintext.txt	32	also mi identification symptom part psychotic syndrome distressing carers patient instance education family member rather drug treatment required
0.23731914.12456513.html.plaintext.txt	33	pharmacological treatment drug treatment bpsd evidence based targeted specific syndrome clinically significant frequency pervasiveness impact
0.23731914.12456513.html.plaintext.txt	34	depression dementia although little placebo controlled evidence guide practice clinical experience indicates selective serotonin re uptake inhibitor safe effective
0.23731914.12456513.html.plaintext.txt	35	neuroleptic agent shown effective placebo aggression psychosis agitation dementia devanand et al num de deyn et al num street et al num novel agent superior conventional neuroleptic term tolerability side effect profile
0.23731914.12456513.html.plaintext.txt	36	non neuroleptic treatment carbamazepine demonstrated efficacy placebo treatment agitation tariot et al num
0.23731914.12456513.html.plaintext.txt	37	recent placebo controlled study suggest cholinesterase inhibitor improve apathetic syndrome alzheimers disease also decrease psychotic symptom particularly hallucination alzheimers disease lewy body dementia cummings num mckeith et al num
0.23731914.12456513.html.plaintext.txt	38	non pharmacological treatment dearth controlled evidence psychological intervention bpsd
0.23731914.12456513.html.plaintext.txt	39	individualised music therapy bright light treatment specific behaviour intervention found improve certain troubling behavioural symptom dementia evidence required area devanand lawlor num
0.23731914.12456513.html.plaintext.txt	40	intervention carer boosting caregiver support increasing time self providing carer education training management bpsd effective decreasing burden mollifying impact carer ostwald et al num
0.23731914.12456513.html.plaintext.txt	41	intervention carers may decrease carer burden improve tolerability particular symptom hepburn et al num also positive impact patient behaviour marriott et al num possibly delay institutionalisation brodaty et al num teri num
0.23731914.12456513.html.plaintext.txt	42	behavioural psychological symptom dementia accepted important therapeutic target
0.23731914.12456513.html.plaintext.txt	43	management strategy including pharmacological non pharmacological treatment together carer focused training education approach effective decreasing bpsd require concerted multi disciplinary team input
0.23731914.12456513.html.plaintext.txt	44	old age psychiatry team well positioned address care need patient bpsd certain resource training need attached delivery care
0.23731914.12456513.html.plaintext.txt	45	degree special interest development area bpsd encouraged within multi disciplinary team adoption evidence based guideline standardised assessment promoted
0.23731914.12456513.html.plaintext.txt	46	ongoing training professional education team member bpsd given priority highest standard care provided patient carers
0.23731914.12456513.html.plaintext.txt	47	american psychiatric association num diagnostic statistical manual mental disorder numth edn dsm iv
0.23731914.12456513.html.plaintext.txt	48	et al num time institutionalization death patient dementia
0.23731914.12456513.html.plaintext.txt	49	role caregiver training risk factor
0.23731914.12456513.html.plaintext.txt	50	archive neurology num num num
0.23731914.12456513.html.plaintext.txt	51	num psychiatric phenomenon alzheimers disease
0.23731914.12456513.html.plaintext.txt	52	disorder thought content
0.23731914.12456513.html.plaintext.txt	53	british journal psychiatry num num num
0.23731914.12456513.html.plaintext.txt	54	et al num behaviour disturbance predictor carer burden alzheimers disease
0.23731914.12456513.html.plaintext.txt	55	international journal geriatric psychiatry num num num
0.23731914.12456513.html.plaintext.txt	56	conum jlinktypedoicrossrefmedline
0.23731914.12456513.html.plaintext.txt	57	num cholinesterase inhibitor new class psychotropic compound
0.23731914.12456513.html.plaintext.txt	58	american journal psychiatry num num num
0.23731914.12456513.html.plaintext.txt	59	et al num neuropsychiatric inventory comprehensive assessment psychopathology dementia
0.23731914.12456513.html.plaintext.txt	60	et al num randomised trial risperidone placebo haloperidol behavioral symptom dementia
0.23731914.12456513.html.plaintext.txt	61	num treatment behavioral psychological symptom dementia
0.23731914.12456513.html.plaintext.txt	62	et al num course psychopathologic feature mild moderate alzheimer disease
0.23731914.12456513.html.plaintext.txt	63	archive general psychiatry num num num
0.23731914.12456513.html.plaintext.txt	64	et al num randomized placebo controlled dose comparison trial haloperidol psychosis disruptive behavior alzheimers disease
0.23731914.12456513.html.plaintext.txt	65	american journal psychiatry num num num
0.23731914.12456513.html.plaintext.txt	66	et al num behavioral psychological sign symptom dementia consensus statement current knowledge implication research treatment
0.23731914.12456513.html.plaintext.txt	67	international psychogeriatrics num suppl
0.23731914.12456513.html.plaintext.txt	68	et al num behavioral syndrome alzheimers disease description correlate
0.23731914.12456513.html.plaintext.txt	69	dementia geriatric cognitive disorder num num num
0.23731914.12456513.html.plaintext.txt	70	et al num dementia family caregiver training affecting belief caregiving caregiver outcome
0.23731914.12456513.html.plaintext.txt	71	journal american geriatric society num num num
0.23731914.12456513.html.plaintext.txt	72	num psychosis alzheimers disease related dementia
0.23731914.12456513.html.plaintext.txt	73	diagnostic criterion distinct syndrome
0.23731914.12456513.html.plaintext.txt	74	american journal geriatric psychiatry num num num
0.23731914.12456513.html.plaintext.txt	75	et al num mental behavioral disturbance dementia finding cache county study memory aging
0.23731914.12456513.html.plaintext.txt	76	american journal psychiatry num num num
0.23731914.12456513.html.plaintext.txt	77	et al num prevalence pharmacological management behavioural psychological symptom amongst dementia sufferer living care environment
0.23731914.12456513.html.plaintext.txt	78	international journal geriatric psychiatry num num num
0.23731914.12456513.html.plaintext.txt	79	conum flinktypedoicrossrefmedline
0.23731914.12456513.html.plaintext.txt	80	et al num efficacy rivastigmine dementia lewy body randomised double blind placebo controlled international study
0.23731914.12456513.html.plaintext.txt	81	et al num effectiveness cognitive behavioural family intervention reducing burden care carers patient alzheimers disease
0.23731914.12456513.html.plaintext.txt	82	british journal psychiatry num num num
0.23731914.12456513.html.plaintext.txt	83	et al num incontinence troublesome behavior predict institutionalisation dementia
0.23731914.12456513.html.plaintext.txt	84	journal geriatric psychiatry neurology num num num
0.23731914.12456513.html.plaintext.txt	85	et al num provisional diagnostic criterion depression alzheimers disease
0.23731914.12456513.html.plaintext.txt	86	american journal geriatric psychiatry num num num
0.23731914.12456513.html.plaintext.txt	87	et al num reducing caregiver burden randomized psychoeducational intervention caregiver person dementia
0.23731914.12456513.html.plaintext.txt	88	et al num incidence risk factor hallucination delusion patient probable ad
0.23731914.12456513.html.plaintext.txt	89	et al num behavioral symptom alzheimers disease phenomenology treatment
0.23731914.12456513.html.plaintext.txt	90	journal clinical psychiatry num suppl
0.23731914.12456513.html.plaintext.txt	91	et al num psychiatric symptom nursing home placement patient alzheimers disease
0.23731914.12456513.html.plaintext.txt	92	american journal psychiatry num num num
0.23731914.12456513.html.plaintext.txt	93	et al num olanzapine treatment psychotic behavioral symptom patient alzheimers disease nursing care facility double blind placebo controlled trial
0.23731914.12456513.html.plaintext.txt	94	archive general psychiatry num num num
0.23731914.12456513.html.plaintext.txt	95	et al num efficacy tolerability carbamazepine agitation aggression dementia
0.23731914.12456513.html.plaintext.txt	96	american journal psychiatry num num num
0.23731914.12456513.html.plaintext.txt	97	num training family provide care effect people dementia
0.23731914.12456513.html.plaintext.txt	98	international journal geriatric psychiatry num num num
0.23731914.12456513.html.plaintext.txt	99	conum jlinktypedoicrossrefmedline
0.23731914.12456513.html.plaintext.txt	100	received publication january num num
0.23731914.12456513.html.plaintext.txt	101	accepted publication april num num
0.24103056.11823327.html.plaintext.txt	0	vascular dementia diagnosis running time robert stewart mrcpsych
0.24103056.11823327.html.plaintext.txt	1	institute psychiatry de crespigny park denmark hill london senum numaf uk
0.24103056.11823327.html.plaintext.txt	2	tel num numnum num num fax num numnum num num
0.24103056.11823327.html.plaintext.txt	3	supported research training fellowship clinical epidemiology wellcome trust
0.24103056.11823327.html.plaintext.txt	4	background concept vascular dementia long history usefulness diagnostic category called question
0.24103056.11823327.html.plaintext.txt	5	aim evaluate vascular disease risk factor dementia interface cerebrovascular pathology alzheimers disease
0.24103056.11823327.html.plaintext.txt	6	method literature topic selectively reviewed synthesised
0.24103056.11823327.html.plaintext.txt	7	result risk factor cerebrovascular disease also risk factor dementia
0.24103056.11823327.html.plaintext.txt	8	however course dementia developed appears frequently determined alzheimers disease
0.24103056.11823327.html.plaintext.txt	9	conclusion public health measure modification vascular risk represents potentially powerful mean prevent dementia delaying onset
0.24103056.11823327.html.plaintext.txt	10	however effect progression dementia developed yet established
0.24103056.11823327.html.plaintext.txt	11	traditional view vascular dementia alzheimers disease distinguishable condition becoming steadily le tenable
0.24103056.11823327.html.plaintext.txt	12	upon time around first half last century late onset dementia viewed essentially homogeneous condition
0.24103056.11823327.html.plaintext.txt	13	main underlying cause assumed atherosclerosis pathological substrate old age
0.24103056.11823327.html.plaintext.txt	14	pioneering work around nums early nums challenged assumption establishing importance alzheimer pathological change majority case
0.24103056.11823327.html.plaintext.txt	15	however multiple cerebral infarction also appeared underlie substantial proportion
0.24103056.11823327.html.plaintext.txt	16	led division dementia two condition alzheimers disease multi infarct dementia
0.24103056.11823327.html.plaintext.txt	17	system persisted day coming increasing criticism particularly wish investigate vascular disease risk factor dementia
0.24103056.11823327.html.plaintext.txt	18	following section current status future direction vascular dementia considered diagnostic category heading broad field research
0.24103056.11823327.html.plaintext.txt	19	research diagnostic criterion treat alzheimers disease diagnosis exclusion mckhann et al num
0.24103056.11823327.html.plaintext.txt	20	system may useful examining issue relating disorder pure entity
0.24103056.11823327.html.plaintext.txt	21	however may also miss potentially important influence factor vascular disease excluded definition
0.24103056.11823327.html.plaintext.txt	22	addition begun excluding major vascular disease clinical stroke multiple cerebral infarction computed tomographic imaging study use diagnostic system consider evidence subtle subclinical disease white matter abnormality seen magnetic resonance imaging
0.24103056.11823327.html.plaintext.txt	23	increasingly sophisticated measurement cerebrovascular disease vivo raise question exclusion criterion stop
0.24103056.11823327.html.plaintext.txt	24	detectable level vascular disease continue excluded pure alzheimers disease group become progressively smaller defining increasingly select group person whatever reason remained free vascular disease old age
0.24103056.11823327.html.plaintext.txt	25	question course level vascular disease may cause dementia answered using criterion assume cause
0.24103056.11823327.html.plaintext.txt	26	major problem concept multi infarct dementia diagnostic criterion tried thing alzheimers disease define pure entity
0.24103056.11823327.html.plaintext.txt	27	however alzheimers disease least reasonably well defined pathological basis true dementia related cerebrovascular disease
0.24103056.11823327.html.plaintext.txt	28	vascular dementia subsumed multi infarct dementia term recognition heterogeneity large number subtypes subsequently proposed konno et al num
0.24103056.11823327.html.plaintext.txt	29	range syndrome dementia appears resulted small discrete strategic infarction bilateral thalamic infarction lesion angular gyrus dementia associated diffuse cerebrovascular disease ischaemic haemorrhagic cortical subcortical brun num
0.24103056.11823327.html.plaintext.txt	30	diffuse disease obviously exists across spectrum severity advancing age increasingly likely comorbid alzheimers disease raising question whether two distinguished diagnostic system
0.24103056.11823327.html.plaintext.txt	31	additional obstacle research term vascular dementia make assumption causation therefore limited use come investigating potential cause
0.24103056.11823327.html.plaintext.txt	32	would considered particularly noteworthy study report people stroke likely hypertension diabetes
0.24103056.11823327.html.plaintext.txt	33	similarly would surprising found higher mortality higher level depression
0.24103056.11823327.html.plaintext.txt	34	problem vascular dementia term comparison alzheimers disease control group inevitably comparison population different rate cerebrovascular disease impossible conclude related cerebrovascular disease related particular dementia syndrome
0.24103056.11823327.html.plaintext.txt	35	perhaps preferable consider vascular dementia series question rather diagnosis
0.24103056.11823327.html.plaintext.txt	36	vascular disease cause dementia type type dementia cause
0.24103056.11823327.html.plaintext.txt	37	vascular disease cause dementia
0.24103056.11823327.html.plaintext.txt	38	system dementia classification major obstacle investigating question previously discussed
0.24103056.11823327.html.plaintext.txt	39	another problem age group dementia common contain extent healthy survivor respect vascular disease
0.24103056.11823327.html.plaintext.txt	40	also people condition together higher mortality therefore le likely identified cross sectional prospective study
0.24103056.11823327.html.plaintext.txt	41	particularly high rate dementia observed following clinical stroke approximately nine fold increase risk first year followed smaller two fold raised annual risk found persist least num year later kokmen et al num
0.24103056.11823327.html.plaintext.txt	42	vascular risk factor hypertension diabetes hypercholesterolaemia also established risk factor dementia large prospective study stewart num
0.24103056.11823327.html.plaintext.txt	43	early report smoking might protective factor least alzheimers disease confirmed rigorously designed investigation anything report raised risk subtypes dementia smoker ott et al num
0.24103056.11823327.html.plaintext.txt	44	important issue arising study concern stage cognitive decline factor effect
0.24103056.11823327.html.plaintext.txt	45	raised blood pressure mid life instance strong risk factor later cognitive impairment elia et al num
0.24103056.11823327.html.plaintext.txt	46	however blood pressure later life tends lower association dementia skoog et al num
0.24103056.11823327.html.plaintext.txt	47	therefore hypertension appears exert effect early stage cognitive decline association may longer apparent time cognitive function deteriorated sufficiently classified dementia
0.24103056.11823327.html.plaintext.txt	48	pattern described raised cholesterol concentration notkola et al num important potential implication preventive therapeutic intervention
0.24103056.11823327.html.plaintext.txt	49	type dementia cause
0.24103056.11823327.html.plaintext.txt	50	traditional diagnostic criterion hampered investigation question
0.24103056.11823327.html.plaintext.txt	51	increasing body epidemiological evidence suggests vascular risk factor hypertension diabetes hyperlipidaemia risk factor development vascular dementia also alzheimers disease stewart num
0.24103056.11823327.html.plaintext.txt	52	community based research criticised neuroimaging routinely used diagnostic assessment subclinical level cerebrovascular disease may missed mixed dementia misidentified alzheimers disease
0.24103056.11823327.html.plaintext.txt	53	issue however consideration mechanism vascular risk factor associated dementia rather one arbitrarily defined diagnostic category
0.24103056.11823327.html.plaintext.txt	54	post stroke study found dementia appears follow alzheimers disease like course majority case kokmen et al num approximately num people post stroke dementia gradually deteriorating cognitive function stroke occurred pohjasvaara et al num
0.24103056.11823327.html.plaintext.txt	55	since alzheimers disease long latency period assumed substantial proportion may subclinical disease
0.24103056.11823327.html.plaintext.txt	56	becoming increasingly apparent dementia associated vascular disease frequently resembles alzheimers disease clinical course many case obviously explained multiple infarction mechanism
0.24103056.11823327.html.plaintext.txt	57	one possibility vascular process cause gradually progressive dementia syndrome
0.24103056.11823327.html.plaintext.txt	58	however recent pathological study suggested isolated cerebrovascular disease
0.24103056.11823327.html.plaintext.txt	59	alzheimer lesion rarely found association dementia hulette et al num
0.24103056.11823327.html.plaintext.txt	60	finding contrast early post mortem series although borne mind people dementia late nums would expected display much florid severe cerebrovascular disease
0.24103056.11823327.html.plaintext.txt	61	next question whether vascular disease may directly cause drive alzheimers disease process
0.24103056.11823327.html.plaintext.txt	62	many potential mechanism exist proposed vascular induction alzheimers disease including amyloid deposition secondary ischaemia peri infarct inflammation microglial activation
0.24103056.11823327.html.plaintext.txt	63	abnormal protein glycation may provide link diabetes alzheimers disease
0.24103056.11823327.html.plaintext.txt	64	furthermore growing appreciation cerebrovascular pathology alzheimers disease vascular amyloid deposition microangiopathy
0.24103056.11823327.html.plaintext.txt	65	apolipoprotein e apoe genotype may also provide potential explanation association
0.24103056.11823327.html.plaintext.txt	66	however although apoe num variant associated increased vascular risk neither lipid level vascular disease found mediating factor num risk alzheimers disease prince et al num
0.24103056.11823327.html.plaintext.txt	67	although many feasible mechanism proposed direct link vascular alzheimers disease process pathological evidence far suggests interact principally clinical effect
0.24103056.11823327.html.plaintext.txt	68	nun study found direct association cerebrovascular disease level alzheimer pathology instead found le alzheimer pathology required produce dementia cerebrovascular disease also present snowdon et al num
0.24103056.11823327.html.plaintext.txt	69	one possible explanation memory impairment secondary hippocampal pathology alzheimers disease likely manifest clinical dementia also impairment executive function secondary vascular subcortical pathology
0.24103056.11823327.html.plaintext.txt	70	executive function impairment important although frequently unmeasured factor associated memory decline decline executive function alone important potential consequence cerebrovascular disease suggested dementia syndrome right royall num
0.24103056.11823327.html.plaintext.txt	71	considering length time vascular disease accepted common potentially reversible risk factor dementia evidence intervention modify risk woefully scant
0.24103056.11823327.html.plaintext.txt	72	summarised table num likely success intervention depends crucially mechanism association
0.24103056.11823327.html.plaintext.txt	73	particular interest clinician extent patient dementia may benefit treatment vascular disease risk factor
0.24103056.11823327.html.plaintext.txt	74	however optimally designed trial intervention
0.24103056.11823327.html.plaintext.txt	75	treatment vascular risk factor may impact cognitive decline preventing stroke increasing evidence suggests may upper age limit stroke prevention staessen et al num
0.24103056.11823327.html.plaintext.txt	76	addition would benefit vascular disease accelerating progression alzheimer lesion
0.24103056.11823327.html.plaintext.txt	77	hand vascular disease predominantly accelerates age onset alzheimers disease treatment directed alzheimers disease rather vascular component dementia developed
0.24103056.11823327.html.plaintext.txt	78	issue become particularly important licensing pharmacological agent use alzheimers disease
0.24103056.11823327.html.plaintext.txt	79	stroke continues considered exclusion criterion large number people alzheimers disease fail receive appropriate treatment comorbid disease
0.24103056.11823327.html.plaintext.txt	80	whatever lie ahead treatment dementia associated cerebro vascular disease potential prevention likely substantial since vascular risk factor high prevalence rate
0.24103056.11823327.html.plaintext.txt	81	modest reduction vascular risk across population could therefore expected result large reduction future case dementia delaying clinical onset
0.24103056.11823327.html.plaintext.txt	82	supporting preliminary finding large systolic hypertension europe syst eur trial antihypertensive treatment older people suggested num reduction incident dementia principally alzheimers disease occurring treated calcium channel blocker compared placebo forette et al num
0.24103056.11823327.html.plaintext.txt	83	view table table num pathway association vascular disease dementia implication respect preventive therapeutic intervention
0.24103056.11823327.html.plaintext.txt	84	investigation mechanism underlying link vascular alzheimer pathological process likely provide important avenue risk modification
0.24103056.11823327.html.plaintext.txt	85	addition evidence adequately designed therapeutic preventive trial even negative likely provide useful information regarding underlying mechanism
0.24103056.11823327.html.plaintext.txt	86	may well become increasingly apparent dementia late stage considering useful intervention
0.24103056.11823327.html.plaintext.txt	87	one challenge develop public health strategy affect large population reducing vascular risk earlier life aim decreasing burden dementia generation num num year later
0.24103056.11823327.html.plaintext.txt	88	however clinical standpoint directed towards individual rather population level risk also need move towards identifying cognitive decline much earlier stage dementia
0.24103056.11823327.html.plaintext.txt	89	particular regard vascular disease focus memory decline influenced alzheimers disease need shift towards appreciation executive function impairment bowler hachinski num
0.24103056.11823327.html.plaintext.txt	90	therefore vascular dementia certainly convenient subject heading rapidly accelerating field research
0.24103056.11823327.html.plaintext.txt	91	le clear whether retains usefulness diagnosis
0.24103056.11823327.html.plaintext.txt	92	vascular dementia implies primary cause cerebrovascular disease linked specific consequence distinguishable dementia syndrome
0.24103056.11823327.html.plaintext.txt	93	however increasing evidence suggests dementia associated vascular disease involves broad spectrum manifestation strategic infarct syndrome alzheimers disease
0.24103056.11823327.html.plaintext.txt	94	addition although vascular disease powerful risk factor dementia questionable often actually sole cause dementia absence underlying vulnerability comorbid disease
0.24103056.11823327.html.plaintext.txt	95	dementia research suffered common area epidemiology simplistic conceptual framework risk factor outcome relationship
0.24103056.11823327.html.plaintext.txt	96	increasingly evident many potential factor operating across entire life course possibly extending back previous generation may influence mediate others effect table num
0.24103056.11823327.html.plaintext.txt	97	designing appropriate study system analysis take account multiple influence interaction likely provide major challenge future research
0.24103056.11823327.html.plaintext.txt	98	view table table num life course model aetiology cognitive decline dementia
0.24103056.11823327.html.plaintext.txt	99	meantime done vascular dementia recent editorial suggested rather tinkering existing criterion discarded replaced wholesale bowler hachinski num
0.24103056.11823327.html.plaintext.txt	100	certain syndrome reasonably considered diagnosis example dementia due strategic infarct genetic disorder cadasil cerebral autosomal dominant arteriopathy subcortical infarct leucoencephalopathy
0.24103056.11823327.html.plaintext.txt	101	however majority vascular dementia syndrome arising later life although may manifest pure disorder questionable whether valid distinction truly drawn sub category vascular dementia alzheimers disease
0.24103056.11823327.html.plaintext.txt	102	result clinical research diagnostic criterion vascular dementia involve high degree subjective judgement skoog aevarsson num leading inevitably poor agreement raters lopez et al num different diagnostic instrument chui et al num
0.24103056.11823327.html.plaintext.txt	103	depression feel need define life event depression poor physical health depression rather direct treatment symptom holding mind formulation possible underlying cause attempt modify potential maintaining factor risk factor recurrence
0.24103056.11823327.html.plaintext.txt	104	perhaps may lesson learned cognitive impairment dementia
0.24103056.11823327.html.plaintext.txt	105	complex picture overlapping interacting pathological entity one challenge reward health care older age group enthuse student trainee
0.24103056.11823327.html.plaintext.txt	106	diagnostic system attempt separate process artificially pure diagnosis u treat favour
0.24103056.11823327.html.plaintext.txt	107	clinical implication limitation
0.24103056.11823327.html.plaintext.txt	108	clinical implication modification vascular risk status mid life likely important mean reducing subsequent risk dementia population evidence lacking effect course dementia developed
0.24103056.11823327.html.plaintext.txt	109	usefulness vascular dementia diagnostic category questionable since involves high degree subjective judgement subsumes large number potentially heterogeneous condition overlap considerably alzheimers disease
0.24103056.11823327.html.plaintext.txt	110	current system classifying dementia mutually exclusive subtypes poorly reflects mixed disease older age group become important issue since diagnosis determine eligibility pharmacological intervention
0.24103056.11823327.html.plaintext.txt	111	limitation review literature selective limited
0.24103056.11823327.html.plaintext.txt	112	review look relationship vascular disease dementia population level rather specific discrete syndrome within vascular dementia
0.24103056.11823327.html.plaintext.txt	113	focus review relationship cerebrovascular disease alzheimers disease two overlapping disorder take account comorbid pathology
0.24103056.11823327.html.plaintext.txt	114	num criterion vascular dementia replacing dogma data
0.24103056.11823327.html.plaintext.txt	115	archive neurology num num num
0.24103056.11823327.html.plaintext.txt	116	num neuropathology vascular dementia
0.24103056.11823327.html.plaintext.txt	117	cerebrovascular disease dementia pathology neuropsychiatry management ed e
0.24103056.11823327.html.plaintext.txt	118	et al num clinical criterion diagnosis vascular dementia
0.24103056.11823327.html.plaintext.txt	119	archive neurology num num num
0.24103056.11823327.html.plaintext.txt	120	et al num untreated blood pressure level inversely related cognitive functioning framingham study
0.24103056.11823327.html.plaintext.txt	121	american journal epidemiology num num num
0.24103056.11823327.html.plaintext.txt	122	et al num prevention dementia randomised double blind placebo controlled systolic hypertension europe syst eur trial
0.24103056.11823327.html.plaintext.txt	123	et al num clinical neuropathological finding multi infarct dementia report six autopsied case
0.24103056.11823327.html.plaintext.txt	124	et al num dementia ischemic stroke population based study rochester minnesota num num
0.24103056.11823327.html.plaintext.txt	125	et al num classification diagnosis treatment vascular dementia
0.24103056.11823327.html.plaintext.txt	126	et al num reliability ninds airen clinical criterion diagnosis vascular dementia
0.24103056.11823327.html.plaintext.txt	127	et al num clinical diagnosis alzheimers disease
0.24103056.11823327.html.plaintext.txt	128	report nincds adrda work group auspex department health human service task force alzheimers disease
0.24103056.11823327.html.plaintext.txt	129	et al num serum total cholesterol apolipoprotein e num allele alzheimers disease
0.24103056.11823327.html.plaintext.txt	130	et al num smoking risk dementia alzheimers disease population based cohort study rotterdam study
0.24103056.11823327.html.plaintext.txt	131	et al num clinical radiological determinant prestroke cognitive decline stroke cohort
0.24103056.11823327.html.plaintext.txt	132	journal neurology neurosurgery psychiatry num num num
0.24103056.11823327.html.plaintext.txt	133	et al num association apoe dementia mediated neither vascular disease risk factor aged cohort survivor hypertension
0.24103056.11823327.html.plaintext.txt	134	num executive cognitive impairment novel perspective dementia
0.24103056.11823327.html.plaintext.txt	135	neuroepidemiology num num num
0.24103056.11823327.html.plaintext.txt	136	num epidemiology vascular dementia europe
0.24103056.11823327.html.plaintext.txt	137	cerebrovascular disease dementia pathology neuropsychiatry management ed e
0.24103056.11823327.html.plaintext.txt	138	et al num num year longitudinal study blood pressure dementia
0.24103056.11823327.html.plaintext.txt	139	et al num brain infarction clinical expression alzheimer disease
0.24103056.11823327.html.plaintext.txt	140	et al num risk untreated treated isolated systolic hypertension elderly meta analysis outcome trial
0.24103056.11823327.html.plaintext.txt	141	num cardiovascular factor alzheimers disease
0.24103056.11823327.html.plaintext.txt	142	journal neurology neurosurgery psychiatry num num num
0.24103056.11823327.html.plaintext.txt	143	received publication march num num
0.24103056.11823327.html.plaintext.txt	144	revision received april num num
0.24103056.11823327.html.plaintext.txt	145	accepted publication april num num
0.24103056.11823327.html.plaintext.txt	146	highlight issue elizabeth walsh bjp num num num
0.24103056.11823327.html.plaintext.txt	147	old age psychiatry alistair burn ian g
0.2476838.9328480.html.plaintext.txt	0	distortion allelic expression apolipoprotein e alzheimers disease
0.2476838.9328480.html.plaintext.txt	1	jean charles lambertnumnum jordi perez turnumnum marie joelle dupirenum douglas galaskonum david mannnum philippe amouyelnum john hardynum andre delacourtenum marie christine chartier harlinnumnum
0.2476838.9328480.html.plaintext.txt	2	numinserm unite num place de verdun num lille cedex france numinserm cjfnum num institut pasteur de lille num rue de calmette num lille cedex france numbirdsall building mayo clinic jacksonville num san pablo road jacksonville fl num usa numucsd medical centre pulman ambulatory care centre num campus point drive la jolla ca num usa numdepartment pathological science stopford building university manchester oxford road manchester mnum numpt uk
0.2476838.9328480.html.plaintext.txt	3	received july num num revised accepted august num num
0.2476838.9328480.html.plaintext.txt	4	apoe epsisnum allele strong genetic susceptibility factor alzheimers disease
0.2476838.9328480.html.plaintext.txt	5	interaction biological factor may modulate effect apoe isoforms
0.2476838.9328480.html.plaintext.txt	6	however previous work suggested genetic variability within apoe locus influencing effect epsisnum allele may exist
0.2476838.9328480.html.plaintext.txt	7	variability could modify expression apoe gene particular level expression apoe allele could important determinant disease pathogenesis
0.2476838.9328480.html.plaintext.txt	8	test hypothesis examined level expression apoe heterozygote ad control using new method semi quantitation
0.2476838.9328480.html.plaintext.txt	9	report relative epsisnum mrna expression increased ad compared control suggest genetic variability neural expression apoe contributes disease risk
0.2476838.9328480.html.plaintext.txt	10	epsisnum allele apoe gene major risk factor late onset alzheimers disease load num also implicated risk factor early onset disease population numnum
0.2476838.9328480.html.plaintext.txt	11	previous study described epsisnum homozygote higher risk developing disease epsisnumepsisnum heterozygote
0.2476838.9328480.html.plaintext.txt	12	however individual bearing one two epsisnum allele inevitably develop disease
0.2476838.9328480.html.plaintext.txt	13	detailed genetic analysis around apoe locus suggested existence genetic variability region could contribute disease risk num
0.2476838.9328480.html.plaintext.txt	14	two possible explanation observation another genetically variable locus vicinity apoe gene involved pathogenesis disease ii genetic variability control expression apoe gene num
0.2476838.9328480.html.plaintext.txt	15	little examination mrna expression apoe ad numnum
0.2476838.9328480.html.plaintext.txt	16	available evidence suggests apoe expression increased neuronal damage numnum bulk expression occurs astrocyte num
0.2476838.9328480.html.plaintext.txt	17	expression believed part compensatory mechanism aimed aiding reafferentation reactive synaptogenesis num
0.2476838.9328480.html.plaintext.txt	18	study examined expression apoe protein ad case control relative apoe genotype numnum
0.2476838.9328480.html.plaintext.txt	19	suggested amount apoe protein could inversely correlated number epsisnum allele carried subject higher level observed epsisnum homozygote lower epsisnum homozygote intermediate level epsisnumepsisnum heterozygote num
0.2476838.9328480.html.plaintext.txt	20	hypothesised since epsisnum homozygote higher risk developing disease epsisnumepsisnum heterozygote high proportion individual latter genotype reach greater age without developing ad likely explanation genetic variability neural expression apoe locus epsisnumepsisnum heterozygote individual high epsisnum expressors andor low epsisnum expressors likely develop ad individual high epsisnum expressors andor low epsisnum expressors
0.2476838.9328480.html.plaintext.txt	21	identification apoe allele transcription product easily achieved rt pcr using restriction fragment length polymorphism
0.2476838.9328480.html.plaintext.txt	22	developed semi quantitative assay measure allelic expression apoe mrna rt pcr using silver staining num
0.2476838.9328480.html.plaintext.txt	23	method quantitation applied brain heterozygote subject collected various centre used ass percentage epsisnum mrna expression epsisnumepsisnum epsisnumepsisnum subject epsisnum mrna expression epsisnumepsisnum individual
0.2476838.9328480.html.plaintext.txt	24	carried ad case control
0.2476838.9328480.html.plaintext.txt	25	selected series epsisnumepsisnum epsisnumepsisnum epsisnumepsisnum ad case n num control n num order measure relative level expression apoe allele frontal cortex fig
0.2476838.9328480.html.plaintext.txt	26	observed epsisnum mrna expression consistently greater epsisnum mrna expression case fig
0.2476838.9328480.html.plaintext.txt	27	addition clear consistent difference epsisnum allelic expression ratio ad case control fig
0.2476838.9328480.html.plaintext.txt	28	num ad case showing higher relative expression epsisnum mrna control num
0.2476838.9328480.html.plaintext.txt	29	regarding heterozygous genotype small size group prevented u reaching definite conclusion
0.2476838.9328480.html.plaintext.txt	30	nevertheless trend towards situation observed epsisnumepsisnum group could noted increase expression epsisnum allele epsisnumepsisnum group num
0.2476838.9328480.html.plaintext.txt	31	num control whereas nothing apparent epsisnumepsisnum group num
0.2476838.9328480.html.plaintext.txt	32	num ad case versus num
0.2476838.9328480.html.plaintext.txt	33	furthermore difference allelic expression ratio epsisnumepsisnum epsisnumepsisnum ad case observed since epsisnumepsisnum patient showed num
0.2476838.9328480.html.plaintext.txt	34	num fold increase epsisnum allele ratio p num
0.2476838.9328480.html.plaintext.txt	35	figure num semi quantitation epsisnum allele ratio control case
0.2476838.9328480.html.plaintext.txt	36	final epsisnum allele ratio calculated data num
0.2476838.9328480.html.plaintext.txt	37	figure num differential expression apoe mrna three heterozygote genotype alzheimers disease case control
0.2476838.9328480.html.plaintext.txt	38	epsisnum mrna percentage measured epsisnumepsisnum population epsisnum mrna percentage epsisnumepsisnum epsisnumepsisnum population
0.2476838.9328480.html.plaintext.txt	39	average level expression indicated bold line category
0.2476838.9328480.html.plaintext.txt	40	brain sample rt pcr semi quantitation repeated three time
0.2476838.9328480.html.plaintext.txt	41	important note measurement ratio expression two allele heterozygote likely much robust measurement determination absolute level mrna expression tissue since latter profoundly affected post mortem delay agonal state cell population density
0.2476838.9328480.html.plaintext.txt	42	seen figure num level expression epsisnum allele consistently higher epsisnum allele ad group well control group
0.2476838.9328480.html.plaintext.txt	43	data suggest either differential stability different mrna specie genetic variability expression two allele disequilibrium coding polymorphism
0.2476838.9328480.html.plaintext.txt	44	however addition clear consistent difference epsisnum allelic expression ratio ad case control
0.2476838.9328480.html.plaintext.txt	45	result consistent notion part least genetic risk developing ad encoded apoe locus relates expression protein brain
0.2476838.9328480.html.plaintext.txt	46	would seem heterozygote individual express relatively high proportion epsisnum allele greater risk developing disease expressing relatively low proportion
0.2476838.9328480.html.plaintext.txt	47	observation different allele apoe equally expressed may importance formulation hypothesis relating role apoe pathogenesis ad general
0.2476838.9328480.html.plaintext.txt	48	present much speculation experimentation designed determine nature role different allele apoe pathogenesis ad
0.2476838.9328480.html.plaintext.txt	49	previously suggested enum isoform may facilitate num limit num amyloid substance deposition
0.2476838.9328480.html.plaintext.txt	50	isoform would protect oxidative stress conversely enum isoform num
0.2476838.9328480.html.plaintext.txt	51	finally suggested enum enum isoforms may prevent aggregation tau protein enum isoform may prevent paired helical filament formation num
0.2476838.9328480.html.plaintext.txt	52	however hypothesis based premise apoe allele isoforms equally expressed present similar concentration brain
0.2476838.9328480.html.plaintext.txt	53	isoform specific difference could enhanced different representation isoform individual
0.2476838.9328480.html.plaintext.txt	54	date seems difficult link apoe mrna apoe protein level
0.2476838.9328480.html.plaintext.txt	55	several study explored issue reporting contradictory finding brain numnum cerebrospinal fluid numnum plasma num
0.2476838.9328480.html.plaintext.txt	56	even apoe level tested according apoe genotype none previous study able determine relative ratio different isoforms thus result comparable
0.2476838.9328480.html.plaintext.txt	57	development isoform specific monoclonal antibody would help determine whether variation observed population also present protein level num
0.2476838.9328480.html.plaintext.txt	58	two major finding work
0.2476838.9328480.html.plaintext.txt	59	first expression epsisnum allele consistently higher expression epsisnum allele
0.2476838.9328480.html.plaintext.txt	60	second expression epsisnum allele beyond certain level seems greatly influence vulnerability individual alzheimers disease
0.2476838.9328480.html.plaintext.txt	61	interesting note apoe regulated consequence insult
0.2476838.9328480.html.plaintext.txt	62	showed increase level expression apoe mrna rat lesioning cerebral cortex num
0.2476838.9328480.html.plaintext.txt	63	showed apoe mrna increased ad brain num
0.2476838.9328480.html.plaintext.txt	64	together result support event may lead increase apoe mrna parallel distortion allelic expression
0.2476838.9328480.html.plaintext.txt	65	distortion allelic expression may specific brain possibly restricted certain area num
0.2476838.9328480.html.plaintext.txt	66	suggests neural genetic susceptibility ad associated apoe gene
0.2476838.9328480.html.plaintext.txt	67	interestingly templeton reached similar conclusion using cladistic analysis previously reported genetic data num
0.2476838.9328480.html.plaintext.txt	68	using haplotype data marker surrounding apoe locus including apoe polymorphism templeton showed coding polymorphism apoe gene sufficient explain increased risk ad num
0.2476838.9328480.html.plaintext.txt	69	data suggest influence non coding polymorphism apoe expression may supply rest answer
0.2476838.9328480.html.plaintext.txt	70	material method rna extraction
0.2476838.9328480.html.plaintext.txt	71	fourteen late onset ad case caucasian origin mean age num
0.2476838.9328480.html.plaintext.txt	72	num year five male nine female num control mean age num
0.2476838.9328480.html.plaintext.txt	73	num year five male seven female selected function apoe genotype num
0.2476838.9328480.html.plaintext.txt	74	mean age sampling num
0.2476838.9328480.html.plaintext.txt	75	num year ad case genotyped epsisnumepsisnum num
0.2476838.9328480.html.plaintext.txt	76	num year control genotyped epsisnumepsisnum
0.2476838.9328480.html.plaintext.txt	77	diagnosis confirmed neuropathological examination
0.2476838.9328480.html.plaintext.txt	78	total rna extraction performed frontal lobe sample described gilmour et al
0.2476838.9328480.html.plaintext.txt	79	num digested dnase eurogentec
0.2476838.9328480.html.plaintext.txt	80	dna contamination observed dnase digestion detected pcr digested product
0.2476838.9328480.html.plaintext.txt	81	rt pcr amplification apoe mrna
0.2476838.9328480.html.plaintext.txt	82	rt reaction performed num h num min num degree c using fnum primer numprime acagaattcgccccggcctggta numprime num pmol num mug total rna template m mlv reverse transcriptase following condition described supplier gibcobrl
0.2476838.9328480.html.plaintext.txt	83	pcr step carried fnum primer numprime taagcttggcacggctgtccaagga numprime num pmol final volume num mul num cycle num min num degree c num min num degree c num min num degree c cycle remain linear range reaction
0.2476838.9328480.html.plaintext.txt	84	briefly pcr performed total volume num mul containing num
0.2476838.9328480.html.plaintext.txt	85	num mm dntp num mm dtt num
0.2476838.9328480.html.plaintext.txt	86	num triton x num num vv glycerol using whole rt reaction template
0.2476838.9328480.html.plaintext.txt	87	rt pcr dna digested num u cfoi endonuclease promega dna fragment resolved num polyacrylamide gel acrylamidebisacrylamide numnum num h num vcm
0.2476838.9328480.html.plaintext.txt	88	num mul rt pcr product loaded
0.2476838.9328480.html.plaintext.txt	89	gel fixed num min num vv ethanol num
0.2476838.9328480.html.plaintext.txt	90	two washing deionised water gel placed silver nitrate solution num mgml num min
0.2476838.9328480.html.plaintext.txt	91	gel washed twice deionised water
0.2476838.9328480.html.plaintext.txt	92	dna polymorphism fragment stained num min num
0.2476838.9328480.html.plaintext.txt	93	num formaldehyde vv hydroxyde nitrate num mgml
0.2476838.9328480.html.plaintext.txt	94	finally reaction stopped sodium carbonate solution num mgml
0.2476838.9328480.html.plaintext.txt	95	developer silver nitrate solution prepared extemporaneously
0.2476838.9328480.html.plaintext.txt	96	gel digitalised sharp jx num high resolution colour scanner fragment intensity measured using image master software pharmacia appropriate background subtract
0.2476838.9328480.html.plaintext.txt	97	percentage epsisnum allele calculated equation described ref
0.2476838.9328480.html.plaintext.txt	98	roman n o sup epsilon roman num m r n roman n o sup epsilon roman num m r n roman n o sup epsilon roman num o r epsilon roman num m r n roman alpha sup prime epsilon roman num m r n roman alpha sup prime epsilon roman num m r n alpha sup prime epsilon roman num o r epsilon roman num m r n
0.2476838.9328480.html.plaintext.txt	99	noepsisnum mrna noepsisnum mrna initial number epsisnum epsisnum mrna
0.2476838.9328480.html.plaintext.txt	100	alphaprimeepsisnum mrna alphaprimeepsisnum epsisnum mrna coefficient allowing silver staining phenomenon saturation due staining integrated normalised
0.2476838.9328480.html.plaintext.txt	101	coefficient proportionality correcting length difference restriction fragment
0.2476838.9328480.html.plaintext.txt	102	digestion cfoi epsisnum epsisnum epsisnum allele characterised num num num bp fragment respectively
0.2476838.9328480.html.plaintext.txt	103	coefficient therefore calculated numnum epsisnumepsisnum individual numnum epsisnumepsisnum individual numnum epsisnumepsisnum population
0.2476838.9328480.html.plaintext.txt	104	epsisnum epsisnum allele give restriction length fragment num bp aodepsisnum mrna odepsisnum mrna odnum bp
0.2476838.9328480.html.plaintext.txt	105	initial epsisnum allele percentage epsisnumepsisnum population calculated
0.2476838.9328480.html.plaintext.txt	106	roman n o sup epsilon roman num m r n roman n o sup epsilon roman num m r n roman n o sup epsilon roman num m r n roman alpha sup roman prime epsilon roman num m r n alpha prime sup num num roman b p
0.2476838.9328480.html.plaintext.txt	107	detail calculation modelling method described ref
0.2476838.9328480.html.plaintext.txt	108	tested viability approach apoe allele using genomic dna template different parameter initial concentration dna template initial percentage allele compared another num
0.2476838.9328480.html.plaintext.txt	109	num reduced survival patient early onset alzheimers disease carry apolipoprotein egrnum allele
0.2476838.9328480.html.plaintext.txt	110	french alzheimers disease collaborative group num evidence apolipoprotein e epsisnum association early onset alzheimers patient late onset relative
0.2476838.9328480.html.plaintext.txt	111	num apolipoprotein e epsisnum allele major risk factor sporadic early late onset form alzheimers disease analysis numqnum
0.2476838.9328480.html.plaintext.txt	112	num neuropathological change scrapie alzheimers disease associated increased expression apolipoprotein e cathepsin d astrocyte
0.2476838.9328480.html.plaintext.txt	113	num astrocytic apolipoprotein e mrna gfap mrna hippocampus entorhinal cortex lesioning
0.2476838.9328480.html.plaintext.txt	114	num apolipoprotrein e cholesterol transport protein expanding role cell biology
0.2476838.9328480.html.plaintext.txt	115	num regulation apolipoprotein e gene expression injury rat sciatic nerve
0.2476838.9328480.html.plaintext.txt	116	num low density lipoprotein pathway central nervous system apolipoprotein e isoform specific difference
0.2476838.9328480.html.plaintext.txt	117	iqbal mortimer winblad wisniewski ed research advance alzheimers disease related disorder
0.2476838.9328480.html.plaintext.txt	118	num association apolipoprotein e genotype brain level apolipoprotein e apolipoprotein j clusterin alzheimer disease
0.2476838.9328480.html.plaintext.txt	119	num overcoming normalisation signal saturation due silver staining way quantify allele specific rt pcr product
0.2476838.9328480.html.plaintext.txt	120	num binding human apolipoprotein e synthetic amyloid beta peptide isoform specific effect implication late onset alzheimer disease
0.2476838.9328480.html.plaintext.txt	121	num apolipoprotein e kinetic thermodynamic inhibitor amyloid formation implication pathogenesis treatment alzheimers disease
0.2476838.9328480.html.plaintext.txt	122	num apolipoprotein e allele specific antioxidant activity effect cytotoxicity oxidative insult beta amyloid peptide
0.2476838.9328480.html.plaintext.txt	123	num hypothesis microtubule instability paired helical filament formation alzheimer disease related apolipoprotein e genotype
0.2476838.9328480.html.plaintext.txt	124	num brain expression apolipoprotein e j alzheimers disease
0.2476838.9328480.html.plaintext.txt	125	num apolipoprotein e apoe polymorphism influence apoe concentration cerebrospinal fluid finnish patient alzheimers disease
0.2476838.9328480.html.plaintext.txt	126	num relevance quantification apolipoprotein e cerebrospinal fluid alzheimers disease
0.2476838.9328480.html.plaintext.txt	127	num increased plasma apolipoprotein e apoe level alzheimers disease
0.2476838.9328480.html.plaintext.txt	128	num monoclonal antibody polymorphic site distinguishes apolipoprotein egrnum isoforms
0.2476838.9328480.html.plaintext.txt	129	num accumulation apolipoprotein e b amyloid like protein trace hippocampal canum pyramidal cell layer ischaemic delayed neuronal death neuroreport num num num
0.2476838.9328480.html.plaintext.txt	130	num cladistic analysis phenotypic association haplotype inferred restriction endonuclease mapping dna sequencing
0.2476838.9328480.html.plaintext.txt	131	analysis casecontrol sampling design alzheimers disease apolipoprotein e locus
0.2476838.9328480.html.plaintext.txt	132	num restriction isotyping human apolipoprotein e gene amplification cleavage hhai
0.2476838.9328480.html.plaintext.txt	133	num biosynthesis protamine trout testis
0.2476838.9328480.html.plaintext.txt	134	correspondence addressed inserm cjfnum num institut pasteur de lille num rue de calmette num lille cedex france
0.2476838.9328480.html.plaintext.txt	135	tel num num num num num num fax num num num num num num email marie christine
0.2476838.9328480.html.plaintext.txt	136	fr page maintained oup admin
0.2476838.9328480.html.plaintext.txt	137	last updated sat oct num numnumnum bst num
0.2476838.9328480.html.plaintext.txt	138	part oup journal world wide web service
0.2476838.9328480.html.plaintext.txt	139	copyright oxford university press num
0.24991155.16154999.html.plaintext.txt	0	amyloid protein degraded cellular angiotensin converting enzyme ace elevated ace inhibitor matthew l
0.24991155.16154999.html.plaintext.txt	1	center neurologic disease brigham woman hospital harvard medical school boston massachusetts num
0.24991155.16154999.html.plaintext.txt	2	received publication august num num revised form september num num
0.24991155.16154999.html.plaintext.txt	3	somatic angiotensin converting enzyme ace zinc metalloprotease containing two homologous region termed n c domain proteolytically active num
0.24991155.16154999.html.plaintext.txt	4	ace single transmembrane domain cleaved cell surface low rate resulting secretion ectodomain medium cultured cell plasma num num
0.24991155.16154999.html.plaintext.txt	5	ace intensively characterized role regulation blood pressure cleaving angiotensin angiotensin ii inactivating bradykinin num
0.24991155.16154999.html.plaintext.txt	6	function ace modulated pharmacologically ace inhibitor bind competitively active site zinc prevent substrate hydrolysis
0.24991155.16154999.html.plaintext.txt	7	commonly prescribed class drug used treatment hypertension disorder
0.24991155.16154999.html.plaintext.txt	8	addition regulating vasoactive peptide ace show broad substrate specificity including several neuropeptides able metabolize substrate using exopeptidase endopeptidase activity num
0.24991155.16154999.html.plaintext.txt	9	interestingly despite homology n c domain display differential capacity degrade substrate inhibited selectively certain ace inhibitor num num
0.24991155.16154999.html.plaintext.txt	10	recently ace found participate c jun n terminal kinase signal transduction pathway apparently independently proteolytic function num
0.24991155.16154999.html.plaintext.txt	11	potential relationship ace ad first suggested human genetic study reported insertion ideletion d polymorphism within intron num ace gene associate ad num
0.24991155.16154999.html.plaintext.txt	12	specifically allele associated increased risk ad whereas d allele associated protection num num
0.24991155.16154999.html.plaintext.txt	13	potential mechanistic relevance inheritance d allele associated increased plasma ace level num
0.24991155.16154999.html.plaintext.txt	14	regarding disease specificity allele found associate positively ad vascular dementia vascular pathology num num
0.24991155.16154999.html.plaintext.txt	15	ii genotype also linked smaller volume hippocampus amygdala num
0.24991155.16154999.html.plaintext.txt	16	importantly post mortem analysis ad patient determined ii genotype trend toward increased brain anum load compared dd genotype num
0.24991155.16154999.html.plaintext.txt	17	single nucleotide polymorphism ace gene also shown associate ad decrease prevalence ad susceptible genotype increased age consistent modulation longevity num
0.24991155.16154999.html.plaintext.txt	18	post mortem study patient ad found elevated level ace temporal cortex specifically within pyramidal cortical neuron num num well significantly increased ace activity medial hippocampus parahippocampal gyrus frontal cortex caudate nucleus num
0.24991155.16154999.html.plaintext.txt	19	mechanistic link ace ad suggested affinity purified ace shown degrade synthetic num num aspnum sernum bond vitro producing truncated num residue peptide exhibited decreased aggregation cytotoxic potential num
0.24991155.16154999.html.plaintext.txt	20	plausible interpretation genetic neuropathological biochemical finding ace implicated ad via direct proteolysis peptide modulating level within brain
0.24991155.16154999.html.plaintext.txt	21	hypothesis suggests reduced ace activity either genetic mechanism chronic pharmacological inhibition could increase cerebral level anum andor anum thus presumably increase risk developing ad andor contribute progression
0.24991155.16154999.html.plaintext.txt	22	address hypothesis intact living cell cloned characterized human neural ace determined role clearance secreted
0.24991155.16154999.html.plaintext.txt	23	demonstrate ace promotes clearance naturally produced anum anum lead secondary degradation specie
0.24991155.16154999.html.plaintext.txt	24	using site directed mutagenesis context full length enzyme show n c domain ace capable promoting degradation similar capacity
0.24991155.16154999.html.plaintext.txt	25	finally demonstrate treatment secreting cell commonly prescribed ace inhibitor prevents ace mediated clearance result accumulation peptide
0.24991155.16154999.html.plaintext.txt	26	cell culture chinese hamster ovary cho human embryonic kidney num heknum cell grown dulbeccos modified eagle medium containing num fetal bovine serum num mm l glutamine num microgml penicillin num microgml streptomycin
0.24991155.16154999.html.plaintext.txt	27	heknum cell stably expressing appnum bearing knumnmnuml swedish ad causing mutation num selected medium containing num microgml gnum
0.24991155.16154999.html.plaintext.txt	28	cho cell stably transfected appnum vnumf ad causing mutation pfrtlaczeo construct enabling flp intm invitrogen competence grown num microgml gnum num microgml zeocin
0.24991155.16154999.html.plaintext.txt	29	successful genomic recombination pcdnanumfrt construct occurred flp host cell lost zeocin resistance selected num microgml hygromycin b
0.24991155.16154999.html.plaintext.txt	30	effect capoten captopril sigma assayed num h preincubation cell drug followed num h conditioning period cell grown serum free dulbeccos modified eagle medium invitrogen captopril
0.24991155.16154999.html.plaintext.txt	31	expression cloned construct cho heknum cell transient transfections cho heknum cell line performed using geneporter num gts expression assayed num num h posttransfection
0.24991155.16154999.html.plaintext.txt	32	cho cell line stably expressing appnum vnumf mutation either empty vector ace mutant ace construct generated using flp intm system invitrogen
0.24991155.16154999.html.plaintext.txt	33	allowed stable integration construct genomic locus single cell line
0.24991155.16154999.html.plaintext.txt	34	immunoblotting cell tissue lysed num mm tris hcl ph num
0.24991155.16154999.html.plaintext.txt	35	num num mm nacl num nonidet p num protease inhibitor mixture roche applied science num mm numnum phenanthroline num mm edta extract centrifuged numnum x g num min remove nucleus
0.24991155.16154999.html.plaintext.txt	36	protein concentration determined using bicinchoninic acid based assay pierce
0.24991155.16154999.html.plaintext.txt	37	sample subject sd page western blotting
0.24991155.16154999.html.plaintext.txt	38	ace detected using polyclonal antibody raised amino acid num num human ace sc num santa cruz biotechnology inc
0.24991155.16154999.html.plaintext.txt	39	full length human app detected using numenum reactive app num num appnum gift p
0.24991155.16154999.html.plaintext.txt	40	app cnum cnum c terminal fragment detected using polyclonal antibody cnum specific residue num num appnum
0.24991155.16154999.html.plaintext.txt	41	total cellular ide detected using polyclonal ide num raised amino acid num num human ide num
0.24991155.16154999.html.plaintext.txt	42	ha tagged ide detected using anti ha monoclonal numfnum roche applied science
0.24991155.16154999.html.plaintext.txt	43	deglycosylation performed using peptide n glycosidase f remove n linked sugar mixture o deglycosylating enzyme sialidase o glycanase num num galactosidase n acetylglucosaminidase prozyme
0.24991155.16154999.html.plaintext.txt	44	western blot probed anti mouse anti rat anti rabbit secondary antibody conjugated alexa fluor num molecular probe inc
0.24991155.16154999.html.plaintext.txt	45	eugene irdye num rockland immunochemicals
0.24991155.16154999.html.plaintext.txt	46	blot detected band sized quantified using odyssey infrared imaging system li cor
0.24991155.16154999.html.plaintext.txt	47	ace activity assay ace proteolytic activity assayed using substrate hippuryl l histidyl l leucine hip leu sigma described previously num several modification
0.24991155.16154999.html.plaintext.txt	48	cell lysed num mm tris ph num
0.24991155.16154999.html.plaintext.txt	49	num nonidet p num nucleus cell debris pelleted numnum x g num min
0.24991155.16154999.html.plaintext.txt	50	num microg cell lysate incubated num mm hip leu num
0.24991155.16154999.html.plaintext.txt	51	num m nacl total volume num microl num num min num degree c
0.24991155.16154999.html.plaintext.txt	52	assaying sample captopril num min preincubation drug performed num degree c substrate addition
0.24991155.16154999.html.plaintext.txt	53	time num value calculated addition edta final concentration num mm prior addition hip leu
0.24991155.16154999.html.plaintext.txt	54	enzymatic reaction terminated addition edta num mm final concentration
0.24991155.16154999.html.plaintext.txt	55	sample developed first addition num microl num
0.24991155.16154999.html.plaintext.txt	56	num m naoh followed num min room temperature incubation num microl num mgml o phthaldialdehyde sigma
0.24991155.16154999.html.plaintext.txt	57	reaction terminated acidification num microl num n hcl
0.24991155.16154999.html.plaintext.txt	58	fluorescence liberated o phthaldialdehyde modified leu assayed num well plate format using victornum multilabel plate reader excitation num emission num perkinelmer life science
0.24991155.16154999.html.plaintext.txt	59	num degradation defined maximal fluorescence signal achieved digestion num mm hip leu num
0.24991155.16154999.html.plaintext.txt	60	num microg ace transfected cell lysate num min
0.24991155.16154999.html.plaintext.txt	61	enzyme linked immunosorbant assay conditioned medium sample harvested removing cellular debris centrifugation num x g num min protease inhibitor added final concentration num microgml leupeptin num microgml aprotinin num microgml pepstatin num mm numnum phenanthroline num mm edta
0.24991155.16154999.html.plaintext.txt	62	elisa performed previously described num following modification
0.24991155.16154999.html.plaintext.txt	63	num well elisa plate costar coated num
0.24991155.16154999.html.plaintext.txt	64	num microgml capture antibody
0.24991155.16154999.html.plaintext.txt	65	num num num num measured capturing antibody specific c terminal num numgnum num numfnum residue
0.24991155.16154999.html.plaintext.txt	66	captured detected num
0.24991155.16154999.html.plaintext.txt	67	num microgml biotinylated numdnum specific residue num num n terminus
0.24991155.16154999.html.plaintext.txt	68	elisa measuring x num x num form captured identically numgnum numfnum detected num
0.24991155.16154999.html.plaintext.txt	69	num microgml biotinylated num specific residue num num
0.24991155.16154999.html.plaintext.txt	70	total measured capture antibody num detection num
0.24991155.16154999.html.plaintext.txt	71	num microgml biotinylated numdnum antibody gift elan pharmaceutical san francisco ca
0.24991155.16154999.html.plaintext.txt	72	elisa development accomplished incubating bound biotinylated detection antibody avidin horseradish peroxidase vector followed tetramethylbenzidine elisa pierce
0.24991155.16154999.html.plaintext.txt	73	plate washed three time num min incubation tris buffered saline num
0.24991155.16154999.html.plaintext.txt	74	statistical analysis data analyzed using one way analysis variance tukeys post hoc comparison two way analysis variance bonferroni post hoc comparison appropriate
0.24991155.16154999.html.plaintext.txt	75	calculated comparison p num
0.24991155.16154999.html.plaintext.txt	76	characterize ace cellular level cloned full length num
0.24991155.16154999.html.plaintext.txt	77	num kb cdna human neuroblastoma cell line sk n sh
0.24991155.16154999.html.plaintext.txt	78	ace cdna cloned mammalian expression vector pcdnanumfrt shown conform reported human ace sequence restriction mapping dna sequencing
0.24991155.16154999.html.plaintext.txt	79	transient transfection ace construct cho heknum cell yielded indistinguishable result assay performed fig
0.24991155.16154999.html.plaintext.txt	80	neither cell line expressed detectable endogenous level ace protein western blotting although ace mrna detected heknum cell reverse transcription pcr data shown
0.24991155.16154999.html.plaintext.txt	81	ace predicted contain num n type glycosylation site o type glycosylation site
0.24991155.16154999.html.plaintext.txt	82	determine whether transfected ace protein processed similarly tissue derived ace compared glycosylation pattern mouse kidney tissue ace ace transfected either cho heknum cell
0.24991155.16154999.html.plaintext.txt	83	expected deglycosylation several enzyme specific o linked sugar produced shift ace size whereas removal n linked modification yielded shift ace protein num num kda fig
0.24991155.16154999.html.plaintext.txt	84	ace known secreted vivo vitro cell surface low level secretase dependent manner num
0.24991155.16154999.html.plaintext.txt	85	concentration conditioned medium heknum cho cell transiently transfected ace cdna found contain low level ace protein whereas control cell transfected empty vector corresponding signal fig
0.24991155.16154999.html.plaintext.txt	86	view larger version numk figure num
0.24991155.16154999.html.plaintext.txt	87	brain distribution schematic diagram angiotensin converting enzyme
0.24991155.16154999.html.plaintext.txt	88	num microg murine tissue homogenate designated brain region well peripheral tissue known lack highly express ace probed western blotting ace specific antibody
0.24991155.16154999.html.plaintext.txt	89	note brain ace occurs doublet arising alternate glycosylation
0.24991155.16154999.html.plaintext.txt	90	asterisk indicates nonspecific band detected liver previously reported num
0.24991155.16154999.html.plaintext.txt	91	b schematic representation human full length ace protein
0.24991155.16154999.html.plaintext.txt	92	wild type enzyme contains signal peptide sp two homologous catalytic domain gray box single transmembrane segment tm small c terminal cytoplasmic tail
0.24991155.16154999.html.plaintext.txt	93	metalloprotease catalytic sequence domain indicated corresponding amino acid numbering first n terminal residue mature protein
0.24991155.16154999.html.plaintext.txt	94	determine whether transfected ace enzymatically active incubated lysates cell transiently transfected ace empty vector commonly used synthetic ace substrate hip leu standard assay condition num mm substrate num
0.24991155.16154999.html.plaintext.txt	95	num m sodium borate buffer num
0.24991155.16154999.html.plaintext.txt	96	lysates cell transfected ace exhibited robust degradation hip leu completely blocked num microm concentration competitive ace inhibitor captopril
0.24991155.16154999.html.plaintext.txt	97	contrast lysates cell transfected empty vector detectable ace activity fig
0.24991155.16154999.html.plaintext.txt	98	taken together result demonstrate cloned transfected ace construct processed similarly tissue ace retains proteolytic activity sensitivity ace inhibitor
0.24991155.16154999.html.plaintext.txt	99	transiently expressed ace promotes clearance secondary degradation determine whether ace modulate level intact living cell transiently transfected equal dna amount plasmid encoding either empty vector ide ace pcdnanumfrt heknum cell stably expressing human appnum bearing swedish ad causing mutation measured level resulting conditioned medium
0.24991155.16154999.html.plaintext.txt	100	transfection ha tagged ide served positive control proteolysis since shown lower cultured cell num num
0.24991155.16154999.html.plaintext.txt	101	using elisa specific num num num num ide found reduce cell derived level num num respectively control cell transfected empty vector p num
0.24991155.16154999.html.plaintext.txt	102	transfections ace yielded similar result reducing num num level num num num level num control p num
0.24991155.16154999.html.plaintext.txt	103	thus ace ide transfected cell significantly reduced level principal specie compared control significantly different
0.24991155.16154999.html.plaintext.txt	104	view larger version numk figure num
0.24991155.16154999.html.plaintext.txt	105	characterization processing enzymatic activity cloned human ace
0.24991155.16154999.html.plaintext.txt	106	lysates mouse kidney cho cell transiently transfected ace cdna construct subjected deglycosylation enzyme specific n o linked sugar subject western blot analysis ace specific antibody
0.24991155.16154999.html.plaintext.txt	107	asterisk indicates calculated molecular weight deglycosylated band
0.24991155.16154999.html.plaintext.txt	108	b conditioned medium cho cell transiently transfected ace empty vector concentrated analyzed western blot reflecting low rate ace ectodomain secretion sace previously reported num
0.24991155.16154999.html.plaintext.txt	109	c ace enzymatic activity measured incubating num
0.24991155.16154999.html.plaintext.txt	110	num microg lysate heknum cell transfected indicated construct num mm substrate hip leu num min num degree c
0.24991155.16154999.html.plaintext.txt	111	num degradation defined maximal fluorescence produced num min substrate incubation num
0.24991155.16154999.html.plaintext.txt	112	num microg lysate cell transfected ace cdna
0.24991155.16154999.html.plaintext.txt	113	value c represent mean plus minus
0.24991155.16154999.html.plaintext.txt	114	obtained four independent experiment
0.24991155.16154999.html.plaintext.txt	115	blot b representative least four independent experiment
0.24991155.16154999.html.plaintext.txt	116	deglycosylation secretion enzymatic activity assay identical transfected cho heknum cell line
0.24991155.16154999.html.plaintext.txt	117	ace shown cleave aspnum sernum vitro num hypothesized remaining fragment beginning sernum might either accumulate undergo secondary degradation cellular context
0.24991155.16154999.html.plaintext.txt	118	discriminate possibility used elisa specific internal residue num num capture either num num c terminus detection measured specie denoted x num x num
0.24991155.16154999.html.plaintext.txt	119	found ide decrease x num level num x num level num control cell p num
0.24991155.16154999.html.plaintext.txt	120	ace mirrored reduction x num decreased num x num decreased num control p num
0.24991155.16154999.html.plaintext.txt	121	x num x num value ide ace significantly different control different
0.24991155.16154999.html.plaintext.txt	122	thus human cell line transfected human cdna encoding app either ide ace level significantly reduced
0.24991155.16154999.html.plaintext.txt	123	cell derived ace transfected cell showed greater secondary degradation peptide reported vitro num
0.24991155.16154999.html.plaintext.txt	124	result suggests ace degrades additional site cellular context andor specie cleaved ace subsequently degraded cellular protease
0.24991155.16154999.html.plaintext.txt	125	transfection efficiency assayed western blot analysis fig
0.24991155.16154999.html.plaintext.txt	126	whereas transfected construct resulted robust expression total ide level increased num
0.24991155.16154999.html.plaintext.txt	127	num fold endogenous ide fig
0.24991155.16154999.html.plaintext.txt	128	contrast detectable endogenous ace expressed heknum cell fig
0.24991155.16154999.html.plaintext.txt	129	generation catalytically inactive ace mutant ace contains two homologous catalytic region termed n c domain containing canonical zinc metalloprotease active site fig
0.24991155.16154999.html.plaintext.txt	130	determine active site mediates clearance generated three ace mutant construct two containing one functional catalytic domain one catalytically inactive enzyme bearing mutation site
0.24991155.16154999.html.plaintext.txt	131	mutation made site directed mutagenesis change active site sequence hemgh hdmgh conservative mutation previously shown inactivate ace proteolysis num
0.24991155.16154999.html.plaintext.txt	132	c domain inactivated mutating ace glutamate residue num aspartate termed enumd n domain similarly mutated changing glutamate residue num aspartate termed enumd
0.24991155.16154999.html.plaintext.txt	133	singly mutated construct combined restriction digestion ligation form catalytically inactive double mutant enumdenumd
0.24991155.16154999.html.plaintext.txt	134	construct analyzed restriction digestion dna sequencing ensure mutation made outside produced site directed mutagenesis
0.24991155.16154999.html.plaintext.txt	135	cloned pcdnanumfrt achieve identical level cellular expression
0.24991155.16154999.html.plaintext.txt	136	cho cell line stably expressing human appnum bearing ad causing vnumf mutation flp acceptor locus used make stable cell line expressing wild type ace wtace enumd enumd enumdenumd empty vector
0.24991155.16154999.html.plaintext.txt	137	thus stable cell line contained app well one transfected construct integrated genomic locus site directed recombination pcdnanumfrt vector cell line designated app x x integrated construct
0.24991155.16154999.html.plaintext.txt	138	resulting ace stable line produced identical level wtace mutant ace protein well indistinguishable level human app fig
0.24991155.16154999.html.plaintext.txt	139	notably app empty vector line expressed estimated num higher level app four app ace line fig
0.24991155.16154999.html.plaintext.txt	140	numa middle panel presumably result modest cytomegalovirus promoter competition app ace construct
0.24991155.16154999.html.plaintext.txt	141	enumd enumd enumdenumd mutant protein posttranslationally modified secreted similar level wtace protein fig
0.24991155.16154999.html.plaintext.txt	142	canonical enzymatic activity mutant construct confirmed degradation substrate hip leu fig
0.24991155.16154999.html.plaintext.txt	143	wtace enumd protein found degrade substrate similar rate whereas enumd far reduced efficiency hydrolysis conforming published kinetic parameter active site hip leu num
0.24991155.16154999.html.plaintext.txt	144	enzymatically inactive enumdenumd wtace protein incubated num microm captopril produced detectable degradation product fig
0.24991155.16154999.html.plaintext.txt	145	view larger version numk figure num
0.24991155.16154999.html.plaintext.txt	146	transfected human ace promotes clearance secondary degradation cell derived human anum anum
0.24991155.16154999.html.plaintext.txt	147	heknum cell stably transfected human appnum bearing ad causing swedish mutation transiently transfected empty vector well characterized degrading protease ide ace
0.24991155.16154999.html.plaintext.txt	148	medium conditioned cell num h level determined elisa specific intact specie beginning residue num ending either residue num solid barsor num hatched bar elisa specific middle region peptide residue num num denoted x either residue num solid bar num hatched bar b
0.24991155.16154999.html.plaintext.txt	149	data represent mean plus minus
0.24991155.16154999.html.plaintext.txt	150	num num independent experiment measured duplicate
0.24991155.16154999.html.plaintext.txt	151	value normalized empty vector allow combination data set compared empty vector p num
0.24991155.16154999.html.plaintext.txt	152	c immunoblots transient transfections heknum cell
0.24991155.16154999.html.plaintext.txt	153	ace ide panel indicate total cellular expression protein whereas ha ide panel indicates expression tagged ide construct
0.24991155.16154999.html.plaintext.txt	154	immunoblot representative least four independent experiment
0.24991155.16154999.html.plaintext.txt	155	n c domain ace promote degradation determine effect ace active site level conditioned medium doubly stable line analyzed total content elisa
0.24991155.16154999.html.plaintext.txt	156	normalizing value app empty vector condition app content significant difference level app empty vector catalytically inactive app enumdenumd
0.24991155.16154999.html.plaintext.txt	157	n c catalytic domain ace found decrease cell derived level quantitatively similar degree wtace
0.24991155.16154999.html.plaintext.txt	158	enumd reduced level num enumd num wtace num app empty vector condition fig
0.24991155.16154999.html.plaintext.txt	159	single mutant wtace enzyme significantly different app empty vector p num
0.24991155.16154999.html.plaintext.txt	160	num significantly different
0.24991155.16154999.html.plaintext.txt	161	difference content could ascribed ace enzyme altering level secretase generated app c terminal fragment since cnum cnum significantly changed compared app empty vector fig
0.24991155.16154999.html.plaintext.txt	162	thus using conservative mutation inactivate ace catalytic domain experiment demonstrate n c domain capable mediating clearance naturally produced cell derived intact cell
0.24991155.16154999.html.plaintext.txt	163	level increased ace inhibition determine whether decreasing ace activity small molecule inhibitor could elevate cell derived level preincubated cell num h presence prototypical ace inhibitor captopril conditioned medium num h presence drug
0.24991155.16154999.html.plaintext.txt	164	increasing dos captopril tested resulting conditioned medium analyzed elisa total content
0.24991155.16154999.html.plaintext.txt	165	value normalized cell line drug treatment
0.24991155.16154999.html.plaintext.txt	166	captopril found significant effect level catalytically inactive app enumdenumd cell line expected
0.24991155.16154999.html.plaintext.txt	167	contrast captopril treated app wtace cell accumulated nearly num fold untreated cell drug concentration num microm p num
0.24991155.16154999.html.plaintext.txt	168	num microm captopril lowest concentration tested level elevated num
0.24991155.16154999.html.plaintext.txt	169	num fold app wtace cell compared cell line without drug p num
0.24991155.16154999.html.plaintext.txt	170	result demonstrate widely prescribed ace inhibitor promote accumulation natural cell derived blocking ace proteolytic activity
0.24991155.16154999.html.plaintext.txt	171	reported recently n domain ace c domain responsible degradation synthetic anum vitro num
0.24991155.16154999.html.plaintext.txt	172	study ace catalytic domain cloned isolation producing recombinant truncation protein bearing one ace active site
0.24991155.16154999.html.plaintext.txt	173	contrast find n c domain ace able degrade naturally produced cellular context
0.24991155.16154999.html.plaintext.txt	174	study used conservative mutation inactivate catalytic domain molecule conserving overall structure sequence full length protein
0.24991155.16154999.html.plaintext.txt	175	possible c domain able degrade intact cell vitro
0.24991155.16154999.html.plaintext.txt	176	evidence catalytic domain ace regulates activity num suggesting full length protein required normal substrate recognition degradation
0.24991155.16154999.html.plaintext.txt	177	c domain expressed outside context full length enzyme may retain tertiary structure required degrade larger substrate whereas much smaller substrate still processed num
0.24991155.16154999.html.plaintext.txt	178	unlikely incomplete inactivation n domain enumd mutant enzyme could account observed decrease domain inactivated enumdenumd ace construct observe change level compared empty vector control
0.24991155.16154999.html.plaintext.txt	179	view larger version numk figure num
0.24991155.16154999.html.plaintext.txt	180	cell derived degraded n c domain ace elevated ace inhibition
0.24991155.16154999.html.plaintext.txt	181	cho cell stably transfected human appnum bearing vnumf ad causing missense mutation either empty vector human wild type ace indicated ace mutant construct
0.24991155.16154999.html.plaintext.txt	182	immunoblots showing expression ace app app c terminal fragment stable cell line
0.24991155.16154999.html.plaintext.txt	183	note slightly higher expression human app happ app empty vector line resulting presumably modest cytomegalovirus promoter competition app ace construct
0.24991155.16154999.html.plaintext.txt	184	immunoblots representative least four independent determination
0.24991155.16154999.html.plaintext.txt	185	b conditioned medium stable line concentrated probed presence secreted ace sace protein
0.24991155.16154999.html.plaintext.txt	186	c ace activity assay incubating num
0.24991155.16154999.html.plaintext.txt	187	num microg cell lysate num mm hip leu indicated time point num degree c
0.24991155.16154999.html.plaintext.txt	188	value represent mean plus minus
0.24991155.16154999.html.plaintext.txt	189	obtained num num independent experiment
0.24991155.16154999.html.plaintext.txt	190	d cell line conditioned num h medium harvested probed elisa total content
0.24991155.16154999.html.plaintext.txt	191	due elevated app expression value app empty vector condition normalized app expression app ace doubly stable line
0.24991155.16154999.html.plaintext.txt	192	data represent mean plus minus
0.24991155.16154999.html.plaintext.txt	193	seven independent experiment measured duplicate
0.24991155.16154999.html.plaintext.txt	194	value normalized app empty vector allow combination data set p num
0.24991155.16154999.html.plaintext.txt	195	num compared empty vector
0.24991155.16154999.html.plaintext.txt	196	e fold change content conditioned medium app wtace app enumdenumd cell line num h pretreatment num h conditioning presence captopril
0.24991155.16154999.html.plaintext.txt	197	data point normalized untreated cell num microm captopril doubly transfected cell line
0.24991155.16154999.html.plaintext.txt	198	data represent mean plus minus
0.24991155.16154999.html.plaintext.txt	199	four independent experiment measured duplicate ace compared enumdenumd dose p num
0.24991155.16154999.html.plaintext.txt	200	growing genetic evidence suggests ace potential risk factor ad
0.24991155.16154999.html.plaintext.txt	201	writing approximately num published study examined relationship majority finding significant association ace genotype ad
0.24991155.16154999.html.plaintext.txt	202	post mortem analysis ad brain tissue shown significant elevation ace protein compared control num perhaps representing regulation clearance mechanism
0.24991155.16154999.html.plaintext.txt	203	interestingly initiation ace mediated signal transduction substrate shown regulate enzyme expression via c jun n terminal kinase pathway num num
0.24991155.16154999.html.plaintext.txt	204	feedback system provides hypothetical mechanism ace could modulate expression depending level substrate leading elevated level ace ad cortex
0.24991155.16154999.html.plaintext.txt	205	observation ace inhibition cell expressing human app ace promotes accumulation secreted may bear clinical relevance
0.24991155.16154999.html.plaintext.txt	206	given neuron produce app ace neuronal ace regulated ad num hypothesize chronic pharmacological inhibition ace could increase level brain reducing ace dependent proteolysis
0.24991155.16154999.html.plaintext.txt	207	study yet examined consequence chronic ace inhibition level brain plasma human
0.24991155.16154999.html.plaintext.txt	208	clinical trial ace inhibitor analyzed effect cognitive decline ad subject result date inconclusive num num
0.24991155.16154999.html.plaintext.txt	209	study effect ace deficiency overexpression metabolism vivo reported
0.24991155.16154999.html.plaintext.txt	210	study may problematic interpretation endogenous murine amino acid difference human peptide immediately surrounding putative site cleavage ace could affect property substrate
0.24991155.16154999.html.plaintext.txt	211	future vivo study examine ace inhibition deficiency overexpression mouse expressing human app may instructive regarding role ace alzheimer disease
0.24991155.16154999.html.plaintext.txt	212	context new finding earlier study reviewed hypothesize decreased activity ace aged human brain originating either genetic polymorphism pharmacological inhibition may promote accumulation thus modulate likelihood development alzheimer disease andor neuropathological severity
0.24991155.16154999.html.plaintext.txt	213	finding suggest need analysis biological effect ace genetic deficiency ace pharmacological inhibition experimental model ad large human population currently experiencing chronic ace inhibition
0.24991155.16154999.html.plaintext.txt	214	footnote work supported national institute health grant agnum d
0.24991155.16154999.html.plaintext.txt	215	predoctoral fellowship harvard center neurodegeneration repair m
0.24991155.16154999.html.plaintext.txt	216	cost publication article defrayed part payment page charge
0.24991155.16154999.html.plaintext.txt	217	article must therefore hereby marked advertisement accordance num u
0.24991155.16154999.html.plaintext.txt	218	section num solely indicate fact
0.24991155.16154999.html.plaintext.txt	219	num correspondence addressed harvard institute medicine num num ave
0.24991155.16154999.html.plaintext.txt	220	louis pasteur boston ma num
0.24991155.16154999.html.plaintext.txt	221	num num num fax num num num e mail dselkoeatrics
0.24991155.16154999.html.plaintext.txt	222	num abbreviation used ad alzheimer disease ace angiotensin converting enzyme app amyloid precursor protein cho chinese hamster ovary heknum human embryonic kidney num amyloid protein ide insulin degrading enzyme nep neprilysin elisa enzyme linked immunosorbant assay hip leu hippuryl l histidyl l leucine ace insertion d ace deletion wtace wild type ace ha hemagglutinin
0.24991155.16154999.html.plaintext.txt	223	acknowledgment thank w
0.24991155.16154999.html.plaintext.txt	224	rappley technical advice discussion d
0.24991155.16154999.html.plaintext.txt	225	walsh providing cho cell line stably transfected pfrtlaczeo vector flp system
0.24991155.16154999.html.plaintext.txt	226	hemming support encouragement
0.2581098.12411259.html.plaintext.txt	0	brain ageing dementia make difference lawrence j
0.2581098.12411259.html.plaintext.txt	1	university aberdeen clinical research centre royal cornhill hospital aberdeen abnum numzh uk
0.2581098.12411259.html.plaintext.txt	2	correspondence tel num num e mail l
0.2581098.12411259.html.plaintext.txt	3	hold career development award wellcome trust
0.2581098.12411259.html.plaintext.txt	4	boundary non pathological brain ageing dementia unclear contentious
0.2581098.12411259.html.plaintext.txt	5	neuropathological examination detect occasional individual microscopic feature typical late onset alzheimers disease present yet clinical history dementia absent
0.2581098.12411259.html.plaintext.txt	6	occasion converse seems true individual seriously disabled life dementia show death mild pathological feature alzheimers disease
0.2581098.12411259.html.plaintext.txt	7	observation type although often made experienced neuropathologists widely discussed molecular neurobiologist among assumption largely prevailed alzheimers disease well validated nosological entity discontinuous ageing discrete molecular pathology
0.2581098.12411259.html.plaintext.txt	8	reasoning extends repeated proposition understanding pathogenesis amyloid deposition provide sound sufficient basis develop novel therapy alzheimers disease selkoe num
0.2581098.12411259.html.plaintext.txt	9	finding medical research council cognitive function ageing study mrc cfas challenge assumption least two front
0.2581098.12411259.html.plaintext.txt	10	first encourage dementia researcher re examine basis belief valid boundary non pathological normal ageing absence dementia dementia
0.2581098.12411259.html.plaintext.txt	11	second suggest central role often assigned amyloid deposition requires review
0.2581098.12411259.html.plaintext.txt	12	longitudinal follow study mrc cfas raise important issue nature phenomenon explained
0.2581098.12411259.html.plaintext.txt	13	editorial considers early contribution brain development influence cognitive decline later life
0.2581098.12411259.html.plaintext.txt	14	turn approach requires deeper understanding yet available brain mechanism process affected ageing
0.2581098.12411259.html.plaintext.txt	15	margaret esiri colleague esiri et al num described large community based neuropathological study distinction dementia brain ageing absence dementia shortage data
0.2581098.12411259.html.plaintext.txt	16	impossible accept validity contemporary neuropathological criterion dementia definition boundary existed dementia normal ageing
0.2581098.12411259.html.plaintext.txt	17	study showed num old people weighted contain num people met clinical criterion dementia death majority showed mixed alzheimer vascular pathology
0.2581098.12411259.html.plaintext.txt	18	postmortem examination brain dementia non dementia subject overlapped neuritic diffuse plaque density single pathological criterion reliably distinguished group
0.2581098.12411259.html.plaintext.txt	19	coexistent vascular lesion provide sufficient explanation presence dementia encourage view interaction alzheimer vascular pathology may critical determinant progression clinical dementia
0.2581098.12411259.html.plaintext.txt	20	mrc cfas data provide strongest evidence yet relationship normal brain ageing dementia best represented continuum
0.2581098.12411259.html.plaintext.txt	21	also much weaken pivotal position claimed amyloid deposition pathogenesis alzheimers disease
0.2581098.12411259.html.plaintext.txt	22	without inclusion factor factor amyloid cascade hypothesis alzheimers disease longer tenable
0.2581098.12411259.html.plaintext.txt	23	mrc cfas programme may yet identify factor
0.2581098.12411259.html.plaintext.txt	24	sample size doubled improved description quantification vascular lesion possible begin disentangle pathological process contribute clinical presentation dementia critically establish true relationship age
0.2581098.12411259.html.plaintext.txt	25	rate cognitive change caseness
0.2581098.12411259.html.plaintext.txt	26	longitudinal psychological study cognitive ageing identify single point transition normal ageing dementia
0.2581098.12411259.html.plaintext.txt	27	several cognitive domain used predict later onset dementia cognitive decline typically non uniform across domain exception early memory impairment largely inclusion among criterion dementia chen et al num
0.2581098.12411259.html.plaintext.txt	28	presymptomatic pattern cognitive decline reliably distinguished normal variation cognitive function late life almost half attributable original childhood iq deary num
0.2581098.12411259.html.plaintext.txt	29	psychologist psychiatrist alike familiar problem type comfortable search antecedent may extend earlier developmental epoch
0.2581098.12411259.html.plaintext.txt	30	link increased late life dementia risk lower educational attainment suggest association dementia childhood iq reported whalley et al num
0.2581098.12411259.html.plaintext.txt	31	explanation association type complex mutually exclusive
0.2581098.12411259.html.plaintext.txt	32	least strong intergenerational lifelong continuity material advantage award entry safer healthier environment mentally able youngster
0.2581098.12411259.html.plaintext.txt	33	usual concept mature brain posse sufficient reserve redundancy withstand age related pathology described esiri et al num reserve determined early life experience
0.2581098.12411259.html.plaintext.txt	34	belief childhood educational attainment mental ability could determine threshold brain ageing dementia pathology must sufficient exceed cause dementia supported data reported whalley et al num
0.2581098.12411259.html.plaintext.txt	35	association lower childhood iq dementia confined late onset case marked presenting age num year
0.2581098.12411259.html.plaintext.txt	36	mrc cfas programme represents successful application epidemiological neuropathological method study distinction clinical case non case age disease onset occur
0.2581098.12411259.html.plaintext.txt	37	usual contemporary approach age related disease disease interest case dementia defined present absent
0.2581098.12411259.html.plaintext.txt	38	contrast second potentially powerful research method investigates rate change premorbid characteristic specified age interval national institute aging working group aging genetic epidemiology num
0.2581098.12411259.html.plaintext.txt	39	risk factor dementia examined simply contributing duration survival becoming case dementia possible determinant rate timing change parameter believed closely linked pathogenesis dementia
0.2581098.12411259.html.plaintext.txt	40	age related abnormality glucose metabolism one hypothetical parameter
0.2581098.12411259.html.plaintext.txt	41	diabetes mellitus risk factor stroke possible risk factor alzheimers disease vascular dementia luchsinger et al num
0.2581098.12411259.html.plaintext.txt	42	matureonset type num diabetes also associated cardiovascular risk factor include hypertension hyperlipidaemia may cause accelerate unrecognised progressive cerebrovascular disease
0.2581098.12411259.html.plaintext.txt	43	least two plausible biological mechanism link enduring age related abnormality glucose metabolism neuronal death formation advanced glycation end product age hyperinsulinaemia
0.2581098.12411259.html.plaintext.txt	44	separate strand evidence link foetal growth adult hypertension impaired glucose tolerance age num year hale et al num
0.2581098.12411259.html.plaintext.txt	45	taken together observation advocate longitudinal study individual difference glucose metabolism age related cognitive variation
0.2581098.12411259.html.plaintext.txt	46	study type extend across life span subsumed title life course approach late onset dementia dementia associated trait
0.2581098.12411259.html.plaintext.txt	47	sometimes suggest parallel experimental route better understanding mechanism age related cognitive impairment strachan et al num
0.2581098.12411259.html.plaintext.txt	48	explanation association suboptimal foetal infant growth late onset disease include failure acquire lasting control complex central regulatory system
0.2581098.12411259.html.plaintext.txt	49	brain development foetal nutritional hormonal environment also important critical role expression specific gene dauncey et al num
0.2581098.12411259.html.plaintext.txt	50	major difference foetal infant nutritional environment induce large difference expression hormonal receptor isoforms may provide mean whereby dietary micro nutrient affect cognitive function across life span
0.2581098.12411259.html.plaintext.txt	51	nutritional influence apparently diverse contribution folate vitamin bnum neurodevelopment greater age related cognitive impairment linked dietary plasma folate concentration miller num duthie et al num
0.2581098.12411259.html.plaintext.txt	52	diversity timing nature single nutritional influence represents important obstacle taking life course approach understanding dementia
0.2581098.12411259.html.plaintext.txt	53	obscure best route elucidate molecular mechanism early nutritional experience affect neurodevelopment later cognitive performance
0.2581098.12411259.html.plaintext.txt	54	example observational study late life suggest hyperhomocysteinaemia attributed reduced transformation homocysteine methionine folate vitamin bnum possible risk factor cerebrovascular disease miller num dementia seshadri et al num
0.2581098.12411259.html.plaintext.txt	55	polymorphism gene encoding methylenetetrahydrofolate reductase mthfr enzyme essential folate metabolism therefore possible susceptibility factor age related cognitive decline however posse potential influence brain metabolism throughout life
0.2581098.12411259.html.plaintext.txt	56	similar critique made study interaction gene early nutrition
0.2581098.12411259.html.plaintext.txt	57	may specific influence peripheral insulin sensitivity neuro development factor might influence synaptogenesis late life
0.2581098.12411259.html.plaintext.txt	58	brain ageing cognitive decline
0.2581098.12411259.html.plaintext.txt	59	association brain ageing age related cognitive decline uncertain
0.2581098.12411259.html.plaintext.txt	60	largely ageing study beginning brain ageing yet linked informatively known neurobiological basis cognitive decline
0.2581098.12411259.html.plaintext.txt	61	higher brain function comprise ability like language learning memory planning abstract reasoning self awareness impaired age related cognitive decline progress dementia
0.2581098.12411259.html.plaintext.txt	62	neural foundation higher function supported complex organisation synaptic connection
0.2581098.12411259.html.plaintext.txt	63	one current paradigm attache central role modulation synaptic function enduring majority especially brain area serving higher function require constant remodelling respond optimally environmental demand
0.2581098.12411259.html.plaintext.txt	64	brain area provide higher function appear susceptible effect ageing alzheimers disease
0.2581098.12411259.html.plaintext.txt	65	one disease model progression age related cognitive decline dementia best represented reversal corticogenesis arendt num
0.2581098.12411259.html.plaintext.txt	66	develop model requires better understanding ageing process available
0.2581098.12411259.html.plaintext.txt	67	biological component ageing certainly involve complex interplay intrinsic mostly genetic extrinsic mostly environmental factor
0.2581098.12411259.html.plaintext.txt	68	recent progress encourages optimism small number highly conserved gene affect life span similarly small number metabolic process
0.2581098.12411259.html.plaintext.txt	69	view contrast previous degenerative position held biological ageing haphazard amenable study
0.2581098.12411259.html.plaintext.txt	70	generation metabolite oxygen termed reactive oxygen specie ro important cause oxidative stress ro intimately involved biology ageing finkel holbrook num
0.2581098.12411259.html.plaintext.txt	71	parallel ageing altered metabolic state induced lower organism adverse circumstance surprisingly similar yeast nematode fruit fly mammal guarente kenyon num
0.2581098.12411259.html.plaintext.txt	72	permit postponement reproduction unfavourable environmental condition control expression gene protect ro damage gene involved insulin signalling finch ruvkun num
0.2581098.12411259.html.plaintext.txt	73	reduced expression ageing gene involved insulin like receptor signalling extends life span may specific property neuron boulianne num
0.2581098.12411259.html.plaintext.txt	74	extrinsic contribution brain ageing poorly understood lag way behind elegant scientific study intrinsic component
0.2581098.12411259.html.plaintext.txt	75	acquired defence ro damage largely derived dietary antioxidant oppose ro production
0.2581098.12411259.html.plaintext.txt	76	ro defence falter additional burden placed brain capacity maintain structural integrity often threatened increased peroxidation neuronal lipid membrane oxidative damage dna large regulatory molecule whalley num
0.2581098.12411259.html.plaintext.txt	77	terminally differentiated cell neuron dispose dna damage cell division must rely dna repair enzyme
0.2581098.12411259.html.plaintext.txt	78	type damage may compromise performance neuronal sub population provide higher mental function also impair capacity make good compensate performance decrement
0.2581098.12411259.html.plaintext.txt	79	arendt num summarised much available evidence support hypothesis age related cognitive decline alzheimers disease best understood progressive failure synaptic remodelling
0.2581098.12411259.html.plaintext.txt	80	view much compelling evidence accept first abnormal dendritic sprouting occurs alzheimers disease second morphoregulatory molecule involved neurodevelopment re emerge part alzheimer molecular pathology
0.2581098.12411259.html.plaintext.txt	81	suggests example conserved function amyloid precursor protein app presenilins apolipoprotein e implicated alzheimers disease key role morphoregulatory molecule synaptic formation turnover stabilisation
0.2581098.12411259.html.plaintext.txt	82	preferentially expressed adult brain area retain capacity modify synaptic function
0.2581098.12411259.html.plaintext.txt	83	morphogenesis neuron enormous relevance understanding neurodevelopment differential survival cell type
0.2581098.12411259.html.plaintext.txt	84	arendt num extends significance late life
0.2581098.12411259.html.plaintext.txt	85	first argues molecular process underpin functional sculpting used immature brain self organise acquisition higher function language
0.2581098.12411259.html.plaintext.txt	86	second identifies among detritus dementia feature imply reactivation brain self organising molecular machinery
0.2581098.12411259.html.plaintext.txt	87	arendt view reactivation trigger cascade event result eventually selective loss cortical neuron
0.2581098.12411259.html.plaintext.txt	88	model arendt num add lifelong accumulation noxious influence brain function source diverse malnutrition neurotoxin cerebrovascular disease
0.2581098.12411259.html.plaintext.txt	89	age related endogenous oxidative damage neuron summarised stress brain adaptive mechanism
0.2581098.12411259.html.plaintext.txt	90	gradual pervasive result jeopardise high investment made neuron retain capacity synaptic remodelling completion brain maturation
0.2581098.12411259.html.plaintext.txt	91	missing arendt model mechanism account individual gender difference rate change trait associated dementia
0.2581098.12411259.html.plaintext.txt	92	dilemma familiar developmental neuroscientist strong likeness current research problem molecular genetics cognition plomin craig num
0.2581098.12411259.html.plaintext.txt	93	potentially hormonal genetic contribution synaptic remodelling could relevant
0.2581098.12411259.html.plaintext.txt	94	example evidence oestrogen induce synapse formation rat hippocampus induction dependent apolipoprotein e stone et al num
0.2581098.12411259.html.plaintext.txt	95	diversity efficiency self organisation may contribute variation childhood mental ability difference may extend late life leading divergence brain ageing dementia
0.2581098.12411259.html.plaintext.txt	96	understanding individual difference age related cognitive decline beset difficulty
0.2581098.12411259.html.plaintext.txt	97	neuropathological evidence hypothetical discontinuity normal ageing dementia lacking best available evidence suggests boundary
0.2581098.12411259.html.plaintext.txt	98	detection source variation rate cognitive decline requires considerable investment longitudinal population based study
0.2581098.12411259.html.plaintext.txt	99	mrc cfas finding outcome longitudinal study continue informative many year
0.2581098.12411259.html.plaintext.txt	100	quite rightly study focused dementia outcome age interval risk dementia high
0.2581098.12411259.html.plaintext.txt	101	problem boundary brain ageing dementia remains
0.2581098.12411259.html.plaintext.txt	102	demand detailed attention analysis current longitudinal database future research design
0.2581098.12411259.html.plaintext.txt	103	clarification seems certain recommendation national institute aging working group aging genetic epidemiology num come influence brain ageing research goal practice
0.2581098.12411259.html.plaintext.txt	104	precise tool molecular biology applied phenomenon ageing boundary may brought focus
0.2581098.12411259.html.plaintext.txt	105	far seems boundary clinical data suggested
0.2581098.12411259.html.plaintext.txt	106	ultimate research goal postpone perhaps even prevent dementia research type certain inform timing successful intervention
0.2581098.12411259.html.plaintext.txt	107	num alzheimers disease disorder mechanism underlying structural brain self organization
0.2581098.12411259.html.plaintext.txt	108	num neuronal regulation lifespan clue fly worm
0.2581098.12411259.html.plaintext.txt	109	mechanism ageing development num num num
0.2581098.12411259.html.plaintext.txt	110	et al num pattern cognitive decline presymptomatic alzheimer disease
0.2581098.12411259.html.plaintext.txt	111	archive general psychiatry num num num
0.2581098.12411259.html.plaintext.txt	112	et al num nutrition hormone receptor gene interaction implication development disease
0.2581098.12411259.html.plaintext.txt	113	proceeding nutrition society num num num
0.2581098.12411259.html.plaintext.txt	114	num looking human intelligence psychometrics brain pp
0.2581098.12411259.html.plaintext.txt	115	oxford oxford university press
0.2581098.12411259.html.plaintext.txt	116	et al num homocysteine b vitamin status cognitive function elderly
0.2581098.12411259.html.plaintext.txt	117	american journal clinical nutrition num num num
0.2581098.12411259.html.plaintext.txt	118	et al num pathological correlate late onset dementia multicentre community based population england wale
0.2581098.12411259.html.plaintext.txt	119	annual review genomics human genetics num num num
0.2581098.12411259.html.plaintext.txt	120	num oxidant oxidative stress biology ageing
0.2581098.12411259.html.plaintext.txt	121	num genetic pathway regulate ageing model organism
0.2581098.12411259.html.plaintext.txt	122	et al num fetal infant growth impaired glucose tolerance age num
0.2581098.12411259.html.plaintext.txt	123	et al num diabetes mellitus risk alzheimers disease dementia stroke multiethnic cohort
0.2581098.12411259.html.plaintext.txt	124	american journal epidemiology num num num
0.2581098.12411259.html.plaintext.txt	125	num homocysteine alzheimers disease cognitive function
0.2581098.12411259.html.plaintext.txt	126	national institute aging working group aging genetic epidemiology num genetic epidemiologic study age specified trait
0.2581098.12411259.html.plaintext.txt	127	american journal epidemiology num num num
0.2581098.12411259.html.plaintext.txt	128	num genetics environment cognitive ability review work progress towards genome scan quantitative trait locus association using dna pooling
0.2581098.12411259.html.plaintext.txt	129	british journal psychiatry num suppl
0.2581098.12411259.html.plaintext.txt	130	num translating cell biology therapeutic advance alzheimers disease
0.2581098.12411259.html.plaintext.txt	131	et al num plasma homoscysteine risk factor dementia alzheimers disease
0.2581098.12411259.html.plaintext.txt	132	new england journal medicine num num num
0.2581098.12411259.html.plaintext.txt	133	et al num increased synaptic sprouting response estrogen via apolipoprotein e dependent mechanism implication alzheimers disease
0.2581098.12411259.html.plaintext.txt	134	journal neuroscience num num num
0.2581098.12411259.html.plaintext.txt	135	num type ii diabetes associated increased risk cognitive dysfunction critical review published study
0.2581098.12411259.html.plaintext.txt	136	london weidenfeld nicolson
0.2581098.12411259.html.plaintext.txt	137	et al num childhood mental ability dementia
0.2581098.12411259.html.plaintext.txt	138	received publication december num num
0.2581098.12411259.html.plaintext.txt	139	revision received april num num
0.2581098.12411259.html.plaintext.txt	140	accepted publication april num num
0.2582762.9751483.html.plaintext.txt	0	regulation multicatalytic enzyme activity insulin insulin degrading enzymenum frederick g
0.2582762.9751483.html.plaintext.txt	1	veteran affair medical center department medicine pharmacology f
0.2582762.9751483.html.plaintext.txt	2	biochemistry molecular biology r
0.2582762.9751483.html.plaintext.txt	3	university nebraska medical center omaha nebraska num num
0.2582762.9751483.html.plaintext.txt	4	address correspondence request reprint william c
0.2582762.9751483.html.plaintext.txt	5	university nebraska medical center num south numnd street omaha nebraska num num
0.2582762.9751483.html.plaintext.txt	6	regulatory property ide relatively new finding
0.2582762.9751483.html.plaintext.txt	7	ide associate activates cytosolic glucocorticoid androgen receptor num num
0.2582762.9751483.html.plaintext.txt	8	ide also complex proteasome regulates activity num
0.2582762.9751483.html.plaintext.txt	9	substrate bind ide including insulin various growth factor inhibit proteasome activity ide complexed multicatalytic proteinase mcp separation two protein num num
0.2582762.9751483.html.plaintext.txt	10	furthermore insulin inhibits proteasome activity toward artificial substrate intact cell num
0.2582762.9751483.html.plaintext.txt	11	led hypothesis intracellular action insulin growth factor cellular protein turnover due interaction ide inhibition proteolysis proteasome
0.2582762.9751483.html.plaintext.txt	12	ide metalloenzyme containing znnum possibly mnnum num degradative activity requires one divalent cation num
0.2582762.9751483.html.plaintext.txt	13	addition znnum mnnum canum shown affect degradative activity ide vitro intact cell num num
0.2582762.9751483.html.plaintext.txt	14	canum divalent cation implicated activity insulin num present study directed examination ide binding regulatory degradative function special emphasis effect metal
0.2582762.9751483.html.plaintext.txt	15	measurement degradative activity insulin degradation measured trichloroacetic acid precipitation num expressed percent soluble per num min
0.2582762.9751483.html.plaintext.txt	16	degradation llvy lstr lle measured incubating enzyme sample num microm fluorogenic peptide num
0.2582762.9751483.html.plaintext.txt	17	num assay volume num ml num min num c metabolic shaker num
0.2582762.9751483.html.plaintext.txt	18	inhibitor activator included concentration indicated
0.2582762.9751483.html.plaintext.txt	19	reaction stopped addition num
0.2582762.9751483.html.plaintext.txt	20	increase fluorescence measured fluorometer excitation emission wavelength num num nm llvy lstr num num nm lle
0.2582762.9751483.html.plaintext.txt	21	data expressed change fluorescence unit per num min normalized respect activity untreated uninhibited enzyme
0.2582762.9751483.html.plaintext.txt	22	view larger version numk figure num
0.2582762.9751483.html.plaintext.txt	23	restoration canum edta inhibited insulin degrading enzyme
0.2582762.9751483.html.plaintext.txt	24	edta treatment ide inhibits enzyme almost half readdition canum restores activity even increase num num m
0.2582762.9751483.html.plaintext.txt	25	value mean plus minus sem ide activity expressed percentage ide without edta treatment
0.2582762.9751483.html.plaintext.txt	26	regulatory function ide also affected edta
0.2582762.9751483.html.plaintext.txt	27	figure numa show insulin inhibits llvy degradation untreated ide mcp complex
0.2582762.9751483.html.plaintext.txt	28	addition canum slightly increase activity untreated complex alter effect insulin
0.2582762.9751483.html.plaintext.txt	29	edta treatment ide mcp complex decrease chymotrypsin like activity mcp reflected decreased degradation llvy fig
0.2582762.9751483.html.plaintext.txt	30	addition num num num num m canum restores llvy degradation insulin effect although wide variability result seen
0.2582762.9751483.html.plaintext.txt	31	view larger version numk figure num
0.2582762.9751483.html.plaintext.txt	32	effect canum readdition mcp edta treated mcp egta treated mcp
0.2582762.9751483.html.plaintext.txt	33	addition canum slight stimulatory effect llvy degradation effect insulin inhibition
0.2582762.9751483.html.plaintext.txt	34	b edta treatment reduces llvy activity num eliminates response insulin
0.2582762.9751483.html.plaintext.txt	35	calcium addition reactivates llvy degradation restore insulin sensitivity
0.2582762.9751483.html.plaintext.txt	36	c egta treatment reduces llvy activity essentially eliminates response insulin
0.2582762.9751483.html.plaintext.txt	37	calcium addition restores degrading activity response insulin
0.2582762.9751483.html.plaintext.txt	38	value shown mean plus minus sem llvy activity expressed percentage untreated enzyme
0.2582762.9751483.html.plaintext.txt	39	evidence ide contains one divalent cation num tightly bound znnum easily dissociable mnnum different cation may different effect ide activity
0.2582762.9751483.html.plaintext.txt	40	thus effect different chelator egta examined fig
0.2582762.9751483.html.plaintext.txt	41	llvy degradation decreased slight effect insulin
0.2582762.9751483.html.plaintext.txt	42	canum however restored llvy degradative activity effect insulin
0.2582762.9751483.html.plaintext.txt	43	similar study edta egta treated ide mcp complex performed readdition cation znnum mnnum conum alter ide degradative activity fig
0.2582762.9751483.html.plaintext.txt	44	effect canum shown comparison
0.2582762.9751483.html.plaintext.txt	45	metal variable effect restoring mcp activity edta treated complex none restores insulin effect
0.2582762.9751483.html.plaintext.txt	46	however znnum canum conum restore regulatory function ide mcp activity egta treated material
0.2582762.9751483.html.plaintext.txt	47	manganese appeared restore insulin sensitivity reach statistical significance p num
0.2582762.9751483.html.plaintext.txt	48	view larger version numk figure num
0.2582762.9751483.html.plaintext.txt	49	effect edta treatment metal readdition llvy degrading activity inhibition insulin
0.2582762.9751483.html.plaintext.txt	50	graph show activity ide mcp complex toward llvy various treatment without open bar closed bar addition num microm insulin
0.2582762.9751483.html.plaintext.txt	51	partially purified ide mcp complex dialyzed overnight sodium acetate sodium acetate num mm edta readdition various metal
0.2582762.9751483.html.plaintext.txt	52	value shown mean plus minus sem llvy degrading activity normalized activity untreated enzyme insulin added
0.2582762.9751483.html.plaintext.txt	53	metal chloride concentration used maximally restored ide activity toward radiolabeled insulin follows znnum num num m canum num num m mnnum num x num num m conum num num m
0.2582762.9751483.html.plaintext.txt	54	view larger version numk figure num
0.2582762.9751483.html.plaintext.txt	55	effect egta treatment metal readdition llvy degrading activity inhibition insulin
0.2582762.9751483.html.plaintext.txt	56	graph show activity ide mcp complex toward llvy various treatment without open bar closed bar addition num microm insulin
0.2582762.9751483.html.plaintext.txt	57	partially purified ide mcp complex dialyzed overnight sodium acetate sodium acetate num mm egta readdition various metal
0.2582762.9751483.html.plaintext.txt	58	value shown mean plus minus sem llvy degrading activity normalized activity untreated enzyme insulin added
0.2582762.9751483.html.plaintext.txt	59	egta treatment little effect insulin degrading activity metal concentration used used edta treated enzyme znnum num num m canum num num m mnnum num x num num m conum num num m
0.2582762.9751483.html.plaintext.txt	60	mcp multiple catalytic site
0.2582762.9751483.html.plaintext.txt	61	insulin ide regulate trypsin like lstr degradation well chymotrypsin like llvy degradation activity
0.2582762.9751483.html.plaintext.txt	62	edta treatment dramatically decrease lstr degradation eliminates insulin effect fig
0.2582762.9751483.html.plaintext.txt	63	readdition divalent cation canum conum restores degrading activity insulin effect
0.2582762.9751483.html.plaintext.txt	64	egta treatment reduces lstr activity change achieve significance remove insulin inhibition mcp activity fig
0.2582762.9751483.html.plaintext.txt	65	view larger version numk figure num
0.2582762.9751483.html.plaintext.txt	66	effect edta treatment metal readdition lstr degrading activity inhibition insulin
0.2582762.9751483.html.plaintext.txt	67	view larger version numk figure num
0.2582762.9751483.html.plaintext.txt	68	effect egta treatment metal readdition lstr degrading activity inhibition insulin
0.2582762.9751483.html.plaintext.txt	69	num num support role easily dissociable divalent cation essential insulin effect complex egta effect
0.2582762.9751483.html.plaintext.txt	70	edta treatment however result profound alteration perhaps due partial removal tightly bound cation subsequent conformational change
0.2582762.9751483.html.plaintext.txt	71	simple addition individual cation restore functional control complex insulin
0.2582762.9751483.html.plaintext.txt	72	explore regulatory role ide control mcp selected inhibitor examined table num
0.2582762.9751483.html.plaintext.txt	73	metalloproteinase inhibitor numnum phenanthroline inhibited ide abolished insulin effect llvy degradation similar edta
0.2582762.9751483.html.plaintext.txt	74	n ethylmaleimide bacitracin known inhibitor ide also blocked effect insulin
0.2582762.9751483.html.plaintext.txt	75	phenylmethylsulfonylfluoride low concentration appreciable effect
0.2582762.9751483.html.plaintext.txt	76	effect various inhibitor ide mcp complex
0.2582762.9751483.html.plaintext.txt	77	table num compare effect inhibitor ide proteolytic activity ide mcp complex purified mcp
0.2582762.9751483.html.plaintext.txt	78	phenanthroline n ethylmaleimide bacitracin inhibit llvy degradation mcp complexed ide agent ineffective purified mcp
0.2582762.9751483.html.plaintext.txt	79	finding support regulatory activating effect ide mcp activity
0.2582762.9751483.html.plaintext.txt	80	effect inhibitor ide mcp activity
0.2582762.9751483.html.plaintext.txt	81	importance activation mcp ide supported effect removal ide purification
0.2582762.9751483.html.plaintext.txt	82	reported previously num num ide mcp llvy degradation copurify various standard affinity procedure separated ion exchange column
0.2582762.9751483.html.plaintext.txt	83	ide mcp complex purified ammonium sulfate fractionation diethylaminoethyl batch separation phenyl sepharose pnum chromatofocusing
0.2582762.9751483.html.plaintext.txt	84	preparation chromatographed mono q hplc column llvy degrading activity eluting sharp symmetrical peak shown
0.2582762.9751483.html.plaintext.txt	85	recovery llvy degrading activity ion exchange column num
0.2582762.9751483.html.plaintext.txt	86	num specific activity decreased num
0.2582762.9751483.html.plaintext.txt	87	num fluorescent unit per microg proteinh
0.2582762.9751483.html.plaintext.txt	88	ide control mcp activity may due conformational change mcp enzyme responsive reagent alter conformation num
0.2582762.9751483.html.plaintext.txt	89	sd low concentration increase activity higher concentration inhibiting num
0.2582762.9751483.html.plaintext.txt	90	explore dose response curve sd performed ide mcp complex without insulin effect llvy lstr lle activity examined fig
0.2582762.9751483.html.plaintext.txt	91	llvy degrading activity stimulated sd concentration num
0.2582762.9751483.html.plaintext.txt	92	insulin inhibited llvy lstr lle degradation absence sd effect even slight stimulatory effect presence sd
0.2582762.9751483.html.plaintext.txt	93	view larger version numk figure num
0.2582762.9751483.html.plaintext.txt	94	insulin effect peptide degradation sd activated multicatalytic proteinase
0.2582762.9751483.html.plaintext.txt	95	enzyme ammonium sulfate purified complex incubated increasing concentration sd num num
0.2582762.9751483.html.plaintext.txt	96	num wtvol presence absence num microm insulin
0.2582762.9751483.html.plaintext.txt	97	degradation peptide expressed fluorescence liberated arbitrary unit per num min
0.2582762.9751483.html.plaintext.txt	98	lle degradation expressed thousand
0.2582762.9751483.html.plaintext.txt	99	determine insulin effect complex could restored ide mcp activated sd sd removed table num
0.2582762.9751483.html.plaintext.txt	100	degradation llvy monitored continuously insulin added achieve sequential concentration num num num num num num m
0.2582762.9751483.html.plaintext.txt	101	seen mcp activity inhibited insulin concentration removal sd
0.2582762.9751483.html.plaintext.txt	102	effect insulin mcp treatment removal sd
0.2582762.9751483.html.plaintext.txt	103	stimulatory effect ide proteasomes glucocorticoid androgen receptor established present previous report num num mechanism
0.2582762.9751483.html.plaintext.txt	104	reversible nature activation argues proteolytic activation complex ide
0.2582762.9751483.html.plaintext.txt	105	possibility include conformational change complex ide degradation ligand proteolytic product generated ide combination
0.2582762.9751483.html.plaintext.txt	106	present study provides evidence divalent cation involved activity control ide mcp complex
0.2582762.9751483.html.plaintext.txt	107	treatment partially purified enzyme edta significantly reduced activity ide restored addition canum little num num m
0.2582762.9751483.html.plaintext.txt	108	effect presumably mediated removal znnum found active site ide required activity
0.2582762.9751483.html.plaintext.txt	109	treatment also reduces chymotrypsin like trypsin like activity proteasome eliminates ability insulin inhibit activity
0.2582762.9751483.html.plaintext.txt	110	addition canum conum restores chymotrypsin like trypsin like activity fails restore insulin responsiveness
0.2582762.9751483.html.plaintext.txt	111	znnum mnnum show relatively little effect
0.2582762.9751483.html.plaintext.txt	112	also examined effect egta complex
0.2582762.9751483.html.plaintext.txt	113	egta slightly higher affinity num
0.2582762.9751483.html.plaintext.txt	114	num time canum edta num numnum time le affinity cation including znnum num
0.2582762.9751483.html.plaintext.txt	115	condition experiment egta effect ide activity data shown reduce chymotrypsin like activity proteasome effectively eliminated insulin effect
0.2582762.9751483.html.plaintext.txt	116	similar reduction seen trypsin like activity although reach statistical significance
0.2582762.9751483.html.plaintext.txt	117	insulin ability inhibit restored cation canum conum
0.2582762.9751483.html.plaintext.txt	118	data suggest two metal involved complex reported previously num
0.2582762.9751483.html.plaintext.txt	119	propose one metal zinc tightly bound ide essential activity possibly mnnum canum loosely bound required productive interaction ide proteasome
0.2582762.9751483.html.plaintext.txt	120	edta chelate tightly bound znnum loosely bound metal associated complex
0.2582762.9751483.html.plaintext.txt	121	inhibits ide thereby lessening stimulatory effect proteasome
0.2582762.9751483.html.plaintext.txt	122	loss znnum molecule cause conformational change ide dissociating proteasome disrupting ability insulin alter proteasome activity
0.2582762.9751483.html.plaintext.txt	123	readdition divalent cation restores ide activity longer part complex ide alter proteasome function
0.2582762.9751483.html.plaintext.txt	124	however egta effect loosely bound metal disrupts ide ability affect chymotrypsin like activity cause ide dissociate complex
0.2582762.9751483.html.plaintext.txt	125	thus addition cation restore insulin sensitivity
0.2582762.9751483.html.plaintext.txt	126	fact ide must active complex proteasome mediate regulatory effect supported data presented table num num
0.2582762.9751483.html.plaintext.txt	127	agent inhibit ide lessen proteasome activity effectively eliminate insulin inhibitory effect
0.2582762.9751483.html.plaintext.txt	128	finally studied ide proteasome interaction using sd shown alter proteasome conformation
0.2582762.9751483.html.plaintext.txt	129	num chymotrypsin trypsin like activity proteasome insulin sensitive absence sd lose sensitivity considerable activity num
0.2582762.9751483.html.plaintext.txt	130	presumably due sd altering interaction ide proteasome
0.2582762.9751483.html.plaintext.txt	131	higher concentration sd alters conformation proteasome stimulates chymotrypsin like peptidyl glutamyl degrading activity
0.2582762.9751483.html.plaintext.txt	132	however high concentration ide still unable interact proteasomes insulin inhibit
0.2582762.9751483.html.plaintext.txt	133	data presented characterize support idea ide serve regulator proteasome
0.2582762.9751483.html.plaintext.txt	134	metal ion play important role interaction
0.2582762.9751483.html.plaintext.txt	135	first ide metalloproteinase must active insulin inhibitory effect
0.2582762.9751483.html.plaintext.txt	136	second loosely bound divalent cation required ide mediate effect
0.2582762.9751483.html.plaintext.txt	137	change protein conformation important illustrated loss activity ide active site metal removed change activity induced sd
0.2582762.9751483.html.plaintext.txt	138	physiological effect insulin inhibit cellular protein degradation greater effect catabolic state e
0.2582762.9751483.html.plaintext.txt	139	starvation diabetes traumatic stress
0.2582762.9751483.html.plaintext.txt	140	cell survival requires continued protein turnover would expected insulin could totally inhibit mcp activity completely block protein degradation
0.2582762.9751483.html.plaintext.txt	141	rather ide mcp interaction may serve activator basal cellular protein degradation analogous activation glucocorticoid androgen receptor ide num insulin substrate acting inhibit stimulated process
0.2582762.9751483.html.plaintext.txt	142	thus selective effect cellular protein degradation insulin sensitive cell control insulin ide interaction
0.2582762.9751483.html.plaintext.txt	143	mcp comprises relatively large proportion protein many cell num ide although expressed high level tissue num present sufficient quantity tissue universal regulator mcp activity
0.2582762.9751483.html.plaintext.txt	144	result show insulin substantially inhibits two activity mcp chymotrypsin trypsin like activity
0.2582762.9751483.html.plaintext.txt	145	proteasome may many five different proteolytic activity num
0.2582762.9751483.html.plaintext.txt	146	also remains determined whether degradation ubiquitinylated protein inhibited insulin ide
0.2582762.9751483.html.plaintext.txt	147	although widely appreciated many study shown biological activity intracellular insulin num num alteration insulin activity inhibition cellular insulin processing num num
0.2582762.9751483.html.plaintext.txt	148	recent study provided potential mechanism previously unexplained observation
0.2582762.9751483.html.plaintext.txt	149	scheme ide portion complex act intracellular receptor insulin possibly growth factor
0.2582762.9751483.html.plaintext.txt	150	insulin ide interaction alters activity protein complex
0.2582762.9751483.html.plaintext.txt	151	mcp glucocorticoid receptor androgen receptor perhaps others contributes biological action insulin
0.2582762.9751483.html.plaintext.txt	152	insulin effect mcp prevented altering activity ide
0.2582762.9751483.html.plaintext.txt	153	although speculative cellular activity regulated ide complex may affected cellular redox state divalent cation distribution due change ide
0.2582762.9751483.html.plaintext.txt	154	alteration insulin action associated ion flux redistribution redox state
0.2582762.9751483.html.plaintext.txt	155	effect could explained part regulatory effect ide
0.2582762.9751483.html.plaintext.txt	156	acknowledgment author thank janet corr preparation manuscript
0.2582762.9751483.html.plaintext.txt	157	footnote num work supported department veteran affair research service bly memorial research fund
0.26019153.11581097.html.plaintext.txt	0	diabetes mellitus risk alzheimers disease dementia stroke multiethnic cohort
0.26019153.11581097.html.plaintext.txt	1	luchsingernumnum ming xin tangnumnum yaakov sternnumnumnum steven sheanumnum richard mayeuxnumnum num
0.26019153.11581097.html.plaintext.txt	2	num taub institute research alzheimers disease aging brain columbia university new york ny
0.26019153.11581097.html.plaintext.txt	3	num division general medicine department medicine college physician surgeon columbia university new york ny
0.26019153.11581097.html.plaintext.txt	4	num division biostatistics joseph p
0.26019153.11581097.html.plaintext.txt	5	mailman school public health columbia university new york ny
0.26019153.11581097.html.plaintext.txt	6	sergievsky center columbia university new york ny
0.26019153.11581097.html.plaintext.txt	7	num department psychiatry college physician surgeon columbia university new york ny
0.26019153.11581097.html.plaintext.txt	8	num division epidemiology joseph p
0.26019153.11581097.html.plaintext.txt	9	mailman school public health columbia university new york ny
0.26019153.11581097.html.plaintext.txt	10	num department neurology college physician surgeon columbia university new york ny
0.26019153.11581097.html.plaintext.txt	11	alzheimer disease dementia diabetes mellitus survival analysis
0.26019153.11581097.html.plaintext.txt	12	abbreviation ci confidence interval nincds adrda national institute neurological communicative disorder stroke alzheimers disease related disorder association ninds airen national institute neurological disorder stroke association internationale pour la recherche et lenseignement en neuroscience
0.26019153.11581097.html.plaintext.txt	13	association diabetes vascular dementia may depend presence subclinical cerebrovascular disease frank stroke num num may mediated traditional cardiovascular disease risk factor specifically hyperlipidemia hypertension num num
0.26019153.11581097.html.plaintext.txt	14	relation diabetes alzheimers disease le obvious although role glycated end product pathogenesis alzheimers disease hypothesized num num
0.26019153.11581097.html.plaintext.txt	15	several longitudinal study demonstrated association history diabetes cognitive deficit num num dementia num num
0.26019153.11581097.html.plaintext.txt	16	finding associa tion diabetes alzheimers disease inconsistent
0.26019153.11581097.html.plaintext.txt	17	two report rotterdam study showed relation diabetes alzheimers disease relative risk num
0.26019153.11581097.html.plaintext.txt	18	num num percent confidence interval ci num
0.26019153.11581097.html.plaintext.txt	19	relative risk alzheimers disease among subject treated insulin higher among subject treated oral hypoglycemic agent compared subject without diabetes one study num recent report cohort risk alzheimers disease elevated among diabetic subject treated insulin risk elevated among subject treated oral hypoglycemic agent num
0.26019153.11581097.html.plaintext.txt	20	one study rochester minnesota num reported doubling risk alzheimers disease among men diabetes compared men without diabetes relative risk num
0.26019153.11581097.html.plaintext.txt	21	num non statistically significant increased risk among woman relative risk num
0.26019153.11581097.html.plaintext.txt	22	another study british cohort also reported higher risk alzheimers disease among subject diabetes compared subject without relative risk num
0.26019153.11581097.html.plaintext.txt	23	study relative risk alzheimers disease lower overall dementia vascular dementia risk attenuated case stroke excluded
0.26019153.11581097.html.plaintext.txt	24	incidence vascular dementia varies considerably depending criterion used num case vascular dementia classified alzheimers disease finding weak relation diabetes alzheimers disease may due misclassification
0.26019153.11581097.html.plaintext.txt	25	one study used sensitive criterion detection vascular dementia found association diabetes alzheimers disease relative risk alzheimers disease subject diabetes compared subject without diabetes num
0.26019153.11581097.html.plaintext.txt	26	num researcher considered num year history diabetes num year history diabetes respectively num
0.26019153.11581097.html.plaintext.txt	27	thus finding relation diabetes dementia specifically alzheimers disease vascular dementia may depend criterion used define vascular dementia accuracy diagnostic procedure employed
0.26019153.11581097.html.plaintext.txt	28	none previous study examining relation diabetes dementia included large number black hispanic
0.26019153.11581097.html.plaintext.txt	29	objective study clarify association diabetes different type dementia
0.26019153.11581097.html.plaintext.txt	30	prevalence diabetes black hispanic higher white num num also examined whether difference could account higher risk dementia reported non white num num
0.26019153.11581097.html.plaintext.txt	31	diagnosis dementia cognitive impairment diagnosis dementia assignment specific cause made group neurologist psychiatrist neuropsychologists consensus basis information gathered initial visit follow visit
0.26019153.11581097.html.plaintext.txt	32	dementia diagnosis based criterion diagnostic statistical manual mental disorder fourth edition num required evidence cognitive deficit neuropsychological test battery well evidence impairment social occupational functioning clinical dementia rating num
0.26019153.11581097.html.plaintext.txt	33	diagnosis alzheimers disease based criterion national institute neurological communicative disorder stroke alzheimers disease related disorder association nincds adrda num
0.26019153.11581097.html.plaintext.txt	34	diagnosis dementia associated stroke hereafter called stroke associated dementia made subject dementia stroke judged main cause dementia based evidence focal effect stroke temporal relation dementia
0.26019153.11581097.html.plaintext.txt	35	brain imaging available num percent case stroke remainder world health organization criterion used define stroke num
0.26019153.11581097.html.plaintext.txt	36	subject without dementia history stroke baseline examination included analysis
0.26019153.11581097.html.plaintext.txt	37	diagnosis cognitive impairment without dementia hereafter called nondementia cognitive impairment made neuropsychological testing detected memory impairment one standard deviation lower normal subject age individual reported impairment mild impairment social occupational activity clinical dementia rating num
0.26019153.11581097.html.plaintext.txt	38	diagnosis diabetes covariates presence diabetes based reported use insulin oral hypoglycemic agent clinical history diabetes
0.26019153.11581097.html.plaintext.txt	39	hypertension heart disease smoking based self report clinical history
0.26019153.11581097.html.plaintext.txt	40	ethnic group based self report using format num u census num
0.26019153.11581097.html.plaintext.txt	41	individual asked whether hispanic origin
0.26019153.11581097.html.plaintext.txt	42	subject assigned one three ethnic group non hispanic black hispanic non hispanic white
0.26019153.11581097.html.plaintext.txt	43	year education obtained self report
0.26019153.11581097.html.plaintext.txt	44	apolipoprotein e genotyping obtained amplification genomic dna polymerase chain reaction subjected cfoi restriction analysis using apolipoprotein e primer condition similar described hixson vernier num
0.26019153.11581097.html.plaintext.txt	45	fasting plasma total cholesterol triglyceride level determined initial assessment using standard enzymatic technique
0.26019153.11581097.html.plaintext.txt	46	high density lipoprotein cholesterol determined precipitation apolipoprotein b containing lipoprotein phosphotungstic acid num
0.26019153.11581097.html.plaintext.txt	47	low density lipoprotein cholesterol level calculated using formula friedewald et al
0.26019153.11581097.html.plaintext.txt	48	data analysis prevalence diabetes covariates compared subject without alzheimers disease subject without stroke associated dementia
0.26019153.11581097.html.plaintext.txt	49	continuous variable compared analysis variance categorical variable compared num test
0.26019153.11581097.html.plaintext.txt	50	cox proportional hazard modeling used multivariate analysis
0.26019153.11581097.html.plaintext.txt	51	time event variable age onset dementia model stratified year entry cohort order control period effect recommended longitudinal study num
0.26019153.11581097.html.plaintext.txt	52	one model outcome mentioned
0.26019153.11581097.html.plaintext.txt	53	covariates treated time constant covariates using baseline value
0.26019153.11581097.html.plaintext.txt	54	num num subject diabetes diagnosis made baseline person treated diabetes baseline
0.26019153.11581097.html.plaintext.txt	55	additional analysis carried treating diabetes time dependent covariate taking account date reporting diabetes diagnosis analysis conducted examine definition diabetes baseline v
0.26019153.11581097.html.plaintext.txt	56	follow affected analysis
0.26019153.11581097.html.plaintext.txt	57	similar analysis carried treating variable time dependent covariates beginning exposure used beginning observation later num subject diagnosed diabetes baseline compare result time constant covariate model
0.26019153.11581097.html.plaintext.txt	58	subject without outcome censored time last follow visit
0.26019153.11581097.html.plaintext.txt	59	subject type dementia different one considered specific model censored time onset dementia
0.26019153.11581097.html.plaintext.txt	60	example alzheimers disease examined outcome person stroke associated dementia censored time dementia onset
0.26019153.11581097.html.plaintext.txt	61	additional analysis performed using nondementia cognitive impairment without stroke nondementia cognitive impairment stroke outcome person nondementia cognitive impairment baseline excluded
0.26019153.11581097.html.plaintext.txt	62	population attributable risk par diabetes relation dementia calculated ethnic group using formula par prhr numnum prhr num hr adjusted hazard ratio obtained multivariate model pr prevalence diabetes ethnic group cohort num percent confidence interval calculated population attributable risk using method described prospective study num
0.26019153.11581097.html.plaintext.txt	63	sa window version num sa institute inc
0.26019153.11581097.html.plaintext.txt	64	cary north carolina used analysis
0.26019153.11581097.html.plaintext.txt	65	table num show comparison characteristic subject sample subject alzheimers disease stroke associated dementia nondementia cognitive impairment without stroke nondementia cognitive impairment stroke
0.26019153.11581097.html.plaintext.txt	66	person alzheimers disease older fewer year education higher proportion black higher prevalence heart disease person without alzheimers disease
0.26019153.11581097.html.plaintext.txt	67	person stroke associated dementia older higher prevalence diabetes higher level low density lipoprotein cholesterol higher prevalence hypertension higher prevalence heart disease person without stroke associated dementia
0.26019153.11581097.html.plaintext.txt	68	exclusion num case nondementia cognitive impairment baseline numnum person left analysis nondementia cognitive impairment
0.26019153.11581097.html.plaintext.txt	69	person nondementia cognitive impairment without stroke older fewer year education higher proportion ever smoker higher proportion hispanic person without
0.26019153.11581097.html.plaintext.txt	70	person nondementia cognitive impairment stroke higher prevalence hypertension heart disease person without
0.26019153.11581097.html.plaintext.txt	71	characteristic subject baseline washington height inwood columbia aging project new york city num num
0.26019153.11581097.html.plaintext.txt	72	multivariate adjusted hazard ratio alzheimers disease relation diabetes compared absence diabetes num
0.26019153.11581097.html.plaintext.txt	73	num hazard ratio stroke associated dementia relation diabetes num
0.26019153.11581097.html.plaintext.txt	74	population attributable risk diabetes relation stroke associated dementia num percent num percent ci num num among hispanic num percent num percent ci num num among non hispanic black num percent num percent ci num num among non hispanic white
0.26019153.11581097.html.plaintext.txt	75	hazard ratio dementia cognitive impairment person diabetes mellitus compared person without diabetes washington height inwood columbia aging project new york city num num
0.26019153.11581097.html.plaintext.txt	76	hazard ratio nondementia cognitive impairment without stroke person diabetes compared person without diabetes num
0.26019153.11581097.html.plaintext.txt	77	hazard ratio nondementia cognitive impairment stroke relation diabetes num
0.26019153.11581097.html.plaintext.txt	78	person nondementia cognitive impairment increased risk developing alzheimers disease compared person without nondementia cognitive impairment num therefore conducted analysis examining relation diabetes composite outcome alzheimers disease nondementia cognitive impairment without stroke
0.26019153.11581097.html.plaintext.txt	79	hazard ratio composite outcome relation diabetes compared absence diabetes num
0.26019153.11581097.html.plaintext.txt	80	performed subgroup analysis examining relation diabetes stroke associated dementia num person stroke estimate effect diabetes independent stroke
0.26019153.11581097.html.plaintext.txt	81	adjusted hazard ratio stroke associated dementia relation diabetes compared absence diabetes num
0.26019153.11581097.html.plaintext.txt	82	performed another analysis reclassifying num case alzheimers disease stroke case stroke associated dementia hazard ratio alzheimers disease relation diabetes compared absence diabetes unchanged relative risk num
0.26019153.11581097.html.plaintext.txt	83	hazard ratio alzheimers disease relation diabetes also remained unchanged excluded case stroke analysis
0.26019153.11581097.html.plaintext.txt	84	performed additional analysis examining effect diabetes treatment relation diabetes alzheimers disease
0.26019153.11581097.html.plaintext.txt	85	previous study reported increased risk alzheimers disease among subject treated insulin smaller increase increase risk among subject using oral hypoglycemic agent comparison subject without diabetes num num
0.26019153.11581097.html.plaintext.txt	86	model built including dummy variable insulin oral hypoglycemic agent subject without diabetes used reference group
0.26019153.11581097.html.plaintext.txt	87	hazard ratio alzheimers disease relation diabetes compared absence diabetes num
0.26019153.11581097.html.plaintext.txt	88	num person reporting insulin use num
0.26019153.11581097.html.plaintext.txt	89	num person reporting use oral hypoglycemic agent
0.26019153.11581097.html.plaintext.txt	90	hazard ratio stroke associated dementia among insulin using subject diabetes num
0.26019153.11581097.html.plaintext.txt	91	num hazard ratio among diabetic subject using oral hypoglycemic agent num
0.26019153.11581097.html.plaintext.txt	92	hazard ratio composite outcome alzheimers disease nondementia cognitive impairment without stroke among subject using insulin subject using oral hypoglycemic agent compared subject without diabetes materially different hazard ratio subject diabetes
0.26019153.11581097.html.plaintext.txt	93	model covariates hypertension diabetes treated time constant covariates assume lifetime exposure may thereby overestimated exposure
0.26019153.11581097.html.plaintext.txt	94	therefore also fitted model specifying covariates time dependent covariates beginning exposure set beginning observation
0.26019153.11581097.html.plaintext.txt	95	num subject diabetes cohort num diagnosis diabetes made baseline examination thus fitted another model time dependent covariates taking account time diabetes diagnosis num subject
0.26019153.11581097.html.plaintext.txt	96	hazard ratio two model using time dependent covariates close main model
0.26019153.11581097.html.plaintext.txt	97	risk vascular dementia increase greatly stroke num num may caused large small vessel disease num num associated diabetes
0.26019153.11581097.html.plaintext.txt	98	likely diabetes affect risk vascular dementia partly contributing dyslipidemia hypertension
0.26019153.11581097.html.plaintext.txt	99	hyperlipidemia hypertension reported investigator associated vascular dementia num num num association also present data
0.26019153.11581097.html.plaintext.txt	100	strong though statistically nonsignificant hazard ratio stroke associated dementia diabetic person compared nondiabetic person among subject stroke hazard ratio num
0.26019153.11581097.html.plaintext.txt	101	num suggests diabetes contributes risk stroke associated dementia additional mechanism
0.26019153.11581097.html.plaintext.txt	102	one mechanism proposed diabetes related impairment cerebral vasoreactivity accompanying change blood flow num num
0.26019153.11581097.html.plaintext.txt	103	mechanism underlying possible association diabetes alzheimers disease remain unclear
0.26019153.11581097.html.plaintext.txt	104	one possibility production glycation end product num num
0.26019153.11581097.html.plaintext.txt	105	however reduction plasma amyloid precursor protein reported elevation plasma level glucose insulin num insulin reported decrease s amyloid neurotoxicity vitro num
0.26019153.11581097.html.plaintext.txt	106	finding raise possibility hyperinsulinemia one characteristic type ii diabetes may decrease deposition amyloid protein brain key step pathogenesis alzheimers disease num num
0.26019153.11581097.html.plaintext.txt	107	mechanism underlying weak relation diabetes alzheimers disease remain clarified
0.26019153.11581097.html.plaintext.txt	108	three longitudinal study reported increased risk dementia including alzheimers disease among person diabetes num num
0.26019153.11581097.html.plaintext.txt	109	two study used nincds adrda criterion diagnosis alzheimers disease num num num one showed risk alzheimers disease lower risk overall dementia person diabetes num showed risk alzheimers disease subject decreased excluding subject stroke although risk remained significant num
0.26019153.11581097.html.plaintext.txt	110	third study used criterion diagnostic statistical manual mental disorder third edition revised diagnosis dementia based medical record review autopsy data num
0.26019153.11581097.html.plaintext.txt	111	study limited ability detect vascular dementia
0.26019153.11581097.html.plaintext.txt	112	definition vascular dementia controversial depending criterion used incidence vascular dementia vary severalfold num
0.26019153.11581097.html.plaintext.txt	113	case stroke associated dementia misclassified case alzheimers disease risk factor stroke associated dementia appear predict alzheimers disease
0.26019153.11581097.html.plaintext.txt	114	one study used nincds adrda criterion diagnosis alzheimers disease criterion california state alzheimers disease diagnostic treatment center diagnosis vascular dementia found relation diabetes vascular dementia alzheimers disease num
0.26019153.11581097.html.plaintext.txt	115	criterion california alzheimers disease diagnostic treatment center sensitive diagnosis vascular dementia num would therefore classify fewer case stroke associated dementia case alzheimers disease
0.26019153.11581097.html.plaintext.txt	116	thus appears relation diabetes alzheimers disease sensitive criterion used define vascular dementia
0.26019153.11581097.html.plaintext.txt	117	addressed issue reclassifying subject alzheimers disease also stroke subject stroke associated dementia including case temporal relation dementia stroke unclear hazard ratio analysis remained essentially unchanged
0.26019153.11581097.html.plaintext.txt	118	criterion diagnosis stroke associated dementia used last analysis consistent national institute neurological disorder stroke association internationale pour la recherche et lenseignement en neuroscience ninds airen num
0.26019153.11581097.html.plaintext.txt	119	ninds airen criterion sensitive detection vascular dementia california criterion used study found relation diabetes alzheimers disease num
0.26019153.11581097.html.plaintext.txt	120	however misclassification case stroke associated dementia case alzheimers disease unlikely explanation finding relation diabetes alzheimers disease result unchanged exclusion stroke case analysis reclassification dementia subtypes described
0.26019153.11581097.html.plaintext.txt	121	finding slightly greater risk alzheimers disease among subject using insulin among using oral hypoglycemic agent consistent finding rotterdam study num num may reflect possibility diabetic subject used insulin severe prolonged diabetes
0.26019153.11581097.html.plaintext.txt	122	performed additional analysis using nondementia cognitive impairment outcome analysis yielded result similar dementia
0.26019153.11581097.html.plaintext.txt	123	inconsistent report association diabetes cognitive impairment num num num
0.26019153.11581097.html.plaintext.txt	124	subject cognitive deficit functional disability determined higher risk dementia num
0.26019153.11581097.html.plaintext.txt	125	thus association diabetes cognitive impairment would expected similar diabetes dementia
0.26019153.11581097.html.plaintext.txt	126	finding nondementia cognitive impairment support result main analysis
0.26019153.11581097.html.plaintext.txt	127	one explanation finding nonsignificant weak association diabetes alzheimers disease may relation truly exists study lacked statistical power detect
0.26019153.11581097.html.plaintext.txt	128	analysis using composite outcome alzheimers disease nondementia cognitive impairment without stroke showing statistically significant association diabetes compared absence diabetes hazard ratio num
0.26019153.11581097.html.plaintext.txt	129	num consistent interpretation
0.26019153.11581097.html.plaintext.txt	130	another possible explanation nonsignificant finding misclassification error diabetes alzheimers disease may diluted relation diabetes alzheimers disease
0.26019153.11581097.html.plaintext.txt	131	self reported diabetes used study almost certainly underestimated true prevalence diabetes true prevalence reported twice prevalence self reported disease subject undiagnosed diabetes considered num
0.26019153.11581097.html.plaintext.txt	132	study important strength
0.26019153.11581097.html.plaintext.txt	133	longitudinal study nondemented elderly subject three ethnic group used standardized procedure diagnosis dementia subtypes prospective fashion
0.26019153.11581097.html.plaintext.txt	134	main limitation study lack data duration diabetes severity diabetes presence undiagnosed diabetes
0.26019153.11581097.html.plaintext.txt	135	multivariate model assumed lifetime duration exposure could resulted error measurement exposure diabetes lipid level hypertension
0.26019153.11581097.html.plaintext.txt	136	however noted appreciably affect hazard ratio diabetes relation alzheimers disease stroke associated dementia
0.26019153.11581097.html.plaintext.txt	137	finding study support previous longitudinal study reported weak association diabetes alzheimers disease strong association diabetes stroke associated dementia extend observation minority population group
0.26019153.11581097.html.plaintext.txt	138	population attributable risk diabetes relation stroke associated dementia significantly greater black hispanic white
0.26019153.11581097.html.plaintext.txt	139	acknowledgment support work provided grant national institute aging agnum agnum charles
0.26019153.11581097.html.plaintext.txt	140	robertson memorial gift fund research alzheimers disease blanchette hooker rockefeller foundation
0.26019153.11581097.html.plaintext.txt	141	note reprint request dr
0.26019153.11581097.html.plaintext.txt	142	sergievsky center ph num columbia university num west numth street new york ny num e mail rpmnumatcolumbia
0.26308063.11581098.html.plaintext.txt	0	mortality dementia result french prospective community based cohort
0.26308063.11581098.html.plaintext.txt	1	inserm u num universite de bordeaux ii bordeaux france
0.26308063.11581098.html.plaintext.txt	2	alzheimer disease dementia mortality prognosis
0.26308063.11581098.html.plaintext.txt	3	abbreviation cep certificat detudes primaires ci confidence interval dsm iii r diagnostic statistical manual mental disorder third edition revised paquid personnes agee quid rr relative risk
0.26308063.11581098.html.plaintext.txt	4	num study carried survival dementia found increased risk dying among person dementia compared without
0.26308063.11581098.html.plaintext.txt	5	however data often obtained community based study selected group institution clinical setting applied general population
0.26308063.11581098.html.plaintext.txt	6	indeed review literature van dijk et al
0.26308063.11581098.html.plaintext.txt	7	num found survival conditioned reference population lower survival study conducted institution community based study
0.26308063.11581098.html.plaintext.txt	8	addition even among community based study num year survival found vary num percent num percent probably depending study design num
0.26308063.11581098.html.plaintext.txt	9	majority study conducted community based sample num num based prevalent case onset disease known
0.26308063.11581098.html.plaintext.txt	10	onset dementia insidious progressive thus determined exactly
0.26308063.11581098.html.plaintext.txt	11	onset often considered either time first symptom disease time first consultation
0.26308063.11581098.html.plaintext.txt	12	however earlier one see patient onset precise estimation onset thus onset estimated precisely incident prevalent case
0.26308063.11581098.html.plaintext.txt	13	community based study used incident case dementia num num dementia case actively screened one num
0.26308063.11581098.html.plaintext.txt	14	active detection dementia make possible take account case undiagnosed practitioner scenario frequent france num
0.26308063.11581098.html.plaintext.txt	15	recent study sweden based kungsholmen project num risk death among alzheimers disease case estimated num
0.26308063.11581098.html.plaintext.txt	16	num compared nondemented person
0.26308063.11581098.html.plaintext.txt	17	however latter study onset disease considered time diagnosis statistical analysis take account problem interval censoring cohort study participant followed continually receive repeated cross sectional screening time interval
0.26308063.11581098.html.plaintext.txt	18	could bias result particularly lack accuracy determination disease onset
0.26308063.11581098.html.plaintext.txt	19	aim paper evaluate survival risk factor mortality dementia quantify impact dementia total mortality using statistical model dealing interval censoring french prospective population based cohort active search incident case dementia follow screening
0.26308063.11581098.html.plaintext.txt	20	data collection data collected mean questionnaire administered home trained psychologist
0.26308063.11581098.html.plaintext.txt	21	initial interview included item sociodemographic characteristic objective subjective physical health functional assessment depressive symptomatology battery neuropsychological test including evaluation global mental status mini mental state examination num
0.26308063.11581098.html.plaintext.txt	22	physical health evaluated self reported disease symptom
0.26308063.11581098.html.plaintext.txt	23	treated diabetes history heart disease stroke hypertension dyspnea considered
0.26308063.11581098.html.plaintext.txt	24	variable comorbidity created participant reported history least one disease symptom
0.26308063.11581098.html.plaintext.txt	25	functional status evaluated using activity daily living scale excluding item maintaining continence num
0.26308063.11581098.html.plaintext.txt	26	participant needed help least one five activity classified disabled
0.26308063.11581098.html.plaintext.txt	27	initial interview participant followed baseline procedure num num num num year gironde num num num year dordogne
0.26308063.11581098.html.plaintext.txt	28	data vital status collected throughout follow
0.26308063.11581098.html.plaintext.txt	29	date cause death collected death certificate way national registry mortality statistic
0.26308063.11581098.html.plaintext.txt	30	cause death classified according international classification disease ninth revision num cancer code num num num num cardiovascular disease excluding cerebrovascular disease code num num num num cerebrovascular disease code num num respiratory disease code num num
0.26308063.11581098.html.plaintext.txt	31	diagnosis dementia baseline intellectual functioning examined series psychometric test shown among sensitive assessing cognitive decline elderly person
0.26308063.11581098.html.plaintext.txt	32	psychologist systematically filled standardized questionnaire designed obtain memory impairment b impairment least one cognitive function c interference social professional life criterion dementia according diagnostic statistical manual mental disorder third edition revised dsm iii r num
0.26308063.11581098.html.plaintext.txt	33	second stage participant met dsm iii r criterion seen senior neurologist confirmed completed dsm iii r criterion dementia filled national institute neurological communicative disorder stroke alzheimers disease related disorder association nincds adrda criterion alzheimers disease num hachinski score vascular dementia num document dementia diagnosis etiology probable possible alzheimers disease vascular dementia alzheimers disease cerebrovascular disease type dementia
0.26308063.11581098.html.plaintext.txt	34	informant consulted neurologist available
0.26308063.11581098.html.plaintext.txt	35	ancillary information considered including medical chart brain imaging available
0.26308063.11581098.html.plaintext.txt	36	finally consensus meeting allowed u definitely classify case
0.26308063.11581098.html.plaintext.txt	37	comparable procedure screening dementia usually used cohort study num
0.26308063.11581098.html.plaintext.txt	38	diagnosis incident dementia case followed procedure follow assessment baseline screening order increase screening sensitivity another criterion added qualify neurologic examination
0.26308063.11581098.html.plaintext.txt	39	participant selected stage met b c dsm iii r criterion dementia lost three point mini mental state examination score
0.26308063.11581098.html.plaintext.txt	40	statistical analysis mortality dementia analyzed according age sex educational level
0.26308063.11581098.html.plaintext.txt	41	educational level divided two category least primary school level validated diploma certificat detudes primaires cep versus diploma num
0.26308063.11581098.html.plaintext.txt	42	analysis performed dementia due cause alzheimers disease
0.26308063.11581098.html.plaintext.txt	43	first impact mortality dementia general population considered comparing mortality among person incident dementia without partitioning competing cause death
0.26308063.11581098.html.plaintext.txt	44	analyzed mortality dementia among person incident dementia
0.26308063.11581098.html.plaintext.txt	45	quantify impact dementia total mortality performed cox model delayed entry time scale age participant num taking occurrence dementia time dependent variable considering age onset dementia middle interval last follow without dementia first follow dementia
0.26308063.11581098.html.plaintext.txt	46	relative risk death dementia alzheimers disease provided num percent confidence interval
0.26308063.11581098.html.plaintext.txt	47	relative risk competing cause death provided
0.26308063.11581098.html.plaintext.txt	48	mortality among person incident dementia onset clinical stage death analyzed using multistate approach semi markov model
0.26308063.11581098.html.plaintext.txt	49	performed statistical model dealing interval censoring common problem cohort study
0.26308063.11581098.html.plaintext.txt	50	indeed paquid study participant followed continuously cross sectional screening discrete time
0.26308063.11581098.html.plaintext.txt	51	thus onset disease known exactly information available onset occurred two follow time
0.26308063.11581098.html.plaintext.txt	52	therefore used semi markov model includes two transition
0.26308063.11581098.html.plaintext.txt	53	first transition represents age specific incidence rate dementia
0.26308063.11581098.html.plaintext.txt	54	second transition represents mortality rate person dementia
0.26308063.11581098.html.plaintext.txt	55	model us information incidence data people cohort
0.26308063.11581098.html.plaintext.txt	56	fact time onset dementia known taken account penalized likelihood approach num
0.26308063.11581098.html.plaintext.txt	57	distribution participant interviewed follow according diagnosis dementia sociodemographic characteristic paquid cohort france num num
0.26308063.11581098.html.plaintext.txt	58	numnum reevaluated participant included numnum num
0.26308063.11581098.html.plaintext.txt	59	num percent woman numnum num percent participant aged num year older
0.26308063.11581098.html.plaintext.txt	60	mean delay two follow evaluation num
0.26308063.11581098.html.plaintext.txt	61	follow num participant developed incident dementia including num alzheimer type dementia num vascular mixed dementia num type dementia
0.26308063.11581098.html.plaintext.txt	62	person incident dementia included num num
0.26308063.11581098.html.plaintext.txt	63	mean age onset dementia num standard deviation num
0.26308063.11581098.html.plaintext.txt	64	num percent person dementia died versus num
0.26308063.11581098.html.plaintext.txt	65	person dementia died cardiovascular pathology num
0.26308063.11581098.html.plaintext.txt	66	num percent respiratory pathology num
0.26308063.11581098.html.plaintext.txt	67	num percent symptom sign ill defined condition including senile dementia num
0.26308063.11581098.html.plaintext.txt	68	proportion respectively num
0.26308063.11581098.html.plaintext.txt	69	num percent person without dementia
0.26308063.11581098.html.plaintext.txt	70	impact dementia mortality impact dementia total mortality analyzed using cox proportional hazard model delayed entry adjusted sex educational level index comorbidity baseline dependency activity daily living scale comparing participant dementia without
0.26308063.11581098.html.plaintext.txt	71	total population relative risk dying developing dementia estimated num
0.26308063.11581098.html.plaintext.txt	72	num num percent confidence interval ci num
0.26308063.11581098.html.plaintext.txt	73	alzheimers disease risk num
0.26308063.11581098.html.plaintext.txt	74	however significant interaction dementia age relative risk rr num
0.26308063.11581098.html.plaintext.txt	75	num lower impact dementia mortality increasing age
0.26308063.11581098.html.plaintext.txt	76	relative risk dying dementia estimated num
0.26308063.11581098.html.plaintext.txt	77	num among participant aged num year older num
0.26308063.11581098.html.plaintext.txt	78	num among participant aged num year older
0.26308063.11581098.html.plaintext.txt	79	risk similar men woman
0.26308063.11581098.html.plaintext.txt	80	according cause death relative risk significantly increased cancer rr num
0.26308063.11581098.html.plaintext.txt	81	num cardiovascular disease rr num
0.26308063.11581098.html.plaintext.txt	82	num among person dementia whereas relative risk num
0.26308063.11581098.html.plaintext.txt	83	num cerebrovascular disease num
0.26308063.11581098.html.plaintext.txt	84	tendency alzheimers disease increased risk respiratory disease rr num
0.26308063.11581098.html.plaintext.txt	85	num risk cerebrovascular disease reach significance rr num
0.26308063.11581098.html.plaintext.txt	86	survival dementia risk factor median survival time onset disease estimated num
0.26308063.11581098.html.plaintext.txt	87	num year among person incident dementia
0.26308063.11581098.html.plaintext.txt	88	model provides result age dementia onset chose provide result person developing dementia num num year
0.26308063.11581098.html.plaintext.txt	89	median time survival according risk factor summarized table num
0.26308063.11581098.html.plaintext.txt	90	whatever age onset dementia median time survival higher among woman among men
0.26308063.11581098.html.plaintext.txt	91	among person alzheimers disease protective effect female sex risk dying adjusted educational level comorbidity activity daily living scale dependency time diagnosis rr num
0.26308063.11581098.html.plaintext.txt	92	tendency dementia cause although relative risk reach statistical significance rr num
0.26308063.11581098.html.plaintext.txt	93	median time survival person dementia alzheimers disease according sex educational level paquid cohort france num num
0.26308063.11581098.html.plaintext.txt	94	dementia alzheimers disease median survival time shorter participant cep without dementia began num year difference survival observed according cep num year table num
0.26308063.11581098.html.plaintext.txt	95	educational level significantly influence survival among person dementia
0.26308063.11581098.html.plaintext.txt	96	relative risk dying participant without cep estimated num
0.26308063.11581098.html.plaintext.txt	97	adjustment sex comorbidity activity daily living scale dependency time diagnosis modify relative risk num
0.26308063.11581098.html.plaintext.txt	98	although effect sex educational level seemed differ according age dementia onset significant interaction found either age sex rr num
0.26308063.11581098.html.plaintext.txt	99	num age cep rr num
0.26308063.11581098.html.plaintext.txt	100	studying mortality dementia general population raise special difficulty
0.26308063.11581098.html.plaintext.txt	101	first one need conduct study community dementia diagnosed hospital nursing home setting representative case general population
0.26308063.11581098.html.plaintext.txt	102	second dementia actively screened widely underdiagnosed population num num
0.26308063.11581098.html.plaintext.txt	103	third necessary use incident case dementia disease onset better known
0.26308063.11581098.html.plaintext.txt	104	finally incident case dementia followed long time observe death
0.26308063.11581098.html.plaintext.txt	105	methodological difficulty previous study investigated mortality dementia community using incident case dementia num num
0.26308063.11581098.html.plaintext.txt	106	even study onset disease difficult ass
0.26308063.11581098.html.plaintext.txt	107	indeed unless participant screened dementia continuously onset dementia always imprecise clearly insidious onset also interval censoring last time participant considered dementia free first time diagnosed dementia
0.26308063.11581098.html.plaintext.txt	108	thus onset estimated even incident case dementia
0.26308063.11581098.html.plaintext.txt	109	paquid study opportunity analyze actively screened incident case dementia prospectively followed several year
0.26308063.11581098.html.plaintext.txt	110	addition applied statistical model taking account fact disease onset known precisely
0.26308063.11581098.html.plaintext.txt	111	several methodological issue may influenced result
0.26308063.11581098.html.plaintext.txt	112	twenty percent participant cohort never reevaluated among large part num percent died follow others refused follow examination
0.26308063.11581098.html.plaintext.txt	113	participant refused follow examination could higher risk developing dementia thus nonresponse could lead underestimation incidence dementia
0.26308063.11581098.html.plaintext.txt	114	however could bias prognosis group person dementia mortality among person dementia refused follow differed mortality among person dementia evaluated unlikely
0.26308063.11581098.html.plaintext.txt	115	participant short survival onset dementia occurred two follow ups died rapidly onset diagnosed cohort thus included survival analysis person incident dementia
0.26308063.11581098.html.plaintext.txt	116	study could overestimate survival time dementia
0.26308063.11581098.html.plaintext.txt	117	however specific illness death model dealing interval censoring taking account case dementia short survival could establish extent survival overestimated
0.26308063.11581098.html.plaintext.txt	118	model developed
0.26308063.11581098.html.plaintext.txt	119	another methodological problem due difficulty diagnosis dementia subgroup person particularly old people person living institution illiterate deaf depressive person
0.26308063.11581098.html.plaintext.txt	120	lead either false diagnosis dementia delay diagnosis among person could bias survival among person incident dementia
0.26308063.11581098.html.plaintext.txt	121	demonstrate possible bias problem interval censoring taken account result three state approach compared using standard model kaplan meier curve describe survival among incident participant dementia cox model delayed entry analyze effect sex educational level risk mortality among
0.26308063.11581098.html.plaintext.txt	122	standard model onset dementia considered middle interval last follow without dementia first follow
0.26308063.11581098.html.plaintext.txt	123	although difference two model slight median survival developing dementia num month longer standard model three state approach
0.26308063.11581098.html.plaintext.txt	124	larger interval two follow evaluation greater overestimation survival
0.26308063.11581098.html.plaintext.txt	125	addition using standard model tended increase effect risk factor mortality among person dementia also slightly underestimate confidence interval
0.26308063.11581098.html.plaintext.txt	126	particularly visible effect sex led erroneous significant factor
0.26308063.11581098.html.plaintext.txt	127	impact dementia mortality three state approach used describe mortality among person dementia take account fact time disease onset known could applied evaluate impact dementia mortality among general population
0.26308063.11581098.html.plaintext.txt	128	indeed estimate date onset participant cohort
0.26308063.11581098.html.plaintext.txt	129	however although estimation onset dementia prime importance describe survival dementia affect time survival several year depending number year two follow evaluation estimation le important evaluation impact dementia mortality age participant time scale model
0.26308063.11581098.html.plaintext.txt	130	relative risk dying study estimated num
0.26308063.11581098.html.plaintext.txt	131	num alzheimers disease decreased age
0.26308063.11581098.html.plaintext.txt	132	result agreement slightly lower found previous community based study ranging num
0.26308063.11581098.html.plaintext.txt	133	num alzheimers disease num
0.26308063.11581098.html.plaintext.txt	134	num dementia num num num num num even higher rr num
0.26308063.11581098.html.plaintext.txt	135	num among younger participant num num
0.26308063.11581098.html.plaintext.txt	136	explained inclusion incident rather prevalent case dementia study fact took account morbidity evaluating risk death
0.26308063.11581098.html.plaintext.txt	137	two cause death particularly increased among person dementia cerebrovascular respiratory disease
0.26308063.11581098.html.plaintext.txt	138	increase death cerebrovascular disease essentially due vascular dementia however even among person alzheimers disease trend increased risk cerebrovascular disease concordant implication vascular mechanism alzheimer pathology num
0.26308063.11581098.html.plaintext.txt	139	death due respiratory disease already found important cause death among alzheimers person num num also increased person dementia alzheimers disease compared without dementia
0.26308063.11581098.html.plaintext.txt	140	survival among person dementia general population median duration survival among person dementia dependent sex age participant
0.26308063.11581098.html.plaintext.txt	141	median survival time observed study longer reported previous study prevalent case community num num num num even study incident case num
0.26308063.11581098.html.plaintext.txt	142	incident case considered lead automatically longer survival
0.26308063.11581098.html.plaintext.txt	143	however clinical study alzheimer center study reported median survival time long longer num num num year survival
0.26308063.11581098.html.plaintext.txt	144	several explanation may account longer survival
0.26308063.11581098.html.plaintext.txt	145	first person referred clinical setting memory probably interested health others may le medical comorbidity
0.26308063.11581098.html.plaintext.txt	146	second treatment management person dementia present clinical setting could increase survival
0.26308063.11581098.html.plaintext.txt	147	finally mean age patient clinical setting often lower community based study
0.26308063.11581098.html.plaintext.txt	148	effect sex survival protective effect female sex observed study particularly alzheimers disease concordant result several study done different methodology num num num num num num
0.26308063.11581098.html.plaintext.txt	149	general population woman dementia lower risk mortality men
0.26308063.11581098.html.plaintext.txt	150	although interaction age sex risk dying among person dementia significant effect sex seemed decrease age greater difference woman men num year num year
0.26308063.11581098.html.plaintext.txt	151	result concordant observed kungsholmen project sex affected survival among person dementia num year num
0.26308063.11581098.html.plaintext.txt	152	factor explain longer survival among woman general population could remain unchanged course disease
0.26308063.11581098.html.plaintext.txt	153	trial currently progress test hypothesis estrogen replacement therapy could affect progression alzheimers disease
0.26308063.11581098.html.plaintext.txt	154	however paquid study woman taken therapy explain longer survival woman dementia sample
0.26308063.11581098.html.plaintext.txt	155	effect education survival effect educational level survival dementia low study observed among participant developed dementia youngest age
0.26308063.11581098.html.plaintext.txt	156	previous result concerning relation education mortality among person dementia controversial author found increased risk mortality associated high educational level num num whereas others replicated finding num even found opposite num
0.26308063.11581098.html.plaintext.txt	157	hypothesis brain reserve capacity according development cerebral lesion alzheimers disease time diagnosis advanced among highly educated people others proposed explain association high educational level increased risk mortality num num
0.26308063.11581098.html.plaintext.txt	158	also observed tendency although slight nonsignificant lower survival person dementia cep among youngest
0.26308063.11581098.html.plaintext.txt	159	possible bias detecting dementia according educational level excluded
0.26308063.11581098.html.plaintext.txt	160	indeed participant low educational level low premorbid cognitive performance thus could detected earlier highly educated participant
0.26308063.11581098.html.plaintext.txt	161	however bias probably reduced taking account dsm iii r criterion also loss mini mental state examination score screening procedure
0.26308063.11581098.html.plaintext.txt	162	conclusion data provide evidence malignancy dementia strong predictor death short survival time disease onset high risk dying associated
0.26308063.11581098.html.plaintext.txt	163	future data survival dementia make possible evaluate whether development medical social therapy dementia lead increased survival person pathology
0.26308063.11581098.html.plaintext.txt	164	acknowledgment study supported grant fondation de france novartis pharma axa insurance group caisse nationale dassurance maladie caisse primaire dassurance maladie de dordogne conseil general de la dordogne conseil general de la gironde conseil regional daquitaine danone ministere de la recherche et de la technologie mutualite sociale agricole de gironde et dordogne mutuelle generale de leducation nationale societe pechiney num medium caisse de retraite interentreprise capimmec institut du cerveau direction regionale de affaire sanitaires et sociales daquitaine
0.26308063.11581098.html.plaintext.txt	165	note correspondence dr
0.26308063.11581098.html.plaintext.txt	166	catherine helmer case num inserm u num universite de bordeaux ii num rue leo saignat num bordeaux cedex france e mail catherine
0.2649917.9811940.html.plaintext.txt	0	genetic association alphanum macroglobulin valnumile polymorphism alzheimers disease
0.2649917.9811940.html.plaintext.txt	1	alzheimer research unit neurology service massachusetts general hospital num numth street cny num charlestown ma num usa numuniversity hamburg hamburg germany numirccs
0.2649917.9811940.html.plaintext.txt	2	giovanni de dio fbf brescia italy numuniversity basel basel switzerland
0.2649917.9811940.html.plaintext.txt	3	received july num num revised accepted august num num
0.2649917.9811940.html.plaintext.txt	4	alphanum macroglobulin anumm proteinase inhibitor found association senile plaque sp alzheimers disease ad
0.2649917.9811940.html.plaintext.txt	5	anumm implicated biochemically binding degradation amyloid beta abeta protein accumulates sp
0.2649917.9811940.html.plaintext.txt	6	studied relationship alzheimers disease common anumm polymorphism valnum gtcilenum atc occurs near thiolester active site molecule
0.2649917.9811940.html.plaintext.txt	7	initial exploratory data set num control num alzheimers disease noted increased frequency gg genotype num
0.2649917.9811940.html.plaintext.txt	8	therefore tested hypothesis gg genotype represented alzheimers disease additional independent data set group num control num alzheimers disease patient
0.2649917.9811940.html.plaintext.txt	9	hypothesis testing cohort gg genotype increased num
0.2649917.9811940.html.plaintext.txt	10	num alzheimers disease p num
0.2649917.9811940.html.plaintext.txt	11	odds ratio alzheimers disease associated gg genotype num
0.2649917.9811940.html.plaintext.txt	12	num combination apoenum num
0.2649917.9811940.html.plaintext.txt	13	presence g allele associated increase abeta burden small series
0.2649917.9811940.html.plaintext.txt	14	anumm receptor anumm rlrp multifunctional receptor whose ligand include apolipoprotein e amyloid precursor protein
0.2649917.9811940.html.plaintext.txt	15	four protein genetically linked alzheimers disease suggesting may participate common disease pathway
0.2649917.9811940.html.plaintext.txt	16	alphanum macroglobulin anumm proteinase inhibitor inhibits proteinase class steric trapping mechanism
0.2649917.9811940.html.plaintext.txt	17	tetrameric anumm structure undergoes conformational change upon cleavage peptide bond bait region proteinase conformational change trap proteinase
0.2649917.9811940.html.plaintext.txt	18	anumm implicated several pathophysiological process alzheimers disease
0.2649917.9811940.html.plaintext.txt	19	anumm immunostains senile plaque sp num num bind amyloid beta protein abeta num num high affinity apparent kd num
0.2649917.9811940.html.plaintext.txt	20	moreover recent data suggest serine proteinase anumm complex degrade abeta num trypsin activated anumm efficiently degrades abeta vitro prevents vitro formation thioflavin positive abeta fibril well abeta induced toxicity cultured human cortical neuronal cell num
0.2649917.9811940.html.plaintext.txt	21	activated anumm cleared anumm rlow density lipoprotein receptor related protein anumm rlrp
0.2649917.9811940.html.plaintext.txt	22	anumm rlrp multifunctional receptor interestingly also primary neuronal apolipoprotein e apoe receptor numnum
0.2649917.9811940.html.plaintext.txt	23	lrp also bind clear kunitz proteinase inhibitor containing isoforms amyloid precursor protein app num
0.2649917.9811940.html.plaintext.txt	24	thus anumm potentially impact apoe app metabolism brain
0.2649917.9811940.html.plaintext.txt	25	biological link alzheimers disease studied possible association previously reported polymorphism anumm gene alzheimers disease
0.2649917.9811940.html.plaintext.txt	26	num screened num normal num pulmonary disease patient anumm polymorphism near active site reported three anumm polymorphism
0.2649917.9811940.html.plaintext.txt	27	common occurred num amino acid downstream thiolester site interchanging valnum gtc ilenum atc num
0.2649917.9811940.html.plaintext.txt	28	numbering based cdna sequence includes num amino acid signal peptide corresponds valilenum mature protein
0.2649917.9811940.html.plaintext.txt	29	allele frequency num probands num
0.2649917.9811940.html.plaintext.txt	30	difference anumm serum level associated two allele
0.2649917.9811940.html.plaintext.txt	31	polymorphism especially interesting potential biologically relevant function anumm proteinase inhibitor occurs near thiolester active site molecule
0.2649917.9811940.html.plaintext.txt	32	initial exploratory experiment tested possibility le common form anumm g allele would associated alzheimers disease
0.2649917.9811940.html.plaintext.txt	33	potential error due multiple hypothesis testing planned use initial data set exploratory data set intent formulate specific hypothesis would tested formally second independent data set
0.2649917.9811940.html.plaintext.txt	34	genotyped num non alzheimers individual either undergone screening test blessed dementia scale num whose dna isolated autopsy material demonstrated alzheimers disease num individual either clinical diagnosis alzheimers disease neuropathologically proven alzheimers disease table num
0.2649917.9811940.html.plaintext.txt	35	genotype determined pcr amplification dna restriction enzyme digestion fig
0.2649917.9811940.html.plaintext.txt	36	control series g allele frequency num
0.2649917.9811940.html.plaintext.txt	37	num six num individual contained gg genotype num
0.2649917.9811940.html.plaintext.txt	38	alzheimers disease set g allele frequency num
0.2649917.9811940.html.plaintext.txt	39	noticed gg genotype frequency increased alzheimers group num
0.2649917.9811940.html.plaintext.txt	40	result suggest possible influence anumm polymorphism genetic risk factor alzheimers disease
0.2649917.9811940.html.plaintext.txt	41	electrophoresis pattern restriction digest demonstrating band representing g num bp allele num bp
0.2649917.9811940.html.plaintext.txt	42	representation anumm gg genotype alzheimers disease n g allele gg genotype exploratory data set control num num
0.2649917.9811940.html.plaintext.txt	43	num hypothesis testing data set control num num
0.2649917.9811940.html.plaintext.txt	44	numa combined data set total control num num
0.2649917.9811940.html.plaintext.txt	45	formally test hypothesis gg genotype anumm represented alzheimers disease collected genotyped additional independent group patient control
0.2649917.9811940.html.plaintext.txt	46	power analysis showed num alzheimers disease control individual would necessary num chance showing difference genotype frequency num
0.2649917.9811940.html.plaintext.txt	47	therefore collected case control several site order approximate number sample
0.2649917.9811940.html.plaintext.txt	48	second data set consisted individual met criterion alzheimers disease control hypothesis generating set derived sporadic alzheimers disease patient massachusetts three european center probands multicenter u study sib pair small family
0.2649917.9811940.html.plaintext.txt	49	result second data set supported hypothesis gg genotype frequency num
0.2649917.9811940.html.plaintext.txt	50	num alzheimers disease p num
0.2649917.9811940.html.plaintext.txt	51	num fisher exact test table num
0.2649917.9811940.html.plaintext.txt	52	g allele represented data set control num
0.2649917.9811940.html.plaintext.txt	53	difference age onset gg non gg found second data set
0.2649917.9811940.html.plaintext.txt	54	multivariate analysis showed site collection influence genotype frequency
0.2649917.9811940.html.plaintext.txt	55	also compared rate control subset num clinic based alzheimers disease case gg frequency num
0.2649917.9811940.html.plaintext.txt	56	num subset num familial alzheimers disease sample gg frequency num
0.2649917.9811940.html.plaintext.txt	57	num found essentially equal representation gg
0.2649917.9811940.html.plaintext.txt	58	data support association gg genotype alzheimers disease
0.2649917.9811940.html.plaintext.txt	59	carried series exploratory analysis using pooled data individual num alzheimers disease patient num control
0.2649917.9811940.html.plaintext.txt	60	gg genotype present num
0.2649917.9811940.html.plaintext.txt	61	num alzheimer patient num
0.2649917.9811940.html.plaintext.txt	62	genotype frequency control consistent hardy weinberg equilibrium
0.2649917.9811940.html.plaintext.txt	63	age onset different alzheimers disease patient gg num
0.2649917.9811940.html.plaintext.txt	64	num mean plus minus sd non gg carrier num
0.2649917.9811940.html.plaintext.txt	65	multivariate logistic model controlled presence apoenum allele gender showed odds ratio num
0.2649917.9811940.html.plaintext.txt	66	num presence anumm gg genotype
0.2649917.9811940.html.plaintext.txt	67	presence apoenum model associated odds ratio num
0.2649917.9811940.html.plaintext.txt	68	odds ratio combination gg apoenum num
0.2649917.9811940.html.plaintext.txt	69	num relative neither risk factor
0.2649917.9811940.html.plaintext.txt	70	explore whether gg mediated risk influenced presence absence apoenum stratified sample presence absence apoenum
0.2649917.9811940.html.plaintext.txt	71	similar representation gg genotype seen stratum without apoenum suggesting effect two risk factor independent
0.2649917.9811940.html.plaintext.txt	72	multivariate analysis interaction gg genotype either apoenum gender demonstrated interaction p num
0.2649917.9811940.html.plaintext.txt	73	analysis based mantel haenszel estimator suggested heterogeneity odds ratio stratum without apoenum p num
0.2649917.9811940.html.plaintext.txt	74	num consistent absence interaction anumm apoenum logistic regression model
0.2649917.9811940.html.plaintext.txt	75	next turned attention possible biological effect inheritance anumm gg genotype
0.2649917.9811940.html.plaintext.txt	76	previous study anumm immunohistochemistry alzheimer brain suggested sp different case stained varying intensity num
0.2649917.9811940.html.plaintext.txt	77	explored possibility variability due different genotype immunostaining eight alzheimers disease case known gg aa genotype
0.2649917.9811940.html.plaintext.txt	78	instance anumm immunoreactivity present robustly sp astrocyte neuron qualitative difference observed genotype group
0.2649917.9811940.html.plaintext.txt	79	also explored effect inheritance anumm gg genotype neuropathological phenotype alzheimers disease table num
0.2649917.9811940.html.plaintext.txt	80	previously used stereological technique quantitative image analysis measure amount abeta present amyloid burden neocortical association area surrounding superior temporal sulcus number neurofibrillary tangle present region num
0.2649917.9811940.html.plaintext.txt	81	thirty one previously analyzed alzheimers disease case anumm genotyped selected analysis
0.2649917.9811940.html.plaintext.txt	82	initial inspection data suggested increase abeta individual ag gg difference two group
0.2649917.9811940.html.plaintext.txt	83	statistically significant increase abeta deposition seen comparing g containing case non g containing case num
0.2649917.9811940.html.plaintext.txt	84	effect appears primarily due presence least one g allele difference ag gg genotype observed although sample size limit power comparison
0.2649917.9811940.html.plaintext.txt	85	statistically significant difference neurofibrillary tangle number g allele suggesting specific effect abeta deposition
0.2649917.9811940.html.plaintext.txt	86	neuropathological correlate anumm genotype genotype n amyloid burden neurofibrillary tangle x num aa num num
0.2649917.9811940.html.plaintext.txt	87	exploratory study genetic risk factor run risk type error large number hypothesis either explicitly implicitly tested
0.2649917.9811940.html.plaintext.txt	88	alternatively type ii error occur sample size insufficient
0.2649917.9811940.html.plaintext.txt	89	order overcome difficulty inherent exploratory study genetic risk factor used independent data set first generate test hypothesis gg genotype associated alzheimers disease
0.2649917.9811940.html.plaintext.txt	90	two separate control population gave identical genotype frequency hypothesis testing data set made two group sporadic ad probands multicenter study alzheimers disease sib pair small family gave essentially identical genotype frequency representation gg genotype
0.2649917.9811940.html.plaintext.txt	91	anumm gg effect dependent apoe genotype effect additive substantial odds ratio gg presence apoenum allele showed almost num fold increased risk
0.2649917.9811940.html.plaintext.txt	92	power analysis using size effect observed combined data set using num sample suggests group size num control num alzheimers disease patient would necessary alpha num
0.2649917.9811940.html.plaintext.txt	93	num beta num hypothesis gg genotype increased num
0.2649917.9811940.html.plaintext.txt	94	association gg anumm genotype risk factor alzheimers disease lead several interesting mechanistic interpretation
0.2649917.9811940.html.plaintext.txt	95	previous data shown anumm immunostains sp implicated anumm amyloid precursor protein metabolism num well possible interaction binding abeta num mediation degradation abeta numnum
0.2649917.9811940.html.plaintext.txt	96	anumm abeta complex undergo endocytosis via anumm rlrp receptor num
0.2649917.9811940.html.plaintext.txt	97	anumm associate abeta prevents fibril formation num
0.2649917.9811940.html.plaintext.txt	98	addition anumm viewed subacute phase reactive molecule potent proteinase inhibitor might participate inflammatory response alzheimer brain
0.2649917.9811940.html.plaintext.txt	99	interestingly anumm also implicated trophic factor possibly result binding transporting number polypeptide growth factor cytokine num
0.2649917.9811940.html.plaintext.txt	100	like apoe anumm may serve binding protein targeting various bioactive molecule site action clearing num
0.2649917.9811940.html.plaintext.txt	101	finally fact apoe app two ligand anumm rlrp receptor clearly involved pathophysiology alzheimers disease support plausibility idea anumm polymorphism might contribute risk alzheimers disease
0.2649917.9811940.html.plaintext.txt	102	fact polymorphism anumm rlrp recently reported two study show genetic association alzheimers disease numnum
0.2649917.9811940.html.plaintext.txt	103	although strong biological rationale involvement anumm polymorphism alzheimers disease possibility remains genetic association observe reflects linkage another mutation polymorphism either anumm gene nearby gene chromosome num
0.2649917.9811940.html.plaintext.txt	104	anumm gene resides num cm distal marker dnumsnum yielded maximal lod score recent linkage study suggesting chromosome num contains alzheimer risk factor num
0.2649917.9811940.html.plaintext.txt	105	however likelihood anumm risk factor supported result recent separate study observed association intronic numprime splice site exon num pentanucleotide deletion allele num within anumm gene alzheimers disease sibship analysis alzheimers disease sib pair small alzheimers disease family num
0.2649917.9811940.html.plaintext.txt	106	current result extend observation showing linkage missense mutation case control sample rather family based association
0.2649917.9811940.html.plaintext.txt	107	currently studying two anumm polymorphism relate one another preliminary result consistent hypothesis act independent risk factor
0.2649917.9811940.html.plaintext.txt	108	initial study group evaluated polymorphism suggests g allele inherited num allele num g chromosome examined num gg individual num allele num num allele num compared allele num frequency num p num
0.2649917.9811940.html.plaintext.txt	109	num chinum analysis yates correction
0.2649917.9811940.html.plaintext.txt	110	taken together believe polymorphism anumm gene may contribute risk alzheimers disease
0.2649917.9811940.html.plaintext.txt	111	moreover data focus attention mechanism pathophysiology impact anumm rlrp ligand including clearance mechanism mediated anumm rlrp numnum suggest anumm rlrp ligand may candidate alzheimers disease gene well
0.2649917.9811940.html.plaintext.txt	112	initial hypothesis generating data set established num alzheimers disease patient clinical history probable alzheimers disease num age compatible control individual primarily spouse patient
0.2649917.9811940.html.plaintext.txt	113	second hypothesis testing data set collected several source attempt approximate num patient control estimated power analysis adequately test hypothesis gg genotype represented alzheimers disease
0.2649917.9811940.html.plaintext.txt	114	individual included additional case num sporadic alzheimer disease num control matched site primarily cognitively tested spouse collected massachusetts general hospital memory disorder unit consortium european center university hamburg germany university basel switzerland
0.2649917.9811940.html.plaintext.txt	115	cuore fatebenefratelli hospital brescia italy num probands multicenter study alzheimer disease sib pair small alzheimers disease family num
0.2649917.9811940.html.plaintext.txt	116	genomic dna isolated brain tissue blood amplified pcr presence oligonucleotide sense primer cnum numprime atc cct gaa act gcc acc aa numprime antisense primer asnum numprime gta act gaa acc tac tgg aa numprime num mm tris hcnum num mm kcnum ph num
0.2649917.9811940.html.plaintext.txt	117	num mm mgcnum num mm dntps num pmol primer num
0.2649917.9811940.html.plaintext.txt	118	pcr carried touchdown procedure stepped annealing temperature increase primer specificity follows one cycle num degree c num min four cycle num degree c num num degree c num num degree c num min four cycle num degree c num num degree c num num degree c num min four cycle num degree c num num degree c num num degree c num min num cycle num degree c num num degree c num num degree c num min one cycle num degree c num min
0.2649917.9811940.html.plaintext.txt	119	reaction mixture mboi added amplified product num bp digestion carried num degree c num h producing fragment num g allele num bp allele
0.2649917.9811940.html.plaintext.txt	120	digested product loaded onto num agarose gel treated ethidium bromide num
0.2649917.9811940.html.plaintext.txt	121	num electrophoresed num h constant voltage num v sufficient separate digested product num num bp band distinguished
0.2649917.9811940.html.plaintext.txt	122	electrophoresis dna fragment visualized uv illumination using bio rad gel doc system
0.2649917.9811940.html.plaintext.txt	123	incomplete digestion monitored continued presence num bp product
0.2649917.9811940.html.plaintext.txt	124	immunohistochemical analysis used anti anumm antibody numnum zymed
0.2649917.9811940.html.plaintext.txt	125	goat cynum linked secondary antibody jackson immunoresearch used visualize immunostaining
0.2649917.9811940.html.plaintext.txt	126	instance double immunofluorescence carried abeta counterstain antibody numdnum courtesy dr d
0.2649917.9811940.html.plaintext.txt	127	schenk athena neuroscience using bodipy fluorescein linked secondary antibody molecular probe second fluorochrome
0.2649917.9811940.html.plaintext.txt	128	quantitative neuropathological technique measuring abeta burden neurofibrillary tangle number superior temporal sulcus area previously published num
0.2649917.9811940.html.plaintext.txt	129	comparison anumm allele frequency proportion chromosome allele present genotype frequency proportion individual genotype performed num x num table using fisher exact test significance
0.2649917.9811940.html.plaintext.txt	130	age onset alzheimers disease normally distributed compared test
0.2649917.9811940.html.plaintext.txt	131	multivariate analysis odds alzheimers disease performed logistic regression apoe genotype coded according presence absence apoenum
0.2649917.9811940.html.plaintext.txt	132	similar result obtained group apoenum coded separately heterozygote homozygote allele
0.2649917.9811940.html.plaintext.txt	133	odds ratio presented num confidence interval ci
0.2649917.9811940.html.plaintext.txt	134	analysis performed stata software college park tx
0.2649917.9811940.html.plaintext.txt	135	significance test two tailed
0.2649917.9811940.html.plaintext.txt	136	maschke technical assistance
0.2649917.9811940.html.plaintext.txt	137	thank massachusetts alzheimers research center agnum brain bank dr e
0.2649917.9811940.html.plaintext.txt	138	hedley whyte neuropathological specimen
0.2649917.9811940.html.plaintext.txt	139	additional neurological pathological specimen obtained brain tissue research center mhns num
0.2649917.9811940.html.plaintext.txt	140	work supported nih grant agnum agnum
0.2649917.9811940.html.plaintext.txt	141	num alphanum macroglobulin expression neuritic type plaque patient alzheimers disease
0.2649917.9811940.html.plaintext.txt	142	num multiple diverse senile plaque associated protein ligand apolipoprotein e receptor alpha num macroglobulin receptorlow density lipoprotein receptor related protein
0.2649917.9811940.html.plaintext.txt	143	num alpha num macroglobulin beta amyloid peptide binding plasma protein
0.2649917.9811940.html.plaintext.txt	144	num degradation amyloid beta protein serine protease alpha num macroglobulin complex
0.2649917.9811940.html.plaintext.txt	145	num inhibition alpha num macroglobulinproteinase mediated degradation amyloid beta peptide apolipoprotein e alpha num antichymotrypsin
0.2649917.9811940.html.plaintext.txt	146	num apolipoprotein e sporadic alzheimers disease allelic variation receptor interaction
0.2649917.9811940.html.plaintext.txt	147	num sequence identity alphanum macroglobulin receptor low density lipoprotein receptor related protein suggests molecule multifunctional receptor
0.2649917.9811940.html.plaintext.txt	148	num ldl receptor related protein multifunctional apoe receptor bind secreted beta amyloid precursor protein mediates degradation
0.2649917.9811940.html.plaintext.txt	149	num cloning human alpha num macroglobulin gene detection mutation two functional domain bait region thiolester site
0.2649917.9811940.html.plaintext.txt	150	num association quantitative measure dementia senile change cerebral grey matter elderly subject
0.2649917.9811940.html.plaintext.txt	151	num neuronal loss parallel exceeds tangle formation alzheimers disease
0.2649917.9811940.html.plaintext.txt	152	num alpha num macroglobulin synthesis interleukin num stimulated human neuronal sh synumy neuroblastoma cell
0.2649917.9811940.html.plaintext.txt	153	num alpha num macroglobulin complex mediates endocytosis beta amyloid peptide via cell surface low density lipoprotein receptor related protein
0.2649917.9811940.html.plaintext.txt	154	num alpha num macroglobulin associate beta amyloid peptide prevents fibril formation
0.2649917.9811940.html.plaintext.txt	155	num alphanum macroglobulin multifunctional binding protein targeting characteristic
0.2649917.9811940.html.plaintext.txt	156	num genetic association low density lipoprotein receptor related protein gene lrp apolipoprotein e receptor late onset alzheimers disease
0.2649917.9811940.html.plaintext.txt	157	num confirmation association polymorphism exon num low density lipoprotein receptor related protein gene alzheimers disease
0.2649917.9811940.html.plaintext.txt	158	num complete genomic screen late onset familial alzheimer disease
0.2649917.9811940.html.plaintext.txt	159	evidence new locus chromosome num
0.2649917.9811940.html.plaintext.txt	160	num alpha num macroglobulin genetically associated alzheimers disease
0.2649917.9811940.html.plaintext.txt	161	num apoe num age onset alzheimers disease nimh genetics initiative
0.2649917.9811940.html.plaintext.txt	162	correspondence addressed
0.2649917.9811940.html.plaintext.txt	163	tel num num num num fax num num num num email bhymanhelix
0.2649917.9811940.html.plaintext.txt	164	edu page run oxford university press great clarendon street oxford oxnum numdp part oup journal comment feedback www adminatoup
0.2649917.9811940.html.plaintext.txt	165	uk u d last modification num nov num copyright oxford university press num
0.2674377.16162502.html.plaintext.txt	0	resveratrol promotes clearance alzheimers disease amyloid peptide philippe marambaudnum haitian zhao peter davy
0.2674377.16162502.html.plaintext.txt	1	litwin zucker research center study alzheimers disease memory disorder north shore long island jewish institute medical research manhasset new york num
0.2674377.16162502.html.plaintext.txt	2	received publication july num num revised form september num num
0.2674377.16162502.html.plaintext.txt	3	amyloidogenic pathway amyloid precursor protein app cleaved aspartic protease secretasebacenum yield membrane anchored c terminal fragment cnum cnum
0.2674377.16162502.html.plaintext.txt	4	cnum endoproteolyzed secretase proteolytic complex produce various peptide
0.2674377.16162502.html.plaintext.txt	5	major cleavage take place val num producing anum
0.2674377.16162502.html.plaintext.txt	6	alternative nonamyloidogenic pathway app endoproteolyzed within region secretase generate c terminal fragment cnum soluble n terminal fragment secreted app
0.2674377.16162502.html.plaintext.txt	7	finally secretase mediated cleavage app allows intracellular release transcriptionally active app intracellular domain aid num aicd num num
0.2674377.16162502.html.plaintext.txt	8	epidemiological study shown moderate wine intake reduces risk developing ad num num
0.2674377.16162502.html.plaintext.txt	9	resveratrol polyphenol occurs abundance grape red wine suspected afford antioxidant neuroprotective property therefore contribute beneficial effect wine consumption neurodegenerative process num num
0.2674377.16162502.html.plaintext.txt	10	report resveratrol potent anti amyloidogenic activity reducing level produced different cell line expressing wild type swedish mutant appnum
0.2674377.16162502.html.plaintext.txt	11	show resveratrol act promoting intracellular degradation mechanism implicates proteasome
0.2674377.16162502.html.plaintext.txt	12	cell line transfections drug treatment heknum cell stably transfected human appnum provided dr
0.2674377.16162502.html.plaintext.txt	13	dadamio albert einstein college medicine bronx ny
0.2674377.16162502.html.plaintext.txt	14	nnuma cell stably transfected wild type swedish mutant human appnum cdna obtained dr
0.2674377.16162502.html.plaintext.txt	15	robakis mount sinai school medicine new york ny
0.2674377.16162502.html.plaintext.txt	16	appnum heknum transfectants grown dulbeccos modified eagle medium plus num fetal bovine serum penicillin streptomycin num microgml puromycin
0.2674377.16162502.html.plaintext.txt	17	appnum nnuma cell maintained numnum dulbeccos modified eagle mediumopti mem supplemented num fetal bovine serum penicillin streptomycin num
0.2674377.16162502.html.plaintext.txt	18	drug treatment cell treated confluence indicated concentration incubation time
0.2674377.16162502.html.plaintext.txt	19	medium changed treatment continued another num h allow secretion
0.2674377.16162502.html.plaintext.txt	20	sirna directed silencing num pmol purified sirna directed proteasome subunit num smartpool dharmacon transfected num microl lipofectamine num invitrogen appnum heknum cell plated num mm dish
0.2674377.16162502.html.plaintext.txt	21	num h post transfection cell incubated absence presence num microm resveratrol another num h
0.2674377.16162502.html.plaintext.txt	22	cell conditioned medium harvested analyzed western blotting wb proteasome activity assay described
0.2674377.16162502.html.plaintext.txt	23	western blotting cell washed phosphate buffered saline solubilized ice cold hepes buffer num mm hepes ph num
0.2674377.16162502.html.plaintext.txt	24	num num mm nacl numx complete protease inhibitor mixture roche applied science containing num sd
0.2674377.16162502.html.plaintext.txt	25	ten microgram extract analyzed sd page
0.2674377.16162502.html.plaintext.txt	26	total sa wb conditioned medium subjected num
0.2674377.16162502.html.plaintext.txt	27	twenty microliters medium electrophoresed num
0.2674377.16162502.html.plaintext.txt	28	num tris tricine gel transferred onto num
0.2674377.16162502.html.plaintext.txt	29	num microm nitrocellulose membrane
0.2674377.16162502.html.plaintext.txt	30	membrane microwaved num min phosphate buffered saline blocked num fat free milk tb incubated numenum numnum pierce superblock overnight num degree c
0.2674377.16162502.html.plaintext.txt	31	standard ecl detection procedure used
0.2674377.16162502.html.plaintext.txt	32	immunoprecipitations ip cell solubilized ice cold ripa buffer num mm tris hcl ph num num mm nacl num
0.2674377.16162502.html.plaintext.txt	33	num sodium deoxycholate numx complete
0.2674377.16162502.html.plaintext.txt	34	five hundred microgram cell extract total intracellular ip num ml corresponding conditioned medium diluted numx ripa buffer sanum sanum ip precleared protein protein g sepharose amersham bioscience num h num degree c
0.2674377.16162502.html.plaintext.txt	35	supernatant incubated overnight num degree c num microl antibody numgnum total intracellular ip fcanum sanum ip fcanum sanum ip
0.2674377.16162502.html.plaintext.txt	36	supernatant treated num h num degree c protein sepharose polyclonal antibody protein g sepharose monoclonal antibody
0.2674377.16162502.html.plaintext.txt	37	ip washed ice cold ripa buffer analyzed wb using numenum antibody described
0.2674377.16162502.html.plaintext.txt	38	enzyme linked immunosorbent assay elisa numenum capture antibody coated num microgml coating buffer num
0.2674377.16162502.html.plaintext.txt	39	num gliter nannum num well immunoassay plate num h num degree c
0.2674377.16162502.html.plaintext.txt	40	num tween num tb ttbs blocked pierce tb starting block buffer num h room temperature
0.2674377.16162502.html.plaintext.txt	41	sample conditioned medium anum num standard biotinylated numgnum reporter antibody num
0.2674377.16162502.html.plaintext.txt	42	num microgml num pierce superblock added plate incubated room temperature num h
0.2674377.16162502.html.plaintext.txt	43	following washing ttbs streptavidin horseradish peroxidase southern biotech num
0.2674377.16162502.html.plaintext.txt	44	num microgml num superblock added well num h room temperature
0.2674377.16162502.html.plaintext.txt	45	fluorogenic substrate amplex ultra red molecular probe added plate incubated num min
0.2674377.16162502.html.plaintext.txt	46	reaction product quantified using tecan genios pro plate reader num nm excitation num nm emission
0.2674377.16162502.html.plaintext.txt	47	enzymatic activity assay neprilysin nep activity assay intact cell incubated num degree c num h opti mem containing num microm suc aaf amc absence presence num microm thiorphan
0.2674377.16162502.html.plaintext.txt	48	cell homogenized protein concentration determined using bradford assay bio rad
0.2674377.16162502.html.plaintext.txt	49	chymotrypsin like activity endogenous proteasome determined solubilizing cell activity assay buffer num mm hepes ph num
0.2674377.16162502.html.plaintext.txt	50	cell extract num microg incubated num degree c num h num microl activity assay buffer containing num microm suc llvy amc absence presence num microm alln
0.2674377.16162502.html.plaintext.txt	51	purified proteasome activity assay num
0.2674377.16162502.html.plaintext.txt	52	num microgml purified human num proteasome incubated num degree c num h num microl activity assay buffer containing num microm suc llvy amc
0.2674377.16162502.html.plaintext.txt	53	release amc measured fluorescence spectrophotometry using wavelength num nm excitation num nm emission tecan genios pro
0.2674377.16162502.html.plaintext.txt	54	enzymatic activity expressed nmol amcminmg protein
0.2674377.16162502.html.plaintext.txt	55	view larger version numk figure num
0.2674377.16162502.html.plaintext.txt	56	structure quercetin catechin resveratrol
0.2674377.16162502.html.plaintext.txt	57	view larger version numk figure num
0.2674377.16162502.html.plaintext.txt	58	effect resveratrol quercetin catechin level appnum heknum cell
0.2674377.16162502.html.plaintext.txt	59	b cell treated num h indicated concentration polyphenols dissolved menumso
0.2674377.16162502.html.plaintext.txt	60	medium changed drug treatment continued another num h allow secretion
0.2674377.16162502.html.plaintext.txt	61	total sa analyzed elisa wb b panel
0.2674377.16162502.html.plaintext.txt	62	b sanum b sanum c total intracellular panel d total ia analyzed ip wb see experimental procedure
0.2674377.16162502.html.plaintext.txt	63	full length app b panel e analyzed wb
0.2674377.16162502.html.plaintext.txt	64	c cell treated different period time indicated concentration resveratrol
0.2674377.16162502.html.plaintext.txt	65	total sa analyzed b
0.2674377.16162502.html.plaintext.txt	66	final concentration menumso adjusted num
0.2674377.16162502.html.plaintext.txt	67	histogram show mean plus minus
0.2674377.16162502.html.plaintext.txt	68	num num independent experiment
0.2674377.16162502.html.plaintext.txt	69	western blot shown representative least three independent experiment
0.2674377.16162502.html.plaintext.txt	70	view larger version numk figure num
0.2674377.16162502.html.plaintext.txt	71	effect resveratrol app processing nnuma cell expressing wild type swedish appnum
0.2674377.16162502.html.plaintext.txt	72	wild type appnum nnuma cell treated num h increasing concentration resveratrol num microm secretase inhibitor l numnum first lane
0.2674377.16162502.html.plaintext.txt	73	medium changed drug treatment continued another num h allow secretion
0.2674377.16162502.html.plaintext.txt	74	total sa level analyzed wb panel
0.2674377.16162502.html.plaintext.txt	75	app c terminal fragment cnum cnum cnum panel b short film exposure panel c long film exposure app intracellular domain aicd panel d analyzed wb using rnum antibody
0.2674377.16162502.html.plaintext.txt	76	full length app panel e secreted app sapp panel f probed antibody numcnum numenum respectively
0.2674377.16162502.html.plaintext.txt	77	b swedish appnum nnuma cell treated resveratrol l numnum described
0.2674377.16162502.html.plaintext.txt	78	total sa analyzed
0.2674377.16162502.html.plaintext.txt	79	western blot shown representative least three independent experiment
0.2674377.16162502.html.plaintext.txt	80	vitro secretase assay vitro assay performed described previously num
0.2674377.16162502.html.plaintext.txt	81	briefly cell resuspended num
0.2674377.16162502.html.plaintext.txt	82	num mlnum mm dish hypotonic buffer num mm mop ph num
0.2674377.16162502.html.plaintext.txt	83	num num mm kcl homogenized ice
0.2674377.16162502.html.plaintext.txt	84	postnuclear supernatant prepared centrifugation num x g num min num degree c
0.2674377.16162502.html.plaintext.txt	85	crude membrane isolated postnuclear supernatant centrifugation numnum x g num min num degree c
0.2674377.16162502.html.plaintext.txt	86	membrane resuspended num microlof assay buffer num mm sodium citrate ph num
0.2674377.16162502.html.plaintext.txt	87	num numx complete incubated num degree c num h absence presence indicated drug
0.2674377.16162502.html.plaintext.txt	88	sample analyzed wb
0.2674377.16162502.html.plaintext.txt	89	view larger version numk figure num
0.2674377.16162502.html.plaintext.txt	90	resveratrol affect secretase activity vitro
0.2674377.16162502.html.plaintext.txt	91	panel membrane preparation appnum heknum cell see experimental procedure incubated vitro num degree c lane num num degree c lane num num num h absence presence indicated drug
0.2674377.16162502.html.plaintext.txt	92	total produced vitro analyzed wb numenum antibody
0.2674377.16162502.html.plaintext.txt	93	panel b c membrane appnum heknum cell treated culture num h absence presence indicated drug incubated described
0.2674377.16162502.html.plaintext.txt	94	total n cadherin derived c terminal fragment n cadctfnum n cadctfnum analyzed wb antibody numenum panel b cnum panel c respectively
0.2674377.16162502.html.plaintext.txt	95	exclude cell line specific effect also treated appnum transfected mouse neuroblastoma nnuma cell resveratrol
0.2674377.16162502.html.plaintext.txt	96	showed resveratrol inhibited total secreted concentration range another cell line fig
0.2674377.16162502.html.plaintext.txt	97	secreted produced nnuma cell overexpressing appnum bearing familial ad swedish mutation also reduced similar treatment fig
0.2674377.16162502.html.plaintext.txt	98	determine whether resveratrol affect app metabolism monitored wb level app holoprotein proteolytic fragment
0.2674377.16162502.html.plaintext.txt	99	concentration resveratrol neither affected full length app level fig
0.2674377.16162502.html.plaintext.txt	100	numa panel e reduced secreted app immunoreactivity fig
0.2674377.16162502.html.plaintext.txt	101	addition resveratrol affect steady state level app c terminal fragment cnum cnum cnum fig
0.2674377.16162502.html.plaintext.txt	102	numa panel b c app intracellular domain aicd fig
0.2674377.16162502.html.plaintext.txt	103	together data indicate resveratrol effect secretase mediated cleavage app stability app c terminal fragment
0.2674377.16162502.html.plaintext.txt	104	therefore resveratrol affect app metabolism production
0.2674377.16162502.html.plaintext.txt	105	confirm resveratrol inhibit secretase directly resveratrol used cell free assay designed produce vitro
0.2674377.16162502.html.plaintext.txt	106	vitro assay membrane preparation isolated appnum heknum cell incubated num degree c num h absence presence increasing concentration resveratrol
0.2674377.16162502.html.plaintext.txt	107	production affected presence resveratrol vitro fig
0.2674377.16162502.html.plaintext.txt	108	however level produced vitro membrane isolated cell treated culture polyphenol significantly reduced fig
0.2674377.16162502.html.plaintext.txt	109	numb indicating resveratrol promoted reduction without directly affecting secretase
0.2674377.16162502.html.plaintext.txt	110	view larger version numk figure num
0.2674377.16162502.html.plaintext.txt	111	proteasome inhibition prevents resveratrol mediated decrease
0.2674377.16162502.html.plaintext.txt	112	appnum heknum cell incubated num h increasing concentration resveratrol
0.2674377.16162502.html.plaintext.txt	113	thiorphan sensitive endoproteolytic activity nep activity determined intact cell described experimental procedure
0.2674377.16162502.html.plaintext.txt	114	b appnum heknum cell treated num h resveratrol num microm vehicle dimethyl sulfoxide dmso absence control presence phosphoramidon num microm thiorphan num microm insulin num microm lactacystin num microm z gpfl cho num microm yunum num microm
0.2674377.16162502.html.plaintext.txt	115	total sa analyzed elisa described fig
0.2674377.16162502.html.plaintext.txt	116	c appnum heknum cell transfected num sirnas buffer control treated num h resveratrol num microm vehicle dimethyl sulfoxide dmso
0.2674377.16162502.html.plaintext.txt	117	cell harvested analyzed wb anti num antibody panel anti tubulin antibody panel c
0.2674377.16162502.html.plaintext.txt	118	total sa panel b analyzed wb described fig
0.2674377.16162502.html.plaintext.txt	119	alln sensitive endoproteolytic activity proteasome activity determined described experimental procedure
0.2674377.16162502.html.plaintext.txt	120	d purified human num proteasome incubated num min lactacystin num microm dimethyl sulfoxide resveratrol num microm
0.2674377.16162502.html.plaintext.txt	121	proteasome activity monitored c
0.2674377.16162502.html.plaintext.txt	122	e appnum heknum cell treated num h dimethyl sulfoxide resveratrol num microm
0.2674377.16162502.html.plaintext.txt	123	cell harvested analyzed wb anti num proteasome subunit antibody panel anti catenin antibody panel b
0.2674377.16162502.html.plaintext.txt	124	five hundred nanogram purified human num proteasome analyzed wb panel last lane
0.2674377.16162502.html.plaintext.txt	125	value mean plus minus
0.2674377.16162502.html.plaintext.txt	126	num num independent experiment
0.2674377.16162502.html.plaintext.txt	127	secretase target several type protein including cell cell adhesion receptor e n cadherins num num
0.2674377.16162502.html.plaintext.txt	128	cleavage n cadherin secretase produce transcriptionally active intracellular fragment n cadctfnum proteolytic cleavage intermediate c terminal fragment n cadctfnum num
0.2674377.16162502.html.plaintext.txt	129	using similar cell free assay determined production n cadctfnum affected resveratrol treatment fig
0.2674377.16162502.html.plaintext.txt	130	numc confirming absence inhibitory effect resveratrol secretase activity
0.2674377.16162502.html.plaintext.txt	131	together observation resveratrol affect level app holoprotein c terminal proteolytic fragment data indicate resveratrol target producing activity rather promoted clearance
0.2674377.16162502.html.plaintext.txt	132	based observation aimed determine whether resveratrol treatment promotes degradation
0.2674377.16162502.html.plaintext.txt	133	peptide degraded vivo least four metalloendopeptidases nep endothelin converting enzyme num num ece num num insulin degrading enzyme ide num
0.2674377.16162502.html.plaintext.txt	134	recent evidence indicates long term treatment resveratrol promotes nep activity sk n sh cell num
0.2674377.16162502.html.plaintext.txt	135	using thiorphan sensitive enzymatic assay intact heknum cell confirmed nep activity significantly increased upon resveratrol treatment fig
0.2674377.16162502.html.plaintext.txt	136	however inhibition nep phosphoramidon thiorphan appnum heknum cell could prevent decrease level triggered resveratrol fig
0.2674377.16162502.html.plaintext.txt	137	phosphoramidon also inhibits ece num num concluded enzymatic activity also involved resveratrol mediated decrease
0.2674377.16162502.html.plaintext.txt	138	pretreatment insulin act competitive inhibitor ide rescue level resveratrol treatment fig
0.2674377.16162502.html.plaintext.txt	139	thus resveratrol promote degradation nep ece num num ide heknum cell
0.2674377.16162502.html.plaintext.txt	140	converging evidence indicates resveratrol promotes proteasomal degradation specific subset protein including cyclin dnum num estrogen receptor num hypoxia inducible factor num num
0.2674377.16162502.html.plaintext.txt	141	proteasome shown modulate level num asked whether proteasome inhibition rescue level upon resveratrol treatment
0.2674377.16162502.html.plaintext.txt	142	numb show treatment selective proteasome inhibitor lactacystin z gpfl cho yunum significantly prevented resveratrol induced decrease
0.2674377.16162502.html.plaintext.txt	143	confirm involvement proteasome anti amyloidogenic effect resveratrol sought regulate proteasome activity sirna directed silencing
0.2674377.16162502.html.plaintext.txt	144	proteasome multicatalytic protease complex formed different subunit encoded several gene num
0.2674377.16162502.html.plaintext.txt	145	yunum highly selective chymotrypsin like activity proteasome num subunit num critical proteolytic activity num asked whether sirna directed silencing proteasome subunit num prevents resveratrol induced decrease
0.2674377.16162502.html.plaintext.txt	146	transfection sirnas directed subunit num strongly decreased num protein expression fig
0.2674377.16162502.html.plaintext.txt	147	numc panel inhibited num chymotrypsin like activity proteasome fig
0.2674377.16162502.html.plaintext.txt	148	condition observed strong inhibition resveratrol induced decrease fig
0.2674377.16162502.html.plaintext.txt	149	view larger version numk figure num
0.2674377.16162502.html.plaintext.txt	150	effect resveratrol analogue level
0.2674377.16162502.html.plaintext.txt	151	appnum heknum cell treated num h indicated concentration resveratrol analogue dissolved menumso
0.2674377.16162502.html.plaintext.txt	152	total sa analyzed fig
0.2674377.16162502.html.plaintext.txt	153	final concentration menumso adjusted num
0.2674377.16162502.html.plaintext.txt	154	histogram show relative amount total sa detected wb upper panel
0.2674377.16162502.html.plaintext.txt	155	investigated whether resveratrol directly stimulates proteasome activity
0.2674377.16162502.html.plaintext.txt	156	numd chymotrypsin like activity purified proteasome monitored upon vitro incubation resveratrol
0.2674377.16162502.html.plaintext.txt	157	activity also assessed endogenous proteasome cell extract treatment polyphenol cell culture fig
0.2674377.16162502.html.plaintext.txt	158	significant effect resveratrol chymotrypsin like activity purified endogenous proteasome observed histogram fig
0.2674377.16162502.html.plaintext.txt	159	resveratrol effectively reduced level num h incubation also asked whether resveratrol modifies proteasome subunit transcription
0.2674377.16162502.html.plaintext.txt	160	found resveratrol treatment markedly affect steady state level several proteasome subunit heknum cell fig
0.2674377.16162502.html.plaintext.txt	161	together result demonstrate resveratrol promotes proteasome dependent intracellular degradation via mechanism increase total proteasome activity
0.2674377.16162502.html.plaintext.txt	162	consistent conclusion level catenin cytosolic protein degraded ubiquitin proteasome system num affected resveratrol heknum cell fig
0.2674377.16162502.html.plaintext.txt	163	investigated anti amyloidogenic effect several resveratrol analogue
0.2674377.16162502.html.plaintext.txt	164	three analogue tested piceatannol trans numnumnumnum tetrahydroxystilbene contains additional hydroxyl group c num two methoxy analogue trimethoxy resveratrol trans numnumnum trimethoxystilbene tm
0.2674377.16162502.html.plaintext.txt	165	interestingly three analogue able decrease level fig
0.2674377.16162502.html.plaintext.txt	166	however compared resveratrol fig
0.2674377.16162502.html.plaintext.txt	167	numa piceatannol trimethoxy resveratrol le potent whereas tm comparable potency reducing amount fig
0.2674377.16162502.html.plaintext.txt	168	additional study needed fully elucidate role proteasome mechanism intracellular clearance
0.2674377.16162502.html.plaintext.txt	169	number possible function proteasome regulation metabolism ascribed multicatalytic complex num
0.2674377.16162502.html.plaintext.txt	170	proteasome target degradation cnum three core component secretase complex presenilins aph num pen num num suggesting proteasome activation may decrease level reducing amount cnum available altering secretase activity
0.2674377.16162502.html.plaintext.txt	171	data show reduction cnum level fig
0.2674377.16162502.html.plaintext.txt	172	numa panel c alteration secretase mediated cleavage app n cadherin upon resveratrol treatment fig
0.2674377.16162502.html.plaintext.txt	173	num num thus excluding possibility resveratrol lower promoting proteasomal degradation cnum secretase component
0.2674377.16162502.html.plaintext.txt	174	recent evidence also suggests degraded proteasome dependent endoplasmic reticulum er associated degradation num
0.2674377.16162502.html.plaintext.txt	175	using cell free reconstitutions er derived brain microsome schmitz et al
0.2674377.16162502.html.plaintext.txt	176	num show translocate er cytosol directly degraded proteasome
0.2674377.16162502.html.plaintext.txt	177	conceivable resveratrol promotes clearance mechanism
0.2674377.16162502.html.plaintext.txt	178	however er represents small fraction total produced small pool produced er appears controlled er associated degradation unlikely severe reduction level observed presence resveratrol entirely due increase clearance mechanism
0.2674377.16162502.html.plaintext.txt	179	therefore hypothesize resveratrol may act indirectly selectively stimulating proteasomal degradation yet identified critical regulator clearance
0.2674377.16162502.html.plaintext.txt	180	also important determine molecular target resveratrol pathway clearance
0.2674377.16162502.html.plaintext.txt	181	resveratrol interacts several protein including member sirtuin family
0.2674377.16162502.html.plaintext.txt	182	sirtuins evolutionarily conserved deacetylases important function longevity num
0.2674377.16162502.html.plaintext.txt	183	resveratrol found act potent activator human sirtuin sirtnum vitro yeast homologue sirnum vivo mechanism may extend life span yeast num
0.2674377.16162502.html.plaintext.txt	184	moreover resveratrol sirtnum activation recently linked neuroprotective pathway model axonal degeneration num neuronal dysfunction caused mutant polyglutamines num
0.2674377.16162502.html.plaintext.txt	185	would therefore interest determine whether sirtnum involved resveratrol induced decrease
0.2674377.16162502.html.plaintext.txt	186	evidence compelling decrease proteasome activity occurs ad brain num num
0.2674377.16162502.html.plaintext.txt	187	unclear however whether decrease proteasome activity parallel increase level
0.2674377.16162502.html.plaintext.txt	188	proposed may lead proteasome inhibition num suggesting high level ad brain may create vicious cycle inhibiting proteasome blocking degradation critical regulator clearance
0.2674377.16162502.html.plaintext.txt	189	context data reveal important mechanism selective proteasome activation anti amyloidogenic effect resveratrol support therapeutic potential natural polyphenol
0.2674377.16162502.html.plaintext.txt	190	footnote work supported national institute mental health grant num grant american health assistance foundation
0.2674377.16162502.html.plaintext.txt	191	cost publication article defrayed part payment page charge
0.2674377.16162502.html.plaintext.txt	192	article must therefore hereby marked advertisement accordance num u
0.2674377.16162502.html.plaintext.txt	193	section num solely indicate fact
0.2674377.16162502.html.plaintext.txt	194	num correspondence addressed litwin zucker research center study alzheimers disease memory disorder north shore long island jewish institute medical research num community dr
0.2674377.16162502.html.plaintext.txt	195	num num num e mail pmarambaataecom
0.2674377.16162502.html.plaintext.txt	196	num abbreviation used ad alzheimers disease suc succinyl tm trans numnumnumnum tetramethoxystilbene alln n acetyl ll norleucinal cho elisa enzyme linked immunosorbent assay ece endothelin converting enzyme ide insulin degrading enzyme amyloid app amyloid precursor protein amc amido num methylcoumarin tricine n num hydroxy numnum bishydroxymethylethylglycine wb western blotting ip immunoprecipitation nep neprilysin mop num morpholinepropanesulfonic acid er endoplasmic reticulum sirna small interfering rna tb tris buffered saline sa secreted amyloid z benzyloxycarbonyl
0.2674377.16162502.html.plaintext.txt	197	acknowledgment thank drs
0.2674377.16162502.html.plaintext.txt	198	mehta generously providing u antibody cdna cell line
0.2674377.16162502.html.plaintext.txt	199	home help feedback subscription archive search table content asbmb journal molecular cellular proteomics journal lipid research biochemistry molecular biology education copyright num american society biochemistry molecular biology
0.2710359.15003956.html.plaintext.txt	0	meta analysis association cathepsin d alanumval gene polymorphism risk alzheimer disease huge gene disease association review christos ntaisnum anastasia polycarpounum john p
0.2710359.15003956.html.plaintext.txt	1	num clinical molecular epidemiology unit department hygiene epidemiology university ioannina school medicine ioannina greece
0.2710359.15003956.html.plaintext.txt	2	num biomedical research institute foundation research technology hellas ioannina greece
0.2710359.15003956.html.plaintext.txt	3	num institute clinical research health policy study department medicine tuft new england medical center tuft university school medicine boston ma
0.2710359.15003956.html.plaintext.txt	4	received publication august num num accepted publication october num num
0.2710359.15003956.html.plaintext.txt	5	alzheimer disease cathepsin d ctsd epidemiology genetics meta analysis polymorphism genetics
0.2710359.15003956.html.plaintext.txt	6	abbreviation abbreviation ci confidence interval odds ratio
0.2710359.15003956.html.plaintext.txt	7	molecular epidemiologic study presented seemingly contradictory result concerning potential role ctsd polymorphism alzheimer disease num num
0.2710359.15003956.html.plaintext.txt	8	also controversy whether polymorphism may interact apolipoprotein e num allele apoenum best known genetic determinant sporadic alzhei mer disease num
0.2710359.15003956.html.plaintext.txt	9	single study may underpowered detect interaction even overall effect
0.2710359.15003956.html.plaintext.txt	10	given amount accumulated data deemed important perform quantitative synthesis evidence using rigorous method
0.2710359.15003956.html.plaintext.txt	11	thus conducted comprehensive meta analysis available study relating ctsd polymorphism risk alzheimer disease
0.2710359.15003956.html.plaintext.txt	12	case control study eligible determined distribution ctsd genotype alzheimer disease case regardless age onset concurrent control group dementia free subject using molecular method genotyping
0.2710359.15003956.html.plaintext.txt	13	case alzheimer disease eligible regardless whether family history alzhei mer disease
0.2710359.15003956.html.plaintext.txt	14	however excluded family based study pedigree several affected case per family analysis based linkage consideration
0.2710359.15003956.html.plaintext.txt	15	data extraction two investigator independently extracted data reached consensus item
0.2710359.15003956.html.plaintext.txt	16	following information sought report author journal year publication country origin selection characteristic alzheimer disease case control demographic ethnic group study population eligible genotyped case control number case control ctsd genotype
0.2710359.15003956.html.plaintext.txt	17	study including subject different ethnic group data extracted separately ethnicity whenever possible
0.2710359.15003956.html.plaintext.txt	18	furthermore examined whether matching used whether specific mention blinding personnel performed genotyping clinical status subject whether genotyping method validated
0.2710359.15003956.html.plaintext.txt	19	meta analysis primary analysis compared alzheimer disease case control contrast versus c allele
0.2710359.15003956.html.plaintext.txt	20	analysis aim detect overall difference
0.2710359.15003956.html.plaintext.txt	21	also examined contrast extreme homozygote tt versus cc
0.2710359.15003956.html.plaintext.txt	22	finally examined contrast tt versus ct cc contrast ct tt versus cc
0.2710359.15003956.html.plaintext.txt	23	contrast correspond recessive dominant effect respectively allele
0.2710359.15003956.html.plaintext.txt	24	odds ratio used metric choice
0.2710359.15003956.html.plaintext.txt	25	genetic contrast estimated study heterogeneity across eligible comparison using chi square based q statistic num
0.2710359.15003956.html.plaintext.txt	26	heterogeneity considered significant p num
0.2710359.15003956.html.plaintext.txt	27	data combined using fixed effect mantel haenszel random effect dersimonian laird model num
0.2710359.15003956.html.plaintext.txt	28	random effect incorporate estimate study variance tend provide wider confidence interval result constituent study differ among
0.2710359.15003956.html.plaintext.txt	29	absence study heterogeneity two method provide identical result
0.2710359.15003956.html.plaintext.txt	30	random effect appropriate heterogeneity present num
0.2710359.15003956.html.plaintext.txt	31	also performed cumulative meta analysis num recursive cumulative meta analysis num num evaluate whether summary odds ratio versus c contrast changed time data accumulated whether strength association changed first hypothesis generating study excluded calculation num
0.2710359.15003956.html.plaintext.txt	32	inverted funnel plot begg mazumdar publication bias diagnostic nonparametric correlation coefficient num evaluated whether magnitude observed association related variance study whether large study gave different result compared smaller one num
0.2710359.15003956.html.plaintext.txt	33	finally evaluated whether summary result different analysis limited study intensive effort exclude alzheimer disease control clearly performed neuropsychological testing control
0.2710359.15003956.html.plaintext.txt	34	previous investigation alluded possibility allele may interact apoenum allele conferring susceptibility alzheimer disease num num
0.2710359.15003956.html.plaintext.txt	35	thus also evaluated effect allele carriage risk alzheimer disease separately apoenum positive apoenum negative subject
0.2710359.15003956.html.plaintext.txt	36	moreover evaluated genetic effect conferred presence apoenum separately subject carrying allele carrying allele
0.2710359.15003956.html.plaintext.txt	37	odds ratio combined fixed random effect model described
0.2710359.15003956.html.plaintext.txt	38	data reported communicated primary investigator obtain information whenever possible
0.2710359.15003956.html.plaintext.txt	39	analysis performed spss num
0.2710359.15003956.html.plaintext.txt	40	chicago illinois meta analyst joseph lau boston massachusetts software
0.2710359.15003956.html.plaintext.txt	41	whenever num value num x num table added num
0.2710359.15003956.html.plaintext.txt	42	num four cell odds ratio could calculated
0.2710359.15003956.html.plaintext.txt	43	characteristic study included meta analysis specific matching age described five study num num num
0.2710359.15003956.html.plaintext.txt	44	one study also matched sex num
0.2710359.15003956.html.plaintext.txt	45	one study num specifically mentioned blinding personnel performed genotyping
0.2710359.15003956.html.plaintext.txt	46	appropriate molecular method genotyping used
0.2710359.15003956.html.plaintext.txt	47	study used polymerase chain reaction two study num num also used dynamic allele specific hybridization
0.2710359.15003956.html.plaintext.txt	48	meta analysis database eligible study summarized table num included total numnum case alzheimer disease numnum control numnum numnum respectively genotype data
0.2710359.15003956.html.plaintext.txt	49	allele highly represented among control american descent overall prevalence num
0.2710359.15003956.html.plaintext.txt	50	num percent num percent confidence interval ci num
0.2710359.15003956.html.plaintext.txt	51	num control european num
0.2710359.15003956.html.plaintext.txt	52	significant heterogeneity prevalence rate allele even across control subject european descent rate num
0.2710359.15003956.html.plaintext.txt	53	num percent among hispanic american num
0.2710359.15003956.html.plaintext.txt	54	num percent spain lower rate northern european country num
0.2710359.15003956.html.plaintext.txt	55	num percent united kingdom num
0.2710359.15003956.html.plaintext.txt	56	num percent germany lowest prevalence rate num
0.2710359.15003956.html.plaintext.txt	57	num percent polish population
0.2710359.15003956.html.plaintext.txt	58	overall prevalence tt homozygosity num
0.2710359.15003956.html.plaintext.txt	59	num percent control subject american european asian descent respectively
0.2710359.15003956.html.plaintext.txt	60	respective prevalence rate ct heterozygosity num
0.2710359.15003956.html.plaintext.txt	61	num percent respective rate cc homozygosity num
0.2710359.15003956.html.plaintext.txt	62	distribution genotype control group consistent hardy weinberg equilibrium study
0.2710359.15003956.html.plaintext.txt	63	distribution ctsd allele among alzheimer disease case control included study overall effect trend suggesting allele may confer increased susceptibility alzheimer disease figure num
0.2710359.15003956.html.plaintext.txt	64	shown table num summary odds ratio num
0.2710359.15003956.html.plaintext.txt	65	num significant heterogeneity among num study comparison p num
0.2710359.15003956.html.plaintext.txt	66	found evidence association tt genotype risk alzheimer disease relative cc genotype
0.2710359.15003956.html.plaintext.txt	67	significant study heterogeneity
0.2710359.15003956.html.plaintext.txt	68	evidence association alzhei mer disease discerned also recessive model examined effect trend association seen dominant model random effect num
0.2710359.15003956.html.plaintext.txt	69	study heterogeneity recessive model contrast significant heterogeneity p num
0.2710359.15003956.html.plaintext.txt	70	num still seen dominant model contrast
0.2710359.15003956.html.plaintext.txt	71	subgroup analysis study case control european descent yielded similar result num comparison numnum allele num
0.2710359.15003956.html.plaintext.txt	72	view larger version numk figure num
0.2710359.15003956.html.plaintext.txt	73	meta analysis effect allele versus c allele risk alzheimer disease
0.2710359.15003956.html.plaintext.txt	74	comparison presented name first author year publication
0.2710359.15003956.html.plaintext.txt	75	h signifies hispanic subject j signifies japanese subject
0.2710359.15003956.html.plaintext.txt	76	comparison point estimate odds ratio accompanying num confidence interval ci shown
0.2710359.15003956.html.plaintext.txt	77	represents summary random effect estimate comparison along respective num confidence interval
0.2710359.15003956.html.plaintext.txt	78	value num denote increased risk alzheimer disease allele
0.2710359.15003956.html.plaintext.txt	79	summary odds ratio various contrast bias diagnostics cumulative meta analysis recursive cumulative meta analysis magnitude summary odds ratio stable time changed considerably per year apparent dissipation postulated effect random effect summary v
0.2710359.15003956.html.plaintext.txt	80	excluding first hypothesis generating study num found summary odds ratio became num
0.2710359.15003956.html.plaintext.txt	81	num significant study heterogeneity p num
0.2710359.15003956.html.plaintext.txt	82	num evidence association even comparison homozygote tt v
0.2710359.15003956.html.plaintext.txt	83	num study heterogeneity
0.2710359.15003956.html.plaintext.txt	84	relation effect size variance study suggesting larger study agreed result smaller study
0.2710359.15003956.html.plaintext.txt	85	analysis limited study intensive effort exclude alzheimer disease control yielded similar result num comparison numnum allele num
0.2710359.15003956.html.plaintext.txt	86	interaction apoe genotype nine study num num num num num num obtained data ctsd apoe genotype
0.2710359.15003956.html.plaintext.txt	87	one study num separating male female subject num comparison became available
0.2710359.15003956.html.plaintext.txt	88	nine comparative study tended gave slightly inflated effect allele compared full meta analysis num comparison summary random effect num
0.2710359.15003956.html.plaintext.txt	89	num complete meta analysis thus inference cautious
0.2710359.15003956.html.plaintext.txt	90	among carrier high risk apoenum allele allele carrier random effect odds ratio num
0.2710359.15003956.html.plaintext.txt	91	num alzheimer disease compared subject carrying allele
0.2710359.15003956.html.plaintext.txt	92	among subject carrying apoenum allele respective odds ratio num
0.2710359.15003956.html.plaintext.txt	93	significant study heterogeneity apoenum positive group p num
0.2710359.15003956.html.plaintext.txt	94	two effect size overlapped widely
0.2710359.15003956.html.plaintext.txt	95	among carrier allele presence apoenum increased risk alzheimer disease num
0.2710359.15003956.html.plaintext.txt	96	num study heterogeneity
0.2710359.15003956.html.plaintext.txt	97	among subject without allele presence apoenum increased risk alzheimer disease num
0.2710359.15003956.html.plaintext.txt	98	num significant study heterogeneity p num
0.2710359.15003956.html.plaintext.txt	99	two estimate overlapped widely individual study overall typically odds ratio larger group allele carrier figure num
0.2710359.15003956.html.plaintext.txt	100	meta analysis finding may interpreted postulated biologic context ctsd polymorphism
0.2710359.15003956.html.plaintext.txt	101	cathepsin d intracellular acid protease beta secretase activity vitro num num cleave amyloid precursor protein tau protein generate fragment intact microtubule binding domain num might play role pathogenesis paired helical filament
0.2710359.15003956.html.plaintext.txt	102	one study shown ctsd polymorphism associated increased secretion altered intracellular maturation procathepsin d num
0.2710359.15003956.html.plaintext.txt	103	noted clear whether ctsd polymorphism functional consequence mature form enzyme
0.2710359.15003956.html.plaintext.txt	104	although exclude biologic effect ctsd polymorphism finding accordance result recent full genome scan showing significant linkage alzheimer disease short arm chromosome num region ctsd gene located num num
0.2710359.15003956.html.plaintext.txt	105	attention given design individual study
0.2710359.15003956.html.plaintext.txt	106	result meta analysis may affected methodological problem potential bias design constituent study
0.2710359.15003956.html.plaintext.txt	107	nondifferential misclassification error may dilute strength observed association
0.2710359.15003956.html.plaintext.txt	108	alzheimer disease case generally selected according appropriate criterion
0.2710359.15003956.html.plaintext.txt	109	however young control subject may developed alzheimer disease older age
0.2710359.15003956.html.plaintext.txt	110	choice appropriate age window assessing postulated genetic risk factor alzheimer disease difficult
0.2710359.15003956.html.plaintext.txt	111	study younger subject may suitable identifying risk factor result early onset alzhei mer disease
0.2710359.15003956.html.plaintext.txt	112	conversely selection younger subject may le appropriate influence postulated genetic risk factor important late onset alzhei mer disease
0.2710359.15003956.html.plaintext.txt	113	subgroup effect effect modification e
0.2710359.15003956.html.plaintext.txt	114	differential effect genetic polymorphism early v
0.2710359.15003956.html.plaintext.txt	115	late onset alzheimer disease case familial v
0.2710359.15003956.html.plaintext.txt	116	sporadic disease complex interaction gene may also need considered num
0.2710359.15003956.html.plaintext.txt	117	analysis addressed interaction apoenum major known genetic determinant alzhei mer disease
0.2710359.15003956.html.plaintext.txt	118	interaction genetic environmental factor studied
0.2710359.15003956.html.plaintext.txt	119	trend stronger effect apoenum presence allele carriage interesting light data suggesting carriage may affect general intelligence num
0.2710359.15003956.html.plaintext.txt	120	however subgroup interaction analysis interpreted cautiously since difference subgroup may occur chance num validation would require study even larger sample size several thousand included meta analysis
0.2710359.15003956.html.plaintext.txt	121	finally population stratification may theoretically affected result constituent study meta analysis num since documented frequency allele varied considerably among different ethnic group even among different ethnic group european descent
0.2710359.15003956.html.plaintext.txt	122	however study strictly ethnically defined population stratification effect unlikely considerable magnitude
0.2710359.15003956.html.plaintext.txt	123	increasing prevalence alzheimer disease worldwide crucial identify genetic risk factor neurodegenerative disease
0.2710359.15003956.html.plaintext.txt	124	thus list identified polymorphism may influence risk alzheimer disease continuously expanding num num reported association candidate gene date remain nonreplicated least controversial subsequent investigation
0.2710359.15003956.html.plaintext.txt	125	early small genetic association study may come spurious finding num num num
0.2710359.15003956.html.plaintext.txt	126	even genetic association replicated usually major public health impact would lead screening recommendation num
0.2710359.15003956.html.plaintext.txt	127	nevertheless knowledge could improve understanding pathogenesis complex disease alzheimer disease
0.2710359.15003956.html.plaintext.txt	128	acknowledgment author thank jonathan
0.2710359.15003956.html.plaintext.txt	129	prince patrizia mecocci anthony j
0.2710359.15003956.html.plaintext.txt	130	brooke providing additional data study
0.2710359.15003956.html.plaintext.txt	131	note correspondence dr
0.2710359.15003956.html.plaintext.txt	132	ioannidis department hygiene epidemiology university ioannina school medicine ioannina num greece e mail jioannidatcc
0.2731872.12196314.html.plaintext.txt	0	risk factor alzheimer disease prospective analysis canadian study health aging joan lindsaynumnum danielle laurinnumnum rene verreaultnumnum rejean hebertnum barbara helliwellnum gerry b
0.2731872.12196314.html.plaintext.txt	1	num department epidemiology community medicine faculty medicine university ottawa ottawa canada
0.2731872.12196314.html.plaintext.txt	2	num surveillance risk assessment division health canada ottawa canada
0.2731872.12196314.html.plaintext.txt	3	num laval university geriatric research unit beauport qc canada
0.2731872.12196314.html.plaintext.txt	4	num department social preventive medicine laval university quebec qc canada
0.2731872.12196314.html.plaintext.txt	5	num sherbrooke university geriatric institute sherbrooke qc canada
0.2731872.12196314.html.plaintext.txt	6	num elisabeth bruyere health centre ottawa canada
0.2731872.12196314.html.plaintext.txt	7	received publication december num num accepted publication may num num
0.2731872.12196314.html.plaintext.txt	8	alzheimer disease anti inflammatory agent non steroidal apolipoproteins cohort study education exercise risk factor wine
0.2731872.12196314.html.plaintext.txt	9	abbreviation abbreviation apoe apolipoprotein e apoenum apolipoprotein e num allele ci confidence interval csha canadian study health aging eurodem european community concerted action epidemiology prevention dementia nsaid nonsteroidal anti inflammatory drug odds ratio numms modified mini mental state
0.2731872.12196314.html.plaintext.txt	10	even though investigation using prospective design reveal defined picture pathogenesis alzheimer disease result obtained far consistent
0.2731872.12196314.html.plaintext.txt	11	european community concerted action epidemiology prevention dementia eurodem group associated smoking higher risk alzheimer disease num whereas study observe significant relation smoking onset alzheimer disease num num
0.2731872.12196314.html.plaintext.txt	12	eurodem group also found female sex low educational level associated increased risk alzheimer disease
0.2731872.12196314.html.plaintext.txt	13	conversely sex education reported risk factor incident alzheimer disease study num num
0.2731872.12196314.html.plaintext.txt	14	methodological difference duration follow selection number study participant may account discrepancy
0.2731872.12196314.html.plaintext.txt	15	canadian study health aging csha large national multicenter longitudinal study dementia elderly people focusing prevalence num incidence num risk factor num num
0.2731872.12196314.html.plaintext.txt	16	part first phase csha num case control study conducted
0.2731872.12196314.html.plaintext.txt	17	age family history dementia educational level arthritis use nonsteroidal anti inflammatory drug nsaid significantly related alzheimer disease num
0.2731872.12196314.html.plaintext.txt	18	report result prospective analysis risk factor incident case late onset alzheimer disease based risk factor data collected csha num cognitively normal diagnosis incident alzheimer disease num year later csha num
0.2731872.12196314.html.plaintext.txt	19	initial assessment csha num num num representative sample men woman aged num year older drawn num urban surrounding rural area num canadian province covered
0.2731872.12196314.html.plaintext.txt	20	numnum participant numnum lived community numnum resided institution excluded analysis
0.2731872.12196314.html.plaintext.txt	21	community interviewed health presence specific disorder limitation performing basic instrumental activity daily living based older american resource service activity daily living scale num
0.2731872.12196314.html.plaintext.txt	22	participant screened dementia using modified mini mental state numms examination num num
0.2731872.12196314.html.plaintext.txt	23	screened positive numms examination score numnum random sample screened negative score num invited participate extensive clinical evaluation followed three stage protocol
0.2731872.12196314.html.plaintext.txt	24	nurse first readministered numms examination collected information participant medical family history
0.2731872.12196314.html.plaintext.txt	25	next physician conducted standardized physical neurologic examination
0.2731872.12196314.html.plaintext.txt	26	finally participant deemed testable numms examination score num psychometrist administered series neuropsychological test num interpreted later neuropsychologist
0.2731872.12196314.html.plaintext.txt	27	independent preliminary diagnosis made physician neuropsychologist followed case conference consensus diagnosis reached according diagnostic statistical manual mental disorder third edition revised criterion dementia num national institute neurological communicative disorder stroke alzheimer disease related disorder association nincds adrda criterion alzheimer disease num specific criterion cognitive impairment num vascular dementia num
0.2731872.12196314.html.plaintext.txt	28	diagnosis comprised following category cognitive impairment cognitive impairment dementia probable possible alzheimer disease vascular dementia specific dementia unclassifiable dementia
0.2731872.12196314.html.plaintext.txt	29	detailed information risk factor gathered self administered questionnaire completed csha num participant found cognitively normal basis either screening test clinical examination
0.2731872.12196314.html.plaintext.txt	30	risk factor questionnaire covered sociodemographic characteristic occupational environmental exposure lifestyle smoking alcohol consumption intake selected food item regular exercise family medical history prior head injury without loss consciousness chronic disease medication use
0.2731872.12196314.html.plaintext.txt	31	participant asked whether engaged regular exercise yesno regular explicitly defined
0.2731872.12196314.html.plaintext.txt	32	regular consumption beer wine spirit defined least week
0.2731872.12196314.html.plaintext.txt	33	regular consumption tea coffee defined nearly every day
0.2731872.12196314.html.plaintext.txt	34	follow study csha num num num subject could contacted agreed participate second wave study interviewed measure change health status functioning average num year csha num
0.2731872.12196314.html.plaintext.txt	35	participant took part diagnostic process one used csha num including screening test nurse evaluation clinical evaluation
0.2731872.12196314.html.plaintext.txt	36	two diagnosis dementia made consensus conference one according criterion used csha num according recent diagnostic statistical manual mental disorder fourth edition criterion num alzheimer disease national institute neurological disorder stroke association internationale pour la recherche et l enseignement en neuroscience ninds airen criterion vascular dementia num
0.2731872.12196314.html.plaintext.txt	37	recent criterion used define case current analysis
0.2731872.12196314.html.plaintext.txt	38	blood sample collected apolipoprotein e apoe allele status determined subsample subject examined clinically num
0.2731872.12196314.html.plaintext.txt	39	participant died follow study conducted date cause death obtained relevant provincial registrar vital statistic relative informant interviewed ass subject physical cognitive status num month prior death
0.2731872.12196314.html.plaintext.txt	40	subject died follow probability dementia estimated three different source num num mention dementia death certificate num information proxy diagnosis memory problem alzheimer disease senile dementia prior death num logistic regression model based analysis num people died within num num month complete diagnostic evaluation estimating probability deceased person demented prior death
0.2731872.12196314.html.plaintext.txt	41	estimate available numnum decedent num
0.2731872.12196314.html.plaintext.txt	42	procedure permit diagnosis type dementia decedent omitted main analysis
0.2731872.12196314.html.plaintext.txt	43	secondary analysis conducted ass potential impact omitting decedent death classified due dementia included alzheimer disease case death due dementia considered control
0.2731872.12196314.html.plaintext.txt	44	phase csha approved ethic review committee num participating study center well coordinating center
0.2731872.12196314.html.plaintext.txt	45	participant proxy provided informed consent component study
0.2731872.12196314.html.plaintext.txt	46	however resident province newfoundland omitted prospective analysis num legal interpretation province advance directive legislation prohibited use proxy consent person unable give full informed consent participate research study
0.2731872.12196314.html.plaintext.txt	47	interpretation meant people dementia could provide consent clinical examination
0.2731872.12196314.html.plaintext.txt	48	outcome measure could obtained
0.2731872.12196314.html.plaintext.txt	49	therefore newfoundland participant excluded
0.2731872.12196314.html.plaintext.txt	50	analysis analysis included participant living community csha num
0.2731872.12196314.html.plaintext.txt	51	case control analysis conducted incident case control selected csha num
0.2731872.12196314.html.plaintext.txt	52	included participant initial screening result negative csha num participant clinically diagnosed without num cognitive impairment dementia num dementia
0.2731872.12196314.html.plaintext.txt	53	case diagnosed probable possible alzheimer disease csha num
0.2731872.12196314.html.plaintext.txt	54	comparison made control csha num remained without cognitive impairment dementia dementia according clinical evaluation screening test follow
0.2731872.12196314.html.plaintext.txt	55	difference case control regarding mean proportion compared using test chi square test respectively
0.2731872.12196314.html.plaintext.txt	56	univariate multivariate logistic regression model used calculate crude adjusted odds ratio various risk factor
0.2731872.12196314.html.plaintext.txt	57	rare disease assumption odds ratio considered valid estimate relative risk
0.2731872.12196314.html.plaintext.txt	58	age sex education age education continuous variable num year increment introduced multivariate model potential confounders
0.2731872.12196314.html.plaintext.txt	59	modification risk age sex apoe num allele apoenum status examined using interaction term
0.2731872.12196314.html.plaintext.txt	60	view larger version numk figure num
0.2731872.12196314.html.plaintext.txt	61	study sample analysis risk factor incident alzheimer disease canadian study health aging csha num num csha num num num csha num
0.2731872.12196314.html.plaintext.txt	62	clinical clinical examination cind cognitive impairment dementia
0.2731872.12196314.html.plaintext.txt	63	characteristic participant decedent subject refused data missing risk factor analysis alzheimer disease canadian study health aging num num using recent criterion diagnosing alzheimer disease resulted change status fewer num percent case included analysis
0.2731872.12196314.html.plaintext.txt	64	new criterion identified num incident case probable alzheimer disease compared num case old criterion used num case possible alzheimer disease compared num
0.2731872.12196314.html.plaintext.txt	65	result analysis conducted including case probable alzheimer disease consistent result presented
0.2731872.12196314.html.plaintext.txt	66	demographic characteristic subject summarized table num
0.2731872.12196314.html.plaintext.txt	67	distribution age sex education across case control significantly different
0.2731872.12196314.html.plaintext.txt	68	case older control median age range csha num screening num year range num num v
0.2731872.12196314.html.plaintext.txt	69	case also completed fewer year education median num v
0.2731872.12196314.html.plaintext.txt	70	table num also present adjusted odds ratio age sex education
0.2731872.12196314.html.plaintext.txt	71	expected advanced age strongly associated higher risk alzheimer disease controlled sex education
0.2731872.12196314.html.plaintext.txt	72	age treated continuous variable risk alzheimer disease increased num percent num percent confidence interval ci num
0.2731872.12196314.html.plaintext.txt	73	age sex adjusted risk alzheimer disease lowest level education almost twice educated participant
0.2731872.12196314.html.plaintext.txt	74	association observed sex risk alzheimer disease
0.2731872.12196314.html.plaintext.txt	75	distribution alzheimer disease risk estimate age sex education canadian study health aging num num table num show odds ratio selected putative risk factor adjustment age sex education
0.2731872.12196314.html.plaintext.txt	76	family history alzheimer disease senile dementia associated late onset alzheimer disease
0.2731872.12196314.html.plaintext.txt	77	participant least one apoenum allele num
0.2731872.12196314.html.plaintext.txt	78	num time risk alzheimer disease compared two num allele
0.2731872.12196314.html.plaintext.txt	79	antecedent coexisting chronic condition included risk factor questionnaire arthritis significantly related reduced risk alzheimer disease
0.2731872.12196314.html.plaintext.txt	80	statistically significant relation observed alzheimer disease risk high blood pressure stroke heart disease depression head trauma diabetes thyroid condition cancer type stomach ulcer
0.2731872.12196314.html.plaintext.txt	81	use nsaid reduced risk alzheimer disease num percent
0.2731872.12196314.html.plaintext.txt	82	effect due mostly nonsalicylates
0.2731872.12196314.html.plaintext.txt	83	inclusion nsaid use arthritis along age sex education model yielded similar odds ratio estimate factor remained protective alzheimer disease testing interaction nsaid arthritis significant p num
0.2731872.12196314.html.plaintext.txt	84	association alzheimer disease antihypertensive agent antacid corticosteroid estrogen therapy found
0.2731872.12196314.html.plaintext.txt	85	association selected risk factor alzheimer disease canadian study health aging num num table num show age sex education adjusted risk estimate alzheimer disease lifestyle related variable
0.2731872.12196314.html.plaintext.txt	86	num year follow smoking significantly associated alzheimer disease risk
0.2731872.12196314.html.plaintext.txt	87	regular alcohol consumption associated reduced risk alzheimer disease particularly wine consumption reduced risk num percent
0.2731872.12196314.html.plaintext.txt	88	variable observed significantly associated lower risk alzheimer disease daily coffee consumption regular physical activity num percent reduction
0.2731872.12196314.html.plaintext.txt	89	association tea drinking antiperspirant use depression noted
0.2731872.12196314.html.plaintext.txt	90	reported risk factor evidence found modification risk age sex apoenum status
0.2731872.12196314.html.plaintext.txt	91	furthermore relation risk alzheimer disease observed marital status parental age subject birth birth order occupational history exposure ink paint solvent rubber glue pesticide fumigant radiation anesthetic family history syndrome mental retardation parkinson disease thyroid disease data shown
0.2731872.12196314.html.plaintext.txt	92	association specific lifestyle variable risk alzheimer disease canadian study health aging num num table num present estimate odds ratio selected risk factor
0.2731872.12196314.html.plaintext.txt	93	decedent excluded addition death classified due dementia included alzheimer disease case death due dementia included control
0.2731872.12196314.html.plaintext.txt	94	beneficial effect regular physical activity remained strong highly significant whereas association arthritis nsaid use wine consumption coffee consumption remained num
0.2731872.12196314.html.plaintext.txt	95	num longer statistically significant
0.2731872.12196314.html.plaintext.txt	96	found increasing age low educational level apoenum allele associated increased risk incident alzheimer disease arthritis regular use nsaid wine consumption coffee consumption regular physical activity associated reduced risk
0.2731872.12196314.html.plaintext.txt	97	note family history dementia smoking related risk alzheimer disease
0.2731872.12196314.html.plaintext.txt	98	addition estrogen shown protective
0.2731872.12196314.html.plaintext.txt	99	however result subject potential limitation
0.2731872.12196314.html.plaintext.txt	100	first eligible community subject baseline risk factor questionnaire available numnum num
0.2731872.12196314.html.plaintext.txt	101	num percent died num year follow period included main analysis
0.2731872.12196314.html.plaintext.txt	102	group decedent included proportionately men generally older le educated suffered frequently chronic disease subject completed follow
0.2731872.12196314.html.plaintext.txt	103	exclusion participant may distorted result example subject frequently exposed particular risk factor higher risk developing alzheimer disease
0.2731872.12196314.html.plaintext.txt	104	result simulation included subject died suggest although arthritis nsaid use wine consumption coffee consumption might potentially valid protective factor alzheimer disease bias due exclusion decedent follow might also partially explain association
0.2731872.12196314.html.plaintext.txt	105	another limitation analysis possibility bias assessing risk factor exposure
0.2731872.12196314.html.plaintext.txt	106	spite prospective nature study result could explained least part preclinical cognitive decline yet detectable screening clinical evaluation csha num among subject developed alzheimer disease csha num
0.2731872.12196314.html.plaintext.txt	107	although ruled explanation seems improbable view extensive screening clinical evaluation process used csha num diagnose cognitive impairment dementia well dementia along relatively long follow period
0.2731872.12196314.html.plaintext.txt	108	nevertheless test possibility result reanalyzed excluding case whose symptom alzheimer disease reported proxy started within num year csha num end num
0.2731872.12196314.html.plaintext.txt	109	persistence protective effect alzheimer disease nsaid odds ratio num
0.2731872.12196314.html.plaintext.txt	110	num physical activity num
0.2731872.12196314.html.plaintext.txt	111	num support hypothesis preclinical decline explains result
0.2731872.12196314.html.plaintext.txt	112	since multiple comparison performed possible statistically significant association may occurred chance
0.2731872.12196314.html.plaintext.txt	113	new association found example protective effect coffee drinking replication study needed determine validity association
0.2731872.12196314.html.plaintext.txt	114	result generalizable population largely european descent
0.2731872.12196314.html.plaintext.txt	115	inclusion different ethnic group living canada determined ability speak either english french
0.2731872.12196314.html.plaintext.txt	116	family history dementia similar advancing age apoenum allele frequently associated increased risk alzheimer disease generally considered definite risk factor num
0.2731872.12196314.html.plaintext.txt	117	csha num case control study found increased risk alzheimer disease increased significantly two threefold family history dementia num
0.2731872.12196314.html.plaintext.txt	118	however eurodem pooled data set num prospective analysis csha data find association
0.2731872.12196314.html.plaintext.txt	119	contradictory finding might reflect misclassification information recall bias andor uncertainty information collected help informant retrospective investigation compared longitudinal study
0.2731872.12196314.html.plaintext.txt	120	case control study mayeux et al
0.2731872.12196314.html.plaintext.txt	121	num observed relative patient whose onset alzheimer disease began age num year older increased risk alzheimer disease whereas increased risk first degree relative patient whose onset occurred prior age num year
0.2731872.12196314.html.plaintext.txt	122	thus would seem reasonable observe association older cohort
0.2731872.12196314.html.plaintext.txt	123	may surprising family history dementia associated alzheimer disease increased risk alzheimer disease observed subject apoenum allele since family history dementia believed potential indicator genetic factor
0.2731872.12196314.html.plaintext.txt	124	however suggested apoenum allele explain large part family history dementia num
0.2731872.12196314.html.plaintext.txt	125	study num percent least one apoenum allele reported parent dementia compared num percent num allele
0.2731872.12196314.html.plaintext.txt	126	association low educational level risk alzheimer disease consistent finding several retrospective prospective study num num num num
0.2731872.12196314.html.plaintext.txt	127	large scale population based study csha case ascertained mean two phase diagnostic procedure screening clinical examination
0.2731872.12196314.html.plaintext.txt	128	cutpoint screening numms examination chosen achieve high sensitivity even though cutpoint could missed mild case alzheimer disease people higher level education could still perform well cognitive screening test
0.2731872.12196314.html.plaintext.txt	129	whether risk alzheimer disease associated le education corresponds artifact represents true risk factor still unclear
0.2731872.12196314.html.plaintext.txt	130	explanation education effect include increased brain reserve num selection bias resulting selective attrition use two phase diagnostic procedure num num confounding indicator socioeconomic status linked education diet lifestyle occupational history num num
0.2731872.12196314.html.plaintext.txt	131	present analysis support hypothesis negative association nsaid risk alzheimer disease
0.2731872.12196314.html.plaintext.txt	132	protective relation also found several population based case control study including csha num analysis num
0.2731872.12196314.html.plaintext.txt	133	least one longitudinal study support protective effect anti inflammatory drug alzheimer disease dementia num study remain inconclusive num num
0.2731872.12196314.html.plaintext.txt	134	regular wine consumption also associated reduced risk alzheimer disease
0.2731872.12196314.html.plaintext.txt	135	result paquid study longitudinal study community resident showed similar negative relation wine consumption alzheimer disease num
0.2731872.12196314.html.plaintext.txt	136	protective effect remained significant depth statistical analysis conducted num
0.2731872.12196314.html.plaintext.txt	137	suggested specific substance wine alcoholic beverage could responsible positive effect nerve cell dementia num
0.2731872.12196314.html.plaintext.txt	138	analysis regular consumption coffee seemed protective alzheimer disease
0.2731872.12196314.html.plaintext.txt	139	low coffee intake reported related mental disability num year follow num finnish men num
0.2731872.12196314.html.plaintext.txt	140	without confirmation prospective study alzheimer disease finding may due chance
0.2731872.12196314.html.plaintext.txt	141	potential protective effect regular physical activity risk alzheimer disease important represents modifiable lifestyle habit
0.2731872.12196314.html.plaintext.txt	142	epidemiologic study evaluated possible protective role regular physical activity risk cognitive impairment dementia elderly result inconsistent num num
0.2731872.12196314.html.plaintext.txt	143	however clinical trial exercise shown benefit cognitive function num num
0.2731872.12196314.html.plaintext.txt	144	recently regular physical activity found protective cognitive impairment well type dementia including alzheimer disease interaction sex reported suggesting greater protection woman men num
0.2731872.12196314.html.plaintext.txt	145	conclusion large scale prospective study older age onset alzheimer disease confirmed frequently suggested etiologic hypothesis disease
0.2731872.12196314.html.plaintext.txt	146	intriguing protective association observed study warrant research
0.2731872.12196314.html.plaintext.txt	147	preventive strategy alzheimer disease explored
0.2731872.12196314.html.plaintext.txt	148	regular physical activity could represent novel safe preventive strategy alzheimer disease many condition examined
0.2731872.12196314.html.plaintext.txt	149	acknowledgment data reported paper collected part csha study
0.2731872.12196314.html.plaintext.txt	150	core study funded senior independence research program national health research development program nhrdp health canada project
0.2731872.12196314.html.plaintext.txt	151	additional funding provided pfizer canada incorporated medical research councilpharmaceutical manufacturer association canada health activity program nhrdp project
0.2731872.12196314.html.plaintext.txt	152	num num num r bayer incorporated british columbia health research foundation project
0.2731872.12196314.html.plaintext.txt	153	study coordinated university ottawa division aging senior health canada
0.2731872.12196314.html.plaintext.txt	154	rene verreault supported laval university chair geriatric research
0.2731872.12196314.html.plaintext.txt	155	danielle laurin supported part national health ph
0.2731872.12196314.html.plaintext.txt	156	fellowship provided nhrdp project
0.2731872.12196314.html.plaintext.txt	157	num num num laval university chair geriatric research
0.2731872.12196314.html.plaintext.txt	158	author grateful richard aylesworth louis rochette statistical assistance
0.2731872.12196314.html.plaintext.txt	159	note reprint request dr
0.2731872.12196314.html.plaintext.txt	160	joan lindsay department epidemiology community medicine university ottawa num smyth road ottawa knumh nummnum canada e mail joanlindsayathc sc
0.28510132.11581121.html.plaintext.txt	0	nice guideline treatment alzheimers disease evidence based medicine may discriminatory r
0.28510132.11581121.html.plaintext.txt	1	institute psychiatry de crespigny park london senum numaf uk
0.28510132.11581121.html.plaintext.txt	2	arshad et al num raise important concern uk guideline treatment alzheimers disease national institute clinical excellence nice num may counterproductive patient learning disability
0.28510132.11581121.html.plaintext.txt	3	potential discrimination mean stop
0.28510132.11581121.html.plaintext.txt	4	particular difficulty highlight central role mini mental state examination mmse instrument determining treatment eligibility response
0.28510132.11581121.html.plaintext.txt	5	score mmse strongly influenced previous education cross cultural validity poor
0.28510132.11581121.html.plaintext.txt	6	guideline therefore unhelpful people lower educational attainment growing number older people minority ethnic group uk
0.28510132.11581121.html.plaintext.txt	7	comorbid cerebrovascular disease also frequent people disadvantaged background particular minority ethnic group african caribbean population stewart et al num
0.28510132.11581121.html.plaintext.txt	8	reduces likelihood diagnosis alzheimers disease therefore eligibility anti cholinesterase treatment according standard diagnostic criterion mckhann et al num despite growing evidence overlapping pathological process dementia holmes et al num
0.28510132.11581121.html.plaintext.txt	9	sub population represented clinical trial sample minority ethnic group people lower educational attainment people learning disability people comorbid cerebrovascular disease best hoped considerably weaker evidence base might emerge year future
0.28510132.11581121.html.plaintext.txt	10	time large number people may failed receive potentially beneficial treatment
0.28510132.11581121.html.plaintext.txt	11	problem lie treatment guideline applied level individual service particular regarding group alzheimers disease num year old cognitive screen andor num year old diagnostic criterion unhelpful
0.28510132.11581121.html.plaintext.txt	12	evidence based medicine noble ideal
0.28510132.11581121.html.plaintext.txt	13	however clinical practice restricted evidence base may amount institutionalised discrimination
0.28510132.11581121.html.plaintext.txt	14	num treatment alzheimers disease people learning disability nice guideline letter
0.28510132.11581121.html.plaintext.txt	15	british journal psychiatry num num
0.28510132.11581121.html.plaintext.txt	16	et al num validity current clinical criterion alzheimers disease vascular dementia dementia lewy body
0.28510132.11581121.html.plaintext.txt	17	british journal psychiatry num num num
0.28510132.11581121.html.plaintext.txt	18	et al num clinical diagnosis alzheimers disease
0.28510132.11581121.html.plaintext.txt	19	report nincds adrda work group auspex department health human service task force alzheimers disease
0.28510132.11581121.html.plaintext.txt	20	national institute clinical excellence num guidance use donepezil rivastigmine galantamine treatment alzheimers disease
0.28510132.11581121.html.plaintext.txt	21	et al num ethnic difference incidence stroke prospective study stroke register
0.28510132.11581121.html.plaintext.txt	22	british medical journal num num num
0.29024228.15781953.html.plaintext.txt	0	physical activity apoe genotype dementia risk finding cardiovascular health cognition study laura jean podewilsnum eliseo guallarnumnum lewis h
0.29024228.15781953.html.plaintext.txt	1	lopeznum michelle carlsonnum constantine g
0.29024228.15781953.html.plaintext.txt	2	num department epidemiology john hopkins bloomberg school public health baltimore md num welch center prevention epidemiology clinical research john hopkins medical institution baltimore md num department epidemiology university pittsburgh graduate school public health pittsburgh pa num department medicine center aging health john hopkins medical institution baltimore md num department neurology university pittsburgh school medicine pittsburgh pa num department mental health center aging health john hopkins medical institution baltimore md num division geriatric psychiatry neuropsychiatry department psychiatry behavioral science john hopkins medical institution baltimore md
0.29024228.15781953.html.plaintext.txt	3	lyketsos division geriatric psychiatry neuropsychiatry osler num john hopkins hospital baltimore md num e mail kostasatjhmi
0.29024228.15781953.html.plaintext.txt	4	received publication january num num
0.29024228.15781953.html.plaintext.txt	5	accepted publication november num num
0.29024228.15781953.html.plaintext.txt	6	aged alzheimer disease dementia exercise motor activity physical fitness risk factor
0.29024228.15781953.html.plaintext.txt	7	abbreviation apoe apolipoprotein e genotype chcs cardiovascular health cognition study chs cardiovascular health study mri magnetic resonance imaging numms modified mini mental state
0.29024228.15781953.html.plaintext.txt	8	mounting body evidence support role physical activity mean maintain cognitive performance
0.29024228.15781953.html.plaintext.txt	9	physical activity may preserve neuronal plasticity increase synapsis dendritic receptor following injury release hormonal factor may assist neuronal creation function brain derived neurotrophic factor epinephrine num
0.29024228.15781953.html.plaintext.txt	10	addition physical activity lower cardiovascular risk decrease blood pressure increase high density lipoprotein cholesterol level glucose tolerance num may related neuronal integrity cognitive function num num
0.29024228.15781953.html.plaintext.txt	11	finally engaging physical activity may indicate enriched social environment may decrease dementia risk num
0.29024228.15781953.html.plaintext.txt	12	several randomized trial reported enhanced neurocognitive function following exercise training num
0.29024228.15781953.html.plaintext.txt	13	addition observational study num num shown inverse association physical activity cognitive decline among older adult
0.29024228.15781953.html.plaintext.txt	14	however inverse association physical activity alzheimers disease found num num num num num study
0.29024228.15781953.html.plaintext.txt	15	diminished physical activity may also different role various form dementia
0.29024228.15781953.html.plaintext.txt	16	study examined relation physical activity incident dementia subtypes alzheimers disease vascular dementia using data large community based cohort older adult
0.29024228.15781953.html.plaintext.txt	17	also assessed possibility association physical activity dementia may different apoe num carrier versus noncarriers
0.29024228.15781953.html.plaintext.txt	18	cardiovascular health cognition study chcs num num ancillary study chs started num chs participant invited undergo cerebral magnetic resonance imaging mri participate cognitive testing
0.29024228.15781953.html.plaintext.txt	19	chcs cohort consisted numnum num
0.29024228.15781953.html.plaintext.txt	20	num percent participation rate num person brain mri available numnum person mri measure cognition assessed time
0.29024228.15781953.html.plaintext.txt	21	compared nonparticipant chcs participant younger educated le likely cardiovascular disease num
0.29024228.15781953.html.plaintext.txt	22	institutional review board participating institution approved research protocol chs chcs
0.29024228.15781953.html.plaintext.txt	23	participant provided written informed consent
0.29024228.15781953.html.plaintext.txt	24	data collection physical activity
0.29024228.15781953.html.plaintext.txt	25	information physical activity collected trained interviewer chs baseline num num chcs baseline num num
0.29024228.15781953.html.plaintext.txt	26	modified minnesota leisure time activity questionnaire num num asked participant frequency duration num different type activity previous num week
0.29024228.15781953.html.plaintext.txt	27	activity selected previously shown common among older adult num
0.29024228.15781953.html.plaintext.txt	28	included walking household chore mowing raking gardening hiking jogging biking exercise cycling dancing aerobics bowling golfing general exercise swimming
0.29024228.15781953.html.plaintext.txt	29	activity assigned metabolic equivalent ml onumminute mets according intensity num leisure time energy expenditure kilocaloriesweek estimated person
0.29024228.15781953.html.plaintext.txt	30	kilocalorie expenditure chs baseline chcs baseline averaged obtain estimate habitual physical activity level older adulthood used current analysis
0.29024228.15781953.html.plaintext.txt	31	single measure physical activity used participant value missing one testing period n num
0.29024228.15781953.html.plaintext.txt	32	express diversity physical activity activity index calculated number different activity subject participated previous num week
0.29024228.15781953.html.plaintext.txt	33	raking mowing collapsed single category represent yard work resulting potential range index num num activity
0.29024228.15781953.html.plaintext.txt	34	activity index chs baseline chcs baseline averaged represent activity index used present study
0.29024228.15781953.html.plaintext.txt	35	similar aggregate score physical activity used previous study dementia risk num num
0.29024228.15781953.html.plaintext.txt	36	method apoe genotyping chs described elsewhere num
0.29024228.15781953.html.plaintext.txt	37	briefly genomic dna extracted whole blood sample amplified using polymerase chain reaction
0.29024228.15781953.html.plaintext.txt	38	cleaving electrophoresis agarose gel restriction pattern determined according method hixson vernier num
0.29024228.15781953.html.plaintext.txt	39	apoe genotype grouped apoe num carrier numnum numnum numnum genotype noncarriers numnum numnum numnum genotype
0.29024228.15781953.html.plaintext.txt	40	measurement obtained chcs baseline examination also considered
0.29024228.15781953.html.plaintext.txt	41	sociodemographic variable included age gender educational level ethnicity
0.29024228.15781953.html.plaintext.txt	42	information smoking alcohol intake postmenopausal hormone replacement therapy use self reported
0.29024228.15781953.html.plaintext.txt	43	prevalent case myocardial infarction angina stroke transient ischemic attack congestive heart failure baseline ascertained participant self report physician diagnosis
0.29024228.15781953.html.plaintext.txt	44	functional impairment measured using modified version instrument assessing basic activity daily living instrumental activity daily living national health interview survey num
0.29024228.15781953.html.plaintext.txt	45	social network assessed using lubben social network scale num series question asking participant life satisfaction personal relationship summed represent measure social support
0.29024228.15781953.html.plaintext.txt	46	center epidemiologic study depression scale num administered chcs baseline sensitive version mini mental state examination modified mini mental state numms examination num administered annually
0.29024228.15781953.html.plaintext.txt	47	numms ass several domain cognition greater detail mini mental state examination score ranging num num higher score reflect better performance
0.29024228.15781953.html.plaintext.txt	48	person receive clinical evaluation attempt made evaluate cognition using telephone interview cognitive status num
0.29024228.15781953.html.plaintext.txt	49	participant died examination information obtained using informant questionnaire cognitive decline elderly num data concerning circumstance death
0.29024228.15781953.html.plaintext.txt	50	self reported weight height also recorded chcs baseline
0.29024228.15781953.html.plaintext.txt	51	body mass index calculated weight kilogram per height meter squared
0.29024228.15781953.html.plaintext.txt	52	blood pressure measured standardized manner trained personnel participant seated num minute
0.29024228.15781953.html.plaintext.txt	53	average two reading calculated analysis
0.29024228.15781953.html.plaintext.txt	54	hypertension defined previous diagnosis hypertension taking hypertensive medication current systolic blood pressure num mmhg diastolic blood pressure num mmhg
0.29024228.15781953.html.plaintext.txt	55	total cholesterol high density lipoprotein cholesterol triglyceride determined fasting sample using standard method low density lipoprotein cholesterol estimated friedewald formula num
0.29024228.15781953.html.plaintext.txt	56	person considered diabetic validated medical diagnosis diabetes fasting glucose level num mgdl higher
0.29024228.15781953.html.plaintext.txt	57	cerebral mri conducted chcs baseline scored overall severity white matter lesion according scale developed chs researcher num
0.29024228.15781953.html.plaintext.txt	58	white matter lesion severity score num considered within normal limit group older adult whereas score num considered indicative neurodegenerative change
0.29024228.15781953.html.plaintext.txt	59	diagnosis dementia dementia status type chcs classified num num using multistage process num num
0.29024228.15781953.html.plaintext.txt	60	initially participant classified local study site dementia risk stratum high low
0.29024228.15781953.html.plaintext.txt	61	person deemed high risk num numms score num within last two study visit num decline num point numms within follow period num telephone interview cognitive status score num informant questionnaire cognitive decline elderly score num
0.29024228.15781953.html.plaintext.txt	62	num num incident stroke num diagnosis dementia documented medical record num resided nursing home study period
0.29024228.15781953.html.plaintext.txt	63	pittsburgh site participant alive could traced invited center num num full neuropsychiatric examination regardless dementia risk
0.29024228.15781953.html.plaintext.txt	64	three remaining site high risk participant described minority participant participant cognitive data incomplete invited comprehensive evaluation
0.29024228.15781953.html.plaintext.txt	65	attend clinic visit medical record proxy previous telephone interview used diagnosis
0.29024228.15781953.html.plaintext.txt	66	diagnosis based deficit performance two cognitive domain sufficiently severe affect subject activity daily living history normal intellectual function
0.29024228.15781953.html.plaintext.txt	67	dementia criterion designed identify subject syndrome could include relatively preserved memory function e
0.29024228.15781953.html.plaintext.txt	68	frontotemporal dementia thus memory deficit required diagnosis dementia num
0.29024228.15781953.html.plaintext.txt	69	participant identified dementia reviewed adjudication committee made neurology psychiatry expert
0.29024228.15781953.html.plaintext.txt	70	diagnosis alzheimers disease based national institute neurological communicative disorder stroke alzheimers disease related disorder association nincds adrda num criterion diagnosis vascular dementia based alzheimers disease diagnostic treatment center criterion num
0.29024228.15781953.html.plaintext.txt	71	time dementia onset established first diagnosis recorded medical record otherwise midpoint two annual chs follow interview marked change cognition leading final dementia diagnosis
0.29024228.15781953.html.plaintext.txt	72	statistical analysis survival analysis used ass association activity level time onset dementia using cox proportional hazard regression
0.29024228.15781953.html.plaintext.txt	73	multivariate model adjusted age gender race apoe genotype educational level difficulty activity daily living instrumental activity daily living lubben social network scale social support baseline numms score white matter grade
0.29024228.15781953.html.plaintext.txt	74	hazard ratio num percent confidence interval computed
0.29024228.15781953.html.plaintext.txt	75	test linear trend across quartile physical activity computed introducing cox model variable median quartile continuous variable
0.29024228.15781953.html.plaintext.txt	76	effect modification assessed stratification introducing product term multivariate cox model
0.29024228.15781953.html.plaintext.txt	77	statistical analysis performed using stata software version num
0.29024228.15781953.html.plaintext.txt	78	view larger version numk figure num
0.29024228.15781953.html.plaintext.txt	79	cardiovascular health cognition study sample selection num num follow num num united state
0.29024228.15781953.html.plaintext.txt	80	vad vascular dementia ad alzheimers disease
0.29024228.15781953.html.plaintext.txt	81	table num describes participant characteristic chcs baseline
0.29024228.15781953.html.plaintext.txt	82	developed dementia compared older lower educational level likely carry apoe num allele poorer cognitive performance numms baseline physical difficulty likely show white matter disease cerebral mri
0.29024228.15781953.html.plaintext.txt	83	incident dementia case also likely history stroke cardiovascular disease hypertension
0.29024228.15781953.html.plaintext.txt	84	baseline characteristic participant cardiovascular health cognition study united state num num
0.29024228.15781953.html.plaintext.txt	85	average leisure time physical activity expenditure numnum kcal per week standard deviation numnum num participant completely sedentary leisure time kilocalorie expenditure num
0.29024228.15781953.html.plaintext.txt	86	person reported engaging num num different activity mean num
0.29024228.15781953.html.plaintext.txt	87	walking household chore common num
0.29024228.15781953.html.plaintext.txt	88	num percent active person engaging activity respectively
0.29024228.15781953.html.plaintext.txt	89	approximately one third sample engaged activity gardening yard work organized exercise program
0.29024228.15781953.html.plaintext.txt	90	relation physical activity participant characteristic displayed table num
0.29024228.15781953.html.plaintext.txt	91	male caucasian participant higher educational level person fewer functional difficulty activity daily livinginstrumental activity daily living level physical activity higher
0.29024228.15781953.html.plaintext.txt	92	relatively sedentary participant quartile num likely hypertensive diabetic smoke higher level high density lipoprotein cholesterol triglyceride compared active participant
0.29024228.15781953.html.plaintext.txt	93	similar association found baseline characteristic activity index number activity table num
0.29024228.15781953.html.plaintext.txt	94	spearman correlation energy expenditure activity index num
0.29024228.15781953.html.plaintext.txt	95	participant characteristic quartile leisure time energy expenditure cardiovascular health cognition study united state num num
0.29024228.15781953.html.plaintext.txt	96	participant characteristic activity index
0.29024228.15781953.html.plaintext.txt	97	activity previous num week cardiovascular health cognition study united state num num
0.29024228.15781953.html.plaintext.txt	98	leisure time energy expenditure inversely associated risk dementia although adjustment age covariates trend longer significant table num
0.29024228.15781953.html.plaintext.txt	99	point estimate suggested inverse relation alzheimers disease vascular dementia none analysis vascular dementia reached significance
0.29024228.15781953.html.plaintext.txt	100	hazard ratio incident dementia level leisure time energy expenditure cardiovascular health cognition study united state num num
0.29024228.15781953.html.plaintext.txt	101	number physical activity inversely associated dementia risk table num
0.29024228.15781953.html.plaintext.txt	102	inverse association persisted multivariate adjustment
0.29024228.15781953.html.plaintext.txt	103	adjusted hazard ratio cause dementia incidence num
0.29024228.15781953.html.plaintext.txt	104	num num num num num num activity respectively p trend num
0.29024228.15781953.html.plaintext.txt	105	trend remained significant model adjusted total energy expenditure data shown
0.29024228.15781953.html.plaintext.txt	106	hazard ratio incident dementia activity index
0.29024228.15781953.html.plaintext.txt	107	activity previous num week cardiovascular health cognition study united state num num
0.29024228.15781953.html.plaintext.txt	108	analysis stratified apoe num carrier state inverse association energy expenditure activity index dementia risk limited apoe num noncarriers table num figure num
0.29024228.15781953.html.plaintext.txt	109	multivariate adjusted hazard ratio type dementia comparing highest lowest quartile energy expenditure apoe num noncarriers num
0.29024228.15781953.html.plaintext.txt	110	num hazard ratio comparing highest lowest quartile activity index num
0.29024228.15781953.html.plaintext.txt	111	corresponding hazard ratio energy expenditure activity index apoe num carrier num
0.29024228.15781953.html.plaintext.txt	112	p value interaction energy expenditure activity index apoe num carrier status num
0.29024228.15781953.html.plaintext.txt	113	pattern observed alzheimers disease vascular dementia figure num
0.29024228.15781953.html.plaintext.txt	114	hazard ratio incident dementia level physical activity stratified apoe cardiovascular health cognition study united state num num
0.29024228.15781953.html.plaintext.txt	115	view larger version numk figure num
0.29024228.15781953.html.plaintext.txt	116	five year cumulative incidence dementia function leisure time energy expenditure activity index among apolipoprotein e genotype apoe num carrier noncarriers united state cardiovascular health cognition study num num
0.29024228.15781953.html.plaintext.txt	117	bold curve cause dementia thin solid curve alzheimers disease dashed curve vascular dementia bar frequency distribution physical activity within apoe genotype stratum
0.29024228.15781953.html.plaintext.txt	118	person may le active le physically able active
0.29024228.15781953.html.plaintext.txt	119	therefore repeated analysis excluding subject one instrumental activity daily living impairment one activity daily living impairment association energy expenditure activity index dementia risk effect modification apoe carrier status similar
0.29024228.15781953.html.plaintext.txt	120	finding prospective study physical activity dementia inconsistent num num num num num num num
0.29024228.15781953.html.plaintext.txt	121	among japanese elder regular physical activity associated lower risk alzheimers disease vascular dementia incidence num
0.29024228.15781953.html.plaintext.txt	122	similarly older french participant engaged three social leisure activity versus none num percent lower overall dementia risk num num
0.29024228.15781953.html.plaintext.txt	123	canadian study health aging physical activity inversely associated cause dementia alzheimers disease num inverse association vascular dementia observed woman num
0.29024228.15781953.html.plaintext.txt	124	num however observe association physical activity dementia incidence social mental productive activity accounted although investigator examined three type physical activity subject participated activity
0.29024228.15781953.html.plaintext.txt	125	religious order study num bronx aging study num also failed identify relation activity physical per se risk dementia report association cognitive activity reduced dementia incidence
0.29024228.15781953.html.plaintext.txt	126	neither study accounted apoe genotype analysis however
0.29024228.15781953.html.plaintext.txt	127	although measure cognitive activity directly physical activity often occur conjunction social cognitive stimulation
0.29024228.15781953.html.plaintext.txt	128	physical activity may protect dementia risk several mechanism
0.29024228.15781953.html.plaintext.txt	129	experimental study demonstrated physical exercise activity facilitates learning increasing expression gene promoting neurogenesis neural plasticity num num
0.29024228.15781953.html.plaintext.txt	130	although several neural substrate may mediate exercise induced effect neuronal structure integrity research suggests central role brain derived neurotrophic factor num num level factor hippocampus diminished patient alzheimers disease num
0.29024228.15781953.html.plaintext.txt	131	nonneural vascular adaptation also enhanced exercise including increased cerebral blood flow substrate exchange num increased cerebral capillary density num decreased accumulation radical oxidative protein num
0.29024228.15781953.html.plaintext.txt	132	addition physical activity may surrogate overall life engagement greater social activity
0.29024228.15781953.html.plaintext.txt	133	person developed social network lower risk cause mortality person socially isolated social support attenuate rate cognitive decline older adult num
0.29024228.15781953.html.plaintext.txt	134	social network may also promote overall health particularly cardiovascular risk factor thereby may impact dementia risk
0.29024228.15781953.html.plaintext.txt	135	similarly involvement physical activity associated mastery self efficacy num
0.29024228.15781953.html.plaintext.txt	136	turn attribute may motivate person attentive health need health behavior
0.29024228.15781953.html.plaintext.txt	137	adjusted social network social support multivariate model however activity index continued associated dementia risk
0.29024228.15781953.html.plaintext.txt	138	physical activity operating social mechanism appears level captured two measure social functioning
0.29024228.15781953.html.plaintext.txt	139	involvement number different activity likely requires organization memory skill necessary flexibly schedule attend shift among activity
0.29024228.15781953.html.plaintext.txt	140	organizational executive memory process regulated neuroanatomical region adversely affected aging dementing illness
0.29024228.15781953.html.plaintext.txt	141	exercising may help buffer preserve cognitive reserve face cognitive decline via continued use corresponding cortical synaptic stimulation intact neuron num
0.29024228.15781953.html.plaintext.txt	142	cross sectional study variety lifestyle activity positively associated index cognition among nondemented older woman particularly domain memory m
0.29024228.15781953.html.plaintext.txt	143	carlson john hopkins medical institution unpublished manuscript
0.29024228.15781953.html.plaintext.txt	144	alternatively physical activity may index healthier lifestyle resulting le exposure factor affect cognitive function precipitate dementia
0.29024228.15781953.html.plaintext.txt	145	current study engaging larger number different activity generally associated favorable health profile health behavior
0.29024228.15781953.html.plaintext.txt	146	previous study num num apoe num carrier attain benefit noncarriers physical activity term blood pressure lipid pattern
0.29024228.15781953.html.plaintext.txt	147	similarly finding suggest differing risk pattern dementia physical activity apoe genotype imply potential protective effect associated physical activity enough overcome effect apoe num allele physical activity dementia simply unrelated person apoe num genotype
0.29024228.15781953.html.plaintext.txt	148	however finding contrast previous study inverse association physical activity cognitive decline observed predominantly apoe num carrier num
0.29024228.15781953.html.plaintext.txt	149	difficult know whether finding extend dementia elderly person experience cognitive decline progress clinical dementia
0.29024228.15781953.html.plaintext.txt	150	note however interaction physical activity apoe num study based num case cognitive decline thus subject considerable variability
0.29024228.15781953.html.plaintext.txt	151	replication finding larger study required resolve apparent discrepancy
0.29024228.15781953.html.plaintext.txt	152	chcs one largest prospective study older adult comprehensive information subclinical clinical cognitive functioning dementia status cardiovascular factor
0.29024228.15781953.html.plaintext.txt	153	addition physical activity collected using standardized method num prospective design chcs enabled u collect information physical activity advance dementia diagnosis therefore minimizing selection recall bias
0.29024228.15781953.html.plaintext.txt	154	update information physical activity follow preclinical symptom may reduce activity level compromising ability establish temporality
0.29024228.15781953.html.plaintext.txt	155	although misclassification exposure possible participant present analysis cognitively stable numms score num time physical activity information collected
0.29024228.15781953.html.plaintext.txt	156	furthermore able adjust baseline numms cognitive score analysis
0.29024228.15781953.html.plaintext.txt	157	basis consideration reasonable suggest misclassification exposure would nondifferential would biased result toward null
0.29024228.15781953.html.plaintext.txt	158	finding without limitation
0.29024228.15781953.html.plaintext.txt	159	able ass physical activity level older adult life unclear period life physical activity relevant preserving cognition impacting dementia risk
0.29024228.15781953.html.plaintext.txt	160	finding number activity stronger association dementia risk kilocalorie expenditure may artifact measurement
0.29024228.15781953.html.plaintext.txt	161	reliability minnesota leisure time activity questionnaire may lower low moderate level activity num level older adult participate
0.29024228.15781953.html.plaintext.txt	162	therefore possible number activity may sensitive indicator level
0.29024228.15781953.html.plaintext.txt	163	furthermore person established physical activity habit may precise recall person exercise sporadically
0.29024228.15781953.html.plaintext.txt	164	similarly recall number activity may reliable specific exercise frequency duration factor heavily weighted calculating total energy expenditure
0.29024228.15781953.html.plaintext.txt	165	sample number activity significantly positively correlated total physical activity energy expenditure
0.29024228.15781953.html.plaintext.txt	166	understanding component physical activity reduce dementia risk deserves attention
0.29024228.15781953.html.plaintext.txt	167	must also consider possibility reduction number different physical activity early symptom dementia
0.29024228.15781953.html.plaintext.txt	168	addressed possibility using several different approach
0.29024228.15781953.html.plaintext.txt	169	first excluded person numms score le num prevalent dementia baseline
0.29024228.15781953.html.plaintext.txt	170	however possible numms sensitive enough detect person subclinical dementing illness person included study
0.29024228.15781953.html.plaintext.txt	171	second adjusted analysis baseline cognitive function inverse association number physical activity dementia risk persisted
0.29024228.15781953.html.plaintext.txt	172	third reran analysis excluding person developed incident dementia within first year follow result essentially unchanged
0.29024228.15781953.html.plaintext.txt	173	furthermore used information physical activity two time point approximately num year apart obtain stable estimate regular physical activity older adulthood prior dementia onset
0.29024228.15781953.html.plaintext.txt	174	finally also evaluated association physical activity dementia risk excluding person one difficulty activity daily living instrumental activity daily living result similar
0.29024228.15781953.html.plaintext.txt	175	summary study provides support hypothesis engaging number different physical activity protects subsequent risk cause dementia alzheimers disease vascular dementia average num
0.29024228.15781953.html.plaintext.txt	176	num year follow although potential benefit exercise may limited apoe num noncarriers
0.29024228.15781953.html.plaintext.txt	177	physical activity already recommended enhance cardiovascular health help maintain independence quality life older adult num
0.29024228.15781953.html.plaintext.txt	178	confirmation finding substantiation biologic mechanism activity reduces dementia risk may provide additional impetus person remain become active number activity later life
0.29024228.15781953.html.plaintext.txt	179	acknowledgment research reported article supported contract nnum hc num nnum hc num nnum hc num nnum hc num national heart lung blood institute nhlbi grant agnum national institute aging
0.29024228.15781953.html.plaintext.txt	180	author thank corrine dulberg annette fitzpatrick assistance data used analysis roberto pastor barriuso help preparing figure
0.29024228.15781953.html.plaintext.txt	181	chs conducted supported nhlbi collaboration chs investigator
0.29024228.15781953.html.plaintext.txt	182	manuscript reviewed chs nhlbi scientific content consistency data interpretation previous chs publication significant comment incorporated prior submission publication
0.29024228.15781953.html.plaintext.txt	183	participating chs investigator institution investigator listed provided signed permission acknowledged
0.29024228.15781953.html.plaintext.txt	184	steering committee chairman dr
0.29024228.15781953.html.plaintext.txt	185	furberg wake forest university school medicine winston salem north carolina nhlbi project office dr
0.29024228.15781953.html.plaintext.txt	186	jean olson wake forest university school medicine dr
0.29024228.15781953.html.plaintext.txt	187	burke wake forest university ecg reading center dr
0.29024228.15781953.html.plaintext.txt	188	rautaharju university california davis dr
0.29024228.15781953.html.plaintext.txt	189	john robbins john hopkins university baltimore maryland dr
0.29024228.15781953.html.plaintext.txt	190	fried john hopkins university mri reading center dr
0.29024228.15781953.html.plaintext.txt	191	beauchamp university pittsburgh pittsburgh pennsylvania dr
0.29024228.15781953.html.plaintext.txt	192	kuller university california irvine echocardiography reading center baseline dr
0.29024228.15781953.html.plaintext.txt	193	gardin georgetown medical center echocardiography reading center washington dc follow dr
0.29024228.15781953.html.plaintext.txt	194	gottdiener new england medical center boston ultrasound reading center massachusetts dr
0.29024228.15781953.html.plaintext.txt	195	oleary university vermont central blood analysis laboratory burlington vermont dr
0.29024228.15781953.html.plaintext.txt	196	tracy university arizona tucson pulmonary reading center dr
0.29024228.15781953.html.plaintext.txt	197	paul enright retinal reading center university wisconsin madison dr
0.29024228.15781953.html.plaintext.txt	198	ronald klein university washington coordinating center seattle dr
0.29024228.15781953.html.plaintext.txt	199	full list participating chs investigator institution found following website httpwww
0.29792902.15632261.html.plaintext.txt	0	meta analysis nonsteroidal antiinflammatory drug use risk dementia anton j
0.29792902.15632261.html.plaintext.txt	1	de craen jacobijn gussekloo bram vrijsen rudi g
0.29792902.15632261.html.plaintext.txt	2	section gerontology geriatrics department general internal medicine leiden university medical center leiden netherlands
0.29792902.15632261.html.plaintext.txt	3	received publication march num num accepted publication august num num
0.29792902.15632261.html.plaintext.txt	4	alzheimer disease anti inflammatory agent non steroidal dementia meta analysis
0.29792902.15632261.html.plaintext.txt	5	abbreviation ci confidence interval nsaid nonsteroidal antiinflammatory drug
0.29792902.15632261.html.plaintext.txt	6	eligibility criterion data collection study eligible inclusion satisfied following three criterion num case control cohort study human num exposure defined use nsaid num case defined alzheimer disease dementia cognitive impairment
0.29792902.15632261.html.plaintext.txt	7	data independently extracted study two reviewer
0.29792902.15632261.html.plaintext.txt	8	recorded study design characteristic exposure definition case control prevalent incident case ascertainment total number case exposed group total number case unexposed group measure association odds ratio relative risk hazard ratio magnitude association corresponding num percent confidence interval variable adjusted analysis
0.29792902.15632261.html.plaintext.txt	9	separate result reported within one study alzheimer disease dementia result dementia recorded
0.29792902.15632261.html.plaintext.txt	10	varying level nsaid use reported took result largest group nsaid user
0.29792902.15632261.html.plaintext.txt	11	statistical analysis result cohort study typically expressed relative risk hazard ratio result case control study usually expressed odds ratio
0.29792902.15632261.html.plaintext.txt	12	hazard ratio ratio instantaneous probability outcome event alzheimer disease dementia cognitive decline exposed group compared nonexposed group considered relative risk
0.29792902.15632261.html.plaintext.txt	13	dementia rare event num percent odds ratio case control study also good estimate relative risk
0.29792902.15632261.html.plaintext.txt	14	simplicity refer relative risk three type measure association
0.29792902.15632261.html.plaintext.txt	15	logarithm relative risk corresponding standard error taken directly study calculated reported num percent confidence interval provided data point meta analysis
0.29792902.15632261.html.plaintext.txt	16	used dersimonian laird num random effect model compute pooled relative risk ass statistical heterogeneity
0.29792902.15632261.html.plaintext.txt	17	exclude outlier simply basis statistical test heterogeneity expected meta analysis epidemiologic study searched source
0.29792902.15632261.html.plaintext.txt	18	subgroup sensitivity analysis carried appropriate
0.29792902.15632261.html.plaintext.txt	19	evaluated publication bias mean visual inspection funnel plot formal statistical testing num
0.29792902.15632261.html.plaintext.txt	20	funnel plot relative risk study displayed weight study inverse square standard error
0.29792902.15632261.html.plaintext.txt	21	funnel plot generally show peak
0.29792902.15632261.html.plaintext.txt	22	point study smaller standard error found usually represents point approximate true effect
0.29792902.15632261.html.plaintext.txt	23	formal statistical assessment funnel plot asymmetry done linear regression analysis log odds ratio divided standard error regressed inverse standard error num
0.29792902.15632261.html.plaintext.txt	24	reported p value intercept regression analysis provides measure asymmetry
0.29792902.15632261.html.plaintext.txt	25	case control study incident dementia case cohort study classified study incident case
0.29792902.15632261.html.plaintext.txt	26	study cognition main outcome interest among user nonusers nsaid classified study cognitive decline case
0.29792902.15632261.html.plaintext.txt	27	description study use nonsteroidal antiinflammatory drug risk dementia table num present individual relative risk num retrieved study
0.29792902.15632261.html.plaintext.txt	28	divided report study prevalent case study incident case study cognitive decline endpoint
0.29792902.15632261.html.plaintext.txt	29	funnel plot figure num show relative risk num study plotted weight
0.29792902.15632261.html.plaintext.txt	30	relative risk smaller one indicates use nsaid beneficial
0.29792902.15632261.html.plaintext.txt	31	pooled relative risk three group study num
0.29792902.15632261.html.plaintext.txt	32	num num percent confidence interval ci num
0.29792902.15632261.html.plaintext.txt	33	num study prevalent dementia case num
0.29792902.15632261.html.plaintext.txt	34	num study incident dementia case num
0.29792902.15632261.html.plaintext.txt	35	num study cognitive decline endpoint
0.29792902.15632261.html.plaintext.txt	36	within subgroup heterogeneity present study prevalent case p num
0.29792902.15632261.html.plaintext.txt	37	num study incident case p num
0.29792902.15632261.html.plaintext.txt	38	statistical testing heterogeneity study cognitive decline used endpoint gave p value num
0.29792902.15632261.html.plaintext.txt	39	within three subgroup indication presence publication bias study prevalent case p num
0.29792902.15632261.html.plaintext.txt	40	num whereas indication study incident case p num
0.29792902.15632261.html.plaintext.txt	41	num study cognitive decline used endpoint p num
0.29792902.15632261.html.plaintext.txt	42	funnel plot relative risk num study use nonsteroidal antiinflammatory drug risk dementia
0.29792902.15632261.html.plaintext.txt	43	weight study weight calculated inverse square standard error log relative risk
0.29792902.15632261.html.plaintext.txt	44	furthermore analyzed case control study incident dementia case cohort study separately
0.29792902.15632261.html.plaintext.txt	45	case control study incident dementia case gave pooled relative risk num
0.29792902.15632261.html.plaintext.txt	46	num cohort study gave pooled relative risk estimate num
0.29792902.15632261.html.plaintext.txt	47	finally result randomized clinical trial evaluated efficacy nsaid placebo presented table num
0.29792902.15632261.html.plaintext.txt	48	trial included patient alzheimer disease patient probable alzheimer disease
0.29792902.15632261.html.plaintext.txt	49	none trial showed statistically significant reduction cognitive decline
0.29792902.15632261.html.plaintext.txt	50	least three form bias could explain benefit nsaid larger study prevalent case study incident case recall bias prescription bias publication bias
0.29792902.15632261.html.plaintext.txt	51	first subject study prevalent case impaired memory time study make data collection case control likely different resulting recall bias
0.29792902.15632261.html.plaintext.txt	52	second prescription bias occurs frequently study prevalent case demented patient reduced perception pain num num possibly leading reduced use nsaid
0.29792902.15632261.html.plaintext.txt	53	moreover adverse effect nsaid physician might le inclined prescribe nsaid demented subject
0.29792902.15632261.html.plaintext.txt	54	hence study prevalent case reduced intake nsaid might consequence dementia cause
0.29792902.15632261.html.plaintext.txt	55	third apparent funnel plot study prevalent case heterogeneous skewed left follow study resulting larger pooled estimate benefit nsaid use study
0.29792902.15632261.html.plaintext.txt	56	found difference relative risk case control study incident dementia case cohort study although potential recall bias case control study theoretically higher
0.29792902.15632261.html.plaintext.txt	57	however total number num study investigate presence recall bias rather small
0.29792902.15632261.html.plaintext.txt	58	therefore interpretation absence significant difference two type design incident dementia case interpreted caution
0.29792902.15632261.html.plaintext.txt	59	num study incident case dementia
0.29792902.15632261.html.plaintext.txt	60	within num study four case control study incident dementia case six cohort study
0.29792902.15632261.html.plaintext.txt	61	type study gave similar pooled estimate relative risk
0.29792902.15632261.html.plaintext.txt	62	recall bias major form bias relative risk case control study smaller
0.29792902.15632261.html.plaintext.txt	63	however wide confidence interval around estimate small number study difficult ascertain whether study truly equal estimate
0.29792902.15632261.html.plaintext.txt	64	significant association nsaid use study incident case dementia significant association study cognitive decline used outcome
0.29792902.15632261.html.plaintext.txt	65	prescription bias might also cause difference
0.29792902.15632261.html.plaintext.txt	66	incident subject cognitive decline relatively free cognitive dysfunction baseline incident case dementia relatively later stage disease
0.29792902.15632261.html.plaintext.txt	67	earlier stage disease prescription bias might present
0.29792902.15632261.html.plaintext.txt	68	explore whether prescription bias cause observed association nsaid use alzheimer disease whether true beneficial effect decided upon randomized clinical trial whose patient without early sign alzheimer disease num
0.29792902.15632261.html.plaintext.txt	69	period nsaid use disease onset relatively short difficult differentiate cause effect
0.29792902.15632261.html.plaintext.txt	70	short period exposure outcome reduced intake nsaid among subject dementia could also consequence disease
0.29792902.15632261.html.plaintext.txt	71	four study num num num num tried avoid bias evaluating use acetaminophen control differing pattern drug use demented nondemented subject
0.29792902.15632261.html.plaintext.txt	72	many author argued demented nondemented subject differ acetaminophen use vary nsaid use nsaid must associated better cognitive function
0.29792902.15632261.html.plaintext.txt	73	think however demented patient might report le pain nondemented subject nsaid first drug prescribed le frequently
0.29792902.15632261.html.plaintext.txt	74	mean study prevalent case likely suffer prescription bias study incident case
0.29792902.15632261.html.plaintext.txt	75	alzheimer disease common dementia insidious onset also important know different study used index date
0.29792902.15632261.html.plaintext.txt	76	study prevalent case took date diagnosis dementia three study incident dementia case took date first symptom disease num num num seven study incident dementia case used date diagnosis dementia
0.29792902.15632261.html.plaintext.txt	77	three study date onset symptom used similar relative risk estimate seven study date diagnosis used
0.29792902.15632261.html.plaintext.txt	78	publication used meta analysis originate one cohort
0.29792902.15632261.html.plaintext.txt	79	example canadian study health aging rotterdam study contributed two publication
0.29792902.15632261.html.plaintext.txt	80	however case one publication addressed association prevalent dementia case publication addressed association incident dementia case
0.29792902.15632261.html.plaintext.txt	81	hence decided include article analysis
0.29792902.15632261.html.plaintext.txt	82	moreover study named established population epidemiologic study elderly consists four cohort
0.29792902.15632261.html.plaintext.txt	83	analysis used estimate reported separate cohort
0.29792902.15632261.html.plaintext.txt	84	study reported saag et al
0.29792902.15632261.html.plaintext.txt	85	num us data iowa cohort hanlon et al
0.29792902.15632261.html.plaintext.txt	86	num use data duke cohort
0.29792902.15632261.html.plaintext.txt	87	study reported rozzini et al
0.29792902.15632261.html.plaintext.txt	88	num us data east boston massachusetts new haven connecticut iowa cohort
0.29792902.15632261.html.plaintext.txt	89	discussing result rozzini et al
0.29792902.15632261.html.plaintext.txt	90	indicate study saag et al
0.29792902.15632261.html.plaintext.txt	91	substantially different measure cognitive functioning analytical approach
0.29792902.15632261.html.plaintext.txt	92	making comparability study study problematic num p
0.29792902.15632261.html.plaintext.txt	93	including study rozzini et al
0.29792902.15632261.html.plaintext.txt	94	analysis would overweighted data iowa cohort established population epidemiologic study elderly
0.29792902.15632261.html.plaintext.txt	95	could chosen include study reported rozzini et al
0.29792902.15632261.html.plaintext.txt	96	analysis instead study saag et al
0.29792902.15632261.html.plaintext.txt	97	would resulted lower pooled relative risk
0.29792902.15632261.html.plaintext.txt	98	however including study reported rozzini et al
0.29792902.15632261.html.plaintext.txt	99	instead study saag et al
0.29792902.15632261.html.plaintext.txt	100	affect interpretation data
0.29792902.15632261.html.plaintext.txt	101	five study used cognitive decline endpoint used different cognitive measure
0.29792902.15632261.html.plaintext.txt	102	hence exclude nsaid might beneficial effect specific cognitive domain
0.29792902.15632261.html.plaintext.txt	103	however average effect use nsaid cognitive decline null consistent finding randomized trial far shown beneficial effect course dementia measured cognitive subscale alzheimer disease assessment scale
0.29792902.15632261.html.plaintext.txt	104	moreover two study excluded meta analysis num num relative risk could extracted showed association use nsaid cognitive decline
0.29792902.15632261.html.plaintext.txt	105	recent meta analysis nsaid risk dementia concluded nsaid offer protection development alzheimer disease num p
0.29792902.15632261.html.plaintext.txt	106	conclusion based mainly observation short term user num month far le risk reduction long term user num month relative risk num
0.29792902.15632261.html.plaintext.txt	107	author address possible confounding factor num explain discrepancy study prevalent case study incident case
0.29792902.15632261.html.plaintext.txt	108	discrepancy risk reduction short term long term user well explained recall bias prescription bias
0.29792902.15632261.html.plaintext.txt	109	including study cognitive decline endpoint thereby creating distance exposure effect demonstrate bias confounding likely explanation observed association
0.29792902.15632261.html.plaintext.txt	110	traditional teaching hold alzheimer disease vascular dementia two separate clinical entity differentiated careful clinical necropsy evaluation
0.29792902.15632261.html.plaintext.txt	111	several recent observation however suggest situation might different
0.29792902.15632261.html.plaintext.txt	112	vascular risk factor also contribute alzheimer disease num conversely s amyloid deposition also frequently found subject vascular dementia num
0.29792902.15632261.html.plaintext.txt	113	hence likely alzheimer disease vascular dementia two extreme expression one disease entity dementia num
0.29792902.15632261.html.plaintext.txt	114	prominent feature disease entity progressive cognitive decline
0.29792902.15632261.html.plaintext.txt	115	hence combining comparing various endpoint one analysis give good indication possible benefit nsaid various stage disease
0.29792902.15632261.html.plaintext.txt	116	randomized clinical trial found beneficial effect nsaid preventing cognitive decline num num
0.29792902.15632261.html.plaintext.txt	117	might three explanation negative study
0.29792902.15632261.html.plaintext.txt	118	first protective effect nsaid
0.29792902.15632261.html.plaintext.txt	119	second study carried subject early sign cognitive impairment
0.29792902.15632261.html.plaintext.txt	120	administration antiinflammatory drug point disease process might simply late
0.29792902.15632261.html.plaintext.txt	121	third recently demonstrated various nsaid differential propensity inflammatory response deposition s amyloid num
0.29792902.15632261.html.plaintext.txt	122	finding call identification critical pathway inflammatory response corresponding drug capable interfering pathway
0.29792902.15632261.html.plaintext.txt	123	conclusion benefit nsaid preventing dementia cognitive impairment num percent study prevalent dementia case declined num percent study incident dementia case absent study cognitive decline used endpoint
0.29792902.15632261.html.plaintext.txt	124	indicates beneficial effect nsaid observational study likely result recall bias prescription bias publication bias
0.29792902.15632261.html.plaintext.txt	125	large costly trial designed ass potential protective effect nsaid specific critical pathway inflammatory process dementia amendable drug intervention identified
0.29792902.15632261.html.plaintext.txt	126	note correspondence dr
0.29792902.15632261.html.plaintext.txt	127	de craen section gerontology geriatrics cnum r leiden university medical center p
0.29792902.15632261.html.plaintext.txt	128	box num leiden num rc netherlands e mail craenatlumc
0.3005403.12566388.html.plaintext.txt	0	identification multiple locus alzheimer disease consanguineous israeli arab community lindsay
0.3005403.12566388.html.plaintext.txt	1	farrernumnumnumnumnum abdalla bowirratnum robert p
0.3005403.12566388.html.plaintext.txt	2	friedlandnum kristin waraskanum amos d
0.3005403.12566388.html.plaintext.txt	3	numdepartment medicine genetics program numdepartment neurology numdepartment genetics genomics numdepartment epidemiology numdepartment biostatistics numcenter human genetics boston university school medicine public health boston ma num usa numdepartment neurology case western reserve university cleveland oh num usa numdepartment neurology tel aviv university tel aviv israel
0.3005403.12566388.html.plaintext.txt	4	received october num num accepted december num num
0.3005403.12566388.html.plaintext.txt	5	basis common late onset form ad le well understood
0.3005403.12566388.html.plaintext.txt	6	genetic risk factor highest attributable risk ad num allele apoe gene chromosome numq num
0.3005403.12566388.html.plaintext.txt	7	among caucasian odds ad num homozygote numnum heterozygote num
0.3005403.12566388.html.plaintext.txt	8	num respectively greater associated num homozygote num
0.3005403.12566388.html.plaintext.txt	9	many gene studied possible role gene product disease proximity known ad locus
0.3005403.12566388.html.plaintext.txt	10	evidence implicating susceptibility gene much le compelling
0.3005403.12566388.html.plaintext.txt	11	association reported fewer num gene numnum yet none clearly established ad risk factor
0.3005403.12566388.html.plaintext.txt	12	linkage study implicated region chromosome num num num num num num num num
0.3005403.12566388.html.plaintext.txt	13	candidate gene region include insulin degrading enzyme ide chromosome num num macroglobulin anumm low density lipoprotein receptor related gene lrpnum chromosome num numnumnum although none proven ad gene num num
0.3005403.12566388.html.plaintext.txt	14	report examined genetic basis dementia alzheimer type dat unique community
0.3005403.12566388.html.plaintext.txt	15	population based study screened resident age num year older nnum wadi ara arab community near tel aviv northern israel observed prevalence higher found israel china europe usa even adjustment age education gender numnum
0.3005403.12566388.html.plaintext.txt	16	unusually high prevalence apparently due increased frequency apoe num allele actually reduced community num
0.3005403.12566388.html.plaintext.txt	17	num non demented elder compared caucasian num
0.3005403.12566388.html.plaintext.txt	18	hypothesized increased prevalence dat wadi ara associated limited number unique susceptibility allele whose frequency enriched inbreeding
0.3005403.12566388.html.plaintext.txt	19	current resident wadi ara member num hamulas family group
0.3005403.12566388.html.plaintext.txt	20	recently minimal immigration emigration community
0.3005403.12566388.html.plaintext.txt	21	designed carried efficient num cm genome scan exploiting unique population structure
0.3005403.12566388.html.plaintext.txt	22	result study confirm existence dat locus chromosome num num num provide evidence new dat locus chromosome num
0.3005403.12566388.html.plaintext.txt	23	marker showing association ad genome wide scan follow study marker whose allele frequency distribution differed significantly p num
0.3005403.12566388.html.plaintext.txt	24	num case control genotyped enlarged sample num dat case num control selected entire cohort
0.3005403.12566388.html.plaintext.txt	25	result remained significant enlarged sample pursued analysis additional marker flanking positive signal
0.3005403.12566388.html.plaintext.txt	26	significant allelic association remained location chromosome num num num fig
0.3005403.12566388.html.plaintext.txt	27	also genotyped several marker region chromosome num implicated linkage study numnumnumnum genome scan evidence allelic association also found location fig
0.3005403.12566388.html.plaintext.txt	28	view larger version numk figure num
0.3005403.12566388.html.plaintext.txt	29	association ad marker chromosome num num num num
0.3005403.12566388.html.plaintext.txt	30	allelic association test result plotted
0.3005403.12566388.html.plaintext.txt	31	significance level expressed log scale
0.3005403.12566388.html.plaintext.txt	32	region showing association chromosome num num
0.3005403.12566388.html.plaintext.txt	33	num cm interval dnumsnum dnumsnum
0.3005403.12566388.html.plaintext.txt	34	significant allelic distribution difference observed dnumsnum global pnum
0.3005403.12566388.html.plaintext.txt	35	genotype level remarkable difference found dnumsnum located num cm away
0.3005403.12566388.html.plaintext.txt	36	marker num dat case num control carrier num bp allele pnum
0.3005403.12566388.html.plaintext.txt	37	chromosome num significant allelic association observed four marker located interval num num cm fig
0.3005403.12566388.html.plaintext.txt	38	association three marker dnumsnum dnumsnum dnumsnum due representation specific allele
0.3005403.12566388.html.plaintext.txt	39	examination revealed significant excess homozygosity marker allele marker allele dnumsnum dat case compared non demented subject table num
0.3005403.12566388.html.plaintext.txt	40	observation allele size num bp greater num
0.3005403.12566388.html.plaintext.txt	41	num dat case none control contributed highly significant association afmnumxfnum pnum
0.3005403.12566388.html.plaintext.txt	42	evidence additive recessive ad locus chromosome num taking account result genome scan previous linkage study evaluated intensively num cm interval chromosome num fig
0.3005403.12566388.html.plaintext.txt	43	although significant allelic association observed marker located separate linkage group e
0.3005403.12566388.html.plaintext.txt	44	num conservative conclusion dat susceptibility gene located interval num cm num
0.3005403.12566388.html.plaintext.txt	45	num cm contains four contiguous marker dnumsnum dnumsnum dnumsnum dnumsnum showing evidence allelic association fig
0.3005403.12566388.html.plaintext.txt	46	num genotypic association involving carrier associated allele data shown
0.3005403.12566388.html.plaintext.txt	47	concomitant allelic genotypic association observed two chromosome num marker dnumsnum dnumsnum
0.3005403.12566388.html.plaintext.txt	48	genotyping effort chromosome num focused region near distal lrpnum implicated linkage association study outbred population numnumnum
0.3005403.12566388.html.plaintext.txt	49	whereas association evident among marker within num cm lrpnum six marker num num cm distal lrpnum associated dat population fig
0.3005403.12566388.html.plaintext.txt	50	allele num dnumsnum present num dat case num control pnum
0.3005403.12566388.html.plaintext.txt	51	three allele numnumnum dnumsnum accounted num dat chromosome absent control pnum
0.3005403.12566388.html.plaintext.txt	52	allele num dnumsnum significantly represented pnum
0.3005403.12566388.html.plaintext.txt	53	num chromosome dat case num compared control num
0.3005403.12566388.html.plaintext.txt	54	arguably strategy genome scan high false negative rate failed detect dat locus chromosome num
0.3005403.12566388.html.plaintext.txt	55	motivated linkage finding previous study outbred population genotyped many closely spaced marker region adjacent distal lrpnum observed significant association dat
0.3005403.12566388.html.plaintext.txt	56	careful inspection result genome scan revealed two marker flanking linked region dnumsnum num
0.3005403.12566388.html.plaintext.txt	57	num cm failed show association genome scan follow fig
0.3005403.12566388.html.plaintext.txt	58	unfortunately genotyping assay one marker interval dnumsnum num
0.3005403.12566388.html.plaintext.txt	59	num cm yielded significant result follow analysis failed genome scan thus accounting false negative result locus
0.3005403.12566388.html.plaintext.txt	60	large number allele per locus table num may increased false negative rate
0.3005403.12566388.html.plaintext.txt	61	observation illustrate potentially serious limitation num cm genome scan using subject
0.3005403.12566388.html.plaintext.txt	62	nonetheless strategy successfully detected locus chromosome num num num
0.3005403.12566388.html.plaintext.txt	63	polymorphism characteristic among marker region showing linkage result study attest utility genetic isolates including region middle east num num mapping gene responsible disease susceptibility outbred caucasian population
0.3005403.12566388.html.plaintext.txt	64	strategy evaluating linkage disequilibrium microsatellite marker allele dat differs traditional linkage approach genetic isolates several respect
0.3005403.12566388.html.plaintext.txt	65	first focused effort region identified genome scan including num individual
0.3005403.12566388.html.plaintext.txt	66	second dat patient current cohort purportedly descendant num founder mating member distinct pedigree
0.3005403.12566388.html.plaintext.txt	67	gene mapping design rely linkage family based association approach num num thus suitable situation relationship individual sample distant unclear
0.3005403.12566388.html.plaintext.txt	68	third although efficacy linkage disequilibrium mapping isolated founder population recessive trait demonstrated hastbacka colleague num efficacy approach proven complex trait
0.3005403.12566388.html.plaintext.txt	69	notably allele frequency dependent homozygosity mapping method enabled localization gene recessive deafness bali using num affected individual num require evaluation dna parent thus perhaps well suited wadi ara population however effectively limited recessive trait
0.3005403.12566388.html.plaintext.txt	70	four chromosomal region implicated study reported previously suggesting may authentic locus rather chance finding
0.3005403.12566388.html.plaintext.txt	71	marker chromosome num showing significant association dat dnumsnum located num num cm two marker showing linkage disequilibrium case control sample finland num
0.3005403.12566388.html.plaintext.txt	72	chromosome num location overlap peak observed two study overlapping data set numnum chromosome num location several study numnumnumnum
0.3005403.12566388.html.plaintext.txt	73	detected evidence association chromosome num population precise region num num cm distal linkage peak observed others num numnumnum
0.3005403.12566388.html.plaintext.txt	74	thus unclear region identified chromosome num reported study
0.3005403.12566388.html.plaintext.txt	75	multiple marker tested chromosome num num num num finding reconsidered transforming p value significant result location lod score z
0.3005403.12566388.html.plaintext.txt	76	according guideline interpreting linkage result num location chromosome num num highly significant znum
0.3005403.12566388.html.plaintext.txt	77	num respectively chromosome num locus certainly suggestive linkage znum
0.3005403.12566388.html.plaintext.txt	78	significant result chromosome num znum
0.3005403.12566388.html.plaintext.txt	79	num fall cutoff num
0.3005403.12566388.html.plaintext.txt	80	num proposed suggestive linkage however finding would still considered significant replicates prior linkage finding num
0.3005403.12566388.html.plaintext.txt	81	identification multiple locus genetic isolate unexpected
0.3005403.12566388.html.plaintext.txt	82	one locus might represent false positive result although discussed four locus correspond approximate location identified study population
0.3005403.12566388.html.plaintext.txt	83	likely explanation unfortunate aggregation multiple susceptibility locus single community
0.3005403.12566388.html.plaintext.txt	84	heterogeneity consistent remarkably high prevalence dat wadi ara num
0.3005403.12566388.html.plaintext.txt	85	alternatively high prevalence dat explained oligogenic mode transmission requiring coincident inheritance susceptibility allele multiple locus
0.3005403.12566388.html.plaintext.txt	86	discrimination among hypothesis require simultaneous examination marker haplotype preferably actual susceptibility allele locus group affected non demented individual
0.3005403.12566388.html.plaintext.txt	87	wadi ara one highest prevalence rate dat world num low frequency apoe num allele non demented individual num
0.3005403.12566388.html.plaintext.txt	88	num indicates genetic basis disorder population due entirely locus num
0.3005403.12566388.html.plaintext.txt	89	low impact apoe ad risk reported yoruba living nigeria baseline frequency num num incidence ad low numnum
0.3005403.12566388.html.plaintext.txt	90	contrast pericak vance colleague observed apoe numnum genotype among ad case amish inbred religious sect num
0.3005403.12566388.html.plaintext.txt	91	however amish lower prevalence dementia wadi ara even outbred caucasian population european origin
0.3005403.12566388.html.plaintext.txt	92	non genetic factor including diet low level education physical activity may also partly responsible high prevalence disease wadi ara num
0.3005403.12566388.html.plaintext.txt	93	surprised high degree marker polymorphism suggesting might greater degree admixture population predicted see table num
0.3005403.12566388.html.plaintext.txt	94	alternatively large number allele may due relative instability microsatellilte marker generation generation
0.3005403.12566388.html.plaintext.txt	95	interestingly substantial marker polymorphism also observed study ad num member genetic isolate finland num
0.3005403.12566388.html.plaintext.txt	96	finnish study global test allelic association significant num
0.3005403.12566388.html.plaintext.txt	97	num level num num marker tested genome wide two third region confirmed follow analysis additional linked marker
0.3005403.12566388.html.plaintext.txt	98	high proportion marker heterozygosity perhaps enabling detection individual marker association hindered meaningful haplotype analysis without parental data establish linkage phase power estimating haplotype sample poor even assistance maximum likelihood approach num
0.3005403.12566388.html.plaintext.txt	99	efficacious strategy assessing linkage disequilibrium small interval defined haplotype ultimately identifying candidate gene evaluation single nucleotide polymorphism snp
0.3005403.12566388.html.plaintext.txt	100	result study implicate several potential ad gene
0.3005403.12566388.html.plaintext.txt	101	apob adamnum located candidate region chromosome num
0.3005403.12566388.html.plaintext.txt	102	apob main apolipoprotein chylomicron low density lipoprotein ldl important lipid cholesterol metabolism
0.3005403.12566388.html.plaintext.txt	103	adamnum disintegrin metalloprotease responsible snum cleavage notchnum
0.3005403.12566388.html.plaintext.txt	104	cleavage make notchnum susceptible cleavage gamma secretase like protease leading activation notch pathway num
0.3005403.12566388.html.plaintext.txt	105	analogous action presenilins also act notch pathway
0.3005403.12566388.html.plaintext.txt	106	peak chromosome num dnumsnum dnumsnum includes several gene previously associated ad including cholesterol num hydroxylase chnumh encodes membrane protein synthesizes oxysterol regulator lipid metabolism num insulin degrading enzyme ide neutral metalloproteinase shown degrade beta amyloid num important protein found plaque seen ad urinary plasminogen activator plau protease convert plasminogen plasmin elevated ad patient num
0.3005403.12566388.html.plaintext.txt	107	observation excess chromosome num marker homozygosity among dat patient consistent recessive inheritance
0.3005403.12566388.html.plaintext.txt	108	known gene familial early onset ad
0.3005403.12566388.html.plaintext.txt	109	app psnum psnum expressed autosomal dominant fashion effect apoe num one bona fide gene late onset ad ad risk additive numnum
0.3005403.12566388.html.plaintext.txt	110	although genetic modeling study based data outbred family found evidence recessive inheritance num num recessive model rejected analysis family lacking apoe num allele num
0.3005403.12566388.html.plaintext.txt	111	consanguineous population provide unique opportunity discern recessively behaving gene disease manifesting late life
0.3005403.12566388.html.plaintext.txt	112	potential caveat study lack neuropathological evidence ad patient community
0.3005403.12566388.html.plaintext.txt	113	unfortunately brain autopsy could performed violates religious custom
0.3005403.12566388.html.plaintext.txt	114	therefore possible subject dementing illness especially vascular dementia may misclassified dat
0.3005403.12566388.html.plaintext.txt	115	however concern lessened corroborating evidence brain mri scan performed portion dat patient see method
0.3005403.12566388.html.plaintext.txt	116	diagnostic validity also supported finding linkage three region previously implicated harboring ad locus
0.3005403.12566388.html.plaintext.txt	117	identification chromosomal segment showing association linkage first step toward discovery genetic defect increase susceptibility ad
0.3005403.12566388.html.plaintext.txt	118	together large amount gene information available feasible systematically identify snp potential candidate gene evaluate association ad
0.3005403.12566388.html.plaintext.txt	119	given snp map considerably dense microsatellite marker map likely candidate region reduced significantly haplotype analysis using small block snp
0.3005403.12566388.html.plaintext.txt	120	dna analysis dna extracted whole blood according procedure described previously num
0.3005403.12566388.html.plaintext.txt	121	fluorescently labeled primer microsatellite marker used study purchased applied biosytem abi used num microl pcr reaction num ng genomic dna
0.3005403.12566388.html.plaintext.txt	122	product different size fluorescent label combined applied either abi num gel based dna sequencer abi num capillary dna sequencer
0.3005403.12566388.html.plaintext.txt	123	genotyper program abi used determine allele size
0.3005403.12566388.html.plaintext.txt	124	laboratory technician blinded subject identifying information associated sample id number
0.3005403.12566388.html.plaintext.txt	125	plate contained multiple control sample ensure quality genotyping allele determination
0.3005403.12566388.html.plaintext.txt	126	statistical analysis allele genotype association assessed using sa version num
0.3005403.12566388.html.plaintext.txt	127	exact test used evaluate association genome scan global num test used follow study enlarged sample
0.3005403.12566388.html.plaintext.txt	128	number allele genotype microsatellite marker far exceeded expected genetic isolate many num allele num genotype frequency distribution global test inspected visually suggest one two single allele collapsed genotype group test
0.3005403.12566388.html.plaintext.txt	129	reported significant p value pnum
0.3005403.12566388.html.plaintext.txt	130	num based latter test unless indicated otherwise adjusted multiple testing
0.3005403.12566388.html.plaintext.txt	131	correct testing multiple marker chromosome follow study p value transformed lod score using equivalence
0.3005403.12566388.html.plaintext.txt	132	adapted allele sharing model developed kong cox num
0.3005403.12566388.html.plaintext.txt	133	lod score interpreted according criterion recommended lander kruglyak num
0.3005403.12566388.html.plaintext.txt	134	marker position obtained online genethon linkage map available www
0.3005403.12566388.html.plaintext.txt	135	footnote correspondence addressed genetics program l num boston university school medicine num albany street boston ma num usa
0.3005403.12566388.html.plaintext.txt	136	tel num num num fax num num email farreratbu
0.3005403.12566388.html.plaintext.txt	137	apoe alzheimer disease meta analysis consortium num effect age gender ethnicity association apolipoprotein e genotype alzheimer disease
0.3005403.12566388.html.plaintext.txt	138	num genetics alzheimers disease
0.3005403.12566388.html.plaintext.txt	139	num genetics late onset alzheimers disease
0.3005403.12566388.html.plaintext.txt	140	num identification novel gene late onset alzheimers disease
0.3005403.12566388.html.plaintext.txt	141	num susceptibility locus alzheimers disease chromosome num
0.3005403.12566388.html.plaintext.txt	142	num linkage plasma anum quantitative locus chromosome num late onset alzheimers disease pedigree
0.3005403.12566388.html.plaintext.txt	143	num evidence genetic linkage alzheimers disease chromosome numq
0.3005403.12566388.html.plaintext.txt	144	num complete genomic screen late onset familial alzheimer disease evidence new locus chromosome num
0.3005403.12566388.html.plaintext.txt	145	num evidence alzheimer disease susceptibility locus chromosome num locus heterogeneity
0.3005403.12566388.html.plaintext.txt	146	num chromosome num mapping late onset alzheimer disease among caribbean hispanic
0.3005403.12566388.html.plaintext.txt	147	num alpha num macroglobulin genetically associated alzheimer disease
0.3005403.12566388.html.plaintext.txt	148	num genetic association low density lipoprotein receptor related protein gene lrp apolipoprotein e receptor late onset alzheimers disease
0.3005403.12566388.html.plaintext.txt	149	num substantial linkage disequilibrium across insulin degrading enzyme locus association late onset alzheimers disease
0.3005403.12566388.html.plaintext.txt	150	num genetic association lrp receptor sporadic late onset familial alzheimer disease
0.3005403.12566388.html.plaintext.txt	151	num comprehensive examination num macroglobulin insertion deletion polymorphism alzheimer disease
0.3005403.12566388.html.plaintext.txt	152	num num macroglobulin gene early late onset alzheimer disease
0.3005403.12566388.html.plaintext.txt	153	num prevalence alzheimers type dementia elderly arab population
0.3005403.12566388.html.plaintext.txt	154	num frequency distribution alzheimers disease europe collaborative study num num prevalence finding
0.3005403.12566388.html.plaintext.txt	155	num high prevalence alzheimers disease arab population explained apoe num allele frequency
0.3005403.12566388.html.plaintext.txt	156	num chromosome num num locus late onset alzheimers disease genetic linkage case control association study
0.3005403.12566388.html.plaintext.txt	157	num fine mapping chromosome num late onset alzheimer disease locus potential genetic phenotypic heterogeneity
0.3005403.12566388.html.plaintext.txt	158	num assignment gene wilson disease chromosome num linkage esterase d locus
0.3005403.12566388.html.plaintext.txt	159	num linkage congential recessive deafness dfnbnum human chromosome numqnum middle eastern druze population evidence genetic heterogeneity
0.3005403.12566388.html.plaintext.txt	160	num linkage congenital recessive deafness dfnbnum chromosome numqnum
0.3005403.12566388.html.plaintext.txt	161	num linkage disequilibrium mapping isolated founder population diastrophic dysplasia finland
0.3005403.12566388.html.plaintext.txt	162	jr num gene congenital recessive deafness dfnbnum map pericentric region chromosome num
0.3005403.12566388.html.plaintext.txt	163	num genome wide linkage disequilibrium mapping late onset alzheimer disease finland
0.3005403.12566388.html.plaintext.txt	164	num full genome screen alzheimer disease stage ii analysis
0.3005403.12566388.html.plaintext.txt	165	num full genome scan late onset alzheimer disease
0.3005403.12566388.html.plaintext.txt	166	num evidence linking late onset alzheimer disease chromosome num
0.3005403.12566388.html.plaintext.txt	167	num genetic dissection complex trait guideline reporting interpreting linkage result
0.3005403.12566388.html.plaintext.txt	168	num lack association apolipoprotein e num alzheimers disease elderly nigerian
0.3005403.12566388.html.plaintext.txt	169	num incidence dementia alzheimer disease num community yoruba residing ibadan nigeria african american residing indianapolis indiana
0.3005403.12566388.html.plaintext.txt	170	num alzheimers disease apolipoprotein e num allele amish population
0.3005403.12566388.html.plaintext.txt	171	num genetic environmental risk factor alzheimers disease israeli arab
0.3005403.12566388.html.plaintext.txt	172	num handbook human genetic linkage
0.3005403.12566388.html.plaintext.txt	173	john hopkins university press baltimore md
0.3005403.12566388.html.plaintext.txt	174	num novel proteolytic cleavage involved notch signaling role disintegrin metalloprotease tace
0.3005403.12566388.html.plaintext.txt	175	num cdna cloning mouse human cholesterol num hydroxylases polytopic membrane protein synthesize potent oxysterol regulator lipid metabolism
0.3005403.12566388.html.plaintext.txt	176	num insulin degrading enzyme rapidly remove beta amyloid precursor protein intracellular domain aicd
0.3005403.12566388.html.plaintext.txt	177	num excessive urokinase type plasminogen activator activity euglobulin fraction patient alzheimer type dementia
0.3005403.12566388.html.plaintext.txt	178	num genetics dementia patient
0.3005403.12566388.html.plaintext.txt	179	num genetic transmission alzheimer disease among patient identified dutch population based survey
0.3005403.12566388.html.plaintext.txt	180	num multiple etiology alzheimer disease revealed segregation analysis
0.3005403.12566388.html.plaintext.txt	181	num influence apolipoprotein e genotype transmission alzheimer disease community based sample
0.3005403.12566388.html.plaintext.txt	182	num evidence major gene inheritance alzheimer disease family patient without apoe num
0.3005403.12566388.html.plaintext.txt	183	apa num diagnostic statistical manual mental disorder numth edn
0.3005403.12566388.html.plaintext.txt	184	american psychiatric association washington dc
0.3005403.12566388.html.plaintext.txt	185	num clinical diagnosis alzheimers disease report nincds adrda work group auspex department health human service task force alzheimers disease
0.3005403.12566388.html.plaintext.txt	186	num allele sharing model lod score accurate linkage test
0.30746758.9300660.html.plaintext.txt	0	genetics parkinson disease genetics parkinson disease robert l
0.30746758.9300660.html.plaintext.txt	1	laboratory genetic disease research national human genome research institute bethesda md num num usa
0.30746758.9300660.html.plaintext.txt	2	past num year research parkinson disease pd predominantly province epidemiologist interested pursuing connection disease environmental factor viral infection neurotoxin
0.30746758.9300660.html.plaintext.txt	3	hereditary influence actually discounted high monozygotic twin discordance rate found study later shown inadequate inconclusive
0.30746758.9300660.html.plaintext.txt	4	recently resurgence interest investigating hereditary factor pd became apparent positive family history major risk factor disease
0.30746758.9300660.html.plaintext.txt	5	meanwhile also became increasingly apparent neuropathological study common idiopathic form parkinson disease fact pathological correlate
0.30746758.9300660.html.plaintext.txt	6	existence lewy body eosinophilic cytoplasmic inclusion body distributed diffusely throughout substnatia nigra hypothalamus hippocampus autonomic ganglion olfactory tract
0.30746758.9300660.html.plaintext.txt	7	although candidate gene approach linkage pd family rewarding genome wide scan mapped pd numqnum num one large family pd diffuse lewy body candidate gene alpha synuclein resides
0.30746758.9300660.html.plaintext.txt	8	gene encodes presynaptic protein peptide fragment known constituent alzheimers disease plaque
0.30746758.9300660.html.plaintext.txt	9	identification missense mutation alpha synuclein gene four independent pd family suggests least fraction familial pd diffuse lewy body result abnormal protein interferes normal protein degradation leading development inclusion ultimately neuronal cell death
0.30746758.9300660.html.plaintext.txt	10	may common pathogenetic mechanism involved alpha synuclein mutation pd beta amyloid presenilin gene mutation alzheimers disease
0.30746758.9300660.html.plaintext.txt	11	parkinson disease pd first described james parkinson num num num year diagnosis remained primarily clinical one
0.30746758.9300660.html.plaintext.txt	12	disease common prevalence num num num num num united state num
0.30746758.9300660.html.plaintext.txt	13	life time risk num num making pd second common neurodegenerative disease alzheimers disease ad num
0.30746758.9300660.html.plaintext.txt	14	well num year neurologist aware significant role heredity development pd number factor quite recently hampered genetic research pd
0.30746758.9300660.html.plaintext.txt	15	first factor lack agreement precisely constitutes typical pd whether familial form disease real pd
0.30746758.9300660.html.plaintext.txt	16	attitude typified one medical school professor hospital round colleague asserted lack family history diagnostic criterion pd
0.30746758.9300660.html.plaintext.txt	17	result research pd emphasized familial form disease seen mark directed real pd
0.30746758.9300660.html.plaintext.txt	18	idea little genetic contribution etiology pd strengthened series twin study num num nums failed demonstrate increased concordance rate pd monozygotic versus dizygotic twin
0.30746758.9300660.html.plaintext.txt	19	second reason research effort may emphasized role heredity pd striking result epidemiological study linking pd environmental agent virus neurotoxin
0.30746758.9300660.html.plaintext.txt	20	much research community energy effort became focused identifying nature effect environmental agent thought responsible causing disease
0.30746758.9300660.html.plaintext.txt	21	num influenza pandemic associated encephalitis lethargica late sequela post encephalitic pd pointed viral infection major cause pd num
0.30746758.9300660.html.plaintext.txt	22	significance association seemed strong one point one investigator suggested pd would disappear num clinical entity survivor pandemic grew old died num
0.30746758.9300660.html.plaintext.txt	23	strong support environmental cause pd occurrence irreversible symptom sign pd occurring injection illicit drug preparation contaminated n methyl num phenyl numnumnumnum tetrahydropyridine mptp num num
0.30746758.9300660.html.plaintext.txt	24	mptp metabolite interfere complex electron transport chain thus depleting cell product oxidative phosphorylation exposing dopaminergic neuron substantia nigra irreversible damage energy depletion oxidative stress free radical num num
0.30746758.9300660.html.plaintext.txt	25	although viral encephalitis environmental toxin mptp clearly capable damaging substantia nigra nums seen re emergence interest genetic cause idiopathic pd primarily effort neurologist r
0.30746758.9300660.html.plaintext.txt	26	result currently much research investigating role heredity gene environment interaction causing pd
0.30746758.9300660.html.plaintext.txt	27	rather choosing false dichotomy exclusive environmental genetic etiology geneticist attempting synthesis epidemiological genetic data focusing three area inquiry inherited somatic mitochondrial genome abnormality causing defect energy metabolism ii candidate gene linkage association study gene encoding drug metabolizing enzyme iii whole genome scan locate identify gene involved family highly penetrant autosomal dominant pd
0.30746758.9300660.html.plaintext.txt	28	two excellent relatively recent review genetic aspect parkinson disease published num num
0.30746758.9300660.html.plaintext.txt	29	many area genetics definition phenotype one difficult contentious obstacle facing geneticist
0.30746758.9300660.html.plaintext.txt	30	accurate clinical diagnosis crucial trying categorize patient family genetic study certainly heterogeneous disorder multiple etiology
0.30746758.9300660.html.plaintext.txt	31	generally accepted motor symptom pd parkinsonism result deficiency dysfunction dopamine neuron producing dopamine par compacta substantia nigra regardless etiology
0.30746758.9300660.html.plaintext.txt	32	however idiopathic pd common form disease difficult approach genetic study name mean different thing different researcher
0.30746758.9300660.html.plaintext.txt	33	clinician diagnosis parkinson disease based finding least two four primary motor sign disease tremor bradykinesia muscular rigidity postural instability
0.30746758.9300660.html.plaintext.txt	34	also frequently seen considered primary diagnostic criterion dementia defect gastrointestinal motility dysautonomia responsiveness l dopa therapy
0.30746758.9300660.html.plaintext.txt	35	disease progressive usually insidious onset mid late adulthood
0.30746758.9300660.html.plaintext.txt	36	one study num num patient three quarter patient carrying diagnosis pd determined qualified neurologist actually disease confirmed autopsy
0.30746758.9300660.html.plaintext.txt	37	study clinical diagnostic criterion made stringent retrospectively specificity rose num expense drop sensitivity num
0.30746758.9300660.html.plaintext.txt	38	neuropathologist autopsy demonstration diffuse lewy body disease come hallmark pd num
0.30746758.9300660.html.plaintext.txt	39	diffuse lewy body disease lewy body characteristic intracellular cytoplasmic inclusion named beginning numth century discoverer found many region brain particularly neuron substantia nigra nucleus brain stem hypothalamus hippocampus autonomic neuron esophagus gastrointestinal tract occasionally cortex num
0.30746758.9300660.html.plaintext.txt	40	lewy body frequently found brain patient dying pd even though extreme variation age onset severity clinical manifestation pd
0.30746758.9300660.html.plaintext.txt	41	num patient carrying diagnosis pd came autopsy num patient lewy body found pd instead cause clinical sign num
0.30746758.9300660.html.plaintext.txt	42	however presence lewy body per se uniquely pathognomic pd
0.30746758.9300660.html.plaintext.txt	43	form alzheimers disease known lewy body variant ad described lewy body found brain cortex along pathognomic amyloid plaque neurofibrillary tangle ad num
0.30746758.9300660.html.plaintext.txt	44	conversely possible motor dysfunction characteristic pd even familial basis without pathological process whose characteristic marker lewy body reviewed num
0.30746758.9300660.html.plaintext.txt	45	example hereditary parkinsonism syndrome without diffuse lewy body disease include juvenile autosomal recessive parkinsonism mapping chromosome numqnum num num rapidly progressive autosomal dominant parkinsonism associated dementia dystonia disinhibition located chromosome numqnum x linked dystonia parkinsonism num num
0.30746758.9300660.html.plaintext.txt	46	well defined rare familial disorder motor sign parkinsonism common diffuse lewy body pd certainly different disease
0.30746758.9300660.html.plaintext.txt	47	case acquired parkinsonism due mptp toxicity typical lewy body pathology pd seen acute mptp exposure human monkey undergoing chronic mptp administration although atypical inclusion reported brain animal num num
0.30746758.9300660.html.plaintext.txt	48	thus past num year neurologist come accept highly prevalent disorder idiopathic pd distinctive disorder usually occurring middle late adulthood characteristic pathology diffuse lewy body disease classical motor central nervous system manifestation parkinsonism num num num
0.30746758.9300660.html.plaintext.txt	49	purpose review concentrate genetics common form disease
0.30746758.9300660.html.plaintext.txt	50	familial clustering pd observed century ago num num num num pd patient reported positive family history
0.30746758.9300660.html.plaintext.txt	51	accurate measurement frequency pd among relative affected patient made difficult inaccuracy making diagnosis pd history relative insensitivity lack specificity clinical exam variability age onset rarity autopsy data required making diagnosis diffuse lewy body disease relative reported pd
0.30746758.9300660.html.plaintext.txt	52	nums genetic contribution pd thought highly unlikely series twin study failed demonstrate increased concordance pd monozygotic versus dizygotic twin num num
0.30746758.9300660.html.plaintext.txt	53	pointed however num study interpretable number twin studied duration observation either support reject genetic contribution pd inadequate
0.30746758.9300660.html.plaintext.txt	54	nearly num function dopaminergic neuron substantia nigra must lost symptom occur num reliance clinical diagnosis alone lack follow make determination concordance extremely insensitive
0.30746758.9300660.html.plaintext.txt	55	evidence clinical evaluation determine concordance twin study far insensitive come use positron emission tomography measure numfluorodopa uptake basal ganglion num
0.30746758.9300660.html.plaintext.txt	56	concordance rate among monozygotic twin increased numfluorodopa uptake basal ganglion used diagnosis preclinical dysfunction substantia nigra num
0.30746758.9300660.html.plaintext.txt	57	result lack increased concordance twin study essentially discounted result inconclusive insensitive methodology
0.30746758.9300660.html.plaintext.txt	58	recently number epidemiological study num num differing methodological approach study population published found support familial contribution pd
0.30746758.9300660.html.plaintext.txt	59	case control study positive family history found single greatest risk factor pd num num num
0.30746758.9300660.html.plaintext.txt	60	family study family history positive pd found num num patient relative risk pd first degree relative pd patient ranged num num
0.30746758.9300660.html.plaintext.txt	61	largest study frequency pd num num first degree relative num pd patient significantly higher frequency num seen num first degree relative num age matched control num
0.30746758.9300660.html.plaintext.txt	62	attempt integrate current knowledge familial nature pd possible role defect energy metabolism causing disease toxicity mptp research proceeded two parallel track looking mitochondrial genome abnormality pd applying linkage association method affected individual using polymorphism drug metabolizing enzyme
0.30746758.9300660.html.plaintext.txt	63	modest deficiency complex electron transport chain reviewed num reported substantia nigra num muscle num num peripheral blood cell num num pd patient whether abnormality primary secondary disease process unknown
0.30746758.9300660.html.plaintext.txt	64	mitochondrial genome aging brain demonstrate striking departure normal num num analysis mitochondrial genome blood brain pd patient failed reveal consistent hereditary somatic deletion pd patient compared age matched control blood brain sample reviewed num
0.30746758.9300660.html.plaintext.txt	65	small study suggested significant association certain mitochondrial dna polymorphism pd sample size small replication ongoing num num
0.30746758.9300660.html.plaintext.txt	66	thus appears consistent abnormality oxidative phosphorylation particularly complex pd direct causative role inherited acquired mutation mitochondrial genome remains unproved
0.30746758.9300660.html.plaintext.txt	67	view possible involvement neurotoxin pd research also directed towards identifying variation certain drug metabolizing enzyme might predispose certain individual greater toxicity environmental agent
0.30746758.9300660.html.plaintext.txt	68	association study pd focused polymorphism drug metabolizing enzyme cytochrome pnumianum encoded cypianum gene debrisoquine num hydroxylase cytochrome pnum encoded cypnumdnum gene well monoamine oxidase b enzyme encoded maoa maob
0.30746758.9300660.html.plaintext.txt	69	association study always fraught difficulty arising unrecognized ascertainment bias stratification
0.30746758.9300660.html.plaintext.txt	70	unfortunately nature late onset disease mean parental genotype required permit use dependable transmission disequilibrium test association usually available num
0.30746758.9300660.html.plaintext.txt	71	nonetheless number study suggested significant association pd locus encoding cytochrome pnum enzyme monoamine oxidase
0.30746758.9300660.html.plaintext.txt	72	japan mspi restriction fragment length polymorphism cypinuma found associated num fold higher risk pd heterozygote num
0.30746758.9300660.html.plaintext.txt	73	num fold higher homozygote num
0.30746758.9300660.html.plaintext.txt	74	association study cypnumdnum gene revealed highly significant num fold increased risk among patient disease onset age num spanish population although association seen united state british sample num num
0.30746758.9300660.html.plaintext.txt	75	particular haplotype maoa locus found num fold common among pd patient compared control another haplotype num fold le common among affected patient num
0.30746758.9300660.html.plaintext.txt	76	association found maob locus num num
0.30746758.9300660.html.plaintext.txt	77	thus preliminary data support modest association certain allele locus pd history many association study replication finding difficult requires larger carefully controlled study accepted definite
0.30746758.9300660.html.plaintext.txt	78	view association apolipoprotein e allele num late onset ad num clearly interest investigate whether similar association exists pd either without dementia apolipoprotein enum allele
0.30746758.9300660.html.plaintext.txt	79	least two study failed show association num num
0.30746758.9300660.html.plaintext.txt	80	note one study find significant association apoenum lewy body variant ad pd supporting idea lewy body variant ad pd distinct disorder num
0.30746758.9300660.html.plaintext.txt	81	genetic contribution pd received substantial support identification number family pd diffuse lewy body disease inherited autosomal dominant trait num num num num
0.30746758.9300660.html.plaintext.txt	82	penetrance appeared age dependent rising num early adulthood num age num
0.30746758.9300660.html.plaintext.txt	83	one family town contursi near salerno italy num linkage analysis allowed gene pd autopsy proven diffuse lewy body disease mapped long arm chromosome num numqnum qnum num
0.30746758.9300660.html.plaintext.txt	84	positive mapping study published date although essentially negative linkage study reported variety candidate gene pedigree apparent autosomal dominant inheritance lewy body positive pd num
0.30746758.9300660.html.plaintext.txt	85	note anticipation seen family multiple generation affected pd num num ascribed primarily ascertainment bias family num
0.30746758.9300660.html.plaintext.txt	86	repeat expansion detection method failed show evidence expanded cag trinucleotide repeat contursi pd kindred num
0.30746758.9300660.html.plaintext.txt	87	sequence exon num alpha synuclein gene control individual
0.30746758.9300660.html.plaintext.txt	88	b sequence exon num mutant allele individual affected parkinson disease contursi kindred
0.30746758.9300660.html.plaintext.txt	89	arrow indicate transition mutation g resulting missense mutation ala thr position num protein
0.30746758.9300660.html.plaintext.txt	90	particularly prescient paper published num sommer rocca suggested autosomal dominant pd might caused missense mutation cellular protein change physical chemical property leading accumulation abnormal protein neuronal death num
0.30746758.9300660.html.plaintext.txt	91	hypothesis received substantial support
0.30746758.9300660.html.plaintext.txt	92	linkage mapping pd numqnum qnum contursi pedigree suggested number candidate gene pd mapped region
0.30746758.9300660.html.plaintext.txt	93	one alpha synuclein particularly good candidate
0.30746758.9300660.html.plaintext.txt	94	protein neuron specific presynaptic membrane protein num originally identified encodes peptide named nacp non abeta component ad amyloid isolated plaque ad num num
0.30746758.9300660.html.plaintext.txt	95	sequencing alpha synuclein gene affected individual contursi kindred fig
0.30746758.9300660.html.plaintext.txt	96	num revealed affected member kindred heterozygous missense mutation alanine threonine position num protein segregated pd family num
0.30746758.9300660.html.plaintext.txt	97	missense mutation found three additional unrelated pd family greek origin absent num chromosome control european population including nearly num chromosome obtained random control area near contursi
0.30746758.9300660.html.plaintext.txt	98	evidence mutation cause pd based entirely finding mutation four unrelated family finding absent large set control
0.30746758.9300660.html.plaintext.txt	99	definitive proof requires elucidation mechanism mutation cause disease
0.30746758.9300660.html.plaintext.txt	100	note nearly num different protein identified immunologically lewy body pd lewy body variant ad num including ubiquitin beta amyloid precursor protein implicated ad
0.30746758.9300660.html.plaintext.txt	101	date however published data indicating whether lewy body contain peptide derived alpha synuclein
0.30746758.9300660.html.plaintext.txt	102	interesting note nacp peptide fragment alpha synuclein unusual protein adopts extended non globular conformation known natively unfolded random coil vitro
0.30746758.9300660.html.plaintext.txt	103	random coil domain promote protein protein interaction make protein amyloidogenic vitro num
0.30746758.9300660.html.plaintext.txt	104	discovery alpha synuclein mutated predisposes high probability development pd family autosomal dominant disease suggests structural abnormality protein either changing conformation altering normal proteolytic processing may inciting event protein aggregation leading pd
0.30746758.9300660.html.plaintext.txt	105	similar pathogenic mechanism hypothesized mutant cellular protein presenilins beta amyloid causing ad num
0.30746758.9300660.html.plaintext.txt	106	num nuclear mitochondrial genetics parkinson disease
0.30746758.9300660.html.plaintext.txt	107	num twin study parkinson disease
0.30746758.9300660.html.plaintext.txt	108	num parkinson disease num pair twin set quadruplet
0.30746758.9300660.html.plaintext.txt	109	num low concordance rate parkinson disease twin
0.30746758.9300660.html.plaintext.txt	110	num parkinson disease twin
0.30746758.9300660.html.plaintext.txt	111	num study epidemiology parkinson disease predicting disappearance major clinical entity num
0.30746758.9300660.html.plaintext.txt	112	num chronic parkinsonism secondary intravenous injection meperidine analogue
0.30746758.9300660.html.plaintext.txt	113	num chronic parkinsonism human due product meperidine analog synthesis
0.30746758.9300660.html.plaintext.txt	114	num advance understanding mechanism neurotoxicity mptp related compound
0.30746758.9300660.html.plaintext.txt	115	num genetic factor etiology idiopathic parkinson disease
0.30746758.9300660.html.plaintext.txt	116	num recent advance genetics parkinson disease
0.30746758.9300660.html.plaintext.txt	117	num feature improve accuracy clinical diagnosis parkinson disease clinicopathologic study see comment
0.30746758.9300660.html.plaintext.txt	118	published erratum appears neurology num num num
0.30746758.9300660.html.plaintext.txt	119	num dementia lewy body
0.30746758.9300660.html.plaintext.txt	120	num accuracy clinical diagnosis idiopathic parkinson disease clinico pathological study num case see comment
0.30746758.9300660.html.plaintext.txt	121	num genetic evidence lewy body variant indeed phenotypic variant alzheimers disease
0.30746758.9300660.html.plaintext.txt	122	num localization gene autosomal recessive form juvenile parkinsonism chromosome numqnum
0.30746758.9300660.html.plaintext.txt	123	num localization gene rapidly progressive autosomal dominant parkinsonism dementia pallido ponto nigral degeneration chromosome numqnum
0.30746758.9300660.html.plaintext.txt	124	num assignment dystonia parkinsonism syndrome locus dytnum small region within num
0.30746758.9300660.html.plaintext.txt	125	num localization disinhibition dementia parkinsonism amyotrophy complex numqnum num
0.30746758.9300660.html.plaintext.txt	126	num anatomy pigmentation ventral dorsal subpopulation substantia nigra differential cell death parkinson disease
0.30746758.9300660.html.plaintext.txt	127	num electron microscopy lewy body amygdala parahippocampal region
0.30746758.9300660.html.plaintext.txt	128	comparison inclusion body mptp treated squirrel monkey
0.30746758.9300660.html.plaintext.txt	129	num similarity difference mptp induced parkinsonism parkinson disease
0.30746758.9300660.html.plaintext.txt	130	neuropathologic consideration
0.30746758.9300660.html.plaintext.txt	131	num clinicopathologic spectrum lewy body disease
0.30746758.9300660.html.plaintext.txt	132	num hereditary lewy body parkinsonism evidence genetic etiology parkinson disease
0.30746758.9300660.html.plaintext.txt	133	num twin study genetics parkinson disease reappraisal
0.30746758.9300660.html.plaintext.txt	134	num brain dopamine syndrome parkinson huntington
0.30746758.9300660.html.plaintext.txt	135	clinical morphological neurochemical correlation
0.30746758.9300660.html.plaintext.txt	136	num separating parkinson disease normality
0.30746758.9300660.html.plaintext.txt	137	discriminant function analysis fluorodopa f num positron emission tomography data
0.30746758.9300660.html.plaintext.txt	138	num parkinson disease twin studied numf dopa positron emission tomography
0.30746758.9300660.html.plaintext.txt	139	num risk parkinson disease among first degree relative community based study
0.30746758.9300660.html.plaintext.txt	140	num familial parkinson disease clinical genetic analysis
0.30746758.9300660.html.plaintext.txt	141	num clinical genetic study familial case parkinson disease
0.30746758.9300660.html.plaintext.txt	142	num increased risk parkinson disease parent sibling patient see comment
0.30746758.9300660.html.plaintext.txt	143	num clinical genetic study parkinson disease evidence dominant transmission
0.30746758.9300660.html.plaintext.txt	144	num genetic study parkinson disease
0.30746758.9300660.html.plaintext.txt	145	num environmental genetic risk factor parkinson disease case control study southern italy
0.30746758.9300660.html.plaintext.txt	146	num mitochondrial oxidative phosphorylation defect parkinson disease see comment
0.30746758.9300660.html.plaintext.txt	147	num mitochondrial respiratory chain activity skeletal muscle patient parkinson disease see comment
0.30746758.9300660.html.plaintext.txt	148	num brain skeletal muscle platelet homogenate mitochondrial function parkinson disease
0.30746758.9300660.html.plaintext.txt	149	num respiratory chain enzyme activity lymphocyte untreated patient parkinson disease
0.30746758.9300660.html.plaintext.txt	150	num mitochondrial dna polymorphism substantia nigra
0.30746758.9300660.html.plaintext.txt	151	num mitochondrial dna variant observed alzheimer disease parkinson disease patient
0.30746758.9300660.html.plaintext.txt	152	num mitochondrial dna sequence analysis four alzheimers parkinson disease patient
0.30746758.9300660.html.plaintext.txt	153	num tdt family based test linkage disequilibrium association editorial
0.30746758.9300660.html.plaintext.txt	154	num genetic association cytochrome pnumianum gene susceptibility parkinson disease
0.30746758.9300660.html.plaintext.txt	155	num cypnumdnum allelic frequency young onset parkinson disease
0.30746758.9300660.html.plaintext.txt	156	num debrisoquine hydroxylase gene polymorphism familial parkinson disease
0.30746758.9300660.html.plaintext.txt	157	num hereditary variation monoamine oxidase risk factor parkinson disease
0.30746758.9300660.html.plaintext.txt	158	num allelic association study monoamine oxidase b parkinson disease
0.30746758.9300660.html.plaintext.txt	159	num gene dose apolipoprotein e type num allele risk alzheimers disease late onset family
0.30746758.9300660.html.plaintext.txt	160	num frequency apolipoprotein e epsilon num allele case control study early onset parkinson disease
0.30746758.9300660.html.plaintext.txt	161	num apo e genotype multiple sclerosis parkinson disease schwannomas late onset alzheimers disease
0.30746758.9300660.html.plaintext.txt	162	num western nebraska family family d autosomal dominant parkinsonism
0.30746758.9300660.html.plaintext.txt	163	num autosomal dominant lewy body parkinsonism four generation family
0.30746758.9300660.html.plaintext.txt	164	num anticipation familial parkinson disease reanalysis num united kingdom kindred
0.30746758.9300660.html.plaintext.txt	165	num clinical genetic analysis parkinson disease contursi kindred
0.30746758.9300660.html.plaintext.txt	166	num familial autosomal dominant dopa responsive parkinson disease three living generation showing extreme anticipation childhood onset
0.30746758.9300660.html.plaintext.txt	167	num genetic anticipation parkinson disease
0.30746758.9300660.html.plaintext.txt	168	num mapping gene parkinson disease chromosome numqnum qnum
0.30746758.9300660.html.plaintext.txt	169	num genetic linkage study autosomal dominant parkinsonism evaluation seven candidate gene
0.30746758.9300660.html.plaintext.txt	170	num evidence association familial parkinson disease cag repeat expansion
0.30746758.9300660.html.plaintext.txt	171	num prion analogue twin study parkinson disease
0.30746758.9300660.html.plaintext.txt	172	num precursor protein non beta component alzheimers disease amyloid presynaptic protein central nervous system
0.30746758.9300660.html.plaintext.txt	173	num molecular cloning cdna encoding unrecognized component amyloid alzheimer disease
0.30746758.9300660.html.plaintext.txt	174	num non beta component alzheimers disease amyloid nac amyloidogenic
0.30746758.9300660.html.plaintext.txt	175	num mutation alpha synuclein gene identified family parkinson disease
0.30746758.9300660.html.plaintext.txt	176	num pathology biology lewy body
0.30746758.9300660.html.plaintext.txt	177	num nacp protein implicated alzheimers disease learning natively unfolded
0.30746758.9300660.html.plaintext.txt	178	num presenile presenilin presenilin gene early onset alzheimers disease
0.30746758.9300660.html.plaintext.txt	179	correspondence addressed
0.30746758.9300660.html.plaintext.txt	180	tel num num num num fax num num num num email rlnussnhgri
0.30746758.9300660.html.plaintext.txt	181	page maintained oup admin
0.30746758.9300660.html.plaintext.txt	182	last updated fri sep num numnumnum bst num
0.30746758.9300660.html.plaintext.txt	183	part oup journal world wide web service
0.30746758.9300660.html.plaintext.txt	184	copyright oxford university press num
0.31976065.12765971.html.plaintext.txt	0	polymorphism insulin degrading enzyme gene associated type num diabetes men nhlbi framingham heart study samer karamohamednum serkalem demissienum jeannine volcjaknum chunyu liunum nancy heard costanum jun liunum christina m
0.31976065.12765971.html.plaintext.txt	1	meigsnum peter wilsonnum larry d
0.31976065.12765971.html.plaintext.txt	2	adrienne cupplesnum alan herbertnum
0.31976065.12765971.html.plaintext.txt	3	num framingham heart study genetics laboratory department neurology boston university school medicine boston massachusetts num department biostatistics boston university school public health boston massachusetts num department medicine boston university school medicine boston massachusetts num general internal medicine clinical epidemiology unit general medicine division department medicine massachusetts general hospital harvard medical school boston massachusetts
0.31976065.12765971.html.plaintext.txt	4	one candidate gene numqnum qnum fall edge linkage peak num beneath reported group numnum insulin degrading enzyme ide insulysin ec num
0.31976065.12765971.html.plaintext.txt	5	polymorphism ide associated type num diabetes goto kakizaki gk rat model num
0.31976065.12765971.html.plaintext.txt	6	ide degrade number peptide including insulin igf ii transforming growth factor atrial natriuretic peptide oxidatively damaged protein num
0.31976065.12765971.html.plaintext.txt	7	examine association ide variant fpg mfpg hbanumc analyzed single nucleotide polymorphism snp within near ide gene sample unrelated subject set family framingham heart study fhs table num num num
0.31976065.12765971.html.plaintext.txt	8	snp position minor allele frequency fa november num draft university california santa cruz genome browser given table num shown fig
0.31976065.12765971.html.plaintext.txt	9	ass completeness map linkage disequilibrium ld region evaluated using ldmap program based malecot model one ld unit ldu defined distance kilobases association two marker fall e num fig
0.31976065.12765971.html.plaintext.txt	10	flat line indicates complete ld marker defines haplotype block
0.31976065.12765971.html.plaintext.txt	11	one haplotype block observed num end ide agreement previously published report num another num end fig
0.31976065.12765971.html.plaintext.txt	12	map thus give reasonably complete view recombination history region sample
0.31976065.12765971.html.plaintext.txt	13	view table table num descriptive statistic numnum unrelated individual sex
0.31976065.12765971.html.plaintext.txt	14	view table table num descriptive statistic num family numnum participant sex
0.31976065.12765971.html.plaintext.txt	15	view table table num marker position chromosone num relative ide
0.31976065.12765971.html.plaintext.txt	16	view larger version numk fig
0.31976065.12765971.html.plaintext.txt	17	physical map ld snp association ide locus region
0.31976065.12765971.html.plaintext.txt	18	ld estimate made using program ldmap httpcedar
0.31976065.12765971.html.plaintext.txt	19	one ldu corresponds distance association two marker reduced e num
0.31976065.12765971.html.plaintext.txt	20	position ide shown direction transcription indicated arrow
0.31976065.12765971.html.plaintext.txt	21	b snp map unrelated male subject
0.31976065.12765971.html.plaintext.txt	22	base location snp name given table num
0.31976065.12765971.html.plaintext.txt	23	plotted negative logarithm p value given table num
0.31976065.12765971.html.plaintext.txt	24	position ide shown direction transcription indicated arrow
0.31976065.12765971.html.plaintext.txt	25	examined association snp fpg n numnum hbanumc n numnum unrelated subject
0.31976065.12765971.html.plaintext.txt	26	highly significant association observed rsnum genotype fa num
0.31976065.12765971.html.plaintext.txt	27	num subject hbanumc level p num
0.31976065.12765971.html.plaintext.txt	28	snp also associated fpg p num
0.31976065.12765971.html.plaintext.txt	29	snp num ide gene rsnum fa num
0.31976065.12765971.html.plaintext.txt	30	num showed similar le significant pattern association level fpg p num
0.31976065.12765971.html.plaintext.txt	31	num marker placed num ide gene revealed significant association
0.31976065.12765971.html.plaintext.txt	32	view table table num global p value test association three genotype snp trait unrelated subject men woman
0.31976065.12765971.html.plaintext.txt	33	stronger association found rsnum sex specific analysis unrelated men pooled sample table num
0.31976065.12765971.html.plaintext.txt	34	num negative logarithm p value logp table num plotted snp position table num
0.31976065.12765971.html.plaintext.txt	35	significance association diminished slightly adjustment bmi result shown
0.31976065.12765971.html.plaintext.txt	36	view table table num global p value unrelated male subject test association genotype snp trait value
0.31976065.12765971.html.plaintext.txt	37	attempted replicate rsnum result different sample methodology testing family set using fbat num
0.31976065.12765971.html.plaintext.txt	38	additive model borderline association found rsnum level fpg p num
0.31976065.12765971.html.plaintext.txt	39	found significant association rsnum family set might expected due weaker association observed unrelated sample
0.31976065.12765971.html.plaintext.txt	40	evaluate whether particular polymorphism ide accounted linkage previously reported num num adjusted linkage model rsnum polymorphism
0.31976065.12765971.html.plaintext.txt	41	change either peak height peak position found result shown suggesting another gene present region account linkage signal
0.31976065.12765971.html.plaintext.txt	42	tested whether common polymorphism associated type num diabetes
0.31976065.12765971.html.plaintext.txt	43	unrelated subject considered rsnum snp revealed borderline association type num diabetes p num
0.31976065.12765971.html.plaintext.txt	44	sex specific analysis men conducted table num significant association type num diabetes seen p num
0.31976065.12765971.html.plaintext.txt	45	also analyzed trait using haplotype based snp rsnum minor allele rsnum minor allele c within sample unrelated men
0.31976065.12765971.html.plaintext.txt	46	statistical significance directionality association trait haplotype indicated z score presented fig
0.31976065.12765971.html.plaintext.txt	47	tt haplotype associated lower trait level cc haplotype associated higher level
0.31976065.12765971.html.plaintext.txt	48	estimated regression coefficient trait presented fig
0.31976065.12765971.html.plaintext.txt	49	numb reveal consistent trend lower trait value trait associated tt haplotype higher value cc haplotype
0.31976065.12765971.html.plaintext.txt	50	view larger version numk fig
0.31976065.12765971.html.plaintext.txt	51	two four locus haplotype analysis sample unrelated men
0.31976065.12765971.html.plaintext.txt	52	haplotype constructed using rsnum rsnum association trait fpg n num mfpg n num hbanumc n num determined empirically permutation using haplo
0.31976065.12765971.html.plaintext.txt	53	global haplotype specific p value given test
0.31976065.12765971.html.plaintext.txt	54	b regression coefficient estimate s quantitative trait odds ratio estimate qualitative trait measure association particular haplotype trait num
0.31976065.12765971.html.plaintext.txt	55	value derived using inferred haplotype probability individual predictor
0.31976065.12765971.html.plaintext.txt	56	c haplotype based four locus model hbanumc value global p num
0.31976065.12765971.html.plaintext.txt	57	lower association observed snp rsnum rsnum analyzed individually explained presence major allele haplotype high low trait value thus diminishing contrast minor allele trait value
0.31976065.12765971.html.plaintext.txt	58	adding snp rsnum minor allele rsnum minor allele improve model revealed haplotype tatt fnum associated lowest trait value haplotype ccgc fnum associated highest trait value fig
0.31976065.12765971.html.plaintext.txt	59	numc consistent two locus analysis
0.31976065.12765971.html.plaintext.txt	60	lower association observed snp rsnum rsnum analyzed individually may explained presence major allele haplotype high low trait value thus diminishing contrast minor allele trait value fig
0.31976065.12765971.html.plaintext.txt	61	haplotype analysis performed family due problem obtaining estimated haplotype presence ld num
0.31976065.12765971.html.plaintext.txt	62	also tested association two locus haplotype type num diabetes
0.31976065.12765971.html.plaintext.txt	63	global model significant whole sample tested
0.31976065.12765971.html.plaintext.txt	64	contrast global model sex specific analysis men significant indicated cc haplotype associated increased risk type num diabetes p num
0.31976065.12765971.html.plaintext.txt	65	num global simulated p value model num
0.31976065.12765971.html.plaintext.txt	66	odds ratio type num diabetes cc haplotype relative tt haplotype num
0.31976065.12765971.html.plaintext.txt	67	evaluate whether subject type num diabetes prediabetes accounted sex specific association observed men met criterion impaired plasma glucose ipg excluded analysis
0.31976065.12765971.html.plaintext.txt	68	significant global association rsnum snp glycemic trait level still seen subsidiary male dataset fpg p num
0.31976065.12765971.html.plaintext.txt	69	similarly haplotype tt associated low trait value hbanumc p num
0.31976065.12765971.html.plaintext.txt	70	num cc haplotype high trait value hbanumc p num
0.31976065.12765971.html.plaintext.txt	71	result indicate role ide locus normal glucose homeostasis
0.31976065.12765971.html.plaintext.txt	72	thus present evidence association polymorphic marker ide gene numqnum qnum level fpg mfpg hbanumc type num diabetes
0.31976065.12765971.html.plaintext.txt	73	effect rsnum rsnum trait level individual snp pronounced men
0.31976065.12765971.html.plaintext.txt	74	may partly due increased number men ipg unrelated set compared woman
0.31976065.12765971.html.plaintext.txt	75	however association still statistically significant following exclusion men ipg analysis men suggesting explanation
0.31976065.12765971.html.plaintext.txt	76	male specific susceptibility reported two murine model type num diabetes associated obesity numnum
0.31976065.12765971.html.plaintext.txt	77	one model based cross nonlt obese nzohi mouse number susceptibility gene determine threshold type num diabetes mapped none lie y chromosome num
0.31976065.12765971.html.plaintext.txt	78	android obesity previously described major risk factor type num diabetes num although association reported persist adjustment bmi
0.31976065.12765971.html.plaintext.txt	79	tt haplotype representing minor allele rsnum major allele rsnum associated lowered trait value suggesting encodes ide variant reduced activity increase efficiency insulin signaling
0.31976065.12765971.html.plaintext.txt	80	le insulin would therefore needed reduce blood glucose level
0.31976065.12765971.html.plaintext.txt	81	contrast cc haplotype ide variant may diminish insulin action leading higher trait value type num diabetes
0.31976065.12765971.html.plaintext.txt	82	association hbanumc fpg map num region ide unlikely involve protease domain enzyme lie num end gene num
0.31976065.12765971.html.plaintext.txt	83	similarly mutation ide gk rat model type num diabetes affect protease activity num
0.31976065.12765971.html.plaintext.txt	84	number alternative molecular mechanism provide plausible explanation delayed diminished action ide
0.31976065.12765971.html.plaintext.txt	85	example change num untranslated region ide may affect stability translation message altering level ide protein produced
0.31976065.12765971.html.plaintext.txt	86	alternatively coding polymorphism carboxyl terminal region protein may modify cellular localization homodimerization num interaction protein partner
0.31976065.12765971.html.plaintext.txt	87	gene numqnum qnum appear contribute linkage region reported previously others u glycemic trait num num signal fpg diminished adjustment rsnum snp
0.31976065.12765971.html.plaintext.txt	88	association study may efficient linkage study identifying genetic determinant complex trait allele frequency relatively high effect small num
0.31976065.12765971.html.plaintext.txt	89	finding consistent association see ide cc haplotype fnum twice likely associated type num diabetes tt haplotype
0.31976065.12765971.html.plaintext.txt	90	typing additional snp necessary identify gene variant numqnum num affect glucose homeostasis
0.31976065.12765971.html.plaintext.txt	91	proposed typing one snp per haplotype block sufficient genome wide association study numnum
0.31976065.12765971.html.plaintext.txt	92	show two snp rsnum rsnum haplotype block vary association trait value due different haplotype minor allele found
0.31976065.12765971.html.plaintext.txt	93	typing one snp per haplotype block may sufficient case reliably detect exclude association candidate locus complex disease
0.31976065.12765971.html.plaintext.txt	94	trait measurement previously described num
0.31976065.12765971.html.plaintext.txt	95	sample unrelated subject fpg measured exam cycle num available numnum offspring participant
0.31976065.12765971.html.plaintext.txt	96	mfpg average fpg value numnum offspring three measure fpg five exam spanned num year
0.31976065.12765971.html.plaintext.txt	97	hbanumc determined numnum individual exam num
0.31976065.12765971.html.plaintext.txt	98	family set fpg available num individual mfpg num individual hbanumc num individual
0.31976065.12765971.html.plaintext.txt	99	diabetes status type num diabetes defined either hypoglycemic medication two fpg level num mmoll num mgdl time exam num num
0.31976065.12765971.html.plaintext.txt	100	num men unrelated sample num woman classified diabetic subject table num num
0.31976065.12765971.html.plaintext.txt	101	le stringent criterion ipg defined fpg num
0.31976065.12765971.html.plaintext.txt	102	num mmoll num mgdl num h postchallenge plasma glucose num
0.31976065.12765971.html.plaintext.txt	103	num mmoll num mgdl anyone treated type num diabetes
0.31976065.12765971.html.plaintext.txt	104	questionnaire used collect information alcohol cigarette consumption hormone therapy physical activity index calculated weighted average hour spent various activity level num
0.31976065.12765971.html.plaintext.txt	105	snp scored sequenom maldi tof mass spectrometer num
0.31976065.12765971.html.plaintext.txt	106	standardized residual calculated using linear regression model incorporated age age squared age cubed sex smoking physical activity bmi alcohol consumption covariates
0.31976065.12765971.html.plaintext.txt	107	separate regression model used men woman
0.31976065.12765971.html.plaintext.txt	108	residual model ranked normalized num
0.31976065.12765971.html.plaintext.txt	109	transformation diminished slightly significance result reported
0.31976065.12765971.html.plaintext.txt	110	sample unrelated subject association trait genotype snp evaluated using regression model
0.31976065.12765971.html.plaintext.txt	111	additionally association haplotype tested using haplo
0.31976065.12765971.html.plaintext.txt	112	score num haplotype effect estimated using regression logistic procedure sa
0.31976065.12765971.html.plaintext.txt	113	haplotype effect estimated two stage procedure
0.31976065.12765971.html.plaintext.txt	114	first individual haplotype inferred em algorithm using snphap d
0.31976065.12765971.html.plaintext.txt	115	ukclaytonsoftware inferred haplotype probability used predictor regression model
0.31976065.12765971.html.plaintext.txt	116	effect measure analysis compare haplotype haplotype
0.31976065.12765971.html.plaintext.txt	117	global significance haplotype phenotype association determined using empirical p value numnum permutation obtained haplo
0.31976065.12765971.html.plaintext.txt	118	related individual family based empirical test association implemented program fbat used additive model num
0.31976065.12765971.html.plaintext.txt	119	acknowledgment fhs supported subcontract national heart lung blood institute nhlbi national institute health nih dr
0.31976065.12765971.html.plaintext.txt	120	wolf principal investigator nihnhlbi contract nonum hc num nihnhlbi nnum hc num
0.31976065.12765971.html.plaintext.txt	121	study also supported part grant american diabetes association ada dr
0.31976065.12765971.html.plaintext.txt	122	herbert principal investigator
0.31976065.12765971.html.plaintext.txt	123	supported ada career development award
0.31976065.12765971.html.plaintext.txt	124	thank staff fhs genetics laboratory work performed support study dr
0.31976065.12765971.html.plaintext.txt	125	christopher o donnell careful reading manuscript
0.31976065.12765971.html.plaintext.txt	126	earlier version manuscript reviewed dr
0.31976065.12765971.html.plaintext.txt	127	mark mccarthy thank providing preprint manuscript diabetes num press ide polymorphism u
0.31976065.12765971.html.plaintext.txt	128	footnote address correspondence reprint request alan herbert framingham heart study genetics laboratory department neurology boston university school medicine num albany st
0.31976065.12765971.html.plaintext.txt	129	received publication num october num accepted revised form num february num
0.31976065.12765971.html.plaintext.txt	130	fhs framingham heart study fpg fasting plasma glucose ide insulin degrading enzyme ipg impaired plasma glucose ld linkage disequilibrium ldu ld unit mfpg mean fpg snp single nucleotide polymorphism
0.32454574.11823323.html.plaintext.txt	0	new drug alzheimers disease dementia roger bullock mrcpsych
0.32454574.11823323.html.plaintext.txt	1	department old age psychiatry kingshill research centre avon wiltshire mental health trust victoria hospital swindon sni numhz uk
0.32454574.11823323.html.plaintext.txt	2	tel num numnum num num fax num numnum num num
0.32454574.11823323.html.plaintext.txt	3	worked clinical trial dementia major pharmaceutical company
0.32454574.11823323.html.plaintext.txt	4	background alzheimers disease management involves symptomatic drug treatment passed national institute clinical excellence
0.32454574.11823323.html.plaintext.txt	5	disease modification goal
0.32454574.11823323.html.plaintext.txt	6	aim review current developmental drug alzheimers disease usage clinical context known fact proposed specific model
0.32454574.11823323.html.plaintext.txt	7	method brief evidence based review made using literature available evidence consensus group absent
0.32454574.11823323.html.plaintext.txt	8	result good evidence support use cholinesterase inhibitor perhaps vitamin e
0.32454574.11823323.html.plaintext.txt	9	oestrogen anti inflammatory agent show possibility enough evidence support routine use
0.32454574.11823323.html.plaintext.txt	10	conclusion symptomatic treatment exist alzheimers disease
0.32454574.11823323.html.plaintext.txt	11	observational study increasing knowledge brain biology leading towards treatment option
0.32454574.11823323.html.plaintext.txt	12	old age psychiatrist valuable treatment learn use
0.32454574.11823323.html.plaintext.txt	13	cholinergic hypothesis alzheimers disease davy maloney num led development number strategy enhance failing cholinergic neuron thus neurotransmitter acetylcholine
0.32454574.11823323.html.plaintext.txt	14	consistent therapeutic effect seen using inhibitor enzyme acetylcholinesterase cleaves transmitter cholinergic synapse
0.32454574.11823323.html.plaintext.txt	15	three compound licensed treatment alzheimers disease donepezil rivastigmine galantamine
0.32454574.11823323.html.plaintext.txt	16	increased awareness alzheimers disease unfortunately cost pressure hindered development uk even though experienced user donepezil rivastigmine found consistent result cameron et al num evans et al num matthew et al num
0.32454574.11823323.html.plaintext.txt	17	acetylcholinesterase inhibitor acheis considered stepping stone better disease modifying compound bullock num
0.32454574.11823323.html.plaintext.txt	18	although undoubtedly class drug yet reached clinic acheis remain main treatment option time
0.32454574.11823323.html.plaintext.txt	19	variety protocol treatment harvey num superseded uk national institute clinical excellence num guideline use three drug
0.32454574.11823323.html.plaintext.txt	20	practical dilemma use acetylcholinesterase inhibitor
0.32454574.11823323.html.plaintext.txt	21	achei class drug affect measured domain dementia much way
0.32454574.11823323.html.plaintext.txt	22	consistency effect evident fig
0.32454574.11823323.html.plaintext.txt	23	num show cognition score averaged pivotal trial three licensed compound
0.32454574.11823323.html.plaintext.txt	24	symptomatic response lasting approximately num month followed decline remains significantly placebo group longer period
0.32454574.11823323.html.plaintext.txt	25	support preclinical cholinergic hypothesis davy maloney num
0.32454574.11823323.html.plaintext.txt	26	exciting symptomatic treatment end complex disease process analogous use levodopa parkinson disease
0.32454574.11823323.html.plaintext.txt	27	achei class continues present practical scientific challenge clinician need resolved meanwhile different treatment continue development
0.32454574.11823323.html.plaintext.txt	28	view larger version numk fig
0.32454574.11823323.html.plaintext.txt	29	num combined clinical trial data three licensed acetylcholinesterase inhibitor rivastigmine donepezil galantamine versus placebo
0.32454574.11823323.html.plaintext.txt	30	graph show change cognition score patient assessed num week interval positive change improvement
0.32454574.11823323.html.plaintext.txt	31	ada cog alzheimers disease assessment scale cognitive section
0.32454574.11823323.html.plaintext.txt	32	trial acheis response measured scale used found average num patient studied corey bloom et al num rogers et al num raskind et al num
0.32454574.11823323.html.plaintext.txt	33	compare favourably drug chronic illness acheis low number needed treat nnts livingston katona num
0.32454574.11823323.html.plaintext.txt	34	using score published data donepezil nnt num rivastigmine num galantamine num
0.32454574.11823323.html.plaintext.txt	35	high placebo response often questioned common mental health study mask large non drug treatment effect
0.32454574.11823323.html.plaintext.txt	36	responder non responder identified criterion may harsh nature response need research definition
0.32454574.11823323.html.plaintext.txt	37	currently hard predictor response non response identified schneider farlow num
0.32454574.11823323.html.plaintext.txt	38	apoenum allele suggested marker poor response subsequent study suggested correlation
0.32454574.11823323.html.plaintext.txt	39	absence valid biological marker alzheimers disease measuring effect intervention may disease requires patient treated reasonable length time perhaps num month
0.32454574.11823323.html.plaintext.txt	40	reality depends economics uk prescribers tend work subset mild moderate dementia excluding institutional patient advanced disease prescribing community based patient medication supervised ratified nice guideline
0.32454574.11823323.html.plaintext.txt	41	various model prescribing exist involving titration dose minimise side effect particularly gastrointestinal one
0.32454574.11823323.html.plaintext.txt	42	donepezil advantage two dose step rivastigmine galantamine offer wider range making tailoring individual patient perhaps precise
0.32454574.11823323.html.plaintext.txt	43	whichever drug chosen dose taken maximum tolerated within licence least num month treatment given considering whether inadequate response
0.32454574.11823323.html.plaintext.txt	44	rigidity may mean late responder miss potential benefit within limited budget allow patient exposure treatment
0.32454574.11823323.html.plaintext.txt	45	one drug work intolerable side effect another tried although three drug belong class different
0.32454574.11823323.html.plaintext.txt	46	published information switching drug
0.32454574.11823323.html.plaintext.txt	47	convention switching drug leave interval five time half life first drug commencing second num hour rivastigmine num day donepezil
0.32454574.11823323.html.plaintext.txt	48	consensus suggests num day left treatment rivastigmine galantamine week left following donepezil treatment
0.32454574.11823323.html.plaintext.txt	49	based clinical practice controlled trial published
0.32454574.11823323.html.plaintext.txt	50	three drug similar yet different individual characteristic table num
0.32454574.11823323.html.plaintext.txt	51	clinically relevant difference unproven interesting hypothesis arising
0.32454574.11823323.html.plaintext.txt	52	view table table num attribute three licensed acetylcholinesterase inhibitor
0.32454574.11823323.html.plaintext.txt	53	donepezil donepezil selective acetylcholinesterase ache
0.32454574.11823323.html.plaintext.txt	54	selectivity claimed reduce side effect profile published clinical data shown increased tolerability
0.32454574.11823323.html.plaintext.txt	55	paradoxically alzheimers disease level ache fall disease progress arendt num matched rise butyrylcholinesterase buche function unknown form part plaque appears come activated glial cell
0.32454574.11823323.html.plaintext.txt	56	buche inhibition mean unclear rivastigmine galantamine inhibit donepezil may work differently later disease although published evidence supported
0.32454574.11823323.html.plaintext.txt	57	rivastigmine rivastigmine preferentially inhibits one four ache subtypes gnum found particularly hypothalamus cortex
0.32454574.11823323.html.plaintext.txt	58	subtype implicated plaque maturation whether added clinical benefit specificity unproven
0.32454574.11823323.html.plaintext.txt	59	galantamine galantamine produce effect presynaptic nicotinic receptor called allosteric modulation physostigmine codeine
0.32454574.11823323.html.plaintext.txt	60	produce increased amount acetylcholine synapse direct effect presynaptic release clinical impact unknown published evidence significance desirability required
0.32454574.11823323.html.plaintext.txt	61	may modulation rather agonism protects downregulation post synaptic receptor
0.32454574.11823323.html.plaintext.txt	62	may allow drug work longer study needed confirm
0.32454574.11823323.html.plaintext.txt	63	modulation also improves attention demonstrated galantamine donepezil rivastigmine alzheimers disease
0.32454574.11823323.html.plaintext.txt	64	drug licensed mild moderate alzheimers disease
0.32454574.11823323.html.plaintext.txt	65	patient mild disease already significant illness receive treatment even minimal symptom
0.32454574.11823323.html.plaintext.txt	66	treating mildly affected patient mean smaller response protocol reflect long term follow needed show continuing effect beyond expected clinical trial
0.32454574.11823323.html.plaintext.txt	67	moderate disease cover wide range morbidity trial mini mental state examination mmse folstein et al num score num nice guideline num
0.32454574.11823323.html.plaintext.txt	68	patient scoring lower end range host symptom acheis may valuable symptomatic effect behaviour effect underlying disease
0.32454574.11823323.html.plaintext.txt	69	trial data metrifonate another achei withdrawn side effect showed improvement neuropsychiatric symptom alzheimers disease especially apathy hallucination agitation cummings et al num
0.32454574.11823323.html.plaintext.txt	70	effect noticeable dementia lewy body improvement mmse score neuropsychiatric symptom demonstrated rivastigmine mckeith et al num
0.32454574.11823323.html.plaintext.txt	71	suggests dementia treated time symptomatic delay retention qualify life aim early disease moving towards symptomatic relief progression occurs
0.32454574.11823323.html.plaintext.txt	72	published result available severe dementia though open label follow trial suggests drug continue working cholinergic deficit increase
0.32454574.11823323.html.plaintext.txt	73	acheis dementia plus cholinergic therapy clinical trial ongoing acheis vascular dementia mixed dementia
0.32454574.11823323.html.plaintext.txt	74	result available yet cholinergic system implicated disorder hoped finding positive
0.32454574.11823323.html.plaintext.txt	75	study rivastigmine dementia lewy body produced positive result mckeith et al num
0.32454574.11823323.html.plaintext.txt	76	acetylcholinesterases studied potential treatment mild cognitive impairment rational assumption num patient problem go develop alzheimers disease intervention may profound effect burden disease overall
0.32454574.11823323.html.plaintext.txt	77	study anticholinergic therapy frontotemporal dementia way present
0.32454574.11823323.html.plaintext.txt	78	muscarinic agonist tried alzheimers disease drug narrow therapeutic window side effect become intolerable date clinical trial shown significant effect cognition
0.32454574.11823323.html.plaintext.txt	79	nicotinic drug also still early trial stage similar tolerability problem overcome promising efficacy data
0.32454574.11823323.html.plaintext.txt	80	research alzheimers disease led understanding pathological mechanism involved
0.32454574.11823323.html.plaintext.txt	81	inflammation occurs evidenced inflammatory marker found example complement attack complex level similar found ischaemic heart disease mcgeer mcgeer num
0.32454574.11823323.html.plaintext.txt	82	basic science coupled observation sufferer rheumatoid arthritis lower rate alzheimers disease stewart et al num led trial anti inflammatory drug treatment alzheimers disease
0.32454574.11823323.html.plaintext.txt	83	trial prednisolone successful ongoing work cyclo oxygenase inhibitor especially cox num animal human clinical trial may show benefit
0.32454574.11823323.html.plaintext.txt	84	drug without long term side effect current practice recommend use routinely
0.32454574.11823323.html.plaintext.txt	85	another observational study shown woman hormone replacement therapy hrt reduced rate alzheimers disease robinson et al num
0.32454574.11823323.html.plaintext.txt	86	protective effect oestrogen nervous system vasculature well documented birge num clinical trial progress test efficacy oestrogen therapy num oestradiol particularly
0.32454574.11823323.html.plaintext.txt	87	early treatment study result encouraging mulnard et al num absence published positive study hrt recommended use treatment alzheimers disease although seem use increasing alzheimers disease prophylaxis particularly usa
0.32454574.11823323.html.plaintext.txt	88	antioxidant shown benefit several area chronic ill health including alzheimers disease study selegiline vitamin e effect disease progression sano et al num
0.32454574.11823323.html.plaintext.txt	89	showed positive effect rate increasing dependency delayed institutionalisation
0.32454574.11823323.html.plaintext.txt	90	however yet replicated
0.32454574.11823323.html.plaintext.txt	91	vitamin e inexpensive relatively safe trial high dosage num iu
0.32454574.11823323.html.plaintext.txt	92	institutionalisation expensive return treatment potentially high rigorously proven
0.32454574.11823323.html.plaintext.txt	93	many clinic routinely suggesting use vitamin e patient alzheimers disease usually num iu
0.32454574.11823323.html.plaintext.txt	94	possible may benefit dementia neurodegenerative disease well
0.32454574.11823323.html.plaintext.txt	95	nootropic drug available prescription germany best known gingko biloba extract nicergoline piracetam
0.32454574.11823323.html.plaintext.txt	96	precise mode action unclear yet seem produce effect well controlled study
0.32454574.11823323.html.plaintext.txt	97	glutamate increasingly implicated dementia pathogenesis n methyl d aspartate nmda blockade putative therapy
0.32454574.11823323.html.plaintext.txt	98	memantine nmda blocker positive result reported severe alzheimers disease e
0.32454574.11823323.html.plaintext.txt	99	winblad poritis num leading application regulatory approval use dementia
0.32454574.11823323.html.plaintext.txt	100	nerve cell destruction seems secondary activation glial cell stabilisation glial cell may reduce rate alzheimers disease dementia
0.32454574.11823323.html.plaintext.txt	101	several compound propentofylline purportedly effect especially vitro date shown therapeutic effect clinically
0.32454574.11823323.html.plaintext.txt	102	remains potential area research
0.32454574.11823323.html.plaintext.txt	103	cortical cholinergic system diffusely spread long way cell body
0.32454574.11823323.html.plaintext.txt	104	therefore dependent nerve growth factor ngf sustain reduction ngf may associated alzheimers disease
0.32454574.11823323.html.plaintext.txt	105	study injecting ngf cannulae cerebrospinal fluid showed effect practical solution
0.32454574.11823323.html.plaintext.txt	106	attempt formulate active portion ngf oral preparation cross blood brain barrier ongoing meanwhile xanthine derivative leteprinim potassium seems stimulating effect ngf start clinical trial
0.32454574.11823323.html.plaintext.txt	107	pathological basis alzheimers disease presence amyloid plaque neurofibrillary tangle
0.32454574.11823323.html.plaintext.txt	108	work focused amyloid cascade produce plaque various drug development modify amyloid metabolism
0.32454574.11823323.html.plaintext.txt	109	imminent clinical trial injection beta amyloid protein vaccinate individual produce antibody response might remove amyloid nervous tissue
0.32454574.11823323.html.plaintext.txt	110	mouse procedure relieved symptom genetic alzheimers disease animal model schenk et al num prevented plaque formation younger mouse
0.32454574.11823323.html.plaintext.txt	111	method tried human uk usa represents first true attempt disease modification
0.32454574.11823323.html.plaintext.txt	112	classical pathological change development tangle made abnormal tau protein
0.32454574.11823323.html.plaintext.txt	113	tau pathology known exist neurodegenerative condition important area research treating dementing disease frontotemporal dementia progressive supranuclear palsy
0.32454574.11823323.html.plaintext.txt	114	hyperphosphorylation occurs alzheimers disease may amenable therapeutic intervention experimental model support drug clinical trial yet
0.32454574.11823323.html.plaintext.txt	115	basic science research gradually unlocking pathological sequence dementia especially alzheimers disease provide theoretical treatment opportunity
0.32454574.11823323.html.plaintext.txt	116	began acheis stage amyloid modification
0.32454574.11823323.html.plaintext.txt	117	first time therapeutic option exist alzheimers disease soon available dementia
0.32454574.11823323.html.plaintext.txt	118	may simple using vitamin e combination therapy maximise benefit table num
0.32454574.11823323.html.plaintext.txt	119	although treatment still predominantly symptomatic offer relief patient increased clinician awareness condition
0.32454574.11823323.html.plaintext.txt	120	taken old age psychiatry root social psychiatry point psychopharmacology important role
0.32454574.11823323.html.plaintext.txt	121	challenge learn use treatment effectively
0.32454574.11823323.html.plaintext.txt	122	mean everyone speciality us treatment opportunity contribute debate prospect development next num year make one exciting dynamic area medicine work
0.32454574.11823323.html.plaintext.txt	123	view table table num current potential treatment dementia
0.32454574.11823323.html.plaintext.txt	124	clinical implication limitation
0.32454574.11823323.html.plaintext.txt	125	clinical implication anticholinesterase therapy major contribution therapeutic treatment regimen alzheimers disease endorsed national institute clinical excellence
0.32454574.11823323.html.plaintext.txt	126	psychopharmacology alzheimers disease important addition old age psychiatrist skill professional development requirement
0.32454574.11823323.html.plaintext.txt	127	service need move towards diagnosis early mild dementia rather intervene moderate severe stage
0.32454574.11823323.html.plaintext.txt	128	limitation funding new drug may hard obtain especially area basic service need unmet require attention first
0.32454574.11823323.html.plaintext.txt	129	symptomatic treatment need drug change course illness
0.32454574.11823323.html.plaintext.txt	130	single therapy likely solution alzheimers disease
0.32454574.11823323.html.plaintext.txt	131	need learn best use cholinesterase inhibitor combine new drug arrive
0.32454574.11823323.html.plaintext.txt	132	initiated level primary care
0.32454574.11823323.html.plaintext.txt	133	author thanks colleague used drug date participation various consensus group order fill gap review evidence remains weak
0.32454574.11823323.html.plaintext.txt	134	num change acetylcholinesterase butyrylcholinesterase alzheimers disease resemble embryonic development study molecular form
0.32454574.11823323.html.plaintext.txt	135	neurochemistry international num num num
0.32454574.11823323.html.plaintext.txt	136	num role oestrogen treatment alzheimers disease
0.32454574.11823323.html.plaintext.txt	137	num drug treatment early alzheimers disease
0.32454574.11823323.html.plaintext.txt	138	advance psychiatric treatment num num num
0.32454574.11823323.html.plaintext.txt	139	et al num use donepezil treatment mild moderate alzheimers disease audit assessment treatment patient routine clinical practice
0.32454574.11823323.html.plaintext.txt	140	international journal geriatric psychiatry num num num
0.32454574.11823323.html.plaintext.txt	141	conum mlinktypedoicrossrefmedline
0.32454574.11823323.html.plaintext.txt	142	ena num enum study group num randomised trial evaluating efficacy safety ena num rivastigmine tartrate new acetylcholinesterase inhibitor patient mild moderately severe alzheimers disease
0.32454574.11823323.html.plaintext.txt	143	international journal geriatric psychopharmacology num num num
0.32454574.11823323.html.plaintext.txt	144	et al num metrifonate treatment cognitive deficit alzheimers disease
0.32454574.11823323.html.plaintext.txt	145	num selective loss central cholinergic neurones alzheimers disease
0.32454574.11823323.html.plaintext.txt	146	et al num sustained cognitive improvement following treatment alzheimers disease donepezil
0.32454574.11823323.html.plaintext.txt	147	international journal geriatric psychiatry num num num
0.32454574.11823323.html.plaintext.txt	148	conum mlinktypedoicrossrefmedline
0.32454574.11823323.html.plaintext.txt	149	num mini mental state practical method grading cognitive state patient clinician
0.32454574.11823323.html.plaintext.txt	150	journal psychiatric research num num num
0.32454574.11823323.html.plaintext.txt	151	num review commentary sample num uk guideline drug treatment alzheimers disease
0.32454574.11823323.html.plaintext.txt	152	international journal geriatric psychiatry num num num
0.32454574.11823323.html.plaintext.txt	153	conum tlinktypedoicrossrefmedline
0.32454574.11823323.html.plaintext.txt	154	num useful cholinesterase inhibitor treatment alzheimers disease number needed treat analysis
0.32454574.11823323.html.plaintext.txt	155	international journal geriatric psychiatry num num num
0.32454574.11823323.html.plaintext.txt	156	conum numlinktypedoicrossrefmedline
0.32454574.11823323.html.plaintext.txt	157	et al num donepezil alzheimers disease eighteen month result southampton memory clinic
0.32454574.11823323.html.plaintext.txt	158	international journal geriatric psychiatry num num num
0.32454574.11823323.html.plaintext.txt	159	conum ilinktypedoicrossrefmedline
0.32454574.11823323.html.plaintext.txt	160	num mechanism cell death alzheimers disease immunopathology
0.32454574.11823323.html.plaintext.txt	161	journal neuronal transmission num suppl
0.32454574.11823323.html.plaintext.txt	162	et al num rivastigmine treatment dementia lewy body preliminary finding open trial
0.32454574.11823323.html.plaintext.txt	163	international journal geriatric psychiatry num num num
0.32454574.11823323.html.plaintext.txt	164	conum numlinktypedoicrossrefmedline
0.32454574.11823323.html.plaintext.txt	165	et al num estrogen replacement therapy treatment mild moderate alzheimer disease
0.32454574.11823323.html.plaintext.txt	166	national institute clinical excellence num guidance use donepezil rivastigmine galantamine treatment alzheimers disease
0.32454574.11823323.html.plaintext.txt	167	et al num galantamine ad num month randomized placebo controlled trial num month extension
0.32454574.11823323.html.plaintext.txt	168	et al num estrogen replacement therapy memory older woman
0.32454574.11823323.html.plaintext.txt	169	journal american geriatric society num num num
0.32454574.11823323.html.plaintext.txt	170	et al num num week double blind placebo controlled trial donepezil patient alzheimers disease
0.32454574.11823323.html.plaintext.txt	171	et al num controlled trial selegiline alpha tocopherol treatment alzheimers disease
0.32454574.11823323.html.plaintext.txt	172	new england journal medicine num num num
0.32454574.11823323.html.plaintext.txt	173	et al num immunisation s amyloid attenuates alzheimer disease like pathology pdapp mouse
0.32454574.11823323.html.plaintext.txt	174	num predicting response cholinesterase inhibitor alzheimers disease possible approach
0.32454574.11823323.html.plaintext.txt	175	et al num risk alzheimers disease duration nsaid use
0.32454574.11823323.html.plaintext.txt	176	num memantine severe dementia result m best study benefit efficacy severely demented patient treatment memantine
0.32454574.11823323.html.plaintext.txt	177	international journal geriatric psychiatry num num num
0.32454574.11823323.html.plaintext.txt	178	conum numlinktypedoicrossrefmedline
0.32454574.11823323.html.plaintext.txt	179	received publication april num num
0.32454574.11823323.html.plaintext.txt	180	revision received may num num
0.32454574.11823323.html.plaintext.txt	181	accepted publication june num num
0.32454574.11823323.html.plaintext.txt	182	highlight issue elizabeth walsh bjp num num num
0.32454574.11823323.html.plaintext.txt	183	old age psychiatry alistair burn ian g
0.34450078.11823322.html.plaintext.txt	0	genotype phenotype alzheimers disease clive holmes mrcpsych
0.34450078.11823322.html.plaintext.txt	1	thornhill research unit university southampton moorgreen hospital botley road west end southampton sonum numjb uk
0.34450078.11823322.html.plaintext.txt	2	background patient alzheimers disease show wide variation clinical phenotype
0.34450078.11823322.html.plaintext.txt	3	genetic research largely concerned role mutation common variant risk factor disease
0.34450078.11823322.html.plaintext.txt	4	genetic factor also influence clinical phenotype
0.34450078.11823322.html.plaintext.txt	5	aim examine evidence genetic factor influence clinical expression disease addition influencing risk
0.34450078.11823322.html.plaintext.txt	6	method selective review made key literature
0.34450078.11823322.html.plaintext.txt	7	result mutation three gene coding amyloid precursor protein presenilin num presenilin num common variation num another gene apoe shown lead earlier development disease
0.34450078.11823322.html.plaintext.txt	8	recently genetic association twin study suggested role genetic factor development aspect clinical phenotype notably appearance non cognitive symptom
0.34450078.11823322.html.plaintext.txt	9	conclusion alzheimers disease genetic variation influence number aspect clinical phenotype
0.34450078.11823322.html.plaintext.txt	10	early family twin study indicated number gene important part play development alzheimers disease
0.34450078.11823322.html.plaintext.txt	11	variation gene including rare mutation common polymorphism appears confer increased risk development disease
0.34450078.11823322.html.plaintext.txt	12	however apparent increased risk may largely explained effect genetic variation clinical phenotype alzheimers disease particularly age disease present
0.34450078.11823322.html.plaintext.txt	13	recently proposed genetic variation may also explain feature clinical phenotype including development non cognitive symptom
0.34450078.11823322.html.plaintext.txt	14	clearest evidence genetic contribution aetiology alzheimers disease existence family disease transmitted clear autosomal dominant pattern
0.34450078.11823322.html.plaintext.txt	15	study one large pedigree revealed transmission generation generation single point mutation gene amyloid precursor protein app found chromosome num family member developing early onset alzheimers disease
0.34450078.11823322.html.plaintext.txt	16	study family led discovery point mutation gene later presence mutation two gene encoding presenilin num p num presenilin num p num found chromosome num num respectively
0.34450078.11823322.html.plaintext.txt	17	date num alzheimers disease related mutation discovered app gene num mutation p num gene num mutation p num gene
0.34450078.11823322.html.plaintext.txt	18	significantly research suggests different mutation three gene lead common result increase s anum peptide fragment app form core neuritic plaque found brain people alzheimers disease
0.34450078.11823322.html.plaintext.txt	19	finding immense importance term elucidating biological pathogenesis alzheimers diease important recognise three causal gene may account num num autosomal dominant early onset case around num familial early onset case cruts et al num
0.34450078.11823322.html.plaintext.txt	20	thus given majority case num alzheimers disease occurs age num year clear genetic mutation make small contribution risk developing disease general
0.34450078.11823322.html.plaintext.txt	21	inheritance late onset alzheimers disease complex early onset form
0.34450078.11823322.html.plaintext.txt	22	cross sectional study presence positive family history late onset alzheimers disease consistent risk factor subject late onset form clear autosomal dominant pattern inheritance rare
0.34450078.11823322.html.plaintext.txt	23	twin family study suggest polygenic multifactorial mode inheritance consequence elucidation genetic risk factor late onset alzheimers disease requires different method used early onset disease simple mendelian pattern inheritance
0.34450078.11823322.html.plaintext.txt	24	association study far dominated genetics late onset alzheimers disease
0.34450078.11823322.html.plaintext.txt	25	study look variation frequency allele sample unrelated patient late onset alzheimers disease compared unrelated control subject
0.34450078.11823322.html.plaintext.txt	26	study resulted number candidate gene proposed importance risk factor late onset alzheimers disease include association variation gene encoding low density lipoprotein vldl receptor p num intronic mutation associated early onset alzheimers disease butyrylcholinesterase angiotensin num converting enzyme num antichymotrypsin human leucocyte antigen hla complex num macroglobulin low density lipoprotein like receptor serotonin transporter interleukin num
0.34450078.11823322.html.plaintext.txt	27	typically interest candidate diminished independent replication forthcoming little evidence remains important role genetic variation vldl receptor p num num antichymotrypsin gene development late onset alzheimers disease
0.34450078.11823322.html.plaintext.txt	28	candidate gene still advocate remain hotly disputed
0.34450078.11823322.html.plaintext.txt	29	recently result number linkage study become available
0.34450078.11823322.html.plaintext.txt	30	method used linkage study complex non mendelian disease late onset alzheimers disease le powerful used early onset form
0.34450078.11823322.html.plaintext.txt	31	however study reveal area interest genome might later explored association study
0.34450078.11823322.html.plaintext.txt	32	complete genomic screen series multiplex family affected late onset alzheimers disease revealed five region interest chromosome num num num num num
0.34450078.11823322.html.plaintext.txt	33	excluding effect apoenum locus maximum log likelihood ratio lod score study occurred region located short arm chromosome num pericak vance et al num
0.34450078.11823322.html.plaintext.txt	34	however two subsequent study following similar method blacker et al num wu et al num unable confirm linkage area
0.34450078.11823322.html.plaintext.txt	35	large sibpair study kehoe et al num revealed many possible locus showing linkage late onset alzheimers disease
0.34450078.11823322.html.plaintext.txt	36	include locus chromosome num num num num num num num close apoe num close app gene
0.34450078.11823322.html.plaintext.txt	37	currently main focus attention chromosome num two independent study showing evidence susceptibility locus region ertekin taner et al num myers et al num
0.34450078.11823322.html.plaintext.txt	38	however clear large number locus implicated disagreement study predicted area interest
0.34450078.11823322.html.plaintext.txt	39	finding demonstrate limitation approach also serve emphasise polygenic nature late onset alzheimers disease
0.34450078.11823322.html.plaintext.txt	40	exploration area association study positional candidate approach likely dominate genetics alzheimers disease future
0.34450078.11823322.html.plaintext.txt	41	genetic risk factor advocated role development late onset alzheimers disease least controversial remains increased risk associated possession one copy apoenum allele coding apolipoprotein e apoe variant num
0.34450078.11823322.html.plaintext.txt	42	significantly importance apoenum determined using positional candidate gene approach
0.34450078.11823322.html.plaintext.txt	43	since finding study artiga et al num bullido et al num lambert et al num also suggested association number polymorphism within transcriptional regulatory region apoe gene late onset alzheimers disease independent apoe num status
0.34450078.11823322.html.plaintext.txt	44	based data suggested two independent mechanism risk late onset alzheimers disease modified apoe gene first variation coding region alter functional property apoe second presence promoter variant result quantitative difference apoe expression artiga et al num
0.34450078.11823322.html.plaintext.txt	45	however hypothesis controversial recent study helisalmi et al num zurutuza et al num failed support independence apoe promoter variant development alzheimers disease
0.34450078.11823322.html.plaintext.txt	46	genetic influence clinical phenotype
0.34450078.11823322.html.plaintext.txt	47	age onset family carrying mutation app gene age onset largely within range num num year
0.34450078.11823322.html.plaintext.txt	48	date app mutation carrier reported unaffected beyond age num year
0.34450078.11823322.html.plaintext.txt	49	family carrying mutation p num gene earliest age onset fall largely within range num num year although one family member recently recorded onset num year wisniewski et al num
0.34450078.11823322.html.plaintext.txt	50	mutation largely associated early onset familial alzheimers disease least two mutation alanumval hisnumtyr observed late onset alzheimers disease may non penetrant cruts et al num
0.34450078.11823322.html.plaintext.txt	51	family carrying mutation p num gene age onset largely within range num num year thus show overlap late onset alzheimers disease
0.34450078.11823322.html.plaintext.txt	52	penetrance high may num least two reported case non penetrance age num year bird et al num
0.34450078.11823322.html.plaintext.txt	53	familial influence age onset late onset alzheimers disease may substantial
0.34450078.11823322.html.plaintext.txt	54	thus one study affected sib pair suggests shared familial effect may account num variance tunstall et al num
0.34450078.11823322.html.plaintext.txt	55	indeed study shown late onset disease age onset approximately num year earlier individual carry two copy apoenum allele compared non carrier
0.34450078.11823322.html.plaintext.txt	56	led suggestion apoenum allele risk factor alzheimers disease mainly old age alzheimers disease death competing risk
0.34450078.11823322.html.plaintext.txt	57	factor leading earlier age onset alzheimers disease elderly hence development disease prior death associated alzheimers disease
0.34450078.11823322.html.plaintext.txt	58	evidence confirming hypothesis come large study approximately num individual meyer et al num
0.34450078.11823322.html.plaintext.txt	59	study showed clear decline relative risk developing late onset alzheimers disease subject increasing age clear plateau beyond new case disease reported
0.34450078.11823322.html.plaintext.txt	60	age plateau reached earlier carrier apoenum allele
0.34450078.11823322.html.plaintext.txt	61	thus appears clear apoenum allele predominant effect determining individual develops late onset alzheimers disease meyer et al num
0.34450078.11823322.html.plaintext.txt	62	non cognitive feature genetic risk factor alzheimers disease associated non cognitive symptom one might anticipate subject family history disease increased frequency symptom
0.34450078.11823322.html.plaintext.txt	63	likewise one would expect association known genetic risk factor alzheimers disease including gene app p num p num apoe num allele symptom alzheimers disease
0.34450078.11823322.html.plaintext.txt	64	fact appears little consistent evidence association either positive family history alzheimers disease variation known candidate gene increase frequency non cognitive symptom occurring first time within disease
0.34450078.11823322.html.plaintext.txt	65	thus seems unlikely major genetic risk factor development late onset alzheimers disease substantial role play development non cognitive symptom within late onset disease
0.34450078.11823322.html.plaintext.txt	66	however mean symptom genetic basis since gene may influence phenotypic expression disease without involved directly aetiology
0.34450078.11823322.html.plaintext.txt	67	indeed early study shown evidence association positive family history depressive illness increase frequency depressive symptom occurring first time within alzheimers disease pearlson et al num
0.34450078.11823322.html.plaintext.txt	68	early finding supported sib pair study tunstall et al num showing familial factor role development depressive illness late onset alzheimers disease
0.34450078.11823322.html.plaintext.txt	69	addition small study also suggests role familial factor wide variety non cognitive symptom including agitation aggression psychosis
0.34450078.11823322.html.plaintext.txt	70	direct approach also adopted whereby common genetic polymorphism previously showing association neuropsychiatric condition found associated non cognitive symptom late onset alzheimers disease
0.34450078.11823322.html.plaintext.txt	71	example one study holmes et al num people late onset alzheimers disease found association common polymorphic variation num htnuma num htnumc serotonin receptor gene num tc cysnumser polymorphism respectively previously implicated schizophrenia bipolar affective disorder psychotic symptom alzheimers disease
0.34450078.11823322.html.plaintext.txt	72	association found presence cnum allele presence visual auditory hallucination presence sernum allele visual hallucination
0.34450078.11823322.html.plaintext.txt	73	another study sweet et al num found evidence suggest association psychosis aggression patient alzheimers disease carry common polymorphism dopamine receptor gene drdnum drdnum
0.34450078.11823322.html.plaintext.txt	74	study need replicated suggest common receptor polymorphism may role genesis psychotic non cognitive symptom implicated genetic risk factor late onset alzheimers disease
0.34450078.11823322.html.plaintext.txt	75	cognitive decline study date looked rate decline carrier app p num p num mutation patient late onset alzheimers disease positive family history alzheimers disease show evidence increased rate decline
0.34450078.11823322.html.plaintext.txt	76	majority study also failed show relationship possession apoenum allele increased rate decline
0.34450078.11823322.html.plaintext.txt	77	lack association interesting since implies genetic factor may determine disease start rate degeneration
0.34450078.11823322.html.plaintext.txt	78	clearly caution required interpreting negative finding may association always difficult establish large number confounding factor may influence cognitive deterioration well difficulty use psychometric scale short period
0.34450078.11823322.html.plaintext.txt	79	indeed study craft et al num suggested increased rate cognitive decline apoenum carrier may detectable using long follow period
0.34450078.11823322.html.plaintext.txt	80	duration mean duration illness family p num mutation significantly shorter range num
0.34450078.11823322.html.plaintext.txt	81	num year family p num range num
0.34450078.11823322.html.plaintext.txt	82	num year app mutation range num
0.34450078.11823322.html.plaintext.txt	83	num num year reflecting severity p num associated alzheimers disease
0.34450078.11823322.html.plaintext.txt	84	study late onset alzheimers disease suggest duration illness tends longer people positive family history carrier apoenum allele
0.34450078.11823322.html.plaintext.txt	85	however since shown relationship longer hold true confounding effect age onset taken account
0.34450078.11823322.html.plaintext.txt	86	thus late onset alzheimers disease increased survival directly related earlier age onset influenced number factor exclusively genetic
0.34450078.11823322.html.plaintext.txt	87	clinical implication limitation
0.34450078.11823322.html.plaintext.txt	88	clinical implication number gene implicated risk factor development alzheimers disease
0.34450078.11823322.html.plaintext.txt	89	variation gene appears major effect determining disease develop
0.34450078.11823322.html.plaintext.txt	90	aspect clinical phenotype notably non cognitive symptom also influenced genetic variation
0.34450078.11823322.html.plaintext.txt	91	limitation number risk gene yet identified
0.34450078.11823322.html.plaintext.txt	92	influence unknown gene clinical phenotype yet undetermined
0.34450078.11823322.html.plaintext.txt	93	influence genetic variation non cognitive symptom relatively unexplored
0.34450078.11823322.html.plaintext.txt	94	et al num risk alzheimers disease correlate transcriptional activity apoe gene
0.34450078.11823322.html.plaintext.txt	95	human molecular genetics num num num
0.34450078.11823322.html.plaintext.txt	96	et al num wide range age onset chromosome related familial alzheimers disease
0.34450078.11823322.html.plaintext.txt	97	annals neurology num num num
0.34450078.11823322.html.plaintext.txt	98	et al num alpha num macroglobulin genetically associated alzheimers disease
0.34450078.11823322.html.plaintext.txt	99	et al num polymorphism regulatory region apoe associated risk alzheimers dementia
0.34450078.11823322.html.plaintext.txt	100	et al num accelerated decline apolipoprotein e epsilonnum homozygote alzheimers disease
0.34450078.11823322.html.plaintext.txt	101	et al num estimation genetic contribution presenilin num num mutation population based study presenile alzheimer disease
0.34450078.11823322.html.plaintext.txt	102	human molecular genetics num num num
0.34450078.11823322.html.plaintext.txt	103	et al num linkage plasma s num quantitative locus chromosome num late onset alzheimers disease pedigree
0.34450078.11823322.html.plaintext.txt	104	et al num promoter polymorphism numat apoe gene finnish alzheimers disease patient control individual
0.34450078.11823322.html.plaintext.txt	105	journal neurology num num num
0.34450078.11823322.html.plaintext.txt	106	et al num num htnuma num htnumc receptor polymorphism psychopathology late onset alzheimers disease
0.34450078.11823322.html.plaintext.txt	107	human molecular genetics num num num
0.34450078.11823322.html.plaintext.txt	108	et al num full genome scan late onset alzheimers disease
0.34450078.11823322.html.plaintext.txt	109	human molecular genetics num num num
0.34450078.11823322.html.plaintext.txt	110	et al num pronounced impact thnumenum c mutation compared num mutation neural apoe gene expression risk developing alzheimers disease
0.34450078.11823322.html.plaintext.txt	111	human molecular genetics num num num
0.34450078.11823322.html.plaintext.txt	112	et al num apoe genotype predicts whether one predisposed develop alzheimer disease
0.34450078.11823322.html.plaintext.txt	113	et al num susceptibility locus alzheimers disease chromosome num
0.34450078.11823322.html.plaintext.txt	114	et al num association family history affective disorder depressive syndrome alzheimers disease
0.34450078.11823322.html.plaintext.txt	115	american journal psychiatry num num num
0.34450078.11823322.html.plaintext.txt	116	et al num complete genomic screen late onset familial alzheimer disease
0.34450078.11823322.html.plaintext.txt	117	evidence new locus chromosome num
0.34450078.11823322.html.plaintext.txt	118	et al num dopamine receptor genetic variation psychosis aggression alzheimers disease
0.34450078.11823322.html.plaintext.txt	119	archive neurology num num num
0.34450078.11823322.html.plaintext.txt	120	et al num familial influence variation age onset behavioural phenotype alzheimers disease
0.34450078.11823322.html.plaintext.txt	121	british journal psychiatry num num num
0.34450078.11823322.html.plaintext.txt	122	et al num novel polish presenilin num mutation pnuml associated familial alzheimers disease lead death early age num year
0.34450078.11823322.html.plaintext.txt	123	et al num genetic study chromosome num late onset alzheimer disease
0.34450078.11823322.html.plaintext.txt	124	et al num apoe promoter polymorphism confer independent risk alzheimers disease french population
0.34450078.11823322.html.plaintext.txt	125	european journal human genetics num num num
0.34450078.11823322.html.plaintext.txt	126	received publication may num num
0.34450078.11823322.html.plaintext.txt	127	revision received may num num
0.34450078.11823322.html.plaintext.txt	128	accepted publication may num num
0.34450078.11823322.html.plaintext.txt	129	highlight issue elizabeth walsh bjp num num num
0.34450078.11823322.html.plaintext.txt	130	old age psychiatry alistair burn ian g
0.3856874.12716770.html.plaintext.txt	0	association haplotype analysis insulin degrading enzyme ide gene strong positional biological candidate type num diabetes susceptibility christopher j
0.3856874.12716770.html.plaintext.txt	1	grovesnumnum steven wiltshirenumnum damian smedleynum katherine r
0.3856874.12716770.html.plaintext.txt	2	fraylingnum mark walkernum graham
0.3856874.12716770.html.plaintext.txt	3	levynum stephen o rahillynum stephan menzelnum andrew
0.3856874.12716770.html.plaintext.txt	4	num oxford centre diabetes endocrinology metabolism oxford u
0.3856874.12716770.html.plaintext.txt	5	num wellcome trust centre human genetics oxford u
0.3856874.12716770.html.plaintext.txt	6	num genetics genomics research institute imperial college faculty medicine hammersmith hospital london u
0.3856874.12716770.html.plaintext.txt	7	num centre molecular genetics peninsular medical school exeter u
0.3856874.12716770.html.plaintext.txt	8	num school clinical medical science university newcastle newcastle u
0.3856874.12716770.html.plaintext.txt	9	num department diabetes metabolic medicine bart london queen mary school medicine dentistry london u
0.3856874.12716770.html.plaintext.txt	10	num department medicine clinical biochemistry addenbrooke hospital cambridge u
0.3856874.12716770.html.plaintext.txt	11	linkage disequilibrium analysis within candidate gene represents final common pathway identification diabetes susceptibility gene
0.3856874.12716770.html.plaintext.txt	12	candidate selection typically based positional information linkage study human rodent model andor perceived match gene function pathophysiology condition
0.3856874.12716770.html.plaintext.txt	13	several independent line evidence suggest role gene encoding insulin degrading enzyme ide locuslink reference num ec reference num
0.3856874.12716770.html.plaintext.txt	14	num type num diabetes pathogenesis making promising candidate analysis
0.3856874.12716770.html.plaintext.txt	15	first ide map region chromosome numq showing evidence linkage type num diabetes several population
0.3856874.12716770.html.plaintext.txt	16	type num diabetic pedigree evidence linkage multipoint logarithm odds lod num
0.3856874.12716770.html.plaintext.txt	17	num peaked near dnumsnum num mb ide conditional analysis suggested epistatic interaction well replicated susceptibility locus chromosome numq num
0.3856874.12716770.html.plaintext.txt	18	linkage numq also reported finn num north american european num mexican american num french num though latter two map num num cm telomeric may reflect distinct locus
0.3856874.12716770.html.plaintext.txt	19	second rat homolog ide directly implicated type num diabetes susceptibility
0.3856874.12716770.html.plaintext.txt	20	gk rat model numnum locus poststimulation glycemia mapped region rat chromosome num syntenic human numqnum num numnum subsequently localized num cm region around ide num
0.3856874.12716770.html.plaintext.txt	21	two amino acid substitution ide found susceptible congenic strain together conferred postprandial hyperglycemia reduced insulin degradation isolated muscle cell diabetes related phenotype num
0.3856874.12716770.html.plaintext.txt	22	third known presumed function ide consistent role type num diabetes pathogenesis
0.3856874.12716770.html.plaintext.txt	23	ide num kda znnum regulated metalloproteinase display wide expression profile including insulin responsive tissue
0.3856874.12716770.html.plaintext.txt	24	strong specie conservation attests important biological function diverse cellular metabolic role proposed numnum
0.3856874.12716770.html.plaintext.txt	25	although remain controversial num ide seems play major role breakdown insulin insulin responsive tissue num thereby influencing extent cellular response insulin num
0.3856874.12716770.html.plaintext.txt	26	association ide activity insulin clearance resistance supported vitro clinical study num num
0.3856874.12716770.html.plaintext.txt	27	furthermore substrate specificity ide coincides peptide capable amyloid formation including amylin insulin indicating ide may prevent accumulation amyloidogenic peptide num
0.3856874.12716770.html.plaintext.txt	28	disruption scavenging function might thereby promote aggregation islet amyloid characteristic type num diabetes contribute deficient s cell capacity
0.3856874.12716770.html.plaintext.txt	29	congruence positional biological candicacy led u evaluate role ide variation diabetes susceptibility human
0.3856874.12716770.html.plaintext.txt	30	mutation screening exon adjacent intronic sequence num bp num sequence probands numq linked pedigree identified six confirmed variant table num fig
0.3856874.12716770.html.plaintext.txt	31	convenience termed ide single nucleotide polymorphism snp num num num num num num accordance previous nomenclature num
0.3856874.12716770.html.plaintext.txt	32	detect uncommon idenum idenum variant previously reported num idenum idenum mapped outside sequence surveyed
0.3856874.12716770.html.plaintext.txt	33	none variant appeared strong functional credential based sequence context
0.3856874.12716770.html.plaintext.txt	34	putative nonsynonymous exon num coding polymorphism reported dbsnp rsnum validated sequencing direct genotyping
0.3856874.12716770.html.plaintext.txt	35	analysis num european collection cell culture ecacc control sample confirmed extensive linkage disequilibrium across gene pairwise d value num
0.3856874.12716770.html.plaintext.txt	36	six common haplotype hapnum hapnum identified accounting num chromosome fig
0.3856874.12716770.html.plaintext.txt	37	basis allele frequency idenum idenum idenum num intermarker linkage disequilibrium pattern idenum concordant idenum snp num num num num num num selected genotyping
0.3856874.12716770.html.plaintext.txt	38	view table table num ide variant relevant study
0.3856874.12716770.html.plaintext.txt	39	view larger version numk fig
0.3856874.12716770.html.plaintext.txt	40	genomic position linkage disequilibrium relationship haplotype frequency variant within ide gene
0.3856874.12716770.html.plaintext.txt	41	depiction ide gene display exon distribution scale see distance provided genomic location snp examined study
0.3856874.12716770.html.plaintext.txt	42	middle panel detail linkage disequilibrium parameter d diagonal p value calculated num random u
0.3856874.12716770.html.plaintext.txt	43	sample ecacc sample six snp genotyped
0.3856874.12716770.html.plaintext.txt	44	lower panel list ten frequent haplotype estimated typed data set frequency connum control subject made ecacc dif sample wnump case set
0.3856874.12716770.html.plaintext.txt	45	snp hardy weinberg equilibrium data set except idenum p num
0.3856874.12716770.html.plaintext.txt	46	num diabetes family study dif control sample
0.3856874.12716770.html.plaintext.txt	47	sample retyped num concordance haplotype pattern provided indication mistyping novel haplotype generated
0.3856874.12716770.html.plaintext.txt	48	modest departure equilibrium likely therefore reflect stochastic variation exceptional given number test performed
0.3856874.12716770.html.plaintext.txt	49	allele genotype frequency warren num proband wnump case n num control group connum subject n num shown table num see research design method group characteristic
0.3856874.12716770.html.plaintext.txt	50	nominally significant association detected wnump connum sample idenum genotype p num
0.3856874.12716770.html.plaintext.txt	51	num odds ratio c allele num
0.3856874.12716770.html.plaintext.txt	52	global difference haplotype frequency distribution fig
0.3856874.12716770.html.plaintext.txt	53	however since hapnum defined c allele idenum haplotype also frequent probands connum control subject p num
0.3856874.12716770.html.plaintext.txt	54	male female differ snp haplotype frequency additional association uncovered sex stratified analysis
0.3856874.12716770.html.plaintext.txt	55	view table table num genotype allele frequency ide haplotype tag ht snp
0.3856874.12716770.html.plaintext.txt	56	determine whether association might evident family apparent numq linkage subdivided wnump sample according family nonparametric linkage npl score numq locus
0.3856874.12716770.html.plaintext.txt	57	linkage partitioning method applied several recent type num diabetes study num num
0.3856874.12716770.html.plaintext.txt	58	used linkage partitioning purely exploratory capacity given uncertainty statistical property method evidence linkage confirmed well possible consequence partitioning bias stratifying proband genotype alone
0.3856874.12716770.html.plaintext.txt	59	difference evident linked unlinked probands ide haplotype frequency p num
0.3856874.12716770.html.plaintext.txt	60	association previously seen idenum wnump connum attenuated linked probands considered genotype p num
0.3856874.12716770.html.plaintext.txt	61	difference idenum genotype frequency numq linked probands connum control subject p num
0.3856874.12716770.html.plaintext.txt	62	however complementary analysis testing whether ide genotype partitioned evidence numq linkage encouraging
0.3856874.12716770.html.plaintext.txt	63	family proband carried weakly associated idenum genotype ct cc lod score dnumsnum increased num
0.3856874.12716770.html.plaintext.txt	64	analysis based idenum genotype grouping ga gg yielded lod num
0.3856874.12716770.html.plaintext.txt	65	clarification role idenum idenum variant sought genotyping early onset type num diabetic case ytnumd warren num trio wnumt large control resource connum
0.3856874.12716770.html.plaintext.txt	66	young onset case group similar clinical characteristic table num genotype combined appropriate test homogeneity
0.3856874.12716770.html.plaintext.txt	67	replication cohort average age diagnosis num year earlier sibpair probands however rigorous exclusion non type num diabetes high parental prevalence typical late onset type num diabetes cohort numnum argue appreciable qualitative difference genetic basis type num diabetes susceptibility initial replication cohort
0.3856874.12716770.html.plaintext.txt	68	typing idenum idenum effectively reduces ide haplotypic diversity three common haplotype fig
0.3856874.12716770.html.plaintext.txt	69	genotype allele count shown table num
0.3856874.12716770.html.plaintext.txt	70	data hardy weinberg equilibrium
0.3856874.12716770.html.plaintext.txt	71	replication cohort found significant association either snp idenum genotype p num
0.3856874.12716770.html.plaintext.txt	72	num num num haplotype p num
0.3856874.12716770.html.plaintext.txt	73	num regardless whether data stratified sex
0.3856874.12716770.html.plaintext.txt	74	full exeter family study efs cohort n num association either snp fasting plasma glucose combined sex stratified analysis
0.3856874.12716770.html.plaintext.txt	75	view table table num clinical characteristic population studied
0.3856874.12716770.html.plaintext.txt	76	selected ide basis positional biological candidacy type num diabetes susceptibility gene undertaken detailed survey variation within gene unable compile clear evidence association ide variation type num diabetes
0.3856874.12716770.html.plaintext.txt	77	despite fact analysis utilized several large well characterized population selection diabetic individual early onset positive family history designed enhance detection type num diabetes susceptibility allele
0.3856874.12716770.html.plaintext.txt	78	snp showing association initial case control analysis idenum associated replication set
0.3856874.12716770.html.plaintext.txt	79	however worth noting combined idenum across initial replication set achieve nominal significance combined allele c num
0.3856874.12716770.html.plaintext.txt	80	result demand cautious interpretation given allowance low though unquantifiable prior odds even strong biological candidate ide harbor substantial susceptibility effect lack support analysis performed
0.3856874.12716770.html.plaintext.txt	81	variant emerging initial analysis idenum showed ability partition evidence linkage showed evidence association type num diabetes combined allele num
0.3856874.12716770.html.plaintext.txt	82	survey ide variation covered exon adjacent intronic sequence promoter
0.3856874.12716770.html.plaintext.txt	83	none variant identified earlier screen u
0.3856874.12716770.html.plaintext.txt	84	subject num strong credential impact ide structure andor function
0.3856874.12716770.html.plaintext.txt	85	clearly finding support hypothesis variation within ide exclusively responsible linkage signal detected chromosome numq
0.3856874.12716770.html.plaintext.txt	86	however association study exclude possibility variant typed especially idenum lesser susceptibility role
0.3856874.12716770.html.plaintext.txt	87	present study estimate num power detect association idenum type num diabetes multiplicative model genotypic relative risk num
0.3856874.12716770.html.plaintext.txt	88	fall num stringent significance threshold p num
0.3856874.12716770.html.plaintext.txt	89	num designed reflect modest prior odds candidate selected play biologically significant susceptibility role
0.3856874.12716770.html.plaintext.txt	90	furthermore entirely exclude possibility ide variant studied marked contribution type num diabetes susceptibility
0.3856874.12716770.html.plaintext.txt	91	variant must lie outside region surveyed display limited linkage disequilibrium typed variant
0.3856874.12716770.html.plaintext.txt	92	current understanding linkage disequilibrium pattern within human population indicates analysis seek association using snp capturing haplotypic diversity within gene interest good power detect association yet unidentified common variant within gene num
0.3856874.12716770.html.plaintext.txt	93	gene structure mutation detection
0.3856874.12716770.html.plaintext.txt	94	genomic structure ide determined blast alignment human mrna sequence mnum finished genomic sequence bac clone alnum
0.3856874.12716770.html.plaintext.txt	95	confirmed ide num exon distributed position num
0.3856874.12716770.html.plaintext.txt	96	num mb ncbinum assembly chromosome num
0.3856874.12716770.html.plaintext.txt	97	variant detection performed direct sequencing direction big dye terminator chemistry perkin elmer applied biosystems warrington u
0.3856874.12716770.html.plaintext.txt	98	abinum capillary sequencer
0.3856874.12716770.html.plaintext.txt	99	included exon num bp flanking intron num bp num untranslated region utr num amplicons
0.3856874.12716770.html.plaintext.txt	100	primer sequence provided online table num httpdiabetes
0.3856874.12716770.html.plaintext.txt	101	total num individual sequenced
0.3856874.12716770.html.plaintext.txt	102	eight type num diabetic probands sibships affected identical descent chromosome flanking microsatellites dnumsnum dnumsnum
0.3856874.12716770.html.plaintext.txt	103	probands assuming numq linkage enriched numq susceptibility variant estimate num power detect disease associated variant assuming multiplicative model genotype relative risk num
0.3856874.12716770.html.plaintext.txt	104	three unaffected sibling family doubly discordant numq haplotype covering ide compared affected sib
0.3856874.12716770.html.plaintext.txt	105	selected ide snp genotyped using combination approach including restriction fragment length polymorphism detection artificial induced restriction site tetra primer amplification refractory mutation method
0.3856874.12716770.html.plaintext.txt	106	assay first two type included obligate restriction site internal digest control
0.3856874.12716770.html.plaintext.txt	107	assay detail see online table num httpdiabetes
0.3856874.12716770.html.plaintext.txt	108	genotype allele frequency distribution compared standard contingency table method exact probability estimation using statxact cytel cambridge ma
0.3856874.12716770.html.plaintext.txt	109	genotype comparison used kruskal wallis statistic given ordinal categorization
0.3856874.12716770.html.plaintext.txt	110	wnumt ytnumd set combined contingency table analysis appropriate homogeneity testing
0.3856874.12716770.html.plaintext.txt	111	haplotype pattern estimated maximum likelihood method snphap www gene
0.3856874.12716770.html.plaintext.txt	112	ukclaytonsoftware haplotype frequency distribution compared likelihood ratio testing
0.3856874.12716770.html.plaintext.txt	113	significance determined permutation numnum replicates
0.3856874.12716770.html.plaintext.txt	114	measure linkage disequilibrium snp derived using pm permutation model free analysis program num
0.3856874.12716770.html.plaintext.txt	115	ass evidence linkage partitioning num num two complementary approach adopted
0.3856874.12716770.html.plaintext.txt	116	first wnump probands subdivided linked positive family npl score ide unlinked variant frequency comparison repeated
0.3856874.12716770.html.plaintext.txt	117	second evidence linkage numq recomputed using genehunter plus num conditioning proband ide genotype
0.3856874.12716770.html.plaintext.txt	118	significance change linkage statistic determined permutation numnum replicates
0.3856874.12716770.html.plaintext.txt	119	power calculation described assume simplicity case ascertained affected sibpairs incorporate ascertainment selection control sample population based
0.3856874.12716770.html.plaintext.txt	120	acknowledgment work supported diabetes u
0.3856874.12716770.html.plaintext.txt	121	also supported ascertainment many sample collected european union gift consortium qlgnum ct num num south west national health service research directorate
0.3856874.12716770.html.plaintext.txt	122	career scientist south west national health service research directorate k
0.3856874.12716770.html.plaintext.txt	123	clinical training fellow
0.3856874.12716770.html.plaintext.txt	124	wellcome trust career leave research fellow
0.3856874.12716770.html.plaintext.txt	125	thank participated collection many health professional contributed
0.3856874.12716770.html.plaintext.txt	126	sian ellard laboratory organization diane jarvis dna extraction dr
0.3856874.12716770.html.plaintext.txt	127	lesley jones cardiff sharing ide variant data prof
0.3856874.12716770.html.plaintext.txt	128	paul burton colleague leicester valuable statistical insight
0.3856874.12716770.html.plaintext.txt	129	footnote address correspondence reprint request prof
0.3856874.12716770.html.plaintext.txt	130	mark mccarthy robert turner professor diabetes oxford centre diabetes endocrinology metabolism churchill site old road headington oxford oxnum numlj u
0.3856874.12716770.html.plaintext.txt	131	received publication num november num accepted revised form num february num
0.3856874.12716770.html.plaintext.txt	132	additional information article found online appendix httpdiabetes
0.3856874.12716770.html.plaintext.txt	133	con control dif diabetes family study ecacc european collection cell culture hap haplotype ide insulin degrading enzyme lod logarithm odds ncbi national center biotechnology information npl nonparametric linkage odds ratio snp single nucleotide polymorphism utr untranslated region wnump warren num probands wnumt warren num trio ytnumd young type num diabetes
0.39201447.15277398.html.plaintext.txt	0	quantitative trait locus near insulin degrading enzyme ide gene contribute variation plasma insulin level harvest f
0.39201447.15277398.html.plaintext.txt	1	gunum suad efendicnum sofia nordmannum claes goran ostensonnum kerstin brismarnum anthony j
0.39201447.15277398.html.plaintext.txt	2	num department molecular medicine rolf luft center diabetes research karolinska hospital stockholm sweden num center genomics bioinformatics karolinska institute stockholm sweden
0.39201447.15277398.html.plaintext.txt	3	gene encoding insulin degrading enzyme ide located chromosome numqnum qnum within region linked type num diabetes related quantitative trait num num
0.39201447.15277398.html.plaintext.txt	4	ide major enzyme responsible insulin proteolysis vitro num share structural functional homology bacterial protease iii may function termination insulin response numnum
0.39201447.15277398.html.plaintext.txt	5	mouse ide hypofunction induced ide gene disruption lead hyperinsulinemia num
0.39201447.15277398.html.plaintext.txt	6	furthermore ide activity diabetic goto kakizaki gk rat reduced num polymorphism ide likely main contributing factor num
0.39201447.15277398.html.plaintext.txt	7	congruence positional functional data indicates sequence variation ide may play role modifying insulin metabolism human population
0.39201447.15277398.html.plaintext.txt	8	two recent genetic association study investigated ide region relation type num diabetes
0.39201447.15277398.html.plaintext.txt	9	one produced significant evidence effect type num diabetes plasma glucose level num whereas explored case control model obtained evidence association num
0.39201447.15277398.html.plaintext.txt	10	neither study however attempted directly relate ide variant measure insulin metabolism
0.39201447.15277398.html.plaintext.txt	11	evaluate potential influence genetic variation ide insulin level correlated quantitative trait haplotype tagging strategy used num swedish sample consisting num impaired glucose tolerance igt num nondiabetic control subject table num
0.39201447.15277398.html.plaintext.txt	12	study follows recent report num examined num polymorphic marker extending across ide relation alzheimer disease large swedish population
0.39201447.15277398.html.plaintext.txt	13	used define regional linkage disequilibrium ld structure highlighted ld block spanning num kb around ide
0.39201447.15277398.html.plaintext.txt	14	three single nucleotide polymorphism snp marker identified capable delineating common haplotype num swede subsequently used test association
0.39201447.15277398.html.plaintext.txt	15	view table table num clinical characteristic igt nondiabetic control subject
0.39201447.15277398.html.plaintext.txt	16	present study num snp marker extending locally across ide examined fig
0.39201447.15277398.html.plaintext.txt	17	num including previously identified tag marker
0.39201447.15277398.html.plaintext.txt	18	began genotyping entire male sample define ld structure identify common haplotype
0.39201447.15277398.html.plaintext.txt	19	num marker found hardy weinberg equilibrium
0.39201447.15277398.html.plaintext.txt	20	pairwise marker correlation suggested strong ld region agreement earlier data num
0.39201447.15277398.html.plaintext.txt	21	common haplotype num frequency inferred haplotyper using num marker similar obtained based slightly modified marker set num
0.39201447.15277398.html.plaintext.txt	22	ld estimate inferred haplotype entire sample shown fig
0.39201447.15277398.html.plaintext.txt	23	num used confirm studied region represent ld block
0.39201447.15277398.html.plaintext.txt	24	also confirmed selection three tag marker equivalent previously used num would able delineate common haplotype opted explore use alternative equally valid marker set
0.39201447.15277398.html.plaintext.txt	25	note variety different approach exist defining optimal snp set num explored use
0.39201447.15277398.html.plaintext.txt	26	issue may relevance attempt replicating refuting present data ld structure differ markedly divergent population k
0.39201447.15277398.html.plaintext.txt	27	view larger version numk fig
0.39201447.15277398.html.plaintext.txt	28	detail examined snp ide
0.39201447.15277398.html.plaintext.txt	29	view larger version numk fig
0.39201447.15277398.html.plaintext.txt	30	pairwise ld num snp marker extending across ide
0.39201447.15277398.html.plaintext.txt	31	view larger version numk fig
0.39201447.15277398.html.plaintext.txt	32	common haplotype extending across ide
0.39201447.15277398.html.plaintext.txt	33	initial analysis intention reduce number exploratory test examining critical set phenotype limited number haplotypic genotype also referable diplotypes brevity opted use latter term throughout report
0.39201447.15277398.html.plaintext.txt	34	principal criterion diplotype construction inferred high probability thus reflect fidelity combination common haplotype individual
0.39201447.15277398.html.plaintext.txt	35	presence limited allelic heterogeneity advantageous single marker test fail detect effect due insufficient complex pattern ld pathogenic variant
0.39201447.15277398.html.plaintext.txt	36	addition testing many single marker requires substantial degree multiple testing
0.39201447.15277398.html.plaintext.txt	37	selection quantitative phenotype analysis included six trait typically examined relation diabetes num num listed table num
0.39201447.15277398.html.plaintext.txt	38	note study numnum investigated ide relation diabetes report effort relate genotype either insulin level obesity
0.39201447.15277398.html.plaintext.txt	39	trait distribution highly skewed partially skewed six studied phenotype thus log transformed data modeled
0.39201447.15277398.html.plaintext.txt	40	correlation trait extremely high expected data shown
0.39201447.15277398.html.plaintext.txt	41	diplotypes inferred using three selected haplotype tagging marker fig
0.39201447.15277398.html.plaintext.txt	42	num tested six trait highlighted table num men woman separately
0.39201447.15277398.html.plaintext.txt	43	six eight possible haplotype predicted using marker sequence hnum tcg hnum tca hnum cca hnum tta hnum ttg hnum ccg
0.39201447.15277398.html.plaintext.txt	44	posterior probability estimate excess num
0.39201447.15277398.html.plaintext.txt	45	num phase call represent various combination haplotype threshold set retaining individual analysis
0.39201447.15277398.html.plaintext.txt	46	significant consistent effect upon trait evident notable exception fasting glucose num h glucose level
0.39201447.15277398.html.plaintext.txt	47	importantly effect evident exclusively men agreement result obtained karamohamed et al
0.39201447.15277398.html.plaintext.txt	48	result analysis shown fig
0.39201447.15277398.html.plaintext.txt	49	num data male sample presented
0.39201447.15277398.html.plaintext.txt	50	analysis combined igt individual nondiabetic control subject adjusted uniform phenotypic difference including group identity factor anova model
0.39201447.15277398.html.plaintext.txt	51	diplotype group interaction term second order factorial anova model significant
0.39201447.15277398.html.plaintext.txt	52	analysis based probabilistically inferred data considered important also explore model entail use phase known data
0.39201447.15277398.html.plaintext.txt	53	accomplished excluding individual heterozygous two site individual one heterozygote site definition phase known
0.39201447.15277398.html.plaintext.txt	54	demonstrate additional analysis performed men four associated trait shown fig
0.39201447.15277398.html.plaintext.txt	55	num insulin num h insulin homeostasis model assessment insulin resistance homa ir bmi
0.39201447.15277398.html.plaintext.txt	56	result revealed association four significance highest bmi fnumnum num
0.39201447.15277398.html.plaintext.txt	57	num data comparison shown
0.39201447.15277398.html.plaintext.txt	58	num group excluded analysis hnumhnum hnumhnum hnumhnum hnumhnum
0.39201447.15277398.html.plaintext.txt	59	view larger version numk fig
0.39201447.15277398.html.plaintext.txt	60	diplotype association quantitative trait men
0.39201447.15277398.html.plaintext.txt	61	mean value plus minus se fasting glucose num h glucose b fasting insulin c num h insulin d homa e bmi f men according diplotype group estimated using haplotyper
0.39201447.15277398.html.plaintext.txt	62	category le six observation excluded
0.39201447.15277398.html.plaintext.txt	63	f ratio anova omnibus test performed log transformed data trait associated p value shown upper right corner diagram
0.39201447.15277398.html.plaintext.txt	64	number individual category shown base column
0.39201447.15277398.html.plaintext.txt	65	attempt refine possible position pathogenic variant region single marker test conducted phenotype provided evidence association diplotype model
0.39201447.15277398.html.plaintext.txt	66	considering multiple testing issue noted strongest individual finding homa ir p num
0.39201447.15277398.html.plaintext.txt	67	num affords num individual test strict multiple testing correction render finding insignificant given num
0.39201447.15277398.html.plaintext.txt	68	test using num marker performed male sample diplotype analysis gave u priori reason suspect latent association single marker would present female set
0.39201447.15277398.html.plaintext.txt	69	result shown fig
0.39201447.15277398.html.plaintext.txt	70	num consistent effect rsnum rsnum seen upon trait
0.39201447.15277398.html.plaintext.txt	71	common allele rsnum rare allele rsnum associated lower trait level
0.39201447.15277398.html.plaintext.txt	72	marker rsnum rsnum tested fasting glucose level latter specifically reported karamohamed et al
0.39201447.15277398.html.plaintext.txt	73	num two marker extremely high ld rnum num
0.39201447.15277398.html.plaintext.txt	74	neither marker showed evidence association acknowledge present study le power aforementioned one
0.39201447.15277398.html.plaintext.txt	75	result rsnum upon multiple phenotype nonetheless support likely presence primary trait modifying sequence num region ide speculated num
0.39201447.15277398.html.plaintext.txt	76	effect rsnum num h insulin level significant however albeit considerably attenuated comparison rsnum
0.39201447.15277398.html.plaintext.txt	77	explore effect rsnum final model fitted rare allele homozygote heterozygote combined compared common allele homozygote
0.39201447.15277398.html.plaintext.txt	78	result follows fnumnum num
0.39201447.15277398.html.plaintext.txt	79	num fasting insulin num h insulin homa ir bmi respectively
0.39201447.15277398.html.plaintext.txt	80	although throughout study test conducted combined igt normal sample correction applied possible difference considered important confirm effect exists population least one analysis
0.39201447.15277398.html.plaintext.txt	81	using model focusing rsnum marker num h insulin trait significant effect observed igt fnumnum num
0.39201447.15277398.html.plaintext.txt	82	num group case common allele homozygote group lowest trait level
0.39201447.15277398.html.plaintext.txt	83	view larger version numk fig
0.39201447.15277398.html.plaintext.txt	84	single marker quantitative trait test men
0.39201447.15277398.html.plaintext.txt	85	summary provide strong evidence sequence variation within near ide contributes variability measure insulin metabolism
0.39201447.15277398.html.plaintext.txt	86	several compelling feature result
0.39201447.15277398.html.plaintext.txt	87	first study study karamohamed et al
0.39201447.15277398.html.plaintext.txt	88	num suggest primary functional variant occurs num region ide
0.39201447.15277398.html.plaintext.txt	89	addition marker previously exhibited maximum evidence association rsnum num strong ld marker rsnum greatest effect present study
0.39201447.15277398.html.plaintext.txt	90	true pathogenic variant likely high ld indeed could one marker
0.39201447.15277398.html.plaintext.txt	91	second study suggest effect either exclusively predominantly male subject
0.39201447.15277398.html.plaintext.txt	92	numerous study detected genetic effect exclusively men numnum sex specificity may major confounding factor genetic analysis num
0.39201447.15277398.html.plaintext.txt	93	third marker strongest association quantitative trait related alzheimer disease recent study num rsnum among num marker
0.39201447.15277398.html.plaintext.txt	94	importantly however present analysis suggest may one functionally relevant polymorphic site near ide
0.39201447.15277398.html.plaintext.txt	95	evident diplotype model single haplotype appears responsible either elevating reducing trait level number possible interaction also apparent
0.39201447.15277398.html.plaintext.txt	96	evidence allelic heterogeneity interaction general make fine mapping responsible variant daunting task num need considered future study investigating ide region
0.39201447.15277398.html.plaintext.txt	97	directly addressed question whether variation ide influence risk type num diabetes
0.39201447.15277398.html.plaintext.txt	98	two study tested relationship produced either modest evidence association despite examining large clinical sample
0.39201447.15277398.html.plaintext.txt	99	study provides evidence association fasting glucose level primary phenotype used distinguish diabetic patient
0.39201447.15277398.html.plaintext.txt	100	rather present data likely capture fundamental influence ide upon circulating insulin level whereby genetically determined deficit enzyme activity may lead hyperinsulinemia
0.39201447.15277398.html.plaintext.txt	101	could manifest modulator role type num diabetes might relevant phenotype coronary heart disease num primary hypertension num
0.39201447.15277398.html.plaintext.txt	102	believe continued replication effort normal morbid population well functional study highly merited needed elucidate molecular basis clinical relevance observed phenotypic effect
0.39201447.15277398.html.plaintext.txt	103	quantitative trait measurement
0.39201447.15277398.html.plaintext.txt	104	insulin resistance assessed homa num
0.39201447.15277398.html.plaintext.txt	105	homa ir calculated present study using formula fasting plasma glucose millimoles per liter x fasting plasma insulin milliunits per milliliternum
0.39201447.15277398.html.plaintext.txt	106	num snp examined study listed table num detail may found dbsnp database httpwww
0.39201447.15277398.html.plaintext.txt	107	govsnp respective id
0.39201447.15277398.html.plaintext.txt	108	surrounding num bp sequence direction examined repeat duplicated sequence using repeatmasker httpwww
0.39201447.15277398.html.plaintext.txt	109	verify snp polymorphic study population snp tested set num swedish control sample
0.39201447.15277398.html.plaintext.txt	110	assay num sample monomorphic excluded analysis
0.39201447.15277398.html.plaintext.txt	111	convenience nomenclature used throughout report refer snp used recent report num
0.39201447.15277398.html.plaintext.txt	112	genotyping snp performed using induced fluorescence resonance energy transfer modification dynamic allele specific hybridization numnum
0.39201447.15277398.html.plaintext.txt	113	pcrs run num num microl volume num
0.39201447.15277398.html.plaintext.txt	114	num mmoll mgclnum using num num ng genomic dna
0.39201447.15277398.html.plaintext.txt	115	oligonucleotide sequence dynamic allele specific hybridization pcr assay snp presented previously num
0.39201447.15277398.html.plaintext.txt	116	deviation hardy weinberg equilibrium genotype individual locus assessed using num statistic
0.39201447.15277398.html.plaintext.txt	117	deviation normality trait distribution assessed using kolgomorov smirnov test
0.39201447.15277398.html.plaintext.txt	118	correlation trait established using spearman statistic
0.39201447.15277398.html.plaintext.txt	119	test association genotype quantitative trait performed using anova log transformed data included age group igt normal covariates analysis
0.39201447.15277398.html.plaintext.txt	120	statistical analysis performed using statview version num
0.39201447.15277398.html.plaintext.txt	121	num abacus concept piscataway nj
0.39201447.15277398.html.plaintext.txt	122	haplotype frequency estimated using haplotyper program num
0.39201447.15277398.html.plaintext.txt	123	ld marker pair estimated using rnum metric num
0.39201447.15277398.html.plaintext.txt	124	acknowledgment study supported novo nordisk consortium swedish research council loo han osterman foundation vetenskapligt arbete inom diabetologi foundation swedish diabetes association
0.39201447.15277398.html.plaintext.txt	125	thank subject participating present study dr
0.39201447.15277398.html.plaintext.txt	126	bo ding ylva behr valuable discussion camilla lagerberg yvonne stromberg excellent assistance
0.39201447.15277398.html.plaintext.txt	127	footnote homa ir homeostasis model assessment insulin resistance ide insulin degrading enzyme igt impaired glucose tolerance ld linkage disequilibrium snp single nucleotide polymorphism
0.39201447.15277398.html.plaintext.txt	128	address correspondence reprint request suad efendic rolf luft center diabetes research department molecular medicine lnumbnum karolinska hospital se num num stockholm sweden
0.39201447.15277398.html.plaintext.txt	129	received publication february num num accepted revised form april num num
0.40214586.14747300.html.plaintext.txt	0	increased risk type num diabetes alzheimer disease juliette jansonnumnum thomas laedtkenum joseph e
0.40214586.14747300.html.plaintext.txt	1	parisinum peter o briennum ronald c
0.40214586.14747300.html.plaintext.txt	2	num endocrine research unit mayo clinic rochester minnesota num department pathology mayo clinic rochester minnesota num department biostatistics mayo clinic rochester minnesota num department neurology health science research mayo clinic rochester minnesota num division endocrinology diabetes keck school medicine university southern california los angeles california
0.40214586.14747300.html.plaintext.txt	3	islet langerhans type num diabetes characterized s cell loss numnum islet amyloid derived islet amyloid polypeptide iapp num num protein coexpressed secreted insulin s cell
0.40214586.14747300.html.plaintext.txt	4	brain dysfunction alzheimer disease characterized loss neocortical neuron num focal amyloid deposit consist locally expressed amyloid s protein assp num num
0.40214586.14747300.html.plaintext.txt	5	prevalence alzheimer disease type num diabetes increase age genetic component num num
0.40214586.14747300.html.plaintext.txt	6	assp iapp spontaneously form amyloid aggregate aqueous environment numnumnumnum
0.40214586.14747300.html.plaintext.txt	7	role aggregate iapp assp s cell cortical neuronal death type num diabetes alzheimer disease controversial
0.40214586.14747300.html.plaintext.txt	8	small amyloid aggregate either protein cytotoxic num num
0.40214586.14747300.html.plaintext.txt	9	mechanism cytotoxicity mediated small protein aggregate hypothesized induction membrane damage num num
0.40214586.14747300.html.plaintext.txt	10	case iapp evidence exists suggest abnormal aggregation occurs initially intracellularly cell death iapp derived fibril accumulate extracellularly numnumnum
0.40214586.14747300.html.plaintext.txt	11	similar mechanism also possible alzheimer disease
0.40214586.14747300.html.plaintext.txt	12	vivo even though iapp assp present aqueous environment health neither protein form fibril suggesting mechanism exist prevent otherwise spontaneous process
0.40214586.14747300.html.plaintext.txt	13	mechanism likely include chaperone protein pathway system protein trafficking via intracellular binding protein chaperone protein bind nascent protein facilitate transport within cell num
0.40214586.14747300.html.plaintext.txt	14	previously hypothesized iapp amyloid formation type num diabetes may occur circumstance genetic variance result relative decreased affinity chaperone protein pathway trafficking iapp num
0.40214586.14747300.html.plaintext.txt	15	plausible low affinity binding one chaperone protein iapp may shared similar low affinity binding assp
0.40214586.14747300.html.plaintext.txt	16	support hypothesis schwartz num suggested might relationship amyloid deposit brain pancreatic islet
0.40214586.14747300.html.plaintext.txt	17	used clinical study living patient community based control subject pathological study examine existence shared risk alzheimer disease type num diabetes
0.40214586.14747300.html.plaintext.txt	18	clinical study took advantage unique community based olmsted county mn cohort well characterized patient alzheimer disease control subject without alzheimer disease num address question type num diabetes common alzheimer disease pathology study studied brain pancreas autopsy case community address hypothesis num islet amyloid frequent patient alzheimer disease control subject without alzheimer disease num amyloid deposit common brain patient type num diabetes nondiabetic human
0.40214586.14747300.html.plaintext.txt	19	view table table num study case clinical study
0.40214586.14747300.html.plaintext.txt	20	protocol num type num diabetes common alzheimer disease recruitment criterion provided total num patient alzheimer disease num non alzheimer disease control subject
0.40214586.14747300.html.plaintext.txt	21	protocol num case control subject classified according criterion american diabetes association one three group nondiabetic num mgdl impaired fasting glucose ifg num num mgdl type num diabetes num mgdl based recent glucose concentration measurement
0.40214586.14747300.html.plaintext.txt	22	individual taking blood glucose lowering treatment diabetes classified type num diabetes regardless recent fasting glucose concentration
0.40214586.14747300.html.plaintext.txt	23	protocol num increase fasting plasma glucose age greater alzheimer disease also examined change fasting plasma glucose fpg aging cohort patient
0.40214586.14747300.html.plaintext.txt	24	subject regressed annual median fpg value age
0.40214586.14747300.html.plaintext.txt	25	used obtain predicted fpg value subject decade also compare slope regression line group alzheimer disease versus control subject using two sided rank sum test
0.40214586.14747300.html.plaintext.txt	26	included analysis patient required fpg value recorded spanned least num consecutive year age num greater least one value available calendar year
0.40214586.14747300.html.plaintext.txt	27	age bordernumnum year considered
0.40214586.14747300.html.plaintext.txt	28	criterion resulted study population num patient alzheimer disease num non alzheimer disease control subject
0.40214586.14747300.html.plaintext.txt	29	pathology study case recruitment
0.40214586.14747300.html.plaintext.txt	30	alzheimer disease patient group num control subject non alzheimer disease group num enrolled mayo clinic adpr study life num
0.40214586.14747300.html.plaintext.txt	31	death non alzheimer disease alzheimer disease case autopsy examination brain diagnosis alzheimer disease absence confirmed using cerad consortium establish registry alzheimer disease criterion num
0.40214586.14747300.html.plaintext.txt	32	pathology study include num case clinically pathologically confirmed alzheimer disease non alzheimer disease num case autopsy including brain pancreas num case fpg documented mayo clinic within num year alzheimer disease num non alzheimer disease num case num year non alzheimer disease num alzheimer disease num complete autopsy death
0.40214586.14747300.html.plaintext.txt	33	mean fpg value subject mean least two independent measurement
0.40214586.14747300.html.plaintext.txt	34	alzheimer disease patient sex age matched control subject life per mayo clinic adpr study still matched age death num plus minus num v
0.40214586.14747300.html.plaintext.txt	35	num plus minus num year alzheimer disease v
0.40214586.14747300.html.plaintext.txt	36	alzheimer disease diagnosed num
0.40214586.14747300.html.plaintext.txt	37	type num diabetes case group num fpg num mgdl identified via mayo clinic autopsy record
0.40214586.14747300.html.plaintext.txt	38	inclusion num died num year preceding study num also olmsted county num autopsy including brain pancreas num general medical examination performed including fpg mayo clinic year death
0.40214586.14747300.html.plaintext.txt	39	exclusion criterion included inadequate preservation pancreatic tissue anatomic study type num diabetes secondary cause diabetes
0.40214586.14747300.html.plaintext.txt	40	diagnosis diabetes cohort num plus minus num year death
0.40214586.14747300.html.plaintext.txt	41	selection criterion yielded num case mean age death younger type num diabetes alzheimer disease case num plus minus num v
0.40214586.14747300.html.plaintext.txt	42	num plus minus num year p num
0.40214586.14747300.html.plaintext.txt	43	therefore identified mayo clinic autopsy record additional control group consisting num case group num age bmi sex matched type num diabetic patient normal fpg documented within num year death also meeting criterion num num group num
0.40214586.14747300.html.plaintext.txt	44	group num num included haphazardly
0.40214586.14747300.html.plaintext.txt	45	consciously biased respect presence absence alzheimer disease
0.40214586.14747300.html.plaintext.txt	46	characteristic four study group summarized table num
0.40214586.14747300.html.plaintext.txt	47	view table table num study case pathology
0.40214586.14747300.html.plaintext.txt	48	protocol num islet amyloid increased patient alzheimer disease address question studied pancreas sample obtained autopsy num case alzheimer disease num without alzheimer disease group num num table num
0.40214586.14747300.html.plaintext.txt	49	addition num case type num diabetes num without type num diabetes studied point reference
0.40214586.14747300.html.plaintext.txt	50	protocol num included total num case
0.40214586.14747300.html.plaintext.txt	51	protocol num brain amyloid common patient type num diabetes address question studied brain sample num case num without type num diabetes group num num table num
0.40214586.14747300.html.plaintext.txt	52	reference num case alzheimer disease num without alzheimer disease studied
0.40214586.14747300.html.plaintext.txt	53	paraffin block superiormidfrontal gyrus available resulting num case entering protocol num
0.40214586.14747300.html.plaintext.txt	54	pancreas brain sample obtained autopsy four group described
0.40214586.14747300.html.plaintext.txt	55	slide examined blinded identity case light microscopy
0.40214586.14747300.html.plaintext.txt	56	sequential section obtained paraffin embedded pancreas tail sample stained hematoxylineosin congo red immunostaining insulin num
0.40214586.14747300.html.plaintext.txt	57	nature pink amyloid deposit congo red stained slide confirmed greenorange birefringence polarized light
0.40214586.14747300.html.plaintext.txt	58	least num islet per specimen scored presence extent islet amyloid
0.40214586.14747300.html.plaintext.txt	59	extent amyloid deposition classified per islet scale num num num deposit num one deposit num small deposit num major deposition num endocrine cell left confluent deposit
0.40214586.14747300.html.plaintext.txt	60	sample superiormidfrontal gyrus collected density neuritic diffuse plaque neurofibrillary tangle nft determined
0.40214586.14747300.html.plaintext.txt	61	visualizing neurofilaments paraffin section superiormidfrontal gyrus stained modified bielschowsky technique
0.40214586.14747300.html.plaintext.txt	62	per sample number neuritic plaque diffuse plague nft determined five microscope field num mmnum
0.40214586.14747300.html.plaintext.txt	63	statistical analysis protocol num num
0.40214586.14747300.html.plaintext.txt	64	rank sum test used compare age num test used compare number group according classification sex diabetic nondiabetic ifg status
0.40214586.14747300.html.plaintext.txt	65	two sided rank sum test used compare slope fasting glucose versus age
0.40214586.14747300.html.plaintext.txt	66	unpaired two tailed student test used compare age bmi group
0.40214586.14747300.html.plaintext.txt	67	nonparametric mann whitney test used compare frequency extent islet amyloid fpg density neuritic plaque diffuse plague nft among group
0.40214586.14747300.html.plaintext.txt	68	num test used compare number alzheimer disease non alzheimer disease subject type num diabetes
0.40214586.14747300.html.plaintext.txt	69	spearman rank correlation used examine relationship among diffuse plague neuritic plaque nft density versus duration diabetes death age death type num diabetes
0.40214586.14747300.html.plaintext.txt	70	view larger version numk fig
0.40214586.14747300.html.plaintext.txt	71	protocol num prevalence diabetes ifg olmsted county community based cohort case alzheimer disease ad control subject non alzheimer disease non ad top
0.40214586.14747300.html.plaintext.txt	72	protocol num slope fpg concentration versus age cohort bottom
0.40214586.14747300.html.plaintext.txt	73	trend fpg aging examined gradual increase aging group p num
0.40214586.14747300.html.plaintext.txt	74	however alzheimer disease group greater increase per year compared non alzheimer disease control subject num
0.40214586.14747300.html.plaintext.txt	75	greater rate increase blood glucose preserved alzheimer disease case diabetes excluded analysis
0.40214586.14747300.html.plaintext.txt	76	pathology study islet amyloid alzheimer disease protocol num brain amyloid type num diabetes protocol num protocol num islet amyloid alzheimer disease
0.40214586.14747300.html.plaintext.txt	77	frequency extent islet amyloid higher alzheimer disease group versus non alzheimer disease group p num
0.40214586.14747300.html.plaintext.txt	78	num despite trend toward lower bmi alzheimer disease num
0.40214586.14747300.html.plaintext.txt	79	expected frequency extent islet amyloid greater type num diabetes group num versus non type num diabetes group num p num
0.40214586.14747300.html.plaintext.txt	80	view larger version numk fig
0.40214586.14747300.html.plaintext.txt	81	protocol num frequency islet amyloid top extent islet amyloid bottom patient alzheimer disease ad control subject non alzheimer disease non ad patient type num diabetes ttdm control group non ttdm
0.40214586.14747300.html.plaintext.txt	82	individual value median line
0.40214586.14747300.html.plaintext.txt	83	inclusion case autopsy protocol blinded respect presence absence diabetes requirement fpg documented
0.40214586.14747300.html.plaintext.txt	84	subsequent analysis fpg concentration revealed prevalence type num diabetes fpg num mgdl alzheimer disease group num non alzheimer disease case num p num
0.40214586.14747300.html.plaintext.txt	85	mean fpg alzheimer disease higher control subject num plus minus num v
0.40214586.14747300.html.plaintext.txt	86	num plus minus num mgdl p num
0.40214586.14747300.html.plaintext.txt	87	protocol num brain amyloid type num diabetes
0.40214586.14747300.html.plaintext.txt	88	density diffuse neuritic plaque nft different patient type num diabetes versus nondiabetic control subject p num
0.40214586.14747300.html.plaintext.txt	89	expected density neuritic plaque diffuse plaque nft greater p num
0.40214586.14747300.html.plaintext.txt	90	num alzheimer disease case group num versus non alzheimer disease group num
0.40214586.14747300.html.plaintext.txt	91	view table table num brain pathology
0.40214586.14747300.html.plaintext.txt	92	num num type num diabetes case year diagnosis diabetes documented
0.40214586.14747300.html.plaintext.txt	93	diffuse plaque detected num neuritic plaque num num case type num diabetes documented age onset diabetes
0.40214586.14747300.html.plaintext.txt	94	positive relationship duration known diabetes extent diffuse plaque r num
0.40214586.14747300.html.plaintext.txt	95	num neuritic plaque r num
0.40214586.14747300.html.plaintext.txt	96	contrast neither type num diabetes non type num diabetes correlation density either plaque age death
0.40214586.14747300.html.plaintext.txt	97	view larger version numk fig
0.40214586.14747300.html.plaintext.txt	98	protocol num relationship density diffuse plaque r num
0.40214586.14747300.html.plaintext.txt	99	num top neuritic plaque r num
0.40214586.14747300.html.plaintext.txt	100	num bottom versus duration diabetes patient type num diabetes
0.40214586.14747300.html.plaintext.txt	101	case included duration diabetes documented respective plaque type detected y equal zero
0.40214586.14747300.html.plaintext.txt	102	study initially undertaken test hypothesis may shared predisposition development islet amyloid brain amyloid patient alzheimer disease type num diabetes respectively
0.40214586.14747300.html.plaintext.txt	103	postulate arose close resemblance pathology brain alzheimer disease islet type num diabetes
0.40214586.14747300.html.plaintext.txt	104	disease locally expressed protein assp alzheimer disease iapp type num diabetes deposited amyloid deposit gradual decline number cell respective protein
0.40214586.14747300.html.plaintext.txt	105	amyloid deposit assp iapp likely oligomeric precursor cytotoxic numnumnum num mechanism may relate membrane disruption num num
0.40214586.14747300.html.plaintext.txt	106	however yet still clear explanation amyloidogenic protein form amyloid fibril develop type num diabetes alzheimer disease
0.40214586.14747300.html.plaintext.txt	107	protein spontaneously form amyloid fibril vitro aqueous environment present cell mechanism must exist health prevent aggregation presumably include chaperone protein pathway num
0.40214586.14747300.html.plaintext.txt	108	newly synthesized protein bound chaperone protein function preventing insoluble protein e
0.40214586.14747300.html.plaintext.txt	109	iapp assp aggregating cell trafficking protein appropriate subcellular location
0.40214586.14747300.html.plaintext.txt	110	chaperon protein described promiscuous chaperone protein bind traffic numerous different protein structurally similar property num
0.40214586.14747300.html.plaintext.txt	111	individual chaperone protein traffic structurally similar peptide possible iapp assp share one chaperone protein
0.40214586.14747300.html.plaintext.txt	112	num amino acid sequence structural property amino acid iappnum num asspnum num shown
0.40214586.14747300.html.plaintext.txt	113	aligned reveal major overlap num structural property iappnum num asspnum num area hydrophobic therefore likely target binding chaperone protein
0.40214586.14747300.html.plaintext.txt	114	furthermore region iapp well established amyloidogenic sequence num asspnum num neurotoxic num
0.40214586.14747300.html.plaintext.txt	115	recently suggested toxic intermediate form iapp assp oligomers recognized antibody suggesting strong structural relationship num
0.40214586.14747300.html.plaintext.txt	116	view larger version numk fig
0.40214586.14747300.html.plaintext.txt	117	structural overlap iapp assp
0.40214586.14747300.html.plaintext.txt	118	major overlap num structural property iappnum num asspnum num amino acid classified acidic basic b nonpolar np polar uncharged pu
0.40214586.14747300.html.plaintext.txt	119	gray boxed hatched area identical amino acid gray boxed area amino acid similar structural property
0.40214586.14747300.html.plaintext.txt	120	chaperone protein pathway trafficking assp iapp shared decreased capacity trafficking either might also shared
0.40214586.14747300.html.plaintext.txt	121	circumstance aggregation either protein might occur resulting development relevant phenotype alzheimer disease andor type num diabetes
0.40214586.14747300.html.plaintext.txt	122	addition type num diabetes alzheimer disease increase prevalence aging cell chaperone protein capacity decline aging num would expected reveal partial deficiency chaperone capacity aging
0.40214586.14747300.html.plaintext.txt	123	therefore one potential explanation reported shared risk alzheimer disease type num diabetes similar pathology iapp assp share one chaperone protein functional defect shared pathway decreased chaperone protein binding decreased chaperone protein availability result shared vulnerability assp aggregate s pleated sheet cortical cell iapp aggregate s cell
0.40214586.14747300.html.plaintext.txt	124	alternative hypothesis account reported overlap islet amyloid brain amyloid subtle hyperglycemia cause alzheimer disease
0.40214586.14747300.html.plaintext.txt	125	possibility reviewed finch cohen num
0.40214586.14747300.html.plaintext.txt	126	finch cohen proposed progressive increase plasma glucose concentration occurs aging general population may important pathogenesis alzheimer disease
0.40214586.14747300.html.plaintext.txt	127	proposed may mediated induction oxidative stress glycosylation key regulatory protein numnum
0.40214586.14747300.html.plaintext.txt	128	current study least partly supportive interesting hypothesis
0.40214586.14747300.html.plaintext.txt	129	present density diffuse neuritic plaque brain increased duration diabetes age
0.40214586.14747300.html.plaintext.txt	130	prolonged exposure hyperglycemia thus might trigger brain plaque formation risk
0.40214586.14747300.html.plaintext.txt	131	however hypothesis overall increase pathological feature alzheimer disease case type num diabetes compared control subject consistent previous pathological report num
0.40214586.14747300.html.plaintext.txt	132	high risk underlying vascular disease diabetes reported increase rate vascular dementia diabetes numnum
0.40214586.14747300.html.plaintext.txt	133	furthermore hypertension hyperlipidemia strongly associated diabetes num risk factor vascular dementia num num
0.40214586.14747300.html.plaintext.txt	134	another potential mechanism decreased cognitive function long standing diabetes recurrent hypoglycemia num num
0.40214586.14747300.html.plaintext.txt	135	however present study included case type num diabetes recurrent hypoglycemia rare comparison type num diabetes
0.40214586.14747300.html.plaintext.txt	136	multiple factor might influence relationship dementia type num diabetes well difference population inclusion criterion likely contribute conflicting epidemiological data field
0.40214586.14747300.html.plaintext.txt	137	study suggest prevalence alzheimer disease increased type num diabetes num num whereas others reported decreased num num comparable numnumnum num
0.40214586.14747300.html.plaintext.txt	138	confounding factor study including current one alzheimer disease often accompanied decreased bmi presumed result decreased food intake
0.40214586.14747300.html.plaintext.txt	139	potent risk factor development type num diabetes increased bmi possible association condition obscured relative protective effect decreased bmi alzheimer disease
0.40214586.14747300.html.plaintext.txt	140	alternatively possible people alzheimer disease exercise le therefore decreased insulin sensitivity increased risk type num diabetes
0.40214586.14747300.html.plaintext.txt	141	type num diabetes tends develop younger age alzheimer disease associated decreased life expectancy early death complication diabetes might obscure subsequent development alzheimer disease
0.40214586.14747300.html.plaintext.txt	142	current pathology study unique inasmuch alzheimer disease non alzheimer disease group fully characterized life autopsy although number small provocative distinct increase risk islet amyloid patient alzheimer disease despite lower bmi
0.40214586.14747300.html.plaintext.txt	143	clinical data protocol num num also community based case defined extensively respect presence absence dementia followed relatively long term num
0.40214586.14747300.html.plaintext.txt	144	interest population based study region showed association type num diabetes alzheimer disease num
0.40214586.14747300.html.plaintext.txt	145	whereas former study examined record known case type num diabetes rochester area time study diagnosis dementia alzheimer disease numnum case present study focused much smaller cohort patient alzheimer disease num case control subject num case enrolled adpr num wherein diagnosis alzheimer disease rigorously established patient followed annually study thereafter deceased included autopsy study
0.40214586.14747300.html.plaintext.txt	146	one factor might caused discrepancy reported study changing definition diabetes
0.40214586.14747300.html.plaintext.txt	147	present study us criterion adopted fpg concentration num expert committee convened american diabetes association num
0.40214586.14747300.html.plaintext.txt	148	consequence report plasma glucose concentration required establish diagnosis diabetes decreased num mgdl num mgdl
0.40214586.14747300.html.plaintext.txt	149	furthermore high risk group established subsequent development diabetes fpg concentration num num mgdl
0.40214586.14747300.html.plaintext.txt	150	study used higher value diagnosis diabetes would report lower prevalence rate alzheimer disease control subject possibly observe difference group might evident criterion used
0.40214586.14747300.html.plaintext.txt	151	another potential confounding factor previous well present study recruitment bias
0.40214586.14747300.html.plaintext.txt	152	study performed major tertiary referral center mayo clinic subject bias
0.40214586.14747300.html.plaintext.txt	153	effort made minimize present clinical study recruitment patient local community community clinic mayo medical center
0.40214586.14747300.html.plaintext.txt	154	patient therefore attending mayo clinic community clinic primary care recruited either alzheimer disease control group clinical study
0.40214586.14747300.html.plaintext.txt	155	nonetheless recruitment bias may introduced study failure affected patient seek medical care therefore unavailable consideration
0.40214586.14747300.html.plaintext.txt	156	present study greater proportion woman men clinical study might part reflection recruitment bias also potentially due shorter life span men woman alzheimer disease diagnosed
0.40214586.14747300.html.plaintext.txt	157	autopsy study alzheimer disease case control subject islet amyloid would subject ascertainment bias adpr since case adpr death
0.40214586.14747300.html.plaintext.txt	158	autopsy study type num diabetes case versus control subject brain amyloid sought minimize deliberate bias including recent autopsy reverse sequence case appropriate inclusion criterion
0.40214586.14747300.html.plaintext.txt	159	people autopsy course subgroup general population bias considered
0.40214586.14747300.html.plaintext.txt	160	notwithstanding limitation opportunity presenting autopsy data case well characterized life compared autopsy study
0.40214586.14747300.html.plaintext.txt	161	conclusion report increased prevalence type num diabetes ifg community cohort patient alzheimer disease followed olmsted county rochester minnesota
0.40214586.14747300.html.plaintext.txt	162	also report increased islet amyloid patient alzheimer disease compared control subject
0.40214586.14747300.html.plaintext.txt	163	however observe increased frequency brain amyloid case type num diabetes although case type num diabetes brain amyloid extent amyloid increased longer duration diabetes correlate extend age patient type num diabetes
0.40214586.14747300.html.plaintext.txt	164	taken together clinical pathological study support possible link neurodegenerative process lead loss cortical brain cell alzheimer disease loss s cell type num diabetes
0.40214586.14747300.html.plaintext.txt	165	acknowledgment study funded grant national institute aging mayo adpr ag num mayo alzheimer disease research center ag num j
0.40214586.14747300.html.plaintext.txt	166	larry hillblom foundation p
0.40214586.14747300.html.plaintext.txt	167	acknowledge excellent technical assistance jane kahl karen laakso staff mayo alzheimer disease research center excellent editorial assistance kim denkers
0.40214586.14747300.html.plaintext.txt	168	thank robert rizza suggestion support
0.40214586.14747300.html.plaintext.txt	169	advisory panel elam pharmaceutical received honorarium pfizer eisai novartis janssen received grantresearch support national institute aging pfizer eisai
0.40214586.14747300.html.plaintext.txt	170	address correspondence reprint request dr
0.40214586.14747300.html.plaintext.txt	171	butler division endocrinology diabetes keck school medicine university southern california num san pablo street bmt bnum los angeles ca num
0.40214586.14747300.html.plaintext.txt	172	received publication august num num accepted revised form october num num
0.40214586.14747300.html.plaintext.txt	173	assp amyloid s protein adpr alzheimer disease patient registry fpg fasting plasma glucose iapp islet amyloid polypeptide ifg impaired fasting glucose nft neurofibrillary tangle
0.40480462.14976159.html.plaintext.txt	0	law mass action applied neurodegenerative disease hypothesis concerning etiology pathogenesis complex disease andrew singleton amanda myers john hardy
0.40480462.14976159.html.plaintext.txt	1	laboratory neurogenetics national institute aging national institute health building num room numcnum mscnum bethesda md num usa
0.40480462.14976159.html.plaintext.txt	2	received january num num revised february num num accepted february num num
0.40480462.14976159.html.plaintext.txt	3	finding well established driven therapeutic research especially allowed development animal model disease well defined therapeutic target num
0.40480462.14976159.html.plaintext.txt	4	example precise pathologic specie protein obscure one debated whether deposit intermediate specie oligomer responsible
0.40480462.14976159.html.plaintext.txt	5	extensively investigated balance recent data favoring smaller intermediate specie toxic entity num however generality fact mutated protein example deposited suggests process pathogenicity related although perhaps separable process deposition
0.40480462.14976159.html.plaintext.txt	6	studying autosomal dominant form disease researcher hope gain insight common sporadic form mechanistic perspective certainly case
0.40480462.14976159.html.plaintext.txt	7	however perhaps surprisingly last num year become clear case many disease least haplotype mendelian pathogenic locus influence disease risk sporadic disease
0.40480462.14976159.html.plaintext.txt	8	review briefly summarise data make prediction concerning etiology pathogenesis neurodegenerative disease
0.40480462.14976159.html.plaintext.txt	9	first though worth noting haplotypic association mean mechanistic perspective absence coding change haplotypic association implies genetic variability either amount expression protein alternate splicing protein contributes disease risk
0.40480462.14976159.html.plaintext.txt	10	alzheimers disease extensive sequencing app gene late onset alzheimers disease failed identify mutation num
0.40480462.14976159.html.plaintext.txt	11	however analysis data sibpairs affected late onset alzheimers disease consistently suggested app locus form disease numnum
0.40480462.14976159.html.plaintext.txt	12	suggests genetic variability app locus contributes disease risk although precise variability identified
0.40480462.14976159.html.plaintext.txt	13	finding consistent longstanding observation individual trisomy num inevitably develop alzheimer pathology fifth decade num however case syndrome caused triplication chromosome num distal app gene develop alzheimers disease num
0.40480462.14976159.html.plaintext.txt	14	thus three copy app gene lead alzheimer pathology fifth decade yet unidentified genetic variability app locus appears contribute disease risk
0.40480462.14976159.html.plaintext.txt	15	frontal temporal dementia tangle disease mutation tau gene cause many case autosomal dominant frontal temporal dementia tau pathology
0.40480462.14976159.html.plaintext.txt	16	many sporadic disease tau pathology occurs usually tangle also pick body argyrophilic grain num
0.40480462.14976159.html.plaintext.txt	17	two genetic haplotype clade caucasian population designated hnum hnum differ intron size promoter sequence wobble base num
0.40480462.14976159.html.plaintext.txt	18	hnum haplotype frequency num caucasian thus hnum homozygote constitute num population
0.40480462.14976159.html.plaintext.txt	19	however individual one three sporadic tau disease progressive supranuclear palsy num corticobasal degeneration num argyrophilic grain disease num although pick disease num guam disease num show robust association hnum homozygosity frequency hnum homozygote num
0.40480462.14976159.html.plaintext.txt	20	data show clearly variability either tau expression tau splicing variability contribute disease risk
0.40480462.14976159.html.plaintext.txt	21	case difficult determine whether control splicing control expression key variable indeed clear many mutation lead mendelian disease altering alternate splicing numnum
0.40480462.14976159.html.plaintext.txt	22	parkinson diseaselewy body dementia mutation synuclein gene cause autosomal dominant parkinson disease synuclein primary component lewy body pathognomic feature parkinson disease num
0.40480462.14976159.html.plaintext.txt	23	genetic variability synuclein promoter contributes risk sporadic parkinson disease numnum associated promoter allele stronger promoter num
0.40480462.14976159.html.plaintext.txt	24	perhaps convincingly triplication whole synuclein locus cause autosomal dominant parkinson diseaselewy body dementia onset age fourth decade num duplication locus lead disease fifth decade num
0.40480462.14976159.html.plaintext.txt	25	thus parkinson disease clear dose relationship synuclein expression disease occurrence normal genetic variability promoter contributing risk typical idiopathic disease multiplication locus causing mendelian disease onset age determined precise dose
0.40480462.14976159.html.plaintext.txt	26	protein study cell line affected individual kindred reveal amount synuclein produced correlate disease
0.40480462.14976159.html.plaintext.txt	27	finding unexpected perhaps
0.40480462.14976159.html.plaintext.txt	28	chemist know power law mass action perhaps surprised u may profound implication determining risk neurodegenerative disease num
0.40480462.14976159.html.plaintext.txt	29	course one therapeutic approach case therefore would aim reduce concentration toxic protein relevant tissue compartment either decreased production increased breakdown
0.40480462.14976159.html.plaintext.txt	30	footnote correspondence addressed
0.40480462.14976159.html.plaintext.txt	31	tel num num fax num num email hardyjatmail
0.40480462.14976159.html.plaintext.txt	32	num coding splice donor site mutation tau cause autosomal dominant dementia ftdp num
0.40480462.14976159.html.plaintext.txt	33	num mutation synuclein gene identified family parkinson disease
0.40480462.14976159.html.plaintext.txt	34	num solved unsolved mystery genetics early onset alzheimers disease
0.40480462.14976159.html.plaintext.txt	35	num role presenilin cofactor gamma secretase complex
0.40480462.14976159.html.plaintext.txt	36	num reconstitution gamma secretase activity
0.40480462.14976159.html.plaintext.txt	37	num genetic classification primary neurodegenerative disease
0.40480462.14976159.html.plaintext.txt	38	num addls protofibrils missing link neurobiol
0.40480462.14976159.html.plaintext.txt	39	num homozygous prion protein genotype predisposes sporadic creutzfeldt jakob disease
0.40480462.14976159.html.plaintext.txt	40	num genetic predisposition iatrogenic creutzfeldt jakob disease
0.40480462.14976159.html.plaintext.txt	41	num sporadic variant creutzfeldt jakob disease associated polymorphism upstream prnp exon num
0.40480462.14976159.html.plaintext.txt	42	num mouse devoid prp resistant scrapie
0.40480462.14976159.html.plaintext.txt	43	num evidence common allelic variation amyloid precursor protein app gene confers susceptibility alzheimers disease
0.40480462.14976159.html.plaintext.txt	44	num genetic variability amyloid beta precursor protein locus may contribute risk late onset alzheimers disease
0.40480462.14976159.html.plaintext.txt	45	num amyloid precursor protein locus late onset alzheimer disease
0.40480462.14976159.html.plaintext.txt	46	num presenile dementia alzheimers disease mongolism
0.40480462.14976159.html.plaintext.txt	47	num molecular mapping alzheimer type dementia down syndrome
0.40480462.14976159.html.plaintext.txt	48	num tau protein pathology neurodegenerative disease
0.40480462.14976159.html.plaintext.txt	49	num association extended haplotype tau gene progressive supranuclear palsy
0.40480462.14976159.html.plaintext.txt	50	num corticobasal degeneration progressive supranuclear palsy share common tau haplotype
0.40480462.14976159.html.plaintext.txt	51	num argyrophilic grain disease sporadic num repeat tauopathy
0.40480462.14976159.html.plaintext.txt	52	num analysis tau haplotype pick disease
0.40480462.14976159.html.plaintext.txt	53	num neurodegenerative disease guam analysis tau
0.40480462.14976159.html.plaintext.txt	54	num missing tau mutation identified
0.40480462.14976159.html.plaintext.txt	55	conum numlinktypedoi crossrefmedline
0.40480462.14976159.html.plaintext.txt	56	num alpha synucleinopathies parkinson disease dementia lewy body multiple system atrophy
0.40480462.14976159.html.plaintext.txt	57	num increased susceptibility sporadic parkinson disease certain combined synucleinapolipoprotein e genotype
0.40480462.14976159.html.plaintext.txt	58	conum xlinktypedoi crossrefmedline
0.40480462.14976159.html.plaintext.txt	59	num synuclein gene haplotype associated parkinson disease
0.40480462.14976159.html.plaintext.txt	60	num functional analysis intra allelic variation nacp repnum synuclein gene
0.40480462.14976159.html.plaintext.txt	61	num synuclein locus triplication cause parkinson disease
0.40480462.14976159.html.plaintext.txt	62	num genomic multiplication alpha synuclein gene three kindred familial lewy body disease
0.40480462.14976159.html.plaintext.txt	63	american society human genetics
0.40480462.14976159.html.plaintext.txt	64	num synuclein implicated parkinson disease present extracellular biological fluid including human plasma
0.40480462.14976159.html.plaintext.txt	65	num functional analysis human promoter polymorphism
0.40480462.14976159.html.plaintext.txt	66	num distortion allelic expression apolipoprotein e alzheimers disease
0.40480462.14976159.html.plaintext.txt	67	num allelic variation human gene expression
0.40480462.14976159.html.plaintext.txt	68	num normal huntington disease hd allele closely linked gene influence age onset hd
0.40480462.14976159.html.plaintext.txt	69	jr num molecular crowding accelerates fibrillization synuclein could increase cytoplasmic protein concentration induce parkinson disease biochemistry num num num
0.43645546.14764623.html.plaintext.txt	0	alzheimers disease one disorder many gene lars bertram rudolph e
0.43645546.14764623.html.plaintext.txt	1	genetics aging research unit department neurology massgeneral institute neurodegenerative disease massachusetts general hospital harvard medical school charlestown ma usa
0.43645546.14764623.html.plaintext.txt	2	received january num num accepted january num num
0.43645546.14764623.html.plaintext.txt	3	overview concordant linkageassociation region observed full genome screen published num disease specific characteristic together advent relatively inexpensive powerful high throughput genotyping technology near completion human genome sequence led steep increase number laboratory studying genetics ad worldwide
0.43645546.14764623.html.plaintext.txt	4	date le num full genome screen using linkage association based methodology published ad using overlapping identical sample employing different set genetic marker andor analytic strategy num num table num
0.43645546.14764623.html.plaintext.txt	5	hand number locus specific candidate gene based ad association study become nearly intractable
0.43645546.14764623.html.plaintext.txt	6	course num num gene reported show either positive negative evidence association different ad phenotype per month peer reviewed journal listed ncbis pubmed
0.43645546.14764623.html.plaintext.txt	7	despite vast effort single gene yet emerged attain nearly degree replication consistency observed literally hundred laboratory studying association apoe num ad
0.43645546.14764623.html.plaintext.txt	8	review present discus finding genetic ad association study published num excluding explicitly searching cause early onset familial ad case
0.43645546.14764623.html.plaintext.txt	9	using data example attempt pinpoint methodological difficulty likely underlie remarkable failure replicate genetic finding using current approach
0.43645546.14764623.html.plaintext.txt	10	candidate gene study searching pubmed www
0.43645546.14764623.html.plaintext.txt	11	govpubmed keywords alzheimer association associated paper published january num december num num retrieved total num study december num num num directly deal genetic association candidate polymorphism ad
0.43645546.14764623.html.plaintext.txt	12	seen table num study examined total num genetic locus locus set marker within num mb genomic interval num different chromosome
0.43645546.14764623.html.plaintext.txt	13	total num analyzed gene within locus found positive judged author num tested negative
0.43645546.14764623.html.plaintext.txt	14	interestingly even num year discovery largest number nnum report focusing single gene dealt association apoe ad using new polymorphism new samplesethnic group new phenotype
0.43645546.14764623.html.plaintext.txt	15	study considered total num positive num negative paper remained
0.43645546.14764623.html.plaintext.txt	16	overview chromosomal locus tested genetic association ad num num represents one prolific vintage late onset ad genetic study next pressing question large quantity study also dilute quality product perhaps even making unpalatable quaff answer opinion yes least majority case
0.43645546.14764623.html.plaintext.txt	17	growing consensus success rate reliability genetic association study complex disease depend fulfillment several criterion numnum three discussed detail
0.43645546.14764623.html.plaintext.txt	18	addition classic requirement least plausible biological andor positional candidacy investigated locus well direct proof pathophysiological consequence positive disease association
0.43645546.14764623.html.plaintext.txt	19	former criterion fulfilled vast majority ad candidate gene investigated thus far latter condition elusive
0.43645546.14764623.html.plaintext.txt	20	due several factor generally bedevil study genetic association complex disease linkage disequilibrium actual functionally relevant disease modifying variant small effect size impede detection significant effect using basic molecular biochemical assay possibly involvement yet unknown pathophysiological mechanism
0.43645546.14764623.html.plaintext.txt	21	situation apoe num ad serf good example genetic association per se extremely well established past decade still consensus association translates pathophysiologically numnum
0.43645546.14764623.html.plaintext.txt	22	thus attempting uncover functional consequence putative new disease association propose emphasis must placed criterion allow better distinction false positive well false negative finding prior initial publication
0.43645546.14764623.html.plaintext.txt	23	power sample size structure enable investigator detect effect size moderate small extent obvious concern report negative outcome power study also governs rate false positive finding
0.43645546.14764623.html.plaintext.txt	24	probability observed significant association indeed genuine observed chance num num
0.43645546.14764623.html.plaintext.txt	25	factor influencing ability detect meaningful effect include attributable risk polymorphism overall genetic variance degree linkage disequilibrium ld associated allele actual disease predisposing variant mode inheritance lesser extent disease prevalence
0.43645546.14764623.html.plaintext.txt	26	variable course difficult estimate true disease gene unknown power given sample size fairly easily calculated variety possible plausible scenario
0.43645546.14764623.html.plaintext.txt	27	practice however still remains exception
0.43645546.14764623.html.plaintext.txt	28	recent study estimated minimal number case control sufficient achieve num power num
0.43645546.14764623.html.plaintext.txt	29	num usually far greater num actual disease allele tested directly even favorable circumstance num
0.43645546.14764623.html.plaintext.txt	30	interesting regardless estimate num study published num still used smaller sample size thus probably suitable use reaching reliable conclusion
0.43645546.14764623.html.plaintext.txt	31	replicability result validatedreplicated independent sample sufficient size report significant association putative candidate gene ad every chromosome human genome past num year num none finding exception apoe num yet replicated consistently
0.43645546.14764623.html.plaintext.txt	32	many seemingly positive result could validated independent dataset prior first publication several author long suggesting guideline proper quality control genetic association finding numnumnumnumnum
0.43645546.14764623.html.plaintext.txt	33	current inflation probable false positive report may avoided independent replication sought earlier
0.43645546.14764623.html.plaintext.txt	34	independent sample found house establishment least temporary consortium collaborative laboratory test others positive signal prior publication would represent easy effective mean restore credibility
0.43645546.14764623.html.plaintext.txt	35	upon review num ad genetics literature le num study either referred finding two independent sample published tandem independent report investigating candidate gene andor genetic variant
0.43645546.14764623.html.plaintext.txt	36	haplotype structure author made attempt elucidate structure underlying haplotype architecture current systematic assessment haplotype structure various region throughout genome past num num year emphasized importance performing haplotype systematic ld analysis searching novel complex disease gene numnum especially effect size expected lower conferred apoe num
0.43645546.14764623.html.plaintext.txt	37	addition increasing power analysis approach also reduces number statistical test need performed lead decrease false positive finding
0.43645546.14764623.html.plaintext.txt	38	several recently published complex disease association would impossible observe without thorough assessment underlying haplotype architecture num num
0.43645546.14764623.html.plaintext.txt	39	along line recent study apoe shown locus would easily identified mean haplotype analysis alone even without prior knowledge num polymorphism numnum
0.43645546.14764623.html.plaintext.txt	40	yet num one third study investigated one polymorphism per locus
0.43645546.14764623.html.plaintext.txt	41	half carried le thorough assessment haplotype structure
0.43645546.14764623.html.plaintext.txt	42	four polymorphism per gene
0.43645546.14764623.html.plaintext.txt	43	num paper published num topic genetic association candidate gene different ad phenotype num num fulfilled least two criterion
0.43645546.14764623.html.plaintext.txt	44	likely many observed discrepancy across study could explained lack methodological thoroughness
0.43645546.14764623.html.plaintext.txt	45	nonetheless three locus addition apoe tested positive across least three study chromosome numpnum numqnum numqnum table num
0.43645546.14764623.html.plaintext.txt	46	locus covered remainder review
0.43645546.14764623.html.plaintext.txt	47	chromosome numpnum chromosomal region implicated harboring putative ad gene early num based association finding variant highly polymorphic major histocompatibility complex region hla num mb ad small case control study num
0.43645546.14764623.html.plaintext.txt	48	two potential ad candidate map within num mb interval gene encoding hereditary haemochromatosis protein hfe num mb tumor necrosis factor alpha tnfa num mb
0.43645546.14764623.html.plaintext.txt	49	num two study reported significant evidence association latter two gene numnum two study confirm finding numnum
0.43645546.14764623.html.plaintext.txt	50	another candidate gene located region hapanumb found associated certain neuropsychological variable num disease risk num
0.43645546.14764623.html.plaintext.txt	51	finally one study investigated variation onset age function hla anum allele small sample ad patient find significant effect num
0.43645546.14764623.html.plaintext.txt	52	literature search association study gene including year num yielded least num positive study num report found evidence genetic involvement factor
0.43645546.14764623.html.plaintext.txt	53	evidence direct involvement tnfa as production toxicity num direct proof pathogenetic relevance genesproteins remains seen
0.43645546.14764623.html.plaintext.txt	54	furthermore full genome screen ad gene consistently yielded signal numpnum residing num num mb whereas associated gene map num mb proximal
0.43645546.14764623.html.plaintext.txt	55	thus increasing evidence supporting existence putative ad locus numpnum general possibility actual disease gene yet identified excluded despite overlapping positive result year past study
0.43645546.14764623.html.plaintext.txt	56	chromosome numqnum six candidate locus analyzed region numqnum numqnum num three reported associated ad phenotype across multiple sample
0.43645546.14764623.html.plaintext.txt	57	cdcnumvrnum tnfrsfnumide gstonumnum
0.43645546.14764623.html.plaintext.txt	58	locus found associated one group investigator located num num mb encompasses gene tnfrsfnum num mb idekiffnumhhex num num
0.43645546.14764623.html.plaintext.txt	59	probably best candidate biological ground ide encoding insulin degrading enzyme protein ide
0.43645546.14764623.html.plaintext.txt	60	metalloprotease shown degrade monomeric as aggregate oligomeric form ultimately s amyloid plaque num
0.43645546.14764623.html.plaintext.txt	61	several issue proposed mode action still remain controversial e
0.43645546.14764623.html.plaintext.txt	62	precise cellular location as cleavage relevance ide functiondysfunction development ad number animal model available showing predicted effect vivo num num
0.43645546.14764623.html.plaintext.txt	63	num two paper published showing allelic association microsatellite marker region numnum two report find association ide variant nearby marker ad numnum
0.43645546.14764623.html.plaintext.txt	64	note data one negative study num actually largely overlap positive paper edland et al
0.43645546.14764623.html.plaintext.txt	65	num important exception author first paper account potential interaction ide apoe num status
0.43645546.14764623.html.plaintext.txt	66	may crucial since latter study found significant effect ide ad risk individual lacking apoe num allele
0.43645546.14764623.html.plaintext.txt	67	clearly study independent sample sufficient size necessary elucidate potential role ide variant development ad general population
0.43645546.14764623.html.plaintext.txt	68	addition ide locus total four gene long arm chromosome num found associated ad
0.43645546.14764623.html.plaintext.txt	69	two cdcnum vrnum map num mb proximal ide two gstonumnum prssnum map num num mb distal
0.43645546.14764623.html.plaintext.txt	70	none association yet confirmed independent ad sample noteworthy two gene also found associated neurodegenerative illness frontotemporal dementia cdcnum num parkinson disease gstonumnum num potentially suggesting common pathway leading neuronal cell death across syndrome
0.43645546.14764623.html.plaintext.txt	71	cdcnum encodes cell division cycle num protein involved phosphorylation tau app found neuron bearing neurofibrillary tangle
0.43645546.14764623.html.plaintext.txt	72	gstonum num encode glutathione transferase omega num num involved physiological response oxidative stress may particular responsible regulating expression inflammatory cytokine like ilnum s
0.43645546.14764623.html.plaintext.txt	73	thus plausible ad candidate gene positional well biologicalbiochemical ground study still necessary elucidate proposed role influencing risk andor age onset ad general population
0.43645546.14764623.html.plaintext.txt	74	chromosome numqnum region near tip long arm chromosome num implicated one full genome screen published date num therefore appear table num
0.43645546.14764623.html.plaintext.txt	75	yet total three study showing significant association ad candidate gene num bace encoding s site app cleaving enzyme s secretase num num
0.43645546.14764623.html.plaintext.txt	76	protein excellent ad candidate biochemical ground s secretase cleavage app as liberated precursor via secretase cleavage
0.43645546.14764623.html.plaintext.txt	77	interestingly contrast putative ad association discussed appears high degree consistency respect site allelic nature underlying finding positive study including initial report nowotny colleague published num num observe representation g allele synonymous snp located codon num exon num ad case compared healthy control
0.43645546.14764623.html.plaintext.txt	78	furthermore study observed effect pronounced carrier apoe num allele yielding significantly elevated odds ratio ranging num num
0.43645546.14764623.html.plaintext.txt	79	contrast four positive association equal number study literature showing apparent effect bace polymorphism ad
0.43645546.14764623.html.plaintext.txt	80	however must pointed one studied early onset familial ad case num remaining study account potential interaction apoe num allele num num
0.43645546.14764623.html.plaintext.txt	81	unless done similar situation encountered variant tested ide see firm conclusion reached whether exon num polymorphism bace genetic risk factor ad sample
0.43645546.14764623.html.plaintext.txt	82	thus three known app cleaving enzyme associated protein adamnumnum num s bace bacenum secretase psennum aphnuma ncstn pennum already tested genetic association ad phenotype bace currently show promise genuine relevant risk factor late onset ad
0.43645546.14764623.html.plaintext.txt	83	case putative ad gene study using sufficiently sized sample appropriate analytic strategy need performed general conclusion reached
0.43645546.14764623.html.plaintext.txt	84	note first study examining putative genetic role bace late onset ad num also report significant effect exon num polymorphism case control sample chinese origin num
0.43645546.14764623.html.plaintext.txt	85	footnote correspondence addressed genetics aging research unit department neurology massachusetts general hospital num numth street charlestown ma num usa
0.43645546.14764623.html.plaintext.txt	86	tel num num fax num num email tanziathelix
0.43645546.14764623.html.plaintext.txt	87	num role heredity late onset alzheimer disease vascular dementia
0.43645546.14764623.html.plaintext.txt	88	num number trait locus late onset alzheimer disease
0.43645546.14764623.html.plaintext.txt	89	num genetics adult onset neuropsychiatric disease complexity conundra science num num num
0.43645546.14764623.html.plaintext.txt	90	num clinical diagnosis alzheimers disease report nincds adrda work group auspex department health human service task force alzheimers disease
0.43645546.14764623.html.plaintext.txt	91	num diagnostic accuracy alzheimers disease neuropathological study
0.43645546.14764623.html.plaintext.txt	92	num accuracy clinical diagnosis alzheimer disease clinical feature patient non alzheimer disease neuropathology
0.43645546.14764623.html.plaintext.txt	93	num result high resolution genome screen num alzheimers disease family
0.43645546.14764623.html.plaintext.txt	94	num complete genomic screen late onset familial alzheimer disease
0.43645546.14764623.html.plaintext.txt	95	evidence new locus chromosome num
0.43645546.14764623.html.plaintext.txt	96	num genome survey novel alzheimer disease risk locus result num cm resolution
0.43645546.14764623.html.plaintext.txt	97	num full genome scan late onset alzheimers disease
0.43645546.14764623.html.plaintext.txt	98	num identification novel gene late onset alzheimers disease
0.43645546.14764623.html.plaintext.txt	99	num novel method two locus linkage analysis applied genome scan late onset alzheimers disease
0.43645546.14764623.html.plaintext.txt	100	num genome wide linkage disequilibrium mapping late onset alzheimers disease finland
0.43645546.14764623.html.plaintext.txt	101	num age onset two common neurodegenerative disease genetically controlled
0.43645546.14764623.html.plaintext.txt	102	num full genome screen alzheimer disease stage ii analysis
0.43645546.14764623.html.plaintext.txt	103	num second locus late onset alzheimer disease genome scan reveals linkage nump epistasis nump amyloid precursor protein region
0.43645546.14764623.html.plaintext.txt	104	num identification multiple locus alzheimer disease consanguineous israeli arab community
0.43645546.14764623.html.plaintext.txt	105	num ordered subset linkage analysis detects novel alzheimer disease locus chromosome numqnum numqnum
0.43645546.14764623.html.plaintext.txt	106	num genetic association study gene search disease
0.43645546.14764623.html.plaintext.txt	107	num association study design complex disease
0.43645546.14764623.html.plaintext.txt	108	num apolipoprotein e alzheimers disease
0.43645546.14764623.html.plaintext.txt	109	num role apoeabeta interaction pathogenesis alzheimers disease cerebral amyloid angiopathy
0.43645546.14764623.html.plaintext.txt	110	num predictive value single diagnostic test unselected population
0.43645546.14764623.html.plaintext.txt	111	num replication validity genetic association study
0.43645546.14764623.html.plaintext.txt	112	num sample size calculation population family based case control association study marker genotype
0.43645546.14764623.html.plaintext.txt	113	num replication refutation status alzheimers disease genetic research
0.43645546.14764623.html.plaintext.txt	114	num proposed guideline paper describing dna polymorphism disease association
0.43645546.14764623.html.plaintext.txt	115	num opinion candidate gene approach studying complex genetic trait practical consideration
0.43645546.14764623.html.plaintext.txt	116	num structure haplotype block human genome
0.43645546.14764623.html.plaintext.txt	117	num using haplotype block map human complex trait locus
0.43645546.14764623.html.plaintext.txt	118	num genetic evidence involvement tau progressive supranuclear palsy
0.43645546.14764623.html.plaintext.txt	119	num genetic variation gene encoding calpain num associated type num diabetes mellitus
0.43645546.14764623.html.plaintext.txt	120	num genetic variation numqnum cytokine gene cluster confers susceptibility crohn disease
0.43645546.14764623.html.plaintext.txt	121	num snping away complex disease analysis single nucleotide polymorphism around apoe alzheimer disease
0.43645546.14764623.html.plaintext.txt	122	num genetic analysis casecontrol data using estimated haplotype frequency application apoe locus variation alzheimers disease
0.43645546.14764623.html.plaintext.txt	123	num histocompatibility antigen alzheimers disease
0.43645546.14764623.html.plaintext.txt	124	num tumour necrosis factor alpha gene polymorphism alzheimers disease
0.43645546.14764623.html.plaintext.txt	125	num association hfe mutation neurodegeneration oxidative stress alzheimers disease correlation apoe
0.43645546.14764623.html.plaintext.txt	126	num association hfe mutation unsuccessful ageing study alzheimers disease patient northern italy
0.43645546.14764623.html.plaintext.txt	127	num tumor necrosis factor alpha polymorphism c numt associated alzheimers disease vascular dementia italian population
0.43645546.14764623.html.plaintext.txt	128	num hspnum num hspanumb associated noncognitive symptom late onset alzheimers disease
0.43645546.14764623.html.plaintext.txt	129	num joint analysis candidate gene related alzheimers disease spanish population
0.43645546.14764623.html.plaintext.txt	130	num association anum allele hla system age onset alzheimers disease
0.43645546.14764623.html.plaintext.txt	131	num inflammation alzheimers disease
0.43645546.14764623.html.plaintext.txt	132	num insulin degrading enzyme ide genetic variant risk alzheimers disease evidence effect modification apolipoprotein e apoe
0.43645546.14764623.html.plaintext.txt	133	num evidence role promoter variant tnfrsfnum gene alzheimer disease
0.43645546.14764623.html.plaintext.txt	134	num genetic variation haplotype block spanning ide influence alzheimer disease
0.43645546.14764623.html.plaintext.txt	135	num insulin degrading enzyme regulates extracellular level amyloid beta protein degradation
0.43645546.14764623.html.plaintext.txt	136	num insulin degrading enzyme regulates level insulin amyloid beta protein beta amyloid precursor protein intracellular domain vivo
0.43645546.14764623.html.plaintext.txt	137	num amyloid beta peptide level brain inversely correlated insulysin activity level vivo
0.43645546.14764623.html.plaintext.txt	138	num enhanced proteolysis beta amyloid app transgenic mouse prevents plaque formation secondary pathology premature death
0.43645546.14764623.html.plaintext.txt	139	num evidence genetic linkage alzheimers disease chromosome numq
0.43645546.14764623.html.plaintext.txt	140	num confirmation association dnumsnum alzheimers disease case control sample
0.43645546.14764623.html.plaintext.txt	141	num substantial linkage disequilibrium across insulin degrading enzyme locus association late onset alzheimers disease
0.43645546.14764623.html.plaintext.txt	142	num polymorphism insulin degrading enzyme gene associated alzheimers disease
0.43645546.14764623.html.plaintext.txt	143	num increased frequency new polymorphism cell division cycle num cdcnum gene patient alzheimers disease frontotemporal dementia
0.43645546.14764623.html.plaintext.txt	144	num glutathione transferase omega num modifiesage onset alzheimer disease parkinson disease
0.43645546.14764623.html.plaintext.txt	145	num specific bacenum genotype provide additional risk late onset alzheimer disease apoe epsilon num carrier
0.43645546.14764623.html.plaintext.txt	146	num polymorphism bace gene influence risk alzheimers disease
0.43645546.14764623.html.plaintext.txt	147	num association study alzheimers disease gene involved abeta biosynthesis aggregation degradation suggestive result bacenum
0.43645546.14764623.html.plaintext.txt	148	num association study using novel polymorphism bacenum bacenum
0.43645546.14764623.html.plaintext.txt	149	num amyloid beta secretase gene bace neither mutated associated early onset alzheimers disease
0.43645546.14764623.html.plaintext.txt	150	num bace gene genomic structure candidate gene study late onset alzheimers disease
0.43645546.14764623.html.plaintext.txt	151	num mutation open reading frame beta site app cleaving enzyme bace locus common cause alzheimers disease
0.43645546.14764623.html.plaintext.txt	152	num association beta site app cleaving enzyme bace cnumg polymorphism alzheimers disease
0.43645546.14764623.html.plaintext.txt	153	num numgc polymorphism exon num bacenum gene may associated sporadic alzheimers disease chinese han
0.43713617.11809755.html.plaintext.txt	0	insulin degrading enzyme rapidly remove amyloid precursor protein intracellular domain aicd dieter edbauer michael willem sven lammich harald steiner christian haass
0.43713617.11809755.html.plaintext.txt	1	department biochemistry laboratory alzheimers parkinson disease research adolf butenandt institute ludwig maximilians university schillerstrasse num num munich germany
0.43713617.11809755.html.plaintext.txt	2	received publication december num num revised form january num num
0.43713617.11809755.html.plaintext.txt	3	current evidence strongly implicates aggregation deposition amyloid peptide anum brain alzheimers disease patient invariant pathological feature num
0.43713617.11809755.html.plaintext.txt	4	generated amyloid precursor protein app endoproteolytic processing
0.43713617.11809755.html.plaintext.txt	5	two sequential cleavage first secretase followed secretase required liberate review see ref
0.43713617.11809755.html.plaintext.txt	6	intramembranous secretase cleavage dependent biologically active presenilins p may unusual aspartyl protease num num probably constitute active site secretase review see ref
0.43713617.11809755.html.plaintext.txt	7	ps involved proteolytic processing app also similar intramembraneous cut notch num
0.43713617.11809755.html.plaintext.txt	8	notch like app type transmembrane protein undergoes similar endoproteolytic processing pathway review see ref
0.43713617.11809755.html.plaintext.txt	9	ectodomain shedding notch cleaved within close transmembrane domain secretase like snum protease activity
0.43713617.11809755.html.plaintext.txt	10	snum cut finally liberates notch intracellular domain nicd key molecule developmental signal transduction num
0.43713617.11809755.html.plaintext.txt	11	cleavage notch snum p dependent blocked secretase inhibitor num
0.43713617.11809755.html.plaintext.txt	12	consistent role ps notch signaling psnumpsnum double knockout mouse phenotype similar notchnum mouse num notch cleavage completely inhibited p deficient cell num num
0.43713617.11809755.html.plaintext.txt	13	requirement ps nicd formation secretase cleavage app provided basis hypothesis secretase generated cytoplasmic domain app may also carry important function nuclear signaling
0.43713617.11809755.html.plaintext.txt	14	recently several report num num described secretase generated cytoplasmic fragment app termed aicd app intracellular domain num analogy nicd
0.43713617.11809755.html.plaintext.txt	15	aicd generated p dependent mechanism since psnum gene knockout well dominant negative psnum mutation dnumn inhibited aicd generation num
0.43713617.11809755.html.plaintext.txt	16	moreover secretase inhibitor including one known bind ps also blocked aicd generation vivo vitro num num num
0.43713617.11809755.html.plaintext.txt	17	interestingly n terminus aicd predominantly generated cut amino acid num num amyloid domain expected secretase cut amino acid num num num num
0.43713617.11809755.html.plaintext.txt	18	cleavage release vivo num amino acid long aicd fragment cytoplasm predicted num num amino acid fragment
0.43713617.11809755.html.plaintext.txt	19	sequence comparison revealed cleavage occurs similar position snum cleavage notch num num
0.43713617.11809755.html.plaintext.txt	20	taken together analogy app notch processing may favor idea aicd like nicd physiological function nuclear signal transduction
0.43713617.11809755.html.plaintext.txt	21	indeed recent finding highly sensitive reporter gene assay supported hypothesis aicd may involved gene transcription num
0.43713617.11809755.html.plaintext.txt	22	however aicd alone sufficient allow detection significant transcriptional activity reporter gene assay
0.43713617.11809755.html.plaintext.txt	23	upon co transfection fenum nuclear adaptor protein shown bind app cytoplasmic tail num num significant transcriptional activity observed num
0.43713617.11809755.html.plaintext.txt	24	may related observation recombinant num amino acid aicd like molecule stabilized co expression fenum num although latter confirmed others num
0.43713617.11809755.html.plaintext.txt	25	cell line cell culture human embryonic kidney num cell heknum cultured dulbeccos modified eagle medium supplemented num fetal bovine serum num penicillinstreptomycin num microgml gnum select app expression num microgml zeocin select ide expression
0.43713617.11809755.html.plaintext.txt	26	heknum cell stably expressing rat ide variant generated transfection heknum cell stably expressing appnum containing swedish mutation swapp num
0.43713617.11809755.html.plaintext.txt	27	mouse neuroblastoma nnuma cell stably expressing swapp cultured described previously num
0.43713617.11809755.html.plaintext.txt	28	protease inhibitor protease inhibitor used following final concentration vitro assay aicd degradation protease inhibitor mix without edta num x complete roche molecular biochemicals dapt num microm gift boehringer ingelheim kg edta num mm sigma numnum o phenanthroline pnt num mm sigma phosphoramidon num microm calbiochem bestatin num microm calbiochem clasto lactacystin lactone num microm sigma mgnum num microm calbiochem n ethylmaleimide nem num
0.43713617.11809755.html.plaintext.txt	29	num num mm sigma dynorphin num num num
0.43713617.11809755.html.plaintext.txt	30	num mm bachem pro ile num mm bachem cfp aay pab cfp num microm gift ian smith insulin num num microgml sigma zincov num microm calbiochem enum num microm roche molecular biochemicals phenylmethylsulfonyl fluoride num mm sigma leupeptin num microgml roche molecular biochemicals aprotinin num microgml roche molecular biochemicals antipain num microgml roche molecular biochemicals pepstatin num microgml calbiochem
0.43713617.11809755.html.plaintext.txt	31	cdna construct rat ide cdna gift r
0.43713617.11809755.html.plaintext.txt	32	nonfunctional ide enumq mutant generated pcr mediated mutagenesis using appropriate primer
0.43713617.11809755.html.plaintext.txt	33	antibody polyclonal antibody num num c terminal amino acid app num monoclonal antibody numbnum human ide num described
0.43713617.11809755.html.plaintext.txt	34	antibody numbnum also recognizes rat ide
0.43713617.11809755.html.plaintext.txt	35	aicd generationdegradation vitro characterize protease activity involved aicd degradation used previously established vitro assay num
0.43713617.11809755.html.plaintext.txt	36	heknum cell resuspended num
0.43713617.11809755.html.plaintext.txt	37	num mlnum cm dish ice cold hypotonic homogenization buffer num mm mop ph num
0.43713617.11809755.html.plaintext.txt	38	num num mm kcl without protease inhibitor incubated ice num min
0.43713617.11809755.html.plaintext.txt	39	following homogenization ice tight fitting homogenizer num stroke post nuclear supernatant prepared centrifugation num x g num min num degree c
0.43713617.11809755.html.plaintext.txt	40	crude membrane isolated post nuclear supernatant centrifugation numnum x g num min num degree c
0.43713617.11809755.html.plaintext.txt	41	membrane resuspended num microlnum cm dish assay buffer num mm sodium citrate ph num
0.43713617.11809755.html.plaintext.txt	42	num supplemented indicated protease inhibitor aicd generated incubation sample num degree c num h volume num microlassay
0.43713617.11809755.html.plaintext.txt	43	termination assay reaction ice sample separated pellet pnum supernatant snum fraction ultracentrifugation num h numnum x g num degree c
0.43713617.11809755.html.plaintext.txt	44	snum fraction separated sd page num num tris tricine gel invitrogen num
0.43713617.11809755.html.plaintext.txt	45	num tris tricine gel num analyzed immunoblotting antibody num detection using enhanced chemiluminescence ecl amersham bioscience
0.43713617.11809755.html.plaintext.txt	46	alkaline extraction membrane crude membrane prepared resuspended num
0.43713617.11809755.html.plaintext.txt	47	num mlnum cm dish num mm nanumconum ph num
0.43713617.11809755.html.plaintext.txt	48	num num incubated ice num min
0.43713617.11809755.html.plaintext.txt	49	ultracentrifugation num h numnum x g num degree c two consecutive wash assay buffer carbonate extracted membrane resuspended num microlnum cm dish assay buffer analyzed aicd degradation
0.43713617.11809755.html.plaintext.txt	50	preparation cytosol cytosol prepared indicated cell line ultracentrifugation post nuclear supernatant fraction numnum x g num h num degree c
0.43713617.11809755.html.plaintext.txt	51	soluble snum fraction used cytosol
0.43713617.11809755.html.plaintext.txt	52	reconstitution aicd degradation vitro cytosol free membrane generated three consecutive wash membrane assay buffer centrifugation numnum x g num min num degree c
0.43713617.11809755.html.plaintext.txt	53	cytosol free membrane resuspended assay buffer num microlassay mixed aliquot num microl cytosol fraction containing indicated protein amount
0.43713617.11809755.html.plaintext.txt	54	aicd generated described
0.43713617.11809755.html.plaintext.txt	55	assay insulin aicd first generated cytosol free membrane described
0.43713617.11809755.html.plaintext.txt	56	ultracentrifugation membrane free snum fraction containing preformed aicd mixed cytosol preparation supplemented indicated amount insulin assayed aicd degradation described
0.43713617.11809755.html.plaintext.txt	57	aicd rapidly degraded metalloprotease activity others previously demonstrated aicd efficiently generated vitro secretase p dependent manner crude membrane fraction prepared centrifugation numnum numnum x g num num
0.43713617.11809755.html.plaintext.txt	58	however vitro generated aicd extremely rapidly degraded addition protease inhibitor mix containing edta necessary stabilize aicd num num
0.43713617.11809755.html.plaintext.txt	59	identify protease involved extremely rapid degradation pathway vitro assay carried presence variety protease inhibitor fig
0.43713617.11809755.html.plaintext.txt	60	absence inhibitor aicd could detected demonstrating num degree c aicd degradation even faster de novo synthesis
0.43713617.11809755.html.plaintext.txt	61	consistent previous result general protease inhibitor mix including edta inhibited aicd degradation
0.43713617.11809755.html.plaintext.txt	62	additional presence secretase inhibitor dapt inhibited aicd generation expected num
0.43713617.11809755.html.plaintext.txt	63	interestingly protease inhibitor mix without edta block aicd degradation suggesting involvement divalent metal ion dependent proteolytic activity aicd generation
0.43713617.11809755.html.plaintext.txt	64	indeed metal chelators edta pnt allowed robust accumulation aicd used either alone combination
0.43713617.11809755.html.plaintext.txt	65	however specific metalloprotease inhibitor phosphoramidon bestatin inhibitor aminopeptidases inhibit degradation aicd
0.43713617.11809755.html.plaintext.txt	66	aicd degradation affected inhibitor cysteine protease enum leupeptin serine protease phenylmethylsulfonyl fluoride aspartyl protease pepstatin data shown
0.43713617.11809755.html.plaintext.txt	67	interestingly potent proteasome inhibitor clasto lactacystin lactone mgnum also block aicd degradation fig
0.43713617.11809755.html.plaintext.txt	68	contrast nicd shown rapidly degraded ubiquitin dependent proteasomal degradation pathway num num num
0.43713617.11809755.html.plaintext.txt	69	thus although aicd nicd generated p dependent protease degraded different proteolytic activity
0.43713617.11809755.html.plaintext.txt	70	taken together conclude likely metalloprotease involved aicd degradation
0.43713617.11809755.html.plaintext.txt	71	view larger version numk fig
0.43713617.11809755.html.plaintext.txt	72	chelators divalent metal ion block aicd degradation
0.43713617.11809755.html.plaintext.txt	73	membrane preparation incubated num degree c num h presence absence indicated protease inhibitor
0.43713617.11809755.html.plaintext.txt	74	membrane pelleted ultracentrifugation aicd analyzed soluble fraction immunoblotting antibody num
0.43713617.11809755.html.plaintext.txt	75	note aicd degradation blocked protease inhibitor mix pi mix well metal chelators edta pnt inhibitor proteasome clasto lactacystin lactone mgnum
0.43713617.11809755.html.plaintext.txt	76	aicd degraded cytoplasmic protease next investigated whether metalloprotease activity involved aicd degradation cytosolic membrane bound
0.43713617.11809755.html.plaintext.txt	77	first assayed crude membrane aicd degradation alkaline extraction nanumconum separate peripheral integral membrane protein num
0.43713617.11809755.html.plaintext.txt	78	numa aicd could recovered absence pntedta nanumconum extracted membrane suggesting aicd degrading activity either peripherally attached membrane soluble
0.43713617.11809755.html.plaintext.txt	79	addition data confirm previous finding secretase integrally membrane bound num
0.43713617.11809755.html.plaintext.txt	80	next separated crude membrane residual cytosol additional centrifugation
0.43713617.11809755.html.plaintext.txt	81	shown crude membrane used vitro assay aicd could recovered absence pntedta fig
0.43713617.11809755.html.plaintext.txt	82	numb due rapid degradation
0.43713617.11809755.html.plaintext.txt	83	contrast crude membrane used additional re centrifugation numnum x g robust accumulation aicd observed absence pntedta fig
0.43713617.11809755.html.plaintext.txt	84	thus data suggest aicd degrading activity soluble protease primarily located within cytoplasm
0.43713617.11809755.html.plaintext.txt	85	prove cytoplasmic localization aicd degrading activity vitro degradation assay performed washed cytosol free membrane allowed robust accumulation aicd absence pntedta
0.43713617.11809755.html.plaintext.txt	86	degrading activity could reconstituted addition increasing amount cytosol heknum mouse neuroblastoma nnuma cell fig
0.43713617.11809755.html.plaintext.txt	87	result conclude cytoplasmic metalloprotease present peripheral well neuronal cell involved aicd degradation
0.43713617.11809755.html.plaintext.txt	88	view larger version numk fig
0.43713617.11809755.html.plaintext.txt	89	aicd degraded cytosolic metalloprotease
0.43713617.11809755.html.plaintext.txt	90	alkaline extraction separate aicd degrading activity aicd generating activity
0.43713617.11809755.html.plaintext.txt	91	crude membrane preparation subjected alkaline extraction nanumconum
0.43713617.11809755.html.plaintext.txt	92	following centrifugation numnum x g two subsequent wash membrane incubated num degree c num h presence absence pntedta aicd analyzed fig
0.43713617.11809755.html.plaintext.txt	93	note aicd recovered absence pntedta upon removal degrading activity alkaline extraction nanumconum without affecting aicd generating secretase activity
0.43713617.11809755.html.plaintext.txt	94	b aicd degrading activity removed ultracentrifugation
0.43713617.11809755.html.plaintext.txt	95	crude membrane preparation incubated directly preparation pnum fraction additional centrifugation numnum x g pnum fraction num degree c num h presence absence pntedta
0.43713617.11809755.html.plaintext.txt	96	aicd analyzed described legend fig
0.43713617.11809755.html.plaintext.txt	97	note aicd recovered even absence pntedta additional ultracentrifugation pnum fraction
0.43713617.11809755.html.plaintext.txt	98	c aicd degrading activity present cytosol
0.43713617.11809755.html.plaintext.txt	99	cytosol free membrane preparation incubated num degree c num h presence absence pntedta together indicated amount cytosol fraction heknum mouse nnuma cell
0.43713617.11809755.html.plaintext.txt	100	aicd analyzed described legend fig
0.43713617.11809755.html.plaintext.txt	101	note dose dependent degradation aicd presence cytosol derived kidney neuronal cell
0.43713617.11809755.html.plaintext.txt	102	identification candidate enzyme responsible aicd degradation based inhibition profile cytoplasmic localization aicd degrading activity searched merops protease data base www
0.43713617.11809755.html.plaintext.txt	103	uk candidate aicd degrading enzyme
0.43713617.11809755.html.plaintext.txt	104	search revealed three cytoplasmic candidate protease two metalloprotease family mnuma mnuma family could responsible degradation aicd thimet oligopeptidase top mnuma family neurolysin mnuma family ide insulysin mnuma family
0.43713617.11809755.html.plaintext.txt	105	consistent candidate protease thiol group dependent num num sh alkylating agent nem strongly inhibited aicd degradation fig
0.43713617.11809755.html.plaintext.txt	106	next discriminate protease could involved aicd degradation vitro assay carried presence absence dynorphin num num known inhibitor top neurolysin num potentially also ide
0.43713617.11809755.html.plaintext.txt	107	dipeptide pro ile highly specific neurolysin inhibitor num cfp aay pab cfp potent top le potent neurolysin inhibitor num insulin well characterized substrate ide function competitive inhibitor investigated well num
0.43713617.11809755.html.plaintext.txt	108	numb weak inhibition aicd degradation dynorphin num num suggests either top neurolysin candidate protease without excluding ide
0.43713617.11809755.html.plaintext.txt	109	however pro ile block aicd degradation ruling neurolysin candidate protease fig
0.43713617.11809755.html.plaintext.txt	110	since cfp also block aicd degradation fig
0.43713617.11809755.html.plaintext.txt	111	numb ide remained candidate aicd degradation
0.43713617.11809755.html.plaintext.txt	112	indeed insulin competed aicd degrading activity present cytosol derived nnuma cell dose dependent manner fig
0.43713617.11809755.html.plaintext.txt	113	bovine serum albumin used control unspecific inhibition degradation effect fig
0.43713617.11809755.html.plaintext.txt	114	similar result obtained cytosol heknum cell data shown
0.43713617.11809755.html.plaintext.txt	115	thus data indicate ide may one aicd degrading enzyme nnuma heknum cell
0.43713617.11809755.html.plaintext.txt	116	view larger version numk fig
0.43713617.11809755.html.plaintext.txt	117	identification candidate metalloproteases involved aicd degradation
0.43713617.11809755.html.plaintext.txt	118	sh alkylating agent nem inhibits aicd degradation
0.43713617.11809755.html.plaintext.txt	119	crude membrane preparation incubated num degree c num h presence absence indicated concentration nem aicd analyzed described legend fig
0.43713617.11809755.html.plaintext.txt	120	b aicd degradation reduced dynorphin num num specific neurolysin inhibitor pro ile specific top inhibitor cfp
0.43713617.11809755.html.plaintext.txt	121	crude membrane preparation assayed aicd degradation fig
0.43713617.11809755.html.plaintext.txt	122	c dose dependent inhibition aicd degradation insulin
0.43713617.11809755.html.plaintext.txt	123	aicd generated incubation cytosol free membrane num h num degree c subsequently separated membrane ultracentrifugation
0.43713617.11809755.html.plaintext.txt	124	snum fraction containing preformed aicd mixed cytosol num microg derived nnuma cell indicated amount insulin bovine serum albumin assayed aicd degradation incubation num h num degree c described legend fig
0.43713617.11809755.html.plaintext.txt	125	note dose dependent inhibition aicd degradation insulin bovine serum albumin
0.43713617.11809755.html.plaintext.txt	126	ide degrades aicd prove whether ide aicd degrading enzyme generated heknum cell line stably overexpressing rat ide inactive ide mutant ide enumq glutamate hxxeh active site motif changed glutamine num num
0.43713617.11809755.html.plaintext.txt	127	numa immunoblotting cytosol fraction confirmed overexpression wt mutant ide protein
0.43713617.11809755.html.plaintext.txt	128	cytosol fraction derived cell overexpressing wt ide contained significantly higher aicd degrading activity cytosol fraction ide enumq overexpressing cell fig
0.43713617.11809755.html.plaintext.txt	129	finally cytosol heknum cell immunodepleted endogenous ide immunoprecipitation excess amount anti ide antibody fig
0.43713617.11809755.html.plaintext.txt	130	aicd generation assayed cytosol free membrane presence fraction
0.43713617.11809755.html.plaintext.txt	131	numd dose dependent aicd degradation observed non depleted control fraction contrast markedly reduced aicd degrading activity ide depleted cytosol fraction
0.43713617.11809755.html.plaintext.txt	132	thus data strongly suggest ide major aicd degrading enzyme
0.43713617.11809755.html.plaintext.txt	133	ps may function facilitating nuclear signaling
0.43713617.11809755.html.plaintext.txt	134	function well proven role p nicd generation
0.43713617.11809755.html.plaintext.txt	135	recently corresponding cytoplasmic fragment app aicd identified num num
0.43713617.11809755.html.plaintext.txt	136	aicd generated remarkably similar molecular mechanism like nicd fig
0.43713617.11809755.html.plaintext.txt	137	aicd function nuclear signaling proposed cao sudhof num one may expect rapid clearance fragment since constitutive uncontrolled signaling must avoided
0.43713617.11809755.html.plaintext.txt	138	indeed case nicd rapidly removed ubiquitin dependent proteasomal degradation pathway num num num
0.43713617.11809755.html.plaintext.txt	139	show aicd degraded proteasome completely different protease namely ide fig
0.43713617.11809755.html.plaintext.txt	140	biochemical property ide make ideal candidate aicd degradation
0.43713617.11809755.html.plaintext.txt	141	highly expressed cellular compartment aicd common enzyme brain tissue abundant app expression observed preferentially degrades small cytoplasmic peptide num num amino acid length review see ref
0.43713617.11809755.html.plaintext.txt	142	view larger version numk fig
0.43713617.11809755.html.plaintext.txt	143	distinct pathway involved degradation aicd nicd
0.43713617.11809755.html.plaintext.txt	144	aicd nicd generated p dependent secretase snum protease cleavage similar site within membrane
0.43713617.11809755.html.plaintext.txt	145	following liberation membrane nicd probably also aicd translocate nucleus
0.43713617.11809755.html.plaintext.txt	146	nucleus nicd activates transcription notch target gene
0.43713617.11809755.html.plaintext.txt	147	proteasomal degradation nicd prevents accumulation constitutive signaling
0.43713617.11809755.html.plaintext.txt	148	contrast nicd aicd degraded ide like neprilysin also involved extracellular degradation secreted
0.43713617.11809755.html.plaintext.txt	149	found extremely rapid turnover aicd even exceeds kinetics de novo production vitro
0.43713617.11809755.html.plaintext.txt	150	consistent high level ide cytoplasm many cell tissue
0.43713617.11809755.html.plaintext.txt	151	although identified ide major aicd degrading enzyme non neuronal neuronal cell lysates exclude possibility enzyme may degrade aicd cell ide activity expression low num
0.43713617.11809755.html.plaintext.txt	152	interestingly overexpressed artificial num amino acid aicd variant localized nucleus extent num num
0.43713617.11809755.html.plaintext.txt	153	however contrast endogenous aicd correct n terminus far detected within nucleus
0.43713617.11809755.html.plaintext.txt	154	due rather rapid turnover endogenous aicd apparent lack nuclear localization one may question function small peptide nuclear signaling
0.43713617.11809755.html.plaintext.txt	155	however one need point nicd could detected nucleus long time sensitive technique lacking
0.43713617.11809755.html.plaintext.txt	156	indeed using hypersensitive reporter gene assay cao sudhof num could provide indirect evidence cytoplasmic fragment app identical vivo existing aicd complexed fenum histone acetyltransferase tipnum could mediate gene transcription
0.43713617.11809755.html.plaintext.txt	157	however nuclear transport authentic aicd formation nuclear tipnum fenum aicd complex remains shown
0.43713617.11809755.html.plaintext.txt	158	identification ide aicd degrading enzyme may facilitate research putative role aicd nuclear signaling since function could strongly enhanced inhibition aicd degradation
0.43713617.11809755.html.plaintext.txt	159	thank ian smith top inhibitor richard roth rat ide cdna antibody numbnum human ide klaus fuchs dapt gopal thinakaran mouse nnuma cell stably expressing swapp magdalena sastre discussion
0.43713617.11809755.html.plaintext.txt	160	work supported boehringer ingelheim pharma kg stipend
0.43713617.11809755.html.plaintext.txt	161	deutsche forschungsgemeinschaft dfg
0.43713617.11809755.html.plaintext.txt	162	cost publication article defrayed part payment page charge
0.43713617.11809755.html.plaintext.txt	163	article must therefore hereby marked advertisement accordance num u
0.43713617.11809755.html.plaintext.txt	164	section num solely indicate fact
0.43713617.11809755.html.plaintext.txt	165	senior author correspondence may addressed
0.43713617.11809755.html.plaintext.txt	166	num num num numnum fax num num num num e mail chaasspbm
0.43713617.11809755.html.plaintext.txt	167	num num num num fax num num num num e mail hsteinerpbm
0.43713617.11809755.html.plaintext.txt	168	published jbc paper press january num num doi num
0.43713617.11809755.html.plaintext.txt	169	abbreviation used amyloid peptide app amyloid precursor protein aicd app intracellular domain ide insulin degrading enzyme nicd notch intracellular domain p presenilin hek human embryonic kidney dapt n n numnum difluorophenacetyl l alanyl phenylglycine butyl ester pnt numnum o phenanthroline nem n ethylmaleimide mop num morpholinepropanesulfonic acid tricine n num hydroxy numnum bishydroxymethylethylglycine top thimet oligopeptidase wt wild type
0.43713617.11809755.html.plaintext.txt	170	copyright num american society biochemistry molecular biology inc
0.5010976.15944156.html.plaintext.txt	0	yeast tractable genetic system functional study insulin degrading enzyme seonil kim andrea n
0.5010976.15944156.html.plaintext.txt	1	department cellular biology biochemistry molecular biology university georgia athens georgia num
0.5010976.15944156.html.plaintext.txt	2	received publication december num num revised form june num num
0.5010976.15944156.html.plaintext.txt	3	stenump axlnump protein saccharomyces cerevisiae significant sequence homology ide num num identity respectively num
0.5010976.15944156.html.plaintext.txt	4	genetic mutational study indicate stenump axlnump required proteolytic maturation yeast factor mating pheromone lipid modified peptide produced multistep process num num
0.5010976.15944156.html.plaintext.txt	5	pheromone produced mata haploid cell required yeast mating fusion mata mat haploid cell form diploid cell
0.5010976.15944156.html.plaintext.txt	6	although stenump axlnump independently promote factor maturation enzyme fully redundant
0.5010976.15944156.html.plaintext.txt	7	stenump significantly le efficient axlnump producing biologically active pheromone num
0.5010976.15944156.html.plaintext.txt	8	axlnump several cellular role
0.5010976.15944156.html.plaintext.txt	9	addition role pheromone production axlnump required efficient post conjugation fusion haploid mating partner num
0.5010976.15944156.html.plaintext.txt	10	role may indirectly related ability axlnump produce factor limiting level pheromone similarly lead fusion defect num
0.5010976.15944156.html.plaintext.txt	11	axlnump also required maintenance axial budding pattern characteristic haploid yeast num num
0.5010976.15944156.html.plaintext.txt	12	absence axlnump haploid yeast exhibit bipolar budding pattern typical diploid cell
0.5010976.15944156.html.plaintext.txt	13	function axlnump process require proteolytic activity suggesting axlnump bi functional enzyme num
0.5010976.15944156.html.plaintext.txt	14	axlnump also represses invasive growth haploid yeast num num
0.5010976.15944156.html.plaintext.txt	15	whether proteolytic bud site selection another activity axlnump required process reported
0.5010976.15944156.html.plaintext.txt	16	contrast axlnump reported cellular role stenump factor production
0.5010976.15944156.html.plaintext.txt	17	additional function enzyme likely stenump expressed mat diploid cell type produce factor
0.5010976.15944156.html.plaintext.txt	18	ide stenump axlnump member mnuma protease subfamily
0.5010976.15944156.html.plaintext.txt	19	mnuma protease characterized core inverted zinc metalloprotease motif typically located within first num residue enzyme pair glutamic acid residue num num amino acid distal core motif
0.5010976.15944156.html.plaintext.txt	20	spacing core motif distal glutamate invariant num mnuma enzyme identified far except case axlnump spacing num residue
0.5010976.15944156.html.plaintext.txt	21	histidine residue distal glutamate residue putative zinc ligand mutational alteration residue inactivates ide axlnump num num num
0.5010976.15944156.html.plaintext.txt	22	member mnuma subfamily including ide sensitive thiol modifier suggesting cysteine residue critical proper structure active site overall tertiary quaternary structure protein num num
0.5010976.15944156.html.plaintext.txt	23	sequence alignment ide yeast orthologs reveals two conserved cysteine residue
0.5010976.15944156.html.plaintext.txt	24	one within core metalloprotease motif residue reportedly altered without affecting enzymatic activity num
0.5010976.15944156.html.plaintext.txt	25	conserved cysteine exactly num amino acid distal extended motif hxxehxnumexnumexnumc
0.5010976.15944156.html.plaintext.txt	26	distal cysteine conserved escherichia coli protease iii bacterial mnuma enzyme insensitive thiol modifier num
0.5010976.15944156.html.plaintext.txt	27	sequence similarity ide stenump axlnump prompted u investigate hypothesis protein conserved enzymatic property substrate specificity
0.5010976.15944156.html.plaintext.txt	28	end present evidence indicating rat ide substitute axlnump stenump factor production known function axlnump
0.5010976.15944156.html.plaintext.txt	29	importantly finding establish yeast genetically tractable system future study ide function
0.5010976.15944156.html.plaintext.txt	30	made practical use system create characterize novel mutation alter enzymatic property ide
0.5010976.15944156.html.plaintext.txt	31	view table table strain used study
0.5010976.15944156.html.plaintext.txt	32	plasmid plasmid used study indicated table ii
0.5010976.15944156.html.plaintext.txt	33	plasmid pnum cen uranum axlnum pnum cen uranum stenum described previously kindly provided dr
0.5010976.15944156.html.plaintext.txt	34	boone university toronto num
0.5010976.15944156.html.plaintext.txt	35	plasmid used study created pcr directed recombination mediated plasmid construction andor standard molecular method num
0.5010976.15944156.html.plaintext.txt	36	view table table ii plasmid used study
0.5010976.15944156.html.plaintext.txt	37	general strategy epitope tagging axlnum stenum ide encoding plasmid involved creation novel restriction site end respective open reading frame subcloning triply iterated ha tag
0.5010976.15944156.html.plaintext.txt	38	pwsnum cen uranum axlnum numha created modifying pnum follows
0.5010976.15944156.html.plaintext.txt	39	ncoi site inserted immediately prior stop codon axlnum dna fragment encoding triply iterated ha tag inserted actuality two tandem copy tag inserted
0.5010976.15944156.html.plaintext.txt	40	plasmid modified delete portion num untranslated region corresponding xhoi fragment order reduce overall size plasmid num
0.5010976.15944156.html.plaintext.txt	41	num kb deletion effect protein expression
0.5010976.15944156.html.plaintext.txt	42	pwsnum cen uranum stenum numha created modifying pnum similar manner described pnum
0.5010976.15944156.html.plaintext.txt	43	instance bamhi site introduced immediately prior stop codon stenum triply iterated ha tag inserted pwsnum two tandem copy tag actually inserted
0.5010976.15944156.html.plaintext.txt	44	pwsnum num micro uranum ppgk ide ha created pcr amplification ide psr rat ide pcr product end homologous parent yeast vector psmnum bglii restriction site immediately stop codon ide num
0.5010976.15944156.html.plaintext.txt	45	bglii site used insertion triply iterated ha epitope tag
0.5010976.15944156.html.plaintext.txt	46	pwsnum identical pwsnum except contains two copy triply iterated ha tag
0.5010976.15944156.html.plaintext.txt	47	restriction digest analysis dna sequencing used confirm presence tag plasmid described
0.5010976.15944156.html.plaintext.txt	48	general strategy creation site directed mutation plasmid also involved pcr directed recombination mediated plasmid construction
0.5010976.15944156.html.plaintext.txt	49	brief dna fragment encoding appropriate segment target open reading frame amplified pcr one oligonucleotides contained mutation interest typically silent restriction site
0.5010976.15944156.html.plaintext.txt	50	dna fragment co transformed target plasmid linearized gapped restriction enzyme near intended site mutation
0.5010976.15944156.html.plaintext.txt	51	recombinant plasmid recovered yeast amplified e
0.5010976.15944156.html.plaintext.txt	52	coli screened restriction analysis andor sequencing verify presence mutation
0.5010976.15944156.html.plaintext.txt	53	mutant allele confirmed immunoblot encode full length protein
0.5010976.15944156.html.plaintext.txt	54	epitope tagging stenump straightforward
0.5010976.15944156.html.plaintext.txt	55	dna sequencing intermediate plasmid construction pwsnum revealed extra nucleotide near num end open reading frame present public sequence stenum
0.5010976.15944156.html.plaintext.txt	56	presence extra nucleotide confirmed stenum sequence derived three different source pnum pcr product derived chromosomal amplification stenum gene two distinct strain background ihnum yphnum
0.5010976.15944156.html.plaintext.txt	57	independent group num proposed recently identical sequence annotation part effort identify mistake published genome sequence
0.5010976.15944156.html.plaintext.txt	58	extra nucleotide alters extends translation stenum open reading frame amino acid num num code num distinct amino acid additional num amino acid gained extension original proposed translation
0.5010976.15944156.html.plaintext.txt	59	protein extract preparation whole cell protein extract western analysis prepared naohtrichloroacetic acid method num
0.5010976.15944156.html.plaintext.txt	60	brief mid log cell amount equivalent num ml num
0.5010976.15944156.html.plaintext.txt	61	num anum culture harvested centrifugation washed cold water resuspended num ml cold water treated solution num n naoh num m mercaptoethanol
0.5010976.15944156.html.plaintext.txt	62	protein released precipitated trichloroacetic acid num
0.5010976.15944156.html.plaintext.txt	63	num final recovered centrifugation resuspended urea sample buffer usb num mm tris ph num
0.5010976.15944156.html.plaintext.txt	64	num bromphenol blue heated cleared insoluble material analysis sd page immunoblotting
0.5010976.15944156.html.plaintext.txt	65	ha tagged protein detected chemiluminescence ecl kit roche applied science immunodecorating protein mouse anti ha horseradish peroxidase conjugated rabbit anti mouse antibody
0.5010976.15944156.html.plaintext.txt	66	particulate fraction used vitro assay prepared mechanical breakage yeast cell expressing either ide stenump axlnump num num
0.5010976.15944156.html.plaintext.txt	67	brief mid log cell harvested washed cold num mm nannum treated trisdithiothreitol num mm tris ph num
0.5010976.15944156.html.plaintext.txt	68	num num mm dithiothreitol num min ice
0.5010976.15944156.html.plaintext.txt	69	cell resuspended oxalyticase buffer num mm kpi ph num
0.5010976.15944156.html.plaintext.txt	70	num m sorbitol num mm nannum containing oxalyticase num microganum enzogenetics corvallis incubated num min num degree c gentle mixing
0.5010976.15944156.html.plaintext.txt	71	spheroplasts harvested centrifugation resuspended cold lysis buffer num mm tris ph num
0.5010976.15944156.html.plaintext.txt	72	num m sorbitol num mm edta containing protease inhibitor num microgml leupeptin chymostatin pepstatin aprotinin num mm phenylmethylsulfonyl fluoride lysed using glass dounce homogenizer
0.5010976.15944156.html.plaintext.txt	73	primary lysate cleared twice cell debris centrifugation num x g num min fractionated supernatant particulate fraction centrifugation numnum x g num min
0.5010976.15944156.html.plaintext.txt	74	fraction adjusted num mgml lysis buffer stored num degree c aliquot
0.5010976.15944156.html.plaintext.txt	75	ass effect chaotropic agent association ide stenump axlnump yeast particulate fraction freshly prepared sample particulate fraction exposed either num m nacl num
0.5010976.15944156.html.plaintext.txt	76	num num sd buffer alone num min ice sample subjected centrifugation numnum x g num min
0.5010976.15944156.html.plaintext.txt	77	equivalent portion supernatant particulate fraction analyzed sd page immunoblot described
0.5010976.15944156.html.plaintext.txt	78	insulin degradation assay insulin degradation assay carried essentially described previously using yeast derived lysates source enzyme activity num
0.5010976.15944156.html.plaintext.txt	79	brief reaction assembled contain num
0.5010976.15944156.html.plaintext.txt	80	num mgml yeast lysate num pm numnum cpm numi insulin linco research st
0.5010976.15944156.html.plaintext.txt	81	charles mo num microl reaction buffer num mm tris num
0.5010976.15944156.html.plaintext.txt	82	sample incubated num degree c time indicated appropriate figure legend
0.5010976.15944156.html.plaintext.txt	83	final sample preparation involved addition bovine serum albumin num final trichloroacetic acid precipitation num final num min ice centrifugation numnum x g num min num degree c
0.5010976.15944156.html.plaintext.txt	84	supernatant containing insulin fragment transferred new tube radioactivity associated supernatant particulate fraction determined using wallac counter perkinelmer life science
0.5010976.15944156.html.plaintext.txt	85	yeast mating assay evaluate ability plasmid transformed mata axlnum stenum strain promote factor production patch mating test performed using ihnum mat lysnum established method num
0.5010976.15944156.html.plaintext.txt	86	test provides indirect assessment mnuma enzyme function factor production mata cell entirely dependent plasmid encoded copy mnuma enzyme
0.5010976.15944156.html.plaintext.txt	87	brief master plate prepared patching mata yeast strain expressing axlnump stenump ide onto yepd agar plate
0.5010976.15944156.html.plaintext.txt	88	num num day growth patch replica printed onto lawn mat cell ihnum spread minimal medium agar plate replica printed plate incubated num day num degree c
0.5010976.15944156.html.plaintext.txt	89	mat cell suspension prepared approximately cell density solution num num num yepd prepared mixture yepd appropriate amount sterile hnumo
0.5010976.15944156.html.plaintext.txt	90	trace amount yepd added minimal medium allows limited survival auxotrophic haploid cell necessary mating process
0.5010976.15944156.html.plaintext.txt	91	decreasing yepd amount shortens survival window haploid cell thus result decreased mating efficiency
0.5010976.15944156.html.plaintext.txt	92	diploid cell result mating event prototrophic thus growth diploid test indicative mating functional mnuma enzyme
0.5010976.15944156.html.plaintext.txt	93	mass spectroscopy factor mating pheromone produced yeast expressing ide stenump axlnump purified according published method analyzed mass spectroscopy num
0.5010976.15944156.html.plaintext.txt	94	brief yeast cultured polypropylene culture tube factor secreted yeast culture recovered washing polypropylene culture tube methanol secreted factor adsorbs polypropylene removed organic solvent
0.5010976.15944156.html.plaintext.txt	95	enriched factor sample concentrated speed vac desalted using zip tip cnum bead millipore washed three time num
0.5010976.15944156.html.plaintext.txt	96	num trifluoroacetic acid eluted num acetonitrile subjected maldi toftof mass spectroscopy using cyano num hydroxycinnamic acid matrix num proteomics analyzer spectrometer applied biosystems foster city ca
0.5010976.15944156.html.plaintext.txt	97	factor halo assay total secreted factor produced saturated culture indicated strain recovered described
0.5010976.15944156.html.plaintext.txt	98	enriched sample dried speed vac resuspended num microl meoh
0.5010976.15944156.html.plaintext.txt	99	num fold serial dilution sample prepared yepd spotted onto lawn rcnum mat sstnum num hisnum metnum cannum cyhnum rcnum mata sstnum num hisnum metnum cannum cyhnum rme adenum num uranum cell latter served control unlikely possibility toxic product produced ide expressing strain num
0.5010976.15944156.html.plaintext.txt	100	formation spot lawn indicative presence pheromone sample relative potency pheromone determined serial dilution sample
0.5010976.15944156.html.plaintext.txt	101	highest dilution biological activity referred end point equivalent concentration num pg microl factor num
0.5010976.15944156.html.plaintext.txt	102	invasive growth assay ability haploid yeast cell invade yeast agar determined using plate washing assay num
0.5010976.15944156.html.plaintext.txt	103	brief cell suspension spotted onto sc ura plate cell grown num day num degree c
0.5010976.15944156.html.plaintext.txt	104	plate washed running hnumo gently rubbing surface agar plate gloved finger
0.5010976.15944156.html.plaintext.txt	105	agar plate scanned prior immediately washing
0.5010976.15944156.html.plaintext.txt	106	view larger version numk fig
0.5010976.15944156.html.plaintext.txt	107	yeast expressed ide expected size associated particulate fraction
0.5010976.15944156.html.plaintext.txt	108	protein extract prepared yeast containing empty vector vector encoding ha tagged axlnump stenump ide
0.5010976.15944156.html.plaintext.txt	109	equivalent amount sample lane num num num num fold serial dilution stenump lane num num ide lane num num sample analyzed sd page immunoblot using anti ha antibody
0.5010976.15944156.html.plaintext.txt	110	b total yeast lysate containing ha tagged ide subjected differential centrifugation numnum x g
0.5010976.15944156.html.plaintext.txt	111	corresponding particulate p supernatant fraction recovered equivalent amount protein num microg analyzed sd page immunoblotting ha monoclonal antibody
0.5010976.15944156.html.plaintext.txt	112	c sample yeast particulate fraction containing epitope tagged axlnump stenump ide treated either lysis buffer num m nacl num
0.5010976.15944156.html.plaintext.txt	113	num num sd separated supernatant particulate p fraction centrifugation
0.5010976.15944156.html.plaintext.txt	114	equivalent percentage sample evaluated sd page immunoblot using anti ha antibody
0.5010976.15944156.html.plaintext.txt	115	strain used ynum transformed prsnum vector pwsnum stenum numha pwsnum ide numha either pwsnum cen axlnum numha pwsnum num micro axlnum numha b c
0.5010976.15944156.html.plaintext.txt	116	budding assay mid log cell grown selective liquid medium harvested concentrate cell suspension num time cell treated num microgml calcofluor sigma num min
0.5010976.15944156.html.plaintext.txt	117	cell washed twice hnumo absorbed onto polylysine coated glass slide viewed xnum zeiss axioplan microscope equipped fluorescence optic
0.5010976.15944156.html.plaintext.txt	118	fluorescent image captured using digital camera optronics dei num
0.5010976.15944156.html.plaintext.txt	119	bud scar num cell evaluated categorized three pattern axial bipolar random
0.5010976.15944156.html.plaintext.txt	120	axial pattern defined bud scar located solely one pole cell bipolar pattern scar pole random pattern displayed least one bud scar region pole num num
0.5010976.15944156.html.plaintext.txt	121	evaluation protein extract strain expressing tagged protease revealed tagged protein could detected protein expected size immunoblot fig
0.5010976.15944156.html.plaintext.txt	122	also observed ide stenump expressed num time higher level axlnump determined comparison immunoblot signal
0.5010976.15944156.html.plaintext.txt	123	constitutive phosphoglycerate kinase pgk promoter used drive ide expression abundant expression ide unexpected
0.5010976.15944156.html.plaintext.txt	124	native promoter used drive stenump axlnump expression relative abundance stenump axlnump somewhat unexpected especially stenump promote factor production efficiently axlnump
0.5010976.15944156.html.plaintext.txt	125	thus reason decreased ability stenump promote mating simply attributed reduced protein expression comparison axlnump
0.5010976.15944156.html.plaintext.txt	126	ide associated particulate yeast fraction subcellular distribution ide mammalian system reported primarily cytosolic extracellular peroxisomal localization also described num num
0.5010976.15944156.html.plaintext.txt	127	ascertain effect heterologous expression subcellular distribution ide subjected total yeast lysate differential fractionation
0.5010976.15944156.html.plaintext.txt	128	comparison equal amount loaded protein immunoblot observed ide yeast mnuma enzyme highly enriched particulate fraction associated numnum x g centrifugation lysate pnum although significant amount stenump found supernatant fraction fig
0.5010976.15944156.html.plaintext.txt	129	particular experiment axlnump encoded multicopy plasmid facilitate detection hence stronger signal relative observed total extract see fig
0.5010976.15944156.html.plaintext.txt	130	although localization stenump reported previously axlnump known transiently associate component form sub plasma membrane complex required establishing bud site
0.5010976.15944156.html.plaintext.txt	131	whether ide stenump assemble complex unknown
0.5010976.15944156.html.plaintext.txt	132	better understand nature association ide axlnump stenump pnum yeast fraction performed extraction particulate fraction various chaotropic agent fig
0.5010976.15944156.html.plaintext.txt	133	analysis revealed high ph detergent treatment significantly disrupted association protein pnum fraction whereas salt buffer alone minor impact
0.5010976.15944156.html.plaintext.txt	134	profile consistent ide stenump axnump peripheral membrane protein andor component large macromolecular complex sediment experimental condition
0.5010976.15944156.html.plaintext.txt	135	yeast expressed ide retains proteolytic activity next determined whether yeast expressed ide could cleave insulin well characterized substrate ide using previously described insulin degradation assay yeast derived particulate fraction num num
0.5010976.15944156.html.plaintext.txt	136	high degree enrichment mnuma enzyme yeast particulate fraction sample used exclusively source activity vitro assay
0.5010976.15944156.html.plaintext.txt	137	analysis enzymatic activity indicated ide containing sample insulin cleaving activity whereas sample containing axlnump stenump activity sample prepared yeast lacking enzyme fig
0.5010976.15944156.html.plaintext.txt	138	source residual activity preparation unknown likely due nonspecific enzymatic activity rather additional ide homolog numnum phenanthroline well documented ide inhibitor inhibit residual activity fig
0.5010976.15944156.html.plaintext.txt	139	whether axlnump stenump protease preparation incapable cleaving insulin altered substrate specificity sub optimal reaction condition reason yet determined
0.5010976.15944156.html.plaintext.txt	140	ide described thiol zinc dependent metalloprotease num
0.5010976.15944156.html.plaintext.txt	141	determined ide heterologously expressed functional form next wanted confirm observed insulin degrading activity detected hallmark ide mediated insulin degradation
0.5010976.15944156.html.plaintext.txt	142	examined effect alkylating
0.5010976.15944156.html.plaintext.txt	143	iodoacetamide n ethylmaleimide metal ion chelating agent
0.5010976.15944156.html.plaintext.txt	144	numnum phenanthroline edta ide activity fig
0.5010976.15944156.html.plaintext.txt	145	alkylating agent inhibited ide dependent insulin degrading activity
0.5010976.15944156.html.plaintext.txt	146	inhibitory effect also observed numnum phenanthroline nonchelating agent numnum phenanthroline structurally similar
0.5010976.15944156.html.plaintext.txt	147	edta measurably inhibit enzymatic activity extensive pretreatment edta reportedly required inhibition ide num
0.5010976.15944156.html.plaintext.txt	148	inhibitor profile observed insulin degrading activity yeast identical reported ide establishes yeast synthesize ide possessing enzymatic property described ide found metazoan num
0.5010976.15944156.html.plaintext.txt	149	view larger version numk fig
0.5010976.15944156.html.plaintext.txt	150	ide functionally expressed yeast
0.5010976.15944156.html.plaintext.txt	151	particulate fraction isolated yeast expressing ide axlnump stenump
0.5010976.15944156.html.plaintext.txt	152	equivalent amount fraction num microg assayed insulin degradation activity time course according established method see experimental procedure
0.5010976.15944156.html.plaintext.txt	153	degradation insulin indicated presence recovered insulin fragment precipitated trichloroacetic acid
0.5010976.15944156.html.plaintext.txt	154	b effect various agent activity yeast expressed ide evaluated
0.5010976.15944156.html.plaintext.txt	155	activity determined num min num min time point
0.5010976.15944156.html.plaintext.txt	156	abbreviation used follows nem num mm n ethylmaleimide iaa num mm iodoacetamide numnum num mm numnum phenanthroline numnum num mm numnum phenanthroline edta num mm edta
0.5010976.15944156.html.plaintext.txt	157	ide promote yeast mating many yeast enzyme required factor production functionally replaced orthologous enzyme specie num num
0.5010976.15944156.html.plaintext.txt	158	similar fashion determined ide expression rescue mating defect yeast strain lacking axlnum stenum mata axlnum stenum fig
0.5010976.15944156.html.plaintext.txt	159	mating defect strain due inability produce yeast factor whether axlnump stenump extension ide participate directly indirectly pheromone production rigorously established num
0.5010976.15944156.html.plaintext.txt	160	nevertheless result establishes ide yeast enzyme axlnump stenump similarly promote yeast factor production thus evolutionarily conserved activity
0.5010976.15944156.html.plaintext.txt	161	simplest explanation finding enzyme directly participate pheromone production enzyme shared substrate specificity respect cleavage factor precursor
0.5010976.15944156.html.plaintext.txt	162	yeast mating sensitive number variable including available nutrient
0.5010976.15944156.html.plaintext.txt	163	depleted nutrient condition mating le efficient
0.5010976.15944156.html.plaintext.txt	164	taken advantage property yeast mating evaluate effectiveness ide rescuing mating defect yeast lacking stenump axlnump
0.5010976.15944156.html.plaintext.txt	165	expected observed decreasing nutrient condition correlated decreased mating strain
0.5010976.15944156.html.plaintext.txt	166	stenump ide expressing strain showed significant reduction mating relative axlnump expressing strain fig
0.5010976.15944156.html.plaintext.txt	167	epitope tagged version enzyme similar activity profile assay fig
0.5010976.15944156.html.plaintext.txt	168	relatively poor ability stenump promote mating respect axlnump consistent previous report property enzyme may attributable number factor including altered substrate specificity andor altered subcellular localization pattern prevents interaction substrate num
0.5010976.15944156.html.plaintext.txt	169	likewise reduced mating observed ide may attributable similar factor
0.5010976.15944156.html.plaintext.txt	170	reduced mating observed ide stenump expressing cell simply due low expression enzyme expressed significantly higher level axlnump see fig
0.5010976.15944156.html.plaintext.txt	171	view larger version numk fig
0.5010976.15944156.html.plaintext.txt	172	yeast expressed ide promotes yeast mating factor pheromone production
0.5010976.15944156.html.plaintext.txt	173	mating competence mata stenum axlnum cell transformed indicated mnuma enzyme encoded plasmid evaluated using patch mating test
0.5010976.15944156.html.plaintext.txt	174	selective growth diploid cell minimal medium indicative mating
0.5010976.15944156.html.plaintext.txt	175	patch mating test conducted using mat lysnum lawn containing various amount nutrient num num num yepd top bottom
0.5010976.15944156.html.plaintext.txt	176	lowering amount yepd lawn increase stringency mating test allows discrimination difference mating efficiency otherwise observable permissive mating condition num yepd
0.5010976.15944156.html.plaintext.txt	177	b patch mating test conducted using mata strain expressing ha epitope tagged mnuma protease mildly stringent mating condition num yepd
0.5010976.15944156.html.plaintext.txt	178	c factor produced strain described b recovered wall culture tube using organic solvent concentrated sample analyzed spot halo test
0.5010976.15944156.html.plaintext.txt	179	strain grown saturation volume medium
0.5010976.15944156.html.plaintext.txt	180	formation spot lawn mat rcnum cell indicative presence pheromone sample relative pheromone potency determined serial dilution sample
0.5010976.15944156.html.plaintext.txt	181	highest dilution activity referred end point equivalent concentration num pg microl factor num
0.5010976.15944156.html.plaintext.txt	182	d num fold serial dilution ide sample prepared yepd spotted onto lawn rcnum mata sstnum num hisnum metnum cannum cyhnum rme adenum num uranum serving control possibility toxic product produced ide expressing strain num
0.5010976.15944156.html.plaintext.txt	183	strain used ihnum transformed prsnum wild type wt ynum transformed prsnum vector pnum axlnum pnum stenum pwsnum ide pwsnum axlnum numha pwsnum stenum numha pwsnum ide numha
0.5010976.15944156.html.plaintext.txt	184	straightforward explanation reduced mating observed stenump ide expressing strain strain reduced factor production comparison axlnump expressing strain
0.5010976.15944156.html.plaintext.txt	185	thus compared relative amount factor produced strain lifetime culture
0.5010976.15944156.html.plaintext.txt	186	used bioassay relies natural growth arrest response mat cell factor pheromone detect quantifiably measure factor activity sample
0.5010976.15944156.html.plaintext.txt	187	analysis revealed ide stenump expressing strain produce significantly le factor axlnump expressing strain despite fact ide stenump significantly overexpressed relative axlnump fig
0.5010976.15944156.html.plaintext.txt	188	ide derived sample also bioassayed using mata cell
0.5010976.15944156.html.plaintext.txt	189	cell fail undergo growth arrest response factor pheromone thus served control unlikely scenario ide expressing strain producing toxic secreted product
0.5010976.15944156.html.plaintext.txt	190	growth inhibition mata cell observed ide derived sample fig
0.5010976.15944156.html.plaintext.txt	191	factor mating pheromone isoprenylated carboxymethylated dodecapeptide yiikgvfwdpacfarnesylmethyl
0.5010976.15944156.html.plaintext.txt	192	alteration chemical form factor e
0.5010976.15944156.html.plaintext.txt	193	lipid removal primary sequence alteration impact function pheromone num
0.5010976.15944156.html.plaintext.txt	194	example factor lacking tyrosine residue num biological activity full length pheromone judged yeast mating test num
0.5010976.15944156.html.plaintext.txt	195	thus reduced production factor pheromone ide stenump expressing yeast could attributable cleavage factor precursor site asn tyr cleavage site recognized axlnump
0.5010976.15944156.html.plaintext.txt	196	determine whether pheromone product produced ide stenump axlnump identical determined mass factor specie generated enzyme using maldi toftof mass spectroscopy
0.5010976.15944156.html.plaintext.txt	197	several major specie detected sample including num da peak corresponds exactly mass bona fide factor fig
0.5010976.15944156.html.plaintext.txt	198	num c ide stenump axlnump sample respectively
0.5010976.15944156.html.plaintext.txt	199	specie negative control fig
0.5010976.15944156.html.plaintext.txt	200	num da specie still observed sample data de isotoped fig
0.5010976.15944156.html.plaintext.txt	201	num e g remained absent negative control fig
0.5010976.15944156.html.plaintext.txt	202	based observation reasoned num da specie indeed factor implies ide stenump axlnump similar cleavage specificity
0.5010976.15944156.html.plaintext.txt	203	although specie apparent de isotoped data ide stenump derived sample indicated mass range additional specie evident sample
0.5010976.15944156.html.plaintext.txt	204	axlnump derived sample three additional specie observed num num num da fig
0.5010976.15944156.html.plaintext.txt	205	one distinct specie observed negative control num da
0.5010976.15944156.html.plaintext.txt	206	additional specie reproducibly detected experiment
0.5010976.15944156.html.plaintext.txt	207	num mass range shown panel inclusive mass theoretical mfanum derived factor specie either lacking n terminal tyrosine num da extended n terminal asparagine num da none four unidentified specie matched alternative factor cleavage product
0.5010976.15944156.html.plaintext.txt	208	nature specie therefore unknown
0.5010976.15944156.html.plaintext.txt	209	genetic evaluation ide mutant ability yeast expressed ide promote factor production suggests yeast mating used phenotype evaluate function ide mutant allele
0.5010976.15944156.html.plaintext.txt	210	test hypothesis created site directed deletion mutation ide tested ability mutant promote mating
0.5010976.15944156.html.plaintext.txt	211	using genetic system confirmed residue comprising core metalloprotease motif hxxeh ide essential promoting mating fig
0.5010976.15944156.html.plaintext.txt	212	residue required activity stenump axlnump well fig
0.5010976.15944156.html.plaintext.txt	213	distal glutamate extended motif hxxehxnumexnume also determined essential activity three enzyme whereas penultimate glutamate dispensable axlnump activity
0.5010976.15944156.html.plaintext.txt	214	penultimate glutamate required activity mitochondrial processing peptidase mnumb protease proposed aid metal coordination enzyme num
0.5010976.15944156.html.plaintext.txt	215	addition addressing importance established active site residue investigated functional importance cysteine residue function ide
0.5010976.15944156.html.plaintext.txt	216	initially investigated role two cysteine residue invariably conserved ide stenump axlnump hxcehxnumexnumexnumc suspecting one residue likely target sulfhydryl modifying agent inactivate certain mnuma enzyme
0.5010976.15944156.html.plaintext.txt	217	independent mutation residue alter ability ide stenump axlnump promote mating fig
0.5010976.15944156.html.plaintext.txt	218	mutation proximal cysteine ide cnuma reportedly alter thiol sensitivity profile ide num similarly found mutation distal cysteine ide cnuma effect thiol sensitivity ide
0.5010976.15944156.html.plaintext.txt	219	num also determined combining mutation one molecule cnumacnuma alter mating function fig
0.5010976.15944156.html.plaintext.txt	220	moreover sensitivity ide thiol modifier unaffected
0.5010976.15944156.html.plaintext.txt	221	num similar result observed cysteine residue conserved ide stenump axlnump cnuma cnuma respectively mutated fig
0.5010976.15944156.html.plaintext.txt	222	mnuma enzyme large protein typically molecular mass excess numnum da
0.5010976.15944156.html.plaintext.txt	223	metalloprotease motif mnuma enzyme localized near n terminal end enzyme
0.5010976.15944156.html.plaintext.txt	224	absence structural data enzyme sought determine whether catalytic domain ide self contained within n terminal portion enzyme
0.5010976.15944156.html.plaintext.txt	225	c terminally truncated form ide created evaluated ability promote pheromone production
0.5010976.15944156.html.plaintext.txt	226	truncation created fusion gfp alter ability ide function fig
0.5010976.15944156.html.plaintext.txt	227	systematic deletion c terminus ide revealed relatively short truncation inactivated ide judged yeast mating test
0.5010976.15944156.html.plaintext.txt	228	deletion analysis axlnump revealed similar requirement intact c terminus although deletion required axlnump inactivation considerably larger fig
0.5010976.15944156.html.plaintext.txt	229	site directed mutation residue conserved ide axlnump functionalnonfunctional truncation boundary axlnump
0.5010976.15944156.html.plaintext.txt	230	ser num ide ser num axlnump reveal essential requirement residue either enzyme fig
0.5010976.15944156.html.plaintext.txt	231	site directed truncation mutant created study evaluated protein expression
0.5010976.15944156.html.plaintext.txt	232	using immunoblots site directed mutant judged expressed well relevant wild type control except stenump enuma expressed level approximately one quarter wild type
0.5010976.15944156.html.plaintext.txt	233	num exception mutant result rule trivial possibility inactive ide axlnump stenump mutant nonfunctional poor expression
0.5010976.15944156.html.plaintext.txt	234	exclude possibility mutant nonfunctional malfolding unknown reason
0.5010976.15944156.html.plaintext.txt	235	evaluation axlnump truncation mutant revealed expressed level similar full length axlnump gfp fusion protein
0.5010976.15944156.html.plaintext.txt	236	contrast ide truncation mutant similarly expressed fig
0.5010976.15944156.html.plaintext.txt	237	observed decreased expression certain truncation suggesting c terminus ide reason unknown required normal steady state expression
0.5010976.15944156.html.plaintext.txt	238	decreased expression alone account loss activity ide one nonfunctional truncation ide num num expressed comparably full length ide gfp fusion
0.5010976.15944156.html.plaintext.txt	239	importantly expression level observed nonfunctional truncation axlnump ide encoded multicopy plasmid significantly respective full length fusion encoded low copy plasmid judged immunoblot analysis suggesting lowered expression alone account absence function mutant
0.5010976.15944156.html.plaintext.txt	240	view larger version numk fig
0.5010976.15944156.html.plaintext.txt	241	mass spectroscopic analysis factor produced ide stenump axlnump expressing yeast strain
0.5010976.15944156.html.plaintext.txt	242	factor specie secreted indicated mata strain enriched conditioned medium described fig
0.5010976.15944156.html.plaintext.txt	243	numc sample subjected maldi toftof mass spectroscopy using cyano num hydroxycinnamic acid matrix
0.5010976.15944156.html.plaintext.txt	244	strain used ynum transformed pwsnum ide numha pwsnum stenum numha pwsnum axlnum numha prsnum vector d respectively
0.5010976.15944156.html.plaintext.txt	245	de isotoping data shown d resulted data presented e h respectively
0.5010976.15944156.html.plaintext.txt	246	strain also contained psmnum num micro trpnum mfanum
0.5010976.15944156.html.plaintext.txt	247	yeast expressed ide substitute known function axlnump axlnump involved regulating several cellular process besides pheromone production
0.5010976.15944156.html.plaintext.txt	248	example axlnump required repressing haploid invasive growth num
0.5010976.15944156.html.plaintext.txt	249	haploid invasion occurs readily upon deletion axlnum phenotype fully reversed introduction plasmid borne copy axlnum
0.5010976.15944156.html.plaintext.txt	250	order address ability ide substitute function axlnump invasive phenotype axlnump deficient strain axlnum expressed ide examined
0.5010976.15944156.html.plaintext.txt	251	also investigated ability protease active site mutant axlnump suppress invasive growth
0.5010976.15944156.html.plaintext.txt	252	found ide expression could repress invasive growth whereas axlnump active site mutant suppressed invasive growth fig
0.5010976.15944156.html.plaintext.txt	253	axlnump also well described role maintenance axial budding pattern haploid yeast num
0.5010976.15944156.html.plaintext.txt	254	stenump reportedly role process
0.5010976.15944156.html.plaintext.txt	255	determine whether ide could substitute function axlnump axial bud site selection expressed ide haploid strain defective axial budding evaluated budding pattern calcofluor staining bud scar
0.5010976.15944156.html.plaintext.txt	256	consistent previous finding observed bipolar budding phenotype absence axlnump expression table iii vector
0.5010976.15944156.html.plaintext.txt	257	axial budding phenotype observed upon introduction plasmid encoding axlnump axlnum strain axlnum whereas bipolar budding predominant pattern either stenum ide introduced
0.5010976.15944156.html.plaintext.txt	258	view table table iii budding pattern observed axlnump stenump ide expressing strain
0.5010976.15944156.html.plaintext.txt	259	view larger version numk fig
0.5010976.15944156.html.plaintext.txt	260	evaluation ide stenump axlnump mutant
0.5010976.15944156.html.plaintext.txt	261	c alanine substitution point mutation created ide stenump b axlnump c function mutant enzyme evaluated patch mating test described fig
0.5010976.15944156.html.plaintext.txt	262	numa permissive condition num yepd
0.5010976.15944156.html.plaintext.txt	263	mutation created site invariably conserved ide stenump axlnump include residue compose extended metalloprotease motif enzyme hxxehxnumexnume
0.5010976.15944156.html.plaintext.txt	264	mutant exhibiting robust mating active unmodified parent enzyme judged mating test stringent condition
0.5010976.15944156.html.plaintext.txt	265	strain used ynum transformed ide encoding plasmid pwsnum ide ha pwsnum ide ha hnuma pwsnum ide ha cnuma pwsnum ide ha enuma pwsnum ide ha hnuma pwsnum ide ha enuma pwsnum ide ha enuma pwsnum ide ha cnuma pwsnum ide ha cnuma pwsnum ide ha cnuma pws num ide hasnuma pwsnum ide ha cnuma cnuma stenump encoding plasmid pwsnum stenum numha pwsnum stenum numha hnuma pwsnum stenum numhanumca pwsnum stenum numha enuma pwsnum stenum numha hnuma pwsnum stenum numha enuma pwsnum stenum numha enuma pwsnum stenum numhacnuma axlnump encoding plasmid pwsnum axlnum numha pwsnum axlnum numha hnuma pwsnum axlnum numha cnuma pwsnum axlnum numha enuma pwsnum axlnum numha hnuma pwsnum axlnum numha enuma pwsnum axlnum numha enuma pwsnum axlnum numha ca pwsnum axlnum numha snuma
0.5010976.15944156.html.plaintext.txt	266	view larger version numk fig
0.5010976.15944156.html.plaintext.txt	267	evaluation gfp labeled ide axlnump truncation mutant
0.5010976.15944156.html.plaintext.txt	268	full length c terminally truncated version ide axlnump created fusion gfp activity fusion evaluated patch mating test permissive condition num yepd
0.5010976.15944156.html.plaintext.txt	269	truncation exhibiting robust mating active full length fusion judged mating test stringent condition except axlnum num num reduced mating phenotype
0.5010976.15944156.html.plaintext.txt	270	amino acid gfp fused indicated arrow shaded gray
0.5010976.15944156.html.plaintext.txt	271	residue within c terminal region ide axlnump conserved shown protein alignment mating test arrowhead
0.5010976.15944156.html.plaintext.txt	272	residue region targeted site directed mutational analysis see fig
0.5010976.15944156.html.plaintext.txt	273	num indicated filled arrowhead
0.5010976.15944156.html.plaintext.txt	274	b protein extract prepared yeast containing vector encoding gfp tagged ide
0.5010976.15944156.html.plaintext.txt	275	equivalent amount sample analyzed sd page immunoblot using anti gfp antibody
0.5010976.15944156.html.plaintext.txt	276	strain used ynum transformed ide encoding plasmid pwsnum ide num num gfp pwsnum ide num num gfp pwsnum ide num num gfp pwsnum ide num num gfp pwsnum ide num num gfp axlnump encoding plasmid pwsnum axlnum num num gfp pwsnum axlnum num num gfp pwsnum axlnum num num gfp pwsnum axlnum num num gfp pwsnum axlnum num num gfp
0.5010976.15944156.html.plaintext.txt	277	view larger version numk fig
0.5010976.15944156.html.plaintext.txt	278	ide repress haploid invasive growth
0.5010976.15944156.html.plaintext.txt	279	plasmid encoding ha tagged axlnump axlnump hnuma ide transformed axlnum haploid strain
0.5010976.15944156.html.plaintext.txt	280	equal cell density suspension strain spotted onto sc ura allowed grow num day plate washed running water remove surface lying cell b
0.5010976.15944156.html.plaintext.txt	281	presence cell washing step indicative invasive growth
0.5010976.15944156.html.plaintext.txt	282	strain used synum transformed prsnum wild type wt synum axlnumhisnum transformed prsnum vector pwsnum axlnum numha pwsnum axlnum numha hnuma pwsnum ide numha
0.5010976.15944156.html.plaintext.txt	283	study developed yeast tractable genetic model system studying functional property ide
0.5010976.15944156.html.plaintext.txt	284	determined yeast used express functional form ide importantly ide promote factor production activity normally associated yeast enzyme axlnump stenump homology ide
0.5010976.15944156.html.plaintext.txt	285	result imply member mnuma metalloprotease family enzyme belong may shared substrate specificity
0.5010976.15944156.html.plaintext.txt	286	fact three enzyme promote factor production support hypothesis
0.5010976.15944156.html.plaintext.txt	287	however inability demonstrate insulin cleavage yeast enzyme implies substrate specificity stenump axlnump may restricted
0.5010976.15944156.html.plaintext.txt	288	whether yeast enzyme cleave established ide substrate currently investigation
0.5010976.15944156.html.plaintext.txt	289	also investigating ability mnuma enzyme cleave factor study enzyme may benefit development tractable genetic system
0.5010976.15944156.html.plaintext.txt	290	additional finding study ide enriched exclusively partition yeast particulate fraction
0.5010976.15944156.html.plaintext.txt	291	suspect heterologously expressed ide either incorporated membrane loosely associated peripheral membrane protein assembling macromolecular complex partially sediment condition used isolation particulate fraction
0.5010976.15944156.html.plaintext.txt	292	although ide reportedly associate peroxisomes localization unlikely experimental condition impose induction required formation yeast peroxisomes num
0.5010976.15944156.html.plaintext.txt	293	moreover putative c terminal peroxisomal targeting signal found ide although potentially functional yeast blocked epitope tag yeast expressed enzyme
0.5010976.15944156.html.plaintext.txt	294	alternatively ide may associating undefined membrane site
0.5010976.15944156.html.plaintext.txt	295	axlnump reported associate transiently component form sub plasma membrane complex required budding num
0.5010976.15944156.html.plaintext.txt	296	thus also conceivable ide assembling complex nonfunctional component
0.5010976.15944156.html.plaintext.txt	297	ultimately defining subcellular localization stenump may provide insight subcellular targeting ide two enzyme appear conserved sequence enzymatic property ide axlnump
0.5010976.15944156.html.plaintext.txt	298	view larger version numk fig
0.5010976.15944156.html.plaintext.txt	299	schematic mnuma enzyme sequence
0.5010976.15944156.html.plaintext.txt	300	sequence ide stenump e
0.5010976.15944156.html.plaintext.txt	301	coli protease iii axlnump represented schematic format top bottom respectively
0.5010976.15944156.html.plaintext.txt	302	schematic drawn scale
0.5010976.15944156.html.plaintext.txt	303	representation divided several domain
0.5010976.15944156.html.plaintext.txt	304	border domain vi operationally defined site insertion num residue found axlnump sequence determined multiple sequence alignment clustalw four protein
0.5010976.15944156.html.plaintext.txt	305	domain end molecule dark gray represent sequence variable length conserved enzyme
0.5010976.15944156.html.plaintext.txt	306	n terminal sequence range num num residue c terminal sequence range num num residue
0.5010976.15944156.html.plaintext.txt	307	relative position shortest c terminal truncation yielding nonfunctional mutant shown filled arrowhead
0.5010976.15944156.html.plaintext.txt	308	value schematic represent percent identity indicated ide domain corresponding domain either stenump e
0.5010976.15944156.html.plaintext.txt	309	coli protease iii axlnump determined using dna strider num
0.5010976.15944156.html.plaintext.txt	310	b d several conserved motif identified within domain b ii c v d
0.5010976.15944156.html.plaintext.txt	311	purpose figure conserved motif defined block amino acid num num identical highly conserved residue
0.5010976.15944156.html.plaintext.txt	312	second motif listed domain found within xnum sequence extended metalloprotease motif whereas third found within xnum sequence
0.5010976.15944156.html.plaintext.txt	313	residue boldface mutated study
0.5010976.15944156.html.plaintext.txt	314	neither cys num found near end domain cys num found beginning domain iv within conserved motif
0.5010976.15944156.html.plaintext.txt	315	genetic model system developed far reaching utility characterization mutant ide allele
0.5010976.15944156.html.plaintext.txt	316	provided practical example utility detailing functional importance residue compose extended metalloprotease motif hxxehxnumexnume
0.5010976.15944156.html.plaintext.txt	317	addition mutational study allows u make certain conclusion cysteine residue imparts sensitivity ide thiol modifier
0.5010976.15944156.html.plaintext.txt	318	provided single cysteine residue target thiol modification ide study excludes target two cysteine residue invariably conserved three enzyme cys num cys num ide two cysteine semi conserved ide yeast mnuma enzyme cys num cys num ide
0.5010976.15944156.html.plaintext.txt	319	double cnumacnuma mutant also remains sensitive thiol modifier
0.5010976.15944156.html.plaintext.txt	320	currently developing vitro assay monitoring activity stenump axlnump
0.5010976.15944156.html.plaintext.txt	321	expect determination whether enzyme sensitive thiol modifier aid final identification cysteine residue targeted thiol modifier enzyme family
0.5010976.15944156.html.plaintext.txt	322	second practical example utility genetic system demonstrate first time c terminal region required activity ide
0.5010976.15944156.html.plaintext.txt	323	absence structural information ide suspect c terminal region may required stabilizing overall tertiary possibly quaternary structure ide active site
0.5010976.15944156.html.plaintext.txt	324	genetic system also useful investigating role residue function ide
0.5010976.15944156.html.plaintext.txt	325	example several conserved sequence motif identified multiple sequence alignment mnuma enzyme fig
0.5010976.15944156.html.plaintext.txt	326	future study aimed determining whether motif important function mnuma enzyme
0.5010976.15944156.html.plaintext.txt	327	addition investigate whether e
0.5010976.15944156.html.plaintext.txt	328	coli protease iii support factor production yeast
0.5010976.15944156.html.plaintext.txt	329	system could conceivably used investigate structurefunction relationship enigmatic protease also lack defined cellular role num
0.5010976.15944156.html.plaintext.txt	330	another potential utility genetic model system theoretical ability rapidly identify ide mutant altered substrate specificity
0.5010976.15944156.html.plaintext.txt	331	already demonstrated system amenable screening specific mutant ide allele ability promote mating
0.5010976.15944156.html.plaintext.txt	332	approach could used identify ide mutant altered specificity toward factor
0.5010976.15944156.html.plaintext.txt	333	envision positive genetic selection take advantage observation ide dependent mating essentially nonexistent reduced nutrient level fig
0.5010976.15944156.html.plaintext.txt	334	highly stringent mating condition yeast harboring ide mutant could screened expectation enhanced factor production would mating competent
0.5010976.15944156.html.plaintext.txt	335	ide mutant would represent candidate improved factor recognition
0.5010976.15944156.html.plaintext.txt	336	altered substrate specificity
0.5010976.15944156.html.plaintext.txt	337	conceivably mutant might also altered specificity insulin andor
0.5010976.15944156.html.plaintext.txt	338	ide mutant enhanced activity toward substrate could potentially used therapeutic agent diabetes alzheimer disease
0.5010976.15944156.html.plaintext.txt	339	data clearly demonstrate axlnumpstenump dependent step factor production supported ide
0.5010976.15944156.html.plaintext.txt	340	result surprising given high degree similarity enzyme
0.5010976.15944156.html.plaintext.txt	341	greater curiosity observation yeast enzyme required factor production functionally replaced mammalian counterpart
0.5010976.15944156.html.plaintext.txt	342	first three step associated factor production
0.5010976.15944156.html.plaintext.txt	343	isoprenylation caax proteolysis carboxymethylation part biosynthetic pathway isoprenylated protein ra rhob
0.5010976.15944156.html.plaintext.txt	344	subsequent two proteolytic step associated factor production analogous counterpart mammal
0.5010976.15944156.html.plaintext.txt	345	thus ability mammalian enzyme promote latter step entirely serendipitous reflects existence orphan biosynthetic pathway integrates step associated factor biosynthesis
0.5010976.15944156.html.plaintext.txt	346	latter analogy suspect molecule produced pathway would serve secreted signaling molecule possibly functioning regulate cell cell fusion event occur development certain tissue
0.5010976.15944156.html.plaintext.txt	347	curiously morphological biochemical differentiation lnum myoblasts myotubes reported involve ide num num
0.5010976.15944156.html.plaintext.txt	348	thus analogy factor production hypothesize role ide cell might produce signaling molecule derived precursor aliphatic amino acid motif n terminal extension readily cleaved ide
0.5010976.15944156.html.plaintext.txt	349	whether molecule exists mammalian system remains determined
0.5010976.15944156.html.plaintext.txt	350	footnote work supported part fund university georgia
0.5010976.15944156.html.plaintext.txt	351	cost publication article defrayed part payment page charge
0.5010976.15944156.html.plaintext.txt	352	article must therefore hereby marked advertisement accordance num u
0.5010976.15944156.html.plaintext.txt	353	section num solely indicate fact
0.5010976.15944156.html.plaintext.txt	354	supported university georgia graduate school assistantship
0.5010976.15944156.html.plaintext.txt	355	correspondence addressed dept
0.5010976.15944156.html.plaintext.txt	356	biochemistry molecular biology num green st
0.5010976.15944156.html.plaintext.txt	357	num num num fax num num num e mail wschmidtatbmb
0.5010976.15944156.html.plaintext.txt	358	num abbreviation used ide insulin degrading enzyme ha hemagglutinin maldi tof matrix assisted laser desorption ionization time flight gfp green fluorescent protein
0.5010976.15944156.html.plaintext.txt	359	schmidt unpublished observation
0.5010976.15944156.html.plaintext.txt	360	acknowledgment grateful drs
0.5010976.15944156.html.plaintext.txt	361	claiborne glover michelle momany ron orlando lance well member respective laboratory technical advice access equipment critical discussion
0.5010976.15944156.html.plaintext.txt	362	also thank pamela freshley chandra moore help plasmid construction
0.5010976.15944156.html.plaintext.txt	363	home help feedback subscription archive search table content asbmb journal molecular cellular proteomics journal lipid research biochemistry molecular biology education copyright num american society biochemistry molecular biology
0.5654884.15749695.html.plaintext.txt	0	mutation active site residue insulin degrading enzyme alters allosteric interaction eun suk song abigail daily michael g
0.5654884.15749695.html.plaintext.txt	1	fried maria aparecida juliano luiz juliano louis b
0.5654884.15749695.html.plaintext.txt	2	department molecular cellular biochemistry university kentucky lexington kentucky num department biophysics escola paulista de medicina sao paulo num num brazil
0.5654884.15749695.html.plaintext.txt	3	received publication february num num
0.5654884.15749695.html.plaintext.txt	4	clearance currently receiving considerable attention key regulatory mechanism brain level
0.5654884.15749695.html.plaintext.txt	5	appear two path clearance brain
0.5654884.15749695.html.plaintext.txt	6	one pathway involves equilibration central nervous system plasma mediated cerebral spinal fluid num num
0.5654884.15749695.html.plaintext.txt	7	pathway involves clearance proteolysis num num
0.5654884.15749695.html.plaintext.txt	8	number peptidase implicated clearance
0.5654884.15749695.html.plaintext.txt	9	received attention supported vivo study peptidase deficient mouse include neprilysin num num insulysin ide num num endothelin converting enzyme num num
0.5654884.15749695.html.plaintext.txt	10	genetic study suggested linkage late onset ad ide
0.5654884.15749695.html.plaintext.txt	11	linkage region chromosome numq late onset alzheimer disease reported several group num num
0.5654884.15749695.html.plaintext.txt	12	region chromosome within num kilobases ide gene
0.5654884.15749695.html.plaintext.txt	13	however date analysis refined point linkage ide unequivocally established
0.5654884.15749695.html.plaintext.txt	14	num ec num kda zinc metallopeptidase containing inverted form signature active site sequence hxxeh thus known inverzincin
0.5654884.15749695.html.plaintext.txt	15	enzyme primarily cytosolic although fraction enzyme peroxisomal due presence c terminal peroxisomal targeting sequence num
0.5654884.15749695.html.plaintext.txt	16	ide also reported located cell surface secreted num num
0.5654884.15749695.html.plaintext.txt	17	num shown naturally occurring ide missense mutation rat result decreased insulin degradation
0.5654884.15749695.html.plaintext.txt	18	primary neuronal culture derived rat secrete increased level peptide however steady state level brain animal unaffected suggesting compensatory mechanism
0.5654884.15749695.html.plaintext.txt	19	specificity ide complex
0.5654884.15749695.html.plaintext.txt	20	enzyme cleaves variety peptide primarily exclusively basic bulky hydrophobic residue num num
0.5654884.15749695.html.plaintext.txt	21	kurochkin num suggested ide cleaves peptide propensity form pleated sheet structure
0.5654884.15749695.html.plaintext.txt	22	cleavage ide result loss neurotoxic effect peptide prevents deposition onto synthetic amyloid deposit num
0.5654884.15749695.html.plaintext.txt	23	recently shown ide exhibit allosteric property activated peptide substrate
0.5654884.15749695.html.plaintext.txt	24	interestingly peptide activated ide toward peptide cleavage toward insulin cleavage num
0.5654884.15749695.html.plaintext.txt	25	established ide exists mixture monomer dimer tetramers
0.5654884.15749695.html.plaintext.txt	26	course study allosteric property ide generated number active site mutant control enzyme
0.5654884.15749695.html.plaintext.txt	27	noted although activity mutant significantly reduced residual catalytic property altered
0.5654884.15749695.html.plaintext.txt	28	report result study
0.5654884.15749695.html.plaintext.txt	29	activity assay ide activity routinely measured fluorogenic peptide abz ggflrkhgq eddnp
0.5654884.15749695.html.plaintext.txt	30	increase fluorescence occurred upon cleavage peptide residue r k num followed spectramax gemini x fluorescence plate reader using excitation wavelength num nm emission wavelength num nm
0.5654884.15749695.html.plaintext.txt	31	ide dependent hydrolysis insulin endorphin amyloid peptide num num dynorphin peptide followed reverse phase hplc using cnum column linear gradient num
0.5654884.15749695.html.plaintext.txt	32	num trifluoroacetic acid num water num acetonitrile num
0.5654884.15749695.html.plaintext.txt	33	num trifluoroacetic acid num water num acetonitrile
0.5654884.15749695.html.plaintext.txt	34	peptide followed absorbance num nm quantified peak area
0.5654884.15749695.html.plaintext.txt	35	preparation purification ide mutant various hisnum glunum rat ide mutant prepared pfast bac htb using site directed mutagenesis kit stratagene
0.5654884.15749695.html.plaintext.txt	36	noted methionine located num residue downstream methionine num ide cdna appears represent major translational start site num
0.5654884.15749695.html.plaintext.txt	37	thus hisnum would actually hisnum glunum would glunum
0.5654884.15749695.html.plaintext.txt	38	however retained original numbering system avoid confusion earlier publication
0.5654884.15749695.html.plaintext.txt	39	oligonucleotides used mutagenesis base change wild type sequence underlined listed table
0.5654884.15749695.html.plaintext.txt	40	view table table oligonucleotides used
0.5654884.15749695.html.plaintext.txt	41	based secondary structure predicting program phd num phdsec num ide predicted helical region residue num num encompasses mutated residue
0.5654884.15749695.html.plaintext.txt	42	none mutation predicted affect ability region form helix
0.5654884.15749695.html.plaintext.txt	43	recombinant ide various mutant expressed sf num cell fusion protein containing n terminal hexahistidine affinity tag followed linker containing tobacco etch virus protease cleavage site num
0.5654884.15749695.html.plaintext.txt	44	wild type ide mutant purified select hc nickel affinity gel column sigma
0.5654884.15749695.html.plaintext.txt	45	experiment enzyme used hisnum ide however verify lack effect n terminal hexahistidine linker tobacco etch virus protease used remove region previously described num
0.5654884.15749695.html.plaintext.txt	46	sedimentation equilibrium analysis analytical ultracentrifugation performed num
0.5654884.15749695.html.plaintext.txt	47	num degree c beckman xl centrifuge using num ti rotor
0.5654884.15749695.html.plaintext.txt	48	scan obtained num nm step size num
0.5654884.15749695.html.plaintext.txt	49	approach equilibrium considered complete scan made num h apart indistinguishable
0.5654884.15749695.html.plaintext.txt	50	typically equilibration time equal greater num h met criterion
0.5654884.15749695.html.plaintext.txt	51	five scan averaged sample rotor speed
0.5654884.15749695.html.plaintext.txt	52	previous result num indicated ide self associate monomer dimer tetramer pattern
0.5654884.15749695.html.plaintext.txt	53	sedimentation equilibrium data therefore analyzed according equation num
0.5654884.15749695.html.plaintext.txt	54	num ar absorbance radial position r mnum dnum tnum absorbance monomer dimer tetramer respectively reference radius ro
0.5654884.15749695.html.plaintext.txt	55	parameter m reduced molecular weight monomer m mmnum numnumrt mm monomer molecular weight partial specific volume solvent density rotor angular velocity r gas constant absolute temperature base line offset
0.5654884.15749695.html.plaintext.txt	56	solvent density measured using mettler density meter
0.5654884.15749695.html.plaintext.txt	57	partial specific volume ide calculated amino acid composition using method cohn edsall num
0.5654884.15749695.html.plaintext.txt	58	data set obtained sample run three different rotor speed fit simultaneously equation num using global fitting method first described johnson co worker num
0.5654884.15749695.html.plaintext.txt	59	two mutant hisnum hnumq hnumd generated well four mutant glunum enumv enuml enuma enumf
0.5654884.15749695.html.plaintext.txt	60	initially compared kinetics various hisnum glunum mutant using fluorogenic substrate abz ggflrkhgq eddnp
0.5654884.15749695.html.plaintext.txt	61	although native ide clearly displayed sigmoidal substrate binding curve fig
0.5654884.15749695.html.plaintext.txt	62	num hisnum mutant four glunum mutant displayed classical hyperbolic substrate binding curve illustrated enumf mutant fig
0.5654884.15749695.html.plaintext.txt	63	table ii summarizes kinetic parameter mutant
0.5654884.15749695.html.plaintext.txt	64	hisnum mutant exhibited num num fold increase km kcat decreased close numnum fold hnumd mutant le num fold hnumq mutant
0.5654884.15749695.html.plaintext.txt	65	mutation active site glutamate valine leucine alanine phenylalanine produced enzyme form effect km variable essentially change enuml enumf mutant greater num fold increase enuma mutant
0.5654884.15749695.html.plaintext.txt	66	range kcat value glunum mutant varied decrease numnum fold enuma decrease numnum fold enuml
0.5654884.15749695.html.plaintext.txt	67	view larger version numk fig
0.5654884.15749695.html.plaintext.txt	68	comparison kinetics wild type ide kinetics enumf mutant
0.5654884.15749695.html.plaintext.txt	69	reaction conducted num mm tris hcl ph num
0.5654884.15749695.html.plaintext.txt	70	num wild type ide num ng enzyme top enumf mutant num microg enzyme bottom using abz ggflrkhgqeddnp variable substrate
0.5654884.15749695.html.plaintext.txt	71	view table table ii kinetic property ide mutant abz ggflrkhgq eddnp substrate
0.5654884.15749695.html.plaintext.txt	72	activity determined num mm potassium phosphate buffer ph num
0.5654884.15749695.html.plaintext.txt	73	also examined effect glunum hisnum mutation hydrolysis three physiological peptide substrate ide insulin endorphin amyloid peptide num num
0.5654884.15749695.html.plaintext.txt	74	shown table iii saturating substrate condition endorphin amyloid peptide num num hydrolysis decreased num fold glunum mutant num fold hisnum mutant
0.5654884.15749695.html.plaintext.txt	75	insulin substrate hydrolysis could detected glunum mutant condition decrease num fold could detected whereas hisnum mutant insulin hydrolysis decreased num x num fold hnumq num fold hnumd
0.5654884.15749695.html.plaintext.txt	76	view table table iii rate hydrolysis physiological peptide ide mutant
0.5654884.15749695.html.plaintext.txt	77	activity determined num mm tris hcl buffer ph num
0.5654884.15749695.html.plaintext.txt	78	rate hydrolysis determined following substrate disappearance hplc
0.5654884.15749695.html.plaintext.txt	79	ide found contain cationic regulatory site distinct active site bind nucleotide triphosphates primarily triphosphate moiety num
0.5654884.15749695.html.plaintext.txt	80	binding polyanion site increase rate small peptide substrate larger physiological substrate insulin amyloid peptide
0.5654884.15749695.html.plaintext.txt	81	since active site histidine glutamate mutation caused loss allosteric interaction tested whether mutant enzyme could still activated atp triphosphate
0.5654884.15749695.html.plaintext.txt	82	shown table iv using abz ggflrkhgq eddnp dynorphin b num substrate glunum mutant activated atp much lesser extent compared wild type enzyme
0.5654884.15749695.html.plaintext.txt	83	similar effect observed triphosphate activator
0.5654884.15749695.html.plaintext.txt	84	view table table iv effect atp pppi mutant ide activity
0.5654884.15749695.html.plaintext.txt	85	activity determined num microm abz ggflrkhgq eddnp num microm dynorphin b num num mm tris hcl buffer ph num
0.5654884.15749695.html.plaintext.txt	86	num presence num mm atp num mm pppi compared absence addition
0.5654884.15749695.html.plaintext.txt	87	specific activity absence added atp pppi abz ggflrkhgq eddnp substrate follows wild type ide numnum nmolminmg enuma num
0.5654884.15749695.html.plaintext.txt	88	num nmolminmg hnumq num nmolminmg
0.5654884.15749695.html.plaintext.txt	89	hisnum mutant affected differently atp triphosphate acted inhibitor rather activator
0.5654884.15749695.html.plaintext.txt	90	hnumq mutant triphosphate effective inhibitor abz ggflrkhgq eddnp hydrolysis micromolar concentration microm microm whereas activation wild type enzyme required millimolar concentration mm mm illustrated fig
0.5654884.15749695.html.plaintext.txt	91	view larger version numk fig
0.5654884.15749695.html.plaintext.txt	92	comparison effect triphosphate hydrolysis abz ggflrkhgq eddnp wild type ide top ide hnumq mutant bottom
0.5654884.15749695.html.plaintext.txt	93	activity determined num mm tris hcl buffer ph num
0.5654884.15749695.html.plaintext.txt	94	num num microm abz ggflrkhgq eddnp substrate indicated concentration pppi
0.5654884.15749695.html.plaintext.txt	95	reaction wild type enzyme contained num ng protein whereas hnumq mutant contained num microg protein
0.5654884.15749695.html.plaintext.txt	96	wild type enzyme activity absence added pppi num
0.5654884.15749695.html.plaintext.txt	97	although shown effect pppi activity wild type enzyme concentration range used hnumq mutant
0.5654884.15749695.html.plaintext.txt	98	used sedimentation equilibrium determine effect active site mutation ide oligomerization fig
0.5654884.15749695.html.plaintext.txt	99	previously reported tris buffer wild type enzyme appeared predominantly mixture monomer dimer num
0.5654884.15749695.html.plaintext.txt	100	monomer predominant specie
0.5654884.15749695.html.plaintext.txt	101	addition num mm triphosphate maintained monomer dominant specie eliminated small amount dimer num
0.5654884.15749695.html.plaintext.txt	102	study found hnumq mutant appeared monomeric trace higher aggregate possibly tetramer present
0.5654884.15749695.html.plaintext.txt	103	addition pppi decreased solubility significantly change distribution oligomeric specie
0.5654884.15749695.html.plaintext.txt	104	contrast hnumd mutant appeared le soluble showed predominantly tetramers
0.5654884.15749695.html.plaintext.txt	105	addition pppi decreased solubility clearly showed presence primarily monomer higher aggregate present
0.5654884.15749695.html.plaintext.txt	106	enuma enumf enuml appeared monomer trace tetramer present
0.5654884.15749695.html.plaintext.txt	107	enumv exhibited poor solubility could analyzed
0.5654884.15749695.html.plaintext.txt	108	addition pppi enuml enuma effect distribution specie induced aggregation enuma complete aggregation enumf
0.5654884.15749695.html.plaintext.txt	109	thus clear correlation oligomeric state enzyme activity
0.5654884.15749695.html.plaintext.txt	110	view larger version numk fig
0.5654884.15749695.html.plaintext.txt	111	sedimentation equilibrium analysis wild type enuma mutant ide protein
0.5654884.15749695.html.plaintext.txt	112	sample dissolved num mm tris hcl buffer ph num
0.5654884.15749695.html.plaintext.txt	113	num brought sedimentation equilibrium numnum rpm num degree c
0.5654884.15749695.html.plaintext.txt	114	open circle wild type ide filled circle enuma mutant ide
0.5654884.15749695.html.plaintext.txt	115	smooth curve represent global fit equation num data set obtained numnum numnum numnum rpm
0.5654884.15749695.html.plaintext.txt	116	small symmetric residual demonstrate compatibility equation data
0.5654884.15749695.html.plaintext.txt	117	data wild type mutant ide consistent mixture monomeric enzyme predominates relatively small mol fraction higher oligomers
0.5654884.15749695.html.plaintext.txt	118	num showed hisnum zinc coordinating residue provided evidence active site zinc lost hnumq mutant
0.5654884.15749695.html.plaintext.txt	119	reexamined issue hnumq hnumd mutant
0.5654884.15749695.html.plaintext.txt	120	accomplish looked ability edta o phenanthroline inhibit residual activity mutant
0.5654884.15749695.html.plaintext.txt	121	shown table v inclusion num
0.5654884.15749695.html.plaintext.txt	122	num mm o phenanthroline assay little effect activity wild type ide
0.5654884.15749695.html.plaintext.txt	123	num mm o phenanthroline effect rate insulin hydrolysis glutamate mutant data shown
0.5654884.15749695.html.plaintext.txt	124	contrast metal chelating agent completely inhibited activity histidine mutant shown table v
0.5654884.15749695.html.plaintext.txt	125	although shown significant inhibition wild type enzyme glutamate mutant observed higher concentration edta num mm o phenanthroline num mm
0.5654884.15749695.html.plaintext.txt	126	thus hisnum mutant appear retain active site zinc zinc bound weakly
0.5654884.15749695.html.plaintext.txt	127	thus looked ability zinc increase reaction rate mutant
0.5654884.15749695.html.plaintext.txt	128	num addition zinc concentration range num
0.5654884.15749695.html.plaintext.txt	129	num num microm caused maximal num
0.5654884.15749695.html.plaintext.txt	130	num fold increase activity hnumq mutant num
0.5654884.15749695.html.plaintext.txt	131	num fold increase activity hnumd mutant
0.5654884.15749695.html.plaintext.txt	132	followed inhibition higher zinc concentration
0.5654884.15749695.html.plaintext.txt	133	contrast zinc concentration tested slightly inhibitory wild type activity
0.5654884.15749695.html.plaintext.txt	134	view table table v effect metal chelators mutant ide activity
0.5654884.15749695.html.plaintext.txt	135	activity determined num mm tris hcl ph num
0.5654884.15749695.html.plaintext.txt	136	num either num microm abz ggflrkhgq eddnp substrate num microm insulin value parenthesis substrate num
0.5654884.15749695.html.plaintext.txt	137	num mm o phenanthroline added indicated
0.5654884.15749695.html.plaintext.txt	138	view larger version numk fig
0.5654884.15749695.html.plaintext.txt	139	effect zinc activity wild type ide hisnum mutant
0.5654884.15749695.html.plaintext.txt	140	activity determined num mm tris hcl buffer ph num
0.5654884.15749695.html.plaintext.txt	141	num num microm abz ggflrkhgq eddnp substrate indicated concentration znclnum
0.5654884.15749695.html.plaintext.txt	142	order determine whether mutation introduced ide affected enzyme specificity looked cleavage pattern three physiological peptide endorphin insulin amyloid peptide num num using mutant listed table ii
0.5654884.15749695.html.plaintext.txt	143	insulin amyloid peptide num num substrate observed initial cleavage product various mutant wild type enzyme
0.5654884.15749695.html.plaintext.txt	144	illustrated insulin cleavage enumf mutant fig
0.5654884.15749695.html.plaintext.txt	145	previously noted num native ide cleaved endorphin thrnum leunum leunum phenum bond two histidine mutant produced cleavage pattern
0.5654884.15749695.html.plaintext.txt	146	however glutamate num mutant produced addition cleavage leunum phenum phenum lysnum cleavage lysnum asnnum metnum thrnum
0.5654884.15749695.html.plaintext.txt	147	based result also compared cleavage small dynorphin related peptide native ide enumv mutant
0.5654884.15749695.html.plaintext.txt	148	found dynorphin num dynorphin num dynorphin num dynorphin b num change cleavage site
0.5654884.15749695.html.plaintext.txt	149	view larger version numk fig
0.5654884.15749695.html.plaintext.txt	150	hplc chromatogram showing cleavage endorphin insulin ide enumf mutant
0.5654884.15749695.html.plaintext.txt	151	top reaction mixture containing num microm insulin num mm tris hcl ph num
0.5654884.15749695.html.plaintext.txt	152	num reacted wild type ide num
0.5654884.15749695.html.plaintext.txt	153	num microg num min b enumq num microg num h c
0.5654884.15749695.html.plaintext.txt	154	reaction product separated gradient hplc vydac cnum reverse phase column described material method
0.5654884.15749695.html.plaintext.txt	155	product peak collected identified mass spectrometry
0.5654884.15749695.html.plaintext.txt	156	peak num insulin bnum num peak num insulin bnum num peak num insulin anum num peak num insulin anum num peak insulin chain peak b insulin b chain
0.5654884.15749695.html.plaintext.txt	157	bottom reaction mixture containing num microm endorphin reacted wild type ide num
0.5654884.15749695.html.plaintext.txt	158	num microg num min b enumf num microg num h c
0.5654884.15749695.html.plaintext.txt	159	peak num endorphin num num peak num endorphin num num peak num endorphin num num peak num endorphin num num peak num endorphin num num peak num endorphin num num peak num endorphin num num
0.5654884.15749695.html.plaintext.txt	160	active site glutamate glunum active site histidine hisnum ide previously mutated num num
0.5654884.15749695.html.plaintext.txt	161	hisnum mutant transiently expressed co cell appeared inactive measured crude extract insulin substrate
0.5654884.15749695.html.plaintext.txt	162	however mutant retained ability bind insulin determined cross linking study num
0.5654884.15749695.html.plaintext.txt	163	noted insulin cross linking actually increased mutant relative wild type enzyme attributed relaxation rigid conformation stabilized zinc
0.5654884.15749695.html.plaintext.txt	164	evidence increased flexibility active site came demonstration treatment native enzyme o phenanthroline increased extent cross linking however o phenanthroline increase cross linking hnumq mutant
0.5654884.15749695.html.plaintext.txt	165	using radioactive zinc concluded hnumq mutant bind zinc
0.5654884.15749695.html.plaintext.txt	166	finding residual activity two hisnum mutant glunum mutant reduced treatment metal chelators indicates mutant contain zinc zinc bound considerably weakly native protein
0.5654884.15749695.html.plaintext.txt	167	thus result hisnum glunum mutant support extend general conclusion perlman rosner num mutation active site histidine cause change conformation active site ide
0.5654884.15749695.html.plaintext.txt	168	result presented suggest due loss zinc binding probably due local conformational change occur within active site
0.5654884.15749695.html.plaintext.txt	169	rather surprising finding mutation either catalytic glutamate zinc coordinating histidine convert substrate velocity curve sigmoidal hyperbolic
0.5654884.15749695.html.plaintext.txt	170	thus homotropic allosteric activation previously reported u num absent mutant
0.5654884.15749695.html.plaintext.txt	171	since established ide exist oligomeric state num num num num one possible explanation active site ide interface two subunit mutation active site residue produce local conformational change affect subunit interaction
0.5654884.15749695.html.plaintext.txt	172	appear case since num perlman et al
0.5654884.15749695.html.plaintext.txt	173	num shown formation oligomers containing active inactive subunit abrogate activity
0.5654884.15749695.html.plaintext.txt	174	however mixed oligomer eliminate allosteric activation num
0.5654884.15749695.html.plaintext.txt	175	thus data probably explained proposal active site mutation produce local conformational change transmitted adjacent subunit
0.5654884.15749695.html.plaintext.txt	176	although end result appears difference local conformational change produced mutating catalytic glutamate mutating zinc coordinating histidine
0.5654884.15749695.html.plaintext.txt	177	evident observation cleavage profile endorphin altered glutamate mutant histidine mutant
0.5654884.15749695.html.plaintext.txt	178	addition active site mutation affecting kinetics substrate binding mutation also desensitized enzyme activation triphosphates form atp triphosphate
0.5654884.15749695.html.plaintext.txt	179	large increase activity seen native enzyme significantly reduced either effect le num fold increase activity glutamate mutant
0.5654884.15749695.html.plaintext.txt	180	even amazing effect seen active site histidine mutant particularly hnumq
0.5654884.15749695.html.plaintext.txt	181	case triphosphate changed activator rather potent inhibitor
0.5654884.15749695.html.plaintext.txt	182	clearly indicates active site mutant conformationally different wild type enzyme modulated additional conformational change produced binding triphosphate moiety
0.5654884.15749695.html.plaintext.txt	183	sedimentation equilibrium data show exception hnumd mutant native enzyme mutant predominantly monomeric
0.5654884.15749695.html.plaintext.txt	184	triphosphate affect qualitative oligomerization mechanism soluble enzyme increased tendency form insoluble aggregate case enuma enumf mutant
0.5654884.15749695.html.plaintext.txt	185	aggregation may reflect conformational change due triphosphate binding
0.5654884.15749695.html.plaintext.txt	186	thus obvious correlation oligomeric state activity finding monomeric native enzyme consistent allosteric property
0.5654884.15749695.html.plaintext.txt	187	hand gel filtration show native enzyme existing dimer tetramers higher protein concentration dynamic light scattering show exclusively tetramers
0.5654884.15749695.html.plaintext.txt	188	thus clear ide exist number different oligomerization state
0.5654884.15749695.html.plaintext.txt	189	would suggest allosteric kinetics observed result substrate induced oligomerization
0.5654884.15749695.html.plaintext.txt	190	case mutant ide perhaps altered local conformational change active site transmitted protein prevents formation oligomers
0.5654884.15749695.html.plaintext.txt	191	footnote work supported part national institute health grant danum l
0.5654884.15749695.html.plaintext.txt	192	grant alzheimers association l
0.5654884.15749695.html.plaintext.txt	193	fundacao de amparo pesquisa estado de sao paulo fapesp l
0.5654884.15749695.html.plaintext.txt	194	conselho nacional de desenvolvimento cientifico e tecnologico cnpq l
0.5654884.15749695.html.plaintext.txt	195	human frontier science progress grant rg numnum m l
0.5654884.15749695.html.plaintext.txt	196	cost publication article defrayed part payment page charge
0.5654884.15749695.html.plaintext.txt	197	article must therefore hereby marked advertisement accordance num u
0.5654884.15749695.html.plaintext.txt	198	section num solely indicate fact
0.5654884.15749695.html.plaintext.txt	199	correspondence sent dept
0.5654884.15749695.html.plaintext.txt	200	molecular cellular biochemistry college medicine university kentucky num rose st
0.5654884.15749695.html.plaintext.txt	201	num num num fax num num num e mail lhershatuky
0.5654884.15749695.html.plaintext.txt	202	num abbreviation used amyloid peptide pppi tripolyphosphate ad alzheimer disease ide insulin degrading enzyme hplc high pressure liquid chromatography abz num aminobenzoyl eddnp n numnum dinitrophenylethylenediamine
0.5654884.15749695.html.plaintext.txt	203	acknowledgment mass spectral data obtained university kentucky mass spectrometry facility mass spectrometry facility university kentucky center structural biology
0.5654884.15749695.html.plaintext.txt	204	goodman haining zhu xiaoning lu assisting mass spectral analysis
0.5654884.15749695.html.plaintext.txt	205	home help feedback subscription archive search table content asbmb journal molecular cellular proteomics journal lipid research biochemistry molecular biology education copyright num american society biochemistry molecular biology
0.5852807.12941771.html.plaintext.txt	0	insulin degrading enzyme inhibitor decrease amylin degradation increase amylin induced cytotoxicity increase amyloid formation insulinoma cell culture robert g
0.5852807.12941771.html.plaintext.txt	1	num department internal medicine university nebraska medical center omaha nebraska num department medical research veteran affair medical center omaha nebraska num endocrinology section carl
0.5852807.12941771.html.plaintext.txt	2	hayden va medical center phoenix arizona num molecular cellular biology program arizona state university tempe arizona num department medicine university arizona tucson arizona
0.5852807.12941771.html.plaintext.txt	3	type num diabetes characterized loss pancreatic s cell mass accompanied presence islet amyloid deposit pancreas num
0.5852807.12941771.html.plaintext.txt	4	major component islet amyloid amylin also known islet amyloid polypeptide polypeptide copackaged cosecreted insulin pancreatic s cell num
0.5852807.12941771.html.plaintext.txt	5	presently unclear whether islet amyloid merely consequence diabetes actually contributes progression disease
0.5852807.12941771.html.plaintext.txt	6	however evidence intermediate precursor amylin fibril cytotoxic s cell whereas mature amyloid fibril toxic suggesting s cell toxicity may precede deposition islet amyloid numnum
0.5852807.12941771.html.plaintext.txt	7	amylin continually produced individual without type num diabetes mere presence amylin insufficient induce amylin induced s cell toxicity islet amyloid
0.5852807.12941771.html.plaintext.txt	8	transgenic animal producing human amyloidogenic amylin fail develop islet amyloid num num additional diabetic trait introduced islet amyloid detected num num
0.5852807.12941771.html.plaintext.txt	9	therefore protective mechanism prevents amyloid deposition normal condition impaired diabetic condition
0.5852807.12941771.html.plaintext.txt	10	proteolysis major pathway regulation protein level degradation amylin may contribute prevention islet amyloid aggregation
0.5852807.12941771.html.plaintext.txt	11	s cell toxicity islet amyloid may therefore result imbalance amylin level impaired degradation amylin
0.5852807.12941771.html.plaintext.txt	12	present understanding proteolytic pathway contribute degradation amylin incomplete
0.5852807.12941771.html.plaintext.txt	13	enzyme responsible cellular proteolysis insulin insulin degrading enzyme ide num
0.5852807.12941771.html.plaintext.txt	14	substrate specificity ide amyloidogenic polypeptide including atrial natriuretic peptide anp glucagon s amyloid peptide found alzheimer disease therefore may act scavenger clear amyloidogenic peptide prevent amyloid deposition numnum
0.5852807.12941771.html.plaintext.txt	15	recently showed amylin also ide substrate num
0.5852807.12941771.html.plaintext.txt	16	therefore ide may involved controlling level amylin degradation similar role regulating level alzheimer related s amyloid peptide num
0.5852807.12941771.html.plaintext.txt	17	gk rat model type num diabetes ide identified diabetes susceptibility gene recently described ide null mouse show impaired glucose metabolism
0.5852807.12941771.html.plaintext.txt	18	model cellular insulin degrading activity found impaired
0.5852807.12941771.html.plaintext.txt	19	therefore possible diabetes ide dysfunction also result impaired amylin degradation increased amylin aggregation eventually islet amyloid deposition
0.5852807.12941771.html.plaintext.txt	20	present study performed address following question num amylin insulin degraded s cell common pathway num inhibition ide alter amylin degradation islet amyloid formation num ide inhibition affect cytotoxic property amylin toward s cell answer question pancreatic s cell derived cell line used characterize amylin degradation
0.5852807.12941771.html.plaintext.txt	21	preparation amylin solution
0.5852807.12941771.html.plaintext.txt	22	amylin solution prepared immediately use num mgml stock solution bsa coated test tube prevent adhesion plastic minimize spontaneous amyloid fibril formation
0.5852807.12941771.html.plaintext.txt	23	variable amount contaminating low molecular weight fragment numi labeled albumin numi amylin purified adsorption cnum sep pak water milford ma eluted num
0.5852807.12941771.html.plaintext.txt	24	num trifluoroacetic acid acetonitrile
0.5852807.12941771.html.plaintext.txt	25	eluent lyophilized resuspended original buffer num
0.5852807.12941771.html.plaintext.txt	26	num bsa frozen aliquot used
0.5852807.12941771.html.plaintext.txt	27	rat insulinoma rin mnumf cell num purchased american type culture collection maintained rpmi num medium supplemented num fetal bovine serum num
0.5852807.12941771.html.plaintext.txt	28	num gl glucose num mmoll l glutamine num microgml gentamicin
0.5852807.12941771.html.plaintext.txt	29	experiment cell subcultured num well plate num
0.5852807.12941771.html.plaintext.txt	30	num x num cellswell medium changed every num day used
0.5852807.12941771.html.plaintext.txt	31	cellular degradation amylin insulin
0.5852807.12941771.html.plaintext.txt	32	degradation amylin insulin rin mnumf cell determined trichloroacetic acid tca solubility assay using variation method previously described num
0.5852807.12941771.html.plaintext.txt	33	briefly rin mnumf cell num well plate changed serum free medium containing num
0.5852807.12941771.html.plaintext.txt	34	medium removed numi amylin numi labeled insulin serum free medium containing num
0.5852807.12941771.html.plaintext.txt	35	num bsa added numnum cpmml cell incubated num degree c time indicated
0.5852807.12941771.html.plaintext.txt	36	experiment bacitracin included num mgml
0.5852807.12941771.html.plaintext.txt	37	medium removed brought num
0.5852807.12941771.html.plaintext.txt	38	num bsa num tca chilled num min ice centrifuged numnumg num min
0.5852807.12941771.html.plaintext.txt	39	radioactivity supernatant pellet counted degrading activity expressed percent tca soluble count
0.5852807.12941771.html.plaintext.txt	40	addition conditioned medium cell removed aliquot tested degrading activity tca solubility described
0.5852807.12941771.html.plaintext.txt	41	lysates prepared rin mnumf cell lysis buffer num mmoll tris ph num
0.5852807.12941771.html.plaintext.txt	42	num moll nacl num triton x num num
0.5852807.12941771.html.plaintext.txt	43	num mmoll phenylmethylsulfonyl fluoride
0.5852807.12941771.html.plaintext.txt	44	aliquot num microg total protein resolved num
0.5852807.12941771.html.plaintext.txt	45	num sd page transferred polyvinylidine fluoride membrane
0.5852807.12941771.html.plaintext.txt	46	immunodetection membrane probed numbnum monoclonal antibody directed ide numnumnum dilution num h room temperature
0.5852807.12941771.html.plaintext.txt	47	probed peroxidase conjugated goat anti mouse igg jackson immunochemicals temecula ca numnumnum dilution num h immunoreactive protein detected chemiluminescence
0.5852807.12941771.html.plaintext.txt	48	amyloid formation rin mnumf culture
0.5852807.12941771.html.plaintext.txt	49	rin mnumf cell seeded onto poly l lysine coated eight well glass chamber slide num cellscmnum
0.5852807.12941771.html.plaintext.txt	50	medium changed serum free rpmi num containing num
0.5852807.12941771.html.plaintext.txt	51	num bsa treatment cell treated human amylin num
0.5852807.12941771.html.plaintext.txt	52	experiment bacitracin included num mgml
0.5852807.12941771.html.plaintext.txt	53	determine involvement ide like proteolytic activity islet amyloid formation cell also treated ide inhibitor bacitracin num mgml time amylin addition
0.5852807.12941771.html.plaintext.txt	54	treatment cell washed pb fixed num min num buffered formalin stained amyloid using modified congo red staining procedure num
0.5852807.12941771.html.plaintext.txt	55	briefly sample counterstained weigert iron hematoxylin num rinsed placed num
0.5852807.12941771.html.plaintext.txt	56	washed sample stained congo red num min
0.5852807.12941771.html.plaintext.txt	57	sample immediately dehydrated xylene mounted
0.5852807.12941771.html.plaintext.txt	58	degree amyloid formation determined fluorescence microscopy using tetramethyl rhodamine isothiocyanate filter set
0.5852807.12941771.html.plaintext.txt	59	cell toxicity study rin mnumf cell cultured num well plate treated human rat amylin without bacitracin described num h
0.5852807.12941771.html.plaintext.txt	60	cell viability measured reduction methylthiazolyldiphenyl tetrazolium bromide mtt previously described num
0.5852807.12941771.html.plaintext.txt	61	data expressed mean plus minus se
0.5852807.12941771.html.plaintext.txt	62	degradation assay comparison difference group made one way anova dunnett posttest degradation assay two way anova bonferroni posttest viability assay
0.5852807.12941771.html.plaintext.txt	63	num interpreted significant
0.5852807.12941771.html.plaintext.txt	64	analysis made using graphpad prismnum software package
0.5852807.12941771.html.plaintext.txt	65	view larger version numk fig
0.5852807.12941771.html.plaintext.txt	66	amylin degradation rin mnumf cell time
0.5852807.12941771.html.plaintext.txt	67	degradation amylin rin mnumf cell time measured production acid soluble product numi amylin cell culture medium
0.5852807.12941771.html.plaintext.txt	68	cell also treated num
0.5852807.12941771.html.plaintext.txt	69	num micromoll unlabeled amylin insulin ide inhibitor bacitracin num mgml
0.5852807.12941771.html.plaintext.txt	70	data expressed percent acid soluble product produced n num
0.5852807.12941771.html.plaintext.txt	71	treatment amylin insulin bacitracin
0.5852807.12941771.html.plaintext.txt	72	view larger version numk fig
0.5852807.12941771.html.plaintext.txt	73	insulin degradation rin mnumf cell time
0.5852807.12941771.html.plaintext.txt	74	degradation insulin rin mnumf cell time measured production acid soluble product numi insulin cell culture medium
0.5852807.12941771.html.plaintext.txt	75	cell also treated num
0.5852807.12941771.html.plaintext.txt	76	num micromoll unlabeled amylin insulin ide inhibitor bacitracin num mgml
0.5852807.12941771.html.plaintext.txt	77	data expressed percent acid soluble product produced n num
0.5852807.12941771.html.plaintext.txt	78	treatment amylin insulin bacitracin
0.5852807.12941771.html.plaintext.txt	79	b lysates rin mnumf probed ide specific monoclonal antibody numbnum immunoreactive protein detected chemiluminescence
0.5852807.12941771.html.plaintext.txt	80	single band num kda detected consistent presence ide
0.5852807.12941771.html.plaintext.txt	81	characterize amylin insulin degradation rin mnumf cell degradation measured increasing dosage unlabeled competitor
0.5852807.12941771.html.plaintext.txt	82	degradation numi amylin decreased dosage dependent manner either unlabeled insulin amylin fig
0.5852807.12941771.html.plaintext.txt	83	concentration unlabeled insulin effective inhibitor amylin
0.5852807.12941771.html.plaintext.txt	84	similarly degradation numi insulin inhibited amylin insulin fig
0.5852807.12941771.html.plaintext.txt	85	num insulin generally effective inhibitor
0.5852807.12941771.html.plaintext.txt	86	observation consistent previously determined enzymatic property ide insulin three sixfold higher affinity purified ide amylin num
0.5852807.12941771.html.plaintext.txt	87	two possible complication cell culture system potential direct interaction human amylin insulin num membrane perturbation may impede receptor mediated uptake substrate num
0.5852807.12941771.html.plaintext.txt	88	rat amylin also ide substrate num interact insulin cause membrane disruption
0.5852807.12941771.html.plaintext.txt	89	rat amylin num nmoll inhibited insulin degradation num
0.5852807.12941771.html.plaintext.txt	90	num baseline insulin degradation result similar found human amylin indicating reciprocal inhibition amylin insulin degradation attributable common pathway proteolysis
0.5852807.12941771.html.plaintext.txt	91	view larger version numk fig
0.5852807.12941771.html.plaintext.txt	92	amylin degradation rin mnumf cell
0.5852807.12941771.html.plaintext.txt	93	degradation amylin rin mnumf cell measured production acid soluble product numi amylin cell culture medium
0.5852807.12941771.html.plaintext.txt	94	cell also treated indicated concentration nmoll unlabeled amylin unlabeled insulin
0.5852807.12941771.html.plaintext.txt	95	data expressed percent acid soluble product produced n num
0.5852807.12941771.html.plaintext.txt	96	view larger version numk fig
0.5852807.12941771.html.plaintext.txt	97	insulin degradation rin mnumf cell
0.5852807.12941771.html.plaintext.txt	98	degradation insulin rin mnumf cell measured production acid soluble product numi amylin cell culture medium
0.5852807.12941771.html.plaintext.txt	99	cell also treated indicated concentration nmoll unlabeled amylin unlabeled insulin
0.5852807.12941771.html.plaintext.txt	100	data expressed percent acid soluble product produced n num
0.5852807.12941771.html.plaintext.txt	101	amylin produced healthy individual without formation islet amyloid mechanism must place prevent amylin aggregation normal condition
0.5852807.12941771.html.plaintext.txt	102	examine whether cellular degradation ide may contribute protective process cell culture system study islet amyloid formation developed
0.5852807.12941771.html.plaintext.txt	103	rin mnumf cell cultured poly l lysine coated glass chamber slide num day culture treated human amylin num numnum nmoll num h
0.5852807.12941771.html.plaintext.txt	104	amyloid detected modified congo red fluorescence staining method num includes acidic iron hematoxylin counterstain minimizes intense autofluorescence seen using original method num
0.5852807.12941771.html.plaintext.txt	105	human amylin induced dosage dependent increase staining detectable num nmoll pronounced num micromoll fig
0.5852807.12941771.html.plaintext.txt	106	finding demonstrated exogenous human amylin form amyloid deposit rin mnumf cell culture
0.5852807.12941771.html.plaintext.txt	107	cell treated ide inhibitor bacitracin amyloid staining markedly increased intensity amylin concentration compared cell without bacitracin including lowest amylin concentration num nmoll
0.5852807.12941771.html.plaintext.txt	108	finding suggest impairment cell ability clear amylin protease characteristic consistent ide
0.5852807.12941771.html.plaintext.txt	109	view larger version numk fig
0.5852807.12941771.html.plaintext.txt	110	bacitracin increase amyloid deposition rin mnumf cell
0.5852807.12941771.html.plaintext.txt	111	rin mnumf cell treated num num num numnum nmoll human amylin indicated
0.5852807.12941771.html.plaintext.txt	112	cell cultured absence left presence right ide inhibitor bacitracin bac
0.5852807.12941771.html.plaintext.txt	113	deposition islet amyloid detected congo red fluorescence
0.5852807.12941771.html.plaintext.txt	114	brightfield exposure cell shown inset
0.5852807.12941771.html.plaintext.txt	115	amylin implicated s cell toxicity effect ide inhibition rin mnumf cell viability determined mtt reduction fig
0.5852807.12941771.html.plaintext.txt	116	treatment human amylin num h decreased cell viability dosage dependent manner peaking num numnum nmoll amylin
0.5852807.12941771.html.plaintext.txt	117	presence bacitracin cell viability markedly lower amylin concentration reaching maximum reduction num num nmoll amylin
0.5852807.12941771.html.plaintext.txt	118	conversely rat amylin effect viability whether without bacitracin
0.5852807.12941771.html.plaintext.txt	119	therefore ide inhibitor increased ability amylin reduce rin mnumf cell viability
0.5852807.12941771.html.plaintext.txt	120	view larger version numk fig
0.5852807.12941771.html.plaintext.txt	121	bacitracin increase amylin induced cytotoxicity
0.5852807.12941771.html.plaintext.txt	122	rin mnumf cell treated num num num numnum nmoll human amylin numnum nmoll rat amylin indicated
0.5852807.12941771.html.plaintext.txt	123	cell cultured absence presence ide inhibitor bacitracin
0.5852807.12941771.html.plaintext.txt	124	cell toxicity assessed degree mtt reduction cell n num
0.5852807.12941771.html.plaintext.txt	125	factor prevent amylin fibril formation s cell death islet amyloid deposition nondisease state understood
0.5852807.12941771.html.plaintext.txt	126	amylin continually produced nondiabetic human amyloid formation mere presence amylin insufficient cause fibril formation
0.5852807.12941771.html.plaintext.txt	127	indeed transgenic animal overexpressing human amylin form amyloid deposit num numnum confirming elevated amylin level alone insufficient amyloid formation
0.5852807.12941771.html.plaintext.txt	128	however diabetic condition introduced ob mutation growth hormonesteroid treatment high fat diet animal develop islet amyloid islet dysfunction reduced insulin secretion hyperglycemia num num
0.5852807.12941771.html.plaintext.txt	129	therefore type num diabetes balance shift amylin clearance deposition either increased amount factor promotes amylin aggregation decreased amount factor clear amylin
0.5852807.12941771.html.plaintext.txt	130	although numerous study regarding amylin synthesis secretion present study amylin degradation
0.5852807.12941771.html.plaintext.txt	131	enzyme responsible intracellular degradation insulin ide cytosolic metallothioprotease also known insulysin numnum
0.5852807.12941771.html.plaintext.txt	132	primary function ide mammalian tissue traditionally thought degradation insulin number protein identified ide substrate including protein structurally related insulin proinsulin igf ii relaxin seemingly unrelated peptide anp glucagon num
0.5852807.12941771.html.plaintext.txt	133	however insulin anp glucagon contain region form s pleated sheet potentially amyloid forming num
0.5852807.12941771.html.plaintext.txt	134	proposed rather targeting primary sequence motif ide specific toward amyloidogenic peptide num concept supported finding ide also degrades amylin s amyloid peptide numnumnum
0.5852807.12941771.html.plaintext.txt	135	recent study supported role ide type num diabetes alzheimer disease two condition characterized amyloid
0.5852807.12941771.html.plaintext.txt	136	possible genetic linkage type num diabetes alzheimer disease mapped chromosomal region ide gene num num
0.5852807.12941771.html.plaintext.txt	137	gk rat model type num diabetes ide identified diabetes susceptibility gene mutation associated model result lower cellular insulin degradation hyperglycemia reduced lipogenesis fat cell reduced glucose uptake vivo num
0.5852807.12941771.html.plaintext.txt	138	recently described ide null mouse model display impaired insulin s amyloid degradation well hyperinsulinemia glucose intolerance cerebral accumulation s amyloid hallmark type num diabetes alzheimer disease num
0.5852807.12941771.html.plaintext.txt	139	thus evidence mounting ide play major role disease characterized amyloid formation
0.5852807.12941771.html.plaintext.txt	140	previous study using cell free extract num ide readily degraded amylin lower affinity insulin
0.5852807.12941771.html.plaintext.txt	141	radiolabeled amylin covalently cross linked ide monoclonal antibody directed ide immunoprecipitated insulin amylin degrading activity confirming ide amylin degrading protease
0.5852807.12941771.html.plaintext.txt	142	extended finding rat s cell derived line
0.5852807.12941771.html.plaintext.txt	143	amylin insulin degraded rin mnumf cell insulin degraded much slowly
0.5852807.12941771.html.plaintext.txt	144	possible reason observation include difference binding internalization different receptor difference receptor availability e
0.5852807.12941771.html.plaintext.txt	145	desensitization cell toxicity
0.5852807.12941771.html.plaintext.txt	146	difference may also attributed nature assay
0.5852807.12941771.html.plaintext.txt	147	unlike amylin multiple cleavage required produce tca soluble fragment insulin therefore assay tends underestimate level insulin degradation
0.5852807.12941771.html.plaintext.txt	148	amylin degradation began quickly leveled time
0.5852807.12941771.html.plaintext.txt	149	probable explanation observation based insulin secretion cell
0.5852807.12941771.html.plaintext.txt	150	cell changed fresh medium containing labeled substrate initially endogenously produced insulin medium
0.5852807.12941771.html.plaintext.txt	151	rin cell rapidly secreted insulin reaching num num nmoll num h would act competitive inhibitor amylin degradation
0.5852807.12941771.html.plaintext.txt	152	amylin present tracer amount sufficient insulin competitively inhibit amylin degradation may well produced within num min
0.5852807.12941771.html.plaintext.txt	153	insulin amylin capable competitive inhibition either substrate insulin general better competitive inhibitor amylin
0.5852807.12941771.html.plaintext.txt	154	discussed likely attributable greater affinity insulin ide possibly also different internalization property insulin amylin
0.5852807.12941771.html.plaintext.txt	155	efficiency unlabeled insulin inhibition insulin degradation consistent previous report showing num inhibition num num nmoll insulin using rin mnumf cell num
0.5852807.12941771.html.plaintext.txt	156	taken together data suggest insulin amylin share common pathway degradation
0.5852807.12941771.html.plaintext.txt	157	specificity amylin insulin degrading activity investigated using ide inhibitor bacitracin
0.5852807.12941771.html.plaintext.txt	158	although bacitracin specific inhibitor ide ide inhibitor e
0.5852807.12941771.html.plaintext.txt	159	n ethylmaleimide numnum phenanthroline highly toxic rin mnumf cell r
0.5852807.12941771.html.plaintext.txt	160	unpublished observation whereas bacitracin well tolerated cell
0.5852807.12941771.html.plaintext.txt	161	amylin insulin degradation rin mnumf cell markedly inhibited bacitracin
0.5852807.12941771.html.plaintext.txt	162	bacitracin also accelerated islet amyloid formation amylin concentration suggesting inhibition amylin degradation accelerates amylin aggregation amyloid deposition
0.5852807.12941771.html.plaintext.txt	163	amylin implicated s cell death cell viability examined condition
0.5852807.12941771.html.plaintext.txt	164	cytotoxicity induced human amylin markedly increased bacitracin treatment whereas rat amylin effect suggesting amylin degradation responsible reducing cell toxicity caused amylin
0.5852807.12941771.html.plaintext.txt	165	amylin induced cytotoxicity s cell shown caused intermediate amylin precursor rather mature amyloid num
0.5852807.12941771.html.plaintext.txt	166	ide degrades amylin monomer formation intermediate precursor amyloid fibril would prevented
0.5852807.12941771.html.plaintext.txt	167	experiment performed num h treatment freshly prepared amylin determine amylin specie caused toxicity rin cell
0.5852807.12941771.html.plaintext.txt	168	however degree cell death seen bacitracin treatment increased maximum attained even lowest amylin concentration could mean toxicity preceded amyloid deposition
0.5852807.12941771.html.plaintext.txt	169	although amylin concentration required detection amyloid cell toxicity num num nmoll high relative circulating level local amylin concentration around s cell unknown may well higher especially condition stimulate insulin amylin secretion
0.5852807.12941771.html.plaintext.txt	170	summary rin mnumf cell clear amylin bacitracin sensitive mechanism property consistent ide
0.5852807.12941771.html.plaintext.txt	171	inhibition mechanism increased amyloid formation cell toxicity
0.5852807.12941771.html.plaintext.txt	172	data consistent emerging concept role ide disease characterized amyloid
0.5852807.12941771.html.plaintext.txt	173	regard interesting note transgenic animal expressing human amylin general develop islet amyloid unless diabetic condition introduced
0.5852807.12941771.html.plaintext.txt	174	one condition high fat diet num
0.5852807.12941771.html.plaintext.txt	175	interestingly shown increased lipid level result impaired insulin degradation num free fatty acid directly inhibit ide activity num
0.5852807.12941771.html.plaintext.txt	176	combination increased expression amyloidogenic amylin impaired insulin degrading activity may result formation islet amyloid model
0.5852807.12941771.html.plaintext.txt	177	therefore possible condition leading impaired ide activity e
0.5852807.12941771.html.plaintext.txt	178	elevated free fatty acid contribute amylin accumulation aggregation s cell toxicity islet amyloid formation progression type num diabetes
0.5852807.12941771.html.plaintext.txt	179	acknowledgment work supported u
0.5852807.12941771.html.plaintext.txt	180	department veteran affair research service bly memorial research fund university nebraska medical center
0.5852807.12941771.html.plaintext.txt	181	address correspondence reprint request robert g
0.5852807.12941771.html.plaintext.txt	182	bennett phd research service num veteran affair medical center num woolworth ave
0.5852807.12941771.html.plaintext.txt	183	received publication january num num accepted revised form june num num
0.5852807.12941771.html.plaintext.txt	184	anp atrial natriuretic peptide ide insulin degrading enzyme mtt methylthiazolyldiphenyl tetrazolium bromide tca trichloroacetic acid
